

**Grants and Contracts Office** 

# Funding Opportunities Monthly Edition June 2024 Due Dates

#### Introduction

This funding opportunity packet contains information on funding opportunities with deadlines in June 2024. The opportunities are organized in the following order:

- 1. National Institutes of Health (NIH)
- 2. National Science Foundation (NSF)
- 3. Other Federal
- 4. Non Federal

SPIN ID	Program Title		Sponsor Name	Sponsor Number			Deadline Date	Funding Amount
SPIN ID	Program Title			Sponsor Name	Sponsor Number	Dea	dline Date	Funding Amount
109720 <mark> </mark>	nternational Bioethics Research 1 Optional)	raining Pr	ogram (D43 Clinical Trial	Fogarty International Center/NIH/DHHS	PAR-22- 116	06-J	un-2024	1,150,000 USD
	Contact Name	Barbara S	ina, Ph.D.					
	Contact Telephone	301-402-9	9467					
	Contact Email	<u>sinab@m</u>	ail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	06-Jun-20	)24					
	Synopsis	and midd conceptu as provide support L mentorec individual Opportun independ trial led b	le-income country (LMIC) resear al ethics research that addresse e research ethics leadership to t MIC-U.S. collaborative institutio d research, advanced theoretical s for positions of ethics scholars ity Announcement (FOA) allows ent clinical trial; or proposing a y another investigator, as part c	rch intensive institutions with the cases s challenging issues in health resear heir institutions, governments and nal bioethics doctoral and postdoct didactic courses and ethics career ship and leadership in health resear appointment of Trainees (D43) pro- separate ancillary clinical trial; or pro- f their research and career develop	apabilities to ch and rese internationa coral researc skills trainin ch institutio oposing to s oposing to s ment.	o cond arch p Il rese ch trai g com ns in erve a gain r	duct original empir policy in these cour earch organizations ning programs tha ponents to prepar LMICs. This Fundin as the lead investig esearch experience	ical or htries as well f. FIC will t incorporate re multiple g rator of an e in a clinical
110400	Paul Calabresi Career Developmer Frial Optional)	<u>nt Award f</u>	or Clinical Oncology (K12 Clinica	I National Cancer Institute/NIH/DHHS	PAR-22- 136	17-J	un-2024	Not Specified
	Contact Name	Mark Dan	nico, Ph.D.					
	Contact Telephone	240-276-5	5639					
	Contact Email	damicom	w@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	17-Jun-20	)24					
	Synopsis	The purpo	ose of the Paul Calabresi Career	Development Award for Clinical On	cology (PCA	.CO) is	s to increase the nu	umber of

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		clinician-s research, allows ap separate investigat	cientists (M.D.s, D.O.s, Pharm.D and to promote their career de pointment of Scholars proposing ancillary clinical trial to an existi or, as part of their research and	D.s, nurses with Ph.D.s, or equivalen velopment as cancer researchers. T g to serve as the lead investigator o ng trial; or proposing to gain resear l career development.	t) trained in clini his Funding Opp f an independen ch experience in	ical and translation ortunity Announce t clinical trial; or p a clinical trial led	nal cancer ement (FOA) roposing a by another
106440	Pancreatic Cancer Detection Cons Optional)	ortium: Re	esearch Units (U01 Clinical Trial	National Cancer Institute/NIH/DHHS	PAR-21- 334 11-	Jun-2024	3,000,000 USD
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	240-276-7 srivasts@ Link to pr 11-Jun-20	2028 mail.nih.gov ogram URL 24				
	Synopsis	Through t Research conduct r to identify research p will suppo and for id be candid identify al molecular develop n and comp The PCDC participat The other companio analysis, c including	his Funding Opportunity Annou Units (RUs), one of the two scie esearch on early detection of pa y those patients who are at high priorities identified in the NCI's 2 ort research for the developmen entifying those patients at high ates for early intervention. The nd test biomarkers measurable - and/or imaging-based marker nolecular- and/or imaging-based utational approaches towards b -RUs will also collect longitudina e in collaborative activities with scientific component of the PCI n PAR-21-335). The PCDC-MDCI coordination, harmonization, da biorepository building effort. Th	ncement (FOA), the National Cance ntific components of the Pancreatic ancreatic ductal adenocarcinoma (P risk of progression to cancer. The F 2014 Scientific Framework for Panc at and testing of new molecular and risk of PDAC (because of genetic fac PCDC-RUs will consist of multi-disci in bodily fluids for early detection of s of pancreatic cysts and determine d approaches for screening populatio iomarker discovery and/or validation other PCDC-RUs and share ideas, b DC will be the Management and Da U will provide support toward study ta management and stewardship for the PCDC-MDCU will also support the	r Institute (NCI) c Cancer Detection DAC) and charact PCDC will continue reatic Ductal Add imaging biomar ctors or presence plinary teams are of PDAC and/or it which ones are ions at high risk on; and conduct pository. Each Pe- piospecimens, an ta Coordination design, protoco per the trans-PCDO	is soliciting application on Consortium (PC sterization of its pro- ue to address one enocarcinoma (PD kers for detecting e of precursor lesion likely to progress for PDAC; use mach biomarker validat CDC-RU is expected d data within the Unit (MDCU; see of development, str C collaborative pro-	ations for the DC), to ecursor lesions of the four AC). The PCDC PDAC early ons) who could tudies to: s; develop to cancer; nine learning ion studies. d to Consortium. atistical jects, Consortium-

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
		wide calls	s, meetings and workshops.					
113074	The Metastasis Research Network Clinical Trial Not Allowed)	<u>(MetNet</u> )	: MetNet Research Projects (U0	11 National Cancer Institute/NIH/DHHS	PAR-22- 2 234 [	20-May-2024 Optional][LOI/Pre-A	2,500,000 pp] USD	
	Contact Name	Joanna M	I. Watson, Ph.D.					
	Contact Telephone	240-276-0	6206					
	Contact Email	watsonjo	@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	20-May-2 [Optional	2024 [Optional][LOI/Pre-App], 20 ][LOI/Pre-App], 20-Jun-2025	D-Jun-2024 , 23-Sep-2024 [Optional]	[LOI/Pre-App]	, 23-Oct-2024 , 20-N	1ay-2025	
The National Cancer Institute's (NCI) Metastasis Research Network (MetNet) is a collection of US4 Research Centers support using systems-level approaches to understand pressing questions in metastasis. The overall goal of the MetN advance our understanding of metastasis as a whole body, systems-level problem to develop a comprehensive and c Synopsis picture of the processes involved. Through this Funding Opportunity Announcement (FOA), the NCI invites applicatio MetNet Research Projects. These Research Projects should be defined as discrete entities that use systems-level app to address gaps and opportunities in metastasis research to integrate into the MetNet and complement ongoing rese across the Network.								
106892	Exploratory Grants in Cancer Cont	trol (R21 C	ilinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-21- 341	)7-Jun-2024	275,000 USD	
	Contact Name	Mukesh \	/erma, Ph.D.					
	Contact Telephone	240-276-	6889					
	Contact Email	vermam@	@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-Jun-20	024 , 08-Oct-2024 , 08-Nov-2024	1				
	Synopsis	Through t explorato behavior,	this funding opportunity annour ory/developmental research gra screening, and understanding e	ncement (FOA), the National Cancer nt (R21) applications that focus on c etiologic factors contributing to the	Institute (NCI lifferent aspec development	) encourages the sub ts of cancer control of cancer, and devel	omission of by modifying oping ways to	

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		control ca novel scie developm impact or	ancer. The overarching goal is to entific ideas that have the poten nent of novel techniques, agents n a field of cancer research (e.g.	provide support to promote the tial to substantially advance popu , interventions, methodologies, n epidemiologic, biomedical, behav	early and cond Ilation-based o nodels, or appl vioral, health c	eptual stages of rese ancer research, such ications that could ha are delivery or clinica	arch efforts on as the ave a major I).
122289	Exploratory Grant Award to Prom Research (R21 Clinical Trial Not A	ote Workf llowed)	orce Diversity in Basic Cancer	National Cancer Institute/NIH/DHHS	PAR-24- 039	18-Jun-2024	275,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website	Laritza M 240-477-9 laritza.roo	. Rodriguez, M.D., Ph.D. 9376 driguez@nih.gov				
	Program URL Deadline Dates (ALL)	<u>Link to pr</u> 18-Jun-20	ogram URL )24 , 19-Nov-2024 , 17-Jun-2025	, 18-Nov-2025 , 15-Jun-2026 , 17	-Nov-2026		
	Synopsis	This notic cancer res backgrout clinical an	e of funding opportunity (NOFC search workforce by recruiting a nds, including from groups that id social sciences. This NOFO wi	<ul> <li>is a continuation of an NCI prog and supporting eligible New Inves have been shown to be nationally Il fund investigators to develop a</li> </ul>	ram to enhanc tigators and Ea y underreprese larger research	te the diversity of the arly Stage Investigato ented in the biomedic o project grant applica	pool of the rs from diverse al, behavioral, ation.
117092	RFA-CA-23-028 Discovery and D Interception and Prevention (UG3	evelopme B/UH3 Clini	nt of Natural Products for Cance ical Trial Not Allowed)	er National Cancer Institute/NIH/DHHS	RFA-CA- 23-028	14-May-2024 [Optional][LOI/Pre-A	Not App] Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	Altaf Moł 240-276-6 <u>wynne.nc</u>	nammed, PhD 5082 o <u>rton@nih.gov</u>				
	Program URL Deadline Dates (ALL)	<u>Link to pr</u> 14-May-2	ogram URL 024 [Optional][LOI/Pre-App], 13	3-Jun-2024 , 13-Jun-2025 , 14-Jun	-2025 [Optiona	al][LOI/Pre-App]	
	Synopsis	Through t developm UG3 phas clinical sa	his Notice of Funding Opportun nent of novel natural products the will provide up to three years mples and preclinical in vivo stu	ity (NOFO), the National Cancer I nat are safe, non-toxic, and effica- of support for milestone-driven in idies, assay development, and/or	nstitute (NCI) i cious for cance nitial target se assay validatic	ntends to support the er interception and pr lection, verification o on for target activity,	e discovery and evention. The f the target in as well as on-

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		target tox scale scre the natur in the UH	xicity screening, and pilot screen ening, identification of active na al product's effect in vitro and ir 3 phase.	ing of natural agents. If UG3 milest atural compounds, full-scale evalua a vivo, and determining the optima	cones are met, tion of screene I dose for subs	support may be proved individual agents, equent studies and s	vided for a full- assessment of afety testing
123579	Modular R01s in Cancer Control a Optional)	ind Popula	tion Sciences (R01 Clinical Trial	National Cancer Institute/NIH/DHHS	PAR-24- 122	5-Jun-2024	1,250,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website	Scott Rog 240-276-( <u>rogerssc@</u>	ers, MPH 5932 @mail.nih.gov				
	Program URL	Link to pr	ogram URL				
	Synopsis	This notic The overa substantia behaviors	e of funding opportunity (NOFO arching goal is to provide suppor ally advance cancer research in s and behavioral interventions, h	) encourages applications for resea t to promote research efforts on n statistical and analytic methods, ep lealth care delivery, digital health a	arch in cancer o ovel scientific i idemiology, ca ind data scienc	control and population deas that have the p ncer survivorship, ca e, and implementati	on sciences. ootential to ancer-related on science.
123027	RFA-CA-24-016 Development o Algorithms for Cancer Research a Optional)	f Innovativ nd Manag	e Informatics Methods and ement (R21 Clinical Trial	National Cancer Institute/NIH/DHHS	RFA-CA- 1 24-016 [	2-May-2024 Optional][LOI/Pre-A	275,000 op] USD
	Contact Name	Juli Klemr	n, Ph.D.				
	Contact Telephone	202-853-7	7889				
	Contact Email	juli.klemn	n@.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	12-May-2	024 [Optional][LOI/Pre-App], 11	-Jun-2024 , 16-Oct-2024 [Optional	J[LOI/Pre-App]	, 15-Nov-2024	
	Synopsis	(R21) for of data ac	ose of this Notice of Funding Op innovative informatics methods cross the cancer research contin	portunity (NOFO) is to invite exploi and algorithms to improve the acc uum including cancer biology, canc	ratory/develop Juisition, analys er treatment a	mental research gra sis, visualization, or i nd diagnosis, early c	nt applications nterpretation ancer

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		detection compone supportin to acceler method o generatio	, risk assessment and prevention nt of the NCI's Informatics Techn g the development of novel info rate or enhance research. To be or algorithm is novel and how it w n and/or data analysis will not b	n, cancer control and epidemiology hology for Cancer Research (ITCR) F irmatics capabilities that involve a l successful, there must be a clear ra vill benefit the cancer research fiel e considered responsive to this fur	, and/or cancer Program, the em high degree of ir htionale for how d. Projects with hding opportunit	health disparities. phasis of this NOF inovation that have the proposed info a significant level o y.	As a D is on e the potential rmatics of data
123030	RFA-CA-24-017 Early-Stage Deve Cancer Research and Managemen	elopment it (U01 Clii	of Informatics Technologies for nical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA- 12 24-017 [O	-May-2024 ptional][LOI/Pre-A	900,000 pp] USD
	Contact Name	Juli Klemr	n, Ph.D.				
	Contact Telephone	202-853-7	7889				
	Contact Email	juli.klemn	n@nih.gov				
	Sponsor Website						
	Program URL	<u>Link to pr</u>	ogram URL				
	Deadline Dates (ALL)	12-May-2	024 [Optional][LOI/Pre-App], 11	-Jun-2024 , 16-Oct-2024 [Optional]	[LOI/Pre-App], 3	L5-Nov-2024	
	Synopsis	The purped developm data and cancer de compone developm NOFO as i ITCR is to cancer res technolog and collab	ose of this Notice of Funding Op nent of enabling informatics tech knowledge across the cancer res tection, risk assessment and pre nt of the NCI's Informatics Tech nent from prototyping to harden initial tool development or the s promote research-driven inform search. In order to be successful gy is needed and how it will bene porators throughout the develop	portunity (NOFO) is to invite Coope anologies to improve the acquisitio search continuum including cancer evention, cancer control and epider hology for Cancer Research (ITCR) F ing and adaptation. Early-stage dev ignificant modification of existing t hatics technology across the develo , proposed development plans must efit the cancer research field. In ado pment process must be included.	rative Agreeme n, management, biology, cancer miology, and/or Program, this NC velopment is def ools for new app opment lifecycle st have a clear ra dition, mechanis	nt (U01) applicatio analysis, and disse treatment and diag cancer health disp FO focuses on ear fined for the purpo plications. The cent to address priority ationale on why the ms to solicit feedb	ns for the emination of gnosis, early arities. As a ly-stage se of this tral mission of needs in e proposed ack from users
123041	RFA-CA-24-019 Sustained Suppo Research and Management (U24 (	ort for Info Clinical Tri	ormatics Technologies for Cancel al Optional)	National Cancer Institute/NIH/DHHS	RFA-CA- 12 24-019 [O	-May-2024 ptional][LOI/Pre-A	Not pp] Specified
	Contact Name	Juli Klemr	n, Ph.D.				
	Contact Telephone	202-853-7	7889				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Email	juli.klemm@nih.gov						
	Sponsor Website	2						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	12-May-2024 [Optional][LOI/Pre-App], :	11-Jun-2024 , 16-Oct-2024 [Option	al][LOI/Pre-App], 1	.5-Nov-2024			
	Synopsis	he purpose of this Notice of Funding Opportunity (NOFO) is to invite Cooperative Agreement (U24) applications for the ontinued development and sustainment of high value informatics research resources to improve the acquisition, nanagement, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer viology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and pidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research ITCR) Program, this NOFO focuses on sustaining operations and improving the user experience and availability of existing, videly-adopted informatics tools and resources. This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR NOFOs. The central mission of ITCR is to promot esearch-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed sustainment plan must provide clear justification for why the research resource should be maintained and how it has benefited and will continue to benefit the cancer research field. In addition, mechanisms for uses and maximizing the value of the resource to researchers and supporting collaboration and deep engagement and how the resource and the targeted research community should be described.						
123034	RFA-CA-24-018 Advanced Deve Cancer Research and Managemer	lopment of Informatics Technologies for nt (U24 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA- 12- 24-018 [Oj	-May-2024 otional][LOI/Pre-A	3,000,000 pp] USD		
	Contact Name	Juli Klemm, Ph.D.						
	Contact Telephone	202-853-7889						
	Contact Email	juli.klemm@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	12-May-2024 [Optional][LOI/Pre-App], :	11-Jun-2024 , 16-Oct-2024 [Option	al][LOI/Pre-App], 1	.5-Nov-2024			
	Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this NOFO focuses						

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		on emerg demonstr enhancen must have addition, included. consult th	ing informatics technology, definated potential to have a signific ment, and has not been widely a e a clear rationale on why the pri mechanisms to solicit feedback Potential applicants who are infinated abor- tion NOFOs listed abor-	ned as one that has passed the init ant and broader impact, has compe dopted in the cancer research field roposed technology is needed and I from users and collaborators throu cerested in early-stage developmen ve.	ial prototyping a elling reasons for . To be successfunow it will benef ghout the develo t or informatics	nd pilot developm further improven al, proposed develo t the cancer resea opment process m resource sustainm	ent stage, has ient and opment plans irch field. In ust be ent should
107027	ntegrating Biospecimen Science A Development (U01 Clinical Trial No	Approache ot Allowed	<u>s into Clinical Assay</u> <u>네</u>	National Cancer Institute/NIH/DHHS	PAR-22- 049	-Jun-2024	1,250,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Abhi Rao, 240-276-5 <u>abhi.rao@</u> <u>Link to pr</u> 07-Jun-20 This Fund facing clir biopsies, funded ur	Ph.D. 5715 Onih.gov ogram URL 024 , 13-Sep-2024 ing Opportunity Announcement nical assay development and sub blood biospecimens utilized as ' nder this FOA may include inves	: (FOA) will support extramural rese osequent analytical validation due t 'liquid biopsies, or other biospecim tigations of preanalytical variability	earch to investig o preanalytical v ens as described associated with	ate and mitigate ch ariability in tumor in this FOA. Extrai the procurement	nallenges tissue mural research and study of
	Synopsis	small biop and esopl experime biomarke understar collection evidence-	osies (core biopsies, small excision hageal aspirates, feces, or bodily nts will explore how different bions rs quantified by a variety of test anding of how analytical quantified processing, and storage procession based standardization of biopsy	on samples), blood utilized for liqui fluids like sweat, urine, CSF, breas ospecimen preanalytical conditions ing platforms. The results from this cation of clinically relevant biomark dures. The overall goal is to expedit handling practices.	d biopsies, tissue t milk and saliva affect emerging research progra ers is affected by the biomarker clin	e swabs, tissue sec Investigator-desig and clinically rele am will improve the variation in biosp ical assay develop	retions, pleural gned vant e ecimen ment through
108548	Epidemiologic Research on Emerg Susceptibility (R01 Clinical Trial No	ing Risk Fa ot Allowed	actors and Liver Cancer	National Cancer Institute/NIH/DHHS	PAR-22- 083	-Jun-2024	Not Specified
	Contact Name Contact Telephone	Tram Kim 240-276-6	Lam, Ph.D., MPH 5967				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email	Tram.Lan	n@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	05-Jun-20	024 , 05-Oct-2024 , 05-Feb-2025				
	Synopsis	The purpe innovativ risk facto histologic	ose of this Funding Opportunity e hypotheses on emerging risk f rs (e.g., viral hepatitis) associate ral subtypes) in the United State	Announcement (FOA) is to promote actors (biological, environmental, a d with the development of liver car s.	e epidemiologic i nd social) and th ncer (hepatocellu	esearch investigat eir interplay with e lar carcinoma and	ing novel and established other
108551	Cancer Tissue Engineering Collabo Engineered Technologies for Canc	orative: En er Resear	abling Biomimetic Tissue- ch (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22- 099	Jun-2024	2,000,000 USD
	Contact Name	Steven Be	ecker, Ph.D.				
	Contact Telephone	240-276-0	5210				
	Contact Email	steven.be	<u>ecker@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	05-Jun-20	)24 , 05-Oct-2024 , 05-Feb-2025				
	Synopsis	This Fund biomimet fields of r generatin hypothes (TEC) Res and ex viv promote	ling Opportunity Announcement cic tissue-engineered technologi egenerative medicine, tissue en g novel experimental models th is. The projects supported by th earch Program. The Cancer TEC vo systems available for cancer r the exploration of cancer pheno	t (FOA) will support the development es for cancer research. Collaborativ gineering, biomaterials, and bioeng at mimic cancer pathophysiology in is FOA will collectively participate in Program will (1) catalyze the advant research, (2) expand the breadth of pomena with biomimetic tissue-engin	nt and charactering ineering with car in the context of a in the Cancer Tission cement of innover these systems to ineered systems.	zation of state-of- ry projects that er neer biology will be testable cancer re ue Engineering Col ative, well charact several cancer ty	the-art lgage the e essential for esearch laborative erized in vitro pes, and (3)
107221	Modulating Human Microbiome F Against Cancer (R01 Clinical Trial N	unction to	o Enhance Immune Responses ed)	National Cancer Institute/NIH/DHHS	PAR-22- 061 05-	Jun-2024	Not Specified
	Contact Name Contact Telephone	Phillip J. [ 240-276-(	Daschner, M.Sc. 6227				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email	מעמעמ	nih gov				
	Contact Emain	<u>PD95u@1</u>	<u>IIII.gov</u>				
	Sponsor website	Link to pr	ogram LIRI				
	Deadline Dates (ALL)	05-lup-20	091 011 0112				
	Synopsis	The purpo which the targets fo microbes sporadic t effectiver	ose of this Funding Opportunity human microbiome inhibits or r cancer prevention strategies. (or consortia) or their metaboli tumor formation. Concentration ness and thus those parameters	Announcement (FOA) is to support enhances anti-tumor immune resp Applications should be focused on o tes target immune responses that e n, timing, and duration of administe should be rigorously addressed in t	basic research t onses, and to ide delineating how l nhance or preve red beneficial mi he application.	hat elucidates med entify potential nov host interactions w ent inflammation-a icrobes may alter in	chanisms by vel molecular vith specific ssociated or ts
123053	National Cancer Institute's Investi Cancer Treatment and Diagnosis (	gator-Initi R01 Clinic	ated Early Phase Clinical Trials fo al Trial Required)	or National Cancer Institute/NIH/DHHS	PAR-24- 085	May-2024	2,499,995 USD
	Contact Name	Lori A. He	nderson, Ph.D.				
	Contact Telephone	240-276-5	5930				
	Contact Email	<u>henderso</u>	nlori@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2025 , 05	024 , 05-Jun-2024 , 07-Sep-202 -Oct-2025 , 07-Jan-2026 , 05-Fel	4 , 05-Oct-2024 , 07-Jan-2025 , 05-F ɔ-2026 , 07-May-2026 , 05-Jun-2026	eb-2025 , 07-Ma 5 , 07-Sep-2026 ,	y-2025 , 05-Jun-20 05-Oct-2026 , 07-J	025 <i>,</i> 07-Sep- lan-2027
	Synopsis	Through t implement therapeurat least 1 Evaluation Alternativ an early p III clinical	this Notice of Funding Opportun at early phase (Phase 0, I, and II) tic interventions of direct releva clinical trial related to the scien n Program, Cancer Imaging Prog ve Medicine Program and/or the phase trial by itself, or in combin trials.	ity (NOFO), the National Cancer Ins investigator-initiated clinical trials ince to the research mission of DCTI tific interests of one or more of the gram, Cancer Diagnosis Program, Ra HIV and AIDS Malignancies Resear ation with another research aim(s)	titute (NCI) is so focused on canc D and OHAM. Th following resear diation Research ch Programs. Ap as appropriate.	liciting research pr er-targeted diagno e proposed projec rch programs: Cano n Program, Comple plicants may propo This NOFO does no	ojects that ostic and t must involve cer Therapy mentary and ose to conduct it accept Phase
123051 <mark>(</mark>	Cancer Prevention and Control Cli Trial Required)	nical Trial	s Grant Program (R01 Clinical	National Cancer Institute/NIH/DHHS	PAR-24- 072 07-	May-2024	Not Specified

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Contact Name Contact Telephone	Brandy H 240-276-7	eckman-Stoddard, Ph.D., M.P.H 7048							
	Contact Email	heckmanl	bm@mail.nih.gov							
	Sponsor Website									
	Program URL	<u>Link to pr</u>	ogram URL							
	Deadline Dates (ALL)	07-May-2 2025 , 05·	024 , 05-Jun-2024 , 07-Sep-202 -Oct-2025 , 07-Jan-2026 , 05-Fel	4 , 05-Oct-2024 , 07-Jan-2025 , 05 b-2026 , 07-May-2026 , 05-Jun-20	-Feb-2025 , 07-Ma 26 , 07-Sep-2026 ,	y-2025 , 05-Jun-20 05-Oct-2026 , 05-J	125 , 07-Sep- Jan-2027			
	Synopsis	investigat investigat NCI Divisi improven survivorsh practice a Health (N described cancer dia	vestigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the CI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through nprovements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or urvivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical ractice and/or public health. Applications submitted to this NOFO must include studies that meet the National Institutes of ealth (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as escribed in this NOFO and the application instructions. This NOFO does not and will not support clinical trials for studies of ancer diagnosis and/or oncologic therapy in patients.							
111847	Innovative Approaches to Studyin Information Ecosystem (R01 Clinic	g Cancer C cal Trial Op	Communication in the New otional)	National Cancer Institute/NIH/DHHS	PAR-22- 05- 164	Jun-2024	2,500,000 USD			
	Contact Name	Kelly D. B	lake, ScD							
	Contact Telephone	240-281-5	5934							
	Contact Email	<u>kelly.blak</u>	e@nih.gov							
	Sponsor Website									
	Program URL	<u>Link to pr</u>	ogram URL							
	Deadline Dates (ALL)	05-Jun-20	024 , 05-Oct-2024 , 05-Feb-2025	, 05-Jun-2025						
	Synopsis	Through t supportin applicatic communi communi	prough this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in poporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and pplication of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply							

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
		communi preventic	cation science approaches to th on and control. Applications sho	e investigation of behavioral target uld utilize one or more innovative c	s and health c ommunicatior	utcomes related to c research methodolo	ancer ogies.			
111859 <mark>-</mark>	Precision Approaches in Radiation Clinical Trial Optional)	n <mark>Synthetic</mark>	Combinations (PAIRS, R01	National Cancer Institute/NIH/DHHS	PAR-22- 198	05-Jun-2024	Not Specified			
	Contact Name	Michael G	Graham Espey, Ph.D.							
	Contact Telephone	240-276-	5609							
	Contact Email	SP@nih.g	<u>ov</u>							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	05-Jun-20	024 , 05-Oct-2024 , 05-Feb-2025	, 05-Jun-2025						
	Synopsis	that seek therapy. synthetic effective	The seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation The seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation The seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation The seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation The seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation The seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation The seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation The seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation The seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation The seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation the seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation the seek to investigate actionable synthetic vulnerabilities that can be conditionable with tumor values actionable synthetic value synthetic values actionable synthetic value synthetic values actionable synthetic valu							
120897	Research Projects to Enhance App Translational Research (R01 Clinic	plicability o cal Trial No	of Mammalian Models for t Allowed)	National Cancer Institute/NIH/DHHS	PAR-23- 281	)5-Jun-2024	2,495,000 USD			
	Contact Name	Joanna W	/atson, Ph.D.							
	Contact Telephone	240-276-0	6206							
	Contact Email	Joanna.W	/atson@nih.gov							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	05-Jun-20	)24 , 05-Oct-2024 , 05-Feb-2025	, 05-Jun-2025 , 05-Oct-2025 , 05-Fe	eb-2026 , 05-Ji	un-2026				
	Synopsis	Through t expand, i through t organoids appropria	Trough this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for projects to spand, improve, or transform the utility of mammalian cancer and tumor models for translational research. The NCI, strough this NOFO encourages submission of projects devoted to demonstrating that mammalian models, including rganoids, tumoroids and cell models, used for translational research are robust representations of human biology, are opropriate to test questions of clinical importance, and provide reliable information for patient benefit. These practical goals							

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	c t c t t	contrast v cancer me cesting, n demonstr mammali cranslatio used tran	with the goals of many mechanis odels, transplantation tumor mo on-clinical research. Among man rations of how to overcome tran an models or their genetics for nal models, test approaches to slationally.	stic, NCI-supported R01 projects odels, or models derived from n ny other possible endeavors, ap islational deficiencies of mamm unexplored translational challer validate and credential models,	s that use mammal nammalian or huma oplicants in respons alian oncology moo nges, advance stand or challenge curre	s, or develop and u an tissues or cells fo e to this NOFO coul lels, define new use lard practices for u nt practices for how	se mammalian or hypothesis- ld propose es of se of v models are
120973	Mechanisms that Impact Cancer Ris Clinical Trial Optional)	<u>sk with U</u>	se of Incretin Mimetics (R01	National Cancer Institute/NIH/DHHS	PAR-23- 279	5-Jun-2024	Not Specified
	Contact Name E Contact Telephone 2 Contact Email Sponsor Website Program URL <u>1</u> Deadline Dates (ALL) 0 i Synopsis i t 1	Edward R 240-276-7 edward.sa .ink to pr 05-Jun-20 Through t nitiated s glucose?c s due to t effect pro cancer bio ncretin m the agent L/GIP-1 R	. Sauter, MD, PhD 7657 auter@nih.gov 0gram URL 024 , 05-Oct-2024 , 05-Feb-2025 this notice of funding opportuni tudies addressing mechanisms lependent insulinotropic polype their reported effects on thyroic file compared to other classes of ology field who may study increa himetics other than GLP-1 RAs o (s) they propose to study are m As. Route of agent administratio	, 05-Jun-2025 , 05-Oct-2025 , 0 ty (NOFO), the National Cancer by which incretin mimetics, spe pide (GIP)-1 receptor agonists ( d, prostate and other cancer rish of incretin mimetics. In addition tin mimetic effects on diseases r GLP-1/GIP-1 RAs, such as dipe ore effective and/or have a more on (oral vs. other) is, by itself, ne	5-Feb-2026 , 05-Jui Institute (NCI) invit cifically glucagon-li RAs), impact cance s, and the generall , this NOFO seeks t other than cancer. ptidyl peptidase (D re favorable side ef ot an adequate just	n-2026 , 05-Oct-202 es applications for ke peptide (GLP)-1 r risk. The focus or y more favorable e o draw in talented s Investigators wishin PP)-4 inhibitors, mu fect profile than GL ification.	26 investigator- or dual GLP-1/ of these agents fficacy and side scientists to the ng to study ust justify why .P-1 or GLP-
109909	Systematic Testing of Radionuclides Clinical Trial Not Allowed)	s in Precl	inical Experiments (STRIPE) (R01	National Cancer Institute/NIH/DHHS	PAR-22- 139	5-Jun-2024	2,500,000 USD
	Contact Name Contact Name Contact Telephone 2 Contact Telephone 2	Vichael G 240-276-7 SP@nih.g	Graham Espey, Ph.D. 7619 <u>ov</u>				



SPIN ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Spon: P Deadline	or Website rogram URL <u>Link to pr</u> Dates (ALL) 05-Jun-20 The purp Synopsis cancer bio therapeu	ogram URL 024 , 05-Oct-2024 , 05-Feb-2025 ose of this Funding Opportunity ology methods and model syster tics (e.g., radiopharmaceutical tl	Announcement (FOA) is to solici ns to study effects of different ty nerapy) on normal tissue, tumor	t R01 research p ypes of radiation cells and the tur	rojects utilizing state used in radionuclide nor microenvironme	-of-the-art -based nt.
120755 Assay Development and or Immunomodulator	nd Screening for Disco s (R01 Clinical Trial No	very of Chemical Probes, Drugs at Allowed)	National Cancer Institute/NIH/DHHS	PAR-23- 264	05-Jun-2024	Not Specified
Co Contact Co Spons Pi Deadline	ntact Name Suzanne I Telephone 240-276- Intact Email forryscs@ Fogram URL Link to pr Dates (ALL) 05-Jun-20 Through 1 discovery probe car this NOF0 implemer 3) hit vali	Forry, Ph.D. 5922 Pmail.nih.gov Ogram URL 024 , 05-Oct-2024 , 05-Feb-2025 this Notice of Funding Opportun r and development of novel, sma ncer biology, to validate cancer t D include: 1) development of the ntation to identify initial screenin dation using a series of assays an	, 05-Jun-2025 , 05-Oct-2025 , 05 ity (NOFO), the National Cancer Ill molecules for cancer. Molecul argets, or as the basis for optimi e primary screen assay(s) and tes ng hits (high throughput target-fo nd initial medicinal chemistry ins	-Feb-2026 , 05-Ju Institute (NCI) in es discovered th zed drugs. Stage ting in an initial p ocused screens, pection to priori	un-2026 tends to stimulate re rough this NOFO may s of discovery resear pilot screen; 2) prima or moderate through tize the hit set.	search in / be used to ch covered by ry screen put screens);
120756 Understanding Expect Trial Required)	ancies in Cancer Symp	otom Management (R01 Clinical	National Cancer Institute/NIH/DHHS	PAR-23- 273	05-Jun-2024	Not Specified
Co Contact Co Spons Pi Doadlino	ntact Name Rebecca I Telephone 240-276-0 Intact Email <u>ferrerra@</u> For Website Fogram URL <u>Link to pr</u>	Ferrer 6914 <u>Omail.nih.gov</u> <u>ogram URL</u> 024 05-0ct-2024 05-5cb-2025	05-lun-2025 05-0ct-2025 05	-Eeb-2026		

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	This Notic effects oc cancer sit defined ir Expectanc cognitive, held by pa applicatic and beha	ce of Funding Opportunity (NOF ccur in a cancer context, elucidat ces, and contexts in which expec in this context as beliefs about fu cies can be evoked by social, psy , behavioral, and biological outco atients, clinicians, family member ons that enroll individuals and gr vioral research.	O) will solicit mechanistic research t te their role in cancer symptom mar tancy effects can be leveraged to im ture outcomes, including one's resp ychological, environmental, and syst omes caused by expectancies. Exper ers, caregivers, and/or dyadic/social roups from populations historically u	hat aims to unden agement, and ic aprove cancer ou conse to cancer o remic factors. Exp ctancy effects ca networks. Progr underrepresente	erstand how and v lentify patients, sy itcomes. Expectan or cancer treatmen pectancy effects a n be generated by ram is particularly d or excluded fror	why expectancy ymptoms, icies are nt. re the y expectancies interested in n biomedical
110471	Imaging, Biomarkers and Digital P Premetastatic Cancer and Precand Phenotypes (R01 Clinical Trial Opt	athomics f cerous Les :ional)	for the Early Detection of ions Associated with Lethal	National Cancer Institute/NIH/DHHS	PAR-22- 131 05-	Jun-2024	Not Specified
	Contact Name	Sudhir Sri	ivastava, Ph.D., MPH				
	Contact Telephone	240-276-7	7028				
	Contact Email	<u>srivasts@</u>	mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	05-Jun-20	024 , 05-Oct-2024 , 05-Feb-2025	, 05-Jun-2025			
	Synopsis	This Fund imaging, l earliest d demonstr clinical de registered strategies supported Program. identifica positives	ling Opportunity Announcement biomarkers, digital pathomic and etection of premetastatic aggres rate an aggressive phenotype. The ecisions in a technology agnostic d, cross-correlated imaging resu s such as artificial intelligence and d by this FOA will collectively pa The goals of the CIB are to: (1) i tion of lethal cancer versus non- and false negatives.	t (FOA) will support the development d other -omic integration strategies ssive cancer as well as identifying pr his FOA specifically attempts to add manner by improving sensitivity an lts integrated with multiplexed bion ad virtual reality visualization for imp rticipate in the existing Consortium mprove diagnostic performance by lethal disease, (2) to minimize/bett	t of state-of-the for improving cu recancerous lesic ress and improve d specificity of a harker data and proving discovery for Imaging and developing meth er manage overc	-art projects that arrent approaches ons that will subse e diagnostic uncer pplied tests. N-dir digital pathomics of y are encouraged. Biomarkers (CIB) I nodology for the e diagnosis and (3) to	include for the quently tainty in nensional co- using analytic The projects Research arly o reduce false
106546	Clinical Characterization of Cance	r Therapy-	induced Adverse Sequelae and	National Cancer	PAR-21- 05-	Jun-2024	Not

Icahn School of Medicine at Mount Sinai

SPIN ID Progra	am		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Mechan	ism-based Interventional	Strategies	(R01 Clinical Trial Optional)	Institute/NIH/DHHS	329		Specified
	Contact Name	Kelly Filips	ski PhD, MPH				
	Contact Telephone	240-276-6	5841				
	Contact Email	Filipskikk(	@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	05-Jun-20	024 , 05-Oct-2024				
Synopsis Synops							
117334 <u>Clinical</u>	Trial Optional)			Institute/NIH/DHHS	153 05	-Jun-2024	Specified
	Contact Name	Curt Della	Valle, Ph.D., MPH				
	Contact Telephone	240-276-7	7225				
	Contact Email	<u>curt.della</u>	valle@nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	05-Jun-20	024 , 05-Oct-2024 , 05-Feb-202	5 , 05-Jun-2025 , 05-Oct-202	5 , 05-Feb-2026		
	Synopsis	This notic the effect survivorsh knowledg	e of funding opportunity (NOF is of climate change across the nip, and ways to prevent or mi ge of the impact of climate cha	O) aims to support innovativ cancer control continuum, fi tigate negative health effects nge related environmental effects	e research relevant to a rom cancer etiology and s. This includes, but is no fects on cancer risks, co	dvancing the unde d cancer risks throu ot limited to, studie ontrol and behavio	rstanding of Igh es to improve rs.
106356 NCI Trar Indepen	nsition Career Developme Ident Clinical Trial Not Allo	nt Award t owed)	o Promote Diversity (K22	National Cancer Institute/NIH/DHHS	PAR-21- 301 12	-Jun-2024	Not Specified
Icahn School of I	Medicine at		NIH Funding Opport	unities Due: June 2024			18

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Name Contact Telephone Contact Email	Mulualem E. Tilahun, D.V.M., Ph.D 240-276-7360 <u>mulualem.tilahun@nih.gov</u>						
	Sponsor Website Program URL	Link to program URL						
	Deadline Dates (ALL) Synopsis	The purpose of the NCI Transition Career Development Award to Promote Diversity (K22) is to assist postdoctoral fell individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a success biomedical career as an independent research scientist. This Funding Opportunity Announcement (FOA) is a continue the NCI Transition Career Development Award to Promote Diversity (K22) to enhance the diversity in the NCI-funded research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been sho nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This award will provide "prote time" through salary and research support for 3 years beginning at the time when the candidate starts a tenure-track position. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research th not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Ap to this FOA are permitted to propose research experience in a clinical trial led by another investigator. Applicants pro- clinical trial or a separate ancillary clinical trial as lead investigator, should apply to the companion FOA (PAR-21-302						
106358	VCI Transition Career Developme Trial Required)	nt Award to Promote Diversity (K22 Clinica	al National Cancer Institute/NIH/DHHS	PAR-21- 302 12-	Jun-2024	Not Specified		
	Contact Name Contact Telephone Contact Email	Mulualem E. Tilahun, D.V.M., Ph.D 240-276-7360 <u>mulualem.tilahun@nih.gov</u>						
	Sponsor Website Program URL Deadline Dates (ALL)	Link to program URL						
	Synopsis	The purpose of the NCI Transition Career individuals in equivalent positions to tran biomedical career as an independent reso the NCI Transition Career Development A	Development Award to Promot sition to positions of assistant p earch scientist. This Funding Opp ward to Promote Diversity (K22)	e Diversity (K22) is to rofessor or equivale portunity Announcer ) to enhance the div	o assist postdocto nt and initiate a s ment (FOA) is a co ersity in the NCI-f	oral fellows or uccessful ontinuation of unded cancer		

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	research workforce by supporting eligible nationally underrepresented in the biom time" through salary and research suppo position. This Funding Opportunity Anno investigator of an independent clinical tri research and career development. Applic experience in a clinical trial led by anothe			e individuals from diverse backgr edical, behavioral, social and clir rt for 3 years beginning at the tir uncement (FOA) is designed spe al, a clinical trial feasibility study ants not planning an independe er investigator, must apply to co	rounds, including gr nical sciences. This a me when the candic cifically for applicar /, or a separate anci nt clinical trial, or p mpanion FOA (PAR-	oups that have be award will provide date starts a tenur its proposing to se illary clinical trial, a roposing to gain re 21-301).	en shown to be "protected e-track faculty rve as the lead as part of their esearch
106354	NCI Mentored Clinical Scientist Res Promote Diversity (K08 Clinical Tria	search Ca al Require	reer Development Award to ed)	National Cancer Institute/NIH/DHHS	PAR-21- 299 12	-Jun-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Mulualen 240-276- <u>mulualen</u> Link to pr 12-Jun-20	n E. Tilahun, D.V.M., Ph.D 7360 <u>n.tilahun@nih.gov</u> ogram URL 124				
	Synopsis	The purpe careers the continuate degree or fields of the designed diverse base and for the research of and for the research of and trainic compete designed feasibility planning a must app	bese of the NCI Mentored Clinica nat have a significant impact on ion of a long-standing NIH progra- a health professional doctoral of iomedical and behavioral resea to enhance the diversity in the l ackgrounds, including groups the ose who are committed to a ca on cancer health disparities. The ng, awardees will develop enha for research project grants (e.g. specifically for applicants propo study, or a separate ancillary cl an independent clinical trial, or ly to companion FOA (PAR-21-3)	Scientist Career Development A the health-related research nee ram that provides support and p degree for an intensive, supervis rch, including translational resea NCI-funded cancer research wor at have been shown to be nation reer in basic biomedical, behavio e expectation is that through this nced research capabilities for ca R03, R21, or R01) funding. This sing to serve as the lead investig inical trial, as part of their resea proposing to gain research expe 00).	Award (K08) progra ds of the nation. The protected time to in sed research career arch. This NCI-spons kforce by supportin nally underrepreser oral or translational s sustained period of incer research career Funding Opportuni gator of an indepen rch and career deven	m is to prepare inc is program represe dividuals with a cli development expe sored K08 award is ne eligible clinical s nted in health-relat cancer research, i of research career ers and be better p ity Announcement dent clinical trial, a elopment. Applicar rial led by another	dividuals for ents the nical doctoral erience in the specifically cientists from ted sciences ncluding development orepared to (FOA) is a clinical trial nts not investigator,

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
106355	NCI Mentored Clinical Scientist Research Promote Diversity (K08 - Independent Cl	Career Development Award to nical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-21- 300 12	-Jun-2024	Not Specified
	Contact Name Mulua	lem E. Tilahun, D.V.M., Ph.D				
	Contact Telephone 240-2	/6-7360				
	Contact Email <u>mulua</u>	lem.tilahun@nih.gov				
	Sponsor Website					
	Program URL Link to	program URL				
	Deadline Dates (ALL) 12-Jur	-2024				
The purpose of the NCI Mentored Clinical Scientist Career Development Award (K08) program is to prepare individuals for careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doct degree or a health professional doctoral degree for an intensive, supervised research career development experience in fields of biomedical and behavioral research, including translational research. This NCI-sponsored K08 award is specifica designed to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible clinical scientists f diverse backgrounds, including groups that have been shown to be nationally underrepresented in health-related science synopsis and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career developm and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared t compete for research project grants (e.g. R03, R21, or R01) funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinic trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research exper in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or a separate ancillary clinical trial as invorting trial develop amentor or too-mentor. Applicants proposing a clinical trial or a separate ancillary clinical trial as invorting the company for Q4 (Q4B 21 200).						
106228	NCI Mentored Research Scientist Develo (K01 Independent Clinical Trial Not Allow	oment Award to Promote Diversity ed)	<u>v</u> National Cancer Institute/NIH/DHHS	PAR-21- 295	-Jun-2024	Not Specified
	Contact Name Mulua Contact Telephone 240-2	lem E. Tilahun, D.V.M., Ph.D 76-7360				

Contact Email mulualem.tilahun@nih.gov

Sponsor Website

Program URL Link to program URL

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	12-Jun-20 This Fund Award to eligible in the biome of "protec designed trial feasil in a clinica investigat	24 , 12-Oct-2024 ing Opportunity Announcement Promote Diversity (K01) to enha dividuals from diverse backgrou edical, behavioral, social and clir cted time" for intensive research specifically for applicants propo bility study, or a separate ancilla al trial led by a mentor or co-me or, should apply to the compan	t (FOA) is a continuation of the NCI I ance the diversity in the NCI-funded inds, including groups that have bee nical sciences. This FOA provides sal in career development under the gui sing research that does not involve ary clinical trial. Applicants to this FO entor. Applicants proposing a clinica ion FOA.	Mentored Resea cancer research en shown to be r ary and research dance of an exp leading an indep DA are permitteo I trial or a separa	rch Scientist Devel workforce by sup ationally underrep support for a sust erienced mentor. T bendent clinical tria to propose reseau te ancillary clinica	opment porting presented in tained period This FOA is al, a clinical rch experience I trial as lead
106230	NCI Mentored Research Scientist D K01 Clinical Trial Required)	Developm	ent Award to Promote Diversity	National Cancer Institute/NIH/DHHS	PAR-21- 296 12-	Jun-2024	Not Specified
	Contact Name	Mulualem	n E. Tilahun, D.V.M., Ph.D				
	Contact Telephone	240-276-7	7360				
	Contact Email	<u>mulualem</u>	n.tilahun@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	12-Jun-20	24 , 12-Oct-2024				
	This Funding Opportunity Announcement (FOA) is a continuation of the NCI Mentored Research Scientist Development Award to Promote Diversity (K01) to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA.						
115286 F	Notice of Special Interest (NOSI): C Research Within the Mission of the National Cancer Institute	Career Dev e Division	velopment Opportunities for of Cancer Prevention at the	National Cancer Institute/NIH/DHHS	NOT-CA- 23-035 07-	May-2024	Not Specified



SPIN ID	Program Title	Spons	sor Name	Sponsor Number		Deadline Date	Funding Amount	
	Contract Norma							
	Contact Name	Jessica Faupei-B	Badger					
		240-276-7296						
	Contact Email	Jessica.Faupei-B	<u>sadger@nin.gov</u>					
	Sponsor Website							
	Program URL	Link to program	<u>1 URL</u>	42.0.1.2024				
	Deadline Dates (ALL)	07-May-2024, 1	12-Jun-2024 , 07-Sep-2024	, 12-Oct-2024				
	Synopsis This NOSI from the NCI expresses continued interest in receiving Career Development Award applications from e scientists conducting research within the mission of the Division of Cancer Prevention.						early career	
106722	Notice of Special Interest (NOSI):	Dietary Effects o	n Nutrient Sensing	National Cancer	NOT-CA-	7 May 2024	Not	
100755	Pathways in Tumor Etiology and F	Prevention		Institute/NIH/DHHS	21-121	-1v1dy-2024	Specified	
	Contact Name	Phillip J. Daschn	ner, MSc					
	Contact Telephone	240-276-6227						
	Contact Email	pd93u@nih.gov	<u>/</u>					
	Sponsor Website							
	Program URL	Link to program	1 URL					
	Deadline Dates (ALL)	07-May-2024 , (	05-Jun-2024 , 12-Jun-2024	, 25-Jun-2024 , 07-Sep-2024				
	Synopsis	Synopsis Synopsis The biology and molecular mechanisms that determine the outcome of key diet/nutrient/cell interactions during early tumor development. Specifically, studies that examine the tumor preventive or tumor-promoting effects of dietary modulation of nutrient sensor signaling pathways during early tumor formation (initiation and malignant progression fro early lesions) in preclinical cell, organoid, and animal models, with the goal of identifying and testing potential molecular intervention targets.						
106036	Notice of Special Interest (NOSI): . Activated Small Molecules	Advancing the Do	evelopment of Tumor Site	<ul> <li>National Cancer Institute/NIH/DHHS</li> </ul>	NOT-CA- 21-101 0	7-May-2024	Not Specified	
	Contact Name	Sharad K. Verma	a, PhD					
	Contact Telephone	202-657-3694						
	Contact Email	sharad.verma@	nih.gov					
	Sponsor Website							

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Program URL Deadline Dates (ALL) Synopsis	Link to pro 07-May-20 This Notic (DCTD) to and biolog profiles fo	ogram URL 024 , 16-Jun-2024 , 07-Sep-202 e of Special Interest (NOSI) see support investigation of the de gy disciplines to support the dis r eventual translation to the cli	4 ks to highlight the interest of NC evelopment of novel therapies fo covery and testing of novel ther nic.	Cl's Division of Cance or cancer-applied re apeutics offering in	er Treatment and I search encompass iproved safety and	Diagnosis ing chemistry efficacy
114550	NCI Small Grants Program for Can 2025 (NCI Omnibus) (R03 Clinical	cer Resear Trial Optio	ch for Years 2023, 2024, and nal)	National Cancer Institute/NIH/DHHS	PAR-23- 058 07	-May-2024	100,000 USD
	Contact Name						
	Contact Telephone						
	Contact Email						
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	07-May-20 2025 , 17-	024 , 20-Jun-2024 , 07-Sep-202 Oct-2025 , 07-Jan-2026	4 , 17-Oct-2024 , 07-Jan-2025 , 2	24-Feb-2025 , 07-Ma	ay-2025 , 20-Jun-20	)25 , 07-Sep-
	Synopsis	This funding period of the feasibility methodole	ng opportunity announcement time with limited resources. Th studies; secondary analysis of e ogy; and development of new r	(FOA) supports small research p e RO3 grant mechanism support existing data; small, self-containe research technology.	projects on cancer t s different types of ed research project	nat can be carried o projects including s; development of	out in a short pilot and research
122281	Assay Validation of High Quality N (UH2/UH3 Clinical Trial Not Allowe	<u>1arkers for</u> ed)	Clinical Studies in Cancer	National Cancer Institute/NIH/DHHS	PAR-23- 313 10	-Jun-2024	Not Specified
	Contact Name	Tracy G. L	ively, Ph.D.				
	Contact Telephone	240-276-5	944				
	Contact Email	<u>livelyt@m</u>	ail.nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	10-Jun-20	24 , 08-Oct-2024 , 14-Feb-2025	, 11-Jun-2025 , 15-Oct-2025 , 13	3-Feb-2026 , 10-Jun	-2026 , 14-Oct-202	6
	Synopsis	Through t	his Notice of Funding Opportur	ity (NOFO), the National Cancer	Institute (NCI) invit	es applications to	support the

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount

validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH2 phase of this NOFO supports analytical validation of assays for these molecular/cellular/imaging markers, which must be achieved within 2 years before assavs may undergo clinical validation. The UH3 phase of this NOFO supports clinical validation of analytically validated assays for up to 3 years using well-annotated biospecimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other cancer clinical trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays. Investigators responding to this NOFO must address both UH2 and UH3 phases. Milestones to be accomplished in the UH2 phase for transition to the UH3 phase must be proposed by the investigators.

122288	Assay Validation of High Quality N Clinical Trials Not Allowed)	Narkers for Clinical Studies in Cancer (UH3	National Cancer Institute/NIH/DHHS	PAR-23- 314	10-Jun-2024	750,000 USD
	Contact Name	Tracy G. Lively, Ph.D.				
	Contact Telephone Contact Email					
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	10-Jun-2024 , 08-Oct-2024 , 14-Feb-2025 ,	11-Jun-2025 , 15-Oct-2025 , 13-Fe	b-2026 , 10	-Jun-2026 , 14-Oct-2026	
	Synopsis	Through this Notice of Funding Opportunit and validation of molecular/cellular/imagir detection, diagnosis, prognosis, monitoring cancer prevention and control. This NOFO	y (NOFO), the National Cancer Inst ng markers (referred to as "marker g, and prediction of response or re will also support the validation of p	titute (NCI) s" or "biom sistance to pharmacod	intends to accelerate the arkers") and assays for ca treatment, as well as mar ynamic markers and mark	adoption ncer kers for ers of

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		toxicity. A similar to increasing multiple r support t clinical tri populatio reproduci proposed statisticia the condu trials/stud	Applicants to this NOFO must ha those for the intended clinical u gly combined with immunothera markers, including immune mar he clinical validation of establish fals or studies. This NOFO may b on studies. Efforts to harmonize ibility of assays across multiple of for this NOFO will require mult ns, and clinical laboratory scien uct of clinical trials but is intended dies as investigational assays.	ve an assay(s) whose performance use of the marker(s) and assay(s). A apies to enhance the durability of a kers, can be developed and validate ned assays for up to 3 years using s e used to validate existing assays for clinical laboratory tests, including i clinical laboratories, are also appro idisciplinary interaction and collabo tists. This NOFO is not intended to ed for validation of assays to the po	has been analyti as chemotherapie onti-cancer respo ed simultaneous pecimens from re or use in other tr nvestigation into priate for this fun pration among so support early-sta pint where they o	cally validated in s es and/or radiation nses, assays for mo y. The UH3 mecha etrospective or pro ials, observational the performance nding opportunity. ientific investigato ge development o could be integrated	pecimens therapies are easuring nism will spective studies, or and Projects ors, oncologists, f technology or d into clinical
112021	Cancer Prevention and Control Cli Clinical Trials Optional)	inical Trial	s Planning Grant Program (U34	National Cancer Institute/NIH/DHHS	PAR-22- 174 07	-May-2024	Not Specified
	Contact Name	Brandy H	eckman-Stoddard, Ph.D., M.P.H				
	Contact Telephone	240-276-7	7048				
	Contact Email	<u>heckman</u>	bm@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	.024 , 25-Jun-2024 , 07-Sep-2024	4 , 25-Oct-2024 , 07-Jan-2025 , 25-I	eb-2025 , 07-Ma	ay-2025 , 25-Jun-20	)25
	Synopsis	clinical tri health be care, and rationale challenge protocol o the need trial desig intervent include a	this Funding Opportunity Annou ials across the cancer prevention haviors, screening, early detect the long-term outcomes of can for conducting a clinical trial, in s, intervention, outcome/ endp completely. These information g for additional time and expense gns, which minimize infrastructu ion, at-risk group, symptom or v pilot/feasibility clinical trial if ne	ncement (FOA), the National Cancer n and control spectrum aimed at in on, healthcare delivery, manageme cer survivors. Although the scientif vestigators often lack critical inforr pints, data/statistical challenges or gaps can result in multiple protocol tes that may prevent study completi re and reduce costs may need to b renue. Preparatory studies may fill ecessary, improving trial design and	er Institute (NCI) nproving prevent ent of treatment ic literature or pr nation about the operational risk changes before on. Further, the e tested in the co information gaps d rigor.	Intends to facilitat ion/ interception, -related symptoms reliminary data ma study population, s necessary to final and after trial start suitability and feas ontext of a particul s and address unkn	e well planned cancer-related ;, supportive y provide the accrual lize the trial :-up, leading to ibility of new ar iowns this can

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
112019	Cancer Prevention and Control Cli Clinical Trials Optional)	nical Trials	Planning Grant Program (R34	National Cancer Institute/NIH/DHHS	PAR-22- 173 07	-May-2024	Not Specified
	Contact Name	Brandy He	eckman-Stoddard, Ph.D., M.P.H				
	Contact Telephone	240-276-7	7048				
	Contact Email	<u>heckman</u> l	om@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	024 , 25-Jun-2024 , 07-Sep-202	4, 25-Oct-2024, 07-Jan-2025, 25-Fe	eb-2025 , 07-Ma	ay-2025 , 25-Jun-20	025
Synopsis challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, le the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns include a pilot/feasibility clinical trial if necessary. improving trial design and rigor.							cancer-related s, supportive ay provide the accrual lize the trial t-up, leading to sibility of new lar
123943	The NCI Transition Career Develop Trial Optional)	oment Awa	ard (K22 - Independent Clinical	National Cancer Institute/NIH/DHHS	PAR-24- 117 12	-Jun-2024	450,000 USD
	Contact Name	Sonia B. J	akowlew, Ph.D.				
	Contact Telephone	240-276-5	5630				
	Contact Email	jakowles@	@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	12-Jun-20 2025 , 12-	24 , 12-Oct-2024 , 12-Nov-2024 Feb-2026 , 12-Mar-2026 , 12-Ju	l , 12-Feb-2025 , 12-Mar-2025 , 12-J in-2026 , 12-Jul-2026 , 12-Oct-2026	un-2025 , 12-Jul , 12-Nov-2026 ,	-2025 , 12-Oct-202 12-Feb-2027 , 12-	25 , 12-Nov- Mar-2027
	Synopsis	This Fund	ing Opportunity Announcemen	t (FOA) represents the continuation	of an NCI progr	am to facilitate the	e transition of

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
		investigat goal is acl independ faculty pc trial, a clin	fors in mentored, non-independ nieved by providing protected ti ent tenure-track faculty positior osition. This FOA is designed spe nical trial feasibility study, or an	ent cancer research positions to inc me through salary and research sup n, or its equivalent, beginning at the cifically for candidates proposing re ancillary clinical trial is optional and	dependent facul oport for the ini- e time when the search in which d replaces both	ty cancer research tial 3 years of the fi candidate starts a leading an indepe PAR-21-128 and PA	positions. This irst tenure-track ndent clinical \R-21-111.		
112622 Biology of Bladder Cancer (R21 Clinical Trial Optional)			Optional)	National Cancer Institute/NIH/DHHS	PAR-22- 219 16	-Jun-2024	275,000 USD		
	Contact Name	Ron Johns	son, Ph. D.						
	Contact Telephone	240-276-6	5250						
	Contact Email	rjohnso2(	@mail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	16-Jun-20	024 , 16-Oct-2024 , 16-Feb-2025	, 16-Jun-2025					
	Synopsis	This Funding Opportunity Announcement (FOA) encourages applications that investigate the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression and malignancy of bladder cancer. Furthermore, our understanding of the biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and contribute to the future development of new interventions.							
106319	Utilizing the PLCO Biospecimens F and Early Detection Research (UO	Resource to 1 Clinical T	o Bridge Gaps in Cancer Etiology Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-21- 330 11	-Jun-2024	Not Specified		
	Contact Name	Claire Zhu	ı, Ph.D.						
	Contact Telephone	240-276-7	7013						
	Contact Email	<u>zhucla@n</u>	nail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	11-Jun-20	024 , 11-Oct-2024						

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Synopsis	Through application the unique Trial. The screened Available clinical dat analyses involve us character Alzheime do not inv	this Funding Opportunity Annou ons that propose to advance result propository resources of the PLCO Biorepository offers high- arm participants, and a onetime data associated with the biospe ata. This FOA supports a wide ra of cancer risk, as well as discove se of PLCO biospecimens and ma ristics of the PLCO biospecimens r's, depression, hip fracture, ost wolve the use of PLCO biospecimens	ncement (FOA), the National Cance earch in cancer etiology and early d e NCI-sponsored Prostate, Lung, Col quality, prospectively collected, ser e collection of buccal cells from bot cimens includes demographic, diet nge of cancer research including, bu ry and validation of early detection ay include other resources; additior . Research on non-cancer outcomes eoporosis and rheumatoid arthritis itens will not be supported under th	er Institute (NCI) etection biomar orectal, and Ova ial pre-diagnost h the screened a , lifestyle, smoki ut not limited to biomarkers. The biomarkers. The hally, it should a s, especially thos ) may also be su is FOA.	encourages the su kers, utilizing the a arian Cancer (PLCO ic blood samples fr and the control arn ng, screening resu , biochemical and g e proposed researc lso take advantage se related to aging pported. Research	bmission of idvantages of ) Screening fom the PLCO n participants. ts, and other genetic th project must of the unique (e.g., projects that		
109910	Systematic Testing of Radionuclid Clinical Trial Not Allowed)	<u>es in Precl</u>	inical Experiments (STRIPE) (R21	National Cancer Institute/NIH/DHHS	PAR-22- 140	-Jun-2024	275,000 USD		
	Contact Name	Michael G	Graham Espey, Ph.D.						
	Contact Telephone	240-276-	40-276-7619						
	Contact Email	<u>SP@nih.g</u>	<u>OV</u>						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	16-Jun-20	)24 , 16-Oct-2024 , 16-Feb-2025						
	Synopsis	The purpe cancer bio therapeu	ose of this Funding Opportunity ology methods and model syste tics (e.g., radiopharmaceutical t	Announcement (FOA) is to solicit R ms to study effects of different type herapy) on normal tissue, tumor ce	21 research pro es of radiation u lls and the tume	jects utilizing state sed in radionuclide or microenvironme	-of-the-art -based nt.		
114679	Co-infection and Cancer (R21 Clin	ical Trial N	lot Allowed)	National Cancer Institute/NIH/DHHS	PAR-23- 056 16	-Jun-2024	275,000 USD		
	Contact Name	Tram Kim	Lam, Ph.D., MPH						
	Contact Telephone	240-276-	6967						
	Contact Email	lamt@ma	ail.nih.gov						
	Sponsor Website								

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Program URL Deadline Dates (ALL) Synopsis	Link to pr 16-Jun-20 The purpo addressin inform pr infections includes to given to in co-infecti	ogram URL 124 , 16-Oct-2024 , 16-Feb-2025 ose of this Funding Opportunity g the roles of co-infection and c evention and treatment strateg by two or more infectious (path both acute and chronic infection nvestigations of co-infections wi ons that engender novel opport	, 16-Jun-2025 , 16-Oct-2025 Announcement (FOA) is to enhance ancer to shed light on presently un tes for infection-related cancers. Co nogenic or non-pathogenic) agents s by viruses, bacteria, parasites, and th known oncogenic agents (excluc unities for prevention and treatme	e mechanistic and established path p-infection is defi – either concurre d/or other micro ling human immunt.	d epidemiologic in ways in carcinoger ned as the occurre ently or sequentia organisms. Prefere unodeficiency viru	vestigations nesis that may ence of Ily – and ence will be s [HIV]) and of
121014	Mechanisms that Impact Cancer R Clinical Trial Not Allowed)	isk with U	se of Incretin Mimetics (R21	National Cancer Institute/NIH/DHHS	PAR-23- 280 16-	Jun-2024	275,000 USD
Contact NameEdward R. Sauter, MD, PhDContact Telephone240-276-7657Contact Emailedward.sauter@nih.govSponsor WebsiteProgram URLDeadline Dates (ALL)Link to program URLDeadline Dates (ALL)16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investSynopsisInitiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or duJglucose-dependent insulinotropic polypeptide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on thagents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorableand side effect profile compared to other classes of incretin mimetics. In addition, this NOFO seeks to draw in talenscientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer							6 nvestigator- or dual GLP- on these rable efficacy alented
111848 <mark> </mark>	nnovative Approaches to Studyin nformation Ecosystem (R21 Clinic	g Cancer ( cal Trial Op	Communication in the New otional)	National Cancer Institute/NIH/DHHS	PAR-22- 165	Jun-2024	275,000 USD
-4	Contact Name Contact Telephone Contact Email Sponsor Website	Kelly D. B 240-281-5 <u>kelly.blak</u>	lake, ScD 5934 <u>e@nih.gov</u>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Program URL Deadline Dates (ALL)	<u>Link to program URL</u> 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025	, 16-Jun-2025			
	Synopsis	hrough this Funding Opportunity Annour supporting meritorious research projects application of new cancer communication communication pilot interventions using cancer communication models emphasiz communication science approaches to th prevention and control. Applications sho	ncement (FOA), the National Cance in three distinct domains related t n surveillance approaches; 2) the d innovative methods and designs; a ing bidirectional influence betweer he investigation of behavioral targe uld utilize one or more innovative o	r Institute (NCI) a o cancer communevelopment and f nd 3) the develop nevels. For such ts and health outo communication re	nnounces its interentication: 1) the util sesting of rapid car oment and testing projects, applicant comes related to c esearch methodolo	est in ity and ncer of multilevel s should apply ancer ogies.
111860	Precision Approaches in Radiation Clinical Trial Optional)	Synthetic Combinations (PAIRS, R21	National Cancer Institute/NIH/DHHS	PAR-22- 199 16-	Jun-2024	275,000 USD
	Contact Name	Michael Graham Espey, Ph.D.				
	Contact Telephone	240-276-5609				
	Contact Email	<u>SP@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025	, 16-Jun-2025			
	Synopsis	Through this Funding Opportunity Annou that seek to investigate actionable synthe therapy. The goal of the Precision Approa synthetic combination strategies and faci effective anticancer treatments.	incement (FOA), the National Canc etic vulnerabilities that can be conc aches in Radiation Synthetic Combi ilitate their adoption into the precis	er Institute (NCI) : litionally paired w nations (PAIRS) p sion medicine toc	solicits R21 researd vith tumor respons rogram is to develo Ikit toward buildin	ch projects ses to radiation op radiation- ng new and
122437	NCI Pathway to Independence Awa Researchers (K99/R00 - Independe Humans Required)	ard for Early-Stage Postdoctoral ent Basic Experimental Studies with	National Cancer Institute/NIH/DHHS	PAR-23- 288 14-	Jun-2024	Not Specified
	Contact Name	Sergey Radaev, PhD				
	Contact Telephone	240-276-5630				
	Contact Email	<u>sradaev@mail.nih.gov</u>				
	Sponsor Website					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Deadline Dates (ALL) 14-Jun-2024, 15-Oct-2024, 14-Feb-2025, 16-Jun-2025, 14-Oct-2025, 1 The purpose of the NCI Pathway to Independence Award for Early-Stage increase and maintain a strong cohort of new and talented, NCI-supported designed for postdoctoral fellows with research and/or clinical doctoral of mentored research training beyond their doctoral degrees. The objective these fellows from their mentored, postdoctoral research positions to in positions. The program will provide independent NCI research support di competitive, independent research careers. Researchers in the scientific cancer data sciences are especially encouraged to work with their institu (NOFO) is designed specifically for candidates proposing to serve as the l clinical trial feasibility study, or a separate ancillary clinical trial, as part o planning an independent clinical trial, or proposing to gain research exper must apply to companion NOFO (PAR-23-286). This Notice of Funding Op involving humans, referred to in NOT-OD-18-212 as "prospective basics studies fall within the NIH definition of a clinical trial and also meet the c should be submitted under this NOFO include studies that prospectively experimentally manipulate independent variables) and that assess biomend purpose of understanding the fundamental aspects of phenomena with products in mind. Applicants not planning an independent clinical trial or to gain research experience in a clinical trial or basic experimental study to the 'Independent Clinical Trial Not Allowed' companion NOFO. The pri interests of one or more of the participating NIH Institutes and Centers (					2026 , 14-Oct-202 chers (K99/R00) p estigators. This pro- require an extend acilitate a timely t tack (or equivalent to help awardees rol, cancer prever lotice of Funding of n independent clin career developme ial led by another c science experime ng human particip earch. Types of st pants to condition butcomes in human on towards proces study with human another investigat be related to the cientific missions.	6 rogram is to ogram is ed period of ransition of :) faculty aunch ition and Opportunity nical trial, a ent. Those not investigator, ental studies bants." These udies that ns (i.e., ins for the ses or is, or proposing tor, must apply programmatic
122436	NCI Pathway to Independence Award fo Researchers (K99/R00 - Independent Clin	Early-Stage Postdoctoral ical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-23- 287 14-	Jun-2024	Not Specified
	Contact Name Serger Contact Telephone 240-2 Contact Email sradad Sponsor Website Program URL Link to Deadline Dates (ALL) 14-Jur	Radaev, PhD 76-5630 w@mail.nih.gov program URL -2024 , 15-Oct-2024 , 14-Feb-2025	5 , 16-Jun-2025 , 14-Oct-2025 , 17-Fe	eb-2026 , 15-Jun-	2026 , 14-Oct-202	:6

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	i Synopsis G G F r	The purpo increase a designed mentorec these fello positions. competiti cancer da (NOFO) is clinical tri planning a must app	ose of the NCI Pathway to Indep and maintain a strong cohort of for postdoctoral fellows with re d research training beyond their ows from their mentored, posto . The program will provide indep ve, independent research caree ta sciences are especially encou designed specifically for candid al feasibility study, or a separate an independent clinical trial, or ly to companion NOFO (PAR-23-	endence Award for Early-Stage Pos new and talented, NCI-supported, search and/or clinical doctoral deg doctoral degrees. The objective of loctoral research positions to indep bendent NCI research support durir rs. Researchers in the scientific are traged to work with their institution lates proposing to serve as the lead e ancillary clinical trial, as part of th proposing to gain research experien -286).	stdoctoral Resear independent inve rees who do not this award is to f pendent tenure-to ag this transition as of cancer cont is to apply. This r investigator of a eir research and nce in a clinical tr	chers (K99/R00) p estigators. This pro require an extende acilitate a timely t rack (or equivalent to help awardees l rol, cancer preven notice of funding o n independent clin career developme ial led by another	rogram is to ogram is ed period of ransition of c) faculty launch ition and opportunity nical trial, a ent. Those not investigator,
122435	NCI Pathway to Independence Awa Researchers (K99/R00 - Independe	ard for Ea Int Clinica	rly-Stage Postdoctoral I Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-23- 286 14-	Jun-2024	Not Specified
	Contact Name	Sergey Ra	idaev, PhD				
	Contact Telephone	240-276-5	5630				
	Contact Email	<u>sradaev@</u>	omail.nih.gov				
	Sponsor Website						
	Program URL <u>I</u>	<u>Link to pr</u>	ogram URL				
	Deadline Dates (ALL)	14-Jun-20	)24 , 15-Oct-2024 , 14-Feb-2025	, 16-Jun-2025 , 14-Oct-2025 , 17-Fe	eb-2026 , 15-Jun-	2026 , 14-Oct-202	6
The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. This Notice of Funding Opportur (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO candidates are permitted to propose a researc experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as I							rogram is to ogram is ed period of ransition of t) faculty to launch otion and Opportunity t clinical trial, a a research trial as lead

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	investigator, should apply to the companion NOFOs (PAR-23-287 or PAR-23-288).								
108550	Epidemiologic Research on Emerg Susceptibility (R21 Clinical Trial No	ing Risk Fa ot Allowed	actors and Liver Cancer )	National Cancer Institute/NIH/DHHS	PAR-22- 084	16-Jun-2024	275,000 USD		
	Contact Name Contact Telephone	Tram Kim 240-276-6	Lam, Ph.D., MPH 5967						
	Contact Email Sponsor Website	Tram.Lam	<u>1@nih.gov</u>						
	Program URL Deadline Dates (ALL)	<u>Link to pr</u> 16-Jun-20	<u>ogram URL</u> )24 , 16-Oct-2024 , 16-Feb-2025						
	Synopsis	The purpo innovative risk factor histologic	ose of this Funding Opportunity e hypotheses on emerging risk f rs (e.g., viral hepatitis) associate al subtypes) in the United State	Announcement (FOA) is to promot actors (biological, environmental, a d with the development of liver car s.	e epidemiolo nd social) an ncer (hepatoo	ogic research investiga Id their interplay with cellular carcinoma and	ting novel and established I other		
108359	Exploratory/Developmental Bioer Clinical Trial Optional)	Igineering	Research Grants (EBRG) (R21	National Cancer Institute/NIH/DHHS	PAR-22- 091	16-Jun-2024	275,000 USD		
	Contact Name	Miguel R.	Ossandon, Ph.D.						
	Contact Telephone	240-276-5	5714						
	Contact Email	<u>ossandor</u>	n@mail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	16-Jun-20	024 , 16-Oct-2024						
	Synopsis	The purpo explorato utility of r problems clinical tri trials in an	ose of this engineering-oriented ry/developmental Bioengineeri new capabilities or improvemen in basic biomedical, pre-clinical als that test functionality or vali ny area of cancer research are n	funding opportunity announcemer ng Research Grant (EBRG) application ts in quality, speed, efficacy, operal , or clinical research, clinical care do idate performance in the chosen se not sought by and will not be support	nt (FOA) is to ons to demon pility, costs, a elivery, or ac tting. Applica rted through	encourage submission nstrate feasibility and and/or accessibility of cessibility. This FOA w ations that propose ph this FOA	ns of potential solutions to vill support ase III clinical		
110931	Notice of Special Interest (NOSI):	Basic Mecl	hanisms of Cannabis and	National Cancer	NOT-CA-	07-May-2024	Not		



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
	Cannabinoid Action in Cancer		Institute/NIH/DHHS	22-085		Specified				
	Contact Name	Ron Johnson, Ph.D.								
	Contact Telephone	240-276-6250								
	Contact Email	rjohnso2@mail.nih.gov								
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Oct-2024 , 12-Oct- 2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16- Deadline Dates (ALL) Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 12-Feb-2026 , 16-Feb-2026 , 07-Jan-2026 , 07-May-2026 , 05-Jun-2026 , 12-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 12-Oct-2026 , 07-Jan- 2027 , 05-Feb-2027 , 12-Feb-2027 , 16-Feb-2027 , 07-May-2027								
	The purpose of this Notice of Special Interest (NOSI) is to promote research in understanding the mechanisms by which Synopsis cannabis and cannabinoids affect cancer biology, cancer interception, cancer treatment and resistance, and management cancer symptoms.									
115117	Notice of Special Interest (NOSI): A	Adaptive Biomaterials for Cancer Biology	National Cancer Institute/NIH/DHHS	NOT-CA- 23-030 07-	May-2024	Not Specified				
	Contact Name	Eric M. Johnson Chavarria, Ph.D.								
	Contact Telephone	240-276-7416								
	Contact Email	eric.johnsonchavarria@nih.gov								
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 12-Jun-2024 2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Fe	¥ , 16-Jun-2024 , 07-Sep-2024 , 05-C b-2025 , 07-May-2025	oct-2024 , 12-Oct	-2024 , 16-Oct-202	4 , 07-Jan-				
	The purpose of this Notice of Special Interest (NOSI) is to promote research focused on the development, adaptation, or Synopsis integration of innovative biomaterials for cancer biology. The applications of these new materials are expected to enable insights into basic cancer research.									
107222	Modulating Human Microbiome F Against Cancer (R21 Clinical Trial N	unction to Enhance Immune Responses Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-22- 062 16-	Jun-2024	275,000 USD				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Name	Phillin I C	aschner M Sc						
	Contact Telephone	240-276-6	5227						
	Contact Email	PD93u@r	ih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	s (ALL) 16-Jun-2024 . 16-Oct-2024							
	Synopsis	The purpo which the targets fo microbes sporadic t effectiver	The purpose of this Funding Opportunity Announcement (FOA) is to support basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumor immune responses, and to identify potential novel molecular cargets for cancer prevention strategies. Applications should be focused on delineating how host interactions with specific microbes (or consortia) or their metabolites target immune responses that enhance or prevent inflammation-associated or sporadic tumor formation. Concentration, timing, and duration of administered beneficial microbes may alter their effectiveness and thus those parameters should be rigorously addressed in the application.						
117338 <mark>  </mark> 	mpacts of climate change across rial Optional)	<u>the cancer</u>	control continuum (R21 Clinica	al National Cancer Institute/NIH/DHHS	PAR-23- 152 16-	Jun-2024	275,000 USD		
	Contact Name	Curt Della	Valle, Ph.D., MPH						
	Contact Telephone	240-276-7	/225						
	Contact Email	<u>curt.della</u>	valle@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	16-Jun-20	24 , 16-Oct-2024 , 16-Feb-2025	, 16-Jun-2025 , 16-Oct-2025 , 16-Fe	b-2026				
	Synopsis	This Notice of Funding Opportunity (NOFO) aims to support innovative research relevant to advancing the understanding of the effects of climate change across the cancer control continuum, from cancer etiology and cancer risks through survivorship, and ways to prevent or mitigate negative health effects. This includes, but is not limited to, studies to improve knowledge of the impact of climate change related environmental effects on cancer risks, control and behaviors.							
117714 📐	lotice of Special Interest (NOSI):	RNA Modit	fications in Cancer Biology	National Cancer Institute/NIH/DHHS	NOT-CA- 23-060 07-	May-2024	Not Specified		

Contact Name Stefan Maas, Ph.D. Contact Telephone 240-276-6230

Icahn School of Medicine at Mount Sinai
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Contact Email	<u>stefan.maas@nih.gov</u>							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 05-Jun-202 2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Fe Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 2	24 , 12-Jun-2024 , 16-Jun-2024 , 07-5 2b-2025 , 12-Feb-2025 , 16-Feb-202 12-Oct-2025 , 16-Oct-2025 , 07-Jan-1	Sep-2024 , 05-Oct 5 , 07-May-2025 , 2026	-2024 , 05-Oct-202 , 05-Jun-2025 , 12-	!4 , 12-Oct- Jun-2025 , 16-			
_	Synopsis	Through this Notice of Scientific Interest RNA modifications in the area of cancer substantial impact on gene expression a modifications and their de-regulation as crosstalk between different types of RNA the modification code are needed to rev cancer phenotype.	rough this Notice of Scientific Interest (NOSI), the National Cancer Institute Intends to stimulate research on the role of IA modifications in the area of cancer biology. Despite the recognition that RNA modifications and editing exert a bstantial impact on gene expression and function, there is a lack of mechanistic insights into the dynamic regulation of RNA odifications and their de-regulation as drivers of cancer formation. A better understanding of the extent, diversity, and osstalk between different types of RNA modification, and the elucidation of the molecular players that read and interpret e modification code are needed to reveal the mechanisms of RNA modifications that underlie cancer formation and the ncer phenotype.						
114360 <mark>P</mark>	ragmatic Trials across the Cancer rial Required)	<u>Control Continuum (UG3/UH3 Clinical</u>	National Cancer Institute/NIH/DHHS	PAR-22- 256 14·	-Jun-2024	Not Specified			
	Contact Name	Wynne E. Norton, PhD							
	Contact Telephone	240-276-6875							
	Contact Email	wynne.norton@nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	14-Jun-2024 , 17-Oct-2024 , 14-Feb-202	5 , 14-Jun-2025 , 17-Oct-2025						
	Synopsis	Synopsis Synopsis Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) intends to accelerate the development of evidence-based cancer-related interventions that reflect the diversity of people, places, contexts, and settings in the United States. Specifically, this FOA will support research that tests the impact of cancer-related interventions on cancer-related outcomes across the cancer control continuum using a pragmatic trial study design. This FOA will use the UG3/UH3 phased cooperative agreement mechanism. The UG3 phase will support refining the cancer-related intervention and finalizing study-related activities in preparation for conducting the pragmatic trial during the UH3 phase.							
103024 <mark>4</mark>	Academic-Industrial Partnerships 1 Diagnosis and Treatment (RO1 - Cl	for Translation of Technologies for inical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-21- 206	-Jun-2024	2,495,000 USD			

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Miguel Ossandon MS 240-276-5714 ossandom@mail.nih.gov Link to program URL 05-Jun-2024 The purpose of this Funding Opportunity engineering developments into methods research to assess risk, detect, prevent, of meet evolving requirements for technolo clinical, clinical and non-clinical settings, institutes. This FOA specifies a partnersh engaging the strengths of academic, indu inter-disciplinary, multi-institutional rese and translate a solution to their chosen p suitable for end users. Each partnership s partnership should plan to transition a te to a status useful in the chosen setting. F translate technologies that address prob of disease status. This FOA defines "innor clinical trials that test functionality or val clinical trials that lack translation as the p cancer research are not sought by and w commercial production or basic research	y Announcement (FOA) is to stimulate or tools that address problems in ba- diagnose, treat, and/or manage disea ogies and methods relevant to the ad domestic or foreign, for conditions an ip structure that is expected to help b ustrial, and other investigators. The p earch team to work in strategic alliand problem. They are expected to plan, or should include at least one academic echnology, method, assay, device, and funding may be requested to enhance lems in biology, pathology, risk assess vation" as likelihood to deliver a new idate performance in the chosen sett primary motivation. Applications that ill not be supported through this FOA projects.	e efforts to tran sic research to u se. The rational vance of researc nd diseases with oridge gaps in kr artners on each te to implement design, and valic and one industr d/or system from e, adapt, optimit sment, diagnosi capability to en ting. This FOA is propose phase or This FOA does	slate scientific dise understand diseas e is to deliver new ch and delivery of nowledge and exp application should a coherent strate late that the solut rial organization. E m a demonstration ze, validate, and o s, treatment, and/ id users. This FOA not intended to si III clinical trials in not propose to su	coveries and e, or in applied capabilities to care in pre- participating erience by d establish an gy to develop ion will be ach of possibility therwise for monitoring will support upport straight any area of upport
114678 🤇	Co-infection and Cancer (R01 Clinio	cal Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-23- 055 05-	Jun-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	Tram Kim Lam, Ph.D., MPH 240-276-6967 <u>lamt@mail.nih.gov</u>				



SPIN ID	Program Title	9	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Program URL Deadline Dates (ALL)	Link to pro 05-Jun-202	gram URL 24 , 05-Oct-2024 , 05-Feb-2025	, 05-Jun-2025 , 05-Oct-2025						
	Synopsis	The purpos addressing inform pre- infections I includes bo given to inv co-infectio	The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.							
112619	Biology of Bladder Cancer (R01 Cl	linical Trial C	<u>Optional)</u>	National Cancer Institute/NIH/DHHS	PAR-22- 218	-Jun-2024	Not Specified			
	Contact Name	Ron Johnso	on, Ph. D.							
	Contact Telephone	240-276-62	250							
	Contact Email	l <u>rjohnso2@</u>	mail.nih.gov							
	Sponsor Website	2								
	Program URL	Link to pro	gram URL							
	Deadline Dates (ALL)	) 05-Jun-202	24 , 05-Oct-2024 , 05-Feb-2025	, 05-Jun-2025						
	This Funding Opportunity Announcement (FOA) encourages applications that investigate the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Becaus of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression and malignancy of bladder cancer. Furthermore, our understanding of the biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and contribute to the future development of new interventions.									
106261	Basic Research in Cancer Health E	Disparities (F	R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-21- 322	-Jun-2024	Not Specified			
	Contact Name	Anu Sharm	an. Ph.D.							

Contact Name Anu Sharman, Ph.D Contact Telephone 240-276-6250

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email Sponsor Website	<u>sharmana</u>	anu@nih.gov				
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	05-Jun-20	)24 , 05-Jul-2024				
	Synopsis	National ( into the b studies de factors as strategies also desig in cancer models, a Research	Cancer Institute (NCI) invites ap piological/genetic causes of cance esigned to investigate biological esociated with cancer disparities s, (2) the development and testi gned to aid and facilitate the gro health disparities research who nd methods that are necessary Project (RO1) award mechanism	plications from investigators interester for health disparities. These research /genetic bases of cancer disparities , including those related to basic re- ng of new methodologies and mode with of a nationwide cohort of scien- can expand available resources and to conduct basic research in cancer n.	sted in conductir ch project grants s, such as (1) meo esearch in cancer els, and (3) secor ntists with a high d tools, such as k r health disparitio	ng basic, mechanis (R01) will support chanistic studies of biology or cancer ndary data analyse level of basic rese biospecimens, patie es. This FOA will us	tic research innovative biological prevention s. This FOA is arch expertise ent derived se the NIH
106282	Mechanisms that Impact Cancer F Optional)	Risk after B	ariatric Surgery (R01 Clinical Tri	al National Cancer Institute/NIH/DHHS	PAR-21- 331	-Jun-2024	2,500,000 USD
	Contact Name	Edward R	. Sauter, M.D., Ph.D.				
	Contact Telephone	240-276-7	7657				
	Contact Email	edward.s	auter@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	05-Jun-20	)24 , 05-Jul-2024				
	Synopsis	Through t of investig talented s weight los	this Funding Opportunity Annou gator-initiated studies addressir scientists who study bariatric su ss and diabetes.	ncement (FOA), the National Cance ng mechanisms by which bariatric so rgery to investigate its effects on ca	er Institute (NCI) urgery impacts c ancer, rather tha	invites application ancer risk, and see n shorter term out	s for support ks to draw in comes such as
105645	Integration of Imaging and Fluid-E	Based Tum	or Monitoring in Cancer Therap	y National Cancer	PAR-21-	May 2024	499,999
105645	(R01 Clinical Trial Optional)			Institute/NIH/DHHS	290 07	-ividy-2024	USD
	Contact Name	Shane Wo	oodward				
	Contact Telephone	240-276-6	5624				
Icahr Mour	a School of Medicine at at Sinai		NIH Funding Opportu	nities Due: June 2024			40

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Contact Email	woodwar	s@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	024 , 05-Jun-2024 , 05-Jul-2024	, 07-Sep-2024 , 05-Oct-2024 , 07-Ja	an-2025			
	Synopsis	National monitorir character mechanis	National Cancer Institute (NCI) invites applications for research projects that integrate imaging and fluid-based tume ionitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities maracterization of therapy response and/or emergence of resistance. This FOA will use the NIH Research Project (RO mechanism.					
107760	Notice of Special Interest (NOSI): and Coordination During Cancer I	<u>Research c</u> Diagnosis a	on Interprofessional Teamwork nd Treatment	National Cancer Institute/NIH/DHHS	NOT-CA- 22-014 07-	May-2024	Not Specified	
	Contact Name	Sallie J. W	/eaver, PhD, MHS					
	Contact Telephone	240-276-6	5254					
	Contact Email	sallie.wea	ver@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2024	024 , 25-May-2024 , 05-Jun-202	4 , 07-Jun-2024 , 16-Jun-2024 , 07-	Sep-2024 , 25-Se	p-2024 , 05-Oct-20	)24 , 08-Oct-	
	Synopsis	This Notic applicatio and treat	e of Special Interest (NOSI) high ns focused on understanding ar ment.	lights the NCI Healthcare Delivery nd improving interprofessional tear	Research Prograr mwork and coord	n's interest in rece ination during car	eiving Icer diagnosis	
113232	Bioengineering Research Grants (	BRG) (R01	Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-22- 242 07-	May-2024	Not Specified	
	Contact Name	Rao Divi,	Ph.D.					
	Contact Telephone	240-276-6	5913					
	Contact Email	<u>divir@ma</u>	<u>il.nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	024 , 05-Jun-2024 , 05-Jul-2024	, 07-Sep-2024 , 05-Oct-2024 , 05-N	lov-2024 , 07-Jan	-2025 <i>,</i> 05-Feb-202	25 , 05-Mar-	

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	2025,07 The purpe that: 1) a optimize, and addre enhancin design-din applying a science.	-May-2025, 05-Jun-2025, 05-Ju ose of this funding opportunity a pply a multidisciplinary bioengir validate, translate or accelerate ess specific research or clinical p g our understanding of health a rected, developmental, discover an integrative approach to incre	al-2025, 07-Sep-2025 announcement is to encourage coll neering approach to the solution of e adoption of promising tools, meth problem in basic, translational, and, and disease, and/or c) improve prac ry-driven, or hypothesis-driven rese hase our understanding of and solve	laborations betwe a biomedical pro hods and techniqu /or clinical science tice of medicine. earch, and this FO e problems in biol	een the life and ph blem; and 2) deve ues: a) that fulfill a e and practice, b) o Applications may p A is appropriate fo ogical, clinical or t	ysical sciences lop, integrate, n unmet need capable of oropose or small teams ranslational
113233	Bioengineering Research Grants (	BRG) (R01	<u>Clinical Trial Optional)</u>	National Cancer Institute/NIH/DHHS	PAR-22- 243	May-2024	Not Specified
	Contact Name	Rao Divi,	Ph.D.				
	Contact Telephone	240-276-0	5913				
	Contact Email	divir@ma	<u>iil.nih.gov</u>				
	Sponsor Website	2					
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2025 , 07	.024 , 05-Jun-2024 , 05-Jul-2024 -May-2025 , 05-Jun-2025 , 05-Ju	, 07-Sep-2024 , 05-Oct-2024 , 05-N Il-2025 , 07-Sep-2025	lov-2024 , 07-Jan-	2025 , 05-Feb-202	25 , 05-Mar-
	Synopsis	The purpe that: 1) a validate, 1 or clinical developm approach support c conventio any area commerc	ose of this funding opportunity a pply a multidisciplinary bioengin translate or otherwise accelerat problem in basic, translational, nental, discovery-driven, or hypo to increase our understanding linical trials that test functionali onal clinical trials that lack transl of research are not sought by ar ial production.	announcement is to encourage coll neering approach to the solution of the adoption of promising tools, or clinical science and practice. An othesis-driven research and is appr of and solve problems in biological ity or validate performance in the c lation as the primary motivation. A nd will not be supported through th	laborations betwe a biomedical pro methods, and tec application may opriate for small , clinical, or transl chosen setting. Th pplications that p his FOA. This FOA	een the life and ph blem; and 2) integ hniques for a spec propose design-di ceams applying an ational science. T is FOA is not inten ropose phase III cl does not propose	ysical sciences rate, optimize, cific research rected, integrative This FOA will ded to support inical trials in to support
108323	Notice of Special Interest (NOSI): and Health Outcomes Among Chi	Disparities Idhood Car	Affecting Healthcare Utilization	National Cancer Institute/NIH/DHHS	NOT-CA- 22-029 07-	May-2024	Not Specified

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
		I							
	Contact Name	Veronica	Chollette, RN, MS						
	Contact Telephone	240-276-6	5969						
	Contact Email	<u>cholletv@</u>	omail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2	024 , 25-May-2024 , 05-Jun-202	24 , 07-Jun-2024 , 16-Jun-2024 , 25-5	sep-2024 , 08-Oc	t-2024			
	Synopsis	Populatio to dispari focus on f interventi to dispari	o disparities in health outcomes and result in inequitable survivorship care are strongly encouraged.						
112442	NCI Clinical and Translational Expl Clinical Trial Optional)	oratory/D	evelopmental Studies (R21	National Cancer Institute/NIH/DHHS	PAR-22- 216 12-	Jun-2024	275,000 USD		
	Contact Name	William C	. Timmer, Ph.D						
	Contact Telephone	240-276-6	5130						
	Contact Email	william.tir	<u>mmer@nih.gov</u>						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	12-Jun-20	24 , 01-Jul-2024 , 10-Oct-2024 ,	, 01-Nov-2024 , 13-Feb-2025 , 01-Ma	ar-2025 , 12-Jun-	2025 , 01-Jul-2025	5		
	Synopsis	This Fund studies, d managem following: treatment approach vitro tumo lines); and new treat	ing Opportunity Announcement irectly related to advancements tent, or reduction of cancer disp a new molecular agents or biolo t-related toxicity; cancer screent es; predictive and prognostic bit for models (including genetically d strategies to address theraped ament strategies may involve re	t (FOA) supports preclinical and earl s in cancer treatment, diagnosis, pre parities. This includes (but is not limi gics for cancer treatment; managen ing or diagnostic tools, such as imag omarkers for patient selection or str r engineered mouse models, patient utic outcome disparities among unde purposed agents or novel combination	y phase clinical r evention, compar- ted to) developm nent strategies for ging techniques; ratification; clinic e-derived xenogra erserved populat ions of intervent	research, as well as rative oncology, sy nent and testing o or cancer-related s cancer preventive cally relevant in viv aft models, organc tions. In addition t ions (including rad	s correlative mptom f the ymptoms or agents or o or in ids, and cell o novel agents, iation), based		

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
on estat health o resistan diagnos (such as risk asse not resp respons providir lead to applicat	olished mechanisms of action. Con lisparities are encouraged to expli- ce to therapeutic interventions. C is of human disease are supporte- studies of cancer-related pathwa essment studies, epidemiological bonsive to this FOA and will not be ive for this FOA). The R21 mechar of support for the early and conce preakthroughs in particular areas, ions that could have a major impa	mparative correlative studies in can ore mechanisms underlying their dif comparative oncology studies in dog d as well. This FOA does not support sys, molecular mechanisms, or mech studies, or studies of behavioral inte e reviewed (see below for a more de nism is intended to encourage explo eptual stages of these projects. Thes or to the development of novel tec act on cancer research (preclinical o	cer patients with ferential respon is investigating s t research that fe anisms of meta erventions. Thes etailed description ratory and deve e studies may in hniques, agents r clinical).	n age, gender, racia ises (efficacy and t strategies for treat ocuses on basic ca stasis), late-stage o e applications will on of studies that a lopmental researc wolve considerable , methodologies, n	al/ethnic, or oxicity) and ment and ncer biology clinical trials, be deemed are not h projects by e risk but may nodels, or		
115306 Notice of Special Interest (NOSI): Research Screening and Prevention of Early-Onset C	on the Etiology, Early Detection, colorectal Cancer	National Cancer Institute/NIH/DHHS	NOT-CA- 23-018 07-	May-2024	Not Specified		
Contact Name Gary De	lla'Zanna						
Contact Telephone 240-276	5-7042						
Contact Email <u>Gary.De</u>	Gary.DellaZanna@nih.gov						
Sponsor Website							
Program URL Link to	program URL						
Deadline Dates (ALL) 07-May 2024 , 0	-2024 , 25-May-2024 , 05-Jun-202 8-Oct-2024 , 10-Oct-2024 , 12-Oc	4 , 07-Jun-2024 , 12-Jun-2024 , 16-J t-2024 , 25-Oct-2024 , 07-Jan-2025 ,	un-2024 , 25-Jur , 16-Feb-2025 , (	n-2024 , 07-Sep-20 07-May-2025 , 16-J	24 , 25-Sep- un-2025		
The pur Synopsis mitigati early-or	pose of this Notice of Special Inte ng risk factors, identifying biomar iset colorectal cancer (EOCRC), de	rest (NOSI) is to solicit applications o kers for early detection, best screen fined as occurring before 50 years o	directed toward iing modalities, a of age.	identifying, charad and preventive int	cterizing, and erventions for		
106264 Basic Research in Cancer Health Disparitie	s (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-21- 323 16-	Jun-2024	400,000 USD		
Contact Name Anu Sha	rman, Ph.D.						
Contact Telephone 240-276	-6250						
Contact Email <u>sharma</u>	nanu@nih.gov						
Sponsor Website							



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL) Synopsis	16-Jun-20 National ( into the b studies de factors as strategies also desig in cancer models, a	024 , 16-Jul-2024 Cancer Institute (NCI) invites appoilogical/genetic causes of cance esigned to investigate biological, esociated with cancer disparities (2) the development and testing red to aid and facilitate the gro health disparities research who	olications from investigators intere- er health disparities. These researce /genetic bases of cancer disparities , including those related to basic re- ng of new methodologies and mod- wth of a nationwide cohort of scien- can expand available resources an- to conduct basic research in cancer	sted in conductir th project grants s, such as (1) mec search in cancer els, and (3) secor ntists with a high d tools, such as b r health disparitie	ng basic, mechanist (R01) will support hanistic studies of biology or cancer ndary data analyses level of basic rese iospecimens, patie	ic research innovative biological prevention s. This FOA is arch expertise ent derived
106265	Basic Research in Cancer Health D	oisparities	(R03 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-21- 324 16-	Jun-2024	100,000 USD
	Contact Name	Anu Shari	man, Ph.D.				
	Contact Telephone	240-276-0	6250				
	Contact Email	sharmana	anu@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	16-Jun-20	)24 , 16-Jul-2024				
	Synopsis	This Fund basic, me will suppo projects s mechanis biology o secondar	ing Opportunity Announcement chanistic research into the biolo ort projects on cancer health dis should propose innovative studie tic studies of biological factors a r cancer prevention strategies, ( y data analyses.	t (FOA) encourages grant application gical/genetic causes of cancer heal parities that can be carried out in a es designed to investigate biologica associated with cancer disparities, i 2) the development and testing of	ons from investiga th disparities. The short period of the ll/genetic bases of ncluding those re new methodolog	ators interested in ese small research time with limited r of cancer disparitie elated to basic rese ties and models, ar	conducting grants (RO3) esources. The s, such as (1) earch in cancer nd (3)
106283	Mechanisms that Impact Cancer F Not Allowed)	Risk after B	Bariatric Surgery (R21 Clinical Tri	al National Cancer Institute/NIH/DHHS	PAR-21- 332 16-	Jun-2024	550,000 USD
	Contact Name Contact Telephone	Edward R 240-276-7	. Sauter, M.D., Ph.D. 7657				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email	edward.sauter@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jun-2024 , 16-Jul-2024				
	Synopsis	Through this Funding Opportunity Annot of investigator-initiated studies addressi talented scientists who study bariatric su weight loss and diabetes.	uncement (FOA), the National C ng mechanisms by which bariat Irgery to investigate its effects o	ancer Institute (NCI) ric surgery impacts ca on cancer, rather tha	invites applicatior ancer risk, and see n shorter term out	is for support ks to draw in comes such as
125154	Notice of Special Interest (NOSI): . and Enhancing Survivorship Care	Administrative Supplements for Assessing	g National Cancer Institute/NIH/DHHS	NOT-CA- 24-041 04-	Jun-2024	100,000 USD
	Contact Name	Michelle Mollica, PhD, MPH, RN, OCN				
	Contact Telephone	240-276-7621				
	Contact Email	michelle.mollica@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	04-Jun-2024				
	Synopsis	The Division of Cancer Control and Popu of Special Interest (NOSI) to encourage of supplement funds to support research w recently developed national survivorship	lation Sciences (DCCPS) at the N urrent grant or cooperative agr rith an overall goal of examining standards. Please note that thi	National Cancer Instit eement awardees to g and improving survi is NOSI is a reissuance	ute (NCI) announc apply for adminis vorship care to ali e of NOT-CA-24-03	es this Notice trative gn with 35.
	Notice of Special Interest (NOSI):	Utilization of Cohorts and Prospective	National Cancer	ΝΟΤ-CΔ-		Not
113746	Study Designs for Liquid Biopsy As	ssay Validation for Early Detection of	Institute/NIH/DHHS	23-004 07-	May-2024	Specified
	Contact Name	Matthew Young, Ph.D.				
	Contact Telephone	240-276-5846				
		matthew.young@nin.gov				
	Sponsor Website					
	Program URL	LINK TO PROGRAM UKL				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2 2024 , 10 May-2025	024 , 05-Jun-2024 , 11-Jun-2024 -Oct-2024 , 11-Oct-2024 , 05-Jar 5 , 05-Jun-2025 , 12-Jun-2025 , 0	4 , 12-Jun-2024 , 01-Jul-2024 , 05-Se n-2025 , 07-Jan-2025 , 05-Feb-2025 , 11-Jul-2025	p-2024 , 07-Sep , 13-Feb-2025 , '	-2024 , 01-Oct-202 01-Mar-2025 , 05-A	4 , 05-Oct- \pr-2025 , 07-
	Synopsis	The purpo biomarke and biore and valida populatio	ose of this Notice of Special Inter r technology developers with as pository researchers. Proposals ation utilizing statistically power ns with a sound study design ar	rest (NOSI) is to encourage research ssays for early cancer detection, and that facilitate early cancer biomarke red retrospective cohorts and/or thr re responsive to this NOSI.	n studies leverag population-bas er assay develo ough prospectiv	ging partnerships b sed researchers, ind pment, verification ve studies in the ap	etween :luding cohort , qualification, propriate
102903	Notice of Special Interest (NOSI): Complementary and Integrative H	Fundamen Iealth App	<u>tal Science Research on</u> roaches	National Center for Complementary and Integrative Health/NIH/DHHS	NOT-AT- 21-006 07	-May-2024	Not Specified
	Contact Name	Wen Chei	n, M.M.Sc., Ph.D.				
	Contact Telephone	301-451-3	3989				
	Contact Email	<u>chenw@</u> r	nail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	024 , 05-Jun-2024 , 16-Jun-2024	4,07-Sep-2024			
	Synopsis	The purport of the pu	ose of this Notice of Special Inte or technology/method develop	rest (NOSI) is to describe NCCIH pric ment research relevant to compleme	orities in innova entary and inte	tive basic and mec grative health appr	nanistic oaches.
124471 <mark> </mark>	RFA-AT-24-008 Leveraging Data mpacts on Whole Person Health	at Scale to (R01 Clinic	o Understand Natural Product al Trial Not Allowed)	National Center for Complementary and Integrative Health/NIH/DHHS	RFA-AT- 28 24-008 [O	-May-2024 ptional][LOI/Pre-Ap	499,999 p] USD
	Contact Name	D. Craig H	lopp, Ph.D.				
	Contact Telephone	301-496-5	5825				
	Contact Email	hoppdc@	nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	28-May-2	024 [Optional][LOI/Pre-App], 28	3-Jun-2024			

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The purper with the p possibly of libraries of potential products NCCIH that generated maintaine	ose of this Funding Opportunity potential to inhibit or induce Pha contributing to pharmacokinetic of complex extracts and/or purif interactions. They may also incl within complex mixtures that ex at includes a U54 Center of Exce d in projects supported under th ed by the U54 Center.	Announcement (FOA) is to solicit ap ase I and Phase II drug metabolizing interactions with other medications ied natural products in suitable med ude isolation and identification of ne whibit pharmacokinetic interactions. Ilence for Natural Product Drug Inte is FOA will be uploaded and made p	oplications that s enzymes and dr s. These in vitro s lium to high thro ovel, or not com This FOA is part traction Research publicly available	eek to identify na ug transporters, t studies may incluc oughput assays to mercially available of a larger investr n. It is expected th through the data	tural products hereby le screening identify e, natural nent from lat data repository
123152	easibility Clinical Trials of Mind a Priority Research Topics (R34 Clini	nd Body Ir cal Trial R	nterventions for NCCIH High equired)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-24- 084 20-	Jun-2024	450,000 USD
	Contact Name	Jennifer N	N. Baumgartner, Ph.D.				
	Contact Telephone	301-402-4	4084				
	Contact Email	jennifer.b	aumgartner@nih.gov				
	Sponsor Website						
	Program URL	<u>Link to pr</u>	ogram URL				
	Deadline Dates (ALL)	20-Jun-20 , 17-Nov-2	)24 , 15-Jul-2024 , 21-Oct-2024 , 2025 , 20-Feb-2026 , 17-Mar-20	13-Nov-2024 , 20-Feb-2025 , 10-Ma 26 , 22-Jun-2026 , 13-Jul-2026 , 20-C	ar-2025 , 20-Jun- Oct-2026 , 13-No	2025 , 14-Jul-2025 v-2026	5 , 20-Oct-2025
	Synopsis	The goal of approach that have clinical tri clinical ef NCCIH exp the propor Under thi scale clini published refining th retention	of this notice of funding opportu es with physical and/or psycholo been identified by NCCIH as hig ials that provide new informatio ficacy or effectiveness study, pro- pects that applications to this No- osed (R34) research is scientifica s R34, the data collected should ical trial, including, but not limited data; tailoring or adapting the he intervention to determine the , and data collection procedures	unity (NOFO) is to support feasibility ogical therapeutic inputs (often calle sh-priority research topics. This fund in that are scientifically necessary for agmatic trial, or dissemination and i OFO will describe the planned future Ily necessary to design or plan the so be used to fill gaps in scientific know ed to the following: examining feasil content or structure of an interventi e most appropriate frequency or du s; refining and assessing the feasibili	trials of comple ed mind and bod ing opportunity r the planning an mplementation e clinical trial and ubsequent comp wledge necessar bility and accept ion to a specific p ration; determin ty of protocolize	mentary and integ y interventions) for is intended to sup nd conduct of a su trial within NCCIH d in so doing dem petitive full-scale of y to develop a con ability of interven population, moda ing feasibility of re-	grative health or conditions oport feasibility ibsequent 's mission. onstrate that clinical trial. mpetitive full- tions lacking lity, or setting; ecruitment, nt

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		interventi have the p encourage applicatio scientific a be withdr guidance	ions; or examining acceptability potential to make a significant ir ed to contact the appropriate N n. This NOFO requires a Plan fo and technical peer review evalu awn. Applicants are strongly en material.	and adherence of control condition mpact on public health. Prior to sul CCIH Scientific/Research contact pe r Enhancing Diverse Perspectives (P ation. Applications that fail to inclu couraged to read the NOFO instruct	s. The subseque omitting to this I rson for the scie EDP), which will de a PEDP will b ions carefully ar	nt full-scale clinica NOFO, applicants a nce area of the pla be assessed as pa e considered incon nd view the availab	al trial should are anned art of the mplete and will ble PEDP
123153 <mark>  </mark>	nvestigator Initiated Clinical Trial nterventions Delivered Remotely	<u>s of Compl</u> or via mH	ementary and Integrative ealth (R01 Clinical Trial Required	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-24- 086 20-	Jun-2024	Not Specified
	Contact Name	Beda Jear	n-Francois, Ph.D.				
	Contact Telephone	202-313-2	2144				
	Contact Email	beda.jean	<u>-francois@nih.govr01</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	20-Jun-20 , 17-Nov-2	)24 , 15-Jul-2024 , 21-Oct-2024 , 2025 , 20-Feb-2026 , 17-Mar-202	13-Nov-2024 , 20-Feb-2025 , 10-Ma 26 , 22-Jun-2026 , 13-Jul-2026 , 20-C	ar-2025 , 20-Jun- Oct-2026 , 13-No	2025 , 14-Jul-2025 v-2026	5 , 20-Oct-2025
This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated fully remotely delivered and conducted clinical trials to assess the efficacy or effectiveness of complementary and integrative health interventions in NCCIH- designated areas of high research priority. Applications submitted under this NOFO are expected to propose a remotely delivered and conducted fully powered clinical trial with no in-person contact between research staff and stude participants and may utilize mHealth tools or technologies. Applicants must provide justification for the remotely delivered approach and provide preliminary data on the feasibility and safety of the approach, along with evidence that the intervention has promise of clinical benefit. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submit to this NOFO. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete a be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.							livered and entions in opose a and study ely delivered the so submitting part of the mplete and will ole PEDP

123147 NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions National Center for PAR-24-

-24- 20-Jun-2024

Not



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	(R01 Clinical Trial Required)			Complementary and Integrative 083 Health/NIH/DHHS		Specified
	Contact Name	Pete Mur	ray, Ph.D.			
	Contact Telephone	301-496-4	1054			
	Contact Email	peter.mu	rray@nih.gov			
	Sponsor Website					
	Program URL	Link to pr	ogram URL			
	Deadline Dates (ALL)	, 13-Nov-2024 , 20-Feb-2025 , 20-Jun-2025 , 15-Jul-2 26 , 14-Jul-2026 , 20-Oct-2026 , 17-Nov-2026	.025 , 20-Oct-2025	, 18-Nov-2025		
	Synopsis	integrativ interventi propose a and condu- trial withi so doing o powered, including, demonstr adherence the feasib preparatio expected published competiti submittin the science be assesse considere and view	e health approaches with physi ions) in NCCIH-designated areas multisite feasibility clinical tria uct of a subsequent clinical effic n NCCIH's mission. NCCIH expec- demonstrate that the proposed full-scale clinical trial. Under the but not limited to the following ating feasibility of recruitment, e to the intervention, as well as ility of protocolized multimoda on for a future fully powered, m to be justified by sufficient prel literature. The data collected s ve fully powered multisite clinic g to this NOFO, applicants are e ce area of the planned application ed as part of the scientific and t d incomplete and will be withdow the available PEDP guidance ma	cal and/or psychological therapeutic inputs (often cases of high research priority. Applications submitted un I that will provide new information that is scientificated or effectiveness study, pragmatic trial, or disserned to the provide new information that is scientificated or effectiveness study, pragmatic trial, or disserned to that applications to this NOFO will describe the provide new information that is scientificated or (R01) research is scientifically necessary to design or is R01, the data collected should be used to fill gaps grassessing whether the intervention can be deliver accrual, and randomization of participants across si retention of participants throughout the study across interventions, and/or demonstrating feasibility of conditisite efficacy or effectiveness trial. The need for minimary data from previous single site feasibility or a hould be used to fill gaps in scientific knowledge and cal trial that has the potential to make a significant intercouraged to contact the appropriate NCCIH Scient on. This NOFO requires a Plan for Enhancing Diverse echnical peer review evaluation. Applications that frawn. Applicants are strongly encouraged to read the aterial.	alled mind and boo nder this NOFO are illy necessary for the nination and imple- lanned future clini r plan the subseque in scientific knowled ed with fidelity acre- tes; demonstrating ss sites; refining and data collection acre- nultisite feasibility acceptability trial(se d be necessary to compact on public he- ific/Research conta- e Perspectives (PEI fail to include a PEI ne NOFO instructio	dy expected to he planning ementation ical trial and in ient fully ledge, ross sites; g participant nd assessing oss sites in r trials is s) or the develop a ealth. Prior to act person for DP), which will DP will be ns carefully

123160 Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated

National Center for

PAR-24- 20-Jun-2024



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Clinical Trials of Mind and Body International Clinical Trial Required)	erventions (Collaborative UG3/UH3	Complementary and Integrative Health/NIH/DHHS	090		Specified
	Contact Name E Contact Telephone	Elizabeth Ginexi, Ph.D. 301-827-0160				
	Contact Email <u>e</u> Sponsor Website	elizabeth.ginexi@nih.gov				
	Program URL <u>I</u> Deadline Dates (ALL)	<u>Link to program URL</u> 20-Jun-2024 , 15-Jul-2024 , 20-Feb-2025 , . 13-Jul-2026	10-Mar-2025 , 20-Jun-2025 , 14-Jul	-2025 , 20-Feb-2	026 , 17-Mar-202	6 , 22-Jun-2026
	Synopsis r a c f r r a c c f r a c c f r a c c c s s r opsis	This notice of funding opportunity (NOFO collaborating Data Coordinating Center (E (Phase III and beyond) application submit companion Clinical Coordinating Center (G comprehensive plan that provides overall support for the proposed clinical trial. Bot simultaneously for consideration by NCCII NCCIH and considered a high priority by the research priorities of NCCIH, applicants are are encouraged to contact the appropriat develop an application prior to submitting (PEDP), which will be assessed as part of the PEDP will be considered incomplete and w carefully and view the available PEDP guid	), utilizing the U24 grant funding me DCC) application that accompanies a ted under companion PAR-24-090. CCC) application. The objective of the project coordination, and administr th a DCC application and a correspon H. Trials for which this NOFO applie the Center. For additional informatio re encouraged to consult the NCCIH e Scientific/Research contact for the g to this NOFO. This NOFO requires the scientific and technical peer revi will be withdrawn. Applicants are str dance material.	echanism, encou n investigator-in The DCC application rative, data man nding CCC applic s must be relevation about the mis website (http:// e area of science a Plan for Enha ew evaluation.	arages application initiated multi site tion must be spec on is to propose a agement, and bio cation need to be ant to the research sion, strategic visi /www.nccih.nih.g e for which they an ncing Diverse Pers Applications that ed to read the NO	s for a clinical trial ific to the statistical submitted h mission of on, and ov). Applicants re planning to spectives fail to include a FO instructions
123155	Data Coordinating Center for NCCII Trials of Mind and Body Intervention Required)	<u>H Multi-Site Investigator-Initiated Clinical</u> ons (Collaborative U24 Clinical Trial	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-24- 087 20	Jun-2024	Not Specified
	Contact Name E Contact Telephone 3 Contact Email <u>6</u> Sponsor Website	Elizabeth Ginexi, Ph.D. 301-827-0160 elizabeth.ginexi@nih.gov				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Program URL	Link to pro	o program URL						
	Deadline Dates (ALL)	20-Jun-20 , 13-Jul-20	)24 , 15-Jul-2024 , 20-Feb-2025 , )26	10-Mar-2025 , 20-Jun-2025 , 14-Jul-	-2025 , 20-Feb-2	026 , 17-Mar-2020	o, 22-Jun-2026		
	Synopsis	collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi site clinical trial (Phase III and beyond) application submitted under companion PAR-24-090. The DCC application must be specific to the companion Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this NOFO applies must be relevant to the research mission of NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of NCCIH, applicants are encouraged to consult the NCCIH website (http://www.nccih.nih.gov). Application are encouraged to contact the appropriate Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this NOFO. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructic carefully and view the available PEDP guidance material.							
123823	<u>Clinical Coordinating Center for N</u> <u>Clinical Trials of Natural Products</u> <u>Required</u> )	<u>CCIH Multi</u> (Collabora	i-Site Investigator-Initiated tive UG3/UH3 Clinical Trial	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-24- 123 21-	Jun-2024	Not Specified		
	Contact Name	Wendy W	eber, N.D., Ph.D, M.P.H.						
	Contact Telephone	, 301-402-1	1272						
	Contact Email	weberwj@	@mail.nih.gov						
	Sponsor Website								
	Program URL	Link to pro	ogram URL						
	Deadline Dates (ALL)	21-Jun-20 , 14-Jul-20	)24 , 15-Jul-2024 , 20-Feb-2025 , )26	10-Mar-2025 , 23-Jun-2025 , 17-Jul-	-2025 , 23-Feb-2	026 , 17-Mar-2026	5 , 22-Jun-2026		
	This Funding Opportunity Announcement (FOA) encourages cooperative agreement applications for investigator-initiated, Synopsis multi-site, clinical trials (Phase III and beyond) to study the effects of natural products in NCCIH designated areas of high research priority. Applicants should describe plans for a Clinical Coordinating Center to develop and implement the proposed								

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		multi-site comprehe responsite conduct, phase, mi Coordinat clinical pr (DCC) app	clinical trial. The objective of the ensive scientific and operational ole for project management, par and dissemination of results. Cli clestone-driven, cooperative agr ting Center application, submitted oject is required. Both a Clinical plication need to be submitted s	e Clinical Coordinating Center is to p plan for the clinical trial. The Clinica ticipant recruitment and retention s nical Coordinating Center applicatio eement (UG3/UH3) funding mechar ed under PAR-24-125, proposing a d Coordinating Center application and imultaneously for consideration by I	provide the design al Coordinating C trategies, perforns submitted un nism. In addition, ata analysis and d a correspondir NCCIH.	gn scientific ration center is expected mance milestones der this FOA will u an accompanying data managemen ng Data Coordinati	ale and a to be s, scientific utilize a two- g Data t plan for the ng Center
<u>N</u> 123835 <u>I</u> P	lotice of Special Interest (NOSI): ntegrative Health (NCCIH) T32 Co ractitioner Supplement Program	National C omplemen 1 for Pre- a	enter for Complementary and tary and Integrative Health nd Postdoctoral Candidates	National Center for Complementary and Integrative Health/NIH/DHHS	NOT-AT- 24-033 03-	Jun-2024	Not Specified
	Contact Name	Jennifer N	I. Baumgartner, Ph.D.				
	Contact Telephone	301-402-4	4084				
	Contact Email	jennifer.b	aumgartner@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	03-Jun-20	024 , 01-Nov-2024 , 03-Mar-202	5 , 02-Jun-2025 , 03-Nov-2025 , 02-N	/lar-2026 , 01-Ju	n-2026 , 02-Nov-2	026
	Synopsis	NCCIH an Institution training s degrees.	nounces an opportunity to allov nal Research Training Grant (T32 lot for predoctoral and postdoct	v existing NCCIH-funded Ruth L. Kirs 2) programs to apply for an administ coral candidates with professional cl	chstein National rative suppleme inical compleme	Research Service nt to support an a ntary and integrat	Award (NRSA) Idditional tive health
124673 P	FA-AT-24-007 Limited Competed Resonation R	ition: Rese ance Data	earch Resource for Natural (R24 Clinical Trial Not Allowed)	National Center for Complementary and Integrative Health/NIH/DHHS	RFA-AT- 10 24-007 [Op	lun-2024 tional][LOI/Pre-Ap	Not pp] Specified
	Contact Name	Patrick C.	Still, Ph.D.				
	Contact Telephone						
	Contact Email	patrick.st	ill@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	10-Jun-20 The Natio applicatio meta-data store, sea wider con of the Cor Program i 008Levera	024 [Optional][LOI/Pre-App], 08- onal Center for Complementary ons for continuation of an establ a from natural products ranging rch and analyze raw NMR data. nmunity inclusiveness of the est nsortium Advancing Research of include the RFA-OD-24-014 Bota aging Big Data to Understand Na	-Jul-2024 and Integrative Health (NCCIH) with lished nuclear magnetic resonance ( from crude extracts to purified sub The purpose of this limited compet tablished NMR research resource. Th n Botanicals and Other Natural Prod anical Dietary Supplements Translati atural Product Impacts on Whole Pe	the Office of Die NMR) research restances; with the ition is to promo nis notice of func ucts (CARBON) P ional Research Te rson Health (R01	tary Supplements esource consisting capacity to uploa te sustainability, s ling opportunity (I rogram. Other ele eams (RM1) and R .).	G (ODS) solicit g of raw and ad, download, caling and NOFO) is part ements of this FA-AT-24-
123623	Notice of Special Interest (NOSI): A Complementary Health Practitione Supplements)	Administra er Researc	ative Supplements for The Experience (Admin	National Center for Complementary and Integrative Health/NIH/DHHS	NOT-AT- 24-032 03	lun-2024	200,000 USD
	Contact Name	Lanay M.	Mudd, Ph.D., FACSM				
	Contact Telephone	301-594-9	9346				
	Contact Email	lanay.mu	dd@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	03-Jun-20	024 , 01-Nov-2024 , 03-Mar-202	5 , 02-Jun-2025 , 03-Nov-2025 , 02-N	/lar-2026 , 01-Jui	1-2026 , 02-Nov-2	026
	Synopsis	The Natio suppleme experienc research.	nal Center for Complementary ents to NCCIH-supported awards that will lead to a better unde	and Integrative Health (NCCIH) enco to support complementary health erstanding of, and practical experien	ourages application practitioners in a ce in, compleme	ons for administra n intensive, super ntary and integrat	tive vised research tive health
123858	Natural Product Multi-Site Clinical (Collaborative U24 Clinical Trial Re	<u>Trial Data</u> equired)	Coordinating Center	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-24- 125 21	lun-2024	Not Specified
	Contact Name	Wendy W	eber, N.D., Ph.D, M.P.H.				
	Contact Telephone	301-402-1	1272				
	Contact Email	<u>weberwj@</u>	@mail.nih.gov				
	Sponsor Website						

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Program URL	nk to program URL							
	Deadline Dates (ALL)	1-Jun-2024 , 15-Jul-2024 , 20-Feb-2025 , 14-Jul-2026	10-Mar-2025 , 23-Jun-2025 , 15-Jul-	-2025 , 20-Feb-2	026 , 17-Mar-2026	5, 22-Jun-2026			
	collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi-site clinical trial (Phase III and beyond) application submitted under PAR-24-123. The DCC application must be specific to the collaborating Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that Synopsis provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this NOFO applies must be relevant to the research mission of the NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priori of the NCCIH, applicants are encouraged to consult the NCCIH website: (http://www.nccih.nih.gov).								
124534	Notice of Special Interest (NOSI): Na Integrative Health (NCCIH) T32 Supp Health Research	tional Center for Complementary and lement Program to Promote Diversity ir	National Center for Complementary and Integrative Health/NIH/DHHS	NOT-AT- 24-034 03-J	lun-2024	Not Specified			
	Contact Name Je	nnifer N. Baumgartner, Ph.D.							
	Contact Telephone 30	01-402-4084							
	Contact Email <mark>je</mark>	nnifer.baumgartner@nih.gov							
	Sponsor Website								
	Program URL <u>Li</u>	nk to program URL							
	Deadline Dates (ALL) 03	3-Jun-2024 , 01-Nov-2024 , 03-Mar-2025	5 , 02-Jun-2025 , 03-Nov-2025 , 02-N	1ar-2026 , 01-Jui	n-2026 , 02-Nov-2	026			
	Synopsis Pi th	NCCIH announces an opportunity to allow institutions with existing NCCIH-funded Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (T32) programs to apply for an administrative supplement to promote diversity in health research. A very limited number of supplementary slots will be available in each fiscal year and the number awarded will depend on the number and merit of applications received and the availability of funds.							
119247	NEI Institutional Mentored Physiciar Optional)	Scientist Award (K12 Clinical Trial	National Eye Institute/NIH/DHHS	PAR-23- 197 09-J	lun-2024	Not Specified			
	Contact Name N Contact Telephone 30	eeraj Agarwal, Ph.D. D1-435-8155							

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
	Contact Email	agarwalnee@nei.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	09-Jun-2024 , 09-Jun-2025 , 09-Jun-2026						
	Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to encourage institutions to propose creative and innovative institutional research career development programs which will prepare clinically trained vision scientists for independent research careers. This NOFO is intended to expand and strengthen the community of clinician investigators engaged in research. This Notice of Funding Opportunity (NOFO) allows appointment of Scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development program. For the career development program scholars are limited to clinical trials that are minimal risk. The existing clinical trial must be NIH-defined clinical trial that fulfills the NIH requirement for minimal risk trial. A minimal risk trial is one in which the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than a ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests Applicants are strongly advised to consult with NEI program staff prior to submitting an application with human subject: determine the appropriate funding opportunity. For the purposes of this announcement, institutions are highly encoura to recruit prospective PIs/PDs, mentors, and scholars from diverse backgrounds, including individuals from underrepres racial and ethnic groups and individuals with disabilities as described in the NOT-OD-22-019 in all of its programs.						
109678	NEI Regenerative Medicine Clinica Not Allowed)	al Trial Planning Grant (R34 - Clinical Trials	National Eye Institute/NIH/DHHS 135	7-May-2024	300,000 USD			
	Contact Name	Donald Everett, MA						
	Contact Telephone	301-435-8181						
	Contact Email	everettd@mail.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2024 , 16-Jun-2024 , 07-Sep-202	4 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-N	/lay-2025				
	Synopsis	The National Eye Institute (NEI) supports trial, it is critical to have clear delineation and procedures in a Manual of Procedure such as obtaining regulatory authorization	regenerative medicine clinical trials. Before a reso and documentation of the trial's rationale, desig es (MOP). Additionally, there are other elements ons or approvals and establishing agreements with	earch team undertal n, analytic technique essential to the laun requisite partners i	xes a clinical es, protocols, ching of a trial, ncluding cell			

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		manufact often cos Medicine MOP and vision in h	uring and production facilities, tly and time-consuming, and the Clinical Trial Planning Grant ma procedures necessary for imple numans through regeneration o	assay or cell analysis centers, and data coord ey may involve collection of preliminary data by be used by applicants to support the prep ementing a clinical trial to evaluate intervent f cells.	linating a to asse aration o ions (or	centers. These act ss feasibility. The of a clinical trial new treatments)	tivities are Regenerative that restore
109530	NEI Clinical Research Study Plann Allowed)	ng Grant F	Program (R34 Clinical Trial Not	National Eye Institute/NIH/DHHS 128	<u>-</u> 07-	May-2024	300,000 USD
	Contact Name	Donald Ev	verett, MA				
	Contact Telephone	301-435-8	3181				
	Contact Email	everettd(	@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	.024 , 16-Jun-2024 , 07-Sep-2024	4 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025	, 07-Ma	y-2025	
	Synopsis	The NEI s eye/vision detailed i environm Procedure grant fund may be us documen NEI FOA i	upports large-scale clinical visio n conditions. At the time of sub- nformation regarding the study ent, organizational structure, an es (MOP), the development of v ding opportunity supports appli sed to support the development t recruitment potential. The gra s applicable to both epidemiolo	n research projects, including randomized comission, applications requesting support for rationale, design, analytic techniques, proto- nd collaborative arrangements. This informa- which represents a costly and time-consumin cants in their planning efforts to conduct co t of a MOP, as well as to conduct preliminar- int must not be used to generate data on the gic and clinical trial research studies.	inical tri these ac ocols and tion is b og activit laborati studies e effects	als and epidemiol ctivities are expect d procedures, facil est conveyed in a cy. This clinical rese ve clinical researc to refine study pu of a proposed int	ogic studies on eed to provide ities and Manual of earch planning h. The grant rocedures or ervention. This
109824	NEI Research Grant for Vision-Rel Trial Not Allowed)	ated Secor	ndary Data Analysis (R21 Clinica	National Eye Institute/NIH/DHHS	<u>-</u> 07-	May-2024	275,000 USD
	Contact Name	Donald Ev	verett, M.A.				
	Contact Telephone	301-435-8	3181				
	Contact Email	everettd(	@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Deadline Dates (ALL) T s Synopsis t s s r	D7-May-2024 , 16-Jun-2024 , 07-Sep-202 This FOA encourages applications from i analyses utilizing existing database reso the original data collection. The NEI supporojects wherein numerous data collection of data generated by these studies ofter questions or develop new analytical app those collected under NEI support, but s secondary data analysis using existing data studies. This FOA may be used to develo must not be used to support the collecti	24, 16-Oct-2024, 07-Jan-2025, 16-Fe nstitutions/organizations that propos urces. Applications may be related to ports an extensive portfolio of clinica ion activities are required to meet ea n provides unique, cost-effective opport roaches secondary to a project's orig uch data are of the highest programmata sets from vision-related clinical tr p new statistical methodologies or te on of new data.	eb-2025 , 07-Ma se to conduct vis , but must be dis l trials and large ort project's spec ortunities to inve ginally-intended matic interest. The ials, epidemiologest hypotheses u	y-2025 sion-related second stinct from, the spe- scale epidemiolog cific aims. The resu estigate additional purpose. Data are he purpose of this gic, and other clinic sing existing data,	dary data ecific aims of gic research Iltant wealth research not limited to FOA is for cal research but this FOA	
117409	Notice of Special Interest (NOSI): D Data Science Technologies, Tools, a	evelopment of Innovative Informatics a and Methods for Vision Research	nd National Eye Institute/NIH/DHHS	NOT-EY- 23-005	May-2024	Not Specified	
	Contact Name J	lames Gao, Ph.D.					
	Contact Telephone	301-594-6074					
	Contact Email j	ames.gao@nih.gov					
	Sponsor Website						
	Program URL <u>L</u>	<u>ink to program URL</u>					
	Deadline Dates (ALL)	07-May-2024 , 16-Jun-2024 , 05-Sep-202 2025 , 07-May-2025 , 16-Jun-2025 , 05-S	24 , 07-Sep-2024 , 16-Oct-2024 , 05-Ja Sep-2025 , 07-Sep-2025 , 16-Oct-2025	an-2025 , 07-Jan 5 , 05-Jan-2026 ,	-2025 , 16-Feb-202 07-Jan-2026 , 16-F	25 <i>,</i> 05-Apr- eb-2026	
	The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants that the National Eye Institute (NEI) interested in supporting research to develop innovative informatics and data science methods, algorithms, and tools to improve data acquisition, analysis, visualization, annotation, integration, and interpretation. The emphasis will be on innovation and its potential impact on vision research, including discovery biology, population studies, as well as clinical a translational research.						
109308	RFA-HL-23-018 Maximizing the So Biospecimen Repository: Scientific (R21)	cientific Value of the NHLBI Biologic Opportunities for Exploratory Research	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL- 23-018 20-	Jun-2024	150,000 USD	

Contact Name Margaret Ochocinska, PhD

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Contact Telephone	301-827-8	3285							
	Contact Email	ochocinm	@mail.nih.gov							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	20-Jun-20	.0-Jun-2024 , 09-Aug-2024 , 21-Oct-2024 , 10-Dec-2024							
	Synopsis	This Fund (http://w Biologic S researche	ing Opportunity Announcement ww.nhlbi.nih.gov/about/org/mi pecimen Repository (Bioreposite ers with an opportunity to gener	(FOA) will support meritorious exp ssion) using the existing biospecime ory), thereby maximizing the scienti ate preliminary data for subsequent	loratory researc n collections tha fic value of the t research propo	h relevant to the N at are stored in the stored collections a psals.	IHLBI mission NHLBI and providing			
107287	Notice of Special Interest (NOSI): Ancillary Studies to Large Ongoing	<u>Heart, Lun</u> g Clinical S	g, Blood and Sleep Focused tudies (Revised)	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL- 21-030 07-	May-2024	Not Specified			
	Contact Name	Jue Chen,	Ph.D.							
	Contact Telephone	301-435-0	)550							
	Contact Email	jue.chen@	<u>@nih.gov</u>							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	07-May-2	024 , 05-Jun-2024 , 07-Sep-2024	، 05-Oct-2024 , 07-Jan-2025 , 05-Fe	eb-2025 , 07-Ma	y-2025				
	Synopsis	This Notice of Special Interest (NOSI) seeks to expand the breadth of scientific research on the clinical course, prevention and treatment of diseases within the mission of the National Heart, Lung, and Blood Institute (NHLBI) by leveraging ongoing clinical research studies through ancillary studies. The purpose of this NOSI is to invite research project applications to conduct focused ancillary studies to large ongoing clinical trials (including late-stage T4 implementation clinical trials), observational studies, and registries. This NOSI also serves as a replacement for NOT-HL-20-755 (expired as of November 6, 2021).								
107093	Notice of Special Interest (NOSI): and Analysis to Health	DEA2Healt	h: Innovative Data Evaluation	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL- 22-001 07-	-May-2024	Not Specified			
	Contact Name	Lucy L. Hs	su, M.P.H.							
	Contact Telephone	301-402-3	3276							
	Contact Email	lucy.hsu@	<u>enih.gov</u>							

SPIN ID	Program Title	Sponsor Name	:	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Link to program URL 07-May-2024 , 05-Jun-2024 , 0 The purpose of this Notice of S science in heart, lung, blood, o to improve health.	7-Sep-2024 Special Inter or sleep (HLE	, 05-Oct-2024 , 07-Jan-2025 est (NOSI) is to stimulate research a 3S) biomedical research, and ultima	and advancemer tely translate ne	nt of methodologie w insights into dee	es in data cision-making
114141	Notice of Special Interest (NOSI): A Cardiovascular Disease (R01 Clinic Trials Allowed)	dvancing Research in Lipoprot al Trials Allowed) and (R01 No (	<u>cein(a) and</u> <u>Clinical</u>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL- 22-052 07-	May-2024	Not Specified
	Contact Name Contact Telephone Contact Email	Lijuan Liu, PhD 301-435-0582 Iliu@nhlbi.nih.gov					
	Sponsor Website Program URL Deadline Dates (ALL)	Link to program URL 07-May-2024 , 05-Jun-2024 , 0 2025 , 05-Oct-2025 , 07-Jan-20	17-Sep-2024 126	, 05-Oct-2024 , 07-Jan-2025 , 05-Fe	b-2025 , 07-Ma	y-2025 , 05-Jun-20	25 , 07-Sep-
	Synopsis	The purpose of this NOSI is to s encourage multidisciplinary co	stimulate re Illaborations	esearch on lipoprotein(a) [Lp(a)] and s to conduct basic, preclinical, and r	l its role in cardi nechanistic clini	ovascular disease cal studies on Lp(a	(CVD). We ) and CVD.

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
116586	Notice of Special Interest (NOSI): TOPMed Data (Parent R01 Clinica	ntegrative Omics Analysis of NHLBI Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL- 23-067	07-May-2024	Not Specified
	Contact Name	James Luo, Ph.D.				
	Contact Telephone	301-435-0533				
	Contact Email	<u>luoja@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2 2025 , 05	024 , 05-Jun-2024 , 07-Sep-202 -Oct-2025 , 07-Jan-2026 , 05-Fe	4 , 05-Oct-2024 , 07-Jan-2025 , 05-Fe b-2026 , 07-May-2026	eb-2025 , 07-Ma	y-2025 , 05-Jun-2(	)25 , 07-Sep-
In the symptom-based diagnosis and treatment of heart, lung, blood, and sleep (HLBS) diseases has vastly improved in recent years, yet an understanding of the molecular mechanisms underlying many of these diseases has remained elusive. Furthermore, in most cases the impact of genetic variation on severity of disease and treatment outcomes remains unknow. Therefore, the NHLBI has created the Trans-omics for Precision Medicine (TOPMed) program, which aims to utilize genomic data to characterize a variety of HLBS diseases. TOPMed is well on its way to collecting whole genome sequence (WGS) from over 194,270 well-phenotyped individuals and is currently generating multi-omics data (e.g., over 31,852 RNA sequences, over 44,342 DNA methylation profiles, and 26,124 metabolomics profiles) from many of these individuals to complement whole genome sequence information. Having produced an unprecedented volume of high-throughput data, TOPMed now seeks to turn its attention to effectively leveraging this resource to uncover biological function and disease pathobiology through novel systems biology analyses and the power of artificial intelligence (AI) and Machine Learning (ML). Although lower costs and technological improvements in sequencing technology have vastly expanded our ability to generate large volumes of omics data, the ability to analyze such large datasets to extract biologically meaningful insights remains challenging. Systems level models incorporating trans-omics analyses will be an important step in uncovering the underlyin biological networks and the gene-gene and gene-environment interactions influencing disease and treatment outcomes. Thus, advanced analyses that incorporate genotype and phenotype datasets from thousands to tens of thousands of individuals are essential to move TOPMed to the next phase of discovery.							ved in recent sive. nains unknown. ilize genomics e (WGS) from sequences, implement DPMed now hobiology Although erate large nains he underlying putcomes. nds of
112260 <u>F</u>	Notice of Special Interest (NOSI): S Pathobiological Mechanisms of Lu Dimensional Cellular Systems (R01	Studies of ng Diseas L)	Cellular/Molecular N es Using Human 3- Ir	ational Heart, Lung, and Blood astitute/NIH/DHHS	NOT-HL- 22-030 07-	May-2024	Not Specified
	Contact Name	Qing Lu, I	٥h.D.				
	Contact Telephone	301-480-9	9158				
	Contact Email	qing.lu@i	nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2025	024 , 05-Jun-2024 , 07-Sep-202	4 , 05-Oct-2024 , 07-Jan-2025 , 05-Fo	eb-2025 <i>,</i> 07-Ma	y-2025 , 05-Jun-20	)25 , 07-Sep-
	Synopsis	The purpo onset and experime	ose of this NOSI is to promote re I progression of lung diseases a ntal systems with cellular heter	esearch characterizing the pathobio t a molecular/cellular level, providin ogeneity and 3-D architecture. It is e	logical processes g a systems-leve expected that pro	and mechanisms I understanding b ojects supported b	that drive the y studying by this NOSI

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
		will utilize lung cells specific p	e ex vivo preparations (e.g., th and will employ state-of-art athobiological processes in sy	nin human lung slices) or 3-D multi-ce multi-omics measures (e.g., spatial or /stems of interacting cell types.	llular in vitro syst single cell/nucle	ems (e.g., organoi us omics) to bette	ds) of human r understand			
106202	Notice of Special Interest (NOSI): Cardiometabolic Health in Early S adolescence Through Adolescence	Promoting tages of th e to Young	<u>Cardiovascular and</u> e Lifecourse: Pre- Adulthood	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL- 21-015 07-	May-2024	Not Specified			
	Contact Name	Alison G.I	M. Brown, PhD, MS, RDN							
	Contact Telephone	301-435-	0583							
	Contact Email	Alison.bro	own@nih.gov							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	07-May-2 2025,05	.024 , 05-Jun-2024 , 07-Sep-2 -Oct-2025 , 07-Jan-2026 , 05-	024 , 05-Oct-2024 , 07-Jan-2025 , 05-I Feb-2026 , 07-May-2026 , 05-Jun-202	Feb-2025 , 07-Ma 6	y-2025 , 05-Jun-20	)25 , 07-Sep-			
	Synopsis	This Notice of Special Interest (NOSI) calls for research to understand and promote cardiovascular and cardiometabolic health during transitionary phases across the lifecourse, from pre-adolescence (6-10 years) through adolescence (11-18 years) to young adulthood (19-39 years). This initiative would support research to: 1) understand the mechanisms and the pathogenesis of cardiometabolic health and cardiovascular disease (CVD) risk in vulnerable groups throughout transitionary phases from pre-adolescence into adolescence and adolescence into young adulthood, and 2) develop precision prevention interventions (at the individual and populations levels) to address cardiovascular and cardiometabolic risk across these transitionary phases								
113286	Notice of Special Interest (NOSI): Circadian Regulation of Heart, Lui	Basic and <sup>·</sup> ng, Blood,	Translational Research on and Sleep Disorders (R01)	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL- 22-043 07-	May-2024	Not Specified			
	Contact Name	Ravi Balij	epalli, Ph.D.							
	Contact Telephone	301-435-	0504							
	Contact Email	<u>ravi.balije</u>	palli@nih.gov							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	07-May-2 2025 , 05	024 , 05-Jun-2024 , 07-Sep-2 -Oct-2025 , 07-Jan-2026 , 05-	024 , 05-Oct-2024 , 07-Jan-2025 , 05- Feb-2026 , 07-May-2026 , 05-Jun-202	Feb-2025 , 07-Ma 6 , 07-Sep-2026 ,	y-2025 , 05-Jun-20 05-Oct-2026 , 07-	)25 , 07-Sep- Jan-2027 , 05-			

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	Feb-2027 This NOSI periphera diagnosis, mechanis multiple i and sleep purpose is preventio clinical ma molecular are appro to assess	127, 07-May-2027, 05-Jun-2027, 07-Sep-2027, 05-Oct-2027, 07-Jan-2028 OSI aims to stimulate research on understanding how circadian rhythms regulate cell function and metabolism of eral tissues, and to find new avenues for the investigation of heart, lung, and blood disease risk, pathogenesis, risis, treatment, and prevention. Basic, translational, and clinical research applications to elucidate circadian-dependent inisms contributing to the pathophysiology of HLBS disorders are invited. This NOSI encourages multidisciplinary and le investigator teams of experts in heart, lung, and blood research fields to synergistically work with circadian biologists eep researchers to provide a comprehensive understanding of the circadian biology in relation to HLBS conditions. The se is to facilitate translational research to identify potential applications of circadian science to the diagnosis, ntion and treatment of HLBS conditions. Mechanism-based studies investigating the circadian rhythm dysregulation, I markers, and/or therapeutic targets of HLBS conditions are encouraged. Behavioral, physiological, pharmacological, ular, and genomic studies aimed at elucidating the relationship between circadian-dependent mechanisms and disease propriate. Studies to delineate circadian-based mechanisms, therapeutic targets, epidemiological risk and clinical trials ess therapeutic safety, efficacy, effectiveness, or implementation may be proposed.				
106893	NHLBI Career Transition Award fo Research Trainees (K22 Independe	r Intramur ent Clinica	al Postdoctoral Fellows and I Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22- 034 12-	Jun-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	Shawn Be 301-827-5 direducat	ediako, Ph.D. 5163 <u>sion@nhlbi.nih.gov</u>				
	Program URL Deadline Dates (ALL) Synopsis	Link to pr 12-Jun-20 The purpe doctoral-l their rese Transition phase (th extramura during the be carried candidate ancillary s	ogram URL 024 ose of the NHLBI Career Trans level researchers currently in arch programs to extramural n Award will support two phas ree years), for a total of five y al phase is not automatic. App e mentored phase as determi d out at the extramural institu es proposing research that doo study to a clinical trial. Applica	ition Award (K22) program is to provio training in the NHLBI Division of Intrar institutions as junior investigators. To ses of research: a mentored intramura ears of combined support. Transition proval of the transition will be based o ned by an NHLBI progress review, whi ition. This Funding Opportunity Annou es not involve leading an independent ants to this FOA are permitted to prop	de highly qualifie mural Research w achieve these ol al phase (up to tw from the intramu on the success of ch will include ar incement (FOA) i c clinical trial, a cl ose research exp	d postdoctoral fel vith the opportuni ojectives, the NHLI vo years) and an ex ural phase of supp the awardee's res n evaluation of a re s designed specific inical trial feasibili perience in a clinica	lows and other ty to transition BI Career xtramural ort to the earch program esearch plan to cally for ity study, or an al trial led by a

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		mentor o companic (K22- Clin	r co-mentor. Those proposing on FOA, PAR-22-040 "NHLBI ( ical Trial Required)".	a clinical trial or an ancillary clinical Career Transition Award for Intramur	trial as lead inve al Postdoctoral f	stigator, should ap fellows and Resear	oly to the ch Trainees
106898	NHLBI Career Transition Award for Research Trainees (K22 Clinical Tr	or Intramur ial Require	ral Postdoctoral Fellows and ed)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22- 040 12	-Jun-2024	Not Specified
	Contact Name	Shawn Be	ediako, Ph.D.				
	Contact Telephone	301-827-	5163				
	Contact Email	direducat	<u>ion@nhlbi.nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	12-Jun-20	)24				
	Synopsis	The purper doctoral- their rese Transition phase (th extramur during the be carried applicant separate serve as l	ose of the NHLBI Career Trans level researchers currently in t earch programs to extramural n Award will support two phas ree years), for a total of five y al phase is not automatic. App e mentored phase as determined out at the extramural institu s proposing to serve as the lead ancillary study to an existing t ead investigator of an indeper	ition Award (K22) program is to prov training in the NHLBI Division of Intra institutions as junior investigators. To ses of research: a mentored intramur ears of combined support. Transition proval of the transition will be based ned by an NHLBI progress review, wh tion. This Funding Opportunity Anno ad investigator of an independent clin rial, as part of their research and car indent clinical trialmust apply to the c	ide highly qualifi mural Research o achieve these of al phase (up to t from the intran on the success o nich will include a uncement (FOA) hical trial, a clinic eer developmen ompanion FOA (	ed postdoctoral fe with the opportun objectives, the NHL wo years) and an e nural phase of supp f the awardee's res in evaluation of a r is designed specifi cal trial feasibility s t. Applicants not pr PAR-22-034).	lows and other ty to transition BI Career xtramural ort to the search program esearch plan to cally for tudy, or a oposing to
112358	Data Coordinating Center for Mu Trials (Collaborative U24 Clinical	ti-Site Inve Frial Requi	estigator-Initiated Clinical red)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22- 10 193	-May-2024	Not Specified
	Contact Name	Nancy Dif	Fronzo, PhD				
	Contact Telephone	301-435-0	0065				
	Contact Email	difronzon	@nhlbi.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Deadline Dates (ALL)	10-May-2 2025	024 , 11-Jun-2024 , 11-Sep-202	4 , 11-Oct-2024 , 10-Jan-2025 , 11-Fe	eb-2025 , 12-Ma	y-2025 , 11-Jun-20	)25 , 11-Sep-	
	Synopsis	This Fund investigat research of FOA appli 15-015). F encourag award and Coordinat COC appli clinical tri submitted appropria	ing Opportunity Announcement cor-initiated multi-site clinical tra- clinical trials. Trials using innova- als may include ones that test d es must be relevant to the rese- for additional information abou- ed to consult the NHLBI website d runs in parallel with a compar- cing Center (CCC). The objective ion, administration, data mana- cation. The application should a al community engagement and d on the same application due of the Scientific/Research contact	t (FOA) supports applications for a co- ials including efficacy, comparative e- ative designs such as platform trials, a ifferent therapeutic, behavioral, and, earch mission of the NHLBI and meet at the mission, strategic vision, and re- e. This FOA will utilize a milestone-du- nion FOA PAR-22-192() that encourage of the DCC application is to present gement, and biostatistical support for also describe its approaches to collab diversity plans. Both a DCC application date for consideration by NHLBI. App prior to submitting an application.	ollaborating Data offectiveness, pra- adaptive, and Ba /or prevention s the NIH definition esearch priorities riven cooperative ges applications a comprehensive or the clinical trianorate with the C tion and a collab licants are stron	a Coordinating Ce agmatic and/or im ayesian designs are trategies. Trials fo on of a clinical tria s of the NHLBI, ap e agreement mec for a collaborating re plan to provide al proposed in the CCC on implement porating CCC appli- gly encouraged to	nter (DCC) for plementation e encouraged. r which this l (see NOT-OD- plicants are hanism of g Clinical overall project collaborating ation of the cation must be contact the	
112357	Clinical Coordinating Center for M Trials (Collaborative UG3/UH3 Clir	Iulti-Site In nical Trial I	westigator-Initiated Clinical N Required) II	lational Heart, Lung, and Blood nstitute/NIH/DHHS	PAR-22- 192 10-	May-2024	Not Specified	
	Contact Name	Nancy Dif	Fronzo, PhD					
	Contact Telephone	301-435-0	0065					
	Contact Email	<u>difronzon</u>	<u>@nhlbi.nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	10-May-2 2025	024 , 11-Jun-2024 , 11-Sep-202	4 , 11-Oct-2024 , 10-Jan-2025 , 11-Fe	eb-2025 , 12-Ma	y-2025 , 11-Jun-20	)25 , 11-Sep-	
	This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian desig are encouraged. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and resear priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone							

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		driven coo for a colla rationale address p dissemina diversity a Center (D strongly e	operative agreement mechanis borating Data Coordinating Ce for the clinical trial and a comp roject management, subject re ation of results. The application as well as reducing health ineq CC) application must be submi encouraged to contact the appl	sm of award and runs in parallel with enter (PAR-22-193). The objective of prehensive scientific and operational ecruitment and retention, performan a should also describe its approaches uities and disparities. Both a CCC app tted on the same application due da copriate Scientific/Research contact	a companion FC the CCC applicat plan that descri to increasing co plication and a co te for considerat prior to submitti	DA that encourage ion is to present th bes it. The applicat cientific conduct o mmunity engagen ollaborating Data C ion by NHLBI. App ng an application.	s applications the scientific tion should f the trial, and thent and Coordinating licants are
112356 <u>Si</u>	ngle-Site Investigator-Initiated C equired)	<u>linical Tria</u>	ls (R61/R33 Clinical Trial	National Heart, Lung, and Blood nstitute/NIH/DHHS	PAR-22- 189	May-2024	Not Specified
	Contact Name	Nahed El	Kassar, MD				
	Contact Telephone	301-435-0	0065				
	Contact Email	nahed.elk	assar@nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	10-May-2 2025	024 , 11-Jun-2024 , 11-Sep-202	24 , 11-Oct-2024 , 11-Jan-2025 , 11-F	eb-2025 , 11-Ma	y-2025 , 11-Jun-20	)25 , 11-Sep-
	Synopsis	This Fund site clinica using inno ones that relevant t additional consult th applicatio describes milestone not requir coordinat inequties	ing Opportunity Announcement al trials including efficacy, comported trials including efficacy, comported to the source of the source of the research mission is to present the scientific ratio is to present the scientific ratio should address, scientific conduct of the triared. Applicants are encouraged ion. The application should als and disparities, and include a lason of the research mission of the research mission should als and disparities.	nt (FOA) supports applications to dev parative effectiveness, pragmatic an m trials, adaptive, and Bayesian designational, and/or prevention strategie NHLBI and meet the NIH definition of n, strategic vision, and research prior Il utilize a bi-phasic, milestone-driver tionale for the clinical trial and a con- ress project management, subject re I, and dissemination of results. The r I to include a PD/PI with expertise in o describe its approaches to increasi Plan for Increasing Diverse Perspective	velop and implen d/or implementa gns are encourag s. Trials for whic f a clinical trial (s rities of the NHLI n mechanism of a nprehensive scie cruitment and re nultiple PD/PI m biostatistics, clir ng community e ves (PDEP).	nent investigator-in ation research clini ged. These trials m h this FOA applies ee NOT-OD-15-01 BI, applicants are e award. The objecti ntific and operatio etention, performa odel is strongly en- nical trial design, an ngagement, reduc	nitiated single cal trials. Trial ay include must be 5). For encouraged to ve of the mal plan that nce couraged but nd ing health

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
113729	RFA-HL-24-005 Limited Competi K01/K08/K23/K25 Recipients (R03	ition: Small Grant Program for NHL Clinical Trial Optional)	BI National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL- 24-005 07-	May-2024	150,000 USD
	Contact Name	Qing Lu, Ph.D.				
	Contact Telephone	301-480-9158				
	Contact Email	<u>Qing.Lu@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2024 , 13-Jun-2024 , 07-Se 2025 , 13-Oct-2025 , 07-Jan-2026	ep-2024 , 17-Oct-2024 , 07-Jan-2025 , 13-	Feb-2025 <i>,</i> 07-Ma	y-2025 , 13-Jun-20	)25 , 07-Sep-
	Synopsis	The purpose of this funding oppor and K25 recipients for small grant resulted from the research conduc support after the notice of award K23, and K25 recipients are eligible NHLBI K award Project Period end recipients to conduct research as t intended to support research proje years) with limited resources and t These studies include, but are not existing data; small, self-contained development of novel experiment the proposed R03 project, is requi application may or may not includ	tunity announcement (FOA) is to solicit c support to expand their current research cted under the K award. Active NHLBI K01 (NoA) for their first type-5 K awards has b to apply for the R03 if the earliest possi date. This FOA is intended to enhance the they complete their transition to fully indu- ects that can be carried out and complete that may generate preliminary data to su limited to, pilot or feasibility studies; pro I research projects; development of new al models. A minimum of 40% protected red from applicants. For current and prev e patient-oriented research.	urrent or recently objectives or to b , K08, K23, and K2 een issued. Recent of R03 start date e capability of NH ependent investig ed within a short p oport a subseque of of concept stud research methodo overall research e ious K23 recipien	completed NHLB pranch out to a ne 25 recipients may ntly completed NH falls within 2 year LBI K01, K08, K23, rator status. This R period of time (no nt R01-equivalent dies; secondary an plogies or technolo ffort, not necessa ts, research propo	K01, K08, K23, w study that apply for R03 ILBI K01, K08, 's of their prior and K25 .03 program is more than two application. alysis of ogies, or rily limited to sed in the R03
122332	NHLBI Clinical Trial Pilot Studies (R	34 Clinical Trial Optional)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-24- 049 07-	May-2024	450,000 USD
	Contact Name	Patrice Desvigne-Nickens, MD				

Contact Telephone 301-435-0504

Contact Email <u>desvignp@mail.nih.gov</u>

Sponsor Website

Program URL Link to program URL

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2 2025, 16 This Notic a Phase II clinical tr subseque sufficient test the e heart, lur for clinica provide n therefore proposed diverse te teams. Th enhancin advancing To suppo perspecti researche well as bi undergra geograph Participat behaviora with disal to benefit will be as considere and view	2024 , 16-Jun-2024 , 07-Sep-2024 -Oct-2025 , 07-Jan-2026 , 16-Fel ce of Funding Opportunity (NOF I-IV clinical trial within NHLBI's n ial and in so doing demonstrate ent trial. Furthermore, this NOFC to inform the future trial witho efficacy, safety, clinical managen ng, blood, or sleep disorders. In c al trials (as described at Clinical T new information that answers a e, informs the final development future clinical trial will require eams working together and capi nere are many benefits that flow g global competitiveness, contri g the likelihood that underserve rt the best science, the NIH enco ves include but are not limited to eas from fields such as computat oethics Engagement from diff duate-focused, minority-serving ic and regional heterogeneity tion of individuals from diverse I al, and clinical research workfor bilities, those from disadvantage t early- and mid-career investiga sessed as part of the scientific a ed incomplete and will be withd the available PEDP guidance ma	4 , 16-Oct-2024 , 07-Jan-2025 , 16- b-2026 , 07-May-2026 , 16-Jun-202 O) supports studies that are both hission. The NHLBI expects that ap that the proposed (R34) research O will support research projects the ut further studies. The planned Ph nent, or implementation of interve contrast to the study start up or pr frial Development Continuum   NI scientific or operational question(st of a Phase II-IV clinical trial. Regard a new application. Plan for Enhand talizing on innovative ideas and di v from a diverse scientific workford buting to robust learning environr d populations participate in, and k ourages inclusivity in research. Exa co: -Transdisciplinary research proj cional biology, physics, engineering erent types of institutions and org g, community-based) Individual a Investigators and teams compose backgrounds, including groups hist ce (see NOT-OD-20-031), such as u ed backgrounds, and women Op ators. This NOFO requires a Plan for nd technical peer review evaluation rawn. Applicants are strongly enco- aterial.	-Feb-2025, 07-May 26, 07-Sep-2026, necessary and suff oplications to this N is scientifically nec at are designed to hase II, III, or IV tria ention(s) in the pre reparation phase o HLBI, NIH), the R34 s) which may be pr rdless of the result cing Diverse Perspe stinct perspectives ce, including: foste ments, improving t benefit from resear amples of structure jects and collabora g, mathematics, co ganizations (e.g., re applications and pa ed of researchers at torically underrepr underrepresented in portunities to enha- or Enhancing Diver burged to read the	y-2025 , 16-Jun-20 16-Oct-2026 , 07- icient to inform the IOFO will describes ressary to design of provide results the l must be primarile vention and/or tr f NHLBI funding of mechanism is inter agmatic in natures s of the R34, supple ectives The NIH re coutperform hom ring scientific inno- he quality of the re rch, and enhancing es that promote di tions among neur mputer and data search-intensive, artnerships that er t different career esented in the bio racial and ethnic g ance the research rese Perspectives (F at fail to include a e NOFO instructio	225,07-Sep- Jan-2027 The planning of the planned or plan the at will be y intended to eatment of pportunities ended to and, out of the cognizes that ogeneous ovation, research, g public trust. verse oscientists and sciences, as hhance stages omedical, groups, those environment PEDP), which a PEDP will be ns carefully
c	Single-Site Investigator-Initiated (	Clinical Tria	als (P61/P22 Clinical Trial N	ational Heart Lung and Blood	DAR-22-		Not

111/75	Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial	National Heart, Lung, and Blood	PAR-22-	10 May 2024	Not
111425	Required)	Institute/NIH/DHHS	189	10-10189-2024	Specified

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name	Nahed El	Kassar, MD				
	Contact Telephone	301-435-0	0065				
	Contact Email	nahed.elk	<u>kassar@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	10-May-2 2025	024 , 11-Jun-2024 , 11-Sep-202	4 , 11-Oct-2024 , 11-Jan-2025 , 11-F	<sup>-</sup> eb-2025 , 11-Maչ	/-2025 , 11-Jun-2(	)25 , 11-Sep-
This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initial site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may in ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. The objective of application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational productions is to present the scientific rationale for the clinical trial and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encour not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination. The application should also describe its approaches to increasing community engagement, reducing h							nitiated single cal trials. Trials ay include must be 5). For encouraged to we of the onal plan that nce couraged but nd ing health
106072 <mark>N</mark>	lotice of Special Interest (NOSI): leart, Lung, Blood and Sleep Disc	Bold New orders and	Bioengineering Research for N Diseases (Reissue)	lational Heart, Lung, and Blood nstitute/NIH/DHHS	NOT-HL- 21-024 07-I	May-2024	Not Specified
	Contact Name	Narasimh	an Danthi, Ph.D.				
	Contact Telephone	301-435-5	5170				
	Contact Email	ndanthi@	)mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	024 , 16-Jun-2024 , 07-Sep-202	24 , 16-Oct-2024 , 07-Jan-2025			
	Synopsis	This Notic	ce of Special Interest is a reissu	e of NOT-HL-20-796. The purpose o	f this NOSI is to ad	lvise potential app	plicants to the

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		National H bioengine commerci research i overlap w pipeline.	Heart, Lung and Blood Institut eering projects which are expe ial products. Please note that into future follow-on funding, with the NHLBI Catalyze Progra	te (NHLBI) of an area of special intere ected to transition their research into this R21 program does not overlap v technologies, or commercial produc am, and it does focus on new investig	est to support ear o future follow-or vith projects whic sts. Please note th gator-initiated ide	rly phases of innovan funding, technolo ch are expected to nat this R21 progra eas that will feed in	ative ogies, or transition their m does not ito the Catalyze
108068	Notice of Special Interest (NOSI): E Tools for Use in Underserved Popu	Diagnostic ulations	s and Disease Management	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL- 22-024 07	-May-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Bishow Ad 301-594-2 adhikarb@ Link to pro 07-May-2 The purpo managem populatios homeless disadvant will be giv partners i	dhikari, Ph.D. 2791 <u>ogram URL</u> 024 , 05-Jun-2024 , 07-Sep-20 ose of this NOSI is to stimulation ns. Underserved populations , low-income individuals, the aged, rural or have few healt ren to technology solutions the s required throughout the pro-	024 , 05-Oct-2024 , 05-Feb-2025 , 05- e research focused on the developme od, or sleep (HLBS) disorders that are , for the purpose of this NOSI, can ind uninsured and people who live in con h care resources. Please see NOT-OD nat are accessible and feasible in thes oject to ensure successful developme	Jun-2025 ent of transforma designed to mee clude racial and e mmunities that a 2-20-031 for NIH se communities. N ent and impleme	ative diagnostics an et the needs of the thnic minorities, in re socioeconomica definitions. Special Working with comr ntation.	Id disease underserved nmigrants, the Illy consideration munity
108064	Notice of Special Interest (NOSI): F Mitochondrial Involvement in Lung	Promoting g Diseases	Fundamental Research on and Sleep Disorders	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL- 22-003 07	-May-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Jining Lu 301-827-2 jining.lu@ Link to pro 07-May-2	2807 2 <u>nih.gov</u> 0gram URL 024 , 05-Jun-2024 , 07-Sep-20	024 , 05-Oct-2024 , 07-Jan-2025 , 05-	Feb-2025		

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
	Synopsis	The purpose of this NOSI is to stimulate research focused on cell-type-specific signatures of mitochondrial behavior in healthy and diseased lungs. Multidisciplinary collaboration among experts in recently developed technologies, such as iPS cell and lung progenitor/organoid culture systems, advanced single cell-and "-omic" technologies, and lung cell biology is encouraged. We encourage investigators to Utilization oflung cells from human donors and animal models with respiratory diseases and/or well-defined congenital mitochondrial diseases is also encouraged.								
125065	NHLBI Early Phase Clinical Trials for HLBS Disorders (R33 CT Required)	or Therapeutics and/or Diagnostics for )	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-24- 172	05-May-2024 [Optional][LOI/Pre- App]	4,545,000 USD				
	Contact Name	Sumita Khatri, MD								
	Contact Telephone	301-402-9673								
	Contact Email	<u>sumita.khatri@nih.gov</u>								
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	<ul> <li>05-May-2024 [Optional][LOI/Pre-App], 04-Jun-2024, 03-Sep-2024 [Optional][LOI/Pre-App], 07-Sep-2024, 02-O Jan-2025 [Optional][LOI/Pre-App], 03-Feb-2025, 05-May-2025 [Optional][LOI/Pre-App], 07-May-2025, 04-Jun</li> <li>(ALL) 2025 [Optional][LOI/Pre-App], 07-Sep-2025, 02-Oct-2025, 04-Jan-2026 [Optional][LOI/Pre-App], 07-Jan-2026 05-May-2026 [Optional][LOI/Pre-App], 07-May-2026, 04-Jun-2026, 03-Sep-2026 [Optional][LOI/Pre-App], 07-Oct-2026, 07-Jan-2027</li> </ul>								
	iated, Phase 1 clinical is in adults and childre O should be ready to i ainment of applicable es, and any necessary d other pre-clinical and 173, which utilizes an	trials for n. The nitiate the regulatory third-party d/or trial R61/R33								
	NHI BI Farly Phase Clinical Trials fo	or Therapeutics and/or Diagnostics	National Heart Lung and Blood	PAR-24-	05-May-2024	Not				

NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics<br/>(R61/R33 Clinical Trial Required)National Heart, Lung, and Blood<br/>Institute/NIH/DHHSPAR-24-<br/>[Optional][LOI/Pre-<br/>App]Not<br/>Specified

Contact Name Sumita Khatri, MD

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Contact Telephone	301-402-9	9673							
	Contact Email	sumita.kh	natri@nih.gov							
	Sponsor Website									
	Program URL	<ul> <li>Link to program URL</li> <li>05-May-2024 [Optional][LOI/Pre-App], 04-Jun-2024, 03-Sep-2024 [Optional][LOI/Pre-App], 07-Sep-2024, 02-Oct-2024</li> <li>Jan-2025 [Optional][LOI/Pre-App], 07-Jan-2025, 03-Feb-2025, 05-May-2025 [Optional][LOI/Pre-App], 07-May-2025, 04-Jan-2026 [Optional][LOI/Pre-App], 07-Jan-03-Feb-2026, 05-May-2026 [Optional][LOI/Pre-App], 07-May-2026, 04-Jun-2026, 03-Sep-2026 [Optional][LOI/Pre-App]</li> <li>Sep-2026, 02-Oct-2026, 07-Jan-2027</li> </ul>								
	Deadline Dates (ALL)									
	The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This FOA will utilize bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities su as stability, shipping studies, and site training.									
<u> </u> 115585 <u>t</u> [	Notice of Special Interest (NOSI): 1 to Evaluate Candidate -Omics Var Blood, or Sleep Disease (R01, R41)	Developm iants Asso , R42, R43,	ent of Functional Assay Sites ciated with Heart, Lung, , R44)	lational Heart, Lung, and Blood nstitute/NIH/DHHS	NOT-HL- 23-066 07-	May-2024	Not Specified			
	Contact Name	Charlene	Schramm, Ph.D.							
	Contact Telephone	301-402-3	3793							
	Contact Email	<u>schramm</u>	<u>c@nih.gov</u>							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL) Deadline Dates (ALL) Synopsis 07-May-2024, 05-Jun-2024, 05-Sep-2024, 07-Sep-2024, 05-Oct-2024, 05-Jan-2025, 07-Jan-2025, 07-Jan-2025, 05-Oct-20 05-Jan-2026, 07-Jan-2026, 05-Feb-2026, 05-Apr-2026, 05-Apr-2026, 05-Jun-2026, 05-Sep-2026, 07-Sep-2026, 07-Sep-2026 The NHLBI is issuing this Notice of Special Interest (NOSI) to highlight interest in receiving grant applications focused of disorders in the following area(s): Development and/or application of moderate- or high-throughput functional assays provide biological validation of candidate human variants associated with HLBS disorders Defining causal relationships									
SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
---------	--	--	--	--	--	--	--			
		between	genotypes and phenotypes Do	evelopment and validation of function	ally informed r	sk predictions				
108514	RFA-HG-22-004 Genome Resear Undergraduates into Genomic Fiel Trial Not Allowed)	<u>ch Experie</u> Ids to Enh	ences to Attract Talented ance Diversity (R25 Clinical	National Human Genome Research Institute/NIH/DHHS	RFA-HG- [O 22-004 Ar	-Jun-2024 ptional][LOI/Pre- p]	1,750,000 USD			
	Contact Name	Tina Gatli	n, Ph.D.							
	Contact Telephone	301-480-2	2280							
	Contact Email	gatlincl@	<u>nih.gov</u>							
	Sponsor website	Link to pr	ogram LIPI							
	Deadline Dates (ALL)	01-lun-20	024 [Optional][I OI/Pre-App]. (	)1- u -2024						
	Synopsis	The NIH F overarchi backgrou studies or mission a undergrad pursue fu accomplis Research into the G provide re Developm research- interest te	Research Education Program ( ng goal of this R25 program is nds, including those from grou careers in research The NIH reas of the NIH. The overarch duates from diverse backgrou rther training and careers in t sh the stated over-arching goa Experiences Courses for Skills Genomic Field to Promote Dive esearch education programs f nent Award (IDeA)-eligible ins- intensive institutions or organ o NHGRI.	R25) supports research education acti to support educational activities that ups underrepresented in the biomedic Research Education Program (R25) su ing goal of this NHGRI R25 program is nds, including those from groups unde he scientific, medical, ethical, social an il, this FOA will support creative educa Development This Genome Research ersity (GREAT) Program will support co or undergraduates enrolled at minorit titutions. A partnership will include a l izations with a suitable research base	vities in the mis encourage indi cal and behavio pports research to support edu errepresented i nd/or legal area tional activities Experiences to ollaborative inst cy-serving instit MSI or IDeA-elia for graduate-le	sion areas of the N viduals from divers ral sciences, to pur- education activities the biomedical w is of genomics rese with a primary foo Attract Talented U itutional partnersh utions (MSIs) or Ins gible institution, an evel training in scien	IH. The se sue further s in the nat encourage orkforce, to arch. To cus on: ndergraduates ips that titutional d one or more ntific areas of			
108325	Notice of Special Interest (NOSI): I Clinical Informatics Tools to Enhan Information	<u>Developm</u> nce Patien	ent and Implementation of ts' Use of Genomic	National Human Genome Research Institute/NIH/DHHS	NOT-HG- 22-011 07	-May-2024	Not Specified			
	Contact Name	Ken Wiley	ι, Jr., Ph.D.							
	Contact Telephone	301-435-5	5540							



SPIN ID	Program Title	Sponsor Name	9	Sponsor Number		Deadline Date	Funding Amount
	Contact Email	ken.wiley@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-May-2024 , 25-May-20	024 , 05-Jun-202	24 , 16-Jun-2024 , 07-Sep-2024			
	Synopsis	The National Human Gen applications to develop a patient-provider electron provider electronic presc	ome Research I nd implement p iic communicati ribing, test tracl	nstitute (NHGRI) is issuing a Notice patient-facing genomic-based clinica on, patient tracking and registry fur king, referral tracking, and health ca	of Special Inter Il informatics to actions, patient are decision-ma	est (NOSI) to encou ools that facilitate of self-management a king.	rage renhance ind support,
107786	Notice of Special Interest (NOSI): Studies of Genetic Variation, Fund	Methods Development for tion, and Disease	<u>r Genomic</u> N Ir	lational Human Genome Research nstitute/NIH/DHHS	NOT-HG- 22-007 0	7-May-2024	Not Specified
	Contact Name	Lisa D. Brooks, Ph.D.					
	Contact Telephone	301-547-1387					
	Contact Email	lisa.brooks@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-20	24 , 16-Jun-2024	4 , 05-Sep-2024 , 07-Sep-2024 , 05-0	Dct-2024		
	Synopsis	The National Human Gen applications that develop relate to genomic functio	ome Research I novel computa n, phenotype, a	nstitute (NHGRI) is issuing this Notion ntional or experimental approaches and disease.	ce of Special In for genomic stu	terest (NOSI) to enc udies of how genetion	ourage : variants
113281	NAID Investigator Initiated Progr Trial Not Allowed)	am Project Applications (P	<u>01 Clinical</u> N Ir	lational Institute of Allergy and nfectious Diseases/NIH/DHHS	PAR-22- 225	7-May-2024	Not Specified
	Contact Name	Mr. Martin Gutierrez, B.S					
	Contact Telephone	240-292-4844					
	Contact Email	mgutierrez@niaid.nih.gov	<u>v</u>				
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-May-2024 , 11-Jun-20	24 , 07-Sep-202	4 , 10-Jan-2025 , 07-May-2025 , 11-	Jun-2025 , 07-9	Sep-2025	

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	This Fund applicatic pathogen developm allergy, as therapeu to this FC overall of	ling Opportunity Announcem ons. The proposed programs s tesis of infectious microbes, in nent and function across the sthma, autoimmunity, immur tics, and diagnostics to preve oA must include at least two r ojective; and an administrativ	ent (FOA) invites submission of invest should address scientific areas relevan including HIV; host-microbe interaction ifespan, and in response to infection nodeficiency, or transplant rejection; nt and treat infectious and immune- elated, synergistic research projects e core. A PO1 may include scientific o	stigator-initiated ant to the NIAID r ons; mechanisms is pathogens; imi and translationa mediated disease that share a com cores, if needed f	Program Project (Penission including: binesion including: binesion including: binesion including in the mune dysfunction restance of the proposed	D1) iology and system esulting in op vaccines, ition submitted focus, and/or search.
123129 <u>(</u>	FA-AI-24-002 Research Initiati UG3/UH3 Clinical Trial Not Allow	ve for Vaco ed)	cine and Antibiotic Allergy	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 2 24-002 A	2-May-2024 )ptional][LOI/Pre- pp]	1,250,000 USD
	Contact Name	Patricia F	ulkerson, MD, PhD				
	Contact Telephone	202-641-4	4535				
	Contact Email	patricia.fu	ulkerson@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	22-May-2	024 [Optional][LOI/Pre-App]	21-Jun-2024			
	Synopsis	The purpo mechanis	ose of this notice of funding on the second se	opportunity (NOFO) is to support resine and antibiotic drug allergy.	earch that enhan	ces understanding	of the
108513 A	IIAID Career Transition Award (K Ilowed)	22 Indeper	ndent Clinical Trial Not	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-22- 075	7-May-2024	Not Specified
	Contact Name						
	Contact Telephone						
	Contact Email	AlTraining	gHelpDesk@niaid.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	024 , 12-Jun-2024 , 07-Sep-2	024 , 12-Oct-2024 , 07-Jan-2025			
	Synopsis	The purp	ose of the NIAID Career Trans	ition Award program is to assist pos	tdoctoral fellows	' transition to posit	ions of

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		assistant Funding C leading ai candidate	professor or equivalent and in Opportunity Announcement ( n independent clinical trial, a es are permitted to propose a	nitiate a successful biomedical caree FOA) is designed specifically for canc clinical trial feasibility study, or an ar research experience in a clinical tria	r as an indepe lidates propos ncillary study t I led by anoth	ndent research scient ing research that doe to a clinical trial. Unde er investigator.	ist. This s not involve r this FOA
115066	NIAID Physician-Scientist Pathway Independent Clinical Trial Not Allo	<u>/ to Indepe owed)</u>	endence Award (K99/R00	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-23- 071	07-May-2024	Not Specified
	Contact Name						
	Contact Telephone	301-594-5	5945				
	Contact Email	AlTraining	gHelpDesk@niaid.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2025 , 12	.024 , 12-Jun-2024 , 07-Sep-20 -Oct-2025 , 07-Jan-2026	024 , 12-Oct-2024 , 07-Jan-2025 , 12·	-Feb-2025 , 07	-May-2025 , 12-Jun-2	025 , 07-Sep-
	Synopsis	The purpe a strong of transitions support d thereby h is designe trial feasi in a clinica should ap	ose of the NIAID Physician-Sci schort of new and talented in of outstanding postdoctoral to independent, tenure-track luring this transition to help a help to address the national p ed specifically for candidates p bility study, or an ancillary clin al trial led by a mentor or co- oply to the companion FOA (P	entist Pathway to Independence Aw dependent physician-scientists. This researchers with a clinical doctorate or equivalent faculty positions. The wardees launch competitive, indepen- hysician-scientist workforce shortage proposing research that does not invinical trial. Under this FOA candidates mentor. Those proposing a clinical tri AR-23-070).	ard (K99/R00) s program is de e degree from i program will j endent researc e. This Funding olve leading a s are permitter ial or an ancill	program is to increas esigned to facilitate a mentored, postdoctor provide independent l ch careers in biomedic g Opportunity Announ n independent clinica d to propose a researd ary clinical trial as lead	e and maintain timely ral research NIAID research al fields and cement (FOA) trial, a clinical ch experience d investigator,
115065	NIAID Physician-Scientist Pathway Clinical Trial Required)	<u>/ to Indepe</u>	endence Award (K99/R00	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-23- 070	07-May-2024	Not Specified
	Contact Name						
	Contact Telephone	301-594-5	5945				
	Contact Email	AlTraining	gHelpDesk@niaid.nih.gov				
	Sponsor Website						

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2 2025 , 07-	024 , 12-Jun-2024 , 12-Oct-202 -Jan-2026	24 , 07-Jan-2025 , 12-Feb-2025 , 07-I	May-2025 , 12-Jur	a-2025 , 07-Sep-20	25 , 12-Oct-		
Synopsis Synopsis Synopsis									
113372	Notice of Special Interest (NOSI):	Halting Tul	berculosis (TB) Transmission	National Institute of Allergy and nfectious Diseases/NIH/DHHS	NOT-Al- 22-064 07-	May-2024	Not Specified		
	Contact Name	Karen Lac	ourciere, Ph.D.						
	Contact Telephone	240-627-3	3297						
	Contact Email	lacourcier	rek@niaid.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2 2025 , 07-	024 , 05-Jun-2024 , 16-Jun-202 -May-2025 , 05-Jun-2025 , 16-J	24 , 07-Sep-2024 , 05-Oct-2024 , 16-0 un-2025 , 07-Sep-2025 , 05-Oct-202	Oct-2024 , 07-Jan 5 , 16-Oct-2025 ,	2025 , 05-Feb-202 07-Jan-2026	5 , 16-Feb-		
	The purpose of this Notice of Special Interest (NOSI) is to highlight NIAID's interest in accepting applications that aim to understand the critical drivers of Tuberculosis (TB) transmission at the individual and population levels in high-burden Synopsis settings. Applicants are encouraged to develop effective methods to measure rates of TB transmission that rely on an increased understanding of the biomedical basis of transmission and related risk factors and to develop and assess poten interventions, including low-cost and low-tech options, to prevent TB transmission.								
113565	Notice of Special Interest (NOSI): a Arthropod Vector	argeting th	ne Pathogen within the I	National Institute of Allergy and nfectious Diseases/NIH/DHHS	NOT-AI- 22-074 07-	May-2024	Not Specified		

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Countries to Norma	A driana C	estave Coint Danis Dh D				
	Contact Telephone		119 <i>1</i>				
	Contact Email	acostero	ກiaid nih gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
Deadline Dates (ALL) 2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2025 , 07-Jan-2025 , 05-Fe							25 , 16-Feb-
	Synopsis	This Notic pathogen	e of Special Interest (NOSI) ir /vector interactions to identi	nvites applications to stimulate multi fy approaches to prevent pathogen t	disciplinary resear transmission to the	rch to better under e vertebrate host.	rstand
114374	Notice of Special Interest (NOSI): mmunology	Compleme	ent in Fundamental	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI- 23-012 07-	May-2024	Not Specified
	Contact Name	Ari Joffe,	PhD				
	Contact Telephone	240-669-5	5084				
	Contact Email	ari.joffe@	nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2025 , 07-	024 , 05-Jun-2024 , 16-Jun-20 May-2025 , 05-Jun-2025 , 16	024 , 07-Sep-2024 , 05-Oct-2024 , 16 -Jun-2025 , 07-Sep-2025 , 05-Oct-20	-Oct-2024 , 07-Jan 25 , 16-Oct-2025 ,	-2025 , 05-Feb-202 07-Jan-2026	25 , 16-Feb-
	Synopsis	The main compone pathogen studies w	objective of this program is t nts and/or receptors in the in ic infections, vaccination, pos ill inform the development of	o support studies that accelerate ou itiation, magnitude, maintenance, a t-infection sequelae, autoimmunity, vaccines or therapeutics that target	r understanding of nd quality of immu allergy, or transpl complement com	f the roles of comp une responses invo antation. The resu aponents.	blement blved in llts of such
105630	Notice of Special Interest (NOSI): of DEAD/H-box Helicases	<u>Understan</u>	ding the Immune Functions	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-Al- 21-066 07-	May-2024	Not Specified
	Contact Name	Qian "Joy	" Liu, M.D., M.Sc.				
	Contact Telephone	301-761-6	5621				
	Contact Email	liujoy@ni	aid.nih.gov				
	Sponsor Website						

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount					
	Program URL	Link to program URL									
	Deadline Dates (ALL)	07-May-2024 . 05-Jun-2024 . 16-Jun-2	2024 . 07-Sep-2024								
	Synopsis	This Notice of Special Interest (NOSI) function, and regulation of DEAD/H-k from such studies may be applied to or treat/prevent immune-mediated o	is Notice of Special Interest (NOSI) supports research aimed at gaining a comprehensive understanding of the expression, nction, and regulation of DEAD/H-box helicases in immune homeostasis, activation, and/or function. Knowledge obtained om such studies may be applied to the design of improved vaccines and immunotherapies to combat pathogenic infections treat/prevent immune-mediated diseases.								
105735	Notice of Special Interest (NOSI): Mouse Model for Immunoregulat	Using the Collaborative Cross (CC) ory and Infectious Disease Research	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-Al- 21-071 07-	May-2024	Not Specified					
	Contact Name	Qian "Joy" Liu, M.D., M.Sc.									
	Contact Telephone	301-761-6621									
	Contact Email	liujoy@niaid.nih.gov									
	Sponsor Website										
	Program URL	Link to program URL									
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2	2024 <i>,</i> 07-Sep-2024								
	Synopsis	The National Institute of Allergy and in receiving grant applications focusin recombinant inbred intercrosses of C understanding of the host genetics in characterize lines suitable for specific immune-mediated diseases, infection	Immunology (NIAID) is issuing this Nor ng on the following area(s): Use mouse C lines (CC-RIX) to more faithfully rep ivolved in immune regulation and func- s studies and disease models within the us diseases).	tice of Special Inter e lines from the Co roduce human imn ction Screen CC mo re mission of NIAID	rest (NOSI) to high Ilaborative Cross nune responses ar puse lines to ident (e.g., fundamenta	light interest (CC) and nd to advance ify and al immunology,					
106991	Notice of Special Interest (NOSI): Improving Mouse Models of Hum	Leveraging Microbial Exposure for an Immunity	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-Al- 21-072 07-	May-2024	Not Specified					
	Contact Name	Qian "Joy" Liu, M.D., M.Sc.									
	Contact Telephone	301-761-6621									
	Contact Email	niaidmousemodelnosi@nih.gov									
	Sponsor Website										
	Program URL	Link to program URL									
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2	2024 , 07-Sep-2024 , 05-Oct-2024 , 16	-Oct-2024 , 07-Jan	-2025						

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis e> of	his Notice of Special Interest (NOSI) s xposures (commonly referred to as " f human immune function in homeos	olicits research on immunologic char dirty mice") to determine their usefu tasis and in response to infectious o	racterization of mi Iness as research r immune-mediate	ce with diverse mi tools to advance u ed diseases.	crobial nderstanding
107851	Notice of Special Interest (NOSI): Ad Develop a Universal Influenza Vaccir	lvancing Research Needed to ne	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI- 22-013 07-	-May-2024	Not Specified
	Contact Name Je Contact Telephone 30 Contact Email Je Sponsor Website Program URL Li Deadline Dates (ALL) 07 Synopsis	ennifer L. Gordon, Ph.D. 01-761-6805 ennifer.gordon2@nih.gov ink to program URL 7-May-2024 , 05-Jun-2024 , 16-Jun-20 he purpose of this Notice of Special In n "A Universal Influenza Vaccine: The	024 , 07-Sep-2024 , 05-Oct-2024 , 16 hterest (NOSI) is to support research Strategic Plan for the National Institu	-Oct-2024 , 07-Jan that contributes t ute of Allergy and	1-2025 o the areas of inte Infectious Disease	rest outlined s."
123682	Understanding Mechanisms and Out Clinical Trial Not Allowed)	tcomes of Trained Immunity (R21	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-24- 111 16	-Jun-2024	275,000 USD
	Contact Name A Contact Telephone 24 Contact Email <u>ar</u> Sponsor Website Program URL <u>Li</u> Deadline Dates (ALL) 16 Th Synopsis in al	ri Joffe, Ph.D. 40-669-5084 <u>ri.joffe@nih.gov</u> ink to program URL 6-Jun-2024 , 16-Oct-2024 , 16-Feb-20 he purpose of this Notice of Funding nechanisms and biomarkers of trained nmunity, related to 1) immune syster llergic diseases, autoimmunity, or rej	25 , 16-Jun-2025 , 16-Oct-2025 , 16- Opportunity (NOFO) is to support re d immunity (i.e., innate immune mer n development and function, 2) imm ection of organ/tissue/cell transplan	Feb-2026 , 16-Jun search that impro nory), plus the fur nunity to vaccines tation.	-2026 , 16-Oct-202 ves understanding actional implication or natural infectio	6 of basic ns of trained ns, or 3)
107638	Notice of Special Interest (NOSI): Act	celerating Malaria Vaccine Discovery	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-Al- 22-014 07	-May-2024	Not Specified

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
Contact Name Annie Ma										
	Contact Name		, PN.D.							
		240-627-3	id nih gov							
		ПОашпа	<u>iu.iiii.gov</u>							
		Link to pr	ogram LIDI							
	Program URL		<u>: to program UKL</u>							
	Deauline Dates (ALL)	The nurne	024,05-Juli-2024,07-Sep-20	24,05-000-2024,07-300-2025	plicants about a	n area of chocial in	toroct to			
Synopsis suitable for further downstream development and clinical evaluation. This NOSI encourages studies that will lead of new vaccine candidates that prevent infection, ameliorate disease, and/or interrupt transmission caused by hu malaria parasites, especially Plasmodium falciparum and Plasmodium vivax.										
123681 <mark>C</mark>	Inderstanding Mechanisms and C Iinical Trial Not Allowed)	outcomes (	of Trained Immunity (R01	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-24- 112	Jun-2024	Not Specified			
	Contact Name	Ari Joffe,	Ph.D.							
	Contact Telephone	240-669-5	5084							
	Contact Email	ari.joffe@	nih.gov							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	05-Jun-20	024 , 05-Oct-2024 , 05-Feb-202	25 , 05-Jun-2025 , 05-Oct-2025 , 05-Fe	eb-2026 , 05-Jun-	2026 , 05-Oct-202	5			
	Synopsis	The purpo mechanis immunity allergic di	ose of this Notice of Funding C ms and biomarkers of trained , related to 1) immune system seases, autoimmunity, or reje	Opportunity (NOFO) is to support rese immunity (i.e., innate immune memo development and function, 2) immu ction of organ/tissue/cell transplanta	earch that improv bry), plus the fun- nity to vaccines o tion.	es understanding ctional implication or natural infectior	of basic s of trained is, or 3)			
113395 <u>P</u>	IIAID Research Opportunities for romote Workforce Diversity (R01	New and ' . Clinical T	'At-Risk" Investigators to rial Optional)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-22- 241 07-	May-2024	Not Specified			
	Contact Name Contact Telephone Contact Email	Diane Adg <u>AITraining</u>	ger-Johnson, MPH							

SPIN ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
Sponsor Websit	e							
Program UR	L Link to pr	ogram URL						
Deadline Dates (ALI	) 07-May-2 2025 , 07	2024 , 05-Jun-2024 , 05-Jul-2024 -May-2025 , 05-Jun-2025 , 05-Ju	4 , 07-Sep-2024 , 05-Oct-2024 , 05-No ul-2025 , 07-Sep-2025	ov-2024 , 07-J	an-2025 , 05-Feb-202	5 <i>,</i> 05-Mar-		
Synopsi	The purpose of this funding opportunity announcement is to encourage applications for research projects within the NIAID mission. This FOA seeks to support either (a) a New Investigator (NI), an individual who has not previously competed successfully for substantial, independent funding from NIH, or (b) are an 'At-Risk' investigator, an individual who had prior support as a PD/PI on a substantial independent research award and unless successful in securing a substantial research gran award in the current fiscal year, will have no substantial research grant funding in the following fiscal year, from diverse backgrounds, including those from groups underrepresented in the health-related sciences.							
124616 RFA-AI-23-077 Center of Excel and Immunity across Biological S	ence for Sy icales (U54	stems Modeling of Infection N Clinical Trial Not Allowed) In	Jational Institute of Allergy and nfectious Diseases/NIH/DHHS	RFA-AI- 23-077	05-May-2024 [Optional][LOI/Pre- App]	15,625,000 USD		
Contact Nam	e Jason Lur	ldgren						
Contact Telephon	e 240-669-2	2973						
Contact Ema	il <u>lundgren</u> j	@mail.nih.gov						
Sponsor Websit	e							
Program UR	L Link to pr	ogram URL						
Deadline Dates (ALI	.) 05-May-2	024 [Optional][LOI/Pre-App], 0	4-Jun-2024					
Synopsi	The purpe (CoE) to c advance I Research accelerat communi scientific be withdr guidance	ose of this notice of funding op coordinate the research commu- ID modeling research across bio Projects to advance and integra e multi-scale model developme ty. This NOFO requires a Plan for and technical peer review evalu- rawn. Applicants are strongly er material.	portunity (NOFO) is to support the e- inity of infectious and immune-medi ological scales. The CoE must include ate bridge models across scales in th ent, sharing and re-use, and support or Enhancing Diverse Perspectives (P uation. Applications that fail to inclu ncouraged to read the NOFO instruct	stablishment of ated disease ( e three (3) Coo e context of II collaboration EDP), which w de a PEDP wil tions carefully	of one (1) Center of E IID) computational m ordinating Cores and t ID, including HIV/AIDS to benefit the entire I vill be assessed as par I be considered incon and view the availab	xcellence odelers and two (2) 5. The CoE will ID research t of the nplete and will le PEDP		
124850 RFA-RM-24-007 Technologies Editing INDs (U01, Clinical Trial N	and Assays lot Allowed	f <u>or Therapeutic Genome</u> N <u>)</u> II	lational Institute of Allergy and nfectious Diseases/NIH/DHHS	RFA-RM- 2 24-007 [	26-Jun-2024 [Optional][LOI/Pre-	Not Specified		

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
					Δ	vpp]			
	Contact Name	Betty Poo	on, Ph.D.						
	Contact Telephone	240-669-5	5024						
	Contact Email	poonb@r	nail.nih.gov						
Sponsor Website									
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	26-Jun-20	024 [Optional][LOI/Pre-App], 26	-Jul-2024					
	Synopsis	The purpe character genome e (https://c ((https://d by the Na	he purpose of this Funding Opportunity Announcement (FOA) is to solicit applications on the optimization and haracterization of technologies and assays with the potential for utilization and adoption in regulatory submissions of enome editing therapeutics. This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative https://commonfund.nih.gov/) through the NIH Office of the NIH Director, Office of Strategic Coordination (https://dpcpsi.nih.gov/). All NIH Institutes and Centers participate in Common Fund initiatives. The FOA will be administered by the National Institute of Allergy and Infectious Diseases (NIAID) on behalf of the NIH.						
124938	RFA-AI-24-010 Feasibility of Nov Countries (FEND for TB) (R01 Clini	vel Diagno ical Trial N	stics for TB in Endemic N ot Allowed) li	lational Institute of Allergy and nfectious Diseases/NIH/DHHS	RFA-AI- 2 24-010 A	9-May-2024 Optional][LOI/Pre- \pp]	3,500,000 USD		
	Contact Name	Karen Lac	courciere, PhD						
	Contact Telephone	240-627-3	3297						
	Contact Email	lacourcie	rek@niaid.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	29-May-2	024 [Optional][LOI/Pre-App], 2	8-Jun-2024					
	Synopsis	The purpose of this notice of funding opportunity (NOFO) is to support the evaluation of early-stage diagnostics and novel diagnostic strategies for Tuberculosis (TB) in the context of existing clinical algorithms in TB endemic countries. Evaluation studies should: 1) perform proof-of principle studies of novel diagnostic tests and strategies for TB, including among people living with HIV (PLWH) and 2) provide feedback to diagnostic developers and policy makers on the performance of the technologies and most effective strategies for use of the diagnostic technologies in an endemic setting.							
124966	RFA-AI-24-009 Limited Interacti Epidemiology of Transmission and	ion Targete d Treatmer	ed Epidemiology: N nt of HIV Among People Who	lational Institute of Allergy and nfectious Diseases/NIH/DHHS	RFA-AI- 3 24-009 [(	0-Jun-2024 Optional][LOI/Pre-	Not Specified		

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Are at Increased Risk for HIV Infect (UG3/UH3 Clinical Trial Optional)	ction in Latin America (LITE-LA)		Ар	p]			
	Contact Name	Gerald B. Sharp, Dr.P.H.						
		240-627-3217						
	Contact Email	<u>GSnarp@niaid.nin.gov</u>						
	Sponsor website	Link to program LIDI						
	Program URL	LINK to program ORL	20 101 2024					
	Synopsis	The purpose of this notice of funding opportunity (NOFO) is to support investigators who will form large, electronically- generated cohorts in Latin America of HIV-negative men who have sex with men (MSM), transgender women (TGW), people who inject drugs (PWID), and/or female sex-workers and follow them to study the epidemiology of HIV incidence. Continued ollow-up of those persons who acquire HIV will be required to study the epidemiology of viral suppression. Descriptions of these groups and comparisons of participants by seroconversion status will provide information on geographic and socially defined areas of high HIV incidence as well as on both personal and structural vulnerabilities to HIV infection. Studies of participants who seroconvert and comparisons of those becoming rapidly engaged in care and who reach non-detectable HIV evels to those whose virus remains detectable will inform on the treatment of HIV in Latin American countries. This NOFO will allow digital trials to determine optimal study approaches, or to pilot evidence-based digital (mHealth and online) HIV prevention and treatment interventions to both reduce HIV incidence and improve treatment in Latin America.						
124968	RFA-AI-24-018 Interaction betw Coinfections (R01 Clinical Trial Op	reen ARVs and Hormones in HIV and tional)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	864-AI- 24-018 800- 800- 800- 800- 800- 800- 800-	Jun-2024 otional][LOI/Pre- p]	Not Specified		
	Contact Name	Cherlynn Mathias						
	Contact Telephone	240-292-4791						
	Contact Email	<u>cmathias@mail.nih.gov</u>						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	30-Jun-2024 [Optional][LOI/Pre-App],	30-Jul-2024					
	Synopsis	The purpose of this Notice of Funding between hormone therapy and antiret	Dpportunity (NOFO) is to support re- roviral drugs (ARVs) used for treatm	search to identify a ent and preventio	and characterize th n of HIV and co-int	ne interaction fections.		

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
124822	<u>RFA-AI-24-011 HIV/AIDS Clinical</u> <u>Required)</u>	Trials Units (UM1 Clinical Trial	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 24-011	30-Jun-2024 [Optional][LOI/Pre- App]	2,000,000 USD
	Contact Name	Leia Novak, Ph.D.				
	Contact Telephone	301-761-7825				
	Contact Email	<u>Leia.novak@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	30-Jun-2024 [Optional][LOI/Pre-App]	, 30-Jul-2024			
	Synopsis	tailored to the participants. The ultim development and prioritization of mo NOFO will support multidisciplinary t intact, rebound-competent HIV reser combinations of HIV curative approa	nate goal is for the results of such proc ore broad-based curative strategies the eams to conduct coordinated basic an rvoirs and immunologic backgrounds a ches that are specifically tailored to th	f-of-concept at will be effe d pre-clinical nd use that in ose participa	clinical studies to infor ective in all people livin research to profile par nformation to develop nts.	rm the g with HIV. This rticipants' and test
124947	<u>RFA-AI-24-008 Strategies for Cor</u> (SCORE-H) (R01 Clinical Trial Not A	ntrolled Release of HIV Vaccines Ilowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 24-008	30-Jun-2024 [Optional][LOI/Pre- App]	Not Specified
	Contact Name	Angela Malaspina, Ph.D.				
	Contact Telephone	301-825-3859				
	Contact Email	angela.malaspina@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	30-Jun-2024 [Optional][LOI/Pre-App]	, 30-Jul-2024			
	Synopsis	The purpose of this Notice of Funding release vaccine strategies to improve single-shot vaccination formulations.	g Opportunity (NOFO) is to support pro immune responses for HIV prevention Timelines with measurable milestone	oduct-focuse n, treatment, s are require	d research to advance and cure and develop d.	controlled simplified or
124933	RFA-AI-24-006 Centers for Resea	arch in Emerging Infectious Diseases	National Institute of Allergy and	RFA-AI-	22-May-2024	4,250,000

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	(CREID) Network (U01 Clinical Tria	Il Not Allov	wed)	Infectious Diseases/NIH/DHHS	24-006	[Optional][LOI/Pre- App]	USD
	Contact Name	Sara E. W	oodson, PhD				
	Contact Telephone	301-761-6	5478				
	Contact Email	woodsons	<u>se@niaid.nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	22-May-2	024 [Optional][LOI/Pre-App],	21-Jun-2024			
	Synopsis	diseases ( readiness investigat humans is related re collaborat	re/EIDs) around the globe wh to address outbreak-related ors will conduct innovative, c interconnected with that of search when necessary in the tive, and cooperative fashion	nere outbreaks are most likely to occ research. Multi- and interdisciplinar collaborative, hypothesis-driven One animal health and the shared enviro eir geographical areas, and will work	cur while deve y teams of do Health (appronment) base across the Cl	eloping expertise, capa omestic and internation oach that recognizes th d research, will underta REID Network in a coor	ity, and al he health of ake outbreak- dinated,
124934	RFA-AI-24-016 Centers for Resea (CREID) Network Coordination Cer	arch in Em nter (U01 (	erging Infectious Diseases Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 24-016	22-May-2024 [Optional][LOI/Pre- App]	7,500,000 USD
	Contact Name	Sara E. W	oodson, PhD				
	Contact Telephone	301-761-6	5478				
	Contact Email	woodsons	<u>se@niaid.nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	22-May-2	024 [Optional][LOI/Pre-App],	21-Jun-2024			
	Synopsis	The purp Infectious NOFO and	ose of this notice of funding 5 Diseases (CREID) Network C 1 the companion NOFO [RFA-	opportunity (NOFO) is to invite appli oordination Center (CC). The CREID AI-24-006], serves to expand knowle	cations for th Network, com edge on re-en	e Centers for Research prised of all recipients nerging and emerging i	in Emerging under this nfectious

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		diseases ( readiness collaborat and non-o fashion.	re/EIDs) around the globe whe to address outbreak-related r tive scientific, data and resourd outbreak periods among the CI	ere outbreaks are most likely to occu esearch. The CC will serve to lead, ac ce management, communication, an REID Network research centers in a c	r while developir lvance, facilitate, d administrative coordinated, colla	ng expertise, capao and coordinate cr activities during b aborative and coop	tity, and ritical and oth outbreak perative
116360	Notice of Special Interest (NOSI): Develop a Coccidioidomycosis (Va	Advancing Iley fever)	Research Needed to I Vaccine I	National Institute of Allergy and nfectious Diseases/NIH/DHHS	NOT-Al- 23-031 07-	May-2024	Not Specified
	Contact Name Contact Telephone	Dona C. L 301-761-7	ove, Ph.D. 7788				
	Contact Email Spopsor Website	Dona.Lov	e@nih.gov				
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2025 , 05- Oct-2025		24 , 05-Sep-2024 , 07-Sep-2024 , 05-0 pr-2025 , 07-May-2025 , 05-Jun-202 )7-Jan-2026	Dct-2024 , 16-Oct 5 , 16-Jun-2025 ,	-2024 , 05-Jan-202 05-Sep-2025 , 07-	25 , 07-Jan- Sep-2025 , 05-
	Synopsis	The purpo outlined i clear relev address g support v	ose of this Notice of Special Int n the NIAID Strategic Plan For vance to the strategic priorities aps in Coccidioides basic resea accine development; 3) develo	erest (NOSI) is to highlight NIAID's ir Research To Develop A Valley Fever s defined in the strategic plan, which rch to support the development of a op and advance vaccines to prevent o	terest in support Vaccine. The pro encompasses th vaccine; 2) deve coccidioidomycos	ting research in the posed research sh ree major researc lop tools and reso sis.	e areas Iould have h areas: 1) Furces to
109336	Notice of Special Interest (NOSI): Allograft Survival	Optimizing	Vascularized Composite	National Institute of Allergy and nfectious Diseases/NIH/DHHS	NOT-Al- 22-023 07-	May-2024	Not Specified
	Contact Name	Patricia K	ehn, Ph.D.				
	Contact Telephone	240-627-3	3547				
	Contact Email	<u>pkehn@N</u>	IIAID.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2025 , 07-	024 , 05-Jun-2024 , 16-Jun-202 May-2025 , 05-Jun-2025 , 16-J	24 , 07-Sep-2024 , 05-Oct-2024 , 16-0 un-2025 , 07-Sep-2025 , 05-Oct-202	Oct-2024 , 07-Jan 5 , 16-Oct-2025 ,	-2025 , 05-Feb-202 07-Jan-2026 , 05-F	25 , 16-Feb- ⁻eb-2026 , 16-

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	Feb-2026 The Nation models or rejection a immunosu	, 07-May-2026 nal Institute of Allergy and In human tissue specimens tha and maximize graft survival a uppression required for long-	fectious Diseases (NIAID) is interested at focus on 1) optimizing treatment and fter vascularized composite allotransp term VCA acceptance.	in supporting pr d graft monitorir lantation (VCA) a	eclinical studies un ng to reduce incide and 2) minimizing	ilizing animal nce of acute
109528	Limited Competition: Small Grant and K25 Recipients (R03) (Clinical	Program fo	or NIAMS K01, K08, K23, Allowed)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-22- 119 19-	Jun-2024	100,000 USD
	Contact Name	Su-Yau Ma	ao, Ph.D.				
	Contact Telephone	301-594-5	032				
	Contact Email	maos2@n	nail.nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	19-Jun-20	24 , 21-Oct-2024 , 19-Feb-20	25			
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) announces a program supported K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant (R03) support at during the second to fourth year of their K award. Through the use of this mechanism, which allows up costs for the entire project period of up to two years, the NIAMS is seeking to enhance the capability or conduct research as they complete their transition to fully independent investigator status. The R03 grassing supports different types of projects, including pilot and feasibility studies; secondary analysis of existing contained research projects; development of research methodology; and development of new research is, therefore, intended to support research projects that can be carried out in a short period of time wi and that provide support, in addition to the career development award, for a subsequent R01, or equivalent to the career development award, for a subsequent R01, or equivalent to the career development award, for a subsequent R01, or equivalent to the career development award, for a subsequent R01, or equivalent to the career development award, for a subsequent R01, or equivalent to the career development award.							
117716	Notice of Special Interest (NOSI): S Exploratory/Developmental Resea Areas	Supporting arch Focuse	ed on NIAMS Core Mission	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	NOT-AR- 23-006 07-	May-2024	Not Specified
	Contact Name Contact Telephone	Jana Eisen 301-594-5	istein 032				



SPIN ID	Program Title	Sponsor	Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Email Sponsor Website	jana.eisenstein@n	ih.gov						
	Program URI	Link to program U	21						
	Deadline Dates (ALL)	07-May-2024 , 05 2025 , 05-Feb-2025 Oct-2025 , 16-Oct- 07-Sep-2026 , 05-0	 Jun-2024 , 16-Jun-202 5 , 16-Feb-2025 , 09-A 2025 , 05-Dec-2025 , 0 0ct-2026 , 16-Oct-2026	4 , 06-Aug-2024 , 07-Sep-2024 , 05-O pr-2025 , 07-May-2025 , 05-Jun-2025 )7-Jan-2026 , 05-Feb-2026 , 16-Feb-2 5 , 07-Jan-2027	oct-2024 , 16-Oct 5 , 16-Jun-2025 , 026 , 07-May-20	t-2024 , 06-Dec-20 06-Aug-2025 , 07- 026 , 05-Jun-2026 ,	24 , 07-Jan- Sep-2025 , 05- 16-Jun-2026 ,		
	Synopsis	The purpose of this announcement is to notify the research community that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is interested in receiving Exploratory/Developmental grant applications focuse on NIAMS core mission areas. Awards will provide support for innovative projects that introduce novel scientific ideas, more systems, tools, agents, targets, and technologies that have the potential for significant impact, and to substantially advance research within the NIAMS mission. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs of high value to the NIAMS research community.							
114290	Notice of Special Interest (NOSI): HIV/AIDS in NIAMS	Promoting Research	n Opportunities on N D	lational Institute of Arthritis and Ausculoskeletal and Skin viseases/NIH/DHHS	NOT-AR- 23-004 07-	May-2024	Not Specified		
	Contact Name	Heiyoung Park, Ph.	D.						
	Contact Telephone	301-594-5032							
	Contact Email	parkh1@mail.nih.g	<u>(OV</u>						
	Sponsor Website								
	Program URL	Link to program U	<u> </u>						
	07-May-2024, 05-Jun-2024, 16-Jun-2024, 06-Aug-2024, 07-Sep-2024, 05-Oct-2024, 16-Oct-2024, 06-Dec-2024, 07-Jan- 2025, 05-Feb-2025, 16-Feb-2025, 09-Apr-2025, 07-May-2025, 05-Jun-2025, 16-Jun-2025, 06-Aug-2025, 07-Sep-2025, 05- Deadline Dates (ALL) Oct-2025, 16-Oct-2025, 05-Dec-2025, 07-Jan-2026, 05-Feb-2026, 16-Feb-2026, 07-May-2026, 05-Jun-2026, 16-Jun-2026, 07-Sep-2026, 05-Oct-2026, 16-Oct-2026, 07-Jan-2027, 05-Feb-2027, 16-Feb-2027, 07-May-2027, 05-Jun-2027, 16-Jun- 2027, 07-Sep-2027, 05-Oct-2027, 16-Oct-2027, 07-Jan-2028								
	Synopsis	The purpose of this and Skin Diseases ( mission.	s announcement is to NIAMS) of an area of	inform potential applicants to the Na special interest in HIV/AIDS-associate	ational Institute ed comorbidities	of Arthritis and Mu s that are within th	usculoskeletal e NIAMS		

SPIN ID	Program Title	Spon	sor Name	Sponsor Number		Deadline Date	Funding Amount
117677	Notice of Special Interest (NOSI): S Applications	Synthetic Biolog	y for Biomedical	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	NOT-EB- 23-002 06-	-May-2024	Not Specified
	Contact Name	Hye-Sook Kim,	Ph.D.				
	Contact Telephone	301-827-6910					
	Contact Email	<u>hye-sook.kim@</u>	nih.gov				
	Sponsor Website						
	Program URL	Link to program	<u>n URL</u>				
	Deadline Dates (ALL)	06-May-2024 , 2025 , 05-May-	05-Jun-2024 , 16-Jun-20 2025 , 05-Jun-2025 , 16-	24 , 06-Sep-2024 , 05-Oct-2024 , 16-O Jun-2025 , 16-Oct-2025	ct-2024 , 08-Jan	-2025 , 05-Feb-202	25 , 16-Feb-
	Synopsis	The purpose of National Cance the National In: Bioengineering the National In: relevant to syn	this Notice is to annour r Institute (NCI), the Nat stitute of Allergy and Inf (NIBIB), the Eunice Ken stitute of General Medic thetic biology.	ice that the National Center for Compl ional Heart, Lung and Blood Institute ( ectious Diseases (NIAID), the National nedy Shriver National Institute of Chilc ral Sciences (NIGMS) are encouraging r	ementary and I NHLBI), the Nat Institute of Bio I Health and Hu new application	ntegrative Health ( ional Institute on <i>i</i> medical Imaging ar man Development s to advance resea	NCCIH), the Aging (NIA), Id (NICHD), and Irch activities
107317	Innovative Screening Approaches Disorders in Newborns (R01 - Clin	and Therapies f ical Trial Option	<u>or Screenable</u> al <u>)</u>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-21- 353	-Jun-2024	Not Specified
	Contact Name	Mollie Minear,	Ph.D.				
	Contact Telephone	301-827-9442					
	Contact Email	mollie.minear@	onih.gov				
	Sponsor Website						
	Program URL	Link to program	<u>n URL</u>				
	Deadline Dates (ALL)	05-Jun-2024 , 0	5-Oct-2024				
	Synopsis	This FOA encou for potentially genetic condition demonstrating screening pane	rages research relevant fatal or disabling conditi ons where screening ma the benefits of early into I. This FOA defines a "hig	to the development of novel screenin ons that have been identified through y be possible in the near future. Havin ervention or treatment, are important gh priority" condition as one where scr	g approaches a newborn scree g an accurate s criteria for incl reening is not c	nd/or therapeutic ning, as well as for creening test, as w uding a condition c urrently recommer	interventions "high priority" ell as on a newborn nded, but

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		infants wi	ith the condition would signifi	cantly benefit from early identification	and treatment		
113756	NCMRR Early Career Research Aw	vard (RO3 C	Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-23- 029 16-	Jun-2024	200,000 USD
	Contact Name	Maria Nu	rminskaya, PhD				
	Contact Telephone	240-591-9	9986				
	Contact Email	Maria.nu	rminskaya@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	16-Jun-20	024 , 16-Oct-2024 , 16-Feb-202	25 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb	o-2026		
	Synopsis	research i the NIH R rehab-pla existing d outcomes Award R0 subseque	inal Center for Medical Rehab both basic and clinical research must be focused on one or mo esearch Plan on Rehabilitation n). The NCMRR ECR Award RC ata; small, self-contained rese s research; and development of 3 is for the Program Director( nt RO1 application.	infation Research (NCMRR) Early Caree of from rehabilitation scientists who are ore of the areas within the mission of N in for strategic priorities (https://www. 03 grant mechanism supports various t earch projects; development of researc of new technology. Irrespective of the s)/Principal Investigator(s) (PD(s)/PI(s))	er Research (ECI e establishing in NCMRR: Applica nichd.nih.gov/n ypes of projects h methodology type of project, ) to obtain suffic	R) Award (R03) is i dependent researd ints are encourage ewsroom/news/1 s including seconda ; translational rese the intent of the i cient preliminary c	ch careers. The d to refer to 10121-NIH- ary analysis of earch; NCMRR ECR data for a
113468	Notice of Special Interest (NOSI): Research for Healthy Pregnancies	<u>High Priori</u> (Reissue)	ty Areas in Placental	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD- 22-049 07-	May-2024	Not Specified
	Contact Name	John V. Ile	ekis, PhD				
	Contact Telephone	301-435-6	5895				
	Contact Email	<u>ilekisj@ni</u>	<u>h.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	.024 , 05-Jun-2024 , 16-Jun-20	24 , 07-Sep-2024 , 16-Oct-2024 , 07-Ja	n-2025 <i>,</i> 05-Feb	-2025 , 16-Feb-202	25
	Synopsis	Although organ for	the placenta is a short-lived of the propagation of our species	organ limited to pregnancy, its importa es and future health of our progeny. Pe	nce is often unc rturbations in a	lerappreciated in language in the second sec	peing a crucial y functions

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		may resul restriction fetus that as obesity help addr	t in many common adverse pr n, stillbirth, and preterm birth. can impact the health of the i v, cardiovascular disease, and o ess a number of major gaps in	egnancy outcomes. These include ear In addition, a poorly functioning place ndividual later in adult life. This incluc diabetes. Thus, a more comprehensive knowledge.	ly pregnancy los enta can lead to les an increased e understanding	ss, preeclampsia, fo aberrant program incidence of adul of the placenta is	etal growth Iming of the t diseases suci necessary to
115063	Archiving and Documenting Child Sets (R03 Clinical Trial Not Allowe	<u>Health and d)</u>	d Human Development Data	National Institute of Child Health and Human Development/NIH/DHHS	PAR-22- 261 16-	Jun-2024	100,000 USD
	Contact Name	Rebecca I	Clark, PhD				
	Contact Telephone	301-496-2	1175				
	Contact Email	rclark@m	ail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	16-Jun-20	024 , 16-Oct-2024 , 16-Feb-202	5 , 16-Jun-2025 , 16-Oct-2025			
	Synopsis	The purpo sets withi (NICHD) in original d	ose of this funding opportunity n the scientific mission of the n order to enable secondary a ata collected with NICHD fund	v announcement (FOA) is to support the Eunice Kennedy Shriver National Instite nalysis of these data by the scientific construction ing.	ne archiving and cute of Child Hea community. The	documentation o alth and Human Do highest priority is	f existing data evelopment to archive
105045	Notice of Special Interest (NOSI): and Uptake among Children, Ado Women, and Persons with Disabil	Promoting lescents, P ities	Vaccine Access, Acceptance regnant and Lactating	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD- 21-038 07-	May-2024	Not Specified
	Contact Name	Regina M	. Bures, Ph.D.				
	Contact Telephone	301-496-9	9485				
	Contact Email	<u>regina.bu</u>	<u>res@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	024 , 16-Jun-2024 , 07-Sep-20	24			
	Synopsis	This NOSI among in	encourages applications that fants, children, adolescents, p	address dimensions of access, accepta regnant and lactating women, and per	ance and uptake sons with disab	of CDC-recomme ilities, especially a	nded vaccines mong

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		populatio	ns who are underserved or ex	perience health disparities.			
107319	Innovative Screening Approaches Disorders in Newborns (R21 - Clin	and Thera ical Trial C	ipies for Screenable Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-21- 355 16-	Jun-2024	275,000 USD
	Contact Name	Mollie Mi	near, Ph.D.				
	Contact Telephone	301-827-9	9442				
	Contact Email	<u>mollie.mi</u>	<u>near@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	16-Jun-20	)24 , 16-Oct-2024				
	Synopsis	for poten genetic co demonstr screening infants w	tially fatal or disabling condition onditions where screening ma rating the benefits of early inte panel. This FOA defines a "hig ith the condition would signifi	to the development of novel screening ons that have been identified through y be possible in the near future. Havin ervention or treatment, are important gh priority" condition as one where scr cantly benefit from early identification	g approaches an newborn scree g an accurate so criteria for inclu reening is not cu n and treatment	ning, as well as for creening test, as w uding a condition o urrently recomment.	"high priority" vell as on a newborn nded, but
107320	Innovative Screening Approaches Disorders in Newborns (R03 - Clin	and Thera ical Trial C	p <u>ies for Screenable</u> Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-21- 354 16-	Jun-2024	100,000 USD
	Contact Name	Mollie Mi	inear, Ph.D.				
	Contact Telephone	301-827-9	9442				
	Contact Email	mollie.mi	<u>near@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	16-Jun-20	)24 , 16-Oct-2024				
	Synopsis	This FOA for poten genetic co demonstr screening	encourages research relevant tially fatal or disabling conditio onditions where screening ma rating the benefits of early inte g panel. This FOA defines a "hig	to the development of novel screenin ons that have been identified through y be possible in the near future. Havin ervention or treatment, are important gh priority" condition as one where scr	g approaches an newborn scree g an accurate so criteria for inclo reening is not cu	nd/or therapeutic ning, as well as for creening test, as w uding a condition o urrently recommen	interventions "high priority" rell as on a newborn nded, but

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
		infants w	ith the condition would signifi	cantly benefit from early identificatior	and treatmer	nt.				
112833	Advancing Research to Understan Clinical Trial Not Allowed)	id Congeni	tal Malformations (R01	National Institute of Child Health and Human Development/NIH/DHHS	PAR-22- 215	5-Jun-2024	2,499,995 USD			
	Contact Name	Reiko Toy	ama, Ph.D.							
	Contact Telephone	301-435-2	2723							
	Contact Email	toyamar@	<u>Dnih.gov</u>							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	05-Jun-20	024 , 05-Oct-2024 , 05-Feb-202	25 <i>,</i> 05-Jun-2025						
_	The purpose of this funding opportunity announcement (FOA) is to support innovative research that will inform our understanding of the mechanisms underlying the formation of structural birth defects using animal models in conjuncti with human translational/clinical approaches. Applicants are encouraged to take advantage of advances in genetics, 'or methods (genomics, proteomics, metabolomics, etc.), and synthetic biology, biochemical and other approaches to developmental biology research to identify specific genetic, epigenetic, environmental, or gene/environment interactic associated with the formation of, susceptibility to, and variability of structural birth defects in human populations.									
124780	RFA-HD-25-004Optimizing Healt Perinatal HIV Exposure (U19 Clinic	<u>:h of Childr</u> cal Trial Op	ren and Adolescents with otional)	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD- 25-004 A	D-Jun-2024 Optional][LOI/Pre- pp]	Not Specified			
	Contact Name	Allahna E	sber, PhD							
	Contact Telephone	301-827-4	4560							
	Contact Email	allahna.e	<u>sber@nih.gov</u>							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	30-Jun-20	024 [Optional][LOI/Pre-App], 3	80-Jul-2024						
	Synopsis	This Notic to suppor NOFO is t term effe	te of Funding Opportunity (NC t the Optimizing Health of Ch o generate information neede cts of in utero/perinatal expos	DFO) invites applications to participate ildren and Adolescents with Perinatal ed to develop and to test interventions sure to antiretroviral therapy (ART) an	in a research HIV Exposure I s for the early o d/or HIV amor	program cooperativ nitiative. The object detection and reduc ng individuals who a	e agreement ive of this tion of long- re HIV exposed			

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		but uninfo IHEUs are R01 or UC IHEUs. Pro scientifica	ected (IHEU). Investigators wi encouraged to apply. A mult 1. The applications should an oposed projects should 1) hav Illy meritorious, and 3) compl	th innovative thinking and new appro i-program project grant is proposed to swer important fundamental questio ve a scope that is well matched to the lement one another, be synergistic, an	aches to add o answer que ns related to resources ar nd support th	ress the public health estions not easily addr long-term health outond the research object e program's overall th	issues facing essed in an comes for ives, 2) be eme.
125122	<u>RFA-HD-25-001 Medical Rehabi</u> <u>Clinical Trial Optional)</u>	litation Re	search Resource (P50	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD- 25-001	30-Jun-2024 [Optional][LOI/Pre- App]	3,750,000 USD
	Contact Name	Joe Bonne	er, PhD				
	Contact Telephone	301-827-8	3303				
	Contact Email	joe.bonne	er@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	30-Jun-20	24 [Optional][LOI/Pre-App], 3	30-Jul-2024			
This Notice of Funding Opportunity (NOFO) invites grant applications from institutions/organizations that propose to be Medical Rehabilitation Research Center. The centers will have a specific rehabilitation research theme and be comprise research project supported by 3 cores. The 3 cores will have functions within the center as well as functions nationwide Together, the cores will support: administrative functions (including an optional pilot program), resource sharing, and community engagement and outreach. The Medical Rehabilitation Research Centers will contribute to medical rehabilities research infrastructure by developing and disseminating techniques, data, theories, research programs, and expertise the goal of enhancing the capability of medical rehabilitation investigators to understand mechanisms of functional re develop therapeutic strategies, identify clinical care gaps, and improve the lives of people with disabilities. Application include a plan for inclusion of People with Lived Experience (as a required other attachment) that is relevant to the restrict the conter and increases the notential impact of the center.							
110993	Short-term Mentored Career Enh Craniofacial Research for Mid-Car Independent Clinical Trial Not Allo	ancement eer and Se owed)	Award in Dental, Oral and nior Investigators (K18	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22- 121	07-May-2024	Not Specified
	Contact Name	Leslie A. F	rieden, PhD				
	Contact Telephone	301-496-4	1263				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Contact Email <u>le</u>	slie.frieden@nih.gov							
	Sponsor Website								
	Program URL Lin	nk to program URL							
	Deadline Dates (ALL) 07	7-May-2024 , 12-Jun-2024 , 07-Sep-20	024 , 12-Oct-2024 , 07-Jan-2025 , 12-	Feb-2025 , 07-Ma	y-2025				
Synopsis oral, and craniofacial health and disease. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, o ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led to mentor or co-mentor.									
108355	NIDCR Dual Degree Dentist Scientist (K99/R00 Basic Experimental Studies	Pathway to Independence Award s Involving Humans Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22- 043 07-	May-2024	Not Specified			
	Contact Name Le	eslie A. Frieden, PhD							
	Contact Telephone 30	01-496-4263							
	Contact Email <u>le</u>	slie.frieden@nih.gov							
	Sponsor Website								
	Program URL Lin	nk to program URL							
	Deadline Dates (ALL) 07	7-May-2024 , 12-Jun-2024 , 07-Sep-20	)24 , 12-Oct-2024 , 07-Jan-2025						
	Tr ar he ye Synopsis su (2 ex pa Ty	ne purpose of the NIDCR Dual Degree and maintain a strong cohort of indepe ealth. This program is designed to fac ostdoctoral research positions to inde ears of mentored training and three t upport is available to accommodate c 5% full-time professional effort) in an operimental studies involving humans articipants." These studies fall within uppes of studies that should be submit	Dentist Scientist Pathway to Indeper endently funded dentist scientists dev ilitate a timely transition of outstand ependent, tenure-track or equivalent to five years of independent research linical training in a dental specialty pro- ny year of the R00 phase. This Fundin 5, referred to in NOT-OD-18-212 as "p the NIH definition of a clinical trial ar ted under this FOA include studies th	ndence Award (KS dicated to improvi ing dual degree de faculty positions . An option for five rogram at no more g Opportunity An prospective basic s and also meet the c hat prospectively a	99/R00) program is ing dental, oral an entist scientists fro by providing supp e years of indeper e than 3 person-m nouncement is for science studies inv definition of basic assign human part	s to develop d craniofacial om mentored, ort for two ident (R00) ionths effort basic science volving human research. icipants to			

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		humans for processes or propos investigat related to scientific	or the purpose of understand s or products in mind. Applica sing to gain research experier cor, must apply to the 'Indepe o the programmatic interests missions.	ling the fundamental aspects of phen nts not planning an independent clin ce in a clinical trial or basic experime ndent Clinical Trial Not Allowed' com of one or more of the participating N	nomena without s nical trial or basic e ntal study with hu npanion FOA. The IH Institutes and (	pecific application experimental study umans led by anot proposed project f Centers (ICs) based	towards / with humans, her must be I on their
108353	NIDCR Dual Degree Dentist Scient (K99/R00 Clinical Trial Not Allowe	<u>ist Pathwa</u> d)	iy to Independence Award	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22- 041 07-	May-2024	Not Specified
	Contact Name	Leslie A. F	rieden, PhD				
	Contact Telephone	301-496-4	4263				
	Contact Email	leslie.fried	den@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	024 , 12-Jun-2024 , 07-Sep-2	024 , 12-Oct-2024 , 07-Jan-2025			
	Synopsis	The purper and main health. Th postdocto years of n support is full-time p specificall feasibility a clinical to trial as lead in human the comp	bse of the NIDCR Dual Degree tain a strong cohort of independis program is designed to factor oral research positions to independent oral research positions to independent or a search positions to independent or a state training and three to available to accommodate or professional effort) in any year or of estimate the state of	e Dentist Scientist Pathway to Indeper endently funded dentist scientists de ilitate a timely transition of outstand ependent, tenure-track or equivalent o five years of independent research linical training in a dental specialty pro- tor of the R00 phase. This Funding Opp search that does not involve leading a o a clinical trial. Applicants to this FO entor. Applicants proposing a clinical to the companion FOA (PAR-22-042). 12 as "prospective basic science stud dies with Humans FOA (PAR-22-043).	ndence Award (KS dicated to improv ling dual degree d faculty positions . An option for five rogram at no more ortunity Annound an independent cl A are permitted to trial or an ancillar . Applicants propo- lies involving hum	99/R00) program is ing dental, oral an entist scientists fro by providing suppo e years of indepen e than 3 person-m cement (FOA) is de inical trial, a clinic o propose research y study to an ongo osing basic experir an participants" sh	s to develop d craniofacial om mentored, ort for two dent (R00) onths (25% esigned al trial n experience in bing clinical nental studies nould apply to
108354	NIDCR Dual Degree Dentist Scient (K99/R00 Clinical Trial Required)	ist Pathwa:	y to Independence Award	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22- 042 07-	May-2024	Not Specified

Contact Name Leslie A. Frieden, PhD

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telenhone	301-496-4	1263				
	Contact Email	leslie.frie	den@nih.gov				
	Sponsor Website		<u> </u>				
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	2024 , 12-Jun-2024 , 07-Sep-202	24 , 12-Oct-2024 , 07-Jan-2025			
The purpose of the NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00) program is and maintain a strong cohort of independently funded dentist scientists dedicated to improving dental, oral and health. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists fro postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing suppo years of mentored training and three to five years of independent research. An option for five years of independ Synopsis support is available to accommodate clinical training in a dental specialty program at no more than 3 person-mo (25% full-time professional effort) in any year of the R00 phase. This Funding Opportunity Announcement (FOA) specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical tri study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicat planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another i must apply to companion FOA (PAR-22-041)							s to develop d craniofacial om mentored, ort for two ident (R00) onths effort donths effort is designed rial feasibility cants not investigator,
117230	NIDCR Research Grants for Analys (Clinical Trial Not Allowed)	ses of Exist	ing Genomics Data (R01)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-23- 133 07-	May-2024	Not Specified
	Contact Name	Noffisat C	Dki				
	Contact Telephone	301-402-6	6778				
	Contact Email	noffisat.o	ki@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2025 , 05·	2024 , 05-Jun-2024 , 07-Sep-202 -Oct-2025 , 07-Jan-2026 , 05-Fe	24 , 05-Oct-2024 , 07-Jan-2025 , 05-ł eb-2026 , 07-May-2026	Feb-2025 , 07-Ma	y-2025 <i>,</i> 05-Jun-20	)25 , 07-Sep-
	Synopsis	The purpe to human available Data anal proposed	ose of this NOFO is to annound a dental, oral, or craniofacial (D genomic data, with or without lysis for each project can be pe project(s), including methods	e support for meritorious research p OC) biology, and diseases and condi other types of complementary data rformed using existing and/or novel for data and metadata mining, data	projects that addr itions, through an , using statistical methods to be do a integration, and	ess research ques alysis of existing a and computationa eveloped in the Artificial Intelliger	tions relevant nd publicly al approaches. nce

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		(AI)/Mach silico wor Projects a priority. P interventi	nine Learning (ML)/Deep Learr k is required to validate the re imed at understanding oral he rojects focused on investigation on targets or defining the pat	ning (DL) methods. In addition to ana sults of the proposed analysis, or to ealth disparities to inform strategies ng and/or characterizing human biol hogenicity of known genetic variants	Ilysis of existing validate a newly for improving he ogical pathways are encouraged	data, experimental v developed analyti ealth for all individu to inform identifica d.	or in c method. uals are a ation of
117461	NIDCR Prospective Observational Cooperative Agreement (U01 Clin	or Biomar iical Trial N	ker Validation Study ot Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-23- 162	7-May-2024	Not Specified
	Contact Name	Lorena Ba	iccaglini, DDS, MS, PhD				
	Contact Telephone	301-435-7	7908				
	Contact Email	lorena.ba	<u>ccaglini@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2025 , 05·	024 , 05-Jun-2024 , 07-Sep-20 ·Oct-2025 , 07-Jan-2026 , 05-F	24 , 05-Oct-2024 , 07-Jan-2025 , 05- eb-2026 , 07-May-2026	Feb-2025 , 07-M	ay-2025 , 05-Jun-20	)25 , 07-Sep-
	Synopsis	This NOFC biomarke data/bios	D will support, through the coor r validation studies that requir pecimens.	operative agreement mechanism, in re prospective collection of data/bio	vestigator-initiat specimens or co	ed observational st ntinued analysis of	udies or
108981	NIDCR Mentored Career Develop Independent Basic Experimental S	<u>ment Awar</u> Studies wit	d to Promote Diversity (K01 h Humans Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22- 052	7-May-2024	Not Specified
	Contact Name	Leslie A. F	rieden, Ph.D.				
	Contact Telephone	301-496-4	1263				
	Contact Email	leslie.fried	den@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	024 , 12-Jun-2024 , 07-Sep-20	24 , 12-Oct-2024 , 07-Jan-2025			
	Synopsis	The purpo early care and socia	ose of the NIDCR Mentored Ca er faculty from diverse backgr l sciences, to ensure a well-tra	reer Development Award to Promot ounds, including those from groups ined dental, oral, and craniofacial re	e Diversity is to underrepresent search workford	support postdocto ed in the biomedica e. This FOA provide	ral fellows and al, behavioral, es salary and

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		research an experi referred t the NIH d under thi independ fundamen planning clinical tri Trial Not	support for a sustained period of enced mentor. This Funding Op to in NOT-OD-18-212 as "prospe efinition of a clinical trial and al s FOA include studies that prosp ent variables) and that assess b ntal aspects of phenomena with an independent clinical trial or l fal or basic experimental study of Allowed' companion FOA.	of "protected time" for intensive re portunity Announcement is for bas ective basic science studies involvin lso meet the definition of basic rese pectively assign human participants iomedical or behavioral outcomes nout specific application towards pr basic experimental study with hum with humans led by another investi	esearch career de sic science experin ig human particip earch. Types of st s to conditions (i.e in humans for the rocesses or produ ans, or proposing gator, must apply	velopment under t mental studies invo ants." These studie udies that should k e., experimentally e purpose of under acts in mind. Applic to gain research e to the 'Independe	he guidance of olving humans, es fall within be submitted manipulate standing the ants not xperience in a ent Clinical
108979	NIDCR Mentored Career Developm Clinical Trial Required)	ment Awa	rd to Promote Diversity (K01 N C	lational Institute of Dental and raniofacial Research/NIH/DHHS	PAR-22- 051	-May-2024	Not Specified
	Contact Name	Leslie A. F	Frieden, Ph.D.				
	Contact Telephone	301-496-4	4263				
	Contact Email	leslie.frie	den@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	024 , 12-Jun-2024 , 07-Sep-202	4 , 12-Oct-2024 , 07-Jan-2025			
	Synopsis	The purpe early care and socia research an experi serve as t existing to proposing 050).	ose of the NIDCR Mentored Car eer faculty from diverse backgro I sciences, to ensure a well-train support for a sustained period o enced mentor. This Funding Op he lead investigator of an indep rial, as part of their research an g to gain research experience in	eer Development Award to Promo- bunds, including those from groups ned dental, oral, and craniofacial re of "protected time" for intensive re portunity Announcement (FOA) is o bendent clinical trial, a clinical trial d career development. Applicants r a clinical trial led by another inves	te Diversity is to s underrepresente search workforce search career de designed specifica feasibility study, o not planning an ir tigator, must app	support postdoctor ed in the biomedica e. This FOA provide velopment under t ally for applicants p or a separate ancill adependent clinica ly to companion FO	al fellows and I, behavioral, s salary and he guidance of proposing to ary study to an I trial, or DA (PAR-22-
108980	NIDCR Mentored Career Developm Independent Clinical Trial Not Allo	<u>ment Awa</u> owed)	rd to Promote Diversity (K01 N C	lational Institute of Dental and raniofacial Research/NIH/DHHS	PAR-22- 050	-May-2024	Not Specified
	Contact Name	Leslie A. F	Frieden, Ph.D.				

Icahn School of Medicine at Mount Sinai

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone	301-496-4	1263				
	Contact Email	leslie.fried	den@nih.gov				
	Sponsor Website		<u></u>				
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2		4 , 12-Oct-2024 , 07-Jan-2025			
	Synopsis	The purpo early care and social research s an experio research t clinical tri mentor. T (PAR-22-0	ose of the NIDCR Mentored Car eer faculty from diverse backgro I sciences, to ensure a well-trai support for a sustained period of enced mentor. This Funding Op that does not involve leading an al. Applicants to this FOA are p Those proposing a clinical trial of 051).	eer Development Award to Promote bunds, including those from groups of ned dental, oral, and craniofacial res of "protected time" for intensive res oportunity Announcement (FOA) is d in independent clinical trial, a clinical ermitted to propose research exper- or an ancillary clinical trial as lead inv	e Diversity is to sunderrepresente search workforce search career dev lesigned specifica I trial feasibility st ience in a clinical vestigator, should	upport postdoctor d in the biomedica . This FOA provide relopment under t illy for candidates tudy, or an ancillar trial led by a men l apply to the comp	al fellows and I, behavioral, s salary and he guidance of proposing y study to a tor or co- panion FOA
100931	NIDCR Small Grant Program for N Allowed)	ew Investi	gators (RO3 Clinical Trial Not C	lational Institute of Dental and Traniofacial Research/NIH/DHHS	PAR-21- 084 07-	May-2024	200,000 USD
	Contact Name	Preethi Cl	hander, PhD				
	Contact Telephone	301-827-4	4620				
	Contact Email	preethi.ch	nander@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	024 , 16-Jun-2024 , 07-Sep-202	4			
	Synopsis	This NIDC the early supports data for a	R Small Grant Program for New stages of establishing an indep pilot or feasibility studies and d subsequent investigator- initia	Investigators supports basic and cli endent research career in oral, dent levelopmental research projects wit ited Research Project Grant (R01) or	inical research co al and craniofacia h the intention o equivalent appli	nducted by scient al research. This R( f obtaining sufficie cation.	ists who are in )3 program ent preliminary
102596	NIDCR Clinical Trial Planning and I Agreement (UG3/UH3 Clinical Tria	mplement al Requirec	ation Cooperative N <u>위</u> C	lational Institute of Dental and Traniofacial Research/NIH/DHHS	PAR-21- 160 07-	May-2024	Not Specified
	Contact Name	Dena Fisc	her, DDS, MSD, MS				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	301-594-4876 dena.fischer@nih.gov Link to program URL 07-May-2024 , 06-Jun-2024 , 06-Sep-2 This Funding Opportunity Announcerr to plan and implement clinical trials w (NIDCR). Studies appropriate for this F biologic, device, or procedure for den for a Food and Drug Administration (F milestone-driven UG3 planning phase The UH3 phase of the award will supp permits both operational and scientifi protocol and preparing other docume Procedures, data management plan). feasibility and/or acceptability of a pla intervention delivery; feasibility of pro- fidelity monitoring procedures) and as trial. The UG3 phase cannot be used t an investigational drug, biologic or den to the FDA prior to the UH3 phase.	024 , 03-Oct-2024 , 08-Jan-2025 ent (FOA) will support UG3/UH3 phas ithin the mission of the National Insti OA are those testing diagnostic, prev cal, oral, or craniofacial diseases or co DA)-regulated product. Awards made with possible transition to a UH3 clir ort the conduct of one investigator-in c planning activities. Operational plan ints to implement the clinical trial (e.g Allowable scientific planning activities nned intervention and associated stu posed data collection procedures; pri sessment of the subject population to o test for intervention safety or effica vice, the investigators must have subr	sed, cooperative a tute of Dental and ention or treatme inditions, including under this FOA w hical trial impleme hitiated clinical tria ming activities inc g., data collection i s include small-sca idy procedures (e. eliminary testing o o determine recru cy. If the applicati mitted the approp	greement researce d Craniofacial Rese nt approaches to g trials for any pha rill initially support ntation phase of u al. The UG3 planni lude, at minimum instruments, Manual ale data collection g., acceptability o of intervention tra itment potential f on proposes a clir riate investigatior	ch applications earch test a drug, ise of testing t a one-year up to five years. ng phase , finalizing the ual of to assess the f mode of ining and for the future ical trial with hal application
110754	Notice of Special Interest (NOSI): / Harnessing Immune System Plasti	Achieving Tissue Robustness Through	National Institute of Dental and Craniofacial Research/NIH/DHHS	NOT-DE- 22-005 07-	May-2024	Not Specified
	Contact Name	Preethi Chander, PhD				
	Contact Telephone	301-827-4620				
	Contact Email	preethi.chander@nih.gov				
	Sponsor Website					
	Program URL Deadline Dates (ALL)	<u>LIFIK to program UKL</u> 07-May-2024 , 05-Jun-2024 , 16-Jun-2 2025 , 07-May-2025 , 05-Jun-2025 , 16	024 , 07-Sep-2024 , 05-Oct-2024 , 16- -Jun-2025 , 07-Sep-2025	Oct-2024 , 07-Jan	-2025 , 05-Feb-20	25 , 16-Feb-

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	r Synopsis t f	NIDCR an underlyin external p response knowledg that shift preventat	nounces its interest in encour g the ability or inability of the perturbations, and to examine to infectious and autoimmune ge derived from this research w the balance between degener tive disease management in a	aging state-of-the-art, systematic res immune system to dynamically main immune mechanisms of protection e diseases of dental, oral, and cranio vill facilitate development of novel, p ative and regenerative processes to patient-specific manner across the li	search approache ntain its functiona against recurrenc facial (DOC) tissue personalized imm ward protection a ifespan.	s to determine me I role against inter e of chronic inflam es. The expectation unomodulatory-ba gainst episodic ree	chanisms nal and mation in n is that new ased therapies currence and
117231	NIDCR Small Research Grants for A (R03 Clinical Trial Not Allowed)	nalyses o	f Existing Genomics Data	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-23- 132 07-	May-2024	200,000 USD
	Contact Name I Contact Telephone 3 Contact Email <u>r</u> Sponsor Website Program URL <u>1</u> Deadline Dates (ALL) Synopsis	Noffisat C 301-402-( <u>noffisat.o</u> Link to pr 07-May-2 2025 , 16 2025 , 16 The purpo to human available Data anal proposed	Oki 5778 <u>ki@nih.gov</u> 0gram URL 024 , 16-Jun-2024 , 07-Sep-20 -Oct-2025 , 07-Jan-2026 , 16-F ose of this NOFO is to annound dental, oral, or craniofacial (E genomic data, with or without ysis for each project can be per project(s), including methods	24 , 16-Oct-2024 , 07-Jan-2025 , 16- eb-2026 , 07-May-2026 ce support for meritorious research DOC) biology, and diseases and cond cother types of complementary data erformed using existing and/or novel s for data and metadata mining, data	Feb-2025 , 07-Ma projects that addr itions, through an a, using statistical methods to be de a integration, and	y-2025 , 16-Jun-20 ess research ques alysis of existing a and computationa eveloped in the Artificial Intelliger	125 , 07-Sep- tions relevant nd publicly al approaches.
	(   k   a	(AI)/Mach biological are encou	nine Learning (ML)/Deep Learr pathways to inform identifica uraged.	ning (DL) methods. Projects focused tion of intervention targets or definition targets or definitity or defini	on investigating a ing the pathogeni	nd/or characterizi city of known gene	ng human etic variants
116699	Notice of Special Interest (NOSI): N Physiological Involvement of Oral C (COVID-19)	IIDCR Sup Cavity in C	port for Research on the Coronavirus Disease 2019	National Institute of Dental and Craniofacial Research/NIH/DHHS	NOT-DE- 23-004 07-	May-2024	Not Specified
	Contact Name A Contact Telephone	Amanda I 301-529-7	Melillo, Ph.D. 7217				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email	amanda.r	nelillo@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2025 , 07 Feb-2026	024 , 05-Jun-2024 , 16-Jun-2024 May-2025 , 05-Jun-2025 , 16-Ju , 07-May-2026	4 , 07-Sep-2024 , 05-Oct-2024 , 16-C In-2025 , 07-Sep-2025 , 05-Oct-2025	oct-2024 , 07-Jan 5 , 16-Oct-2025 ,	-2025 , 05-Feb-202 07-Jan-2026 , 05-F	25 , 16-Feb- Feb-2026 , 16-
	Synopsis	The Natio encourag CoV-2 and	nal Institute of Dental and Cran e research studies focused on tl d/or Coronavirus Disease 2019 (	iofacial Research (NIDCR) is reissuin he physiological involvement of oral (COVID-19).	g this Notice of S cavity and oral r	Special Interest (N nanifestations rela	OSI) to ated to SARS-
106245 [ [	NIDCR Behavioral and Social Inter mplementation Cooperative Agree Required)	vention Cl eement (U	inical Trial Planning and N G3/UH3 Clinical Trial C	ational Institute of Dental and raniofacial Research/NIH/DHHS	PAR-21- 317 07-	May-2024	Not Specified
	Contact Name	Melissa W	/. Riddle, PhD				
	Contact Telephone	301-451-3	3888				
	Contact Email	riddleme	@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	024 , 04-Jun-2024 , 06-Sep-202	4 , 03-Oct-2024 , 07-Jan-2025			
	Synopsis	The purpor research a include cl Applicatic Model fra FOA will in trial imple permit bo assess the (e.g., acce testing of developm	ose of this Funding Opportunity applications to plan and implem inical trials to develop and test ons for NIDCR support of clinical mework, described in detail he nitially support a milestone-drive ementation phase (UH3) of up t oth scientific and operational plate feasibility and/or acceptability eptability of study content or me intervention training and fidelity eptation of the final clinical protoco	Announcement (FOA) is to encoura nent behavioral and social interventi behavior change interventions relat I trials research are expected to ider re and incorporate an experimental yen UG3 planning phase for up to 2 yo o five years. The UG3 phase for bel anning activities. Scientific planning of a planned behavioral or social in ode of delivery; feasibility of propos ty monitoring procedures). Operatic	ge UG3/UH3 pha ion clinical trials. ed to dental, oran ntify research pro- years, with possil havioral and soci activities include tervention and a ed data collectio onal planning active alent: the data m	ased cooperative a Studies appropria I, or craniofacial c oposals using the N ach. Awards made ble transition to a al intervention cline small-scale data of ssociated study pro- n procedures; pre- tivities include, at a management system	agreement te for this FOA onditions. NH Stage under this UH3 clinical nical trials will collection to rocedures liminary minimum, m and other

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		tools for o other esso stages, fro services r considere and Conti	data and quality management, s ential documents. The UH3 pha om early mechanistic research s esearch (Stages IV/V). This FOA d clinical trials based on the NI racts for guidance).	safety and operational oversight plat se will support the conduct of invest and intervention development (e.g., may also support basic behavioral e H's revised clinical trial definition (pl	ns; recruitment tigator-initiated Stages 0/ I) thrc xperimental stu ease see Clinical	and retention strat intervention resea bugh implementation dies with humans Trial Requirement	egies; and rch at all on and health that are ts for Grants
125150	RFA-RM-24-006 Pilot Projects En Fund Data Sets (R03 Clinical Trial N	nhancing L Not Allowe	Utility and Usage of Common N ed) C	lational Institute of Dental and raniofacial Research/NIH/DHHS	RFA-RM- 24-006 27-	Jun-2024	200,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	George J. 301-480-6 george.pa Link to pr 27-Jun-20	Papanicolaou, Ph.D. 5722 ipanicolaou@nih.gov ogram URL 124 iable and widely available data	sets have been generated by multir	le Common Fun	d programs. The p	urnose of this
	Synopsis	NOFO is t (https://c asked to p	o announce the availability of f ommonfund.nih.gov/) data set provide feedback on the utility	unding to demonstrate and enhance s, including generating hypotheses a of the Common Fund data resources	the utility of se nd catalyzing dis	lected Common Fu scoveries. Award re	ecipients are
123758	RFA-DK-23-011 Continuous Keto Sodium-glucose Cotransporter-2 I Clinical trial Required)	one Monit nhibitors i	oring for the Safe Use of N n Type 1 Diabetes (RO1 D	lational Institute of Diabetes and vigestive and Kidney viseases/NIH/DHHS	RFA-DK- 23-011 [O Ap	·May-2024 otional][LOI/Pre- p]	500,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Teresa L. 301-435-2 teresa.jor Link to pr 27-May-2	Z. Jones, M.D. 2996 <u>nes@nih.gov</u> ogram URL 024 [Optional][LOI/Pre-App], 2	7-Jun-2024			
	Synopsis	Sodium-g	lucose co-transporter-2 inhibito	ors (SGLT2i) that were developed for	the treatment of	of type 2 diabetes (	(T2D) have

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		significan currently this popu ketone m of elevati mitigation they may short-tern topics inc clinical pr with SGLT	t protective effects for cardiac approved for individuals with lation. Despite this concern, t onitoring (CKM) is a rapidly ev ons in ketone levels. The purp n strategies that involve the cl benefit from the cardiac and m, clinical trials to gain and dis lude testing optimal insulin de rotocols to control or ameliora [2].	c and renal diseases for people with an type 1 diabetes (T1D) and there is an hese drugs are increasingly being pre- volving technology that could be utiliz ose of this NOFO is to solicit application inical integration of CKM for the safe renal protection and glucose-lowering seeminate knowledge on safety and gl elivery in open and closed loop system te elevated ketone levels in individua	nd without diabe increased risk of scribed off-label ed clinically to pr ons for studies th use of SGLT2i for g effects of this d ucose control wi ns or multiple dat Is with T1D who	etes. However, SGI f diabetic ketoacid for people with T revent DKA by an o nat will develop ar people living with rug class. The NOI ith CKM and SGLT ily injections and c are receiving adju	LT2i are not osis (DKA) for ID. Continuous early warning nd test risk n T1D so that O will support 2i use. Possible developing nct therapy
123309	NIDDK High Risk Multi-Center Clir U01 Clinical Trial Not Allowed)	nical Study	Cooperative Agreement	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-24- 102 05-	Jun-2024	Not Specified
	Contact Name	Tracy Ran	ıkin, Ph.D., M.P.H.				
	Contact Telephone	301-594-4	4748				
	Contact Email	<u>rankint@</u>	<u>mail.nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	05-Jun-20	024 , 05-Oct-2024 , 05-Feb-202	25 , 05-Jun-2025 , 05-Oct-2025 , 05-Fe	b-2026 , 05-Jun-	2026 , 05-Oct-202	6
	Synopsis	This NOF clinical ce Planning planning with NIDE NOFO rec peer revie Applicant (with link	D invites applications for invest enter. Proposed studies should activities must be completed p phase may first apply for an in DK Scientific/Research Staff str quires a Plan for Enhancing Div ew evaluation. Applications th s are strongly encouraged to r to https://braininitiative.nih.g	stigator-initiated, high-risk multi-center I be hypothesis-driven and focus on a prior to submission and are not permin plementation planning cooperative a rongly encouraged prior to the submiss verse Perspectives (PEDP), which will k hat fail to include a PEDP will be consid- read the FOA instructions carefully and gov/about/plan-enhancing-diverse-pe	er observational disease relevant tted under this N agreement (U34; ssion of either a be assessed as pa dered incomplet d view the availa rspectives-pedp	studies involving r to the mission of IOFO. Applicants v see PAR-24-094). U34 or U01 applica art of the scientific e and will be with ble PEDP guidance for "PEDP guidance	nore than one NIDDK. who require a Consultation ation. This and technical drawn. e material. ce material").



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Dysfunction in People with Neuro	developmental Disorders	Digestive and Kidney Diseases/NIH/DHHS	21-024		Specified
	Contact Name	Terez Shea-Donohue, Ph.D.				
	Contact Telephone	301 825-2314				
	Contact Email	terez.shea-donohue@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Sep-20	24			
	Synopsis	The National Institute of Diabetes and I grant applications focused in the follow diagnosis, prevention, or treatment of g Interdisciplinary science in this area pla scientists with expertise in neurodevelo	Digestive and Kidney Diseases is issuir ring area(s) to support basic, translati gastrointestinal dysfunction in people ys a pivotal role and projects are enco opmental disorders and scientists with	ng this Notice to onal, and/or clini with neurodeve ouraged to includ n expertise in neu	highlight interest i cal research on th lopmental disorde de close collaborat urogastroenterolo	n receiving e causes, rs. ion between gy.
123312	NIDDK High Risk Multi-Center Clin (U01 Clinical Trial Required)	ical Study Cooperative Agreement	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-24- 103 05-	Jun-2024	Not Specified
	Contact Name	Tracy Rankin, Ph.D., M.P.H.				
	Contact Telephone	301-594-4748				
	Contact Email	rankint@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024 , 05-Feb-202	25 , 05-Jun-2025 , 05-Oct-2025 , 05-Fe	b-2026 , 05-Jun-	2026 , 05-Oct-202	6
	Synopsis	This NOFO invites applications for invest center. Proposed trials should be hypot focus on a disease relevant to the missi permitted under this NOFO. Applicants cooperative agreement (U34; see PAR- to the submission of either a U34 or U0 which will be assessed as part of the sci	stigator-initiated, high-risk multi-cent shesis-driven, have the potential to ch on of NIDDK. Planning activities must who require a planning phase may fin 24-094). Consultation with NIDDK Scie 11 application. This NOFO requires a P ientific and technical peer review eva	er clinical trials ir lange clinical pra be completed p rst apply for an ir entific/Research lan for Enhancin luation. Applicat	volving more thar ctice and/or public rior to submission nplementation pla staff is strongly en g Diverse Perspect ions that fail to in	n one clinical c health, and and are not inning couraged prior ives (PEDP), clude a PEDP

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
		will be co carefully diverse-p	nsidered incomplete and wil and view the available PEDP erspectives-pedp attached to	l be withdrawn. Applicants are strongl guidance material located at: https://k o "PEDP guidance material".	y encouraged to praininitiative.nil	read the FOA instr h.gov/about/plan-e	ructions enhancing-		
107685	Stimulating Urology Interdisciplin (SUITOR) (R01 Clinical Trial Option	<u>ary Team (</u> nal <u>)</u>	<u>Dpportunity Research</u>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-22- 05 074 05	-Jun-2024	Not Specified		
	Contact Name	Julie Bart	hold, MD						
	Contact Telephone	301-594-9	9655						
	Contact Email	julia.bartl	nold@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	05-Jun-20	024 , 05-Oct-2024 , 05-Feb-20	)25					
	Synopsis	The Stimu high quali Diseases translatio progress opportun to neurou	ulating Urology Interdisciplinativy, interdisciplinary research (NIDDK). The NIDDK invites in nal, or clinical research in sp are particularly timely. As suc ities. The research topic area urology, as described below.	ary Team Opportunity Research (SUITC relevant to the mission of the Nationa nvestigator-initiated research project g ecific benign urologic conditions and d ch, research topics of interest will char previously supported by the SUITOR p	DR) program is ir al Institute of Dia grant application iseases where n age over time to program, urinary	ntended to promot abetes and Digestiv s (R01s) in specific eeds and opportur take advantage of r incontinence, will	e innovative, ve and Kidney areas of basic, ities for emerging now transitio		
108051	Stimulating Hematology Investiga Clinical Trial Not Allowed)	ition: New	Endeavors (SHINE) (R01	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-22- 096	-Jun-2024	Not Specified		
	Contact Name	Shilpa Ha	ttangadi, M.D.						
	Contact Telephone	301-594-7	7726						
	Contact Email	<u>shilpam.h</u>	attangadi@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	05-Jun-20	)24 , 05-Oct-2024						
		•							
SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
-----------------	---	---	---	--	--	---	---	--	--
	Synopsis	The Stimu nonmalig Diseases initiated to invited to that are a and Cont	ulating Hematology Investigation nant hematology research relev (NIDDK), National Institute of A research project grant application this program that supports grout the leading edge of the field w racts and hyperlinked to this FC	on: New Endeavors (SHINE) program vant to the missions of the National aging (NIA), and the National Heart, L ons (R01s) in specific areas of basic a owth in the nonmalignant hematolog will change over time and will be upo DA.	is intended to p Institute of Diab ung, and Blood I and early transla gy research doma dated regularly th	romote innovative etes and Digestive nstitute (NHLBI). I tional hematology ain. Specific emerg nrough the NIH Gu	e, high-quality and Kidney nvestigator- research are ging topics ide to Grants		
112160 <u>1</u>	NIDDK Central Repository Non-re Trial Not Allowed)	newable S	ample Access (X01 Clinical C	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-22- 171 27-	Jun-2024	Not Specified		
	Contact Name	Rebecca	M. Rodriguez, Ph.D						
	Contact Telephone	301-451-	0323						
	Contact Email	rebecca.r	odriguez2@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	27-Jun-20	024 , 29-Oct-2024 , 04-Mar-202	-Mar-2025 , 25-Jun-2025					
	Synopsis	The NIDD initiative about the assessme	K Central Repository houses va allows investigators to apply fo e samples available can be foun ent report from the NIDDK Cent	luable biological samples and data f r access to non-renewable samples d at the Repository's website. Applic ral Repository with the X01 Applicat	rom numerous n from one or mor cants must incluc ion to document	najor clinical studie e of these studies. le a volume and im sample availability	es. This Information apact y.		
116589 <u>S</u>	mall R01s for Clinical Trials Targe NIDDK (R01 Clinical Trial Required	eting Disea I <u>)</u>	ises within the Mission of C C	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-23- 086 07-	May-2024	600,000 USD		
	Contact Name	Aynur Un	alp-Arida, M.D., M.Sc., Ph.D.						
	Contact Telephone	301-594-	8879						
	Contact Email	aynur.una	alp-arida@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2	2024 , 05-Jun-2024 , 07-Sep-202	24 , 05-Oct-2024 , 07-Jan-2025 , 05-F	eb-2025 , 07-Ma	y-2025 <i>,</i> 05-Jun-20	25 , 07-Sep-		

\_

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
SynopsisSynopsis2025, 05-Oct-2025, 07-Jan-2026, 05-Feb-2026, 07-May-2026This Funding Opportunity Announcement encourages the submission of pilot and feasibility clinical trials conducted humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diseases and conditions within the mission of NIDDK. The program will support small, short-term proof-of-concept clinical trials in to acquire preliminary data regarding the effects of the intervention, as well as feasibility data related to recruitmen retention, and study conduct. Applications for clinical trials submitted under this FOA should have clearly described objectives, and have a high likelihood that the trial findings will lead to more definitive, hypothesis-driven trials to in understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clinical p 							cted in ses and als in humans tment and ibed aims and to improve ical practice
113279 <mark> </mark>	imited Competition: Small Grant Recipients (R03 Clinical Trial Opti	<u>: Program f</u> onal <u>)</u>	for NIDDK K01/K08/K23/K25	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-22- 129 07-	May-2024	150,000 USD
	Contact Name	Lisa M. Sp	pain, Ph.D.				
	Contact Telephone	301-451-9	9871				
	Contact Emai	l <u>SpainL@r</u>	niddk.nih.gov				
	Sponsor Website	2					
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2025 , 07	2024 , 16-Jun-2024 , 16-Jul-202 -May-2025 , 16-Jun-2025 , 16-	4 , 07-Sep-2024 , 16-Oct-2024 , 16-No Jul-2025 , 07-Sep-2025	ov-2024 <i>,</i> 07-Jan	-2025 , 25-Feb-202	5 , 16-Mar-
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announces a program that provides NIDDK- supported K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant (R03) support during the latter years of the award period of their K award. Through the use of this mechanism, the NIDDK is seeking to enhance the capability of its K01, K08, K23, and K25 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.							
125058 <mark>8</mark>	FA-DK-24-002 Adaptation of E Adults with T1D (R01 Clinical Tria	<u>Diabetes Co</u> I Optional)	ontrol Technologies for Older	National Institute of Diabetes and Digestive and Kidney	RFA-DK- 17- 24-002 [O	Jun-2024 otional][LOI/Pre-	500,000 USD

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
				Diseases/NIH/DHHS	Арр	p]		
	Contact Name	Guillermo	o Arreaza-Rubín, M.D.					
	Contact Telephone	301-594-4	4724					
	Contact Email	arreazag	@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	17-Jun-20	024 [Optional][LOI/Pre-App], 1	7-Jul-2024				
Synopsis Synopsis								
	Notice of Special Interest (NOSI):	Administra	ative Supplements to	National Institute of Diabetes and	NOT-DK-		150.000	
124080	Enhance Engagement Activity wit	<u>h Underse</u> ain Sunn C	rved Populations Within the	Digestive and Kidney	24-010 01-	Jun-2024	USD	
	Type 1 Diabetes Community (Adm	IIII Supp C	inical frial Not Allowed)	Diseases/ NIH/ DHHS				
	Contact Name	Miranda	M. Broadney MD, MPH					
	Contact Telephone	301-594-:	1176					
	Contact Email	Miranda.	Broadney@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	<u>ogram URL</u>	-				
	Deadline Dates (ALL)	01-Jun-20	J24 , 01-Dec-2024 , 01-Mar-20.	25 	· · · · · · · · · · · · · · · · · · ·	1 dialata (T1D)		
	Synopsis	NIDDK air Understa opportun diabetes- and incor	ms to achieve equitable engage nding that participation in rese ity supports activities which er related health disparities. (ref. poration of leadership from ur	ement in research across all persons earch is inequitable across many grou nhance outreach to and engagement NIH designated health disparities po iderserved T1D populations is deemo	Impacted by type ups impacted by T with underserve opulations). Impro ed essential for a	e 1 diabetes (T1D). T1D, this suppleme d populations whi oved engagement, ddressing dispariti	ent ch experience , participation, es and	

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
		advancing grants inv be used to	ancing health equity in T1D outcomes. This supplement opportunity is available to PD(s)/PI(s) of active NIDDK research Its investigating T1D. Administrative supplements must support work within the scope of the original project and cann Ised to support planning activities for future grants.							
125036	RFA-DK-25-008 Diabetes Resea	rch Center	s (P30 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	28FA-DK- 25-008	0-May-2024 Optional][LOI/Pre- pp]	6,250,000 USD			
	Contact Name	Corinne N	1. Silva, Ph.D.							
	Contact Telephone	301-451-7	7335							
	Contact Email	<u>silvacm@</u>	<u>mail.nih.gov</u>							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	20-May-2	024 [Optional][LOI/Pre-App],	18-Jun-2024						
	This Notice of Funding Opportunity (NOFO) invites applications for Diabetes Research Centers (DRCs) that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases. The purpose of this Centers program is to bring together basic and clinical investigators to enhance communical multidisciplinary collaboration, and effectiveness of ongoing research in Diabetes Research Center topic areas. By providi shared access to specialized technical resources (research cores) and supporting a Pilot and Feasibility Program (P&F), DF are intended to create an environment that provides the capability for accomplishments greater than those that would be possible by individual research project grant support alone. New Center programs that bring in diverse perspectives, proj unique scientific themes, or provide innovative resources are encouraged. Emphasis will be placed on Center programs the propose enhanced synergies with other NIDDK-funded programs as well as providing a rich mentoring environment for fi diabetes researchers. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as pai the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEI									
125054	RFA-DK-23-007 Discovery of Ea in the Human Pancreas [HIRN Cor Survival (CBDS)] (U01 Clinical Tria	rly Type 1 I nsortium o I Not Allow	Diabetes Disease Processes n Beta Cell Death and ved)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK- 1 23-007 A	0-Jun-2024 Optional][LOI/Pre- pp]	2,200,000 USD			
	Contact Name	Olivier Blo	ondel, Ph.D.							
	Contact Telephone	301-263-4	1342							

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Contact Email	<u>blondelol</u>	@niddk.nih.gov							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	10-Jun-20	024 [Optional][LOI/Pre-App], 09	9-Jul-2024						
	Synopsis	This Notic compartr of T1D, th staging of therapeu Consortiu stress and cell mass CBDS is p whose ov are lost ir only supp other ani	mpartment for the discovery of specific signaling or processing pathways that may contribute to the asymptomatic phas T1D, the discovery of early biomarkers of T1D pathogenesis, the development of diagnostic tools for the detection and ging of early T1D in at-risk or recently-diagnosed individuals, and/or the identification and biological validation of grapeutic targets for the development of preventative or early treatment strategies. Successful applicants will join the nsortium on Beta Cell Death and Survival (CBDS), whose mission is to better define and detect the mechanisms of beta c ess and destruction central to the development of T1D in humans, with- the long-term goal of protecting the residual be I mass in T1D patients as early as possible in the disease process, and of preventing the progression to autoimmunity. Th DS is part of a collaborative research framework, the Human Islet Research Network (HIRN, https://hirnetwork.org/), nose overall mission is to support innovative and collaborative translational research to understand how human beta cel e lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans. This NOFO wil ly support studies with a primary focus on increasing our understanding of human disease biology (as opposed to roden her animal models). This NOFO will not accept applications proposing a clinical trial.							
125109 <mark>-</mark>	RFA-DK-25-009 Kidney Technok Program (R25 - Independent Clinic	ogy Develo cal Trial No	opment Research Education ot Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK- 13- 25-009 Ap	May-2024 ptional][LOI/Pre- p]	650,000 USD			
	Contact Name	Daniel Go	ossett, Ph.D.							
	Contact Telephone	301-594-	7723							
	Contact Email	daniel.go	<u>ssett@nih.gov</u>							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	13-May-2	2024 [Optional][LOI/Pre-App], 1	.3-Jun-2024 , 13-May-2025 [Optional	][LOI/Pre-App],	13-Jun-2025				
	Synopsis	The NIH overarchi disciplina arching g	Research Education Program (F ing goal of this R25 program is ry backgrounds to research car oal, this FOA will support creat	R25) supports research education act to support educational activities that eers in biomedical, behavioral and cl ive educational activities with a prim	ivities in the mis help recruit ind inical sciences. T ary focus on: Re	sion areas of the N ividuals with speci To accomplish the search Experience	<pre>IIH. The fic specialty or stated over- s</pre>			

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		This NOF developm ground-b product d undergrad technical degree st	D encourages applications from nent. Successful programs sho reaking technology developme levelopment and navigating re duate students as participants backgrounds, but applicants n udents (e.g., M.D./Ph.D.; Phar	m institutions that propose to establis uld include a collaborative capstone r ent, multidisciplinary/interdisciplinary gulatory pathways, and clinical imme and to engage students from engine nay also propose the inclusion of med m.D./Ph.D.) prior to their qualifying e	sh research expe esearch or desig reamwork, edu rrsion. Applicatio ering and other lical students, g xams and select	eriences in kidney f gn project(s), innov ucation in entrepre ons must include p quantitative scient raduate students a tion of Ph.D. mento	echnology vative and/or neurship, lans to recruit ific and nd/or dual- or.
113566	Notice of Special Interest (NOSI): Effects of Micro and/or Nanoplas	<u>Understan</u> <u>tics</u>	ding Exposure and Health	National Institute of Environmental Health Sciences/NIH/DHHS	NOT-ES- 23-002 07	-May-2024	Not Specified
	Contact Name	Lingaman	aidu V. Ravichandran, Ph.D				
	Contact Telephone	984-287-3	3309				
	Contact Email	lingaman	aidu.ravichandran@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2025 , 07 Feb-2026 16-Feb-20	024 , 05-Jun-2024 , 16-Jun-20 -May-2025 , 05-Jun-2025 , 16- , 07-May-2026 , 05-Jun-2026 )27 , 07-May-2027 , 05-Jun-20	24 , 07-Sep-2024 , 05-Oct-2024 , 16-C Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct- 27 , 16-Jun-2027 , 07-Sep-2027 , 05-C	oct-2024 , 07-Jar 5 , 16-Oct-2025 , 2026 , 16-Oct-2 oct-2027 , 16-Oc	n-2025 , 05-Feb-20 , 07-Jan-2026 , 05-l 026 , 07-Jan-2027 , :t-2027	25 , 16-Feb- Feb-2026 , 16- 05-Feb-2027 ,
	Synopsis	The purpo Environm microplas	ose of this Notice of Special In ental Health Sciences (NIEHS) tics (MPs) and nanoplastics (N	terest (NOSI) is to inform potential ap , has special interest in applications th IPs).	plicants that th nat investigate e	e National Institute exposure to, and he	e of ealth effects of,
119809	RFA-ES-23-011 Time-Sensitive F Environmental Health Sciences (R	Research O 21 Clinical	<u>pportunities in</u> Trial Not Allowed)	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES- 23-011 03	-Jun-2024	275,000 USD
	Contact Name	Toccara C	hamberlain, M.A.				
	Contact Telephone	984-287-4	4482				
	Contact Email	toccara.cl	hamberlain@nih.gov				
	Sponsor Website	h.					
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	03-Jun-20	024 , 01-Aug-2024 , 01-Oct-202	24 , 02-Dec-2024 , 03-Mar-2025 , 02-J	un-2025 , 01-Aเ	ıg-2025 , 01-Oct-20	25 , 01-Dec-

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	2025 This Notic unpredict environm human-m distinguis NIH grant will be ac issuance.	ce of Funding Opportunity (No cable event or policy change p ental exposure data. The prin ade disasters, emerging envir hing feature of an appropriat review/award cycle, for the r hieved by more frequent app The entire cycle, from submis	DFO) is intended to support novel envir rovides a limited window of opportuni nary motivation of the NOFO is to und ronmental public health threats, and po e study is the need for rapid review an research question to be addressed and lication due dates and expediting peer ssion to award, is expected to be within	ronmental healt ity to collect hur erstand the con olicy changes in d funding, subst swiftly impleme review, council n 4-6 months.	th research in whic man biological sam sequences of natu the U.S. and abroa cantially shorter the ented. The shorten concurrence and a	h an Iples or ral and ad. A an the typical led timeframe Iward
107585	NIGMS National and Regional Res Allowed)	ources (R2	2 <mark>4 - Clinical Trial Not</mark>	National Institute of General Medical Sciences/NIH/DHHS	PAR-22- 065 14-	Jun-2024	Not Specified
	Contact Name Contact Telephone	Christina	Liu, Ph.D., PE				
	Contact Email	christina.	liu@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	14-Jun-20	)24				
Synopsis Synopsis Synopsis Synopsis							ide access to ubstantial NIGMS- d through nout regard to es such as ed to current each activities, and stand-
108741	Notice of Special Interest (NOSI): Outcomes in Infectious Disease N	Inclusion c Iodeling St	of Economic Factors and Sudies	National Institute of General Medical Sciences/NIH/DHHS	NOT-GM- 22-021 08-	Apr-2024	Not Specified

Contact Name Veerasamy (Ravi) Ravichandran, Ph.D.

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone						
	Contact Email	Veerasam	nv.ravichandra@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2025	024 , 05-Jun-2024 , 12-Jun-202	24 , 08-Aug-2024 , 07-Sep-2024 , 05-C	oct-2024 , 12-00	ct-2024 , 08-Dec-20	24 , 07-Jan-
Synopsis The National Institute of General Medical Sciences (NIGMS) is issuing this Notice to highlight interest in receiving grant applications focused on infectious disease modeling research that incorporates economic factors. The Institute is partic interested in mathematical and computational modeling studies of infectious disease spread and evolution, and of the of possible intervention strategies, that include consideration of economic influences and feedback.							g grant is particularly I of the effects
111607	Silvio O. Conte Centers for Basic N Health Research (P50 Clinical Tria	leuroscien l Optional)	ce or Translational Mental	National Institute of Mental Health/NIH/DHHS	PAR-22- [O 155 Ap	-May-2024 ptional][LOI/Pre- p]	10,000,000 USD
	Contact Name	Susan Koe	ester, Ph.D.				
	Contact Telephone	301-443-3	3563				
	Contact Email	koesters@	@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	08-May-2	024 [Optional][LOI/Pre-App],	07-Jun-2024 , 10-May-2025 [Optional]	][LOI/Pre-App],	09-Jun-2025	
	Synopsis	This Fund Translatic employing primary o the under the integr our under childhood translatio of the fiel mechanis	ing Opportunity Announceme onal Mental Health Research. T g integrative, novel, and creat bjectives of: (a) advancing the rlying mechanisms that will ult ration and translation of basic rstanding of the neurobehavio I and adolescence. The Conte nal research that demonstrate d. This program is intended or ms.	nt (FOA) encourages applications for s The NIMH seeks teams of researchers ive experimental approaches to addre state of the science in basic brain and imately provide the foundation for ur and clinical neuroscience research on ral developmental mechanisms and to Centers program is intended to suppo es an extraordinary level of synergy, in any for projects that could not be achie	Silvio O. Conte working at diffe ess high-risk, hig d behavior rese derstanding me severe mental rajectories of ps rt interdisciplin tegration, and eved using othe	Centers for Basic Ne erent levels of analy sh-impact questions arch that will uncovental disorders; (b) illnesses; and/or (c sychopathology tha ary basic neuroscie potential for advan r, more standard gr	euroscience or vsis and with the ver and dissect supporting advancing t begin in nce or cing the state rant

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
112626	<u>RFA-MH-22-185 NIMH Biobehav</u> <u>New Scientists (NIMH BRAINS) (R</u>	vioral Research Awards for Innovative 01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH- 22-185	1-May-2024 Dptional][LOI/Pre- pp]	2,500,000 USD			
	Contact Name	Eric R. Murphy, Ph.D.							
	Contact Telephone	301-443-9230							
	Contact Email	eric.murphy@nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	21-May-2024 [Optional][LOI/Pre-App], 2	20-Jun-2024 , 21-May-2025 [Optional]	[LOI/Pre-App]	, 20-Jun-2025				
	mended to support are in the early, forn mission areas of the ic, or services resea or prevention of me the NIMH Strategic	native stages of NIMH. This rch program ntal disorders. Plan.							
114657	Clinical Studies of Mental Illness ( Optional)	Collaborative R01) (Clinical Trial	National Institute of Mental Health/NIH/DHHS	PAR-23- 050	7-May-2024	Not Specified			
	Contact Name	Jonathan Pevsner, Ph.D							
	Contact Telephone	301-728-5618							
	Contact Email	jonathan.pevsner@nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	24 , 05-Oct-2024 , 07-Jan-2025 , 05-Fe	b-2025 , 07-N	1ay-2025 , 05-Jun-20	)25 , 07-Sep-				
Synopsis of psychopathology). Applicants should apply to this FOA when two or more sites are needed to complete the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase the inclusion of women and minorities (NOT-OD-18-014) and NIH-define									

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		health dis paramete centralize Investigat database	parity populations. (see https: rs.html). It is expected that on d administration. For a linked or (PD/PI). The collaborative R management, statistical analy	//www.nimhd.nih.gov/about/strateg e site will be submitted as a coordina set of collaborative R01s, each applic 01 program provides a mechanism fo sis, and reporting.	ic-plan/nih-strat ting R01 for data ation has its owr or cross-R01 coor	egic-plan-definitio a management and a Program Director dination, quality c	ons-and- d/or other r/Principal control,
117750	Assay Development and Screening Hits for Brain Disorders (R01 Clinica	for Discov al Trial No	very of Validated Chemical I at Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-23- 168 07-	May-2024	Not Specified
	Contact Name	Enrique N	1ichelotti, PhD				
	Contact Telephone	301-443-5	5415				
	Contact Email	michelotti	<u>iel@mail.nih.gov</u>				
	Sponsor Website						
	Program URL	<u>Link to pro</u>	ogram URL				
	Deadline Dates (ALL)	07-May-20 2025 , 05-	024 , 05-Jun-2024 , 07-Sep-202 Oct-2025 , 07-Jan-2026 , 05-Fe	24 , 05-Oct-2024 , 07-Jan-2025 , 05-Fe 2b-2026 , 07-May-2026	eb-2025 , 07-Ma	y-2025 , 05-Jun-20	25 , 07-Sep-
	Synopsis	The overa assays for potential of that has th Stages of identify in using a se	rching goal of this Notice of Fu the discovery of validated hits drug candidates for the treatm he desired activity in a compo- discovery research covered by itial screening hits (high throu ries of assays and initial medic	inding Opportunity (NOFO) is to supportunity (NOFO) is to support that can be used in future drug discontent of mental illness. For purposes or und screen and whose activity is confit this NOFO include 1) assay developming target-focused screens, or motion in al chemistry inspection to prioritize	ort the develop overy/developm f this initiative, a irmed upon rete nent; 2) primary derate throughpu e the hit set.	ment and validatic ent efforts for iden "hit" is defined as sting in orthogona screen implement ut screens); and 3)	on of screening ntifying s a compound Il assays. ation to hit validation

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
119663	Schizophrenia and Related Disorders During mid- to Late-Life (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-24- 023	05-Jun-2024	Not Specified
	Contract Name Lawre M. Devidend, Dh. D.				

Contact Name Laura M. Rowland, Ph.D.

Contact Telephone 301-480-8335

Contact Email <u>laura.rowland@nih.gov</u>



SPIN ID	Program Title		Sponsor Name	Spon	sor Number		Deadline Date	Funding Amount		
	Sponsor Website									
	Program URL	Link to pro	ogram URL							
	Deadline Dates (ALL)	05-Jun-20	Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026							
	The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications that will advance translational research to better understand the emergence, trajectory, and outcomes of schizophrenia and related psychotic disord mid- to late-life, and to identify targets for future development of prevention and treatment interventions. This NOFO the R01 grant mechanism, while the companion NOFO (PAR-24-026), uses the R21 mechanism. Investigators proposing risk/high reward projects that lack preliminary data may be more appropriate for the R21 mechanism.									
118003	Notice of Special Interest (NOSI): I Studies of Rare Genetic Neurodev	NIMH Plan velopmenta	ning Grants for Natural History al Disorders		National Institute of Mental Health/NIH/DHHS	NOT-MH- 23-235	7-May-2024	Not Specified		
	Contact Name	Margaret	Grabb, Ph.D.							
	Contact Telephone	301-443-3	3563							
	Contact Email	mgrabb@	mail.nih.gov							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	07-May-2 2025 , 05-	024 , 05-Jun-2024 , 07-Sep-2024 -Oct-2025 , 07-Jan-2026 , 05-Feł	4 <i>,</i> 05- o-202	Oct-2024 , 07-Jan-2025 , 05-Fe 6 , 07-May-2026 , 05-Jun-2026	b-2025 , 07-Ma , 07-Sep-2026	ay-2025 , 05-Jun-20	025 , 07-Sep-		
	Synopsis	The Natio conduct r in functio these stud establish quantitati future clir (see Food	nal Institute of Mental Health (I etrospective natural history stu- n in patients (birth to 25 years of dies is to assess the time of onse potential timepoints for interve ive clinical functional measures nical trials. These retrospective of and Drug Administration's (FDA	NIMH dies t of age et anc ntion ntion or bio natura A's) gu	) is issuing this Notice to highli hat explore the prevalence of o ) with rare genetic neurodevelo I severity of these symptoms, io Additionally, the planning grad markers that could be used as al history studies are expected idance on natural history stud	ght its interest lisabling psychi opmental disor dentify appropi nts should focu prognostics an to enable futur ies for rare diso	in supporting plan atric symptoms an ders (NDD). The pr riate outcome mea s on identifying po d/or measures of o e prospective long orders).	ning grants to d disruptions incipal goal of sures, and tential change in itudinal studies		
118004	Notice of Special Interest (NOSI): I Rare Genetic Neurodevelopmenta	Pre-Clinica al Disorder	l Research on Gene Therapies fo <u>s</u>	<u>or</u>	National Institute of Mental Health/NIH/DHHS	NOT-MH- 23-236	7-May-2024	Not Specified		
	Contact Name Contact Telephone	301-443-3	3563							

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Contact Email	NIMHgen	etherapies@nih.gov					
	Sponsor Website		<u></u>					
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2025 , 05·	 024 , 05-Jun-2024 , 07-Sep-2024 Oct-2025 , 07-Jan-2026 , 05-Fel	4 , 05-Oct-2024 , 07-Jan-2025 , 05-Fe ɔ-2026 , 07-May-2026 , 05-Jun-2026	eb-2025 , 07-M , 07-Sep-2026	ay-2025 , 05-Jun-20	25 , 07-Sep-	
	Synopsis	The National Institute of Mental Health (NIMH) is issuing this Notice of Special Interest (NOSI) to highlight interest in pro- Synopsis clinical research aimed at developing novel approaches for somatic cell gene therapies to treat neurodevelopmental disorders with prominent cognitive, social and/or affective impairment.						
123916	Advancing Learning Health Care R Treatment Settings (R34 Clinical T	esearch in rial Optior	<u>Outpatient Mental Health</u> aal)	National Institute of Mental Health/NIH/DHHS	PAR-24- 1 118 A	7-May-2024 Optional][LOI/Pre- pp]	450,000 USD	
	Contact Name	Michael F	reed, Ph.D.					
	Contact Telephone	301-443-3	3747					
	Contact Email	michael.fr	reed@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	17-May-2 [Optional App], 16-(	024 [Optional][LOI/Pre-App], 16 ][LOI/Pre-App], 16-Feb-2025 , 1 Oct-2025	5-Jun-2024 , 17-Sep-2024 [Optional] 7-May-2025 [Optional][LOI/Pre-App	[LOI/Pre-App], ], 16-Jun-2025	16-Oct-2024 , 17-Ja , 17-Sep-2025 [Opti	n-2025 onal][LOI/Pre-	
	Synopsis	This Notic health car practices to, Certific Administr demonstr certification behaviora staff/serv served by groups or	e of Funding Announcement (N re framework to support adopti in outpatient mental health and ed Community Behavioral Healt ration (SAMHSA) expansion gran ration program, or as a part of in on criteria. This NOFO requires al health partners across all phas ice users and health services res CCBHCs with unique needs, inc underserved communities: (2)	IOFO) solicits exploratory/developm on, implementation, sustainability, a d substance use treatment systems. In Clinics (CCBHCs) funded through t at program and CCBHCs participating independent state programs where the active collaboration between behavious searchers may focus on (1) identifying cluding health disparities experienced workforce development strategies in	ental research and continuous These settings he Substance A g in their states he CCBHCs are ioral health res that are co-des ng subgroups w d by people fro ncluding new a	applications within improvement of ex- could include, but a buse and Mental H ' Section 223 CCBH meeting the federa earchers and comm- igned between com- vithin the population of racial and ethnic approaches to train	the learning vidence-based re not limited ealth Services C Medicaid I CCBHC nunity munity clinic n of individuals minority providers who	

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		vary in ter treatmen treatmen response	rms of prior experience, expertis t; (4) hybrid effectiveness-imple t, or services delivery approache services within CCBHC settings.	se and skills; (3) developing and test mentation trials aimed at implemen s in real-world settings; and (5) rese	ing tools to pror ting and improv earch to establis	mote measuremer ving evidence-base h and/or expand S	nt-based ed prevention, 988 crisis
105330	NIMH Career Transition Award fo No Independent Clinical Trials)	<u>r Tenure-T</u>	rack Intramural Investigators (K2	22 National Institute of Mental Health/NIH/DHHS	PAR-21- 239 12	-Jun-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Ashlee Va 301-443-3 dnbbstrai Link to pr 12-Jun-20	n't Veer, PhD 3107 <u>ningbranch@mail.nih.gov</u> ogram URL 24				
	Synopsis	The prima abbreviat who aim t the extrar fields. Thi involve le	ary goal of the NIMH Career Tran ed as the NIMH Career Transitio to transition from the Division of mural community. Applicants sh s Funding Opportunity Announc ading an independent clinical tri	nsition Award for Tenure-Track Intra n K22 Program) is to provide suppo f Intramural Research Programs (IRF would have a demonstrated record o ement (FOA) is designed specifically al, a clinical trial feasibility study, or	mural Investiga rt for career intr ?) to an indepen f meritorious re for applicants p an ancillary clir	tors (K22) Program ramural investigate dent research face search in mental h proposing research nical trial.	n (hereafter ors at NIMH ulty position in nealth-related n that does not
107489	Basic Neurodevelopmental Biolog Not Allowed)	y of Circui	ts and Behavior (R01 Clinical Tria	<ul> <li>National Institute of Mental Health/NIH/DHHS</li> </ul>	PAR-22- 066	-Jun-2024	2,500,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Andrew B 301-451-3 neurodev Link to pr 05-Jun-20 This Fund	reeden, Ph.D. 3185 <u>elopmentpar@mail.nih.gov</u> ogram URL 24 , 05-Oct-2025 ing Opportunity Announcement	(FOA) encourages research project	s focused on the	e dynamic and me	chanistic links
	Synopsis	This Fund between	ing Opportunity Announcement the maturation of brain circuits a	(FOA) encourages research project and behaviors across development	s focused on the	e dynamic and me ion-human primat	chanistic li es. The go

SPIN ID	Program Title		Sponsor Name	Spon	sor Number		Deadline Date	Funding Amount
		to build a developm focus on r animals. T grant app	foundation for understanding h ent, allowing for the emergence neurodevelopmental trajectorie his FOA uses the R01 grant med lications.	now in e of co s and chanis	nteractions within and among b ognitive, affective and social be investigate questions using in v om, whereas its companion FOA	rain regions haviors. To t vivo neural m A, PAR-22-067	change over pre- and his end, projects sup leasures in awake, b 7, seeks shorter, high	d post-natal ported will ehaving ner-risk R21
112309	Building in vivo Preclinical Assays Therapeutic Development (R01 Cl	of Circuit E inical Trial	ngagement for Application in Not Allowed)		National Institute of Mental Health/NIH/DHHS	PAR-22- 170	07-May-2024	Not Specified
	Contact Name	Jamie Dris	scoll					
	Contact Telephone	301-443-5	5288					
	Contact Email	jdrisco1@	mail.nih.gov					
	Sponsor Website	tint to an						
	Program URL		027 05-100-2027 07-5ep 2027	1 ∩⊑	.0ct_2024 07_12n_2025 05 50	h-2025 07 №	12v-2025 05-lup 20	125  07.5  an
	Deadline Dates (ALL)	2025	024 , 03-Juli-2024 , 07-3ep-2024	+,05-	Oct-2024, 07-Jail-2025, 05-Fe	D-2023,07-1	viay-2023, 03-Juli-20	J25,07-Sep-
	Synopsis	The goal of measures and evalu pharmaco the neuro neurobiol developm neurobiol accomplis developm engageme The effort that are a to build a species ar phase tes	of this Funding Opportunity Ann for use as assays in the early so ate measures of neurophysiolog kinetic/pharmacodynamic (PK/ biology of mental illnesses. The ogy and clinical neuroscience to ent pipeline in which treatment ogical mechanisms of potential hed by supporting basic neuros ent pipeline by advancing the d ent as tools for early phase target s supported by this initiative for daptable across early therapeut suite of assays that are evaluate and healthy humans. In summary ting of novel therapeutic agents	iounce reening gical a PD) m scree o enha t cand clinica cience liscove et vali cus or tic scre ed in f r, this s by in	ement (FOA) is to identify, in ar ng phase of treatment develop and behavioral processes that n parkers of neural processes of c ening assays developed from th ance the scientific value of prec lidates and therapeutic targets al relevance to mental illnesses e aimed at improving the efficie ery of in vivo physiological and idation and therapeutic screeni n measures in animals as a first eens in animals to evaluation in future projects for coherence o FOA will support efforts to imp corporating measures proxima	nimals, in vive ment. This FC nay serve as linical interest is FOA are ex linical animal can be evalu . The objective ency and scie behavioral m ng for menta step in genera humans. Th f assay perfo rove the tool l to neural sy	o neurophysiological DA will support effor at based on available pected to build upout data contributing to ated for their ability ves of this FOA will b ntific value of the th peasures reflecting ci l illness treatment d rating translational a e FOA may be consider mance between the kit of assays availab	and behavioral ts to optimize knowledge of n systems a therapeutic to impact erapeutic rcuit evelopment. ssay measures dered a prequel e preclinical le for early mental health.

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
119702	Cellular and Molecular Biology of Not Allowed)	Complex Brain Disorders (R01 Clinical Tria	National Institute of Mental Health/NIH/DHHS	PAR-24- 024 05	-Jun-2024	Not Specified
	Contact Name	David Panchision				
	Contact Telephone	301-402-3969				
	Contact Email	panchisiond@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025	, 05-Jun-2025 , 05-Oct-2025 , 05-Fel	b-2026 , 05-Jun-	2026	
	Synopsis	This Notice of Funding Opportunity (NOF with complex brain disorders, with a focu purposes of this NOFO , the term "comple environmental) and/or highly distributed generating (unbiased discovery) or hypot paradigms, e.g., model organisms or hum incorporated into the research design to these are neither required nor expected. elucidate the neurobiological impact of ir components and their relationships withi factors, components, and processes. The disseminated with sufficient detail to enr Ontology, Synaptic Gene Ontology, FAIR I mechanism and therapeutic target identi further develop lines of inquiry where fea- research at the early and conceptual stag	O) encourages research on the biolo is on the intracellular, transcellular, a ex" can refer to a multifactorial cont functional features of the brain disc hesis-testing in design and may utiliz an cell-based assays. While behavio facilitate the characterization of intr Studies should not attempt to "mod ndividual or combined risk factor(s), n defined biological process(es). This resulting paradigms, component par ich common and/or federated data Data Informatics) in order to bridge to fication. The present NOFO (R01 act asibility or proof-of-concept has been ges of project development should ap	and circuit subst ribution to risk order. Studies m ze in vivo, in situ ral paradigms an acellular, transc lel" disorders bu such as the affe s can include the thways, and bio resources (e.g., the gap between ivity code) can b n established. A pply to the com	dence risk factors trates of neural fu (e.g., polygenic an ay be either hypo or in vitro experi- nd outcome meas ellular, and circuit at instead should a cted molecular an e fundamental bio logical processes s those contributing n disease risk factor be used for applica- pplicants proposir panion R21 NOFO	associated nction. For the d/or thesis- mental ures can be t mechanisms, aim to d cellular ology of these should be g to the Gene ors, biological ations to ng exploratory PAR-24-025

 
 Instruction
 Matchain Instructe of Mental Health/NIH/DHHS
 PAR-23-097
 05-Jun-2024
 Not Specified

 Instruction
 Contact Name
 Laura M. Rowland, Ph.D.
 Source
 301-480-8335
 Source
 Source

SPIN ID Program Title		Sponsor Name	Spons	sor Number		Deadline Date	Funding Amount
Program URL	Link to pr	ogram URL					
Deadline Dates (ALL)	05-Jun-20	024 , 05-Oct-2024					
Synopsis	The purper and trans perimence behaviora targets for companice lack prelimina	ose of this Funding Opportunity lational research on the onset a opause). In particular, NIMH see al mechanisms of mood disrupti or future mental health interven on FOA (PAR-22-036) uses the R minary data, or studies that utili	y Annou and wo eks rese tion and ntions o R21 me lize exis funding	uncement (FOA) is to encourage presening of mood and psychoti earch that will advance unders d psychosis during the menopa or prevention efforts This FOA echanism. Investigators propose sting data may wish to apply using the F	ge applications f c disorders duri tanding of the u ausal transition uses the R01 gr sing high risk/hig sing the R21 me R01 mechanism.	that will advance n ng the menopausa Inderlying neurobi and that will ident ant mechanism, w gh reward projects echanism, while ap	nechanistic Il transition (or ological and ify novel hile the s, projects that plicants with
115058 Innovative Mental Health Service Clinical Trials Not Allowed)	<u>s Research</u>	Not Involving Clinical Trials (RO	<u>01</u>	National Institute of Mental Health/NIH/DHHS	PAR-23- 095	-Jun-2024	Not Specified
Contact Name	Michael C	C. Freed, Ph.D., EMT					
Contact Telephone	301-443-3	3747					
Contact Emai	michael.f	reed@nih.gov					
Sponsor Website	2						
Program URL	Link to pr	ogram URL					
Deadline Dates (ALL)	05-Jun-20	)24					
Synopsis	The purper support t individua level proj describect access, co services, tools, tec sets to un approach	ose of this Funding Opportunity he delivery of high-quality, cont ls with, or at risk for developing, ects that address NIMH strategi d in Goal 4 of the NIMH Strategic ontinuity, utilization, quality, val which may serve as targets in fu hnologies, measures, or methoc inderstand factors affecting ment es; Wherever possible, leverage	y Annou atinuous g, a mei gic prior ic Plan. alue, and uture se ods and ntal hea ge existi	uncement (FOA) is to encourage sly improving mental health se ntal illness. This announcemer rities that strengthen the publi Proposed research should see d outcomes, including disparit ervice delivery intervention de statistical approaches to study of th services outcomes using ac ng infrastructure and partners	ge innovative re ervices to benefi at invites applica c health impact ek to: Identify m ies in outcomes evelopment; Dev y these issues; In dvanced compu- ships to accomp	search that will inf t the greatest num ations for non-clini of NIMH-supporte utable factors that to, or scalability of n velop and test new integrate and analy tational and predic lish these goals.	form and hber of cal trial R01- ed research as t impact hental health v research vze large data ctive analytic
115044 Initiation of a Mental Health Fam Engagement and Coordination of	ily Navigat Needed N	or Model to Promote Early Acce Iental Health Services for Childr	<u>ess,</u> ren	National Institute of Mental Health/NIH/DHHS	PAR-23- 094 05	-Jun-2024	2,500,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	and Adolescents (R01 Clinical Trial Red	quired)				
	Contact Name Sus	an T. Azrin, Ph.D.				
	Contact Telephone 301	l-443-3267				
	Contact Email azri	inst@mail.nih.gov				
	Sponsor Website					
	Program URL Linl	k to program URL				
	Deadline Dates (ALL) 05-	Jun-2024				
	effe and of r or p trea and Synopsis App and App care nee tecl serv pre	ectiveness and implementation of fam d optimization of mental health treatmental health problems. For the purper paraprofessional whose role is to depl atment and services, work closely with d through the use of technology – to me policants are required to develop and te d optimization of mental health treatme policants are also required to identify an e; detect and interrogate tailoring varies eds of youth to the appropriate level of hnologies to track and monitor the track vices outcomes. This FOA is published eparation for the larger-scale studies d	nily navigator models designed to pro- nent and services for children and ad oses of this FOA, NIMH defines a fam oy a set of strategies designed to rap in the family and other involved treat nonitor the trajectory of mental heal est the navigator model's ability to p nent and services for children and ad nd test components of navigator mo iables that optimize the 'personalize of intensity and frequency of mental ajectory of clinical, functional and be in parallel to a companion R34 FOA, escribed here.	prote early acce olescents who a ily navigator mo oidly engage you ment and servic th symptoms an romote early ac olescents as soo dels that drive in d match' betwee health services; havioral progres PAR-21-292 sup	ess, engagement, o are experiencing es odel as a health ca oth and families in the providers to opt ad outcomes over to cess, engagement, on as symptoms ar mprovements in m en the unique mer and utilize emerging s toward achievin, oporting pilot stud	coordination arly symptoms re professional needed imize care, time. , coordination re detected. nental health ntal health ng novel g intended ies in
115060	Laboratories to Optimize Digital Healt	h (R01 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-23- 096	-Jun-2024	Not Specified
	Contact Name Ada	am Haim, Ph.D.				
	Contact Telephone 301	L-435-3593				
	Contact Email Hai	ma@mail.nih.gov				

Sponsor Website

Program URL Link to program URL



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) ( r s Synopsis r i i	D5-Jun-20 NIMH see and qualit serious m nealth tes optimize nterventi particular	024 , 05-Oct-2024 , 05-Feb-2025 eks applications for innovative re ty of digital mental health interv ental illness. This Funding Oppo st beds that leverage well-establ existing evidence-based digital h ions that are statistically powere ty in populations who experience	esearch projects to test strategies to ventions which may impact mental h ortunity Announcement (FOA) is inte lished digital mental health platform nealth interventions and to conduct ed to provide a definitive answer reg ce health disparities and vulnerable	o increase the rea nealth outcomes ended to support ns and infrastruc clinical research garding the inter populations.	ach, efficiency, effi , including suicide : the development ture to rapidly refi testing digital me vention's effective	ectiveness, behaviors and of digital ne and ntal health ness
115032	Effectiveness of Implementing Sust Practices in Low-Resource Settings Traditionally Underserved Populati	tainable E to Achiev ons (R01	Evidence-Based Mental Health ve Mental Health Equity for Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-23- 092 05	-Jun-2024	Not Specified
	Contact Name	Susan T. A	Azrin, Ph.D.				
	Contact Telephone	301-443-3	3267				
	Contact Email <u>a</u>	azrinst@r	<u>mail.nih.gov</u>				
	Sponsor Website						
	Program URL <u>I</u>	<u>Link to pr</u>	ogram URL				
	Deadline Dates (ALL)	05-Jun-20	)24				
	This Funding Opportunity Announcement (FOA) encourages studies that develop and test the effectiveness of strategies for implementation and sustainable delivery of evidence-based mental health treatments and services to improve mental health outcomes for underserved populations in low-resourced settings in the United States. Studies should identify and use innovative approaches to remediate barriers to provision, receipt, and/or benefit from evidence-based practices (EBPs) and generate new information about factors integral to achieving equity in mental health outcomes for underserved population about factors causing/reducing disparities are strongly encouraged, including due consideration of the needs of individuals across the life span. This FOA is published in parallel to a companion R34, PAR-22 283, that supports pilot studies in preparation for the larger-scale studies described here.						
115033	Utilizing Invasive Recording and Sti Advance Neural Circuitry Understa Clinical Trial Optional)	mulating nding of I	<u>Opportunities in Humans to</u> Mental Health Disorders (R01	National Institute of Mental Health/NIH/DHHS	PAR-23- 093	-Jun-2024	Not Specified

Contact Name David McMullen, M.D.

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone	301-451-0	0180				
	Contact Email	david.mcr	mullen@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	05-Jun-20	)24				
The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue invasive recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparall into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotion functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via th electrodes, allows for direct causal tests by modulating network dynamics. This FOA aims to target a gap in the knowledge of neural circuit function related to mental health disorders. Researchers should target specific que to invasive recording modalities that have high translational potential. Development of new therapies is outsic this FOA, though development of novel tools/methods to enable relevant mental health studies is encouraged the R01 grant mechanism, encouraging longer-term projects, whereas its companion R21 FOA, PAR-21-288, se applications encouraging shorter, higher-risk studies.							
106895	Neuromodulation/Neurostimulati Applications (R01 Clinical Trial No	ion Device t Allowed)	Development for Mental Health	<ul> <li>National Institute of Mental</li> <li>Health/NIH/DHHS</li> </ul>	PAR-22- 039	-Jun-2024	Not Specified
	Contact Name	David Mc	Mullen, M.D.				
	Contact Telephone	301-451-0	0180				
	Contact Email	david.mcr	<u>mullen@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	05-Jun-20	024 , 05-Oct-2024				
The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the nex generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will eith develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, th effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cle Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques of of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the							the next will either 1) ents, the I or cleared. iques capable evelop new on of the

SPIN ID	Program Title		Sponsor Name	Spons	sor Number		Deadline Date	Funding Amount
		device. In Applicatic engineeri or signific should foo to demon should pr	cremental changes to existing d ons should be submitted by mult ng, clinical, and regulatory affair ant enhancement of novel tools cus on the engineering developr strate initial proof of concept is opose design-directed, developr	devices Iti-disci irs. App Is (hard oment a s allowa omenta	(e.g., software updates) are r plinary teams with diverse ex plications submitting in respor ware/software) for brain stim and bench top testing of the to able. Applications to this FOA I, or discovery-driven technol	not within the se pertise includin nse to this FOA s nulation in huma ool, animal and are not expecte ogy research us	cope of this annou g systems neurosc should promote th ans.Although the a limited human tes ed to be hypothesi ing integrative app	ncement. ience, e development pplication ting necessary s-driven, but proaches.
106926	Neuromodulation/Neurostimulation Applications (R01 Clinical Trial Not	on Device Allowed)	Development for Mental Health	<u>:h</u>	National Institute of Mental Health/NIH/DHHS	PAR-22- 039	5-Jun-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	David Mc 301-451-( <u>david.mcr</u>	Mullen, M.D. )180 <u>mullen@nih.gov</u>					
	Program URL Deadline Dates (ALL)	Link to pr	ogram URL 124 05-Oct-2024					
	Synopsis	The purpo generatio develop n effectiver Novel dev of increas capabilitie device. In Applicatic engineeri or signific should for to demon should pr	ose of this funding opportunity a n of brain stimulation devices for ovel brain stimulation devices of tess of brain stimulation devices of rices should move beyond existing ed spatiotemporal precision as the should focus on significant en cremental changes to existing d ons should be submitted by mult ng, clinical, and regulatory affair ant enhancement of novel tools cus on the engineering developr strate initial proof of concept is opose design-directed, developr	announ for trea or 2) sin is that a ing elec well as nhance devices lti-disci irs. App ls (hard oment a s allows omenta	ncement (FOA) is to encourag ting mental health disorders. gnificantly enhance, by means are currently U.S. Food and Dr ctrical/magnetic stimulation a s multi-focal, closed-loop appr ment of the spatial resolution (e.g., software updates) are r plinary teams with diverse ex plications submitting in respor lware/software) for brain stim and bench top testing of the to able. Applications to this FOA I, or discovery-driven technolo	e applications s Applications are s of hardware/s rug Administration develop new roaches. Applica depth of delive not within the se pertise includin isse to this FOA s nulation in huma cool, animal and are not expected ogy research us	eeking to develop e encouraged that oftware improven ion (FDA)-approve v stimulation techn ations seeking to d rery, and/or precisi cope of this annou g systems neurosc should promote th ans.Although the a limited human tes ed to be hypothesi ing integrative app	the next will either 1) nents, the d or cleared. niques capable evelop new ion of the ncement. ience, e development opplication ting necessary s-driven, but proaches.



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	and Violence Against Others		Health/NIH/DHHS	22-095		Specified
	Contact Name					
	Contact Telephone					
	Contact Email	NIMHResearchOnAggres@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 12-Jun-202 2024 , 08-Dec-2024 , 07-Jan-2025	4 , 16-Jun-2024 , 08-Aug-2024 , 07-Se	ep-2024 , 05-Oct	t-2024 , 12-Oct-20	24 , 16-Oct-
	Synopsis	NIMH is issuing this Notice of Special Int prevention of interpersonal aggression a	erest (NOSI) to outline priorities for r and violence against others.	esearch on the e	etiology, risks for,	and
11/15/19	Notice of Special Interest (NOSI): T	he Neural Mechanisms of Multi-Dimens	ional National Institute of Mental	NOT-MH- 07	-May-2024	Not
	Emotional and Social Representation	on	Health/NIH/DHHS	23-120	10109 2024	Specified
	Contact Name	Andrew Breeden, Ph.D.				
	Contact Telephone					
	Contact Email	andrew.breeden@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-202	4,07-Sep-2024,05-Oct-2024,16-O	ct-2024 , 07-Jan	-2025	
	Synopsis	NIMH is issuing this Notice of Special Int perspective into studies of the neural me integrate a broad array of emotional and underlying these processes are not well diverse multi-dimensional emotional and health relevant cognitive, social, and affe of multiple modalities (e.g., social, emot dynamic processes that unfold over a va	erest (NOSI) to outline priorities for r echanisms underlying emotional and, d social information is impaired in ma understood. This NOSI encourages st d/or social cues are represented acro ective behavioral functions. The term ional, visual, and auditory), the effect riety of temporal scales.	esearch that inc /or social repres ny mental disor udies in humans ss brain circuits "multi-dimensions to of complex co	orporates a multi- centations. The abi ders, yet the neur s and animals inve that are importan onal" refers to the ntexts and develo	dimensional lity to al mechanisms stigating how t for mental consideration pment, and/or
107450	Notice of Special Interest (NOSI): S Psychopathology Data	econdary Analysis of Posttraumatic	National Institute of Mental Health/NIH/DHHS	NOT-MH- 22-045	-May-2024	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name Su Contact Telephone 31 Contact Email Su Sponsor Website Program URL Lin Deadline Dates (ALL) 07 NI da Synopsis NI	usan Borja, Ph.D. 10-443-1252 <u>usan.borja@nih.gov</u> <u>nk to program URL</u> 7-May-2024 , 05-Jun-2024 , 12-Jun-202 IMH is issuing this Notice of Special Inte ata to aid in refining phenotypes of pos IMH is also interested in research using	4 , 16-Jun-2024 , 07-Sep-2024 erest (NOSI) to highlight interest in re ttraumatic psychopathology(ies), ma gavailable data to identify potential p	esearch to analy arkers of onset a prevention and t	ze existing and acc nd change, and ris reatment targets a	cumulating k detection. and to
	Address Translation	dvance and refine measurement and va erapeutics research.	lidation of potential novel targets fo	PAR-23-	oment in experime	ntal 
115199	(UG3/UH3 Clinical Trial Optional)		Health/NIH/DHHS	087 21	-Jun-2024	Specified
	Contact Name Ja	mie Driscoll				
	Contact Telephone 30	)1-443-5288				
	Contact Email <u>id</u>	<u>risco1@mail.nih.gov</u>				
	Sponsor Website					
	Program URL <u>Lir</u>	nk to program URL				
The goal of this initiative is to identify neurophysiological measures as potential assays for treatment development The Funding Opportunity Announcement (FOA) will support efforts to optimize and evaluate pharmacodynamic (I measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy hu another species relevant to the therapeutic development pipeline. The initiative will support initial proof of conce aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug a therapies and their targets. Data may also reveal assay measures where performance is dissimilar between precli species and humans, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal finc humans. The ultimate goal of this FOA is to improve the efficiency of the therapeutic development process by ide congruent measures as well as inconsistencies between the preclinical screening pipeline and clinical evaluation of treatment candidates. The objectives of the FOA will be accomplished by supporting partnerships among basic ar						

SPIN ID	Program Title		Sponsor Name	Spor	nsor Number		Deadline Date	Funding Amount
		translatio target val processes pharmaco humans,	nal neuroscientists who are con idation and therapeutic develop s in both animals and in healthy plogic manipulations. In this way suggesting assays for further de	nmitt omen huma /, pro velop	ed to advancing the discovery out. It. Groups will be tasked with de ans. Groups will evaluate assay jects will reveal the potential of oment as tools in the treatment	of in vivo phy eveloping and performance f specific ass developmer	siological measure d optimizing in vive across both speci ays to translate fro at pipeline.	s as tools for assays of brain es in response to m animals to
117822	Mentored Career Transition Awar Required)	<u>d for Intra</u>	mural Fellows (K22 Clinical Trial	<u>s</u>	National Institute of Mental Health/NIH/DHHS	PA-23- 150	12-Jun-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Ashlee Va 301-443-3 dnbbstrai	an't Veer 3107 <u>ningbranch@mail.nih.gov</u> ogram URL 024 , 12-Oct-2024 , 12-Feb-2025 cored Career Transition Award fe ogram that is intended to facilita al Programs (DIRP) from intramu th faculty positions at eligible U.S II provide research support durin programs. This Funding Opportu d investigator of an independer eir research and career develop experience in a clinical trial led I	, 12- or NII ate a ural p 5. inst ng tho unity nt clin ment oy an	Jun-2025 , 12-Oct-2025 , 12-Feb MH Intramural Fellows (K22) is a timely transition of qualified po ostdoctoral research positions t titutions. Both the intramural a e extramural phase to help awa Announcement (FOA) is designe nical trial, a clinical trial feasibilit t. Applicants not planning an inc other investigator, must apply t	o-2026 a two-phase, ostdoctoral fe to extramura nd extramura rdees launch ed specificall ty study, or a dependent cl to companio	mentored career ellows in the NIMH academic tenure al phases will be n competitive, inde y for applicants pr separate ancillary inical trial, or prop n FOA, PAR-23-149	development Division of e-track or hentored, and the pendent oposing to serve clinical trial, as osing to gain
103213	Effectiveness Trials for Post-Acute Longer-term Outcomes (R01 Clinic	e Intervent cal Trial Re	ions and Services to Optimize equired)		National Institute of Mental Health/NIH/DHHS	PAR-21- 210	05-Jun-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Adam Ha 301-435-: <u>haima@n</u> <u>Link to pr</u>	im, Ph.D. 3593 <u>nail.nih.gov</u> <u>ogram URL</u>					

SPIN ID	Program Title		Sponsor Name	Spon	sor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	05-Jun-20 NIMH see for the po Opportun moderato matched managing intensity/ powered effectiver post-acut	024, 05-Oct-2024 eks applications for research pro ost-acute management of menta ity Announcement (FOA) encou ors, mediators, and mechanisms to the stage of illness in terms of residual symptoms/impairmen burden for promoting optimal h to provide a definitive answer m ness trials designed to evaluate to e phase intervention approache	ojects al hea urages s of ac of both nt, pre longer regard the ini es is pl	to evaluate the effectiveness o Ith conditions affecting youth, clinical trials to establish the e tion of post-acute phase thera n their focus (e.g., consolidating venting relapse, promoting adl -term outcomes. This FOA is in ing the effectiveness of the po- itial feasibility, tolerability, accor rovided via the R34, PAR-21-21	of therapeutic adults, and ol effectiveness a peutic and se g and maintai herence and a herence and a stended to su st-acute phas eptability, saf	and service delive der adults. This Fu and test hypothese rvices intervention ining gains from in appropriate service port trials that are e intervention. Sup ety and preliminar	ry interventions Inding es regarding is that are itial treatment, e use) and e statistically oport for pilot ry indications of
119705	Cellular and Molecular Biology of Not Allowed)	Complex E	Brain Disorders (R21 Clinical Tria	<u>al</u>	National Institute of Mental Health/NIH/DHHS	PAR-24- 025	16-Jun-2024	275,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website	David Par 301-402-3 <u>panchisio</u>	nchision 3969 <u>nd@mail.nih.gov</u>					
	Program URL Deadline Dates (ALL)	<u>Link to pr</u> 16-Jun-20	ogram URL )24 , 16-Oct-2024 , 16-Feb-2025	5,16-J	un-2025 , 16-Oct-2025 , 16-Fel	b-2026 , 16-Jı	ın-2026	
	Synopsis	This Notic with com purposes environm generatin paradigm incorpora these are elucidate compone factors, co dissemina	ce of Funding Opportunity (NOF plex brain disorders, with a focu of this NOFO, the term "compl- ental) and/or highly distributed g (unbiased discovery) or hypot s, e.g., model organisms or hum ted into the research design to neither required nor expected. the neurobiological impact of ir nts and their relationships withi omponents and processes. The ated with sufficient detail to enr	O) end us on t lex" ca l funct thesis- nan ce facilit studio ndivid in defi result rich co	courages research on the biolo the intracellular, transcellular a in refer to a multifactorial cont cional features of the brain disc testing in design and may utili Il-based assays. While behavio ate the characterization of intr es should not attempt to "mod ual or combined risk factor(s), ined biological process(es). This ing paradigms, component pat	bgy of high con and circuit sub cribution to ris order. Studies ze in vivo, in s ral paradigms racellular, tran lel" disorders such as the al s can include hways and bi resources (e.	nfidence risk facto ostrates of neural f sk (e.g., polygenic a may be either hyp situ, or in vitro exp s and outcome means cellular and circu but instead should ffected molecular a the fundamental k ological processes g., those contributi	rs associated unction. For the and/or othesis- erimental asures can be lit mechanisms, d aim to and cellular biology of these should be ing to the Gene

SPIN ID	Program Title		Sponsor Name	Spo	nsor Number		Deadline Date	Funding Amount					
		Ontology mechanis develop e data. App to the co	, Synaptic Gene Ontology, FAIR om and therapeutic target ident early stage, high-risk, explorator licants proposing to develop lin mpanion R01 NOFO (PAR-24-02	Data ificati y app les of 4).	Informatics) in order to bridge t ion. The present NOFO (R21 action proaches or establish proof-of-co inquiry where feasibility or pro-	the gap betwe ivity code) car oncept where of of concept	en disease risk facto be used for applica there is little or no has been establishe	ors, biological itions to preliminary d should apply					
124186	<u>RFA-MH-25-100 BRAIN Initiative</u> specific access across vertebrate :	e: Scaled r species (U(	eagent resources for brain cell t D1 Clinical Trial Not Allowed)	ype-	National Institute of Mental Health/NIH/DHHS	RFA-MH- 25-100	L5-May-2024 Optional][LOI/Pre- \pp]	Not Specified					
	Contact Name	Douglas S	S. Kim, Ph.D.										
	Contact Telephone	301-827-0	6463										
	Contact Email	douglas.k	im@nih.gov										
	Sponsor Website												
	Program URL	Link to program URL											
	Deadline Dates (ALL)	15-May-2	024 [Optional][LOI/Pre-App], 14	4-Jun	-2024 , 18-Dec-2024 [Optional][	[LOI/Pre-App]	p], 17-Jan-2025						
	Synopsis	This Not (BRAIN) In study circ supported these too integrate projects a projects a be suppo tools to s close inte funded by be assess considered	ice of Funding Opportunity (NO nitiative is intended to support suit function. Scaled engineering d. Applications are sought for R Is for several vertebrate species scaled engineering, validation, are sought that will develop tens are intended to be distributed to rted separately. This NOFO is par pecifically access, manipulate, a eraction between technologists, y other Armamentarium NOFOs ed as part of the scientific and t	FO) f the so g and ceage s, incl cata s to h o neu art of disse c. Th cechn rawn	rom the NIH Brain Research thra caling up of brain cell type-speci validation of cell type-specific r ent Resource for Design and Dev luding in experimental animals a loguing, and adaptation into eas nundreds of cell type-selective re- proscience researchers via centra the BRAIN Initiative Armamenta onitor brain cell types across m eminators, and neurobiologists i is NOFO requires a Plan for Enha- ical peer review evaluation. Ap	ough Advanci fic molecular eagents are p elopment pro and human ex sily dissemina eagents. Valid alized Product arium project, ultiple verteb n a research c ancing Diverse plications tha	ng Innovative Neuro or genetic access re riorities to be jects that scale up th vivo tissues or cells ole formats of reage ated reagents produ ion and Distribution whose overall goal rate species. This Ne onsortium including e Perspectives (PEDF t fail to include a PEI	technologies agents to ne creation of Projects will nts. Scaled up iced in these Facilities to is to generate OFO will foster ; investigators ?), which will DP will be					
119664	Schizophrenia and Related Disord Optional)	lers During	<u>; mid- to Late-Life (R21 Clinical 1</u>	<u>rial</u>	National Institute of Mental Health/NIH/DHHS	PAR-24-	l6-Jun-2024	275,000 USD					

SPIN ID	Program Title		Sponsor Name	Spo	nsor Number		Deadline Date	Funding Amount				
		1										
	Contact Name	Laura M.	Rowland, Ph.D.									
	Contact Telephone	301-480-8	8335									
	Contact Email	laura.row	<u>land@nih.gov</u>									
	Sponsor Website											
	Program URL	Link to pr	ogram URL									
	Deadline Dates (ALL)	16-Jun-20	-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026									
	Synopsis	research mid- to la the R21 g risk/high prelimina	research to better understand the emergence, trajectory, and outcomes of schizophrenia and related mid- to late-life, and to identify targets for future development of prevention and treatment interver the R21 grant mechanism, while the companion NOFO (PAR-24-023) uses the R01 mechanism. Invest risk/high reward projects that lack preliminary data may be more appropriate for the R21 mechanism preliminary data who seek longer-term funding should apply using the R01 mechanism.									
117821	Mentored Career Transition Awar Not Allowed)	r <mark>d for Intra</mark>	mural Fellows (K22 Clinical Tria	<u>ls</u>	National Institute of Mental Health/NIH/DHHS	PA-23- 149 1	2-Jun-2024	Not Specified				
	Contact Name	Ashlee Va	an't Veer					·				
	Contact Telephone	301-443-3	3107									
	Contact Email	dnbbstrai	ningbranch@mail.nih.gov									
	Sponsor Website											
	Program URL	Link to pr	ogram URL									
	Deadline Dates (ALL)	12-Jun-20		5,12·	-Jun-2025 , 12-Oct-2025 , 12-Fe	b-2026						
	Synopsis	The Ment award pro Intramura equivalen award wil research that does Applicant Applicant	2-Jun-2024, 12-Oct-2024, 12-Feb-2025, 12-Jun-2025, 12-Oct-2025, 12-Feb-2026 ne Mentored Career Transition Award for NIMH Intramural Fellows (K22) is a two-phase, mentored career development ward program that is intended to facilitate a timely transition of qualified postdoctoral fellows in the NIMH Division of itramural Programs (DIRP) from intramural postdoctoral research positions to extramural, academic tenure-track or quivalent faculty positions at eligible U.S. institutions. Both the intramural and extramural phases will be mentored, and t ward will provide research support during the extramural phase to help awardees launch competitive, independent esearch programs. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.									

SPIN ID	Program Title		Sponsor Name	Spoi	nsor Number		Deadline Date	Funding Amount
		23-150.						
108834	Notice of Special Interest (NOSI): I Behaviors (R01 Clinical Trial Optio	<u>Neuro-Glia</u> nal <u>)</u>	Mechanisms Governing Compl	<u>ex</u>	National Institute of Mental Health/NIH/DHHS	NOT-MH- 22-090	'-May-2024	Not Specified
	Contact Name	Michele F	errante, Ph.D.					
	Contact Telephone	301-435-6	5782					
	Contact Email	michele.fe	errante@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2025 , 07-	024 , 05-Jun-2024 , 16-Jun-2024 May-2025	1,07	-Sep-2024 , 05-Oct-2024 , 16-Oc	t-2024 , 07-Jan	-2025 , 05-Feb-202	25 , 16-Feb-
	Synopsis	This Notic neuro-glia	e of Special Interest (NOSI) enco a activity coupling in modulating	oura g com	ges projects to experimentally to plex behaviors.	est mechanistic	hypotheses on the	e role of
115204	Pilot Studies to Test the Initiation Promote Early Access, Engagemer Services for Children and Adolesce	of a Mentant of and Coo ents (R34 (	al Health Family Navigator Mod rdination of Needed Mental He Clinical Trial Required)	<u>el to</u> alth	National Institute of Mental Health/NIH/DHHS	PAR-23- 104 16	-Jun-2024	450,000 USD
	Contact Name	Susan T. A	Azrin, Ph.D.					
	Contact Telephone	301-443-3	3267					
	Contact Email	<u>azrinst@r</u>	nail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	16-Jun-20	24					
	Synopsis	The purpe the effect coordinat early sym care profe in needed optimize	ose of this Funding Opportunity iveness and implementation of ion and optimization of mental ptoms of mental health problen essional or paraprofessional who I treatment and services, work o care, and through the use of teo	Anno exist healt ns. Fo ose ro closel	ouncement (FOA) is to encouraging family navigator models des th treatment and services for ch or the purposes of this FOA, NIN ole is to deploy a set of strategie y with the family and other invo ogy – to monitor the trajectory	e research app igned to promo ildren and adol 1H defines a far es designed to r olved treatment of mental healt	lications to develo ote early access, er escents who are ex mily navigator moc rapidly engage you t and service provio th symptoms and o	p and pilot test ngagement, xperiencing del as a health th and families ders to outcomes over

SPIN ID	Program Title		Sponsor Name	Spon	sor Number		Deadline Date	Funding Amount
		time. App coordinat detected. mental he emerging achieving R01 fundi	licants are required to develop a ion and optimization of mental h Applicants are also required to i ealth care; detect and interrogate ealth needs of youth to the appro- novel technologies to track and intended services outcomes. Th ng mechanism.	and pi health identi te taild opriat I moni his FO	ilot test the navigator model's In treatment and services for ch ify and pilot test components of oring variables that optimize th te level of intensity and freque itor the trajectory of clinical, fu A is published in parallel to a c	ability to prop hildren and ad of navigator m he 'personaliz ency of menta unctional and ompanion RO	note early access, e olescents as soon as odels that drive im ed match' between health services; an behavioral progress LFOA, PAR-23-094 v	ngagement, s symptoms are provements in the unique d utilize toward which uses the
115209	Innovative Pilot Mental Health Se (R34 Clinical Trial Not Allowed)	rvices Res	earch Not Involving Clinical Trials	<u>s</u>	National Institute of Mental Health/NIH/DHHS	PAR-23- 105	16-Jun-2024	450,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Susan T. A 301-443-3 azrinst@r Link to pr 16-Jun-20 The purport support t individual projects t described access, cc services, v tools, tecl and analy and predi	Azrin, Ph.D. 3267 mail.nih.gov ogram URL 024 , 16-Oct-2024 , 16-Feb-2025 ose of this Funding Opportunity , he delivery of high-quality, conti is with, or at risk for developing, hat address NIMH strategic prior in Goal 4 of the NIMH Strategic ontinuity, utilization, quality, valu which may serve as targets in fut hnologies, measures, or methods zing large data sets to understar ctive analytic approaches; Wher	Anno inuou rities Plan. ue, an ture s Is and nd fac rever p	uncement (FOA) is to encourage sly improving mental health se ntal illness. This announcemer to strengthen the public healt Proposed research should see ad outcomes, including disparit service delivery intervention de statistical approaches to study ctors affecting mental health se possible, leverage existing infra	ge innovative ervices to ben in invites appl h impact of N ek to: Identify evelopment; E y these issues ervices outcor astructure and	pilot research that v efit the greatest nur ications for non-clin MH-supported rese mutable factors tha es, or scalability of r vevelop and test new trest the feasibility nes using advanced partnerships to ac	will inform and nber of ical trial pilot arch as t impact mental health w research of integrating computational complish these
115201	Mood and Psychosis Symptoms d Trial Optional)	uring the M	Menopause Transition (R21 Clinic	<u>cal</u>	National Institute of Mental Health/NIH/DHHS	PAR-23- 102	16-Jun-2024	275,000 USD
	Contact Name	Laura M	Rowland Ph D					

Contact Name Laura M. Rowland, Ph.D.

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Talachers	201 490 6	2225				
	Contact Telephone	301-480-8	1220 anih gov				
		<u>Idui a.i Ow</u>	land@mm.gov				
		Link to pr	ogrom LIDI				
	Program URL	LINK to pro					
	Deadline Dates (ALL)	16-Jun-20	124 , 16-UCT-2U24			م مع مدين المع النبي المع	h i - i -
	Synopsis	and trans perimeno behaviora targets fo FOA (PAR prelimina prelimina	lational research on the onset a pause). In particular, NIMH see al mechanisms of mood disrupti r future mental health interven -23-097) uses the R01 grant me ry data, or studies that utilize ex ry data who seek longer-term fu	nd worsening of mood and psychoti ks research that will advance unders on and psychosis during the menopa tions or prevention efforts. This FOA chanism. Investigators proposing hig kisting data may wish to apply using unding may wish to apply using the F	c disorders durin tanding of the u ausal transition a uses the R21 m gh risk/high rewa the R21 mechan R01 mechanism.	ng the menopausa nderlying neurobi and that will ident echanism, while t ard projects, proje nism, while applica	I transition (or ological and ify novel he companion cts that lack ints with
115202	mplementing and Sustaining Evid Resource Settings to Achieve Equi	lence-Base ity in Outco	ed Mental Health Practices in Lo omes (R34 Clinical Trial Require	<ul> <li><u>w-</u> National Institute of Mental</li> <li><u>d</u> Health/NIH/DHHS</li> </ul>	PAR-23- 103 16	-Jun-2024	450,000 USD
	Contact Name	Susan T. A	Azrin. Ph.D.				
	Contact Telephone	301-443-3	3267				
	Contact Email	azrinst@r	nail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	16-Jun-20	)24				
	Synopsis	This Fund strategies in low-res EBPs are r functiona comorbid innovative about fact informatio	ing Opportunity Announcements to deliver evidence-based ments ourced mental health specialty not currently delivered or deliver I outcomes (e.g., employment, substance use disorders) for th e approaches to remediate barr tors integral to achieving equity on about factors causing/reduct	t (FOA) supports pilot work for subse- tal health services, treatment interv and non-specialty settings within the red with fidelity, such that there are educational attainment, stable hous e population(s) served. Implementa- iers to provision, receipt, and/or bear in mental health outcomes for under ing disparities is strongly encouraged	equent studies t entions, and/or e United States. e disparities in m ing, integration i tion strategies sl nefit from EBPs a erserved populat	esting the effective preventive interve The FOA targets s in the community, hould identify and and generate new tions. Research ge consideration for	veness of entions (EBPs) ettings where related treatment of use information nerating new the needs of

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	ii t	ndividuals across the life span. Application he companion R01 announcement PAR-2	ons proposing definitive tests of an i 23-092.	mplementati	on strategy should re	espond to
115200	Utilizing Invasive Recording and Stir Advance Neural Circuitry Understar Clinical Trial Optional)	mulating Opportunities in Humans to nding of Mental Health Disorders (R21	National Institute of Mental Health/NIH/DHHS	PAR-23- 101	16-Jun-2024	275,000 USD
	Contact Name L Contact Telephone 3 Contact Email <u>i</u> Sponsor Website Program URL <u>L</u> Deadline Dates (ALL) 1 T	izzy Ankudowich, Ph.D. 301-480-8187 <u>izzy.ankudowich@nih.gov</u> <u>ink to program URL</u> 16-Jun-2024 The purpose of this Funding Opportunity recording studies focused on mental heal	Announcement (FOA) is to encoura th-relevant questions. Invasive neur	ge applicatio	ns to pursue invasive s provide an unparall	neural eled window
	Synopsis k t t t t t 0	nto the human brain to explore the neur functions, and behaviors with high spatia electrodes, allows for direct causal tests b mowledge of neural circuit function relat o invasive recording modalities that have his FOA, though development of novel to he R21 grant mechanism, encouraging sh 093, seeks R01 grant applications.	al circuitry and neural dynamics und l and temporal resolution. Additiona by modulating network dynamics. Th ed to mental health disorders. Rese high translational potential. Develo pols/methods to enable relevant me norter, higher-risk applications, whe	lerlying comp ally, the abilit his FOA aims archers shou opment of ne ental health s reas its comp	plex moods, emotion y to stimulate, via th to target a gap in the ld target specific que ew therapies is outsic tudies is encouraged panion funding oppor	s, cognitive e same e scientific estions suited le the scope of . This FOA uses rtunity, PAR-23
103214	Pilot Effectiveness Trials for Post-Ac Longer-term Outcomes (R34 Clinica	cute Interventions and Services to Optim al Trial Required)	ize National Institute of Mental Health/NIH/DHHS	PAR-21- 211	16-Jun-2024	450,000 USD
	Contact Name A Contact Telephone 3 Contact Email <u>h</u> Sponsor Website Program URL <u>L</u> Deadline Dates (ALL) 1	Adam Haim, Ph.D. 301-435-3593 naima@mail.nih.gov .ink to program URL 16-Jun-2024 , 16-Oct-2024				

SPIN ID	Program Title		Sponsor Name	Sponsor	Number		Deadline Date	Funding Amount	
	N in b p e Synopsis p e ir a d p	NIMH see nterventi ooth their oreventin effectiven oresumec effectiven nterventi acceptabi design of obase inte	ks applications for pilot projects ons for the post-acute manager focus (e.g., consolidating and n g relapse, promoting adherence less research, the trial should be less of the approach; to address I to underlie the intervention effect ons to improve post-acute outco lity, safety and preliminary indice definitive effectiveness trials. Su erventions is provided via the RO	ts to evalue ment of r maintaini ce and app be designe ss whethe effects; an ectiveness comes. The ications o Support for R01, PAR-2	uate the preliminary effective mental health conditions that ng gains from initial treatme propriate service use) and in ed to evaluate the feasibility r the intervention engages t d to obtain preliminary data is study, practical trial) design is FOA supports pilot resea f effectiveness of post-acute or fully-powered, definitive e 21-210.	veness of thera at are matched ent, managing itensity/burder t, tolerability, a the target(s)/m needed as a p ned to definite rch to evaluate phase interve effectiveness st	peutic and service to the stage of illn residual symptoms I. In this pilot phase cceptability, safety echanisms(s) that i re-requisite to a la y test the effective the feasibility, tole ntion approaches a udies focused on p	delivery ess in terms of /impairment, e of , and potential s/are rger-scale eness of erability, and inform the post-acute	
106896	Neuromodulation/Neurostimulatio Applications (R21 Clinical Trial Not /	n Device Allowed)	Development for Mental Health	<u>th</u> Na He	tional Institute of Mental alth/NIH/DHHS	PAR-22- 038 10	5-Jun-2024	275,000 USD	
	Contact Name D	David Mc	Mullen, M.D.						
	Contact Telephone 3	301-451-0180							
	Contact Email d	david.mcr	<u>nullen@nih.gov</u>						
	Sponsor Website								
	Program URL	<u>ink to pr</u>	ogram URL						
	Deadline Dates (ALL) 1	16-Jun-20 The nurne	24 , 16-Oct-2024 ose of this funding opportunity a	announce	ement (FOA) is to encourage	annlications s	eeking to develop	the next	
	g d e N Synopsis c d A e o	generatio develop n effectiven Novel dev of increas apabilitie device. In Applicatic engineerin or signific	n of brain stimulation devices for ovel brain stimulation devices of ress of brain stimulation devices vices should move beyond existing ed spatiotemporal precision as es should focus on significant en cremental changes to existing d ons should be submitted by multion ng, clinical, and regulatory affair ant enhancement of novel tools	for treatin or 2) sign that are ting electrons well as n nhancem devices (e lti-disciplion irs. Applic ls (hardwa	g mental health disorders. A ificantly enhance, by means currently U.S. Food and Dri ical/magnetic stimulation a nulti-focal, closed-loop appr ent of the spatial resolution .g., software updates) are n nary teams with diverse exp ations submitted in respons are/software) for brain stim	Applications are of hardware/s ug Administrat nd develop new oaches. Applica , depth of deliv ot within the s pertise includin se to this FOA s ulation in hum	e sought that will e oftware improvem on (FDA)-approved v stimulation techr ations seeking to de ery, and/or precisi cope of this announ g systems neurosci hould promote the ans. Although the a	ither 1) ients, the d or cleared. niques capable evelop new on of the ncement. ience, e development application	

SPIN ID	Program Title		Sponsor Name	Spo	nsor Number		Deadline Date	Funding Amount
	5 - -	should foo to demon should pro Applicatio This FOA to opportuni	cus on the engineering develop strate initial proof of concept is opose design-directed, develop ons that seek to study scientific o uses the R21 grant mechanism, ity, PAR-22-039, seeks R01 gran	ment allov ment or cli encc t app	and bench top testing of the to wable. Applications to this FOA a tal, or discovery-driven technolo nical hypotheses that simply uti puraging shorter, higher-risk app plications.	ol, animals and are not expecte ogy research us lize devices are lications, wher	limited human tend d to be hypothesis ng integrative app outside the scope eas its companion	sting necessary odriven, but roaches. of this FOA. funding
106927	Neuromodulation/Neurostimulatic Applications (R21 Clinical Trial Not	on Device Allowed)	Development for Mental Health	<u>1</u>	National Institute of Mental Health/NIH/DHHS	PAR-22- 038	-Jun-2024	275,000 USD
	Contact Name I Contact Telephone 3 Contact Email Sponsor Website Program URL	David Mcl 301-451-0 <u>david.mcr</u> Link to pro	Mullen, M.D. 0180 <u>mullen@nih.gov</u> <u>ogram URL</u>					
	Synopsis /	The purpo generatio develop n effectiven Novel dev of increas capabilitie device. Inc Applicatio engineerin or significa- should foo to demon should pro Applicatio This FOA n	pieze of this funding opportunity a on of brain stimulation devices for ovel brain stimulation devices of itess of brain stimulation devices vices should move beyond existi ed spatiotemporal precision as es should focus on significant en cremental changes to existing d ons should be submitted by mult ng, clinical, and regulatory affair ant enhancement of novel tools cus on the engineering developr strate initial proof of concept is opose design-directed, developr ons that seek to study scientific of uses the R21 grant mechanism, ity, PAR-22-039, seeks R01 gran	anno pr tre r 2) : t that ng el well hand evice ti-dis cs. Ap ment allov ment or cli encc t app	uncement (FOA) is to encourage eating mental health disorders. A significantly enhance, by means t are currently U.S. Food and Dru ectrical/magnetic stimulation at as multi-focal, closed-loop appr cement of the spatial resolution es (e.g., software updates) are n ciplinary teams with diverse exp oplications submitted in response rdware/software) for brain stimu- and bench top testing of the to wable. Applications to this FOA tal, or discovery-driven technolo- nical hypotheses that simply uti- buraging shorter, higher-risk app oplications.	e applications s Applications are of hardware/s ug Administrati nd develop new oaches. Applica , depth of deliv ot within the so pertise including the to this FOA sl ulation in huma ol, animals and are not expected by research usi lize devices are lications, wher	eeking to develop e sought that will e oftware improvem on (FDA)-approved y stimulation techr itions seeking to de ery, and/or precisi cope of this announ g systems neurosci nould promote the ins. Although the a limited human test of to be hypothesis ng integrative app outside the scope eas its companion	the next ither 1) ents, the d or cleared. iques capable evelop new on of the ncement. ence, e development application sting necessary s-driven, but proaches. of this FOA. funding

SPIN ID	Program Title	Sponsor Name	Spo	nsor Number		[	Deadline Date	Funding Amount
107491	Basic Neurodevelopmental Biolog Not Allowed)	gy of Circuits and Behavior (R21 Clinical Tria	<u>al</u>	National Institute of Mental Health/NIH/DHHS	PAR-22- 067	16-J	un-2024	275,000 USD
	Contact Name	Andrew Breeden, Ph.D.						
	Contact Telephone	301-451-3185						
	Contact Email	neurodevelopmentpar@mail.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2025						
	Synopsis	between the maturation of brain circuits to build a foundation for understanding h development, allowing for the emergence focus on neurodevelopmental trajectories animals. This FOA seeks shorter, higher-ri 066 seeks R01 grant applications.	and now i e of o s and isk R	behaviors across development i interactions within and among b cognitive, affective and social be d investigate questions using in 21 grant applications, whereas i	n rodents ai rain regions haviors. To vivo neural i ts companic	nd noi chan this e measu n fun	n-human primat ge over pre- and nd, projects sup ures in awake, bo ding opportunit	es. The goal is I post-natal ported will ehaving y PAR-22-
102507	Pilot Effectiveness Trials for Treat (R34 Clinical Trial Required)	ment, Preventive and Services Interventio	<u>ns</u>	National Institute of Mental Health/NIH/DHHS	PAR-21- 131	15-J	un-2024	450,000 USD
	Contact Name	Joel Sherrill, Ph.D.						
	Contact Telephone	301-443-2477						
	Contact Email	jsherril@mail.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	15-Jun-2024 , 15-Oct-2024						
	Synopsis	NIMH solicits clinical trial applications thr intervention development pipeline, from through to effectiveness trials. The purpo effectiveness research on preventive and broader target populations or for use in c testing of innovative services intervention	rough first ose o ther comm ns. C	h a series of Funding Opportunit -inhuman, early testing of new i f this FOA is to encourage pilot r rapeutic interventions with prev nunity practice settings, and 2) r onsistent with the NIMH experir	y Announce ntervention esearch cor iously demc esearch on nental thera	ment s, con isister instra the de apeut	s (FOAs) that con firmatory efficat nt with NIMH's p ted efficacy, for evelopment and ics approach, thi	ver the cy trials, priorities for: 1) use with preliminary is FOA is

SPIN ID	Program Title		Sponsor Name	Sponsor Number			Deadline Date	Funding Amount
		intended the interv that acco services, o approach FOA supp prelimina service de comparat separate Effectiver effectiver (Collabora of the cor	to support pilot studies of intervention engages the target(s)/munts for changes in clinical/functetc.). In this pilot effectiveness pes that can be justified in terms orts pilot studies and provides rry effectiveness of approaches telivery, and for obtaining the precive effectiveness study, pragma FOAs that utilize the R01 mechaness of Treatment, Preventive, a ness trials (PAR-21-129;"Clinical Tative R01 Clinical Trial Required) mpanion FOAs.	vention effectiven echanism(s) presu- tional outcomes, o ohase of research, of their potential esources for evalu o improve mental eliminary data nee- tic trial). Support nism for single-sit nd Services Interv Trials to Test the E "). Applicants pur-	ess or service deli imed to underlie t changes in provide NIMH places high to substantially in uating the feasibili I health/functiona eded as a pre-requ for fully-powered e effectiveness tri entions (R01).") an Effectiveness of Tr suing other stages	very approact he intervention r behavior, in hest priority of hpact practice ty, tolerability l outcomes, to isite to a large effectiveness als (PAR-21-1 nd collaboration eatment, Pre- of the clinica	hes that explicitly ad on effects (i.e., the m nproved access or co n intervention and s and public health. T y, acceptability and s o modify risk factors er-scale effectivenes s studies is provided 30; "Clinical Trials to ve R01 mechanism f vention, and Service I trial pipeline shoul	dress whether hechanism(s) ontinuity of ervice delivery This afety and , or to improve as trial (e.g., through o Test the for multi-site s Interventions d consider one
102506 <u>(</u>	Clinical Trials to Test the Effective nterventions (R01 Clinical Trial R	eness of Tre equired)	eatment, Preventive, and Service	es National Ins Health/NIH/	titute of Mental /DHHS	PAR-21- 130	15-Jun-2024	Not Specified
	Contact Name	Joel Sheri	rill, Ph.D.					
	Contact Telephone	301-443-2						
	Contact Email	<u>Jsnerrii@</u>	<u>mail.nin.gov</u>					
	Sponsor website	link to pr	ogram LIPI					
	Program UKL	15 - 10 - 20	$\frac{0 \text{grain ORL}}{124}$					
	Synopsis	NIMH sol intervent through t test hypo clinical tri evidence effectiver device-ba trials to to	icits clinical trial applications thr ion development pipeline, from o effectiveness trials. This FOA s theses regarding moderators, m ials designed to test the therape of efficacy, for use in communit ness or increase the clinical impa- ised, rehabilitative and combina est patient-, provider-, organizat	ough a series of F first-inhuman, ea eeks to support cl ediators, and med utic value of treat y and practice set of pharmacolog tion interventions cional-, or systems	unding Opportuni rly testing of new linical trials to esta chanisms of action ment and prevent tings. Applications gic, somatic, psych to prevent or trea -level services into	ty Announcer interventions ablish the effe of these inter tive intervent might includ nosocial (e.g., at mental illne erventions to	ments (FOAs) that co , confirmatory effica ectiveness of interve erventions. This FOA ions for which there e research to evalua psychotherapeutic, ess. This FOA also su improve access, con	over the cy trials, ntions and to supports is already the the behavioral), pports clinical tinuity, quality,

SPIN ID	Program Title		Sponsor Name	Spons	sor Number		Deadline Date	Funding Amount
		equity, ar practice-r sufficient require pr accelerate 129 "Clini FOA is de Applicant	nd/or value of services. The inter elevant questions. This FOA us scope to test effectiveness and articipation of two or more colla e recruitment, or increase samp cal Trials to Test the Effectivene signed for applicants seeking fur s pursuing other stages of the cl	rventiones the examination looratione le dive ss of T nding inical	on research covered under thi RO1 grant mechanism to suppline mediators and moderators ive sites for completion of the ersity and representation) is plate for single-site clinical trials to trial pipeline should consider	s announcem port trials that s of response study (e.g., i rovided throu rvices Interve establish the one of the co	nent is explicitly focus at are adequately pov . Support for multi-sin n order to increase sa ugh a separate FOA, F entions (Collaborative effectiveness of inter mpanion FOAs.	eed on vered and of te trials that ample size, PAR-21- e RO1)." This eventions.
102513	Development of Psychosocial The Mental Disorders (R61/R33 Clinica	rapeutic a al Trial Rec	nd Preventive Interventions for juired)		National Institute of Mental Health/NIH/DHHS	PAR-21- 135	15-Jun-2024	Not Specified
	Contact Name	Alexande	r Talkovsky, Ph.D.					
	Contact Telephone	301-827-7	7614					
	Contact Email	alexander	.talkovsky@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	15-Jun-20	24 , 15-Oct-2024					
	Synopsis	NIMH sol intervent through t psychoso experime processes may inclu processes mechanis intervent substantis testing of maintena that meet target en	icits clinical trial applications thr on development pipeline, from o effectiveness trials. The purpo cial intervention approaches in v ntal therapeutics approach, this is underlying mental disorders int de, but are not limited to, poter is, neural circuits or neural activit ms. Novel psychosocial interven ons for which there is an empiri ally enhance outcomes. Support a novel intervention's impact or nce (target engagement). Up to is the "go/no-go" milestones embi- gagement and to test whether e	ough a first-in se of t which FOA i to pro- ntially to pro- ntially sy subs tions ical rat will b n a tar 3 yea bedde engagin	a series of Funding Opportuni nhuman, early testing of new this FOA is to encourage pilot the target and/or intervention s intended to speed the transl mising novel psychosocial pre modifiable behavioral, cogniti serving specific behaviors or co may be standalone intervention tionale by which the augment e provided for up to two year rget process or mechanism ass rs of additional support (R33 p d in the R61 phase. The R33 p ng the intervention target/me	ty Announcer interventions research dev n strategy is r lation of eme ventative or f ve, affective ognitive proc ons or augme ation (and co s (R61 phase) sociated men ohase) will be hase is intere chanism mec	ments (FOAs) that co s, confirmatory effica- eloping and testing in novel. Consistent with rgent research on me therapeutic intervent and/or interpersonal esses, and/or other r entations to efficaciou rresponding target) in for preliminary miles tal disorder risk, cause provided for studies ded to support the re- diates changes in clini	ver the cy trials, novative n NIMH's echanisms and ions. Targets factors or eurobiologica is s expected to stone-driven ation, or with findings plication of cal outcomes.

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
		Ultimately, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development and/or testing of the intervention. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.								
102530	Early Stage Testing of Pharmacolo Treatment of Mental Disorders (R	gic or Dev 61/R33 Cli	ice-based Interventions for the inical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21- 137	5-Jun-2024	Not Specified			
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Margaret 301-443-3 mgrabb@ Link to pr	Grabb, Ph.D. 3563 <u>Omail.nih.gov</u> <u>ogram URL</u>							
	NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in Synopsis subjects (a prodromal phase) prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early sta testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action the intervention is adequately tested, to provide meaningful information where target modulation yields a well- controlled, dose-dependent neurophysiological/clinical/behavioral effect. The R61/R33 FOAs are intended to support biphasic high-risk applications. Support for a single phased award that does not need the developmental (R61) phase is available in the companion R33, PAR-21-136 . Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.						ver the acy trials, nterventions altered der, anxiety, ntified in port early stage m of action of II- support phase is uld consider			
102528	Early Stage Testing of Pharmacolo Treatment of Mental Disorders (R	gic or Dev 33- Clinica	ice-based Interventions for the Il Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21- 136	-Jun-2024	Not Specified			
	Contact Name Contact Telephone Contact Email	Margaret 301-443-3 mgrabb@	Grabb, Ph.D. 3563 9mail.nih.gov							
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
---------	--	---	---	----------------------	---------------	-------------------	--	--	--	--
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	15-Jun-2024 , 15-Oct-2024								
	Synopsis	VIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the ntervention development pipeline, from first-in human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a well-controlled, dose-dependent neurophysiological/clinical/behavioral effect. Pediatric, adult and geriatric focused intervention are appropriate for this FOA. This R33 FOA supports single-phased clinical trial awards. Applicants proposing high risk project are encouraged to apply to the companion FOA, PAR-21-137or PAR-21-133.								
102511	Development of Psychosocial The Mental Disorders (R33 Clinical Tria	rapeutic and Preventive Interventions for al Required)	National Institute of Mental Health/NIH/DHHS	PAR-21- 15 134 15	5-Jun-2024	Not Specified				
	Contact Name	Alexander Talkovsky, Ph.D.								
	Contact Telephone	301-827-7614								
	Contact Email	alexander.talkovsky@nih.gov								
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	15-Jun-2024 , 15-Oct-2024								
	NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-inhuman, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to encourage pilot research developing and testing innovative synopsis psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH's experimental therapeutics approach, this FOA is intended to speed the translation of emergent research on mechanisms an processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. Targets may include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or									

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		processes mechanis target and interventi substantia engageme designed "go/no-go seeking to the comp	s, neural circuits or neural activit ms. Novel psychosocial interver d/or the intervention strategy is ons for which there is an empir ally enhance outcomes. Support ent findings, and to relate chang so that results, whether positive of decisions about further devel of fund pilot stages of research. A anion FOAs.	ty subserving specific behaviors or ntion strategies might include in-pe- novel. They may also be standalo ical rationale by which the augmen will be provided for up to 3 years ge in the intervention target/mech or negative, will provide informa opment and/or testing of the inte Applicants pursuing other stages o	cognitive process erson or technolog ne interventions of ntation (and corre for studies to rep anism to clinical b tion of high scient rvention. This FOA f the clinical trial p	es, and/or other n gy-assisted deliver or augmentations of sponding target) is licate previous tar benefit. Ultimately, tific utility and will A is designed for ap bipeline should cor	eurobiological y, provided the of efficacious s expected to get , trials must be support oplicants nsider one of
102509 <mark>E</mark>	irst in Human and Early Stage Cli evices for Psychiatric Disorders (	inical Trials (U01 Clinic	of Novel Investigational Drugs al Trial Required)	or National Institute of Mental Health/NIH/DHHS	PAR-21- 15 133	-Jun-2024	Not Specified
	Contact Name	Margaret	Grabb, Ph.D.				
	Contact Telephone	301-443-3	3563				
	Contact Email	mgrabb@	mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	15-Jun-20	24 , 15-Oct-2024				
	Synopsis	NIMH soli interventi through t stage clini psychiatri adult pop pharmacc disorders measures evaluate t "de-risk" disorders, further cli	icits clinical trial applications thr ion development pipeline, from o effectiveness trials. The purper ical trials of novel mechanism of c disorders in areas of unmet m ulations. First in human (FIH) ar ological effects, safety, and toler . Phase II/PoC studies must eval ) and clinical indicators of effect carget engagement, safety, toler novel mechanism of action inve , and devices or combination tre inical development as FDA-appr	rough a series of Funding Opportu first-inhuman, early testing of new ose of this FOA is to encourage coo f action investigational drugs or no redical need. The FOA will support ad Phase Ib studies of novel agents rability to assess feasibility for Pha uate the drug's impact on clinicall t. The FOA also supports FIH and e rability, and efficacy. The overall o stigational drugs, novel drugs for use eatments in order to attract privat oved treatments. A key aspect of	nity Announceme w interventions, co operative agreeme ovel neuromodula milestone-driven a must assess targo se II/proof of conc y relevant physiolo arly feasibility stu bjective is to facili use in pediatric po e or other public f this FOA is the for	nts (FOAs) that cov onfirmatory efficace ent applications to tory devices for th early stage trials in et engagement (br cept (PoC) studies ogical systems (fur dies (EFS) of novel tate rapid collection pulations with psy funding (when app mation of collabor	ver the cy trials, support early e treatment of n pediatric and rain exposure), in psychiatric nctional devices to on of data to rchiatric ropriate) for rative

SPIN ID	Program Title		Sponsor Name	Spo	onsor Number		Deadline Date	Funding Amount
		partnersh device de clinical tri not involv	nips between the biomedical res evelopment. This FOA is designed ials as outlined above. Applicant ving cooperative agreements sho	searo d foi ts pu ould	chers and biotechnology or indu r applicants seeking funding for ursuing other stages of the clinica I consider one of the companion	stry researcl cooperative al trial pipeli FOAs.	ners to facilitate psy- agreements suppor ne or funding for cli	chiatric drug or ing early stage nical research
102508	Confirmatory Efficacy Clinical Tria Mental Disorders (R01 Clinical Tri	ls of Non-I al Require	Pharmacological Interventions for d)	<u>or</u>	National Institute of Mental Health/NIH/DHHS	PAR-21- 132	15-Jun-2024	Not Specified
	Contact Name	Adam Ha	im, Ph.D.					
	Contact Telephone	301-435-3	3593					
	Contact Email	<u>haima@n</u>	nail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	15-Jun-20	)24 , 15-Oct-2024					
	Synopsis	NIMH sol intervent through t therapeur approach high scier dissemina interperse combinat previous efficacy s that inclu and chan determin pipeline s	icits clinical trial applications thr ion development pipeline, from to effectiveness trials. The purpo- tic and preventive interventions . Under this FOA, trials must be ntific utility and will support "go, ation of the intervention. Interve- onal, and device-based (both inv- ion thereof. Interventions appro- demonstration that the interver ignal, and must address an unm des measurement of the hypoth ge in functional or clinical effect e the intervention's potential fo should consider one of the comp	rougg first cose c s for des /no- entior vasiv opria to to to ts. U or sig coanid	the a series of Funding Opportunit t-inhuman, early testing of new of this FOA is to support confirm mental disorders in adults and c igned so that results, whether po- go" decisions about further deve ons to be studied include, but ar ve/surgically implanted as well a ate for efficacy testing must be b n engages and alters the hypothe nerapeutic need. Support will be zed mechanism of action and the ltimately, this FOA is intended to gnificant clinical benefit. Applican on FOAs	ty Announce intervention atory efficac children thro ositive or ne elopment, e e not limited s noninvasiv based on a co esized mech provided fo e relationshi o support a s nts pursuing	ements (FOAs) that c s, confirmatory effic cy testing of non-pha- bugh an experimenta gative, will provide i ffectiveness testing, d to behavioral, cogr e/transcranial) appr ompelling scientific r anism of action, a pr or a trial of the interv p between change in sufficiently-powered other stages of the	over the acy trials, rmacological I therapeutics nformation of or hitive, oaches, or a rationale, eliminary rention's efficacy the mechanism efficacy trial to clinical trial
115030	Building in vivo Preclinical Assays Therapeutic Development (R01 C	of Circuit I linical Trial	Engagement for Application in I Not Allowed)		National Institute of Mental Health/NIH/DHHS	PAR-23- 091	07-May-2024	Not Specified
	Contact Name	Jamie Dri	scoll					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone Contact Email j Sponsor Website Program URL <u>I</u>	301-443-5288 j <u>drisco1@mail.nih.gov</u> <u>Link to program URL</u> 07-May-2024 , 05-Jun-2024 , 07-Sep-202	4 . 05-0ct-2024 . 07-lan-2025 . 05-Fe	•b-2025 . 07-Ma	v-2025 . 05-lun-20	025 . 07-Sep-
	Deadline Dates (ALL)	2025 The goal of this Funding Opportunity Anr measures for use as assays in the early so and evaluate measures of neurophysiolo pharmacokinetic/pharmacodynamic (PK/ the neurobiology of mental illnesses. The neurobiology and clinical neuroscience to development pipeline in which treatmen neurobiological mechanisms of potential accomplished by supporting basic neuros development pipeline by advancing the o engagement as tools for early phase targ The efforts supported by this initiative fo that are adaptable across early therapeur to build a suite of assays that are evaluat species and healthy humans. In summary phase testing of novel therapeutic agents	nouncement (FOA) is to identify, in an creening phase of treatment develop gical and behavioral processes that r (PD) markers of neural processes that r (PD) markers of neural processes of of e screening assays developed from the o enhance the scientific value of pred t candidates and therapeutic targets clinical relevance to mental illnesses science aimed at improving the effici- discovery of in vivo physiological and ret validation and therapeutic screen scus on measures in animals as a first tic screens in animals to evaluation in red in future projects for coherence of y, this FOA will support efforts to imp s by incorporating measures proxima	nimals, in vivo noment. This FOA may serve as clinical interest to his FOA are expectinical animal dates can be evaluated to an be evaluated s. The objectives ency and scienti behavioral meating for mental ill step in generat in humans. The Fof assay perform prove the tool kind al to neural system	europhysiological will support effor based on available cted to build upor ata contributing to ed for their ability of this FOA will b fic value of the th sures reflecting ci lness treatment d ing translational a OA may be consid ance between the t of assays available ems that impact m	and behavioral ts to optimize knowledge of n systems o a therapeutic to impact erapeutic rcuit evelopment. ssay measures dered a prequel e preclinical le for early nental health.
123799 <u>/</u>	Notice of Special Interest (NOSI): In Addressing Social Determinants of Deing for People with Serious Ment	npact of Policy Interventions Aimed at Health to Improve Functioning and Well tal Illnesses	National Institute of Mental Health/NIH/DHHS	NOT-MH- 24-340 05	-Jun-2024	Not Specified
	Contact Name J Contact Telephone 3 Contact Email J Sponsor Website Program URL L	Jennifer Humensky, PhD 301-480-1265 Jennifer.Humensky@nih.gov Link to program URL				

SPIN ID	Program Title		Sponsor Name	Spo	onsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	05-Jun-20 This Notic that addre treatment understar	24 e of Special Interest (NOSI) high ess social determinants of healt t, mental health functioning, an inding the underlying mediators/	iligh h (Si d qu 'cha	ts research priorities on the imp DOH) on improvements in acces ality of life for people with seric nge mechanisms of those policie	act of social s and engag ous mental il es on outcon	and economic policy ement with mental he Inesses, with special a nes.	interventions alth ttention to
124764	RFA-MH-25-110 BRAIN Initiative Clinical Trial Optional)	: Data Arc	hives for the BRAIN Initiative (R	<u>24</u>	National Institute of Mental Health/NIH/DHHS	RFA-MH- 25-110	25-May-2024 [Optional][LOI/Pre- App]	Not Specified
	Contact Name	Ming Zhai	n, Ph.D.					
	Contact Telephone	301-827-3	3678					
	Contact Email	ming.zhar	n@nih.gov					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	25-May-2 [Optional]	024 [Optional][LOI/Pre-App], 24 ][LOI/Pre-App], 24-Jun-2026	l-Jur	1-2024 , 25-May-2025 [Optional]	[LOI/Pre-Ap	p], 24-Jun-2025 , 25-N	/lay-2026
This Funding Opportunity Announcement (FOA) solicits applications to develop web-accessible data archives store, and curate data related to BRAIN Initiative activities. The data archives teams will work with the reseat to incorporate software tools that allow users to analyze and visualize the data, and will use appropriate stat describe the data, but an application with major focus on the creation of such software tools and data stand stand summary information that is broadly available and accessible to the research community for furthering NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scient peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be will be provided to read the NOFO instructions carefully and view the available PEDP guil								a capture, a community ards to is is not iate standards earch. This and technical rawn. ice material.
124716	<u>RFA-MH-25-120 Lethal Means Sa</u> <u>Healthcare and Community Setting</u>	afety Suici gs (R34 Cli	de Prevention Research in inical Trial Required)		National Institute of Mental Health/NIH/DHHS	RFA-MH- 25-120	15-Jun-2024 [Optional][LOI/Pre- App]	450,000 USD
	Contact Name	Stephen C	D'Connor, Ph.D.					
	Contact Telephone	301-480-8	3366					

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
Contact Email stephen.o			o'connor?@nih.gov					
	Sponsor Website	<u>stephen.</u>	<u>o connorz@nin.gov</u>					
	Program URI	Link to pr	ogram URI					
	Deadline Dates (ALL)	15-Jun-20	024 [Optional][LOI/Pre-App], 15	-Jul-2024 . 23-Jan-2025				
	Synopsis	NIMH seeks applications to evaluate the preliminary effectiveness of therapeutic and service delivery interver utilize lethal means safety strategies to reduce suicide risk in healthcare and community settings. Behavioral I that incorporate lethal means counseling into their programming have been associated with significant reduc attempts and death. Yet, the field is lacking strong evidence on the effectiveness of these strategies tested in community settings. Pilot effectiveness research will advance knowledge regarding optimization strategies, the change mechanisms, and inform decisions about whether further effectiveness testing is warranted. The rese provide preliminary evidence on the extent to which lethal means safety interventions more optimally lead to safety (e.g., number/percent of firearms safely stored, overdose injury codes for an individual) and lower suic pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acce and potential effectiveness of the approach; to address whether the intervention engages the target(s)/mech is/are presumed to underlie the intervention effects; and to obtain preliminary data needed as a pre-requisite scale effectiveness trial (e.g., comparative effectiveness study, practical trial) designed to definitively test the the intervention						
102910	Inderstanding and Modifying Ter Activity (R21 Clinical Trial Optiona	<u>mporal Dyi</u> il)	namics of Coordinated Neural	National Institute of Mental Health/NIH/DHHS	PAR-21- 176 16	-Jun-2024	275,000 USD	
	Contact Name	Andrew F	Rossi, Ph.D.					
	Contact Telephone	301-443-:	1576					
	Contact Email	andrew.r	ossi@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	16-Jun-20	024 , 16-Oct-2024					
	Synopsis	A growing coordinat spike-pha for treatn Announce	g body of evidence suggests that ted neural activity. These findin ase correlations, spike populatic nent of cognitive, social, or affe ement (FOA) supports projects	t optimal cognitive, affective, and so gs indicate that oscillatory rhythms, on dynamics, and other patterns mig ctive symptoms in neuropsychiatric that test whether modifying electrop	ocial processes a their co-modula ht be useful driv disorders. This F physiological pat	re associated with tion across freque ers of therapeutic unding Opportuni terns during beha	highly ncy bands, development ty vior can	

SPIN ID Program	n		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		improve of manipula paramete processin affect the systems-l improven systems-l patterns mechanis an establ	cognitive, affective, or social pro- tions to address at least one, ar ers of neural coordination, wher eg; (2) in animals or humans, det e systems-level coordination of e level electrophysiological change nents in healthy persons or clini level aspects to understand the unfold across the brain to impac sm, whereas its companion FOA, ished premise.	ocessing. Applications must use exp ad ideally more, of the following top a manipulated in isolation, improve termine how particular abnormalitie electrophysiological patterns during es in behaving animals predict analo cal populations; and (4) use biologic function and mechanisms by which et cognitive, affective, or social proo , PAR-21-175, seeks R01 grant appli	erimental design particular aspect s at the genomi behavior; (3) de ogous electrophy cally-realistic cor oscillatory and c essing. This FOA cations for large	is that incorporate ls or humans, dete ts of cognitive, affe c, molecular, or ce termine whether vsiological and cog nputational mode other electrophysic uses the R21 expl r research applicat	e active ermine which ective, or social ellular levels in vivo, nitive ls that include plogical oratory grant cions that have
102908 Understan Activity (F	nding and Modifying Ter 101 Clinical Trial Optiona	<u>mporal Dyi</u> il)	namics of Coordinated Neural	National Institute of Mental Health/NIH/DHHS	PAR-21- 175	5-Jun-2024	Not Specified
	Contact Name	Andrew F	Rossi, Ph.D.				
	Contact Telephone	301-443-	1576				
	Contact Email	andrew.r	<u>ossi@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	rogram URL				
	Deadline Dates (ALL)	05-Jun-20	024 , 05-Oct-2024				
	Synopsis	A growing coordinat spike-pha for the tro Announce improve of manipula paramete processin affect the systems-l improven	g body of evidence suggests tha ted neural activity. These finding ase correlations, spike populatio eatment of cognitive, social, or a ement (FOA) supports projects t cognitive, affective, or social pro- tions to address at least one, an ers of neural coordination, when ag; (2) in animals or humans, det e systems-level coordination of e level electrophysiological change ments in healthy persons or clini	t optimal cognitive, affective, and so gs indicate that oscillatory rhythms, n dynamics, and other patterns mig affective symptoms in neuropsychia that test whether modifying electro occssing. Applications must use exp ad ideally more, of the following top manipulated in isolation, improve termine how particular abnormalitie electrophysiological patterns during es in behaving animals predict analo cal populations; and (4) use biological	ocial processes a their co-modula ght be useful driv atric disorders. T physiological pat erimental design vics: (1) in animal particular aspect es at the genomi behavior; (3) de pgous electrophy cally-realistic cor	re associated with tion across freque vers of therapeutic his Funding Oppor terns during beha s that incorporate s or humans, dete ts of cognitive, affe c, molecular, or ce termine whether vsiological and cog nputational mode	h highly ency bands, development tunity vior can active ermine which ective, or social ellular levels in vivo, nitive ls that include

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		systems-l patterns u whereas i	evel aspects to understand the Infold across the brain to impacts ts companion FOA, PAR-21-176	function and mechanisms by which ct cognitive, affective, or social proc 5, seeks shorter, higher-risk R21 gran	oscillatory a essing. This F t applicatior	nd other electrophysic OA uses the R01 gran ns.	ological t mechanism,
104058	NIMH Exploratory/Developmenta Allowed)	al Research	Grant (R21 Clinical Trial Not	National Institute of Mental Health/NIH/DHHS	PA-21- 235	07-May-2024	275,000 USD
	Contact Name	Susan Koe	ester, Ph.D.				
	Contact Telephone	301-443-3	3563				
	Contact Emai	koesters@	omail.nih.gov				
	Sponsor Website	2					
	Program URI	Link to pr	ogram URL				
	Deadline Dates (ALL	07-May-2	024 , 16-Jun-2024 <i>,</i> 07-Sep-202	4 , 16-Oct-2024 , 07-Jan-2025			
	Synopsis	NIMH mis considera models, o major imp	sion by providing support for the ble risk but may lead to a break r strategies, or to the generationation biomedical, behavioral,	he early and conceptual stages of the through or to the development of non of pilot or feasibility data. The pre- or clinical mental health research, o	ese projects. ovel techniq liminary wo r on the deli	. These studies may in Jues, agents, methods rk from these studies very of mental health	volve , measures, could lead to a care.
110192	<u>RFA-NS-22-038 Research Progr</u>	am Award	(R35 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS- 22-038	15-Jun-2024 [Optional][LOI/Pre- App]	6,000,000 USD
	Contact Name	Alisa Scha	efer, Ph.D.				
	Contact Telephone	2					
	Contact Emai	l <u>alisa.scha</u>	efer@nih.gov				
	Sponsor Website	2					
	Program URI	Link to pr	ogram URL				
	Deadline Dates (ALL	15-Jun-20	24 [Optional][LOI/Pre-App], 15	-Jul-2024			
	Synopsis	The purpo flexibility administr	ose of the NINDS Research Prog to Program Directors (PDs)/Prin ative burden of writing and ma	ram Award (RPA) is to provide longencipal Investigators (PIs), to allow th naging multiple grant applications a	er-term supp em to redire nd towards e	oort, and increased fre ct their time away fro engaging in the lab. Th	edom and m the .is RPA affords

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	------------------	--------------	----------------	---------------	-------------------

investigators at most career stages the opportunity to advance their long-term research goals, rigorously explore exciting research opportunities, and mentor students and postdoctorates, which support and align with the mission of NINDS. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PI's recent NINDS support (Part 2, Section II). This greater funding stability will provide eligible investigators increased security, allowing them to undertake research projects that require a longer timeframe or to embark upon research that breaks new ground. Research activities outside of the NINDS mission, or traditionally supported by another NIH Institute or Center, will not be considered through this program. Benefits of the RPA include: A more stable funding environment, facilitating the pursuit of longer-term research goals; Flexible funding, enabling investigators to pursue research opportunities as they arise, not tied to specific aims; Reduced time spent writing grant applications and managing multiple grant awards, allowing investigators to spend more time conducting and overseeing research; More time for PDs/PIs to mentor and foster a diverse workforce in their laboratories. The RPA is a unique program for NINDS, as such NINDS strives to ensure it reflects our commitment to enhancing the diversity and inclusiveness of the neuroscience workforce. A diverse NIHsupported scientific workforce, including individuals from underrepresented groups, fosters scientific innovation, enhances global competitiveness, contributes to robust learning environments, and improves the quality of the research (see NIH's Interest in Diversity). NINDS will work to ensure that it maintains a broad and diverse research portfolio in terms of scientific areas, approaches, regions, institutions, and individuals. Such diversity will optimize returns on the Institute's investments by maximizing the ideas explored and the chances for important breakthroughs. Note that, while this funding opportunity also accepts clinical trials, only applications proposing "mechanistic clinical trials or studies" or basic experimental studies with humans (BESH) will be accepted. For information on the types of clinical trial that are within scope of this funding opportunity announcement, refer to Funding Opportunity Description, below.

104258 NINDS Efficacy Clinical Trials (UG3	3/UH3 Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 237	07-May-2024	Not Specified
Contact Name	Jeremy Brown, MD				
Contact Telephone	301-496-9135				
Contact Email	Jeremy.brown@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2024 , 09-Jun-2024 , 10-Sep-2024 , 09	9-Oct-2024 , 08-Jan-2025			
Synopsis	The purpose of this Funding Opportunity Ann efficacy clinical trials to the National Institute	ouncement (FOA) is to encourag of Neurological Disorders and St	e grant app roke (NIND	lications for investigator S). The trials must addre	-initiated ss questions

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		within the behaviora the NINDS	e mission and research interests Il and rehabilitation therapies. I 5 website (https://www.ninds.n	s of the NINDS and may evaluate drund of the NINDS and may evaluate drund formation about the mission and r nih.gov/).	igs, biologics esearch inte	s, and devices, as well rests of the NINDS cai	as surgical, n be found at
107322	Translational Efforts to Advance ( Neurological and Neuromuscular	Gene-based Disorders	<u>l Therapies for Ultra-Rare</u> (U01 - Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22- 030	07-Jun-2024	Not Specified
	Contact Name	Ann-Mari	e Broome, PhD, MBA				
	Contact Telephone	301-496-1	1779				
	Contact Email	ann-marie	e.broome@nih.gov				
	Sponsor Website	h					
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07 1					
	Deadline Dates (ALL)	07-Jun-20	24 , 10-Oct-2024				
	Synopsis	The Ultra- planning a oligonucle funding o biological specified	24, 10-Oct-2024 Rare Gene-Based Therapy (URG activities for First-in-Human (FIF eotides and viral-based gene the pportunity announcement (FOA rationale and demonstrated pr patient population towards an	GenT) network supports Investigatio H) clinical testing of gene-based or the erapies, for ultra-rare neurological of A) is to accelerate the development roof of concept (POC) data for the in IND filing and the initiation of a clini	nal New Dru ranscript-dir or neuromus of a promisin tended appr cal trial.	ig (IND)-enabling stud ected therapeutics, su cular disorders. The gi ng clinical candidate w roach in a model syste	ies and ich as oal of this vith robust m relevant to a
110549	NINDS Exploratory Clinical Trials (	The Ultra- planning a oligonucle funding o biological specified	24 , 10-Oct-2024 Rare Gene-Based Therapy (URG activities for First-in-Human (FIF eotides and viral-based gene the pportunity announcement (FOA rationale and demonstrated pr patient population towards an <u>Clinical Trial Required</u> )	GenT) network supports Investigation H) clinical testing of gene-based or the erapies, for ultra-rare neurological of A) is to accelerate the development foof of concept (POC) data for the inini IND filing and the initiation of a clinit National Institute of Neurological Disorders and Stroke/NIH/DHHS	nal New Dru ranscript-dir of a promisin tended appr cal trial. PAR-22- 142	ig (IND)-enabling stud ected therapeutics, su cular disorders. The go ng clinical candidate w roach in a model syste 10-Jun-2024	ies and ich as bal of this vith robust m relevant to a Not Specified
110549	NINDS Exploratory Clinical Trials ( Contact Name	The Ultra- planning a oligonucle funding o biological specified	24 , 10-Oct-2024 Rare Gene-Based Therapy (URG activities for First-in-Human (FIF eotides and viral-based gene the pportunity announcement (FOA rationale and demonstrated pr patient population towards an Clinical Trial Required)	GenT) network supports Investigation H) clinical testing of gene-based or the erapies, for ultra-rare neurological of A) is to accelerate the development foof of concept (POC) data for the in IND filing and the initiation of a clinit National Institute of Neurological Disorders and Stroke/NIH/DHHS	nal New Dru ranscript-dir or neuromus of a promisin tended appr cal trial. PAR-22- 142	ig (IND)-enabling stud ected therapeutics, su cular disorders. The ge ng clinical candidate w roach in a model syste 10-Jun-2024	ies and ich as bal of this rith robust m relevant to a Not Specified
110549	NINDS Exploratory Clinical Trials ( Contact Name Contact Telephone	The Ultra- planning a oligonucle funding o biological specified	24 , 10-Oct-2024 Rare Gene-Based Therapy (URG activities for First-in-Human (FIF eotides and viral-based gene the pportunity announcement (FOA rationale and demonstrated pr patient population towards an Clinical Trial Required)	GenT) network supports Investigatio (1) clinical testing of gene-based or the erapies, for ultra-rare neurological of (A) is to accelerate the development foof of concept (POC) data for the in IND filing and the initiation of a clinit National Institute of Neurological Disorders and Stroke/NIH/DHHS	nal New Dru ranscript-dir or neuromuso of a promisin tended appr cal trial. PAR-22- 142	ig (IND)-enabling stud ected therapeutics, su cular disorders. The go ng clinical candidate w oach in a model syste 10-Jun-2024	ies and ich as bal of this vith robust m relevant to a Not Specified
110549	NINDS Exploratory Clinical Trials ( Contact Name Contact Telephone Contact Email	The Ultra- planning a oligonucle funding o biological specified	24 , 10-Oct-2024 Rare Gene-Based Therapy (URG activities for First-in-Human (FIF eotides and viral-based gene the pportunity announcement (FOA rationale and demonstrated pr patient population towards an <u>Clinical Trial Required</u> ) rown MD	GenT) network supports Investigatio H) clinical testing of gene-based or the erapies, for ultra-rare neurological of A) is to accelerate the development foof of concept (POC) data for the in IND filing and the initiation of a clini National Institute of Neurological Disorders and Stroke/NIH/DHHS	nal New Dru ranscript-dir of a promisin tended appr cal trial. PAR-22- 142	ig (IND)-enabling stud ected therapeutics, su cular disorders. The go ng clinical candidate w roach in a model syste 10-Jun-2024	ies and ich as bal of this vith robust im relevant to a Not Specified
110549	NINDS Exploratory Clinical Trials ( Contact Name Contact Telephone Contact Email Sponsor Website	The Ultra- planning a oligonucle funding o biological specified	24 , 10-Oct-2024 Rare Gene-Based Therapy (URG activities for First-in-Human (FIF eotides and viral-based gene the pportunity announcement (FOA rationale and demonstrated pr patient population towards an Clinical Trial Required)	GenT) network supports Investigatio (1) clinical testing of gene-based or the erapies, for ultra-rare neurological of (2) is to accelerate the development (3) is to accelerate the development (3) is to accelerate the development (3) is to accelerate the development (4) is to accelerate the development (3) is to accelerate the development (4) is to accelerate the development (4) is to accelerate the development (5) is to accelerate the development (4) is to accelerate the development (5) is to accelerate the development (6) is to accelerate the development (6) is to accelerate the development (6) is to accelerate the development (7) is to accelerate the development (8) is to accelerate the	nal New Dru ranscript-dir or neuromus of a promisin tended appr cal trial. PAR-22- 142	ig (IND)-enabling stud ected therapeutics, su cular disorders. The ge ng clinical candidate w oach in a model syste 10-Jun-2024	ies and ich as bal of this rith robust m relevant to a Not Specified
110549	NINDS Exploratory Clinical Trials ( Contact Name Contact Telephone Contact Email Sponsor Website Program URL	The Ultra- planning a oligonucle funding o biological specified	24 , 10-Oct-2024 Rare Gene-Based Therapy (URG activities for First-in-Human (FIF eotides and viral-based gene the pportunity announcement (FOA rationale and demonstrated pr patient population towards an <u>Clinical Trial Required</u> ) rown MD	GenT) network supports Investigatio (1) clinical testing of gene-based or the erapies, for ultra-rare neurological of (A) is to accelerate the development foof of concept (POC) data for the in IND filing and the initiation of a clinit National Institute of Neurological Disorders and Stroke/NIH/DHHS	nal New Dru ranscript-dir of a promisin tended appr cal trial. PAR-22- 142	ig (IND)-enabling stud ected therapeutics, su cular disorders. The ging clinical candidate w roach in a model syste 10-Jun-2024	ies and ich as bal of this vith robust m relevant to a Not Specified
110549	NINDS Exploratory Clinical Trials ( Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	The Ultra- planning a oligonucle funding o biological specified	24 , 10-Oct-2024 Rare Gene-Based Therapy (URG activities for First-in-Human (FIF eotides and viral-based gene the pportunity announcement (FOA rationale and demonstrated pr patient population towards an Clinical Trial Required) Town MD Town MD Ogram URL 124 , 08-Oct-2024 , 10-Feb-2025	GenT) network supports Investigatio (1) clinical testing of gene-based or the erapies, for ultra-rare neurological of (3) is to accelerate the development (3) is to accelerate the development (3) is to accelerate the development (4) is to accelerate the development (1) is to accelerate the development (2) is to accelerate the development (3) is to accelerate the development (4) is to accelerate the development (5) is to accelerate the development (5) is to accelerate the development (6) is to accelerate the	nal New Dru ranscript-dir of a promisin tended appr cal trial. PAR-22- 142	ig (IND)-enabling stud ected therapeutics, su cular disorders. The ge ng clinical candidate w roach in a model syste 10-Jun-2024	ies and ich as bal of this vith robust m relevant to a Not Specified

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		explorato trials mus biologics, therapies inform a f Phase 1 si	ry Phase 1 and Phase 2 clinical t address questions within the r feasibility or preliminary efficad . All Phase 1 exploratory trials m future Phase 2 trial that may als tudies be encouraging. This FOA	rials to the National Institute of Nemission and research interests of the vision and research interests of the studies of devices, and early studion st contribute to the justification to be performed as part of the curres uses the UG3/UH3 mechanism.	eurological Disord ne NINDS. They r dies of surgical, b for and provide s ent grant applica	ders and Stroke (Ni nay include studies ehavioral or rehab ome of the data re tion, should the re	NDS). These of drugs and ilitation equired to sults of the
103393	NINDS Faculty Development Awa Research (K01 Clinical Trial Requi	rd to Prom red)	ote Diversity in Neuroscience	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 153 0	7-May-2024	Not Specified
	Contact Name	Michelle	lones-London, Ph.D.				
	Contact Telephone	301-451-7	7966				
	Contact Emai	jonesmich	<u>ne@ninds.nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	024 , 12-Jun-2024 , 07-Sep-2024	4			
The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research the pool of independent neuroscience research investigators by providing junior faculty with resear protected research time and career stage appropriate professional development mentorship in neuroscience research degrees (Ph.D. or equivalent) and are in the tunure track or equivalent position at the time of application. This Funding Opportunity Announcen specifically for candidates proposing to serve as the lead investigator of an independent clinical trial study, or a separate ancillary clinical trial, as part of their research and career development. Those independent clinical trial, or proposing to gain research experience in a clinical trial led by another i companion FOA (PAR-21-152).							to diversify port, esearch. re eligible for rs of a faculty s designed rrial feasibility g an , must apply to
103724	NINDS Faculty Development Awa Research (K01 Independent Clinic	rd to Prom al Trial No	ote Diversity in Neuroscience t Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 0 <sup>.</sup> 234	7-May-2024	Not Specified
	Contact Name Contact Telephone	Michelle J 301-451-7	Jones-London, Ph.D. 7966				
			NIH Funding Opportu	nities Due: June 2024			155

SPIN ID	Program Title		Sponsor Name	Spo	nsor Number		Deadline Date	Funding Amount	
	Contact Email	ionesmic	ne@ninds.nih.gov						
	Sponsor Website		<u> </u>						
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2	024 , 12-Jun-2024 , 07-Sep-2024	4					
	Synopsis	The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K the pool of independent neuroscience research investigators by providing junior faculty with research cosported research time and career stage appropriate professional development mentorship in neuroscience Individuals from diverse backgrounds, including those from groups underrepresented in biomedical research support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (I specifically for candidates proposing research that does not involve leading an independent clinical trial, a feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propo experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary s clinical trial as lead investigator, should apply to the companion FOA (PAR-21-153)							
107186	Clinical Trial Readiness for Functic Optional)	onal Neuro	logical Disorders (U01 Clinical T	<u>rial</u>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22- 053	-Jun-2024	Not Specified	
	Contact Name	Codrin Lu	ngu, MD						
	Contact Telephone	301-496-9	9135						
	Contact Email	lunguci@	<u>ninds.nih.gov</u>						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	05-Jun-20	024 , 05-Oct-2024						
	Functional Neurological Disorders (FNDs) are characterized by symptoms of altered voluntary motor or sensory functi clinical findings providing evidence of incompatibility between the symptoms and recognized neurological or medical conditions. FNDs are highly prevalent and associated with significant morbidity, health care costs, and even mortality some respects, this group of conditions sits at the intersection of neurology and psychiatry, but the majority of cases come to the attention of neurologists. Management is complex and requires interdisciplinary approaches. Given the caused by the symptoms, and the high cost in healthcare utilization and loss of productivity, FNDs amount to a signifi- missed opportunity for therapeutic intervention and therefore, a healthcare crisis. Diagnosis and management of FNI								

SPIN ID	Program Title		Sponsor Name	Spo	nsor Number		Deadline Date	Funding Amount	
		remain ve on positiv more diffi biomarke FNDs. The hampered prediction projects t of biomar for clinica 315, PAR- investigat	ery challenging. Diagnostic crite ve clinical findings, and can be so icult to correctly diagnose than rs can be developed, but signifi- erapies exist and have been stud d by limitations in available out of aggregate treatment respon- hat address critical needs for cli rkers, endpoints and clinical out of trials. Projects involving bioma 21-056, PAR-21-057, PAR-21-05 cors, industry, and patient group	ria ha uppo othe cantl died i come nse h inical come arker 58, PA	ave been proposed but they are rted by laboratory or ancillary i rs. More importantly, laborator y more research is needed in th in select populations but gather e measures. Differential respons as been difficult. This FOA invit trial readiness in FNDs. Project e assessments (COA) that are fit discovery or early validation sh AR-21-059). The initiative will pund will encourage interactions w	e not universa nvestigation f ry-supported o rese areas to a ring high-level ses to treatme es researcher ts appropriate t-for-purpose ould apply to romote partne vith the Food	lly agreed upon. Dia indings. Certain FND diagnosis is possible, advance clinical man evidence through c ents have been recor s to submit prospect for this FOA include and have a defined the relevant FOAs ( erships among acade and Drug Administra	gnosis is based subtypes are and agement of linical trials is ded, and thus, ive clinical the validation context of use PAR-19- emic etion (FDA).	
106361 <u>C</u>	areer Transition Award for NIND rial Not Allowed)	S Intramu	ral Clinician-Scientists (K22 Clini	<u>cal</u>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 328	12-Jun-2024	Not Specified	
	Contact Name	Stephen k	Korn, Ph.D.						
	Contact Telephone								
	Contact Email	<u>korns@ni</u>	inds.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	12-Jun-20	)24 , 12-Oct-2024						
Deadline Dates (ALL) 12-Jun-2024 , 12-Oct-2024 This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon- scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities. This Funding Opportunity Announcement (FOA) is designed specifically fo applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial lead mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investig should apply to the companion FOA PAR-21-327.									
111360 <mark>N</mark> H	otice of Special Interest (NOSI): I ydrocephalus	Disease M	echanisms of Prenatal and Pedi	<u>atric</u>	National Institute of Neurological Disorders and	NOT-NS- 23-004	07-May-2024	Not Specified	

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
				Stroke/NIH/DHHS							
	Contact Name	Jill Morris	s, Ph.D.								
	Contact Telephone	301-496-5	5754								
	Contact Email	jill.morris	@nih.gov								
	Sponsor Website										
	Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	07-May-2 2025 , 05-	024 , 05-Jun-2024 , 07-Sep-202 -Oct-2025	4 , 05-Oct-2024 , 07-Jan-2025 , 05-Fe	eb-2025 , 07-Ma	y-2025 <i>,</i> 05-Jun-20	)25 , 07-Sep-				
	Synopsis	The purpose of this Notice is to inform potential applicants about an area of special interest to NINDS in hypothesis-driven Synopsis research projects that focus on deciphering the molecular, cellular and developmental mechanisms involved in the pathogenesis of prenatal and/or pediatric hydrocephalus and to examine new approaches for treatment.									
1	NINDS Alzheimer's Disease and Al	lzheimer's	Disease-Related Dementias	National Institute of	DAR-32-		Not				
106266 (	(AD/ADRD) Advanced Postdoctora Diversity (K99/R00 Independent C	al Career T Clinical Tria	ransition Award to Promote Il Not Allowed)	Neurological Disorders and Stroke/NIH/DHHS	022 07	-May-2024	Specified				
	Contact Name	Amelie Gu	ubitz, Ph.D.								
	Contact Telephone	301-451-7	7966								
	Contact Email	gubitza@	ninds.nih.gov								
	Sponsor Website										
	Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	07-May-2	.024 , 12-Jun-2024								
	Synopsis	The purpo Postdocto independ conductin from their program independ specificall feasibility	ose of the NINDS Alzheimer's Di oral Career Transition Award to ent investigators from diverse k og AD/ADRD research. The prog r mentored, postdoctoral resea will provide independent NIH re ent research programs in the A ly for applicants proposing rese r study, or an ancillary study to a	isease and Alzheimer's Disease-Relate Promote Diversity (K99/R00) progra backgrounds (e.g. see NOT-OD-20-03 ram is designed to facilitate a timely rch positions to independent, tenuro esearch support during this transition D/ADRD field. This Funding Opportu- arch that does not involve leading and a clinical trial. Applicants to this FOA	ted Dementias (A m is to support a s1, Notice of NIH transition of elig e-track or equiva n in order to help nity Announcen n independent cl are permitted to	AD/ADRD) Advanc a cohort of new ar 's Interest in Diver gible postdoctoral llent faculty positi- o awardees establi- nent (FOA) is desig linical trial, a clinic o propose researc	ed Id talented, rsity) researchers ons. The ish ined al trial h experiences				

SPIN ID	Program Title		Sponsor Name	Spor	nsor Number		Deadline Date	Funding Amount
		in a clinic	al trial led by a mentor or co-me	entor				
106359	Career Transition Award for NIND Trial Required)	<u>S Intramu</u>	ral Clinician-Scientists (K22 Clinic	<u>cal</u>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 327 12	2-Jun-2024	Not Specified
	Contact Name	Stephen I	Korn, Ph.D.					
	Contact Telephone							
	Contact Email	<u>korns@n</u> i	nds.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	12-Jun-20	024 , 12-Oct-2024					
	Synopsis	Inis NINL scientists scientific applicant separate independ companic	25 K22 is specifically designed to to independent, academic facul research as well as clinical activi s proposing to serve as the lead ancillary study to an existing tria ent clinical trial, or proposing to on FOA PAR-21-328.	facil ity po ities. inves al, as gain	itate the transition of NINDS into ositions that support clinician-so This Funding Opportunity Anno stigator of an independent clinic part of their research and caree research experience in a clinica	ramural neurol ientists to enga uncement (FOA cal trial, a clinic er development al trial led by an	ogist- and neurosu age in independent A) is designed spec al trial feasibility st . Applicants not pl other investigator	irgeon- If funded ifically for tudy, or a anning an , must apply to
102747	Innovation Grants to Nurture Initi Neurotherapeutic Agent Characte Clinical Trial Not Allowed)	al Translat rization a	<u>tional Efforts (IGNITE):</u> nd In vivo Efficacy Studies (R61/F	<u>R33</u>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 122 20	)-Jun-2024	750,000 USD
	Contact Name	Becky Ro	of, PhD					
	Contact Telephone	301-496-:	1779					
	Contact Email	<u>rebecca.r</u>	oof@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	20-Jun-20	)24 , 21-Oct-2024					
	Synopsis	This fund efficacy s	ing opportunity announcement ( tudies to demonstrate that prop	(FOA oosec	) provides funding to conduct p I therapeutic agent(s) have suff	harmacodynan icient biological	nic, pharmacokinet activity to warran	tic, and in vivo t further

SPIN ID	Program Title		Sponsor Name	Spons	sor Number		Deadline Date	Funding Amount
	d sı Ir N	evelopm mall mole hitial Trar leurothe	ent to treat neurological or neu ecules, biologics or biotechnolo nslational Efforts (IGNITE) to ad rapeutics Network or other trar	uromu: ogy-der dvance nslatio	scular disorders that fall under rived products. This FOA is par projects to the point where th nal programs.	the NINDS m t of a suite of ey can meet t	ission. Therapeutic Innovation Grants t he entry criteria for	agents include o Nurture the Blueprint
102739	Innovation Grants to Nurture Initial and Validation of Model Systems to (R61/R33 Clinical Trial Not Allowed)	Translati Facilitat	ional Efforts (IGNITE): Developn e Neurotherapeutic Discovery	<u>ment</u>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 123	20-Jun-2024	750,000 USD
	Contact Name B Contact Telephone 3	ecky Roc 01-496-1	of, PhD .779					
	Contact Email <u>re</u> Sponsor Website	ebecca.ro	oof@nih.gov					
	Program URL Li	ink to pro	ogram URL					
	Synopsis fc o st	his fundi uman/ar eurologio elevance deally, mo bllowing f Innovat tages of o	ng opportunity announcement nimal tissue ex vivo systems tha cal or neuromuscular disorder. of animal models or ex vivo sys odels proposed for this FOA wo therapeutic intervention that w cion Grants to Nurture Initial Tra drug discovery.	: (FOA) at reca The go stems t ould ha would b ranslati	encourages the development pitulate the phenotypic and ph pal of this FOA is to promote a that will be utilized to facilitate ve the potential to provide fea be applicable in both preclinica onal Efforts (IGNITE) Program	and validation hysiologic chan significant im e future devel asible and me al and clinical s focused on er	n of animal models a racteristics of a defin provement in the tr opment of neurothe aningful assessment settings. This FOA is nabling the explorat	and ned anslational erapeutics. ts of efficacy part of a suite ory and early
109299	Development of Biomarkers or Bion Neuromuscular Disorders (R61/R33	narker Sij Clinical 1	gnatures for Neurological and Frial Optional)		National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22- 089	)7-May-2024	Not Specified
	Contact Name C Contact Telephone 3 Contact Email <u>ca</u> Sponsor Website Program URL <u>Li</u>	arol Tayl 01-496-1 arol.taylo ink to pro	or-Burds Ph.D .779 or-burds@nih.gov ogram URL					

SPIN ID	Program Title		Sponsor Name	Spo	nsor Number		Deadline Date	Funding Amount	
	Deadline Dates (ALL) Synopsis	07-May-2 The purpo biomarke in clinical identify o independ clinical ut acceptabl standardi biomarke	024, 22-Jun-2024, 07-Sep-2024 ose of this Funding Opportunity rs and biomarker signatures tha practice to help guide clinical ca r confirm candidate biomarkers ent retrospective or prospective ility for a defined Context of Use y identifies or predicts the conc zed human samples or datasets r signatures that are ready for d	4 , 21 Ann at en are d s or b e clin e(s). cept o s. The defini	L-Feb-2025, 07-May-2025 ouncement (FOA) is to promote able more efficient clinical trials ecisions. Specifically, the goal of iomarker signatures using huma ical study to conduct initial clini In the first phase, applicants are of interest and may include opting e overarching purpose of this initi itive analytical and clinical valida	the developm to advance the f this phased fu an samples and cal validation of expected to de mization of the tiative is to del ation studies.	ent of fit-for-purpo erapeutic developm inding mechanism /or data, followed of the biomarker/sig emonstrate that th detection method iver candidate bion	se candidate nent or be used is to first by an gnature's e biomarker using carefully narkers or	
109940	Prospective Observational Compa Neurosciences (UG3/UH3 Clinical	rative Effe Trial Not A	ectiveness Research in Clinical Allowed)		National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22- 0 076 0	7-May-2024	Not Specified	
	Contact Name	Adam L. H	lartman, MD						
	Contact Telephone	301-496-9135							
	Contact Email	adam.hartman@nih.gov							
	Sponsor Website								
	Program URL	<u>Link to pr</u>	ogram URL						
	Deadline Dates (ALL)	07-May-2	024 , 16-Jun-2024 , 07-Sep-2024	4,18	3-Oct-2024 , 07-Jan-2025 , 19-Fe	eb-2025 , 07-M	ay-2025		
	Synopsis	The purper prospecti Stroke (N the mission intervention interested importan	ose of this Funding Opportunity ve observational comparative ef INDS) (note: only prospective ob on and research interests of the ions including drugs, biologics, a d in pragmatic study designs tha t to current clinical practice.	Ann ffect bserv NIN and c at uti	ouncement (FOA) is to encourag iveness research (CER) to the Na vational studies will be considere DS and may evaluate preventive levices, or surgical, behavioral, a lize a cost-effective means of pr	ge grant applica ational Institut ed). The study e strategies, dia and rehabilitati ospectively col	ations for investigat e of Neurological Di must address quest gnostic approaches on therapies. NIND lecting observation	tor-initiated isorders and cions within s, or S is particularly al data	
111323	Notice of Special Interest (NOSI): 7 Pediatric Hydrocephalus	<u>Fools to Er</u>	nhance the Study of Prenatal and	<u>d</u>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	NOT-NS- 23-003 0	7-May-2024	Not Specified	
			RI- R						

Contact Name Jill Morris, Ph.D.

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Telephone 301-	496-5754						
	Contact Email jill.m	orris@nih.gov						
	Sponsor Website							
	Program URL Link	to program URL						
	Deadline Dates (ALL) 07-N 2025	1ay-2024 , 05-Jun-2024 , 16-Jun-2024 5 , 07-May-2025 , 05-Jun-2025 , 16-Ju	4 , 07-Sep-2024 , 05-Oct-2024 , 16-O In-2025 , 07-Sep-2025 , 05-Oct-2025	ct-2024 , 07-Jan , 16-Oct-2025	-2025 , 05-Feb-202	25 , 16-Feb-		
The purpose of this Notice is to inform potential applicants about an area of special interest to NINDS in research t or substantially modify existing cutting-edge tools that will advance prenatal and/or pediatric hydrocephalus resea Synopsis Applications should aim to transform the field of prenatal and/or pediatric hydrocephalus research by generating t including animal and cell models, novel methods and innovative technologies that will be widely used throughout neuroscience community to understand disease mechanisms and/or developing therapeutics.								
124093	<u>RFA-NS-24-032 Development and Va</u> <u>Alzheimer's Disease-Related Dementia</u>	lidation of Human Cellular Models fo s (ADRD) (R01 - Clinical Trial Not Allo	National Institute of Neurological Disorders and <u>wed)</u> Stroke/NIH/DHHS	RFA-NS- [O 24-032 Ap	)-May-2024 ptional][LOI/Pre- pp]	2,500,000 USD		
	Contact Name Lind	a McGavern, PhD						
	Contact Telephone							
	Contact Email <u>mcg</u>	avernIm@ninds.nih.gov						
	Sponsor Website							
	Program URL Link	to program URL						
	Deadline Dates (ALL) 20-N	1ay-2024 [Optional][LOI/Pre-App], 20	0-Jun-2024 , 20-Sep-2024 [Optional]	[LOI/Pre-App], 2	21-Oct-2024			
Synopsis Synopsis Synopsis Synopsis								
108301	RFA-NS-22-034 HEAL Initiative: Disco Safe and Effective Pain Treatment (R01	very and Validation of Novel Targets Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS- 09 22-034	9-Apr-2024	Not Specified		



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Michael L. 301-496-9 <u>michael.or</u> <u>Link to pro</u> 09-Apr-20 The purpo therapeut science dis body that Research s pain treat biologics, develop n responsive for any on headache pain, orofa conditions	Oshinsky, PhD 1964 <u>shinsky@nih.gov</u> <u>ogram URL</u> 24, 04-Jun-2024, 07-Aug-2024 ose of this Funding Opportunity ic targets to facilitate the devel scovery of targets in the periph can be used to develop treatm supported by this FOA must inc ment target. This will lower the natural substances, or devices the ew medical devices is not the for e to this FOA and are encourage the or group of pain conditions. F disorders, osteoarthritis, diabe acial pain, etc. will be considered sor for specific pathological cor	Announcement (FOA) is to promote lopment of pain therapeutics. Speci eral nervous system, central nervou ents that have minimal side effects lude rigorous validation studies to c erisk of adopting the target in transl that interact with this target for new bocus of this FOA. Basic science studie ed in the context of novel pain thera Projects to identify novel targets for tic neuropathy, chemotherapy-indu ed. Projects to identify novel targets nditions will be considered. Projects	e the discovery a fically, the focus is system, immu and little to no a lemonstrate the ational projects y pain treatment es of pain and re peutic target dis acute pain, chro ced neuropathy, for a combination that seek to ide	and validation of no s of this FOA is on t ne system or other abuse/addiction lia robustness of the to develop small n ts. Translational re elated systems in the scovery. This FOA i ponic pain, migraine , sickle-cell pain, p on of chronic over ntify novel targets o be responsive to	ovel the basic r tissues in the bility. target as a nolecules, search to he body are s not specific , other ost stroke apping pain in specific			
115920 [	NIH SIREN Neurologic Clinical Tria	ls (UG3/UF	<del>13 - Clinical Trial Required)</del>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-23- 090 10	)-Jun-2024	Not Specified			
	Contact Name	Jeremy Br	own, MD							
	Contact Telephone	301-594-4	481							
	Contact Ema		own@nih.gov							
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	10-Jun-20	24 , 08-Oct-2024 , 07-Feb-2025	, 06-Jun-2025 , 07-Oct-2025 , 06-Fe	b-2026					
115920 [	Synopsis NIH SIREN Neurologic Clinical Tria Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	body that Research s pain treat biologics, develop no responsive for any on headache pain, orofa conditions population ls (UG3/UH Jeremy Br 301-594-4 jeremy.bro Link to pro 10-Jun-20	can be used to develop treatm supported by this FOA must inc ment target. This will lower the natural substances, or devices t ew medical devices is not the for e to this FOA and are encourage e or group of pain conditions. F disorders, osteoarthritis, diabe acial pain, etc. will be considered s or for specific pathological cor ns such as women, children, old H3 - Clinical Trial Required) own, MD H481 own@nih.gov	ents that have minimal side effects lude rigorous validation studies to d risk of adopting the target in transl that interact with this target for new bocus of this FOA. Basic science studie ed in the context of novel pain thera Projects to identify novel targets for tic neuropathy, chemotherapy-indu ed. Projects to identify novel targets nditions will be considered. Projects der adults or other underrepresente National Institute of Neurological Disorders and Stroke/NIH/DHHS	and little to no a lemonstrate the ational projects v pain treatment es of pain and re opeutic target dis acute pain, chro ced neuropathy, for a combination that seek to ide d groups will als PAR-23- 090 10	abuse/addiction lia robustness of the to develop small n ts. Translational re elated systems in the scovery. This FOA i onic pain, migraine , sickle-cell pain, p on of chronic over ntify novel targets o be responsive to	bility. target as a nolecules, search to he body an s not spec , other ost stroke lapping pa in specific this FOA. Not Specif			

SPIN ID	Program Title		Sponsor Name	Spo	nsor Number		Deadline Date	Funding Amount
	Synopsis	This fundi emergence Clinical Co SIREN Dat affiliated existing Si other U.S emergence the NIH Si	ing opportunity announcement cies. Successful applicants will o pordinating Center (CCC) will wo ta Coordinating Center (DCC) wi clinical sites will provide on-site IREN infrastructure to apply uno . and international consortia new cies. Multi-center clinical trials in trokeNet, and not within SIREN.	(FOA collat ork w ill pro e imp der th cessa n stro	A) encourages applications for moorate and conduct the trial with with the successful applicants to ovide statistical and data manag lementation of the clinical protoch his FOA. The NIH SIREN Network ary to conduct larger, definitive oke treatment, recovery, or prev	nulti-center clinion nin the NIH SIRE implement the p ement support. cocols. Applicants will also be uni trials of promisi vention support	cal trials focused c N Network. The N proposed trial effic The NIH SIREN hu do not need to be quely poised to cc ng interventions fo ed by NINDS will b	on neurological IH SIREN ciently and the ubs and their e part of the ollaborate with or neurological be conducted in
100306 <u>0</u>	IINDS Ruth L. Kirschstein Nationa f Postdoctoral Fellows (F32 Clini	al Research cal Trial Nc	n Service Award (NRSA) for Train ot Allowed)	ning	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 032 07	-May-2024	Not Specified
	Contact Name	Stephen k	Korn, Ph.D.					
	Contact Telephone	301-496-4	4188					
	Contact Email	<u>korns@ni</u>	nds.nih.gov					
	Sponsor Website	l.						
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	024 , 10-Jun-2024 , 07-Sep-2024	4,10	)-Oct-2024 , 07-Jan-2026			
	Synopsis	The purpo outstandi proposed seeks to f candidate seeks inno postdocto reasoning years of a planning a Announce to propos (FOA) doe	ose of this award is to support o ng mentors. Candidates are elig postdoctoral position to within oster early, goal-directed planni to that have the potential for sign ovative research ideas and thou oral fellow into an outstanding s and the quantitative principles and the quantitative principles and timely completion of "ment ement (FOA) does not allow app be research experience in a clinic es not allow applicants to propo	ing a ing a nifica ghtfu cient cient cof e cored blican cal tr se to	anding scientific training of high to apply for support from this p nonths after starting in the prop nd to encourage applications fo nt impact. Inclusion of prelimina al plans for training and mentor tist. Applications are expected to xperimental design and analysis pratory or research environmen I training" within a particular lak its to propose to lead an indepe ial led by a sponsor or co-sponse lead an independent clinical tri	ly promising pos rogram from ~1 posed postdocto r bold and/or in ary data is stron ship that will fac o incorporate st . Support by this t, so as to furthe o or environmen ndent clinical tr or. This Funding al, but does allo	stdoctoral candida 2 months prior to ral position. This novative projects gly discouraged; ra- cilitate the develop rong training in qu s program is limite er encourage early it. This Funding Op ial, but does allow Opportunity Anno- w applicants to pr	ites with the start of the NINDS F32 by the ather, this F32 oment of the iantitative ed to the first 4 i, thoughtful oportunity applicants ouncement ropose

SPIN ID	Program Title		Sponsor Name	Spo	nsor Number		Deadline Date	Funding Amount
		research e	experience in a clinical trial led l	by a :	sponsor or co-sponsor.			
124721	<u>RFA-NS-25-014 Mechanisms of</u> (R01 - Clinical Trial Optional)	<u>Cognitive I</u>	Fluctuations in ADRD Population	<u>ns</u>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS- 25-014	24-Jun-2024	4,125,000 USD
	Contact Name	Debra Bal	ocock, PhD, MD					
	Contact Telephone	301-496-9	9964					
	Contact Email	<u>dbabcock</u>	@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	24-Jun-20	24					
	Synopsis	of cognitiv propose a evaluation of digital	ve fluctuations in people diagno clear hypothesis for one or mo ns, blood tests, electrophysiolog measures capable of capturing f	osed ore et gy, et flucti	with Alzheimer's Disease- Relate iologies that can be measured v cc.) that can be collected across uations in real time are highly en	ed Dementias vith standard multiple time ncouraged.	s (ADRD). Researche ized assessments (e. e points and/or diagn	rs should g., clinical loses. The use
124926	RFA-NS-25-012 HEAL Initiative: (R61/R33 - Clinical Trial Not Allow	Studies to red)	Enable Analgesic Discovery		National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS- 25-012	18-Jun-2024	1,050,000 USD
	Contact Name	Julia L. Ba	chman, PhD					
	Contact Telephone							
	Contact Email	julia.bach	man@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	18-Jun-20 2027	24 , 17-Sep-2024 , 28-Jan-2025	, 16-	May-2025 , 17-Sep-2025 , 16-Ja	n-2026 , 15-N	/lay-2026 , 17-Sep-20	)26 , 15-Jan-
	Synopsis	This notic will enabl funding to	e of funding opportunity (NOFC e a drug discovery program for o develop and validate assays to	D) ain nove D sup	ns to encourage research grant I, non-opioid, and non-addictive port a distinct testing funnel an	applications f e treatments d conduct scr	or initial translationa for pain. The program eening efforts to ide	al efforts that n provides ntify and

SPIN ID	Program Title		Sponsor Name	Spo	nsor Number		Deadline Date	Funding Amount
		character pharmacc projects t translatio discovery	ize potential therapeutic agents okinetic, pharmacodynamic, and o the point where they meet th nal programs. This NOFO is part and preclinical development of	incl l effic e ent of tl safe	uding small molecules, biologics cacy studies may also be suppor cry criteria for the Pain Therape ne NIH Helping to End Addictior and effective therapeutics to t	s, and natural pr rted. The goal of utics Developmo n Long Term (HE reat pain with lif	oducts. Preliminar f this NOFO is to a ent Program or oth AL) initiative to ac ttle or no addiction	y in vivo dvance ner later-stage celerate the n liability.
123614	Analytical Validation of a Candida Neuromuscular Disorders (U44 Cl	te Biomark inical Trial	<u>ker for Neurological or</u> Optional)		National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24- 098 21	-Jun-2024	Not Specified
	Contact Name	Carol Tayl	or-Burds, PhD					
	Contact Telephone	301-496-1	1779					
	Contact Email	carol.taylo	or-burds@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	21-Jun-20	24 , 21-Feb-2025 , 20-Jun-2025	, 20-	Feb-2026 , 22-Jun-2026			
	Synopsis	The purpo measuring must justi biomarke sensitivity and qualit Enhancing Applicatic encourage diverse te teams. Th enhancing advancing To suppor perspectiv researche well as bio	bese of this notice of funding opp g biomarkers for neurological ar fy the unmet need for the biom r(s). Activities supported include and specificity of the detection cy control procedures. Multi-site g Diverse Perspectives (PEDP), w ons that fail to include a PEDP w ed to read the NOFO instruction ams working together and capit ere are many benefits that flow g global competitiveness, contri g the likelihood that underserve t the best science, the NIH enco ves include but are not limited t rs from fields such as computat	oortu nd ne aarke e opt n met e app vhich ill be ns can talizi r fror butir d po ourag o: Tr iona rent	nity (NOFO) is to support rigoro euromuscular disorders for use r(s) and measurement methods imizing and evaluating the accu- thod across multiple sites and o dications are expected but not re- will be assessed as part of the considered incomplete and will refully and view the available PE ng on innovative ideas and disti- n a diverse scientific workforce, by to robust learning environme pulations participate in, and be ges inclusivity in research. Exam- ansdisciplinary research project I biology, physics, engineering, p	bus analytical va in clinical trials of s and specify on aracy, precision, perators and es required. This N scientific and te ll be withdrawn. EDP guidance m nct perspectives , including: foste ents, improving to nefit from resea ples of structure ts and collabora mathematics, co zations (e.g. res	lidation of method or clinical practice. e or two context(s reportable range, tablishing reference OFO requires a Pla chnical peer review Applicants are str aterial. The NIH re s outperform hom ering scientific inno the quality of the r rch, and enhancing es that promote di tions among neuro omputer and data	I(s) used for Applicants ) of use for the and analytical ce intervals an for w evaluation. ongly cognizes that ogeneous ovation, esearch, g public trust. verse oscientists and sciences, as ndergraduate-

SPIN ID	Program Title		Sponsor Name	Spo	nsor Number		Deadline Date	Funding Amount
		focused, r heteroger diverse ba workforce disadvant career inv	minority-serving, community-ba neity. Investigators and teams c ackgrounds, including groups tra e (see NOT-OD-20-031), such as aged backgrounds, and women vestigators."	ompo aditic unde . Opp	. Individual applications and par osed of researchers at different onally underrepresented in the errepresented racial and ethnic portunities to enhance the resea	rtnerships that e career stages. F biomedical, beh groups, those w arch environmer	enhance geographi Participation of ind avioral, and clinica vith disabilities, the nt to benefit early.	c and regional lividuals from Il research ose from - and mid-
123611	Clinical Validation of a Candidate Disorders (U44 Clinical Trial Optic	<u>Biomarker</u> nal)	for Neurological or Neuromusc	<u>ular</u>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24- 096 21	-Jun-2024	Not Specified
	Contact Name	Carol Tay	lor-Burds, PhD					
	Contact Telephone	301-496-1	1779					
	Contact Email	carol.tayl	or-burds@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	21-Jun-20	24 , 21-Feb-2025 , 20-Jun-2025	, 20-	Feb-2026 , 22-Jun-2026			
	Synopsis	The purpo neurologi validation specificity identified clinical ne (PEDP), w PEDP will carefully a capitalizin from a div to robust populatio encourage Transdisci computat	be of this notice of funding opp cal and neuromuscular disorder of biomarker measurements w of the biomarker consistent wi , 2) detection method technolog ed and potential context of use hich will be assessed as part of be considered incomplete and and view the available PEDP gui and view the available PEDP gui or innovative ideas and distir verse scientific workforce, include learning environments, improvi ns participate in, and benefit fro es inclusivity in research. Examp iplinary research projects and co ional biology, physics, engineer	ortu s and rithin th FE gy has has the s will b danc not po ding: ing th com re obles c obles c	nity (NOFO) is to enable clinical d conditions. Specifically, the go the clinical population of intere DA guidelines. This PAR assumes as already been developed and a been identified. This NOFO requires ccientific and technical peer revir be withdrawn. Applicants are strict erspectives outperform homoge fostering scientific innovation, ne quality of the research, advances essearch, and enhancing public to of structures that promote diver orations among neuroscientists mathematics, computer and data	validation of sti pal of this PAR is est to establish t s that 1) a candid analytically valid uires a Plan for B ew evaluation. A rongly encourag that diverse teal eneous teams. T enhancing globa ncing the likeliho rust. To support rse perspectives and researcher ta sciences, as w	rong candidate bio to enable the rigo the clinical sensitiv date biomarker ha lated, and 3) the re Enhancing Diverse Applications that f ed to read the NO ms working togeth here are many be al competitiveness bod that undersere the best science, include but are no s from fields such yell as bioethics. Er	omarkers for rous clinical ity and s already been esearch and/or Perspectives ail to include a FO instructions her and hefits that flow , contributing ved the NIH ot limited to: as ngagement

SPIN ID	Program Title		Sponsor Name	Spoi	nsor Number		Deadline Date	Funding Amount
		from diffe communi Investigat backgrou (see NOT- backgrou investigat	erent types of institutions and o ty-based). Individual applicatior tors and teams composed of res nds, including groups traditiona -OD-20-031), such as underrepr nds, and women. Opportunities tors."	organi ns and searcl Illy ur resent s to er	zations (e.g., research-intensive d partnerships that enhance ge hers at different career stages. nderrepresented in the biomed ted racial and ethnic groups, th nhance the research environme	e, undergraduat ographic and reg Participation of ical, behavioral, ose with disabili ent to benefit ea	e-focused, minorit gional heterogene individuals from d and clinical resear ties, those from di rly- and mid-caree	y-serving, ity. iverse ch workforce sadvantaged r
123610	Analytical Validation of a Candida Neuromuscular Disorders (U01 Cl	<u>te Biomarl</u> inical Trial	ker for Neurological or Optional)		National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24- 095 21	-Jun-2024	Not Specified
	Contact Name	Carol Tay	lor-Burds, PhD					
	Contact Telephone	301-496-2	1779					
	Contact Email	carol.tayl	or-burds@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	21-Jun-20	)24 , 21-Feb-2025 , 20-Jun-2025	, 20-	Feb-2026 , 22-Jun-2026			
	Synopsis	The purpo measurin must just biomarke sensitivity and quali Enhancing Applicatic encourag diverse te teams. Th enhancing advancing To suppor perspecti	ose of this notice of funding opp g biomarkers for neurological an ify the unmet need for the biom r(s). Activities supported include y and specificity of the detection ty control procedures. Multi-site g Diverse Perspectives (PEDP), v ons that fail to include a PEDP w ed to read the NOFOinstruction eams working together and capi here are many benefits that flow g global competitiveness, contri g the likelihood that underserve rt the best science, the NIH enco ves include but are not limited t	portu nd ne narke e opt n met e app which vill be is care italizin v fron ibutin ed pop ourag to: Tr	nity (NOFO) is to support rigoro euromuscular disorders for use r(s) and measurement method imizing and evaluating the accu- chod across multiple sites and o lications are expected but not r will be assessed as part of the considered incomplete and wil efully and view the available PE ng on innovative ideas and disti- n a diverse scientific workforce out to robust learning environme pulations participate in, and be ges inclusivity in research. Exam- ansdisciplinary research projec	bus analytical val in clinical trials of s and specify on uracy, precision, operators and es required. This N scientific and te II be withdrawn. DP guidance ma inct perspectives , including: foste ents, improving t nefit from resea oples of structure ts and collabora	lidation of method or clinical practice. e or two context(s reportable range, tablishing reference NOFO requires a Pl chnical peer review Applicants are str sterial. The NIH rec s outperform hom ering scientific inno the quality of the r rch, and enhancing es that promote di tions among neuro	(s) used for Applicants ) of use for the and analytical ce intervals an for w evaluation. ongly cognizes that ogeneous ovation, esearch, g public trust. verse oscientists and

SPIN ID	Program Title		Sponsor Name	Spon	sor Number		Deadline Date	Funding Amount
		researche well as bi focused, i heteroge diverse ba workforce disadvant career inv	ers from fields such as computation oethics. Engagement from differ minority-serving, community-base neity. Investigators and teams co ackgrounds, including groups trate (see NOT-OD-20-031), such as caged backgrounds, and women. vestigators.	ional rent t sed). ompo aditio unde . Opp	biology, physics, engineering, ypes of institutions and organi Individual applications and pa osed of researchers at different nally underrepresented in the rrepresented racial and ethnic ortunities to enhance the rese	mathematics, co izations (e.g., res rtnerships that e t career stages. F biomedical, beh groups, those w arch environme	omputer and data search-intensive, u enhance geographi Participation of inc avioral, and clinica vith disabilities, the nt to benefit early	sciences, as ndergraduate- ic and regional lividuals from al research ose from - and mid-
123613 <u>C</u>	Clinical Validation of a Candidate Disorders (U01 Clinical Trial Optic	<u>Biomarker</u> onal)	for Neurological or Neuromusco	<u>ular</u>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24- 097 21	-Jun-2024	Not Specified
	Contact Name	Carol Tay	lor-Burds, PhD					
	Contact Telephone	301-496-2	1779					
	Contact Email	carol.tayl	or-burds@nih.gov					
	Sponsor Website	à						
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	21-Jun-20	024 , 21-Feb-2025 , 20-Jun-2025	, 20-F	eb-2026 , 22-Jun-2026			
	Synopsis	The purpo neurologi validation specificity identified clinical ne (PEDP), w PEDP will carefully capitalizin from a div to robust populatio encourag	ose of this notice of funding opp cal and neuromuscular disorder of biomarker measurements with of the biomarker consistent with (2) detection method technolog eed and potential context of use which will be assessed as part of t be considered incomplete and w and view the available PEDP guid ng on innovative ideas and distin verse scientific workforce, includ learning environments, improving ons participate in, and benefit fro es inclusivity in research. Examp	oortur s and ithin th FD gy has has b the so will be dance nct pe ding th om re oles of	hity (NOFO) is to enable clinical conditions. Specifically, the get the clinical population of inter A guidelines. This PAR assume s already been developed and been identified. This NOFO req cientific and technical peer rev e withdrawn. Applicants are st e material. The NIH recognizes respectives outperform homog fostering scientific innovation, e quality of the research, adva search, and enhancing public to f structures that promote dive	validation of str pal of this PAR is est to establish to s that 1) a candid analytically valid uires a Plan for R iew evaluation. A rongly encourag that diverse tea eneous teams. T enhancing globa incing the likeling trust. To support	ong candidate bio to enable the rigo the clinical sensitiv date biomarker ha lated, and 3) the re Enhancing Diverse Applications that f ed to read the NO ms working togeth here are many be al competitiveness ood that underser the best science, include but are no	markers for rous clinical rity and s already been esearch and/or Perspectives ail to include a FO instructions ner and nefits that flow s, contributing ved the NIH ot limited to:

SPIN ID	D Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		Transdisc computat from diffe communi Investigat backgroui (see NOT- backgroui investigat	iplinary research projects and co cional biology, physics, engineer erent types of institutions and o ty-based). Individual application cors and teams composed of res nds, including groups traditiona -OD-20-031), such as underrepr nds, and women. Opportunities cors."	ollaborations among neuroscientist ing, mathematics, computer and da rganizations (e.g., research-intensions and partnerships that enhance g tearchers at different career stages Ily underrepresented in the biomed esented racial and ethnic groups, the to enhance the research environm	ts and researcher ata sciences, as w ve, undergraduate eographic and reg . Participation of dical, behavioral, hose with disabili tent to benefit ea	s from fields such yell as bioethics. Er e-focused, minorit gional heterogene individuals from di and clinical resear ties, those from di rly- and mid-caree	as Igagement y-serving, ity. iverse ch workforce sadvantaged
123196 <mark> </mark>	IIH StrokeNet Clinical Trials and B Recovery, and Prevention (UG3/UI	iomarker H3 Clinica	<u>Studies for Stroke Treatment,</u> I Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24- 20 101	-Jun-2024	Not Specified
	Contact Name	Scott Jani	s, Ph.D.				
	Contact Telephone	301-496-9	9135				
	Contact Email	<u>moyc@ni</u>	<u>nds.nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	20-Jun-20	024 , 18-Oct-2024 , 19-Feb-2025	, 20-Jun-2025 , 20-Oct-2025 , 19-F	eb-2026 , 18-Jun-	2026 , 19-Oct-202	6
	Synopsis	This NOFC interventio preventio within Str review, N StrokeNet efficiently StrokeNet well as or with othe treatmen treatmen consider	D encourages applications for m ions; biomarker or outcome me okeNet. Successful applicants w INDS will prioritize studies amou t National Coordinating Center ( and the National Data Manage t Regional Coordinating Centers n-site implementation of the clir r US and international consortia t, prevention, and recovery. It is t, recovery, or prevention will b funding multi-site stroke clinical	aulti-site exploratory and confirmat asure validation studies that are in d ancillary studies designed to add vill collaborate and conduct the stu ng the highest scoring to be conduct (NCC) will work with the successful ment Center (NDMC) will provide s (RCCs) and their affiliated clinical s nical protocol. The NIH StrokeNet n a necessary to conduct larger, defir s NINDS's intent that all NINDS-sup e conducted within the NIH Stroke trials outside of this network. This	ory clinical trials f mediately prepa- scientific aims to dy within the NIH cted in the NIH St applicant to impl statistical and dat sites will provide i etwork will also b hitive trials of pro- ported multi-cent Net. Only in excepts NOFO uses the b	focused on promis ratory to trials in s active studies beir I StrokeNet. Follow rokeNet infrastruc ement the propos a management su recruitment/reten be uniquely poised mising interventio cer clinical trials in ptional circumstan bi-phasic, mileston	ing troke ig conducted /ing peer ture. The NIH ed study pport. The NIH tion support as to collaborate ns for stroke stroke ces will NINDS ie driven

SPIN ID	Program Title		Sponsor Name	Spo	nsor Number		Deadline Date	Funding Amount
		UG3/UH3 driven pla Only UG3 phase. Ap include pl existing N	cooperative agreement activity anning and start-up phase, with projects that meet the scientific plications submitted in response ans for project management an IIH StrokeNet infrastructure to a	cod poss cmil e to d pe pply	e. Awards made under this NOF ible transition to an implementa estones and award requirement this FOA must address both the rformance milestones for each p under this NOFO.	O will initially ation (UH3) pl ts of the UG3 UG3 and UH3 phase. Applica	support a one-year hase of up to 6 addit phase may transitio phases and are exp ants do not need to	milestone- ional years. n to the UH3 pected to be part of the
115793	Notice of Special Interest (NOSI): Sclerosis (ALS)	Advancing	Research for Amyotrophic Later	ral	National Institute of Neurological Disorders and Stroke/NIH/DHHS	NOT-NS- 23-062	22-Jun-2024	Not Specified
	Contact Name	Amelie G	ubitz, PhD					
	Contact Telephone	301-332-6	5453					
	Contact Email	gubitza@	<u>nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	22-Jun-20	)24					
	Synopsis	The purpo Stroke (N communi	ose of this Notice of Special Inte INDS) encourages applications to ty identified in a recent planning	rest o ad g eff	(NOSI) is to announce that the N vance research activities relevar ort of NINDS.	National Instit nt to strategic	ute of Neurological priorities for the AL	Disorders and S research
122306	RFA-NR-24-002 Short Courses in Education in Nursing Research (R	n Social De 25 Indeper	terminants of Health for Resear Ident Clinical Trial Not Allowed)	<u>ch</u>	National Institute of Nursing Research/NIH/DHHS	RFA-NR- 24-002	)1-Jun-2024 Optional][LOI/Pre- App]	Not Specified
	Contact Name	Liz Perruc	ccio, MS, PhD					
	Contact Telephone	301-402-8	3084					
	Contact Email	liz.perruc	<u>cio@nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	01-Jun-20	024 [Optional][LOI/Pre-App], 01-	Jul-2	2024			
	Synopsis	The NIH F	Research Education Program (R2	5) sı	upports research education activ	vities in the m	ission areas of the N	llH. The

SPIN ID	Program Title		Sponsor Name	Spon	sor Number		Deadline Date	Funding Amount
		overarchi workforce goal, this implemen determin Perspecti fail to inc NOFO ins	ng goal of this R25 program is to e to meet the nation's biomedica NOFO will support educational a nt a program to prepare nurse so ants of health in alignment with ves (PEDP), which will be assesse lude a PEDP will be considered in tructions carefully and view the	o supp al, be activit cienti the N ed as ncom availa	port educational activities that havioral and clinical research n ties with a primary focus on: Co sts, and scientists in aligned fie NNR Strategic Plan. This NOFO part of the scientific and techn plete and will be withdrawn. A able PEDP guidance material.	complement eeds. To acco ourses for Ski lds, to condu requires a Pl ical peer rev pplicants are	and/or enhance the omplish the stated o lls Development Dev ct research on the sc an for Enhancing Div iew evaluation. Appl strongly encourage	e training of a ver-arching velop and ocial verse ications that d to read the
113257 <u>N</u>	IINR Areas of Emphasis for Resea quity (R01 Clinical Trial Optional	arch to Opt ]	imize Health and Advance Healt	: <u>h</u>	National Institute of Nursing Research/NIH/DHHS	PAR-22- 230	07-May-2024	Not Specified
	Contact Name	David L. T	ïlley, MPH, MS, CPH					
	Contact Telephone	301-827-0	5014					
	Contact Email	david.tille	ey@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2025 , 07	024 , 05-Jun-2024 , 05-Jul-2024 -May-2025	, 07-9	Sep-2024 , 05-Oct-2024 , 05-No	v-2024 , 07-J	an-2025 , 05-Feb-20	25 , 05-Mar-
	Synopsis	This fund with the s research nation's r study des	ding announcement solicits R01 scientific framework detailed in t will be rooted in nursing's holisti nost pressing and persistent hea igns to inform practice and polic	grant the 20 ic, co ilth ch cy.	applications that propose inde 022-2026 National Institute of ntextualized approach to under nallenges with a solutions orien	ependent res Nursing Rese rstanding peo station, and e	earch projects that a arch (NINR) Strategi ople and their health employ innovative ar	are consistent c Plan. This 1, address the nd rigorous
113258 <u></u>	IINR Areas of Emphasis for Resea quity (R21 Clinical Trial Optional	arch to Opt )	imize Health and Advance Healt	: <u>h</u>	National Institute of Nursing Research/NIH/DHHS	PAR-22- 231	07-May-2024	200,000 USD
	Contact Name	David L. T	illey, MPH, MS, CPH					
	Contact Telephone	301-827-0	5014					
	Contact Email	david.tille	ey@nih.gov					
	Sponsor Website	<u>a</u>						
	Program URL	Link to pr	ogram URL					

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2 2025 , 07 This fund	024 , 16-Jun-2024 , 16-Jul-2024 -May-2025 ding announcement solicits R21	, 07-Sep-2024 , 16-Oct-2024 , 16-N grant applications that propose ex	lov-2024 , 07-Jan ploratory/develo	-2025 , 16-Feb-202 pmental research	25 , 16-Mar- projects that
	Synopsis	are consis Plan. This address tl rigorous s	stent with the research framework research will be rooted in nursi he nation's most pressing and po- study designs to inform practice	ork detailed in the 2022-2026 Nation ng's holistic, contextualized approa ersistent health challenges with a s and policy.	onal Institute of N ach to understand olutions orientat	lursing Research (I ding people and th ion, and employ ir	NINR) Strategic eir health, novative and
108328	Early and Late Stage Clinical Trials Disease/Alzheimer's Related Dem Clinical Trial Optional)	for the Sp entias and	ectrum of Alzheimer's Age-Related Cognitive Decline	(RO1 Aging/NIH/DHHS	PAR-18- 878 05	-Jun-2024	Not Specified
	Contact Name	Laurie Rya	an				
	Contact Telephone	301-496-9	9350				
	Contact Email	<u>ryanl@m</u> a	ail.nih.gov				
	Sponsor Website						
	Program URL	<u>Link to pr</u>	ogram URL				
	Deadline Dates (ALL)	05-Jun-20	024 , 05-Oct-2024				
	Synopsis	The purpo implemen and neuro disease-re stimulate	ose of this Funding Opportunity nt early to late stage clinical trial opsychiatric changes associated elated Dementias (ADRD) across studies to enhance trial design	Announcement (FOA) is to 1) invite s of promising pharmacological an with age-related cognitive decline the spectrum from pre-symptoma and methods.	e applications tha d non-pharmacol and Alzheimer's itic to more seven	at propose to deve ogical interventior disease (AD) and A re stages of diseas	lop and ns for cognitive Izheimer's e, and 2)
114469	NIA Multi-site Clinical Trial Impler	nentation	Grant (R01 Clinical Trial Require	d) Aging/NIH/DHHS	PAR-23- 057 05	-Jun-2024	Not Specified
	Contact Name	Sergei Ro	mashkan, M.D., Ph.D.				
	Contact Telephone	301-435-3	3047				
	Contact Email	<u>romashks</u>	@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				



SPIN ID	Program Title		Sponsor Name	Spo	onsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	05-Jun-20 This Fund intervent research	024 , 05-Oct-2024 , 05-Feb-2025 ing Opportunity Announcement ional clinical trials (all phases). T mission. Information about NIA	, 05 t (FC The t s mi	-Jun-2025 , 05-Oct-2025 )A) invites applications for imple rials should be hypothesis-driver ssion can be found on the NIA w	mentation c n, milestone ebsite.	of investigator-initiate -defined, and related	d multi-site to NIA's
123842	RFA-AG-25-016 Multi-Scale Mod Alzheimer's Disease (AD) and AD- Not Allowed)	dels Bridgi Related De	ng Levels of Analysis in Aging an ementias (ADRD) (R01 Clinical Tr	i <u>d</u> Tial	National Institute on Aging/NIH/DHHS	RFA-AG- 25-016	13-May-2024 [Optional][LOI/Pre- App]	2,500,000 USD
	Contact Name Contact Telephone	Amanda I 301-827-3	DiBattista, Ph.D. 3342					
	Contact Email	amanda.c	libattista@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	13-May-2	024 [Optional][LOI/Pre-App], 13	8-Jur	ו-2024			
	Synopsis	This notic recapitula broad sco image and molecule	e of funding opportunity (NOFO ating dynamic changes associate ope encompasses a variety of con alysis, artificial intelligence, and s, cells and networks, and cognit	) inv ed w mpu mac tion	vites applications proposing to es ith aging and Alzheimer's disease itational approaches—such as m chine learning—to better unders and behavior.	stablish mul e (AD) and A athematica tand aging p	ti-scale computationa ND-related dementias I and computational n processes and AD/ADF	l models (ADRD). This nodeling, RD across
104436	NIA Advanced Postdoctoral Caree Translational Research for AD/AD	r Transitio RD (K99/R	n Awards to Promote Diversity i 00 Clinical Trial Not Allowed)	i <u>n</u>	National Institute on Aging/NIH/DHHS	PAR-21- 220	12-Jun-2024	Not Specified
	Contact Name	Yuan Luo	, Ph.D.					
	Contact Telephone	301-496-9	9350					
	Contact Email	<u>yuan.luo(</u>	<u>@nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	12-Jun-20	)24			11 · · · ·		
	Synopsis	The purpo for Alzhei	ose of this Funding Opportunity mer's disease and Alzheimer's d	Ann lisea	ouncement (FOA) is to promote se-related dementias (AD/ADRD	diversity in ). This path	the translational rese way to independence	arch workforce award will

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		emphasiz research behaviora translatio program science, p managem does not FOA cand	e the development of skills in da (from populations studies to res al and social research). This awa anal skills in data science and dru is to develop a diverse translatic precision medicine approach to s ment and care. This Funding Opp involve leading an independent idates are permitted to propose	ata science and drug discovery, and search that can lead to new treatme rd will support early career investig ug discovery and transition to resea onal research workforce that can ef studies of AD/ADRD treatment, pre- ortunity Announcement (FOA) is de clinical trial, a clinical trial feasibilit e a research experience in a clinical	their applicatio ents and diagnos ators from diver rch independend fectively particip vention, early de esigned for cand y study, or an ar trial led by a me	n to various aspect stics, including all a rse backgrounds to ce The long-term pate in and/or lead etection, and disea idates proposing re ncillary clinical trial entor or co-mentor	s of AD/ADRD spects of gain critical goal of this a team- se esearch that . Under this
107419 🗛	Izheimer's Drug-Development P	rogram (U	01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-22- 047	5-Jun-2024	5,000,000 USD
	Contact Name	Lorenzo N	И. Refolo, Ph.D.				
	Contact Telephone	301-594-	7576				
	Contact Email	refolol@r	nia.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	05-Jun-20	024 , 05-Oct-2024				
	Synopsis	The goal of clinical (P slow its p therapy of Excretion Manufact Application developm drugs and alone clin	of this Funding Opportunity Ann hase I) development of novel sn rogression, or treat its cognitive levelopment activities such as m , Toxicology (ADMET); efficacy in curing Practices (GMP); Investiga ons not responsive to this FOA in hent of biomarkers, devices, nor combinations therapies; discov ical trials.	nouncement (FOA) is to provide fun- nall-molecule and biologic drug can and behavioral symptoms. Particip nedicinal chemistry; pharmacokinet n animal models; formulation devel ational New Drug (IND) enabling stu- nclude: research on basic mechanism n-pharmacological interventions (e.g very activities such as high-through	ding support for didates that pre pants in this prog ics (PK); Absorpt opment; chemic idies; and initial ms of disease or g., exercise, diet out screening an	the pre-clinical an vent Alzheimer's d gram will receive fu cion, Distribution, N cal synthesis under Phase I clinical test mechanisms of dri , cognitive training d hit optimization;	d early stage isease (AD), inding for Aetabolism, Good ting. ug action; ), repurposed and stand-
123977 📐	IIA Career Transition Award (K22	2 Independ	ent Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-24- 120 12	2-Jun-2024	Not Specified

Contact Name Jamie Lahvic, Ph.D.

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
	Contact Telephone									
	Contact Email NIA	raining@mail.nih.gov								
	Sponsor Website									
	Program URL Link	to program URL								
	Deadline Dates (ALL) , 12-J	12-Jun-2024 , 12-Jul-2024 , 12-Oct-2024 , 12-Nov-2024 , 12-Feb-2025 , 12-Mar-2025 , 12-Jun-2025 , 12-Jul-2025 , 12-Oct-2025 , 12-Nov-2025								
tenure-track or equivalent faculty positions conducting research that advances the mission of NIA. This provide postdoctoral phase funding; therefore, candidates should be prepared to transition to tenure-the faculty positions within 12 months after confirmation of a positive funding decision. After transition to a position at an extramural institution/organization, the award will provide three years of protected research support. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates and research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an										
123983	RFA-AG-25-005 Open Measurement Pharmacological Alzheimer's Disease ( Primary Prevention Trials (U24 Clinical	Coordinating Network for Non- AD) and AD-Related Dementias (ADRI Trail Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG- [O 25-005 Ap	-May-2024 ptional][LOI/Pre- p]	8,000,000 USD				
	Contact Name Luke	Stoeckel. Ph.D.		F						
	Contact Telephone 301-	529-7254								
	Contact Email <u>NIA</u>	DpenMeasure@nih.gov								
	Sponsor Website									
	Program URL Link	to program URL								
	Deadline Dates (ALL) 16-N	1ay-2024 [Optional][LOI/Pre-App], 15	j-Jun-2024							
	Synopsis Solution Synopsis Stan inco goal brai stan	Notice of Funding Opportunity (NOF onal Open Measurement Coordinatin entias (ADRD) Primary Prevention Tr dardizing, and disseminating measure rporate measures and measurement of primary prevention of AD/ADRD con health determinants, outcomes, and ding. Measures and measurement me	O) invites U24 Cooperative Agreeme g Network for Non-Pharmacological ials. The Network will serve as a cen es and measurement methods for Al methods across neuropsychological entered around brain health equity. d resources within and between seg ethods of interest will test outcomes	ent applications Alzheimer's Dis tralized hub for D/ADRD primary , biomarker, and Brain health eq ments of the po s and mechanisr	that propose to es ease (AD) and AD- developing, valida y prevention trials. d functional domai uity is the fair dist pulation, regardle ms of action (e.g., o	tablish a Related ting, It will ns to meet the ribution of ss of social cognitive,				

SPIN ID	Program Title		Sponsor Name	Sponsor Number			Deadline Date	Funding Amount
		behaviora linked to algorithm developm particular	II, structural/social, computatio real-world function. Resources o s, code, documentation, and no lent projects that support AD/A ly interested in proposals that a	nal, biological) tha developed through rmative data, are DRD primary preve im to advance equ	t are customized f this initiative, inc intended to enabl ention research ne uity for population	or individual luding meas e future mea eds. The Na s disproport	s with different need urement instruments asures and measurem itional Institute on Ag ionately impacted by	s and that are , methods, ent-methods- ;ing (NIA) is AD/ADRD.
114865	Pilot Studies for the Spectrum of Related Dementias and Age-Related Optional)	Alzheimer' ed Cogniti	s Disease/Alzheimer's Disease- ve Decline (R61 Clinical Trial	National Inst Aging/NIH/D	titute on DHHS	PAR-23- 083	18-Jun-2024	650,000 USD
	Contact Name	Laurie Rya	an					
	Contact Telephone	301-496-9	9350					
	Contact Email	ryanl@ma	ail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	18-Jun-20	24 , 18-Oct-2024					
	Synopsis	The purpo collection for cognit Alzheime and 2) sti	ose of this Funding Opportunity of pilot data to support early st ive and neuropsychiatric chang r's disease-related dementias (A mulate studies to enhance trial	Announcement (F cage testing of pro- es associated with DRD) across the sp design and method	OA) is to 1) invite mising pharmacol age-related cogni pectrum from pre- ds.	research gra ogical and no tive decline a symptomati	nt applications that e on-pharmacological ir and Alzheimer's disea c to more severe stag	nable the nterventions se (AD) and ges of disease,
120970	Seamless Early-Stage Clinical Drug therapeutic Agents for the Spectr related Dementias (ADRD) (UG3/	<u>g Developn</u> um of Alzh JH3 Clinica	nent (Phase 1 to 2a) for Novel eimer's Disease (AD) and AD- al Trial Required)	National Inst Aging/NIH/D	titute on DHHS	PAR-23- 274	20-Jun-2024	Not Specified
	Contact Name	Akanni Cl	arke					
	Contact Telephone	301-496-9	9350					
	Contact Email	akanni.cla	irke@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	20-Jun-20	24 , 21-Oct-2024 , 21-Feb-2025	, 23-Jun-2025 , 20	-Oct-2025 , 20-Fel	o-2026 , 22-J	un-2026 , 19-Oct-202	6

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The purpe phase 1 c pharmacc evaluated tau mech pre-symp prespecifi developm	ose of this notice of funding opp linical trials with phase 1b/phas ological interventions for Alzheir I through this program, which ca anisms and aim to address cogn tomatic to more severe stages o red, go/no-go safety and tolerat	oortunity (NOFO) is to invite appli e 2a clinical trials to streamline the mer's disease (AD) and AD-relate an include small molecules or bio itive and/or neuropsychiatric syr of disease. This NOFO uses a phase ility milestones that must be me	cations that bur he early-stage e d dementias (AE logics for examp nptoms in indivi sed award activi t to advance fro	ndle independent pro valuation of promisin VRD). Candidate inter ole, must engage non duals across the spec ty code. Applications m phase 1 to latter st	tocols for g ventions -amyloid/non- trum, from must include tages of clinical
124356 <u>R</u>	FA-AG-25-009 Research Traini	ng in Aging	g for Medical Students (T35)	National Institute on Aging/NIH/DHHS	RFA-AG- 25-009	14-May-2024 [Optional][LOI/Pre- App]	750,000 USD
	Contact Name	Jessi Pere	Z				
	Contact Telephone	301-402-7	7739				
	Contact Email	perezj@n	nail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	14-May-2	024 [Optional][LOI/Pre-App], 14	1-Jun-2024			
	Synopsis	The prima obtain ne them to p are eligibl Announce research o	ary goal of this Institutional Rese cessary aging research experien oursue careers in research. Othe e when research training is a m ement (FOA) does not allow app experience in a clinical trial led l	earch Training Grant is to provide ices and technical expertise and s r health professional students m inor part of, or nonexistent in, th ointed Trainees to lead an indep by a mentor or co-mentor.	a short-term tr skills early during ay also benefit f eir doctoral prog endent clinical t	aining for medical stu g their education to e rom such short-term gram. This Funding O rial but does allow th	dents to ncourage training and pportunity em to obtain
108329 R	ilot Studies for the Spectrum of elated Dementias and Age-Relat Optional)	Alzheimer' ed Cogniti	s Disease/Alzheimer's Disease- ve Decline (R61 Clinical Trial	National Institute on Aging/NIH/DHHS	PAR-21- 360	18-Jun-2024	650,000 USD
	Contact Name	Laurie Rya	an				
	Contact Telephone 301-496-9350						
	Contact Email	<u>ryanl@ma</u>	ail.nih.gov				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website Program URL <u>L</u> Deadline Dates (ALL) 1 Synopsis f a	Link to program URL 18-Jun-2024 , 18-Oct-2024 The purpose of this Funding Opportunity collection of pilot data to support early st for cognitive and neuropsychiatric change Alzheimer's disease-related dementias (A and 2) stimulate studies to enhance trial o	Announcement (FOA) is to 1) invite age testing of promising pharmacole es associated with age-related cogni DRD) across the spectrum from pre- design and methods.	research grant a ogical and non-p tive decline and -symptomatic to	applications that e bharmacological in Alzheimer's disea more severe stag	nable the iterventions se (AD) and es of disease,
124189	Notice of Special Interest (NOSI): A Mentored Physician and Clinical Ps Disease (AD) and AD-Related Deme	dministrative Supplements for NIA-VA ychologist Scientist Award in Alzheimer's entias (ADRD)	National Institute on Aging/NIH/DHHS	NOT-AG- 23-054 10	-Jun-2024	875,000 USD
	Contact Name I	Lisa A. Opanashuk, Ph.D.				
	Contact Telephone	301-827-5422				
	Contact Email <u>I</u>	<u>_isa.Opanashuk@nih.gov</u>				
	Sponsor Website					
	Program URL <u>I</u>	<u>ink to program URL</u>				
	Deadline Dates (ALL)	10-Jun-2024 , 09-Dec-2024				
	٦ s c a Synopsis r c i t t	The purpose of this Notice of Special Inte scientists from the U.S. Department of Ve dementias (AD/ADRD) research career. To a two-part opportunity for eligible VA res chrough an IK2 career development awar 030 ) and an administrative supplement f mechanisms, biomarker discovery, diagno determinants of health, caregiver issues, mplementing a collaborative framework the VA, enabling increased coordination b	rest (NOSI) is to attract early stage p eterans Affairs (VA) to an Alzheimer's o accomplish this goal, the VA and th earchers to pair with both VA- and N d from the VA (described in VA RFAs from NIA. The research can focus on psis/clinical assessment, therapeutic and models of care). The VA RFAs ar to facilitate co-funding and support petween the two organizations.	hysician-scientis s disease and Al ne National Insti NIA-funded men s BX-24-030, CX- any aspect of th s, patient care, o nd NIA NOSI will of shared resea	sts and clinical psy zheimer's disease- tute on Aging (NIA tors in the AD/AD 24-030, HX-24-030 e AD/ADRD field ( community care/s also promote dev rch priorities betw	rchologist- -related A) have created RD field D, and RX-24- (e.g., disease ocial eloping and veen NIA and
117878	Small Research Grant Program for t AD/ADRD Research (R03 Clinical Tr	the Next Generation of Researchers in ial Optional)	National Institute on Aging/NIH/DHHS	PAR-23- 179 16	-Jun-2024	200,000 USD



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name	Luci Pobe	orts Dh D				
	Contact Telephone	301-496-	9350				
	Contact Fmail	roberlu@	)mail nih gov				
	Sponsor Website	10000100					
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	L) 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026					
	Synopsis	This Small Research Grant Program (R03) will support meritorious projects to provide needed scientific insight to improve the prevention, diagnosis, treatment, and/or care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Specifically, this NOFO will support projects covering a wide range of topics related to AD/ADRD. The overall goal of this NOFO is (i) to encourage the next generation of researchers to pursue research and academic careers in AD/ADRD research; and (ii) to stimulate established researchers who have not had a major award in AD/ADRD research to perform pilot studies to develop new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from diverse backgrounds, including those from underrepresented groups are always encouraged to apply for NIH support. Investigators who have not successfully competed for an award under this or prior versions of this announcement are specifically encouraged to apply.					
114861 [ 	Early and Late Stage Clinical Trials Disease/Alzheimer's Related Dem Clinical Trial Optional)	for the Sp entias and	Dectrum of Alzheimer's d Age-Related Cognitive Decline	(R01 Aging/NIH/DHHS	PAR-23- 081	-Jun-2024	Not Specified
	Contact Name	Laurie Ry	an				
	Contact Telephone	301-496-	9350				
	Contact Email	ryanl@m	ail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	05-Jun-20	024 , 05-Oct-2024				
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite applications that propose to develop and implement early to late stage clinical trials of promising pharmacological and non-pharmacological interventions for cognitive Synopsis and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD) across the spectrum from pre-symptomatic to more severe stages of disease, and 2) stimulate studies to enhance trial design and methods.					
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
---------	---	---	--	--	--	---	
124637	RFA-AG-25-017 Exploring Proteog Mechanisms of Mis-Folded Protein Trial Not Allowed)	genomic Approaches to Unravel the Accumulation in Tauopathies (R01 Clinic	National Institute on Aging/NIH/DHHS	RFA-AG- 25-017	10-May-2024 [Optional][LOI/Pre- App]	2,500,000 USD	
	Contact Name J. Contact Telephone 3 Contact Email Sponsor Website Program URL <u>L</u> Deadline Dates (ALL) 1 T Synopsis s n O	Austin Yang, Ph.D. 301-496-9350 <u>austin.yang@nih.gov</u> <u>ink to program URL</u> 10-May-2024 [Optional][LOI/Pre-App], 10 This notice of funding opportunity (NOFC proteins in Tauopathies within specific br single-cell or single-cell type proteogenor misfolding responses in neuronal proteor of Alzheimer's Disease (AD) and AD-Relat	0-Jun-2024 0) invites innovative research propos rain regions and cell types. NIA enco mic platforms. These platforms aim t mes and their potential biological co ted Dementias (ADRD).	als to explore urages collabo o shed light c nsequences d	e the accumulation of prative efforts to creation on dynamic changes i luring aging and the o	f misprocessed ate advanced n protein- development	
124485	Notice of Special Interest (NOSI): U.	.S. Health in the International Perspectiv	National Institute on Aging/NIH/DHHS	NOT-AG- 24-004	05-Jun-2024	Not Specified	
	Contact Name K Contact Telephone 2 Contact Email <u>k</u> Sponsor Website Program URL <u>L</u> Deadline Dates (ALL) 0 T Synopsis p t	Kriti M. Jain, Ph.D. 202-740-6701 <u>kriti.jain@nih.gov</u> <u>ink to program URL</u> D5-Jun-2024 This NOSI expresses NIA's interest in rese disadvantage, which refers to worsening particular interest are projects that exame that may drive poor health outcomes.	earch that examines mechanisms and life expectancies and health outcom nine cross-national and U.S. cross-reg	l causes behin es in the U.S. ional or cross	nd the increasing U.S compared to other o s-state differences in	health countries. Of policy context	
122532	Aging Research Dissertation Awards Allowed)	s to Promote Diversity (R36 Clinical Trial	Not National Institute on Aging/NIH/DHHS	PAR-24- 052	16-Jun-2024	Not Specified	

SPIN ID	Program Title		Sponsor Name	Spoi	nsor Number		Deadline Date	Funding Amount
	Contact Name	Jamie Lah	vic, Ph.D.					
	Contact Telephone							
	Contact Email	NIATraini	ng@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	16-Jun-20 , 16-Nov-2	24 , 16-Jul-2024 , 16-Oct-2024 , 2025 , 16-Feb-2026 , 16-Mar-20	,16-N )26,1	lov-2024 , 16-Feb-2025 , 16-Ma l6-Jun-2026 , 16-Jul-2026 , 16-O	ar-2025 , 16-J Oct-2026 , 16·	un-2025 , 16-Jul-2025 Nov-2026	5 , 16-Oct-2025
	Synopsis	This Notic engaged i within NI/	e of Funding Opportunity (NOF n research on aging and aging-r A's strategic priorities.	O) in relate	vites R36 applications to promo d health conditions by providir	ote diversity i ng dissertation	n the scientific resear n awards in all areas o	ch workforce of research
124720	RFA-AG-25-013 Nathan Shock C Not Allowed)	<u>Centers Coo</u>	ordinating Center (U24 Clinical 1	<u>Trial</u>	National Institute on Aging/NIH/DHHS	RFA-AG- 25-013	15-May-2024 [Optional][LOI/Pre- App]	5,000,000 USD
	Contact Name	Christy S.	Carter, Ph.D.					
	Contact Telephone	240-687-0	)644					
	Contact Email	<u>christy.ca</u>	rter@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	15-May-2	024 [Optional][LOI/Pre-App], 1	5-Jun	-2024			
	Synopsis	This Fund Coordinat Centers o to be part internatic sharing of successfu It should a Collabora	ing Opportunity Announcement ing Center (NSC3). The goal of f Excellence in Basic Biology of A of an NSC. Major activities of t mally, improving collaboration a resources, and interacting with application will include a plan also leverage existing bioinform tive Network (RCCN).	it (FO, the N Aging the pr and c h NIA to im natics	A) invites applications to develo ISC3 is to provide logistical and (NSC). Applicants should be fa oposed NSC3 will include impro oordination among NSC, enhan and NSC to develop strategies prove transparency and the int resources. The NSC3 director v	op and mainta organization miliar with N oving visibility icing NSC trai and plans for ceractions of l vill be a partic	ain a Nathan Shock Co support of the Natha SC activities, but they of the NSC nationall hing activities, facilita further developmen NSC with the research sipant in the NIA's Re	enters an Shock do not need y and uting the t. The n community. search Centers

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
SPIN ID F	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
124719 <u>4</u>	RFA-AG-25-012 Nathan Shock Centers Aging (P30 Clinical Trial Not Allowed)	of Excellence in Basic Biology of	National Institute on Aging/NIH/DHHS	RFA-AG- 25-012	15-May-2024 Optional][LOI/Pre- App]	5,500,000 USD		
Contact NameChristy Carter, Ph.D.Contact Telephone301-827-1382Contact Emailchristy.carter@nih.govSponsor WebsiteProgram URLLink to program URLDeadline Dates (ALL)15-May-2024 [Optional][LOI/Pre-App], 14-Jun-2024This FOA aims to provide support, including competitive renewals, for the Centers known as the Nathan Shock Centers o Excellence in Basic Biology of Aging (NSC). These Center grants will provide funding for leadership, training, and research activities that will increase and disseminate scientific knowledge in the research areas supported by the NIA's Division of Aging Biology (https://www.nia.nih.gov/research/dab). The NSC provide intellectual leadership and innovation, training, pertinent cores focused on the needs of the field and opportunities for research career development for future leaders, i within and beyond their institutions. They also collaborate substantially with other NSCs, the NSC Coordinating Center ar other NIA-funded Centers. The NSC awards are intended for institutions committed to research on the basic biology of ar but previous funding in this area is not necessary.								
124752 <mark>(</mark>	New Approaches for Measuring Brain C R01 Clinical Trial Optional)	anges Across Longer Timespans	National Institute on Aging/NIH/DHHS	PAR-24- 160	)5-Jun-2024	Not Specified		
	Contact Name Elizat	eth Newman, Ph.D.						
	Contact Telephone 301-4	80-7937						
	Contact Email elizat	eth.newman@nih.gov						
	Sponsor Website	nrogram LIDI						
		<u>) program UKL</u> )_2024_05_0ct_2024_05_Eab 202	5 05-lun-2025 05-0ct-2025 05 50	h-2026 05 4	1n-2026 05-0ct-202	6 05-Eeh-		
	Deadline Dates (ALL) 2027	-2024 , 03-001-2024 , 03-FeD-202	J, UJ-JUII-ZUZJ, UJ-UCC-ZUZJ, UJ-FE	J-2U2U , U3-Jl	un-2020, 05-0ct-202	0,00-660-		
	Synopsis The p	urpose of this funding opportunity	is to encourage multidisciplinary inv	estigators to o	develop new approac	hes or apply		

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		existing a of neuroo of the ne specific c these dor including opportun epochs of (PEDP), w PEDP will carefully	pproaches in novel ways to mea levelopment. The overarching g urodevelopmental origins of lat linical groups such as those with mains of function. The studies ca genetics/genomics, single cells, ity is intended to encourage teo f the lifespan, to better predict of which will be assessed as part of be considered incomplete and and view the available PEDP gui	asure brain activity, connectivity, ge goal is to extend our understanding er health and disease. Research can n cognitive, motor, or affective regu an focus on longitudinal neuroanato connectomics, neural population a chnological and conceptual innovati outcomes at later ages. This NOFO r the scientific and technical peer rev will be withdrawn. Applicants are st idance material.	enomics, or oth of brain devel n include healt lation challen omical or func activity pattern on to improve requires a Plar view evaluatio trongly encour	her aspects across the opment and aging, in hy human participan ges; and/or animal re- tional changes at any is, and others. This fu- repeated measures in for Enhancing Diver n. Applications that fr raged to read the NC	te age spectrum including studies its of any age; esearch on y level, unding across longer rse Perspectives fail to include a DFO instructions
124754	New Approaches for Measuring E R21 Clinical Trial Optional)	Brain Chang	ges Across Longer Timespans	National Institute on Aging/NIH/DHHS	PAR-24- 160	16-Jun-2024	400,000 USD
	Contact Name	Elizabeth	Newman, Ph.D.				
	Contact Telephone	301-480-	7937				
	Contact Email	l <u>elizabeth</u>	.newman@nih.gov				
	Sponsor Website	2					
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	16-Jun-20 2027	024 , 16-Oct-2024 , 16-Feb-2025	5 , 16-Jun-2025 , 16-Oct-2025 , 16-Fe	eb-2026 , 16-J	un-2026 , 16-Oct-202	26 , 16-Feb-
	Synopsis	The purp new appr other asp developm repeated healthy h challenge functiona and othen high rewa prelimina	ose of this funding opportunity oaches, or innovative application ects across the age spectrum of nent and aging, including studies measures across longer epochs uman participants of any age; s s; and/or animal research on th I changes at any level, including rs. This funding opportunity is in ard funding mechanism to devel ry data. This NOFO requires a F	is to encourage multidisciplinary inv ons of existing approaches, to meas f neurodevelopment. The overarchi s of the neurodevelopmental origin of the lifespan to better predict ou pecific clinical groups such those wi uese domains of function. The studie genetics/genomics, single cells, con ntended to encourage technological lop highly innovative ideas that eith Plan for Enhancing Diverse Perspect	vestigators to sure brain action ng goal is to exist s of later healt tcomes at late th cognitive, r es can focus of nnectomics, n and conceptu- er lack prelim ives (PEDP), w	develop exploratory, vity, connectivity, ge xtend our understan th and disease, by im er ages. Research car notor, or affective re n longitudinal neuroa eural population action throug inary data or need ac rhich will be assessed	, highly novel nomics, or ding of brain proving n include egulation anatomical or ivity patterns, gh this high risk, dditional as part of the

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
		scientific be withdi guidance	and technical peer review evalu rawn. Applicants are strongly en material.	nation. Applications that fail to inclucion contract fail to inclucion couraged to read the NOFO instru	ude a PEDP v actions carefu	vill be considered inco lly and view the availa	mplete and will ble PEDP	
115129	<u>RFA-AG-24-001 Alzheimer's Dis</u> <u>Not Allowed)</u>	ease Resea	arch Centers (P30 Clinical Trial	National Institute on Aging/NIH/DHHS	RFA-AG- 24-001	15-May-2024 [Optional][LOI/Pre- App]	14,750,000 USD	
	Contact Name	Cerise Ell	iott, Ph.D.					
	Contact Telephone	301-496-	9350					
	Contact Emai	elliottce@	amail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	15-May-2	2024 [Optional][LOI/Pre-App], 14	4-Jun-2024 , 27-Aug-2025 [Option	al][LOI/Pre-A	op], 26-Sep-2025		
	Synopsis	This Fund Alzheime of Alzheir preventic collabora	t (FOA) invites applications from in RC). NIA-designated ADRCs serve ed dementias (ADRD) and the deve They create shared resources tha n efforts with other NIH-funded pr	nstitutions pro as a national elopment of r t support der rograms and i	oposing to establish, o resource for research nore effective approac nentia-relevant resear nvestigators.	r renew, an on the nature ches to ch, and they		
108054	Notice of Special Interest (NOSI): and Opioids in Aging	Research o	on Pain, Pain Management,	National Institute on Aging/NIH/DHHS	NOT-AG- 22-004	08-Apr-2024	Not Specified	
	Contact Name	Devon Os	kvig, Ph.D.					
	Contact Telephone	301-827-	5899					
	Contact Emai	devon.os	kvig@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2024 , 25-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 08-Aug-2024 , 05-Sep-2024 , 07-Sep- 2024 , 25-Sep-2024 , 12-Oct-2024 , 25-Oct-2024 , 05-Jan-2025 , 08-Dec-2025						
	Synopsis	The purport receiving	ose of this Notice of Special Inte grant applications focused on p	rest (NOSI) is to highlight that the ain, pain management, and opioid	National Inst Is related to a	itute on Aging (NIA) is aging or older adults ar	interested in nd within NIA's	

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
		mission a pain expe improving competin pain, pair 005.	reas. This NOSI invites research rience with aging; enhancing as g health equity of aging populat g revisions to existing awards an management, and opioids rela	applications that focus on improvin sessment, prevention, and manager ions suffering with pain. New applic re all encouraged through this NOSI. ted to aging or older adults and with	g the understa ment strategie: ations, resubm For administra hin NIA's missio	nding of mechanisn s for pain in older a issions, competing ative supplements f on areas, please see	ns underlying dults; and renewals, and ocused on NOT-AG-22-		
113465	Notice of Special Interest (NOSI): Diagnosis and Clinical Studies in A Dementias (ADRD)	Developm Alzheimer's	ent of Radiotracers for Disease (AD) and AD-Related	National Institute on Aging/NIH/DHHS	NOT-AG- 22-032 07	7-May-2024	Not Specified		
	Contact Name	Lorenzo N	И. Refolo, Ph.D.						
	Contact Telephone	301-594-7	7576						
	Contact Email	<u>refolol@r</u>	<u>nia.nih.gov</u>						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2 2025 <i>,</i> 05	7-May-2024 , 05-Jun-2024 , 09-Jul-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Nov-2024 , 07-Jan-2025 , 05-Feb- 025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 05-Sep-2025						
	Synopsis	This Notic Emission and/or er pathophy	ce of Special Interest (NOSI) invi Tomography (PET) for use in Alz nerging biological process or mo siology of neurodegeneration.	tes applications for research grants zheimer's disease (AD) and AD-relate olecular pathways that have been sh	that propose to ed dementias ( nown to be rele	o develop radiotrac ADRD) research tar evant in the etiology	ers for Positror geting new / and		
120716	Alcohol Treatment, Pharmacothe Trial Required)	rapy, and I	Recovery Research (R01 Clinical	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-23- 250	5-Jun-2024	2,500,000 USD		
	Contact Name	Brett T. H	agman, Ph.D.						
	Contact Telephone	301-443-0	0638						
	Contact Email	brett.hag	man@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	05-Jun-20	024 , 05-Oct-2024 , 05-Feb-2025	, 05-Jun-2025 , 05-Oct-2025 , 05-Fe	b-2026 , 05-Jui	n-2026			

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Synopsis	The Natio focusing o recovery mechanis AUD treat	nal Institute on Alcohol Abuse a on alcohol treatment and recove from alcohol use disorder (AUD ms of behavioral change (MOBC tment and recovery.	and Alcoholism solicits applications f ery research. This NOFO will focus b ), including: medications developme C), recovery, translational research,	for an R01 Clin roadly on topi ent, precision r and innovative	cal Trial Required m s relevant for treat nedicine, behavioral methods and techr	nechanism ment of and therapies and hologies for			
120720 🧍	Ncohol Health Services Research	(R01 Clinic	al Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-23- 251	5-Jun-2024	Not Specified			
	Contact Name	Laura E. K	wako, Ph.D.							
	Contact Telephone	301-451-8	3507							
	Contact Email	laura.kwa	<u>ko@nih.gov</u>							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	05-Jun-20	024 , 05-Oct-2024 , 05-Feb-2025	, 05-Jun-2025 , 05-Oct-2025 , 05-Fe	b-2026 <i>,</i> 05-Ju	n-2026				
	Synopsis	The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.								
120718	<u>lcohol Treatment, Pharmacothe</u> rial required)	rapy, and F	Recovery Research (R34 Clinical	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-23- 249	5-Jun-2024	450,000 USD			
	Contact Name	Brett T. H	agman, Ph.D.							
	Contact Telephone	301-443-0	0638							
	Contact Email	brett.hag	man@nih.gov							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	16-Jun-20	024 , 16-Oct-2024 , 16-Feb-2025	, 16-Jun-2025 , 16-Oct-2025 , 16-Fe	b-2026 , 16-Ju	n-2026				
	Synopsis	The Natio	nal Institute on Alcohol Abuse a	and Alcoholism solicits applications f	for an R34 Clin	cal Trial Required m	nechanism			

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
		focusing c recovery f mechanis AUD treat	on alcohol treatment and recove from alcohol use disorder (AUD ms of behavioral change (MOBC ment and recovery.	ery research. This NOFO will focus b ), including: medications developme C), recovery, translational research,	roadly on topics ent, precision me and innovative r	relevant for treat edicine, behavioral nethods and techr	ment of and I therapies and nologies for			
120721	Alcohol Health Services Research	(R01 Clinic	al Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-23- 252 16-	Jun-2024	450,000 USD			
	Contact Name	Laura E. K	wako, Ph.D.							
	Contact Telephone	301-451-8	3507							
	Contact Emai	<u>laura.kwa</u>	<u>ko@nih.gov</u>							
	Sponsor Website	h								
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	16-Jun-20	24 , 16-Oct-2024 , 16-Feb-2025	, 16-Jun-2025 , 16-Oct-2025 , 16-Fe	b-2026 , 16-Jun-	-2026				
	Synopsis	The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcoh disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disp as a means of addressing the treatment gap in AUD for health disparity populations.								
122636	Prevention and Intervention App Disorders (R61/R33 Clinical Trial (	roaches for Optional)	Fetal Alcohol Spectrum	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-24- 068 17-	Jun-2024	Not Specified			
	Contact Name	William D	unty, PhD							
	Contact Telephone	301-443-7	7351							
	Contact Emai	duntyw@	mail.nih.gov							
	Sponsor Website									
	Program URL	Link to pro	ogram URL							
	Deadline Dates (ALL)	) 17-Jun-2024 , 16-Oct-2024 , 17-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026								
	Synopsis	This Notic disorders	e of Funding Opportunity (NOF (FASD) throughout the lifespan	<ul> <li>O) focuses on prevention and interv</li> <li>The intent of this NOFO is to support</li> </ul>	vention strategie ort research that	s for fetal alcohol advances (1) prev	spectrum /ention			

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
		approach will be ac R61 phase testing th programs to applica consider	es to reduce prenatal alcohol ex complished with the Explorator e will support pilot studies or se e hypotheses can be expanded staff after evaluation of the ach itions with clinical trials. Applica NOFO (PAR-24-067, the R34 opt	xposure and the incidence of FASD a y/Developmental Phased Award (Re condary data analysis for hypothesi in the R33 phase. The transition to t ievement of specific milestones set ants interested in planning clinical tr cion).	and (2) intervent 51/R33) mechani s development a the R33 phase w for the R61 phas ials or adding to	ions for FASD. The sm, clinical trial op ind feasibility, and ill be determined k e. Highest priority current projects m	se objectives otional. The research oy NIAAA will be given nay also		
104867 <u>N</u>	1echanisms of Alcohol Tolerance	e (R21/R33	Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-21- 250 16-	Jun-2024	1,775,000 USD		
	Contact Name	Elizabeth	M Powell, PhD						
	Contact Telephone	301-443-0	0786						
	Contact Email	elizabeth	.powell3@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	16-Jun-20	)24						
	Synopsis	This funding opportunity announcement (FOA) focuses on sensitivity and tolerance mechanisms underlying the development of alcohol use disorder. The intent of this FOA is to: (1) develop hypotheses about cellular, molecular or network mechanism that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol use disorder. These objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, clinical trial optional, in which secondary data analysis or pilot studies can occur during the R21 phase and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R21 phase.							
105028 <mark>N</mark> T	lotice of Special Interest (NOSI): olerance	<u>Genetics o</u>	f Alcohol Sensitivity and	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA- 21-029 07-	May-2024	Not Specified		
	Contact Name	Hemin Ch	iin, PhD						
	Contact Telephone	301-443-2	1282						
	Contact Email	<u>hemin.ch</u>	in@nih.gov						
	Sponsor Website								
	Program URL	<u>Link to pr</u>	ogram URL						

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	07-May-2 The purpe epigeneti and progr and bioint insights in epigenetic model sys controlled	024, 05-Jun-2024 ose of this notice of special inter c factors contributing to biologi ression to AUD. NIAAA is interes formatics approaches to establi nto genetic mechanisms of alcoh c, or transcriptional variation, a stems in which these complex re d environmental conditions.	rest (NOSI) is to provide enhanced u cal processes for individual variation sted in projects that will develop inno sh causality for candidate genes fror nol sensitivity and the development nd gene network and pathway analy elationships can be better studied ur	nderstanding of in sensitivity, th ovative strategie n GWAS and link of tolerance thro rses. Applicants a nder defined gen	genetic, genomic, ne development of s integrating both cage studies and to bugh investigation are encouraged to netic backgrounds	and tolerance, experimental provide of genomic, consider and well-
116584 <u>N</u>	otice of Special Interest (NOSI): A nderstanding and Preventing Alc	Advancing cohol-Rela	mHealth Interventions for ted Domestic Violence	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA- 23-003 07-1	May-2024	Not Specified
	Contact Name	Robert Fr	eeman, Ph.D.				
	Contact Telephone	301-443-8	3820				
	Contact Email	rfreeman	@mail.nih.gov				
	Sponsor Website	Link to ou					
Program URL Link to program URL 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Ja 2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 12-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2 12-Jun-2026 , 16-Jun-2026 , 07-Sep-2026							24 , 07-Jan- Sep-2025 , 05- 05-Jun-2026 ,
	Synopsis	In light of of the glo grant app developin alcohol co victimizat potential (mHealth) the term	the documented increases in b bal COVID-19 pandemic and arr lication solicitation is to annour og, testing, and intervening prox onsumption at levels sufficient t ion. In particular, this solicitation efficacy, and implementation or ) that rely on communication te "domestic violence" will extend iolence (IPV).	oth alcohol misuse (among some inc ray of mandated restrictions enacted nee NIAAA's interest in addressing th simal to drinking occasions, when rish o trigger DV and to provide skills sho on seeks to advance the developmen f scalable, low resource, and remote chnologies for reducing and prevent to child maltreatment (abuse and n	dividuals) and do to mitigate COV e critical need for k of DV is elevate own to reduce ris t, feasibility, acc ly delivered inte cing alcohol cons eglect) and elde	mestic violence (E /ID spread, the pu or research related ed, to decrease the sk of DV perpetrat eptability, pilot te rventions via mob umption and DV. I r abuse, in additio	<ul> <li>&gt;V) as a result</li> <li>rpose of this</li> <li>to</li> <li>likelihood of</li> <li>ion and</li> <li>sting,</li> <li>ile devices</li> <li>For this FOA,</li> <li>n to intimate</li> </ul>

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
122632	Prevention and Intervention Appr Disorders (R34 Clinical Trial Option	oaches foi nal)	r Fetal Alcohol Spectrum	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-24-	16-Jun-2024	450,000 USD
	Contact Name	William D	unty, PhD				
	Contact Telephone	301-443-7	7351				
	Contact Email	duntyw@	mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	16-Jun-20	024 , 16-Oct-2024 , 16-Feb-2025	5 , 16-Jun-2025 , 16-Oct-2025 , 16-Fe	b-2026 , 16-Jı	un-2026 , 16-Oct-202	6
	Synopsis	This Notic strategies that adva FASD. It is and subm explorato	e of Funding Opportunity (NOF for fetal alcohol spectrum disc nces (1) prevention approaches expected that research condu litting subsequent applications ry phased projects may conside	O) for R34 planning grant applicatio orders (FASD) throughout the lifespan s to reduce prenatal alcohol exposur cted via this mechanism will consist for larger scale FASD prevention or i er NOFO (PAR-24-068, the R61/R33 c	ns focuses on n. The intent e and inciden of studies tha ntervention s option).	prevention and inter of this NOFO is to sup ce of FASD and (2) in t are a pre-requisite tudies. Applicants int	vention port research terventions for for preparing erested in
	RFA-AA-24-006Model Continuum	ns of Care	Initiative (MCCI) to Advance			L9-May-2024	
124492	Health Equity and End Health Disp	arities An	ong Women and Girls in	National Institute on Alcohol	RFA-AA-	, Optional][LOI/Pre-	600,000
	Trials Required)	JILLEISEIV			24-000	\pp]	050
	Contact Name	Deidra Ro	ach, M.D.				
	Contact Telephone	301-443-	5820				
	Contact Email	droach@	nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	19-May-2 [Optional	024 [Optional][LOI/Pre-App], 1 ][LOI/Pre-App], 19-Feb-2025	8-Jun-2024 , 19-Sep-2024 [Optional]	[LOI/Pre-App	], 18-Oct-2024 , 20-Ja	ın-2025
	Synopsis	The purpo Health Eq ICO disser minority	ose of this NOFO is to support t uity and End Health Disparities mination and implementation s women and girls of reproductiv	he planning phase of the Model Con Among Women and Girls in Racial/E science initiative to advance racial eq e age. Specifically, the Model Contir	tinuums of Ca thnic Minorit uity and end nuums of Care	are Initiative (MCCI) t y Communities. MCC health disparities in r e Initiative will apply t	o Advance Cl is a multi- acial/ethnic the latest

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount

dissemination and implementation science approaches to significantly reduce the prevalence and impact of multi-morbidity among racial/ethnic minority women and girls of reproductive age at risk and living with mental health disorders, substance use disorders, chronic stress, cardiopulmonary diseases, common metabolic disorders (e.g., diabetes), cancer, and HIV/AIDS. This concept proposes a continuum of care approach that integrates preventive health services, primary care, behavioral health, integrative care, and cardiopulmonary and endocrine specialties to fully address health care needs in each of these domains, and to have maximum impact on the overall health and well-being of racial and ethnic minority and other underserved women and girls. While MCCI is not a maternal health initiative, women and girls ages 15-44 yrs. are centered because it is during the early reproductive period, i.e., adolescence, that multimorbidity typically begins and rapidly progresses, setting the stage for multiple chronic debilitating conditions in later life. Special emphasis will be placed on using stakeholder partnerships, provider training, and infrastructure changes to improve access for subgroups of racial/ethnic minority women and girls who currently have the least access to high quality health care (e.g., racial/ethnic minority women and girls living in low resource settings). Applications that include a partnership between Research Centers in Minority Institutions and other institutions with extensive programs in women's health research are strongly encouraged. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

Notice of Special Interest (NOSI): Epidemiology and Prevention of Alcohol National Institute on Alcohol NOT-AA-Not 107782 Misuse in Understudied Young Adult Populations; Military, Workforce, and 07-May-2024 Specified Abuse and Alcoholism/NIH/DHHS 22-001 **Community College** Contact Name Bradley Kerridge, Ph.D. Contact Telephone 301-827-7493 Contact Email bradley.kerridge@nih.gov Sponsor Website Program URL Link to program URL 07-May-2024, 05-Jun-2024, 16-Jun-2024, 05-Sep-2024, 07-Sep-2024, 05-Oct-2024, 16-Oct-2024, 05-Jan-2025, 07-Jan-Deadline Dates (ALL 2025, 05-Feb-2025, 16-Feb-2025, 05-Apr-2025, 07-May-2025, 05-Jun-2025, 16-Jun-2025, 05-Sep-2025, 07-Sep-2025 The purpose of this future grant application solicitation is to balance the NIAAA research portfolio by supporting research on alcohol misuse among persons aged 18 to 29 who are not enrolled in four-year colleges or universities. These persons are Synopsis commonly in the military, workforce, or community college populations, which are understudied relative to their age peers in four-year colleges. Research on epidemiology, prevention, and screening centered on these understudied populations are all encouraged.

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
105011 RFA-DC-22-001 NIDCD Research	n Grants for Translating Basic Research al Optional)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	RFA-DC- 22-001	21-May-2024 [Optional][LOI/Pre- App]	Not Specified			
Contact Name	Roger L. Miller, Ph.D.							
Contact Telephone	301-402-3458							
Contact Email	millerr@nidcd.nih.gov							
Sponsor Website								
Program URL	Link to program URL							
Deadline Dates (ALL)	21-May-2024 [Optional][LOI/Pre-App], 2	0-Jun-2024						
Synopsis	This Funding Opportunity Announcement scientists to jointly initiate and conduct tools for better human health. The scope findings which will impact the diagnosis, condition must be clearly established an	It (FOA) is intended to provide an ave translational research projects which e of this FOA includes a range of activ treatment and prevention of commu d the outcomes of the grant must ha	nue for bas translate ba ities to enco inication dis ve practical	ic scientists, clinicians asic research findings ourage translation of l orders. Connection to clinical impact.	and clinical into clinical pasic research o the clinical			
123922 NIDCD Research Career Enhancer (K18 Clinical Trial Required)	nent Award for Established Investigators	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24- 140	10-Jun-2024	Not Specified			
Contact Name	Alberto L. Rivera-Rentas, Ph.D.							
Contact Telephone	301-496-1804							
Contact Email	riverara@nidcd.nih.gov							
Sponsor Website								
Program URL	Link to program URL							
10-Jun-2024 , 07-Sep-2024 , 08-Oct-2024 , 07-Jan-2025 , 10-Feb-2025 , 07-May-2025 , 09-Jun-2025 , 07-Sep-2025 , 08-Oct- Deadline Dates (ALL) 2025 , 07-Jan-2026 , 09-Feb-2026 , 07-May-2026 , 08-Jun-2026 , 07-Sep-2026 , 08-Oct-2026 , 07-Jan-2027 , 08-Feb-2027 , 0 May-2027								
May-2027 The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Fundin Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an								

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
		independ research experienc	ent clinical trial, a clinical trial fe and career development. Applic e in a clinical trial led by anothe	easibility study, or a separate ancillar cants not planning an independent cl er investigator, must apply to compa	ry study to an ex inical trial, or pr nion NOFOs PAF	isting trial, as part oposing to gain re R-24-142 and PAR-	of their search 24-143.	
123925	NIDCD Research Career Enhancen (K18 Independent Basic Experime	nent Awar ntal Studie	d for Established Investigators es with Humans Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24- 142 10	lun-2024	Not Specified	
	Contact Name	Alberto L.	Rivera-Rentas, Ph.D.					
	Contact Telephone	301-496-2	1804					
	Contact Email	<u>riverara@</u>	nidcd.nih.gov					
	Sponsor Website							
Program URL Link to program URL								
	Deadline Dates (ALL)	10-Jun-2024, 07-Sep-2024, 08-Oct-2024, 07-Jan-2025, 10-Feb-2025, 07-May-2025, 09-Jun-2025, 07-Sep-2025, 08-Oct- ALL) 2025, 07-Jan-2026, 09-Feb-2026, 07-May-2026, 08-Jun-2026, 07-Sep-2026, 08-Oct-2026, 07-Jan-2027, 08-Feb-2027, 07- May-2027						
	Synopsis	The purper establishes skills to an Opportum "prospect and also r prospectiv biomedica without s basic experise with hum proposed Centers (I applicants separate a independ companic	bese of the NIDCD Research Care ed, proven investigators to augn inswer questions relevant to the ity Announcement is for basic s cive basic science studies involvi meet the definition of basic rese vely assign human participants to al or behavioral outcomes in hu pecific application towards proc erimental study with humans, o ans led by another investigator, project must be related to the p Cs) based on their scientific mis is proposing to serve as the lead ancillary study to an existing tria ent clinical trial, or proposing to on NOFOs PAR-24-140 and PAR-2	er Enhancement Award for Establish nent or redirect their research progr hearing, balance, smell, taste, voice cience experimental studies involvin ing human participants." These studi earch. Types of studies that should s to conditions (i.e., experimentally ma mans for the purpose of understand cesses or products in mind. Applicant r proposing to gain research experie must apply to the 'Independent Clir programmatic interests of one or mo sions. This Notice of Funding Oppor investigator of an independent clinical, as part of their research and caree o gain research experience in a clinica 24-143	ed Investigators ams through the , speech and lan g humans, refer es fall within the ubmit under this anipulate indepe- ing the fundame ts not planning a nce in a clinical nical Trial Not All ore of the partici rtunity (NOFO) is cal trial, a clinica er development. al trial led by and	s (K18) program is e acquisition of ne guage sciences. T red to in NOT-OD- e NIH definition of s FOA include stud endent variables) a ental aspects of ph in independent cli trial or basic expen- lowed' companion ipating NIH Institu s designed specific al trial feasibility st Applicants not pla other investigator,	to enable w research his Funding 18-212 as a clinical trial lies that and that assess nenomena nical trial or rimental study n NOFO. The tes and cally for tudy, or a anning an must apply to	

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
123928	NIDCD Research Career Enhancen (K18 Independent Clinical Trial No	nent Awar ot Allowed	d for Established Investigators	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24- 143 10	)-Jun-2024	Not Specified	
	Contact Name	Alberto L	Rivera-Rentas, Ph.D.					
	Contact Telephone	301-496-2	1804					
	Contact Email	<u>riverara@</u>	nidcd.nih.gov					
	Sponsor Website							
	Program URL	<u>Link to pr</u>	ogram URL					
	Deadline Dates (ALL)	10-Jun-20 2025 , 07 May-2027	024 , 07-Sep-2024 , 08-Oct-2024 -Jan-2026 , 09-Feb-2026 , 07-M 7	, 07-Jan-2025 , 10-Feb-2025 , 07-Ma ay-2026 , 08-Jun-2026 , 07-Sep-2026	iy-2025 , 09-Ju , 08-Oct-2026	n-2025 , 07-Sep-20 , 07-Jan-2027 , 08-I	25 , 08-Oct- Feb-2027 , 07-	
	Synopsis	The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Notice Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this NOFO a permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial ancillary clinical trial as lead investigator, should apply to the companion NOFO (NOFO# PAR-24-140 and PAR-24-142).						
123942	NIDCD's Mentored Research Path Medical Students (R25 - Clinical T	way for Ot rial Not All	<u>colaryngology Residents and</u> owed)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24- [C 127 Ap	l-May-2024 ptional][LOI/Pre- pp]	2,499,990 USD	
	Contact Name	Alberto L	Rivera-Rentas, Ph.D.					
	Contact Telephone	301-496-2	1804					
	Contact Email	<u>riverara@</u>	nidcd.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	14-May-2	024 [Optional][LOI/Pre-App], 14	4-Jun-2024 , 30-Sep-2024 , 29-Jan-20	25 , 29-Sep-20	25 , 29-Jan-2026 , 2	29-Sep-2026	
	Synopsis	The NIH F overarchi	Research Education Program (R2 ng goal of this NIDCD R25 progr	25) supports research education activation activation activation activitient of the support educational activitient of the support education and activitient of the support education activitient	vities in the mi es that help re	ssion areas of the N cruit individuals wit	IIH. The h specific	

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		specialty stated ov	or disciplinary backgrounds to re er-arching goal, this FOA will su	esearch careers in biomedical, behav pport creative educational activities	vioral and clinica with a primary f	ll sciences. To acco ocus on Research	omplish the Experiences.
122439 <u>F</u>	RFA-DC-24-004 In Vivo High-Res /isualization (R01 Clinical Trial op	solution Im tional)	haging for Inner Ear	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	RFA-DC- 24-004 03	lun-2024	2,499,995 USD
	Contact Name	Amy Pore	mba, Ph.D.				
	Contact Telephone	301-997-3	3152				
	Contact Email <u>amy.poremba@nih.gov</u>						
Sponsor Website							
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	03-Jun-20	24 , 01-Oct-2024 , 03-Feb-2025				
	Synopsis	This fund technolog technique detail and importan or contras opportun otoliths, r achieve th encourag advance t applicatio opportun improven criteria: m low risks low-risk t of a clinic applicatio Agreemen	Ing opportunity aims to support gies for the living human inner e es or developing new imaging te l accuracy than currently possib t to the development of new an st agents that can enhance visua ity is expected to significantly ac nembranes, ions, and vasculatu his goal, a multidisciplinary team ed. Studies in humans and inter he needed technology. Any inter n in awake humans or define th ity announcement (NOFO) also nent of human in vivo structural neet the budget limits of this NC to subjects, and intend to gathe rials determined to be Basic Exp al trial and meet the definition of n. High-risk clinical trials not me nt for In Vivo High-Resolution Im	ar. Proposed projects should focus of echniques that can visualize inner ear le. Both structural and functional asy d improved techniques. Projects ma- alization of the inner ear structures. dvance the ability to visualize audito re, in detail in awake patients in a cli n approach that takes advantage of t rmediate studies in mammalian anime ermediate studies must articulate a c se limitations and the usefulness in a supports investigator initiated low-ri and functional imaging technologies DFO, not require FDA oversight, not k r scientific data/evidence to inform s perimental Studies with Humans (BES of basic research. It is advisable that eating all the criteria above are refer- naging for Inner Ear Visualization (Cli	solution structures on improving the r structures in vi pects, including y also focus on o Research suppo ry and vestibula inical setting usi the expertise of nal models may clear path of the nesthetized hun sk clinical trials may clear path of the nesthetized hun sk clinical trials s. Clinical trials s. Clinical trials for an NIH-define subsequent stuc GH). These studie only one clinical red to the comp nical Trial require	ral and functional resolution of cur- vo with significant visualizing dynami developing new in rted in response t r components, suc ng non-invasive te each team membe be proposed to de proposed method nans. This notice addressing the de nust meet ALL the ed Phase III Clinica lies. This NOFO als es fall within the N trial be proposed red) NOFO RFA-DO	Imaging rent imaging Ily greater ic elements are laging probes o this funding ch as hair cells, echniques. To er is highly evelop or dology to of funding velopment or e following I Trial, have so supports IIH definition I in each rative C-24-005.

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
122441	<u>RFA-DC-24-005 Cooperative Ag</u> Imaging for Inner Ear Visualization	reement fo n (U01 Clir	or In Vivo High-Resolution hical Trial Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	RFA-DC- 03 24-005	-Jun-2024	2,499,995 USD
	Contact Name	Amy Pore	emba, Ph.D.				
	Contact Telephone	301-997-	3152				
	Contact Email	amy.pore	emba@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	rogram URL				
	Deadline Dates (ALL)	03-Jun-20	024 , 01-Oct-2024 , 03-Feb-202	5			
This funding opportunity aims to suppor functional imaging technologies for the current imaging techniques or developin significantly greater detail and accuracy dynamic elements, are important to dev imaging probes or contrast agents that or to this funding opportunity is expected t such as hair cells, otoliths, membranes, invasive techniques. To achieve this goa team member is highly encouraged. Stu technology. Any intermediate studies m humans or define the limitations and the cooperative agreement between an NID the following criteria: requires FDA over participants. These investigator-initiate guidance resulting from a cooperative ag funding opportunity. Low risk clinical tria Resolution Imaging for Inner Ear Visualiz encouraged to contact the scientific/res				living human inner ear. Proposed pro- ng new imaging techniques that can v than currently possible. Structural an veloping new and improved technique can enhance visualization of the inner to significantly advance the ability to ions, and vasculature, in detail in awa l, a multidisciplinary team approach t udies in humans must be proposed to ust articulate a clear path of the prop e usefulness in anesthetized humans. CD Project Scientist and an Investigat sight, is intended to formally establis d clinical trials are perceived to benef greement. Only one clinical trial may als not meeting any of the criteria abo cation (R01 - Clinical Trial Optional) RF earch contact, prior to submission, to	jects should fo isualize inner e d functional as es. Projects ma ear structures visualize audito ke patients in hat takes adva develop, adva osed methodo This funding o for to support a h efficacy, or h fit from close in be proposed p ove are referre A-DC-24-004.	cus on improving the ear structures in viv spects, including vis y also focus on dev . Research support ory and vestibular of a clinical setting usin ntage of the expert nce, or test the nee logy to application opportunity support a clinical trial that n as potentially higher eteraction, oversighter er application subn d to the companion Investigators are st the correct NOFO f	ne resolution of o with cualizing eloping new ed in response omponents, ing non- cise of each eded in awake ts a neets ANY of er risks to at, and hitted to this in In Vivo High- rongly or their

^	Notice of Special Interest (NOSI): Fundamental Science Research on the	National Institute on Deatness and	NOT-DC-	07 May 2024	Not
9	Neural Circuits Underlying Sensory Processing	Other Communication	23-001	07-1v1dy-2024	Specified

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
				Disorders/NIH/DHHS				
	Contact Name	Merav Sa	bri, Ph.D.					
	Contact Telephone	301-827-0	0908					
	Contact Email	<u>merav.sa</u>	bri@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2025 , 05 Jan-2026	024 , 05-Jun-2024 , 16-Jun-202 -Feb-2025 , 16-Feb-2025 , 07-M	4 , 25-Jun-2024 , 07-Sep-2024 , 05-O lay-2025 , 05-Jun-2025 , 16-Jun-2025	ct-2024 , 16-Oct , 07-Sep-2025 ,	-2024 , 25-Oct-20 05-Oct-2025 , 16-	24 , 07-Jan- Oct-2025 , 07-	
	Synopsis	The Natic from its n balance, t mechanis cutting-ed imaging, c expected sciences, and comp	ne National Institute on Deafness and Other Communication Disorders (NIDCD) is issuing this Notice to highlight priorities om its new strategic plan, in basic and mechanistic research on neural circuits underlying sensory processing in hearing, alance, taste and smell. NIDCD encourages multidisciplinary and innovative projects, from diverse teams, to advance a echanistic understanding of the behavior of neural circuits at cellular and sub-second temporal resolution by integrating itting-edge technologies and approaches for recording and modulation of cells and circuits (e.g., electrophysiology, optical naging, optogenetics, chemogenetics, sonogenetics, magnetogenetics, pharmacologic modulation). Applications are (pected to integrate appropriate domains of expertise, including but not limited to biological, chemical and physical ciences, engineering, computational modeling, statistical analysis, and bioethics, as appropriate. Mechanistic human studie nd comparative, cross-species projects are highly encouraged.					
123134 <u>P</u>	FA-DC-24-007 NIDCD Research romote Workforce Diversity (RO	<u>n Opportur</u> 1 Clinical T	nities for New Investigators to rial Optional)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	RFA-DC- 24-007 28-	Jun-2024	2,495,000 USD	
	Contact Name	Kelly King	, Au.D., Ph.D.					
	Contact Telephone	301-402-3	3458					
	Contact Email	<u>kingke@r</u>	nidcd.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	28-Jun-20	024 , 28-Oct-2024 , 06-Feb-2025	5				
	Synopsis	This Notio are within	ce of Funding Opportunity (NOF n the scientific mission areas of	O) solicits R01 grant applications that the National Institute on Deafness a	at propose indep nd Other Comm	endent research   unication Disorde	projects that rs (NIDCD).	

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
		This prog groups ur underrep institutio	ram is intended to support Early nderrepresented in the health-re resented groups (e.g., see NOT- ns to apply. Preliminary data ar	v Stage and New Investigators from c elated sciences. Investigators from d OD-20-031, Notice of NIH's Interest e not required for this NOFO.	liverse backgro iverse backgro in Diversity), a	ounds, including the unds, including tho re encouraged to w	se from se from ork with their	
124297	NIDCD Mentored Career Develop Au.D./Ph.D. Audiologists (K01 Clir	ment Awa iical Trial R	rd for Postdoctorate Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24- 149	3-Jun-2024	315,000 USD	
	Contact Name	Alberto L.	Rivera-Rentas, Ph.D.					
	Contact Telephone	301-496-2	1804					
	Contact Email	<u>riverara@</u>	nidcd.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	13-Jun-20 2025 , 07 May-2027	)24 , 07-Sep-2024 , 17-Oct-2024 -Jan-2026 , 13-Feb-2026 , 07-Ma 7	, 07-Jan-2025 , 13-Feb-2025 , 07-Ma ay-2026 , 15-Jun-2026 , 07-Sep-2026	ay-2025 , 13-Ju , 14-Oct-2026	n-2025 , 07-Sep-20 , 07-Jan-2027 , 17-F	25 , 15-Oct- eb-2027 , 07-	
	Synopsis	The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Funding Opportune Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitting propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancill study to an ongoing clinical trial as lead investigator, should apply to the companion FOA PAR-21-085 for Clinical Trial Beautived or for PAR-21-087 for Independent Basic Experimental Studies with Humans Beguired.						
124315	NIDCD Early Career Research(ECR	) Award (R	21 Clinical Trial Optional)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24- 119 18	3-Jun-2024	375,000 USD	
	Contact Name	Bracie Wa	atson, Jr.					
	Contact Telephone	301-402-3	3458					



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Email	watsonb@	Dnidcd.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	18-Jun-20 2027	024 , 17-Oct-2024 , 19-Feb-2025	, 17-Jun-2025 , 17-Oct-2025 , 18-Fe	b-2026 , 17-Jun-3	2026 , 19-Oct-202	3 , 17-Feb-		
	Synopsis	The NIDC who are b research i hearing, b types of p research i Irrespecti Investigat	who are beginning to establish an independent research career. It cannot be used for thesis or dissertation research. research must be focused on one or more of the areas within the biomedical and behavioral scientific mission of the hearing, balance, smell, taste, voice, speech, or language. The NIDCD ECR Award R21 grant mechanism supports diffe types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new research technology. Irrespective of the type of project, the intent of the NIDCD ECR Award R21 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.						
124298	NIDCD Mentored Career Develops Au.D./Ph.D. Audiologists (K01 Indevited) with Humans Required)	ment Awai ependent	rd for Postdoctorate Basic Experimental Studies	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24- 150 13-J	lun-2024	315,000 USD		
	Contact Name	Alberto L.	Rivera-Rentas, Ph.D.						
	Contact Telephone	301-496-1	1804						
	Contact Email	<u>riverara@</u>	<u> Inidcd.nih.gov</u>						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	13-Jun-20 2025 , 07- May-2027	)24 , 07-Sep-2024 , 17-Oct-2024 -Jan-2026 , 13-Feb-2026 , 07-Ma 7	, 07-Jan-2025 , 13-Feb-2025 , 07-Ma ay-2026 , 15-Jun-2026 , 07-Sep-2026	ay-2025 , 13-Jun , 14-Oct-2026 ,	-2025 , 07-Sep-202 07-Jan-2027 , 17-F	25 , 15-Oct- eb-2027 , 07-		
	Synopsis	The purp support c behaviora independ Opportun clinical tri	ose of the NIDCD Mentored Car omprehensive and rigorous pos al, or clinical sciences of promisi ent investigators in scientific he ity (NOFO) is designed specifica al, a clinical trial feasibility study	eer Development Award for Postdo tdoctoral research and career devel ng Au.D./Ph.D. audiologists who hav alth-related research fields relevant lly for applicants proposing to serve y, or a separate ancillary study to an	ctorate Au.D./Ph opment experien re the potential t to NIDCD's miss as the lead inve existing trial, as	n.D. Audiologists (H nces in the biomed to become product ion. This Notice of stigator of an inde part of their resea	(01) is to lical, tive, Funding pendent arch and		

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount					
	career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-24-159).										
124299	NIDCD Mentored Career Develop Au.D./Ph.D. Audiologists (K01 Ind	ment Award for Postdoctorate lependent Clinical Trial Not Allowed)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24- 159 13-	Jun-2024	315,000 USD					
	Contact Name	Alberto L. Rivera-Rentas, Ph.D.									
	Contact Telephone	301-496-1804									
	Contact Email	riverara@nidcd.nih.gov									
	Sponsor Website										
	Program URL	Link to program URL									
	Deadline Dates (ALL)	13-Jun-2024, 07-Sep-2024, 17-Oct-2024, 07-Jan-2025, 13-Feb-2025, 07-May-2025, 13-Jun-2025, 07-Sep-2025, 15-Oct- ates (ALL) 2025, 07-Jan-2026, 13-Feb-2026, 07-May-2026, 15-Jun-2026, 07-Sep-2026, 14-Oct-2026, 07-Jan-2027, 17-Feb-2027, 07- May-2027									
	Synopsis	The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFOs (PAR-24-149 and PAR-24-150).									
117259	Notice of Special Interest (NOSI): within the NIDCD Mission Areas	Encouraging Women's Health Research	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC- 23-006 07-	May-2024	Not Specified					
	Contact Name	Christopher Myers									
	Contact Telephone	301-435-0713									
	Contact Email	myersc@nidcd.nih.gov									
	Sponsor Website	2									
	Program URL	Link to program URL									

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	07-May-2 2025 , 05- Oct-2025 The Natio (NOSI) to to conduc smell, void Strategic I the NIDCE hormonal quality of	024, 05-Jun-2024, 16-Jun-2024 Feb-2025, 16-Feb-2025, 25-Fe , 16-Oct-2025, 25-Oct-2025, 07 nal Institute on Deafness and O stimulate research in areas rega t and support research and rese ce, speech, and language. As no Plan   NIDCD), research projects o mission areas. These projects o mission areas. These projects o no genetic aspects, behavioral life.	4, 25-Jun-2024, 07-Sep-2024, 05-Od b-2025, 07-May-2025, 05-Jun-2025 7-Jan-2026, 05-Feb-2026, 16-Feb-20 ther Communication Disorders (NID arding the health of women within the earch training in the normal and disc ted in the recently issued 2023–202 is to improve the health of women co may include biological studies which traits, societal aspects, or healthcard	ct-2024 , 16-Oct- 5 , 16-Jun-2025 , 026 , 25-Feb-202 CD) is issuing thi he scope of NIDC ordered processe 7 NIDCD Strateg overing the lifesp may incorporat e related activiti	2024, 25-Oct-202 25-Jun-2025, 07-5 6, 07-May-2026 s Notice of Special CD's mission. NID es of hearing, balan ic Plan (2023-2027 oan are encourage e anatomical, stru es that may benef	24,07-Jan- Sep-2025,05- I Interest CD's mission is nce, taste, 7 NIDCD d across all ctural, it a women's
122020	NIDCD Cooperative Agreement for Disorders (U01 - Clinical Trial Requ	<sup>·</sup> Clinical T ired)	rials in Communication	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24- 050 27-J	un-2024	Not Specified
	Contact Name	Trinh T. Ly	<i>ι,</i> Μ.D.				
	Contact Telephone	301-435-4	1085				
	Contact Email	trinh.ly@r	<u>nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	27-Jun-20	24 , 28-Oct-2024 , 27-Feb-2025	, 27-Jun-2025 , 28-Oct-2025 , 27-Fel	b-2026 , 29-Jun-2	2026 , 27-Oct-202	6
The NIDCD is committed to identifying effective interventions for the treatment or prevention of communication disc supporting well-designed and well-executed clinical trials. This funding opportunity supports a cooperative agreement between an NIDCD Project Scientist and an Investigator to support a clinical trial that meets ANY of the following criter requires FDA oversight, is intended to formally establish efficacy, or has potentially higher risks to participants. Clinical applications exceeding the annual direct costs of \$700,000 or more, in certain cases, may also be a criterion for this for opportunity. These investigator-initiated clinical trials are perceived to benefit from close interaction, oversight, and resulting from a cooperative agreement. Only one clinical trial may be proposed per application submitted to this fur opportunity. Low risk clinical trials not meeting any of the criteria above are referred to the companion NIDCD Low R Clinical Trials in Communication Disorders (R01-Clinical Trial Required) PAR-24-051. Investigators are strongly encou contact Dr. Trinh Ly, prior to submission, to ensure this is the correct NOFO for their proposed research.							n disorders by ement g criteria: Clinical trial this funding , and guidance his funding Low Risk encouraged to

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
102240	Notice of Special Interest (NOSI): Access and Affordability	Hearing Healthcare for Adults: Improving	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC- 21-001 07-	May-2024	Not Specified
	Contact Name	Kelly King, Au.D, Ph.D.				
	Contact Telephone	2 301-402-3458				
	Contact Email	kingke@nidcd.nih.gov				
	Sponsor Website	ۮ				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024	4 , 07-Sep-2024			
	Synopsis	The purpose of this Notice of Special Inte in support of improving access and afforc delivering better hearing health care out	erest (NOSI) is to encourage applicati dability. Further research is needed t comes in adults.	ons for research o strengthen th	n on hearing healt e evidence base w	h care in adults vith a goal of
122021	NIDCD Low Risk Clinical Trials in C Trial Required)	Communication Disorders (R01 Clinical	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24- 051 07-	May-2024	2,499,995 USD
	Contact Name	Trinh T. Ly, M.D.				
	Contact Telephone	2 301-435-4085				
	Contact Email	l <u>trinh.ly@nih.gov</u>				
	Sponsor Website	٤				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Sep-2024 2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Fel	4 , 05-Oct-2024 , 07-Jan-2025 , 05-Fe b-2026 , 07-May-2026 , 05-Jun-2026	eb-2025 , 07-Ma , 07-Sep-2026 ,	y-2025 , 05-Jun-20 05-Oct-2026 , 07-	025 , 07-Sep- Jan-2027
	Synopsis	The NIDCD is committed to identifying ef disorders by supporting well-designed an (NOFO) supports investigator initiated low trials must meet ALL the following criteria defined Phase III Clinical Trial, have low ri studies. This NOFO also supports low risk (BESH). These studies fall within the NIH	fective interventions for the diagnosed well-executed clinical trials. This new risk clinical trials addressing the mathematical the budget limits of this NOF isks to subjects, and intends to gather trials determined to be Basic Science definition of a clinical trial and meet	is, prevention, o otice of funding ission and resea O, not require l er scientific data te Experimental the definition o	or treatment of co copportunity anno arch interests of N FDA oversight, not v/evidence to infor Studies involving I f basic research. It	mmunication ouncement IDCD. Clinical an NIH rm subsequent Humans t is advisable

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount					
	that only one clinical trial be proposed in each NIDCD Clinical Trials in Communication Disorders R01 application. High risk clinical trials not meeting all the criteria above are referred to companion U01 NOFO, PAR-24-050, NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders.											
106846	NIDCD Clinical Research Center G	rant (P50 (	Clinical Trial Optional)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-22- 025 06	lun-2024	7,500,000 USD					
	Contact Name	Lana Shel	kim, Ph.D.									
	Contact Telephone	301-496-5	5061									
	Contact Emai	<u>shekiml@</u>	nidcd.nih.gov									
	Sponsor Website											
	Program URL	Link to pr	ogram URL									
	Deadline Dates (ALL)	06-Jun-20	024 , 09-Oct-2024									
	Synopsis	The Natio Center Gr disorders or data/ti studies of disorder of not requi	red to (optional).	other Communication Disorders (NID iagnosis, prevention, treatment, and al Research is defined as research inv ommunication disorder. Examples of pathophysiology, diagnosis, treatme , voice, speech, or language. Applica	CD) invites appli l amelioration of volving individua such research ir nt, managemen tions may propo	cations for Clinica human communic ls with communic nclude but are not t or epidemiology se a low risk clinic	Research cation ation disorder limited to, of a disease o al trial but are					
117406 <u>i</u>	Notice of Special Interest (NOSI): n Minimally Verbal/Non-Speakin	Promoting g Individua	Language and Communication Is with Autism	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC- 23-009 07-	May-2024	Not Specified					
	Contact Name	Holly L. St	orkel, Ph.D.									
	Contact Telephone	301-496-5	5061									
	Contact Emai	holly.stor	<u>kel@nih.gov</u>									
	Sponsor Website											
	Program URL	Link to pr	ogram URL									
	Deadline Dates (ALL)	07-May-2 2024 , 05	024 , 05-Jun-2024 , 16-Jun-2024 -Jan-2025 , 07-Jan-2025 , 05-Fel	4 , 25-Jun-2024 , 05-Sep-2024 , 07-Se p-2025 , 16-Feb-2025 , 05-Apr-2025 ,	ep-2024 , 05-Oct 07-May-2025 ,	-2024 , 16-Oct-202 05-Jun-2025 , 16-J	24 , 25-Oct- un-2025 , 05-					

Sep-2025, 07-Sep-2025, 05-Oct-2025, 16-Oct-2025, 05-Jan-2026, 07-Jan-2026, 05-Feb-2026, 16-Feb-2026, 05- Or-May-2026, 05-Jun-2026         Synopsis       The purpose of this Notice of Special Interest (NOSI) is to encourage applications for research to promote language communication in autistic individuals who are minimally verbal/non-speaking. Further research designs and methods to intervention efforts, and identify meaningful outcome measures.         123100       RFA-DA-25-028 - Development of Clinical Outcome Assessments as New FDA-Qualified Drug Development Tools to Accelerate Therapeutics Development for Opioid and Stimulant Use Disorders (UG3/UH3 Clinical Trial Optional)       National Institute on Drug Abuse/NIH/DHHS       QP-Jun-2024 (Optional)[LOI/Pre- App]         Contact Name Sponsor Website       Tanya Ramey, M.D., Ph.D.       National Institute on Drug App]       QP-Jun-2024 (Optional)[LOI/Pre- App]         Contact Telephone       301-827-5944       Sonsor Website       Program URL       Vink to program URL         Deadline Dates (ALL)       O9-Jun-2024 (Optional)[LOI/Pre-App], 09-Jul-2024       The purpose of this funding opportunity is to support the development of Clinical Outcome Assessments (COA) for Use Disorders (SUD). The COA development plan is expected to progress into the FDA drug development tool quil program. This notice of funding opportunity (NOFO) utilizes the UG3/UH3 Phased Innovation Awards Cooperative grant mechanism that includes two phases. The applications responding to this NOFO should contain a COA develop plan that will cover both UG3 and UH3 phases. In the first 2-year UG3 phase the project must have a set of operative mistores to be completed by the end of this period. Once NIDA program has evaluat	SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
RFA-DA-25-028 Development of Clinical Outcome Assessments as New       National Institute on Drug       RFA-DA-25-028       09-Jun-2024         123100       Evelopment for Opioid and Stimulant Use Disorders (UG3/UH3 Clinical Trial Optional)       National Institute on Drug       RFA-DA-25-028       09-Jun-2024         Contact Name       Tanya Ramey, M.D., Ph.D.       Contact Telephone       301-827-5944       Sontact Email       Earya.ramey@nih.gov         Sponsor Website       Program URL       Link to program URL       Deadline Dates (ALL)       09-Jun-2024 (Optional)[LOI/Pre-App], 09-Jul-2024         Deadline Dates (ALL)       09-Jun-2024 (Iptional)[LOI/Pre-App], 09-Jul-2024       The purpose of this funding opportunity is to support the development of Clinical Outcome Assessments (COA) for         Use Disorders (SUD). The COA development plan is expected to progress into the FDA drug development tool qual program. This notice of funding opportunity (NOFO) utilizes the UG3/UH3 Phased Innovation Awards Cooperative grant mechanism that includes two phases. In the first 2-year UG3 phase the project must have a set of operative milestones to be completed by the end of this period. Once NIDA program has evaluated the progress of the UG3 and UH3 phases. In the first 2-year UG3 phase the project must have a set of operative milestones to be completed by the end of this period. Once NIDA program has evaluated the progress of the UG3 and UH3 phases. The applications responding to this NOFO should contain a COA develed for additional years. The goal of this NOFO is to expand the armamentarium of COA that are FDA qualified as drug dev tool (DDT) in the context of use (COI) of a SUD. Achieving this g		Synopsis	Sep-2025 07-May-2 The purpo communi tailor exis intervent	, 07-Sep-2025 , 05-Oct-2025 , 1 026 , 05-Jun-2026 ose of this Notice of Special Inte cation in autistic individuals wh ting interventions, develop nov ion efforts, and identify meanin	6-Oct-2025 , 05-Jan-2026 , 07-Jan-2 erest (NOSI) is to encourage applicat o are minimally verbal/non-speakin el interventions, develop and apply gful outcome measures.	2026 , 05-Feb-202 tions for research g. Further resear new research de	26 , 16-Feb-2026 , n to promote langu rch is needed to ev esigns and method	05-Apr-2026 , Jage and Valuate and Is to
Contact NameTanya Ramey, M.D., Ph.D.Contact Telephone301-827-5944Contact Emailtanya.ramey@nih.govSponsor WebsiteProgram URLLink to program URL09-Jun-2024 [Optional][LOI/Pre-App], 09-Jul-2024Deadline Dates (ALL)09-Jun-2024 [Optional][LOI/Pre-App], 09-Jul-2024The purpose of this funding opportunity is to support the development of Clinical Outcome Assessments (COA) for Use Disorders (SUD). The COA development plan is expected to progress into the FDA drug development tool qual program. This notice of funding opportunity (NOFO) utilizes the UG3/UH3 Phased Innovation Awards Cooperative. grant mechanism that includes two phases. The applications responding to this NOFO should contain a COA develop plan that will cover both UG3 and UH3 phases. In the first 2-year UG3 phase the project must have a set of operati milestones to be completed by the end of this period. Once NIDA program has evaluated the progress of the UG3 J SynopsisSynopsisdetermined that the UG3 phase has been successfully completed, it transitions to the UH3 phase to be funded for additional years. The goal of this NOFO is to expand the armamentarium of COA that are FDA qualified as drug dev tool (DDT) in the context of use (COI) of a SUD. Achieving this goal will greatly facilitate the development of treatm SUDs. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the second	123100	RFA-DA-25-028 Development of FDA-Qualified Drug Development Development for Opioid and Stimu Trial Optional)	<u>f Clinical O</u> Tools to A ulant Use	utcome Assessments as New accelerate Therapeutics Disorders (UG3/UH3 Clinical	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 09 25-028 [Op App	Jun-2024 tional][LOI/Pre- b]	2,500,000 USD
and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and wi withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PED material.		Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Tanya Ran 301-827-5 tanya.ran Link to pr 09-Jun-20 The purpe Use Disor program. grant mee plan that milestone determine additiona tool (DDT SUDs. Th and techr withdraw material.	mey, M.D., Ph.D. 5944 <u>ney@nih.gov</u> 024 [Optional][LOI/Pre-App], 09 ose of this funding opportunity ders (SUD). The COA developme This notice of funding opportur chanism that includes two phase will cover both UG3 and UH3 pl es to be completed by the end o ed that the UG3 phase has beer I years. The goal of this NOFO is ) in the context of use (COI) of a is NOFO requires a Plan for Enh nical peer review evaluation. Ap n. Applicants are strongly encou	-Jul-2024 is to support the development of Cl ent plan is expected to progress into hity (NOFO) utilizes the UG3/UH3 Pl es. The applications responding to t hases. In the first 2-year UG3 phase of this period. Once NIDA program h is successfully completed, it transition to expand the armamentarium of ( a SUD. Achieving this goal will great ancing Diverse Perspectives (PEDP), plications that fail to include a PEDF uraged to read the NOFO instruction	inical Outcome A o the FDA drug de nased Innovation this NOFO should the project must has evaluated the ons to the UH3 ph COA that are FDA ly facilitate the de which will be as will be consider ns carefully and v	assessments (COA) evelopment tool of Awards Cooperat contain a COA de t have a set of ope progress of the U hase to be funded a qualified as drug evelopment of tre sessed as part of t red incomplete and riew the available	for Substance Jualification ive Agreement velopment rational G3 phase and for three development atments for the scientific d will be PEDP guidance

Icahn School of Medicine at Mount Sinai

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Consequences of COVID-19 in Ind Use Disorders	ividuals Liv	ving with HIV and Substance	Abuse/NIH/DHHS	21-018		Specified
	Contact Name	Raul Man	dler, MD				
	Contact Telephone	301-480-2	2541				
	Contact Email	mandlerr	@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	024 , 05-Jun-2024 , 07-Sep-202	4			
	Synopsis	NIDA is in COVID-19	terested in receiving research a I/HIV/SUDs syndemic.	applications focusing on studying the	e long-term neur	ocognitive conseq	uences of the
103071	Notice of Special Interest (NOSI): Addicted Brain	Decipherir	ng the Mosaic of Glia in the	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-001 07-1	May-2024	Not Specified
	Contact Name	Shang-Yi	Anne Tsai, Ph.D				
	Contact Telephone	301-827-	5842				
	Contact Email	<u>stsai@nih</u>	1.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	.024 , 05-Jun-2024 , 16-Jun-202	4 , 25-Jun-2024 , 07-Sep-2024			
	Synopsis	Synopsis National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) to inform potential applicants of its interest in research project grant submissions that examine the effects of drug use on the structural and functional diversi and plasticity of glia and non-neuronal cells on nervous system process in the context of drug misuse and substance use disorders (SUD). Glial and other non-neuronal cells include astrocytes, microglia, oligodendrocytes and ependymal cells.					
103870	Notice of Special Interest (NOSI): Animal Models to Identify Neural Resilience to Substance Use Disor	Leveraging Mechanis der	<u>t Longitudinal Studies in</u> ms of Vulnerability and	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-003 07-I	May-2024	Not Specified
	Contact Name	Holly Mo	ore				
	Contact Telephone	301-827-7	7376				
	Contact Email	Holly.Mo	ore@nih.gov				
			NIH Euroding Opportu	nitios Duo: Juno 2024			

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Sponsor Website Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2024	4 , 25-Jun-2024 , 07-Sep-2024					
	Synopsis	NIDA seeks to stimulate research in non- SUD to elucidate neural and cognitive de these factors on subsequent emergence appropriate paradigms are strongly enco	human species aimed at modeling velopmental mechanisms that may of SUD-related behaviors. Use of lo uraged.	environmental ar mediate, modera ngitudinal design	d/or biological ris ate, or predict the s and developmer	< factors for effects of Ital-stage-		
104862	Notice of Special Interest (NOSI): A Computational Neuroscience	Advancing HIV/AIDS Research through	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-030 07-	May-2024	Not Specified		
	Contact Name	Yu (Woody) Lin						
	Contact Telephone	301-435-1318						
	Contact Email	<u>ylin1@mail.nih.gov</u>						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2024 , 25-May-2024 , 05-Jun-202 2024 , 25-Oct-2024 , 07-Jan-2025	24 , 12-Jun-2024 , 16-Jun-2024 , 25-	Jun-2024 <i>,</i> 07-Sej	o-2024 , 25-Sep-20	124 , 12-Oct-		
	Synopsis	This Notice of Special Interest [NOSI] is to support computational HIV/AIDS research as it relates to NIDA's mission throug collaborative research between investigators with experimental expertise related to HIV/AIDS and those with computatio proficiency, including scientists from statistics, physics, mathematics, engineering, and computer science. The NOSI will support meritorious and innovative research built on well-established computational strategies (theory, models, and methods) to investigate HIV-related neurocognitive deficits and neuropathogenesis in the context of substance use or substance use disorder (SUD). Investigators are expected to have complementary and integrated expertise in their field(s) but an ongoing collaboration or record of co-authorship is not required.						
109484	Notice of Special Interest (NOSI): I Actionable Insights for Substance	Leveraging Data Science to Bring use Prevention and Treatment	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 23-006 07-	May-2024	Not Specified		
	Contact Name Contact Telephone Contact Email	Janet Kuramoto-Crawford, PhD 301-443-8856 janet.kuramoto-crawford@nih.gov						

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-202 2025 , 07-May-2025 , 05-Jun-2025 , 16-J	24 , 07-Sep-2024 , 05-Oct-2024 , 16-0 un-2025 , 07-Sep-2025	Dct-2024 , 07-Jan-	-2025 , 05-Feb-202	25 , 16-Feb-
	Synopsis	This Notice encourages research project prevention and treatment 2) shorten the or near real-time, and 3) explore methor treatment and prevention. Priority will b health records, syndromic surveillance,	is that 1) leverage data science to pr e time between data capture and da ds and tools that may allow for faste be given to projects that emphasize t claims data, registry data, pharmacy	ovide actionable Ita availability so er or better localiz the use of existing dispensing, socia	insights for substa that data are avail ed responses for s g data streams (e. Il media, and mort	nce use able real-time substance use g., electronic cality records).
109268 <u>N</u>	Notice of Special Interest (NOSI):	Epidemiology of Drug Abuse	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 22-004 07-I	May-2024	Not Specified
	Contact Name	Marsha Lopez, PhD, MHS				
	Contact Telephone	301-443-6504				
	Contact Email	Marsha.Lopez@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-202 2025 , 07-May-2025 , 05-Jun-2025 , 16-J	24 , 07-Sep-2024 , 05-Oct-2024 , 16-0 un-2025 , 07-Sep-2025	Dct-2024 , 07-Jan-	-2025 , 05-Feb-202	25 <i>,</i> 16-Feb-
	Synopsis	The purpose of this Notice is to encoura the nature, extent, distribution, etiology individuals, families, communities, and c risk, resilience, and causation across scie interplay among genetic, environmental outcomes. Priority will be given to resea addition to novel data collection, approa agencies to harness existing data on the treatment programs. The research areas disparities or inequities, familial/genetic interactions.	ge the submission of research project, comorbidities, and consequences of diverse population groups. Of interest entific disciplines, and that apply now neurobiological, and development rch with a well described path towa aches are encouraged that build on t epidemiology and etiology of drug r s noted below should be considered hiability, and physical, psychiatric, a	ct applications the of drug use, misus st are applications vel methods to ad al factors and ass rds translation an the research inves misuse to improve in the context of nd polysubstance	at enhance our un se, and addiction a s that address mu lvance knowledge ociated health and od/or public health stments of NIH an e public health pre topics such as hea comorbidities and	derstanding of across ltiple levels of of the d disease n impact. In d sister HHS evention and alth d

Icahn School of Medicine at Mount Sinai

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Clinical Trials Not Allowed)			Abuse/NIH/DHHS	194		USD			
	Contact Name	Marsha F	. Lopez, Ph.D., M.H.S.							
	Contact Telephone	301-443-6	5504							
	Contact Email	marsha.lo	opez@nih.gov							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	07-May-2 2025 , 16	-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep- 25 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026							
	Synopsis	discipline with the I (nih.gov). disorder ( from indiv Interest in involve le NOFO are	s for up to two years for the con NIDA Strategic Plan (2022-2026 This award will facilitate the er SU(D) research, enhancing the viduals from diverse backgroun in Diversity (NOT-OD-20-031). The ading an independent clinical to e permitted to propose research	mpletion of the doctoral disser NIDA Strategic Plan Director's ntry of promising new investiga pool of highly talented SU(D) re ds, including those from under nis NOFO is designed specificall rial, a clinical trial feasibility stu n experience in a clinical trial lea	tation research projec Message   National Ir tors into the field of s esearchers. Applicatio represented groups a y for applicants propo dy, or an ancillary clir d by a mentor or co-n	ct. Research project institute on Drug Al substance use/sub- ons are particularly is described in the osing research that nical trial. Applicant nentor.	ts should align buse (NIDA) stance use rencouraged Notice of NIH's t does not its to this			
112005	Notice of Special Interest (NOSI):	Health Ser	vices and Economic Research	National Institute on Drug	NOT-DA-	May 2024	Not			
113995	RO3)	<u>n, anu tob</u>	acco use disorders (RU1, R21,	Abuse/NIH/DHHS	23-012	IVIAy-2024	Specified			
	Contact Name	Tisha Wile	ey, Ph.D.							
	Contact Telephone	301-594-4	4381							
	Contact Email	tisha.wile	<u>y@nih.gov</u>							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	07-May-2 2025 , 07	)7-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb- 2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026							
	Synopsis	The purpo interest in	ose of this Notice is to inform pont of grant applications to conduct	otential applications to the Nat rigorous health services and ec	ional Institute on Dru conomic research to n	g Abuse (NIDA) of naximize the availa	special ability and			

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
		delivery o include: ( implemen improven	of efficient, effective drug, alcoh 1) clinical quality improvement; ntation science; (4) availability, ment of research methodology,	iol, and tobacco treatment and re (2) quality improvement in servic demand, access, and financing; (5 analytic approaches, and measure	covery suppor es organizatio ) effectivenes: ment instrum	t services. Examples of on and management; (3 s; and (6) development entation.	such research ) or				
114150	Notice of Special Interest (NOSI): Medical/Psychosocial Consequen	Chemsex a ces, and Ti	ind HIV: Prevalence, reatment	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 24-002	07-May-2024	Not Specified				
	Contact Name Contact Telephone Contact Email Sponsor Website Program UBL	Raul Man 240-281-0 <u>mandlerr</u>	dler, MD 0569 <u>@nih.gov</u> ogram UBI								
	Deadline Dates (ALL)	07-May-2 2025 , 07	7-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb- 025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026								
	Synopsis	The purp therapeu lesbian, g	ose of this notice is to support r tic measures for chemsex in peo ay, bisexual.	esearch on the epidemiology, me ople with HIV and HIV-vulnerable	dical/psychos populations ir	ocial impact, and preve cluding sexual minoriti	ntive and es (SM) e.g.				
124184	<u>RFA-DA-25-043 Transformative</u> Polysubstance use in Addiction (R	<u>Research</u> 01 - Clinic	on the Basic Mechanisms of al Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 23-015	17-Jun-2024 [Optional][LOI/Pre- App]	1,750,000 USD				
	Contact Name	Sunila Na	ir, PhD								
	Contact Telephone	301-827-	5832								
	Contact Email	<u>sunila.nai</u>	r@mail.nih.gov								
	Sponsor Website										
	Program URL	Link to pr	ogram URL	1 1 2024							
	Deadline Dates (ALL)	This Eurod	ing Opportunity Appoundement	-JUI-2024 t (EOA) will support projects prop	ocing machan	ictic ctudioc that will to	ancform our				
	Synopsis	understa of polysu	nding of polysubstance use in a bstance use at the behavioral, c	ddiction. These hypothesis-based, ognitive, cellular, circuit, genetic,	exploratory p epigenetic, pl	armacological and/or	e mechanisms computationa				

SPIN ID	N ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		levels.					
102446	Notice of Special Interest (NOSI): Knowledge and Program Planning	<u>Using Data</u> I	a to Advance HIV Epidemic	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-007 07-	May-2024	Not Specified
	Contact Name	Richard A	. Jenkins PhD				
	Contact Telephone	301-443-1	1923				
	Contact Email	<u>jenkinsri@</u>	@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	.024 , 05-Jun-2024 , 16-Jun-2024	4 , 07-Sep-2024			
Synopsis Synopsis Synopsis Synopsis Synopsis							of substance d to increase ventions, as imercial data n studies bout HIV public policy. and policy to
101829	Notice of Special Interest (NOSI): Risk and Outcome of COVID-19 In	Effects of S fection	Smoking and Vaping on the	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-011 07-	May-2024	Not Specified
	Contact Name	Raul Man	dler, MD; FAAN; FANA				
	Contact Telephone	301-480-2	2541				
	Contact Email	mandlerr	<u>@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	.024 , 05-Jun-2024 , 16-Jun-2024	4 , 07-Sep-2024			
	Synopsis	The purpo	ose of this notice is to communi	icate NIDA's interest in supporting re	esearch on the e	ffects of smoking o	or vaping

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		tobacco or marijuana on the risk of acqu of NOT-DA-20-084.	iring COVID-19 and the clinical cours	se of the infectio	n. This Notice is a i	reissuance
102016	Notice of Special Interest (NOSI): Vaping Drugs of Abuse in Individu	Medical Consequences of Smoking and als with HIV and COVID-19	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-017 07-	May-2024	Not Specified
	Contact Name	Raul Mandler, MD				
	Contact Telephone	301-480-2541				
	Contact Email	mandlerr@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2024	4 , 07-Sep-2024			
	Synopsis	NIDA is interested in receiving research a cocaine and/or methamphetamine to de	applications focusing on individuals v termine the long-term effects of the	with HIV who sm eir use among inc	oke or vape mariju lividuals with HIV	iana, tobacco, and COVID-19.
102120	Notice of Special Interest (NOSI): HIV and Substance Use Disorders	Telehealth Strategies for Individuals with	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-019 07-	May-2024	Not Specified
	Contact Name	Raul Mandler, MD				
	Contact Telephone	301-480-2541				
	Contact Email	mandlerr@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2024	4 , 07-Sep-2024			
	Synopsis	The National Institute on Drug Abuse (NI explore and develop telehealth methods individuals living with HIV and Substance	DA) is issuing this Notice of Special I and strategies for diagnosis, prever Use Disorder (SUD).	nterest (NOSI) in ition, treatment,	viting research ap and population ar	plications to nalysis in
103874	Notice of Special Interest (NOSI): Resources in Model Organisms to Abuse Disorders	Leveraging Transformative Connectome Elucidate the Neurobiology of Substance	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-006 07-	May-2024	Not Specified
	Contact Name	Olivier Berton, Ph.D.				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone	301-827-7771				
	Contact Email	olivier berton@nib.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-202	4,07-Sep-2024			
	Synopsis	The purpose of this notice is to encourage resources in genetically tractable model relevant to substance use disorders (SUE	ge research project submissionsthat organisms to investigate the role of D).	leverage whole-b distributed neuro	orain or large conr onal circuits in bel	nectome naviors
104182	Notice of Special Interest (NOSI): A Elucidate Disease Pathology and Ic	Advanced Computational Approaches to dentify Novel Therapeutics for Addiction	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-004 07-I	May-2024	Not Specified
	Contact Name	Susan Wright, Ph.D.				
	Contact Telephone	301-402-6683				
	Contact Email	susan.wright@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-202	4 , 07-Sep-2024 , 05-Oct-2024 , 16-O	ct-2024 , 07-Jan-	-2025	
	Synopsis	The purpose of this Notice is to inform p in grant applications that will develop or relationships in ways that will rapidly ad- use disorder (SUD) drug discovery and in approaches in one or more of the follow 2) supercomputing/parallel computing, a	otential applicants to the National Ir utilize advanced computational app vance the development of new treat nprove health care. NIDA has a partic ing categories: 1) artificial intelligence and/or 3) quantum computing.	nstitute on Drug / roaches to descr ments, allow for cular interest in a ce, including mac	Abuse (NIDA) of N ibe complex drug targeted funding applications that in hine learning and	IDA's interest disease of substance nclude deep learning,
106007	Notice of Special Interest (NOSI): I	International Research Collaboration on	National Institute on Drug	NOT-DA- 21-064 07-I	May-2024	Not Specified
·				∠⊥ <sup>-</sup> ∪∪ <del>1</del>		Specified
	Contact Name	Steve Gust, Ph.D.				
		SUI-4U2-1118				
	Sponsor Website	<u>sgustænida.nin.gov</u>				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	024 , 05-Jun-2024 , 16-Jun-2024	4 , 07-Sep-2024			
	Synopsis	The purpo the United treatment newly for another c proposal t health sci	ose of this notice is to encourage d States. Applications examining t, recovery, and prevention of d med or well-established partner ountry. All NIH grant application takes advantage of unique resea ence.	e collaborative research applications g all areas of NIDA-supported resear lrug use, misuse, and addiction are e rships between investigators in a U.S ns for research to be conducted outs arch opportunities in other countrie	s that take advar ch addressing th encouraged. Proj 5based instituti side the United S s, speeds scientit	ntage of opportuni le causes, consequ ects may be condu ion and scientists v States must establi fic discovery, and a	ties outside of ences, ucted through vorking in sh that the advances U.S.
115450	Notice of Special Interest (NOSI): Enhancing HIV and Substance Use Jump Into Precision Medicine.	Pharmacos Disorder	genomic Approaches to (SUD) Treatment Strategies, A	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 24-001 07-I	May-2024	Not Specified
	Contact Name	Guifang L	ao, Ph.D.				
	Contact Telephone	301-827-5	5931				
	Contact Email	laog@nih	.gov				
	Sponsor Website						
	Program URL						
	Deadline Dates (ALL)	07-May-2 2025 <i>,</i> 07- Feb-2026	024 , 05-Jun-2024 , 16-Jun-2024 ·May-2025 , 05-Jun-2025 , 16-Ju , 07-May-2026	4 , 07-Sep-2024 , 05-Oct-2024 , 16-O In-2025 , 07-Sep-2025 , 05-Oct-2025	ct-2024 , 07-Jan , 16-Oct-2025 ,	-2025 , 05-Feb-202 07-Jan-2026 , 05-F	25 , 16-Feb- eb-2026 , 16-
	Synopsis	NIDA is in step in the	terested in receiving research p e science of Precision Medicine,	proposals focusing on studying pharr , in the path of personalized care for	nacogenomics ir HIV and drug at	n PLWH with SUD a ouse	is a crucial
123798	Notice of Special Interest (NOSI): and Policies Affecting People Who	Strategies DUse Drug	to Address Stigmatizing Beliefs <u>s</u>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 25-029 05	Jun-2024	Not Specified
	Contact Name Contact Telephone Contact Email	Julia Zur, 301-443-2 julia.zur@	PhD 2261 2nih.gov				
	Sponsor Website						

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Program URL <u>I</u>	Link to program URL				
	Synopsis t t	People who use drugs experience stigmanegative outcomes. Some common stigmuse is a personal choice, that people with and that people with SUD are dishonest and family members as well as through usel, such as through public policies that stigma, which occurs when they internal themselves. As a result, they often opt to	a from different sources and in a vari natizing beliefs directed toward peop h substance use disorders (SUD) can and immoral. These beliefs can man unpleasant encounters with healthca t criminalize people with SUD. Peopl ize stereotypes associated with subs o not disclose to other people that th	ety of contexts, a ble who use drug stop using drugs ifest through neg re providers. Stig e who use drugs tance use and di ney have SUD.	all of which are ass is include the notion if they have enou gative interactions gma also exists at f may also experient rect these beliefs t	ociated with on that drug gh willpower, with friends the structural ce self- toward
102988 <mark>N</mark>	lotice of Special Interest (NOSI): B entanyl Analogs: Signaling, Neuro	asic Research on Fentanyl and Synthetic biology, and Pharmacology	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-033 07-1	May-2024	Not Specified
	Contact Name	Pamela G. Fleming				
	Contact Telephone	301-480-1159				
	Contact Email	ofleming@nih.gov				
	Sponsor Website					
	Program URL <u>I</u>	Link to program URL				
	Deadline Dates (ALL) (	07-May-2024 , 05-Jun-2024 , 07-Sep-202	4			
	۲ Synopsis ر	This Notice informs potential applicants research on fentanyl and synthetic fenta cellular, signaling, and neurobiological m deaths due to overdose of fentanyl and f	to the National Institute on Drug Abo nyl analogs. Of particular interest is nechanisms underlying abuse potenti fentanyl analogs.	use (NIDA) about research that is f al, physical depe	a special interest ocused on elucida ndence, addiction	in basic ting chemical, liability and
103015 <u>S</u>	lotice of Special Interest (NOSI): Sy trategic Approaches to Counterac	ynthetic Psychoactive Drugs and t Their Deleterious Effects	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-028 07-I	May-2024	Not Specified
	Contact Name	Pamela G. Fleming				
	Contact Telephone	301-480-1159				
	Contact Email	ofleming@nih.gov				
	Sponsor Website					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Program URL Deadline Dates (ALL) Synopsis	Link to program URL 07-May-2024, 05-Jun-2024, 07-Sep-2024 This Notice informs potential applicants to the National Institute on Drug Abuse (NIDA) about a special interest in research on chemistry, pharmacology, biological targets and biochemical mechanisms that contribute to the effects of synthetic psychoactive substances.					
123707	RFA-DA-25-053 Harnessing Artifi to Discover Pharmacotherapeutics Clinical Trials Not Allowed)	icial Intelligence and Polypharmacology 6 for Substance Use Disorders (R41/R42	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 25-053 [Op App	Jun-2024 otional][LOI/Pre- o]	Not Specified	
	Contact Name Contact Telephone Contact Email Sponsor Website	Tam Nguyen, Ph.D. 301-451-1203 <u>tam.nguyen@nih.gov</u>					
	Program URL Deadline Dates (ALL)	Link to program URL 25-Jun-2024 [Optional][I OJ/Pre-App], 25	5-Iul-2024				
	Synopsis	This notice of funding opportunity (NOFO) encourages Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) proposing research projects directed towards commercialization to harness artificial intelligence (AI), including machine learning (ML), tools, and polypharmacology to identify pharmacotherapeutics with lower toxicity and higher efficacy to prevent or treat substance use disorders (SUDs).					
123702	RFA-DA-25-054 Harnessing Artifi to Discover Pharmacotherapeutics Clinical Trials Not Allowed)	icial Intelligence and Polypharmacology for Substance Use Disorders (R43/R44	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 25-054 [Op App	Jun-2024 htional][LOI/Pre- b]	Not Specified	
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Tam Nguyen, Ph.D. 301-451-1203 <u>tam.nguyen@nih.gov</u> <u>Link to program URL</u> 25-Jun-2024 [Optional][LOI/Pre-App], 25	5-Jul-2024				
	Synopsis This notice of funding opportunity (NOFO) encourages Small Business Innovation Research (SBIR) grant applications from						
SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
---------	--	---	--	--	---	---	--
		small bus intelligen toxicity a	iness concerns (SBCs) proposing ce (AI), including machine learn nd higher efficacy to prevent or	g research projects directed toward ing (ML), tools, and polypharmaco treat substance use disorders (SU	ds commercializa logy to identify p Ds).	ation to harness arti pharmacotherapeut	ficial ics with lower
111673	Notice of Special Interest (NOSI): I Neuroscience Branch in the Division	High Priori on of Neui	ty Areas in Integrative oscience and Behavior	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 22-058	7-May-2024	Not Specified
	Contact Name Contact Telephone Contact Email	Olivier Be 301-827- <u>Olivier.be</u>	rton, Ph.D. 7771 rton@nih.gov				
	Sponsor Website Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2025 , 05 Sep-2025	024 , 05-Jun-2024 , 12-Jun-2024 -Feb-2025 , 12-Feb-2025 , 16-Fe , 05-Oct-2025 , 12-Oct-2025 , 1	4 , 16-Jun-2024 , 07-Sep-2024 , 05- b-2025 , 07-May-2025 , 07-May-2 6-Oct-2025 , 07-Jan-2026	Oct-2024 , 12-0 025 , 05-Jun-202	ct-2024 , 16-Oct-20 5 , 12-Jun-2025 , 16	24 , 07-Jan- -Jun-2025 , 07-
	Synopsis	The missi human re across the on the ce the regula to, and/o interactio substance induced r	on of the Division of Neuroscier search aimed at identifying the e lifespan and to guide treatmen llular mechanisms and circuitry ation and plasticity of neurotrar r withdrawal from, addictive su ns and their modification by su e use and SUD, and 5) neuroim neuroinflammation.	nce and Behavior (DNB) is to facilit causes and consequences of subs- nt strategies. The Integrative Neur that underlie substance use and S asmitter and neuromoduatory syst bstances, 2) the study of substance bstance use and SUD 4) neuroendo nune modulation of the brain inclu-	ate and promote tance use and su oscience (IN) Bra UD. Research su ems induced by e-induced neuro ocrine modulatic uding the influer	e outstanding basic a obstance use disorde anch within DNB sup pported by the Brar chronic or intermitt toxicity, 3) neuron-go on of neural systems aces of neuroAIDS an	animal and ers (SUD) oports research och covers: 1) ent exposure glia is in relation to nd substance-
114003	Notice of Special Interest (NOSI): <sup>-</sup> Treating Addiction and Substance	Targeting Use Disor	Epigenetic Regulators for ders	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 24-004 08	3-Apr-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Sam Anar 301-435-2 sam.anar Link to pr	ogram URL				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) Jun-2 Synopsis regul	ay-2024 , 05-Jun-2024 , 12-Jun-202 08-Dec-2024 , 07-Jan-2025 , 05-Fe 025 , 16-Jun-2025 , 08-Aug-2025 , 0 ational Institute on Drug Abuse (N I interest in innovative research th stors and mechanisms for the treat	4 , 16-Jun-2024 , 08-Aug-2024 , 07-S eb-2025 , 12-Feb-2025 , 16-Feb-2025 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2 DA) is issuing this Notice of Special I at uses chemical and pharmacologic ment of addiction and substance us	5ep-2024 , 05-Oct 5 , 08-Apr-2025 , 0 2025 , 16-Oct-202 Interest (NOSI) to cal approaches to e disorders.	-2024 , 12-Oct-20 07-May-2025 , 05- 25 , 08-Dec-2025 , 9 inform applicants 9 identify and targe	24 , 16-Oct- Jun-2025 , 12- 07-Jan-2026 s about NIDA's et epigenetic
117589	Exploratory Clinical Neuroscience Resea (R61/R33 Basic Experimental Studies w	rch on Substance Use Disorders h Humans (BESH) Required)	National Institute on Drug Abuse/NIH/DHHS	PAR-23- 158 20	lun-2024	Not Specified
	Contact Name Vani Contact Telephone 301-4 Contact Email <u>vani.</u> Sponsor Website	'ariyadath, Ph.D. 43-3209 <u>ariyadath@nih.gov</u>				
	Program URL Link	o program URL				
	Deadline Dates (ALL) 20-Ju	-2024 , 09-Oct-2024 , 13-Mar-202	5 , 20-Jun-2025 , 09-Oct-2025 , 13-N	1ar-2026		
	This resea mech use. basic meet Synopsis prosp that phen towa Resea resea Gran	otice of Funding Opportunity (NOF rch applications that are explorator anisms underlying substance use d his NOFO is for basic science exper science studies involving human pa- the definition of basic research. Ty ectively assign human participants ssess biomedical or behavioral out omena without specific application d processes or products in mind sh rch on Substance Use Disorders (Re rch approach, applicants are encour (Parent RO1 Basic Experimental St	O) uses a R61/R33 Phased Innovation ry and developmental in nature and isorders (SUD), including fundament imental studies involving humans, re- inticipants." These studies fall within pes of studies that should be submit to conditions (i.e., experimentally m comes in humans for the purpose of towards processes or products in m ould submit under the companion N 61/R33 Clinical Trial Optional) PAR-2 raged to apply under a different act udies with Humans Required)").	on Award activity focus on underst cal circuitry and b eferred to in NOT the NIH definition the NIH definition tanipulate independ f understanding t ind. Studies conco NOFO - Explorato 23-157. For project ivity code (e.g., P	code to support of canding the neurol ehavior relevant t C-OD-18-212 as "proported of a clinical trial OFO include studie endent variables) a he fundamental as lucted with specifi ry Clinical Neuroso cts not requiring a A-20-184 "Researd	linical biological o substance rospective and also es that and studies spects of ic applications cience phased ch Project
117587	Exploratory Clinical Neuroscience Resea (R61/R33 Clinical Trial Optional)	rch on Substance Use Disorders	National Institute on Drug Abuse/NIH/DHHS	PAR-23- 157 20	lun-2024	Not Specified

Contact Name Vani Pariyadath, Ph.D.

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
	Contact Telephone	301-443-3	3209								
	Contact Email	vani.pariy	vadath@nih.gov								
	Sponsor Website										
	Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	20-Jun-20	 024 , 09-Oct-2024 , 13-Mar-2025 , 20-Jun-2025 , 09-Oct-2025 , 13-Mar-2026								
	Synopsis	research a mechanis use. Note science st on Substa a phased 183 "Rese	earch applications that are exploratory and developmental in nature and focus on understanding the neurobiological chanisms underlying substance use disorders (SUD), including fundamental circuitry and behavior relevant to substan 2. Note: For basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic ence studies involving human participants" please use the companion NOFO - Exploratory Clinical Neuroscience Resea Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH)) PAR-23-282 For projects not required research approach, applicants are encouraged to apply under a different funding activity code (e.g., PA-20-3 "Research Project Grant (Parent R01 Clinical Trial Required)").								
117405 👖	Notice of Special Interest (NOSI):	Liveraging	Glial Cells to Treat Addiction	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 24-006 07-I	May-2024	Not Specified				
	Contact Name	Shang-Yi	Anne Tsai, Ph.D.								
	Contact Telephone	301-827-5	5842								
	Contact Email	<u>stsai@nih</u>	1.gov								
	Sponsor Website										
	Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	07-May-2 2025 , 05- Oct-2025 05-Jun-20	2024 , 05-Jun-2024 , 12-Jun-2024 -Feb-2025 , 12-Feb-2025 , 16-Fe , 12-Oct-2025 , 16-Oct-2025 , 0 026 , 12-Jun-2026 , 16-Jun-2026	4 , 16-Jun-2024 , 07-Sep-2024 , 05-C 2b-2025 , 07-May-2025 , 05-Jun-202 7-Jan-2026 , 05-Feb-2026 , 12-Feb-2 , 07-Sep-2026	oct-2024 , 12-Oct 5 , 12-Jun-2025 , 2026 [LOI/Pre-Ap	-2024 , 16-Oct-202 16-Jun-2025 , 07-5 p], 16-Feb-2026 , (	24 , 07-Jan- Sep-2025 , 05- )7-May-2026 ,				
	Synopsis	This Notic develop s substance	ce of Special Interest (NOSI) enc trategies to mitigate Central Ne es or therapeutic avenues for ac	courages studies to exploit the uniquervous System (CNS) damage due to ddiction treatments.	e properties and acute or chronic	functions of glial exposure to addic	cells and tive				
107619	Notice of Special Interest (NOSI): Pharmacology of Addictive Drugs	Research i	n the Chemistry and	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 23-002 07-I	May-2024	Not Specified				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name	Kiran Von	nuri Ph D				
	Contact Telenhone	301-435-	1446				
	Contact Email	kiran ven	uri@nih.gov				
	Sponsor Website	<u>kirdii.ven</u>	<u>lune milgov</u>				
	Program URL	Link to pr	ogram URI				
	Deadline Dates (ALL)	07-May-2	2024 , 05-Jun-2024 , 16-Jun-2024	4,07-Sep-2024,12-Feb-2025			
	Synopsis	animal ar guide trea aspects o encompa synthetic determin agents, an overdose	ad human research aimed at ide atment strategies. As a compon f the chemistry and pharmacolo ssing research on substance use and biosynthetic methodologie ation of 3D structures of ligands nd 3) discover and advance the , emphasizing the pre-clinical st	entifying the causes and consequent ent of the Division, the Chemistry a ogy of addictive drugs. The Branch e disorders (SUD) and overdose des es, structure-activity relationships, s bound to biological targets, 2) des pre-clinical development of new pl ages of target identification throug	ces of drug addict and Pharmacology develops and over signed to: 1) elucio pharmacology and velop new recepto harmacotherapies sh hit-to-lead.	ion across the life Branch supports sees a broad port date mechanisms of toxicity of addict or type and subtyp for the treatment	span and to research on all folio of action, ive drugs, and ie specific : of SUD and
114048 <u>No</u>	otice of Special Interest (NOSI): scovery of Targets and Therape	<u>Chemopro</u> utics to Tr	iteomic Approaches for eat Substance Use Disorders	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 24-005 08-/	Apr-2024	Not Specified
	Contact Name	Sam Anar	nthan, Ph.D.				
	Contact Telephone	301-435-2	2199				
	Contact Email	<u>sam.anar</u>	<u>ithan@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2024 , 08 Jun-2025	2024 , 05-Jun-2024 , 12-Jun-2024 -Dec-2024 , 07-Jan-2025 , 05-Fe , 16-Jun-2025 , 08-Aug-2025 , 0	4 , 16-Jun-2024 , 08-Aug-2024 , 07- b-2025 , 12-Feb-2025 , 16-Feb-202 7-Sep-2025 , 05-Oct-2025 , 12-Oct	Sep-2024 , 05-Oct 5 , 08-Apr-2025 , ( -2025 , 16-Oct-202	:-2024 , 12-Oct-20 07-May-2025 , 05- 25 , 08-Dec-2025 ,	24 , 16-Oct- Jun-2025 , 12- 07-Jan-2026
	The purpose of this Notice is to inform potential applicants to the National Institute on Drug Abuse (NIDA) about a special Synopsis interest in supporting basic research on the application of chemoproteomic approaches for the discovery of targets and for development of drugs to treat addiction and substance use disorders.						
114151 <u>No</u>	otice of Special Interest (NOSI):	Chemsex a	and HIV: Prevalence,	National Institute on Drug	NOT-DA- 07-	May-2024	Not



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Medical/Psychosocial Consequent	ces, and Tr	eatment	Abuse/NIH/DHHS	24-002		Specified	
	Contact Name	Raul Man	dler, MD					
	Contact Telephone	240-281-0	)569					
	Contact Email	mandlerr	@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , Deadline Dates (ALL) 2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Ju Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026							24 , 07-Jan- j-Jun-2025 , 07-	
	Synopsis	The purpose of this notice is to support research on the epidemiology, medical/psychosocial impact, and preventive a therapeutic measures for chemsex in people with HIV and HIV-vulnerable populations including sexual minorities (SN lesbian, gay, bisexual.						
104639	NIDA Animal Genomics Program (	(U01 – Clin	ical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	PAR-21- 244 27	'-Jun-2024	Not Specified	
	Contact Name	Amy C. Lo	ossie, PhD					
	Contact Telephone	301-827-6	5092					
	Contact Email	lossieac@	omail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	27-Jun-20	)24 , 26-Jul-2024					
Deadline Dates (ALL) 27-Jun-2024 , 26-Jul-2024 The purpose of the NIDA Animal Genetics Program is to identify genetic, genomic, and molecular (epi)genetic variants tha underlie: 1. Phenotypes associated with addictive behaviors and/or vulnerability to distinct stages along the substance use disorder (SUD) trajectory (e.g. initial/acute use, escalation of use, acquisition of tolerance, dependence, uncontrolled use, abstinence and relapse or recovery); 2. Behaviors associated with SUD (e.g. impulsivity, novelty seeking, delayed discount and other genetically-associated phenotypes); and 3. Comorbidities that demonstrate genetic correlations with phenotype and behaviors linked with SUD (e.g. anxiety, stress, poor maternal care, social defeat, and other paradigms). Applications i examine any type of variant, including single nucleotide variants (SNVs), indels, large and small structural variants, and all types of mobile DNA. NIDA encourages applications that take genomics, multi-omics, and/or data-based approaches that integrate multi-level 'omics data, deligeate gene networks, and/or uncover the function of known or newly discovered								

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		genetic or the discov aspects or	r epigenetic variants. NIDA expe very of targets for intervention f SUD.	ects these studies to uncover novel and guide the development of indi	mechanisms vidualized the	that contribute to SU erapeutics to treat the	D and facilitate se different
105778	maging - Science Track Award fo Basic Experimental Studies with F	r Research Iumans Re	<u>Transition (I/START) (R03-</u> quired)	National Institute on Drug Abuse/NIH/DHHS	PAR-21- 309	07-May-2024	150,000 USD
	Contact Name	John Fedo	ota, PhD				
	Contact Telephone	301-402-0	0812				
	Contact Emai	john.fedo	ta@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	024 , 16-Jun-2024 , 07-Sep-202	4 , 16-Oct-2024 , 07-Jan-2025			
	Synopsis	investigat seeking to studies. T resources	ing Opportunity Announcemen fors to the area of neuroimaging b adopt neuroimaging methodo he RO3 is intended to support r s.	t (FOA) encourages Small Research g, including both newly independer logies in their research programs, t esearch projects that can be carrie	drant (RO3) ant investigato to enable the d out in a sho	rs and established inv conduct of small "pro rt period of time with	te the entry of estigators of of concept" limited
105780	maging - Science Track Award fo Clinical Trial Optional)	r Research	Transition (I/START) (R03-	National Institute on Drug Abuse/NIH/DHHS	PAR-21- 310	07-May-2024	150,000 USD
	Contact Name	John Fedo	ota, PhD				
	Contact Telephone	301-402-0	0812				
	Contact Emai	john.fedo	ta@mail.nih.gov				
	Sponsor Website	2					
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	024 , 16-Jun-2024 , 07-Sep-202	4 , 16-Oct-2024 , 07-Jan-2025			
	Synopsis	This Fund investigat investigat of concep	ing Opportunity Announcemen fors to the area of neuroimaging fors seeking to adopt neuroimag ot" studies. The R03 is intended	t (FOA) encourages Small Research g, including both newly independer ging methodologies in their researc to support research projects that c	Grant (R03) ht investigato h programs, an be carried	applications to facilita rs and established to enable the conduct out in a short period	te the entry of of small "proof of time with

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
		limited re	sources.					
115679 <u>(</u>	NIMHD Exploratory/Developmen Clinical Trial Optional)	tal Researd	<u>ch Grant Program (R21 -</u>	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-23- 111 0 <sup>-</sup>	7-May-2024	275,000 USD	
	Contact Name							
	Contact Telephone	301-402-	1366					
	Contact Email	GrantsInf	o@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2025 <i>,</i> 16	024 , 16-Jun-2024 , 07-Sep-202 -Oct-2025 , 07-Jan-2026 , 16-Fe	4 , 16-Oct-2024 , 07-Jan-2025 , 16-Fe b-2026 , 07-May-2026	eb-2025 , 07-N	1ay-2025 , 16-Jun-20	025 , 07-Sep-	
	Synopsis	NIMHD ir break nev directions U.S.	nvites applications to support sh w ground in the fields of minorit s or applications that can direct	ort-term exploratory or developmenty ty health and/or health disparities on ly contribute to improving minority h	ntal research p extend previo nealth and/or i	rojects that have th ous discoveries towa reducing health disp	e potential to ard new parities in the	
108296 <mark> </mark>	High-End Instrumentation (HEI) G Allowed)	irant Progr	am (S10 Clinical Trial Not	National Institutes of Health/DHHS	PAR-22- 079	3-Jun-2024	2,000,000 USD	
	Contact Name	Guanghu	(Jeff) Wang, PhD					
	Contact Telephone	301-435-	0772					
	Contact Email	HEI@mai	l.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	03-Jun-20	)24					
Deadline Dates (ALL) 03-Jun-2024 The High-End Instrumentation (HEI) Grant Program encourages applications from groups of NIH-supported investigators t purchase or upgrade a single item of high-end, specialized, commercially available instruments or integrated systems. The Synopsis minimum award is \$600,001. There is no maximum price limit for the instrument; however, the maximum award is \$2,000,000. Instruments supported include, but are not limited to, X-ray diffractometers, high throughput robotic screeni systems, mass spectrometers, nuclear magnetic resonance spectrometers, DNA and protein sequencers, biosensors, elect								

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		and light	microscopes, flow cytometers, a	and biomedical imagers.			
108298	Limited Competition: Basic Instrur Clinical Trial Not Allowed)	nentation	Grant (BIG) Program (S10	National Institutes of Health/DHHS	PAR-22- 081	Jun-2024	250,000 USD
	Contact Name	C. Ashley	Barnes, PhD				
	Contact Telephone	301-435-0	)783				
	Contact Email	ashley.ba	rnes@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	03-Jun-20	)24				
	Synopsis	purchase BIG Progr preceding June 1, 20 2020-202 There is n include, b	a single high-priced, specialized am is limited to institutions that g 3 Federal fiscal years (FY). Use 022, consider S10 funding in FYs 2; for application due date of Ju to maximum price limit for the in but are not limited to, basic cell s	, commercially available instrument have not received S10 instrumenta the following to determine applicab 2019-2021; for application due date ne 3, 2024, consider S10 funding in nstrument; however, the maximum corters, confocal microscopes, ultrar	or an integrate tion funding of le funding peric of June 1, 2023 FYs 2021-2023. award is \$250,0 nicrotomes, gel	d instrumentation \$250,001 or greate ds: for application 6, consider S10 fun The minimum awa 00. Instruments su imagers, or compu	system. The r in any of the due date of ding in FYs rd is \$25,000. pported iter systems.
108564	RFA-MH-22-145 BRAIN Initiative Related to the BRAIN Initiative (RC	e: Standard 1 Clinical	<u>ds to Define Experiments</u> Trial Not Allowed)	National Institutes of Health/DHHS	RFA-MH- 22-145 [Or App	May-2024 otional][LOI/Pre- o]	Not Specified
	Contact Name	Ming Zha	n, Ph.D.				
	Contact Telephone	301-827-3	3678				
	Contact Email	ming.zhar	n@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	15-May-2	024 [Optional][LOI/Pre-App], 14	l-Jun-2024			
	Synopsis	This Fund as part of	ing Opportunity Announcement the BRAIN Initiative. It is expect	: (FOA) aims to develop standards th red that applications will solicit com	at describe exp munity input at	erimental protocol all stages of the pr	s conducted ocess. It is

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		recommended that the first step of sta experimental community in order to er groups. The developed standard is expe	ndard development will involve sharin nsure that the developing standard wil ected to be broadly disseminated for u	g data between l encompass the use and widely a	different key grou data collection ef vailable.	ips in the forts of those
109721	International Research Ethics Edu Award (R25 Clinical Trial Not Allow	ication and Curriculum Development wed)	National Institutes of Health/DHHS	PAR-22- 118 06	lun-2024	1,150,000 USD
	Contact Name Contact Telephone Contact Email	Barbara Sina, Ph.D. 301-402-9467 <u>sinab@mail.nih.gov</u>				
	Sponsor Website Program URL Deadline Dates (ALL)	Link to program URL 06-Jun-2024				
	Synopsis	The NIH Research Education Program ( overarching goal of this R25 program is biomedical, behavioral and clinical rese educational activities that foster a bett implications.) To accomplish the stated focus on: Courses for Skills Development The Fogarty International Bioethics Tra- and middle-income countries (LMICs) the support innovative LMIC master's level culturally appropriate foundational rese- research or practicum experiences, and should equip scientists, health profession principles, processes and policies related competencies needed to provide resear- researchers, their academic or research the application of research ethics princi-	R25) supports research education active to support "the ethics of" educational earch and its implications. (The overarch er understanding of "the ethics of" bio over-arching goal, this FOA will support in Mentoring Activities Curriculum or N ining Program aims to increase the num hat can provide advanced education in research ethics education programs p earch ethics curriculum, research ethics d effective mentoring approaches. Edu onals and academics in these countries ed to international research. Programs rch ethics education, ethical review lear institutions, governments and interna- iples.	vities in the miss l activities that f ching goal of this omedical, behavi ort creative educ Methods Develo mber of researc n international re- croposing integra cs career skills de cation programs s with in-depth l should be desig adership and ex- ational health re-	ion areas of the N oster a better und R25 program is to oral and clinical re ational activities v pment Research E n intensive institut esearch ethics. Thi ited activities to d evelopment course supported by this knowledge of the ned to strengthen pert consultation to search organizatio	IH. The erstanding of o support esearch and it with a primary xperiences tions in low- s FOA will evelop es, ethics s initiative ethical the critical to LMIC ons to enhan



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Nama						
	Sponsor website	California and					
	Program URL	LINK to pr	Ogram URL				
	Deadline Dates (ALL)	01-Jun-20	J24 , 01-Jun-2025				
	Synopsis	to improv announce Down syr	Nvestigation of Co-occurring co ve health and quality-of-life for i es NIH's continued support for a ndrome research objectives rela	nditions across the Lifespan to Unde individuals with Down syndrome (DS idministrative supplement applicatio ted to the NIH INCLUDE Project as lis	rstand Down s ). This Notice c ns for actively ted below.	f Special Interest (N funded projects to i	I Project seeks IOSI) meet NIH
	RFA-NS-23-028 HEAL Initiative:	Interdiscip	olinary Team Science to		REA-NS- 11	-May-2024	Not
117962	Uncover the Mechanisms of Pain I Trial Optional)	Relief by N	Medical Devices (RM1 Clinical	National Institutes of Health/DHHS	23-028 [O Ap	ptional][LOI/Pre- p]	Specified
	Contact Name	Eric Huda	k, Ph.D.				
	Contact Telephone	301-496-3	1779				
	Contact Email	NINDS-De	evices@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	11-May-2	024 [Optional][LOI/Pre-App], 10	0-Jun-2024 , 10-May-2025 [Optional]	[LOI/Pre-App],	09-Jun-2025	
	Synopsis	This fund investigat outcomes develop r objective	ing opportunity announcement te the mechanism of action of p s for FDA-approved or -cleared t new principles and methods for s that will produce major advan	(FOA) is designed to support interdis ain relief by medical devices with the technologies. Teams must leverage a experimentation, analysis, and inter- ices in the understanding of pain relie	sciplinary resea e overall goal o ppropriate mu pretation. Tear ef by medical o	rch teams of multip f optimizing therap Iti-disciplinary expe ns are encouraged evices.	ole PDs/PIs to eutic rtise to to consider
119320	RFA-MH-24-280 BRAIN Initiative Tools to Probe Cell-Specific and Ci Clinical Trial Not Allowed)	: Develop rcuit-Spec	ment and Validation of Novel cific Processes in the Brain (R01	National Institutes of Health/DHHS	RFA-MH- 24-280 Ap	-May-2024 ptional][LOI/Pre- p]	Not Specified
	Contact Name	Eunyoun	g Kim, Ph.D.				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Contact Telephone	301-827-3	3420							
	Contact Email	eunyoung	g.kim@nih.gov							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	08-May-2 [Optional App], 08-I	08-May-2024 [Optional][LOI/Pre-App], 07-Jun-2024 , 08-Jan-2025 [Optional][LOI/Pre-App], 07-Feb-2025 , 07-Sep-2025 [Optional][LOI/Pre-App], 07-Oct-2025 , 09-May-2026 [Optional][LOI/Pre-App], 08-Jun-2026 , 09-Jan-2027 [Optional][LOI/Pre- App], 08-Feb-2027							
The purpose of this Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative is to encour research that will develop and validate novel tools to facilitate the detailed analysis of complex circuits and provide into cellular interactions that underlie brain function. The new tools and technologies should inform and/or exploit and/or circuit-level specificity. Plans for validating the utility of the tool/technology will be an essential feature of a application. The development of new genetic and non-genetic tools for delivering genes, proteins and chemicals to interest or approaches that are expected to target specific cell types and/or circuits in the nervous system with gre precision and sensitivity than currently established methods are encouraged. Tools that can be used in a number of species/model organisms rather than those restricted to a single species are highly desired. Applications that provi- approaches that break through existing technical barriers to substantially improve current canabilities are highly es-							ncourage vide insights ploit cell-type of a successful s to cells of greater er of rovide y encouraged.			
108297	Shared Instrumentation Grant (SI Allowed)	<u>G) Progran</u>	n (S10 Clinical Trial Not	National Institutes of Health/DHHS	PAR-22- 080	lun-2024	750,000 USD			
	Contact Name	Guanghu	(Jeff) Wang, PhD							
	Contact Telephone	301-435-0	)772							
	Contact Email	<u>SIG@mail</u>	.nih.gov							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	03-Jun-20	24							
	Synopsis	The Share or upgrad system. T is \$750,00 magnetic cytomete	ed Instrument Grant (SIG) Progr le a single item of high-priced, s he minimum award is \$50,000. 00. Instruments supported inclu resonance spectrometers, DNA rs, and biomedical imagers.	am encourages applications from gropecialized, commercially available in There is no maximum price limit for Ide, but are not limited to: X-ray diffect and protein sequencers, biosensors	oups of NIH-sup Instruments or inf the instrument; ractometers, ma s, electron and lig	ported investigato tegrated instrumen however, the max ss spectrometers, ght microscopes, f	rs to purchase ntation imum award nuclear ow			

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
117915	<u>RFA-NS-23-025 BRAIN Initiative: E</u> <u>Circuit Programs - eTeamBCP (U01 (</u>	Exploratory Team-Research BRAIN Clinical Trials Optional)	National Institutes of Health/DHHS	RFA-NS- [C 23-025 A	-May-2024 ptional][LOI/Pre- pp]	Not Specified
	Contact Name K	Caren K David, Ph.D.				
	Contact Telephone 3	01-496-9964				
	Contact Email <u>B</u>	BRAINCircuits@nih.gov				
	Sponsor Website					
	Program URL Li	ink to program URL				
	Deadline Dates (ALL) 1	.5-May-2024 [Optional][LOI/Pre-App], 14	4-Jun-2024			
	Synopsis e a a b a a a a s i s	inis funding opportunity announcement pross boundaries of interdisciplinary colla behavioral or neural system. Applications ackled by a synergistic team-based appr idvances. These studies at the explorato heoretical frameworks in preparation fo fargetedBCP (R01) or the multi-compone enable a large-scale analysis of neural system ethologically relevant behavior. Toward expertise, and to integrate experimental by incorporating rich information on cell- inalyses of an ethologically relevant behavior to im for a mechanistic understanding of the uch as those for large-scale recording, m	aboration to elucidate the contributions aboration to elucidate the contributions are encouraged to propose adventu- roach and have the potential to be tra- ry stage are intended for the develop or a future competition for larger-sca- ent, Team-Research BRAIN Circuit Pro- stems and circuits within the context rd this end, teams are expected to as with computational and theoretical -types, on circuit functionality and co- avior of an organism or a well-define he circuits of the central nervous sys- nanipulation, and analysis of neural co-	of three or mo ons of dynami- urous and chal ansformative a oment of expe le or extended ograms (U19). and during th semble and le approaches. To onnectivity, in a neural syste tem (CNS) by a circuits across	re (up to six) PDs/P c circuit activity to a lenging goals that c and/or to enable sig rimental capabilitie efforts, including t The overall goal of e simultaneous me verage multi-discip eams are expected conjunction with so m. Teams are also e applying cutting-edg multiple regions of	Is that seek to a specific an only be mificant s and/or he BRAIN this FOA is to asurement of linary to bridge fields phisticated expected to ge methods the CNS.
115197	In-Depth Phenotyping and Research Mouse Strains Exhibiting Embryonic (R01 Clinical Trial Not Allowed)	n Using IMPC-Generated Knockout c or Perinatal Lethality or Subviability	National Institutes of Health/DHHS	PAR-23- 074 05	j-Jun-2024	2,499,995 USD
	Contact Name M	Mahua Mukhopadhyay, PhD				
	Contact Telephone 3	01-435-6886				

Contact Email <u>mukhopam@mail.nih.gov</u>

Sponsor Website

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Program URL Deadline Dates (ALL)	<u>Link to pr</u> 05-Jun-20	ogram URL )24 , 05-Oct-2024 , 05-Jun-2025	, 05-Oct-2025				
	Synopsis Syn							
113466	Notice of Special Interest (NOSI): Research on Interoception Circuit	<u>BRAIN Init</u> <u>s</u>	iative: Notice of Support for	National Institutes of Health/DHHS	NOT-AT- 23-003 14-	Jun-2024	Not Specified	
	Contact Name							
	Contact Telephone							
	Contact Email							
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	14-Jun-20	)24 , 28-Jun-2024 , 13-Sep-2024	, 21-Sep-2024 , 02-Oct-2024				
	Synopsis	The purpo targeting	ose of this announcement is to in interoceptive processes and cir	notify the research community that cuits, as appropriate to the goals an	NIH welcomes B d requirements	RAIN Initiative app of specific BRAIN Ir	lications nitiative FOAs.	
116697	RFA-OD-23-013 Understanding Women (R21 Clinical Trial Optiona	<u>Chronic Co al)</u>	onditions Understudied Among	National Institutes of Health/DHHS	RFA-OD- 23-013 20- [Op App	May-2024 otional][LOI/Pre- o]	275,000 USD	
	Contact Name	Sarah Ter	nkin, M.D.					
	Contact Telephone	301-402-2	2168					
	Contact Email	<u>temkinsm</u>	n@mail.nih.gov					
	Sponsor Website							
			NIH Euroding Opportu	nitios Duo: Juno 2024				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Program URL	Link to program URL						
	Deadline Dates (ALL)	20-May-2024 [Optional][LOI/Pre-App], 20	0-Jun-2024					
	Synopsis	The purpose of this Notice of Funding Op among women and/or that disproportion underreported in biomedical Research sh Health Research "Advancing Science for t using funds that have been made availab partnering Institutes and Centers across	oportunity (NOFO) is to invite R21 app nately affect populations of women w nould align with Goal 1 of the 2019-20 the Health of Women." The awards u ole through the Office of Research on NIH.	olications on ch vho are underst 023 Trans-NIH S Inder this NOFC Women's Heal	ronic conditions ur :udied, underrepre: 5trategic Plan for W )will be administere th (ORWH) and the	derstudied sented, and 'omen's ed by NIH ICs scientific		
110282	RFA-OD-22-007 INvestigation of Lifespan to Understand Down syn (R21 Clinical Trial Not Allowed)	f Co-occurring conditions across the dromE (INCLUDE) Clinical Trial Readiness	National Institutes of Health/DHHS	RFA-OD- 22-007	Jun-2024 otional][LOI/Pre- o]	275,000 USD		
	Contact Name	Laurie M. Ryan, Ph.D.						
	Contact Telephone	301.496.9350						
	Contact Email	ryanl@mail.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	01-Jun-2024 [Optional][LOI/Pre-App], 01	-Jul-2024					
	The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seek to improve health and quality-of-life for individuals with Down syndrome. This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in Down syndrome. This initiative seeks applications that are intended to facilitate Down syndrome research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials for Down syndrome and its co-occurring conditions, and to increase their likelihood of success through development and testing of biomarkers and clinical outcome assessment measures, development and testing of novel trial methods and recruitment strategies, or by defining the presentation and course of the co-occurring conditions in individuals with Down syndrome to enable the design of future clinical trials.							
110290	RFA-OD-22-010 Clinical Trials De in Individuals with Down syndrom Clinical Trial Required)	evelopment for Co-Occurring Conditions ne: Phased Awards for INCLUDE (R61/R33	National Institutes of Health/DHHS	RFA-OD- 22-010 01- [Or Ap	Jun-2024 ptional][LOI/Pre- o]	Not Specified		

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contract Name		Duran Dh D						
	Contact Name		Ryan, Ph.D.						
		501.490.5							
	Contact Endin Sponsor Website	<u>ryani@nia</u>							
	Program LIBI	Link to pr	ogram LIRI						
	Deadline Dates (ALL)	01-lun-20	09141110112 124 [Ontional][101/Pre-Ann] 01:	-101-2024					
	Synopsis	The NIH II to improv encourag trials to tr should be years. Thi by possibl exceed fiv	The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks o improve health and quality-of-life for individuals with Down syndrome. This Funding Opportunity Announcement (FOA) incourages Exploratory/Developmental Phased Innovation (R61/R33) grant applications to support development of clinical rials to treat critical and co-occurring health conditions in individuals with Down syndrome. The proposed research aims hould be milestone-driven. The total project period for an application submitted in response to this FOA may not exceed fiv rears. This FOA provides support for up to two years (R61 phase) for preliminary/developmental/planning studies, followed by possible transition to clinical trial support (R33) of up to three years, although the total duration of the award may not exceed five years. This FOA requires measurable R61 milestones.						
110376 <u>S</u>	FA-OD-22-008 Small Research haring of Down syndrome-relate R03 Clinical Trial Not Allowed)	<u>Grants for</u> d Researcl	Analysis, Curation, and/or h Data for the INCLUDE Project	National Institutes of Health/DHHS	RFA-OD- 22-008	)1-Jun-2024 Optional][LOI/Pre- \pp]	200,000 USD		
	Contact Name	Huiqing Li	i, PhD						
	Contact Telephone	301-435-0	0554						
	Contact Email	<u>Huiqing.L</u> i	i@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	01-Jun-20	024 [Optional][LOI/Pre-App], 01	-Jul-2024					
The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project to improve health and quality-of-life for individuals with Down syndrome. This FOA is intended to support meritorious survey research projects focused on analyses of genomics other -omics, clinical and phenotypic datasets related to Down syndrome research, with an emphasis on elucidating the underlying etiologies of risk and resiliencies to co-occurring health condit Development of approaches, tools, or algorithms appropriate for analyzing data relevant to Down syndrome and facilita data sharing within the research community through the INCLUDE Data Hub may also be proposed.									

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
113526	INvestigation of Co-occurring con Down syndromE (INCLUDE) Clinica Independent Clinical Trial Not Allo	ditions across the Lifespan to Understand al Research Short Course (R25 owed)	National Institutes of Health/DHHS	PAR-22- 195 27-	Jun-2024	2,000,000 USD		
	Contact Name Contact Telephone Contact Email	Cara Finley, M.P.H. 202-557-4354 <u>cara.finley@nih.gov</u>						
	Sponsor Website Program URL Deadline Dates (ALL)	Link to program URL 27-Jun-2024 , 27-Jun-2025						
	Synopsis Synopsis The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project see to improve health and quality-of-life for individuals with Down syndrome (DS). As part of the INCLUDE Project, NIH is interested in expanding and diversifying the skilled DS clinical research workforce. The intent of this Funding Opportunity Announcement (FOA) is to encourage applications that develop creative and innovative short courses to train the next generation of DS researchers in state-of-the-art clinical research skills that will improve the understanding of the co-occurr clinical features in DS and support development of new treatments for health conditions experienced by those with DS.							
119045	<u>RFA-HG-23-017 Investigator-Init</u> Equity (R01 Clinical Trial Optional)	tiated Research in Genomics and Health )	National Institutes of Health/DHHS	RFA-HG- 23-017 08- [Or Ap	Jun-2024 ptional][LOI/Pre- p]	2,500,000 USD		
	Contact Name	Lucia Hindorff, Ph.D.						
	Contact Telephone	240-271-1509						
	Contact Email	hindorffl@mail.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	08-Jun-2024 [Optional][LOI/Pre-App], 08	-Jul-2024 , 08-Jun-2025 [Optional][L0	DI/Pre-App], 08	-Jul-2025			
	The purpose of this initiative is to support investigator-initiated research in genomics and health equity, with the ultimate goal of developing approaches, generating and disseminating data, and implementing metrics or interventions that will advance the equitable use of genomics to improve health in U.S. populations. Awardees will conduct innovative and generalizable research in genomics and health equity spanning across genomic research areas and will incorporate a plan fo enhancing diverse perspectives. Applications supporting New or Early Stage Investigators from diverse backgrounds,							

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
		including described (NOFO) re not be rev	those from groups traditionally I in the NIH Notice of Interest in equires a Plan for Enhancing Div viewed.	underrepresented in the biomedica Diversity (NOT-OD-20-031), are enc erse Perspectives (PEDP) as part of t	l, behavioral, a ouraged. This N he application.	nd clinical research Iotice of Funding O Applications witho	workforce, as pportunity ut a PEDP will	
117935	RFA-NS-23-024 BRAIN Initiative TargetedBCP (R01 Clinical Trial No	: Targeted ot Allowed	BRAIN Circuits Projects- )	National Institutes of Health/DHHS	RFA-NS- 23-024 [O Ap	-May-2024 ptional][LOI/Pre- p]	Not Specified	
	Contact Name	Karen K D	oavid, PhD					
	Contact Telephone	301-496-9	9964					
	Contact Email	BRAINCire	cuits@NIH.GOV					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	29-May-2	024 [Optional][LOI/Pre-App], 28	3-Jun-2024 , 02-Sep-2024 [Optional]	LOI/Pre-App],	02-Oct-2024		
	Synopsis	This FOA solicits applications for research projects that seek to understand how circuit activity gives rise to mental experience and behavior using innovative, methodologically-integrated approaches. The goal is to support adventurous projects that car realize a potentially transformative outcome within 5 years. Applications are expected to address circuit function in the context of specific behaviors or neural systems, such as sensation, perception, attention, reasoning, intention, decision- making, emotion, navigation, communication, or homeostasis. Projects should link theory, data analysis, and/or computational approaches to experimental design and should produce predictive models (conceptual or quantitative). Projects should aim to improve the understanding of circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating dynamic patterns of neural activity. Diverse species or experimental systems and a cross-species/comparative approach are welcome and should be chosen based on their power to address the specific question at hand and to reveal generalizable and fundamental neuroscience principles.						
117936	<u>RFA-NS-23-023 BRAIN Initiative</u> <u>Projects – TargetedBCPP (R34 Clir</u>	: Targeted Nical Trials	BRAIN Circuits Planning Not Allowed)	National Institutes of Health/DHHS	RFA-NS- 23-023 Ap	-May-2024 ptional][LOI/Pre- p]	450,000 USD	
	Contact Name	Karen K D	avid, PhD					
	Contact Telephone	301-496-9	9964					
	Contact Email	BRAINCire	cuits@NIH.GOV					

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	29-May-20		3-Jun-2024 , 02-Sep-2024 [Optional]	[LOI/Pre-App], (	02-Oct-2024		
	This R34 FOA solicits applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying results that, if successful, would support, enable, and/or lay the groundwork for a potential, Synopsis subsequent Targeted BRAIN Circuits Projects - TargetedBCP R01, as described in the companion FOA (RFA-NS-23-024). Applications should be adventurous, exploratory research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior.							
117668	<u>RFA-MH-23-270 BRAIN Initiative</u> Initiative Data (R01 Clinical Trial N	e: Integration Not Allowed	on and Analysis of BRAIN ]]	National Institutes of Health/DHHS	RFA-MH- 23-270 Ap	-May-2024 otional][LOI/Pre- p]	Not Specified	
	Contact Name	Ming Zhan	n, Ph.D.					
	Contact Telephone	301-827-3	678					
	Contact Email	ming.zhan	@nih.gov					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	08-May-20	024 [Optional][LOI/Pre-App], 07	7-Jun-2024				
This Funding Opportunity Announcement (FOA) solicits applications to develop informatics tools for analyzing, visual and integrating data related to the BRAIN Initiative or to enhance our understanding of the brain. As part of program building the informatics infrastructure for the BRAIN Initiative, the FOA supports several different, but related activit These include modifying existing analysis and visualization tools to deal with BRAIN Initiative data and integrating dif types of BRAIN Initiative datasets. Proposing the development of new tools to deal with BRAIN Initiative data is also permitted. The tools supported under this FOA will make use of relevant data standards and will be built so that they integrated into the data repositories, both of which are created in awards under the other FOAs of the BRAIN initiati informatics program. The tools must be user-friendly in accessing and analyzing data from appropriate data archives should analyze/visualize data without requiring users to download data. The tools should also allow data to be comb								
114889	Notice of Special Interest (NOSI): Archive, Informatics Tools and Da Quantification and Synchronizatio	BRAIN Initia ta Standarc on (BBQS)	ative: Developing Data ds for Brain Behavior	National Institutes of Health/DHHS	NOT-MH- 23-115 07	-Jun-2024	Not Specified	
			NIH Funding Opportur	nities Due: June 2024			224	

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name	Ming Zha	n, Ph.D.				
	Contact Telephone	(301) 827	-3678				
	Contact Email	ming.zhai	<u>n@nih.gov</u>				
	Sponsor Website						
	Program URL	<u>Link to pr</u>	ogram URL				
	Deadline Dates (ALL)	07-Jun-20	24 , 14-Jun-2024				
	Synopsis	The purpo infrastruc through A archive(s) visualizing system; a	ose of this Notice of Special Inte ture for the Brain Behavior Qua dvancing Innovative Neurotech to store and manage BBQS-rela g and integrating BBQS-related o nd c) establishment of data star	rrest (NOSI) is to encourage new app intification and Synchronization (BBC inologies® (BRAIN) Initiative. Specific evant data; b) development of comp data, and for predicting and modelin indards or ontologies that support the	lications for dev QS) research pro- cally, the NOSI su utational tools o g the complex d e BBQS-related s	eloping informatic gram of the Brain upports a) creation or software for ana ynamics of the bra tudies.	s Research of data lyzing, ain-behavior
114327	Research Infrastructure Developm (R61/R33 - Clinical Trial Optional)	<u>ent for In</u>	terdisciplinary Aging Studies	National Institutes of Health/DHHS	PAR-23- 053 03-J	lun-2024	2,499,995 USD
	Contact Name	Dr. Sanoj	Suneja				
	Contact Telephone	301-402-7	7710				
	Contact Email	sunejas@	mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	03-Jun-20	24 , 04-Oct-2024 , 02-Jun-2025	, 03-Oct-2025			
	Synopsis	This Fund that will a utilizes NI support fo this award interdisci	ing Opportunity Announcement dvance the science of aging in s H's R61/R33 Exploratory/Develor initial developmental activitie d, investigators will endeavor to plinary aging research questions	t (FOA) invites applications that prop specific areas requiring interdiscipling opmental Phased Award activity cod es. The R33 phase provides up to 3 ye develop a sustainable research infra s.	oose to develop i ary partnerships le. The R61 phas ears of support f astructure to sup	novel research infi or collaborations. e provides up to 2 for expanded activ oport projects that	astructure This FOA years of ities. Through address key
114328	Advanced-Stage Development and for Interdisciplinary Aging Studies	d Utilizatio (R33 Clini	n of Research Infrastructure cal Trial Optional)	National Institutes of Health/DHHS	PAR-23- 054 03-J	un-2024	2,499,995 USD

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
	Contact Name	Dr. Sanoj	Suneja						
	Contact Telephone	301-402-7	7710						
	Contact Email	<u>sunejas@</u>	<u>mail.nih.gov</u>						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	03-Jun-20	024 , 04-Oct-2024 , 02-Jun-2025	, 03-Oct-2025					
	Synopsis	This Fund and utiliza partnersh support fo or non-NI infrastruc	d utilization of novel research infrastructure to advance the science of aging in specific areas requiring interdisciplinary rtnerships or collaborations. This FOA utilizes NIH's R33 Exploratory/Developmental Grants Phase II activity code to provide oport for expanded activities. Applicants are expected to have an existing research infrastructure developed with other NIH non-NIH support. Through this award, investigators will endeavor to develop a mature and sustainable research rastructure to support projects that address key interdisciplinary aging research questions.						
121493	RFA-EY-23-001 BRAIN Initiative: for Recording and Modulation in t Not Allowed)	New Cond he Nervou	cepts and Early-Stage Research us System (R21) (Clinical Trial	National Institutes of Health/DHHS RFA-EY- 23-001 18-	Jun-2024	400,000 USD			
	Contact Name	Martha Fl	anders, PhD						
	Contact Telephone	301-827-5	5191						
	Contact Email	BRAIN-FO	As@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	18-Jun-20	024 , 17-Jun-2025 , 15-Jun-2026						
	Synopsis	This NOFC stage of d aim to inc precision range of r genetic to manipulat Applicatio	D seeks applications for unique levelopment, including new and crease recording or modulation and selectivity of recording or r modalities are appropriate inclu pols. Invasive or non-invasive ap tion of neural activity, and that ons are encouraged from any qu	and innovative recording and/or modulation techno I untested ideas that are in the initial stages of conc capabilities by many orders of magnitude, while oth nodulation (also referred to as stimulation, perturba ding acoustic, chemical, electrical, magnetic, and op proaches are sought that will enable large-scale rec would ultimately be compatible with experiments in nalified individual, including chemists, physicists, eng	logies that are in the eptualization. Some ers may aim to implation, or manipulat stical, as well as the ording and/or precent humans or behaving gineers, theoreticia	he earliest e projects may prove the ion). A wide use of ise ing animals. ns,			

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
		materials Enhancin evaluatio	scientists, and others from field g Diverse Perspectives (PEDP), v n. Applications that fail to inclu	ds not typically involved with neuros vhich will be assessed as part of the de a PEDP will be considered incomp	cience research. scientific and te plete and will be	This NOFO requir chnical peer reviev withdrawn.	es a Plan for w	
117410	NIH Science Education Partnershi Allowed)	<u>p Award (S</u>	EPA) (R25 - Clinical Trial Not	National Institutes of Health/DHHS	PAR-23- 137 07-	Jun-2024	1,250,000 USD	
	Contact Name	Tony Bec	۲, Ph.D.					
	Contact Telephone	301-480-4	4623					
	Contact Email	<u>beckl@m</u>	ail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-Jun-20	024 , 06-Jun-2025					
	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this NOFO will support educational activities was a primary focus on: Courses for Skills Development Research Experiences Mentoring Activities Curriculum or Methods Development Outreach							
121099	RFA-HG-23-002 Broadening Op and Data Science Education (UE5	portunities – Clinical 1	<u>s for Computational Genomics</u> Trial Not Allowed)	National Institutes of Health/DHHS	RFA-HG- 23-002 10-	Jun-2024	Not Specified	
	Contact Name	Shurjo K.	Sen, Ph.D.					
	Contact Telephone	301-827-7	7028					
	Contact Email	<u>sensh@m</u>	ail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	10-Jun-20	)24					
	Synopsis	The NIH F overarchi backgrou	Research Education Program (UB ng goal of this U35 program is t nds, including those from group	E5) supports research education acti o support educational activities that is underrepresented in the biomedic	vities in the miss encourage indiv al and behavior	sion areas of the N viduals from divers al sciences, to purs	IIH. The se sue further	

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	------------------	--------------	----------------	---------------	-------------------

studies or careers in research. To accomplish the stated over-arching goal, this NOFO will support educational activities with a primary focus on: Curriculum or Methods Development The NIH Research Education Program (UE5) supports research education activities in the mission areas of the NIH. The overarching goal of this UE5 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in computational genomics and data science research. To accomplish the stated over-arching goal, this funding opportunity will support creative educational activities with a primary focus on: Curriculum or Methods Development Specifically, this UE5 program will support faculty members at institutions which have a documented historical and current mission to educate students from any of the populations that have been identified as underrepresented in biomedical research as defined by the National Science Foundation NSF, see http://www.nsf.gov/statistics/wmpd/ or have a documented historical record of recruiting, training and/or educating, and graduating underrepresented students as defined by NSF (see above), to develop undergraduate and master's degreelevel educational content in data science and computational genomics. Content developed will be expected to leverage the resources of NIH cloud computing platforms such as NHGRI'S AnVIL and the All of Us Researcher Workbench. This UE5 funding opportunity is a parallel effort to the recently established Educational Hub for Enhancing Diversity in Computational Genomics and Data Science (hereafter called the CGDS Hub) described in detail in RFA-HG-22-002. Awardees of this funding opportunity (hereafter referred to as the CGDS Sites) are expected to make use of educational support resources developed by the CGDS Hub, and the CGDS Hub awardee will provide educational and hands-on research training and resources in CGDS for the future workforce through the establishment of lasting partnerships with the Sites, facilitate faculty development and student educational and research training at the undergraduate and master's degree levels.

109253	9253 <u>RFA-NS-22-049 BRAIN Initiative Connectivity across Scales (BRAIN</u> 9253 <u>CONNECTS): Specialized Projects for Scalable Technologies (U01 Clinical</u> <u>Trial Not Allowed)</u>		National Institutes of Health/DHHS	RFA-NS- 22-049	13-Jun-2024 [Optional][LOI/Pre- App]	Not Specified
	Contact Name	Edmund Talley				
	Contact Telephone	301-496-1917				
	Contact Email	BRAIN-CONNECTS-Inquiries@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	13-Jun-2024 [Optional][LOI/Pre-App], 13-	Jul-2024			
	Synopsis	: (FOA) supports Specialized Projects connectivity, with an emphasis on h nitted, if their use is well justified an	to develop uman, non- d the goal is	current or emerging tec human primate (NHP), a s test and validate approx	hnologies to nd mouse. aches that	

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		can be ge integratio precise, a develop d companio and poter Specialize aimed at d	neralized across species. Applic n, dissemination, and interpret nd more cost-effective generati istinct capabilities and compete In FOAs, with aims of further de Intially risky approaches. Funded d Projects from this FOA, and C developing the capabilities to ge	ations may address any aspect(s) of data collection, ation of brain connectivity and associated data pipe on and interpretation of brain-wide wiring diagrams encies that may be expected to complement Compre- veloping and optimizing current technologies, or pro- projects will be integrated into the BRAIN CONNEC omprehensive Centers from its companion announce enerate wiring diagrams that can span entire brains	reconstruction, an lines, to enable fas s. Proposals are en ehensive Centers s oposing entirely ne TS Network, consis cements, as a coord across multiple sca	alysis, ter, more couraged to olicited by the ew, disruptive, sting of other dinated effort ales.
118275 <u>(</u> <u>F</u>	RFA-MH-23-295 BRAIN Initiative Cell-Specific and Circuit-Specific P Primate Brain (UG3/UH3 Clinical 1	e: Develop rocesses ir Trial Optior	ment of Novel Tools to Probe n Human and Non-Human nal)	National Institutes of Health/DHHS RFA-MH- 23-295 07-	Jun-2024	Not Specified
	Contact Name	Douglas S	. Kim, Ph.D.			
	Contact Telephone	301-827-6	5463			
	Contact Email	douglas.k	im@nih.gov			
	Sponsor Website					
	Program URL	Link to pro	ogram URL			
	Deadline Dates (ALL)	07-Jun-20	24			
The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative notice of fun opportunity is to encourage applications that will develop and validate novel tools to facilitate the detailed analysis a manipulation of complex circuits in large brains. Critical advances in the treatment of brain disorders in human popu are hindered by our lack of ability to monitor and manipulate circuitry in safe, minimally-invasive ways. Clinical inter with novel cell- and circuit-specific tools will require extensive focused research designed to remove barriers for targ circuit manipulation. In addition to identification and removal of barriers, the need to delineate dysfunctional circuit additional challenges. Neuroscience has experienced an impressive influx of exciting new research tools in the past of especially since the launch of the BRAIN Initiative. However, the majority of these cell- and circuit-specific mapping, monitoring, and manipulating tools has been developed for use in model organisms, primarily rodents, fish and flies. cutting-edge tools are increasingly adaptable to larger mammalian brains and, more importantly, are emerging as po- human therapeutic strategies for brain disorders. A pressing need to develop tools for use in large brains or those th more directly relevant to the human brain is the focus of this initiative. The initiative will support initial proof of prin studies aimed at demonstrating the feasibility of using the cutting-edge approaches in humans and other mammalia (e.g., non-human primate [NHP]/sheep/pigs).						of funding lysis and populations intervention r targeted ircuitry poses past decade, ping, l flies. These as potential ose that are f principle malian species

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
					Crances News	Sponsor	Deadline Date	Funding
SPIN ID	Program Title				sponsor Name	Number	Deadline Date	Amount
106783	Research on Biopsychosocial Facto Wellbeing, Illness, and Recovery (R	rs of Soci 01 Basic	al Connectedness and Isolation Experimental Studies with Hum	<u>on Health,</u> ans Required)	National Institutes of Health/DHHS	PAR-21- 349	21-Jun-2024	Not Specified
	Contact Name	William E	lwood, PhD					
	Contact Telephone	301-402-	0116					
	Contact Email	<u>william.e</u>	lwood@nih.gov					
	Sponsor Website							
	Program URL	<u>Link to pr</u>	ogram URL					
	Deadline Dates (ALL)	21-Jun-2(	)24					
	Synopsis i	This fund processes participan behaviora solation. studies in clinical tr Applicatio under the Health, W	ing opportunity announcement s, and trajectories of social relat all wellbeing. Types of projects s ints to conditions (i.e., experime al outcomes in humans to under NIH considers such studies as B ivolving human participants that ials (see, e.g., NOT-OD-19-024). ons that propose studies includi e companion FOA, PAR-21-350 " /ellbeing, Illness, and Recovery	(FOA) invites re- cionships and ho submitted unde ntally manipula rstand fundame asic Experimen t meet the NIH Applications sh ng model anima Research on Bio (R01 Clinical Tri	esearch projects that by these factors affe or this FOA include str te independent varia ental aspects of phen tal Studies with Hum definition of basic re fould not propose a g al research or observ opsychosocial Factor als Not Allowed).	seek to expl ct outcomes udies that pr bles) and th omena relat ans (BESH) t search and f goal of clinica ational studi s of Social Co	lain the underlying me in human health, illne cospectively assign hun at assess biomedical a red to social connected that are prospective ba fall within the NIH defir al outcomes or product ies involving humans si connectedness and Isola	chanisms, ss, recovery, nan nd/or ness and sic science nition of ss. nould submit ation on
106784	Research on Biopsychosocial Facto Wellbeing, Illness, and Recovery (R	rs of Soci 01 Clinic	al Connectedness and Isolation al Trials Not Allowed)	<u>on Health,</u>	National Institutes of Health/DHHS	PAR-21- 350	21-Jun-2024	Not Specified
	Contact Name	William E	lwood, PhD					
	Contact Telephone	301-402-	0116					
	Contact Email	<u>william.e</u>	lwood@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					

SPIN ID	Program Title		Sponsor Name	Sponsor Numl	ber		Deadline Date	Funding Amount
	Deadline Dates (ALL) 2 T p Synopsis 2 R	1-Jun-20 This fundi processes overall we llowed. F 1-349, "F Recovery	24 ng opportunity announcement , and trajectories of social relat ellbeing. Both animal model and Researchers proposing Basic Exp Research on Biopsychosocial Fac (R01 Basic Experimental Studies	esearch projects that ow these factors affe its research projects lies with Humans (BE Connectedness and Is Required)".	: seek to model t oct outcomes in h are welcome; ho ESH) should consi solation on Healt	he underlying mec ealth, illness, reco wever, clinical tria ider the companio h, Wellbeing, Illne	hanisms, very, and Is are not n FOA, PAR- ss, and	
106790 R	esearch on Biopsychosocial Factor Vellbeing, Illness, and Recovery (R	rs of Socia 01 Clinica	al Connectedness and Isolation Il Trial Required)	on Health,	National Institutes of Health/DHHS	PAR-21- 352 21-J	un-2024	Not Specified
	Contact Name V Contact Telephone 3 Contact Email <u>v</u> Spansor Wabsite	Villiam El 01-402-0 villiam.elv	wood, PhD )116 wood@nih.gov					
	Program URL L Deadline Dates (ALL) 2	<u>ink to pro</u> 1-Jun-20	ogram URL 24					
	T p a t ir Synopsis t p p t t R li 2 R	his fundi processes ind overa rials. Mee nterventi AH-19-00 nfluence n interve hat shoul purpose o products i his FOA's ecovery finited to 1-350, "F	ng opportunity announcement , and trajectories of social relat II wellbeing. Types of projects s chanistic studies are defined as on, a biological or behavioral pr of for examples of clinical trials a clinical outcome, test safety of ention, or analyze the effect size of submit under this FOA includ of understanding the fundament in mind. Researchers proposing companion for basic experiment (R01 Basic Experimental Studies , model animal research or obse Research on Biopsychosocial Fac (R01 Clinical Trials Not Allowed	(FOA) invites re- ionships and ho ubmitted under studies with the rocess, or the p that are/are no or feasibility of a e of an interven e clinical trials f tal aspects of p basic science e ntal studies with s with Humans ervational studies ctors of Social ( ).	esearch projects that by these factors affe er this FOA include m e objective to under athophysiology of a ot considered mecha an intervention, dem tion on clinical outco that assess biomedic henomena without s experimental studies th humans, PAR-21-3 Required)." Applicat ies involving humans Connectedness and Is	seek to explain the chanistic studie stand the mecha disease/condition nistic studies. Clim onstrate the clim omes are ineligible al or behavioral of pecific application involving human 49, "Research or sons proposing sta s should submit u solation on Healt	the underlying me uman health, illne s that are classifie nism(s) of action o n. See NOT-AT-20- nical trials that pro- ical efficacy or eff- e for this FOA. Typ outcomes in huma on towards process participants shou health, Wellbeing tudies that include nder the compani h, Wellbeing, Illne	chanisms, ss, recovery, d as clinical of an 001 and NOT- opose to ectiveness of bes of studies ns for the ses or ld consider g, Illness, and e, but are not on FOA, PAR- ss, and

SPIN ID	Program Title	S	Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
106620 <u> </u>	RFA-OD-21-007 INvestigation of Jnderstand Down syndromE (INC Award (R21 Clinical Trial Not Alloy	f Co-occurrir LUDE) Explo ved)	ng conditions across the Lifesp pratory/Developmental Resea	<u>oan to</u> rch Grant	National Institutes of Health/DHHS	RFA-OD- 01 21-007 [O	-Jun-2024 ptional][LOI/Pre-Ap	275,000 p] USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Melissa A. I 301-435-68 parisima@I Link to prog	Parisi, M.D., Ph.D. 380 <u>mail.nih.gov</u> g <u>ram URL</u>					
Deadline Dates (ALL) 01-Jun-2024 [Optional][LOI/Pre-App], 01-Jul-2024 This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of new explore developmental research projects that address critical needs for Down syndrome projects, as articulated in the INCLU (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) project objectives. For such projects could assess the feasibility of a novel area of investigation or a new experimental system that has the to enhance health-related research. Another example could include the unique and innovative use of an existing methodology to explore a new scientific area. These studies may involve considerable risk but may lead to a breakth a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that co a major impact on a field of biomedical, behavioral, or clinical research.								
116668	RFA-OD-23-014 Understanding Clinical Trial Optional)	Chronic Con	nditions Understudied Among	<u>Women (R01</u>	National Institutes of Health/DHHS	RFA-OD- 20 23-014 [O	-May-2024 ptional][LOI/Pre-Ap	1,400,000 p] USD
	Contact Name Contact Telephone	Sarah Teml 301-402-21	kin, M.D. 168					
	Sponsor Website							
	Program URL	Link to prog	gram URL					
	Deadline Dates (ALL)	20-May-20	24 [Optional][LOI/Pre-App], 20	0-Jun-2024				
	Synopsis	The purpos among wor underrepor Health Rese	e of this Notice of Funding Op men and/or that disproportior rted in biomedical Research sh earch "Advancing Science for t	pportunity (NOI nately affect po nould align with the Health of W	FO) is to invite RO1 ap pulations of women n Goal 1 of the 2019-2 /omen." The awards	plications on cl who are unders 2023 Trans-NIH under this NOF	hronic conditions ur studied, underrepre Strategic Plan for W Owill be administere	nderstudied sented, and /omen's ed by NIH ICs

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
		using fun partnerin	ds that have been made availab g Institutes and Centers across I	le through the NIH.	Office of Research or	n Women's Healt	h (ORWH) and the	scientific
121738	Advancing Research Careers (ARC Promote Diversity (F99/K00 - Clin	:) Predocto ical Trial N	oral to Postdoctoral Transition A ot Allowed)	ward to	National Institutes of Health/DHHS	PAR-23- 222 13-J	un-2024	Not Specified
	Contact Name Contact Telephone	Laurie Ste	epanek, Ph.D.					
	Contact Email	laurie.ste	panek@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL) 2025 , 07-Jan-2026 , 13-Feb-2026 , 07-May-2026 , 13-Jun-2026 , 07-Sep-2026 , 14-Oct-2026 , 07-May-2026 , 15-Jun-2026 , 07-Sep-2026 , 14-Oct-2026 , 07-May-2027					-2025 , 07-Sep-202 07-Jan-2027 , 11-F	5 , 10-Oct- eb-2027 , 07-	
	Synopsis	The purp (F99/K00 underrep research advance i research support f Centers, a and to tra ARC F99 f and profe Diversity research Candidate	ose of the Advancing Research ( ) program is to support promisin resented groups (see Notice of positions. It is anticipated that s n impactful careers in the biome and teaching at a range of instit or late-stage graduate students and Offices (ICOs) to facilitate the ansition into and succeed in post fellows/K00 scholars will be part essional development activities of (UE5) recipients. This Notice of that does not involve leading an es to this NOFO are permitted to	Careers (ARC) P ng, late-stage g NIH's Interest in uccessful comp edical research ution types, inc pursuing resea to completion of tooctoral biom of organized c coordinated by Funding Oppor independent co propose resea	redoctoral to Postdo raduate students from n Diversity), to transi oletion of this phased workforce that typic dustry or government rch related to the mi of doctoral dissertation edical research and co ohorts and will be ex ARC Institutionally-F rtunity (NOFO) is desi- clinical trial, a clinical arch experience in a co	ctoral Transition m diverse backgr tion into and suc l award program cally require post t research). This ssion areas of pa on projects and r career developme pected to partici ocused Research igned specifically trial feasibility st clinical trial led b	Award to Promote ounds, for example ceed in mentored will position ARC s doctoral training (e two-phase award w rticipating NIH Insi esearch training (F ent opportunities ( pate in mentoring, Education Award for candidates pro- cudy, or an ancillar y a sponsor or co-s	<ul> <li>Diversity</li> <li>those from</li> <li>postdoctoral</li> <li>cholars to</li> <li>.g., academic</li> <li>vill provide</li> <li>titutes,</li> <li>99 phase),</li> <li>K00 phase).</li> <li>networking,</li> <li>to Promote</li> <li>oposing</li> <li>y clinical trial.</li> <li>sponsor.</li> </ul>
112126	RFA-TR-22-030 Pilot Projects In	vestigating	g Understudied Proteins Associa	ted with Rare	National Institutes	RFA-TR- 15-J	un-2024	100,000
						22-030 [Up	lionalj[LOI/Pre-Ap	ענט [נ
	Contact Name	Karlie Sha	arma, Ph.D.					
	Contact Telephone	301-451-	4965					

Icahn School of Medicine at Mount Sinai

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
	Contact Email	Druggabl	eGenome@mail.nih.gov					
	Sponsor Website	0105500						
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	15-Jun-20		-Jul-2024				
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to solicit applications for pilot projects to elucidate a re understudied proteins associated with rare diseases. Awards will support generation of preliminary data and/or tools ar eligible understudied protein(s). A list of eligible proteins is provided and are members of druggable protein families that have a known association with a rare disease. This FOA is intended to jumpstart research on understudied proteins that associated with rare diseases and provide applicants with sufficient funding to perform basic biochemical and/or biolog work to further the characterization of understudied proteins associated with rare disease.						
117066 <u> </u>	nstrumentation Grant Program fo	or Resourc	e-Limited Institutions (S10 - Clir	nical Trial Not	National Institutes of Health/DHHS	PAR-23- 138 03-	Jun-2024	250,000 USD
	Contact Name	Dorothy I	Beckett, PhD					
	Contact Telephone							
	Contact Email	dorothy.k	<u>peckett@nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	03-Jun-20	024 , 02-Jun-2025					
	Synopsis	The Instru instrume support b	umentation Grant Program for F nts to enhance the research and piomedical research and educati	Resource-limite deducational m on in basic, tra	ed Institutions suppo hissions of resource-l nslational, biomedic	rts the purchase imited institutio ally-related beha	of state-of-the-art s ns. Requested instr ivioral or clinical fie	scientific uments may lds.
119046 R	FA-HG-23-018Investigator-Init	iated Rese	earch in Genomics and Health Ec	quity (R21	National Institutes	RFA-HG- 08-	Jun-2024	400,000
<u><u> </u></u>	<u> Clinical Trial Optional)</u>	1			of Health/DHHS	23-018 [Op	otional][LOI/Pre-Ap	נ] USD
	Contact Name	Lucia Hin	dorff, Ph.D.					
	Contact Telephone	240-271-3	1509					
	Contact Email	hindorffl(	@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
	Deadline Dates (ALL) ( Synopsis i t t	08-Jun-20 The purpo goal of de advance t generaliza enhancing be carried including developm Stage Inve behaviora encourage the applic	24 [Optional][LOI/Pre-App], 08- ose of this initiative is to suppor veloping approaches, generatin he equitable use of genomics to able research in genomics and h g diverse perspectives.This R21 I out in a short period of time w pilot and feasibility studies; second tent of research methodology; a setigators from diverse backgrou al, and clinical research workforce ed. This Notice of Funding Oppo- nation. Applications without a Pf	Jul-2024, 08-J t investigator-i og and dissemir o improve healt ealth equity sp Notice of Fund ith limited reso ondary analysis and developme unds, including ce, as described ortunity (NOFO EDP will not be	un-2025 [Optional][L nitiated research in g nating data, and impl th in U.S. populations anning across genon ing Opportunity (NO purces. The R21 gran of existing data; sm nt of new research to those from groups t in the NIH Notice of requires a Plan for F reviewed.	OI/Pre-App], 08- enomics and hea ementing metrics a Awardees will on hic research areas FO) will support s t mechanism sup all, self-contained echnology. Applic raditionally unde f Interest in Diverse chancing Diverse	Jul-2025 alth equity, with the s or interventions conduct innovative s and will incorpor small research project cations supporting rrepresented in the rsity (NOT-OD-20-0 e Perspectives (PE	ne ultimate that will e and rate a plan for jects that can bes of projects s; g New or Early ne biomedical, 031), are DP) as part of
114707	RFA-NS-22-023 HEAL Initiative Ad Transition Award in PAIN and SUD with Humans Required)	dvanced F Research	Postdoctoral-to-Independent Ca (Independent Basic Experiment	i <u>reer</u> tal Studies	National Institutes of Health/DHHS	RFA-NS- 22-023 11-J	un-2024	Not Specified
	Contact Name I	DP Moha	patra, Ph.D.					
	Contact Telephone	301-496-9	9964					
	Contact Email <u>c</u>	dp.mohap	<u>patra@nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	11-Jun-20	24 , 11-Oct-2024 , 11-Feb-2025					
	ן i t Synopsis t נ נ נ נ נ נ נ נ נ נ נ נ נ נ נ נ נ נ	The purpo and well-t investigat transition track or en help awar Opportun "prospect and also r	ose of the NIH HEAL Initiative <sup>®</sup> F crained independent investigato or workforce in research areas of eligible postdoctoral researc quivalent faculty positions. The dees establish independent res ity Announcement is for basic s ive basic science studies involvi neet the definition of basic rese	Pathway to Inde ors conducting supported by t hers from thei program will p earch program cience experim ng human part earch. Types of	ependence Award (K Pain and/or SUD rese he NIH HEAL Initiativ r mentored, postdoc rovide independent s in areas supported ental studies involvi icipants." These stud studies that should b	99/R00) program earch, in order to e <sup>®</sup> . This program toral research po NIH research sup by the NIH HEAL ng humans, refer ies fall within the pe submitted und	is to support a co increase the inde is designed to fac sitions to indepen port during this tr Initiative <sup>®</sup> . This For red to in NOT-OD- NIH definition of er this FOA includ	hort of new pendent ilitate a timely dent, tenure- ansition to unding -18-212 as a clinical trial e studies that

SPIN ID	Program Title	Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
		prospectively assign human participants biomedical or behavioral outcomes in hu without specific application towards pro- basic experimental study with humans, or with humans led by another investigator proposed project must be related to the Centers (ICs) based on their scientific mis	to conditions (i mans for the p cesses or produ or proposing to , must apply to programmatic ssions.	.e., experimentally m urpose of understand icts in mind. Applicar gain research experie the 'Independent Cli interests of one or m	nanipulate indepe ding the fundame nts not planning a ence in a clinical f nical Trial Not All ore of the partici	endent variables) a ental aspects of ph in independent cli trial or basic exper owed' companion pating NIH Institu	and that assess enomena nical trial or imental study FOA. The tes and
114700	RFA-NS-22-022 HEAL Initiative A Transition Award in PAIN and SUE Allowed)	Advanced Postdoctoral-to-Independent Ca Research (K99/R00 Independent Clinical	areer Trial Not	National Institutes of Health/DHHS	RFA-NS- 22-022 11-J	un-2024	Not Specified
	Contact Name	DP Mohapatra, Ph.D.					
	Contact Telephone	301-496-9964					
	Contact Email	dp.mohapatra@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	11-Jun-2024 , 11-Oct-2024 , 11-Feb-2025	i				
	Synopsis	The purpose of the NIH HEAL Initiative <sup>®</sup> I and well-trainedindependent investigator investigator workforce in research areas transition of eligible postdoctoral research track or equivalent faculty positions. The help awardees establish independent reso Opportunity Announcement (FOA) is des independent clinical trial, a clinical trial for Experimental Studies with Humans (BESF trial led by a mentor or co-mentor. Those companion FOA (RFA-NS-22-023).	Pathway to Inde supported by t chers from thei program will p search program igned specifica easibility study, d). Applicants to proposing an	ependence Award (K Pain and/or SUD rese he NIH HEAL Initiativ r mentored, postdoc rovide independent s in areas supported Ily for candidates pro an ancillary study to o this FOA are permit independent BESH as	99/R00) program arch, in order to e <sup>®</sup> . This program toral research po NIH research sup by the NIH HEAL posing research a clinical trial, or ted to propose ro s lead investigato	is to support a co increase the indep is designed to fac sitions to indepen port during this tr Initiative <sup>®</sup> . This Fu that does not invo an independent f esearch experienc r, should apply to	hort of new bendent ilitate a timely dent, tenure- ansition to unding lve leading an Basic e in a clinical the
112443	HEAL Initiative: Career Developme Use Prevention and Treatment (K	ent Awards in Implementation Science for 01 - Clinical Trial Required)	Substance	National Institutes of Health/DHHS	PAS-22- 206 12-J	un-2024	Not Specified

Contact Name Lori Ducharme, Ph.D.

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone	301-827-0	6331				
	Contact Emai Sponsor Website	Lori.Duch	arme@nih.gov				
	Program URI	Link to pr	ogram URL				
	Deadline Dates (ALL	) 12-Jun-20	)24 , 12-Oct-2024 , 12-Feb-2025	, 12-Jun-2025 , 12-Oct-202	5		
	Synopsis	The purper Preventic developm investme crisis dep intervent sustained overcome independ capacity t who can I Opportum preventio implement science m treatment specifical study, or planning	bes of this Mentored Research S on and Treatment (K01) is to pro- ment experience leading to resear in the development of evider ends on a cadre of skilled resear ions into routine practice. Imple- use of evidence-based practice e those barriers. While this field ent researchers with dual exper- to respond to continued calls for the called upon to meet ongoing bity Announcement (FOA) will su- on or treatment research and wint attion science. Development a methods to one of the four doma t; harm reduction; or recovery r ly for applicants proposing to se a separate ancillary study to an an independent clinical trial, or onsult the NIH Research Career I	Scientist Development Awar wide support and "protected arch independence in this ar nece-based treatments and p rchers with expertise in imp ementation science focuses is in real world settings and has grown rapidly over the tise in addiction research and research in this area. There and emerging implementat upport early career investiga Il provide support and prote nd execution of an independ ains of the HHS Overdose Pr research) is required. This Fu- research is required. This Fu- research is a part of theil proposing to gain research of Development Awards website	rd in Implementation Scie d time" (3-5 years) for an rea of specialization. Real reventive interventions to lementation science, who on identifying modifiable developing replicable and past 15 years, there remain implementation science is a pressing need for a cion challenges in the add ators who have foundation ected time to acquire trait dent NIH-defined clinical revention Strategy (prevent unding Opportunity Anno of an independent clinical research and career deve experience in a clinical tri- te for alternative funding	ince for Substance intensive, superv izing the return or o address the ong o can help move the barriers to the up d scalable strategi ain a limited numb ce, constraining the deeper bench of r iction field. This F nal training in sub ning and research trial applying impl ntion; evidence-ba uncement (FOA) i al trial, a clinical tr velopment. Applic al led by another opportunities.	Use sed career public oing overdose nese take and es to oer of le field's esearchers unding stance use experience in ementation ased addiction s designed ial feasibility ants not investigator,
111464	Notice of Special Interest (NOSI): Careers of Investigators Pursuing	Mentored Research I	Career Development Awards to Related to Down syndrome as P	<u>o Foster the</u> art of the of Health/D	stitutes NOT-OD- OHHS 22-124 07-N	/lay-2024	Not Specified

Contact Name Charlene Schramm, PhD Contact Telephone 301-402-3793

Contact Email <u>schrammc@nih.gov</u>

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
	Sponsor Website							
	Program LIRI	Link to pr	ogram LIRI					
	Deadline Dates (ALL)	07-May-2	024 . 12-lun-2024 . 07-Sep-2024	4 . 12-Oct-2024				
	Synopsis	The NIH II to improv announce research. developm and suppo	Nvestigation of Co-occurring con- re health and quality-of-life for its NIH support for the profession By providing these scientists with thent of junior investigators in DS port development of new treatm	nditions across ndividuals with nal developmen th training, reso who will lead t ents for health	the Lifespan to Unde Down syndrome (DS nt of early career scie ources, and mentors future research to im conditions experient	erstand Down sy 5). This Notice of entists aiming to hip, the NIH inte pprove the unde ced by those wit	ndromE (INCLUDE Special Interest (N establish a career ends to support the rstanding of the bi h DS.	) Project seeks NOSI) in DS-related career ology of DS
105002	The Role of Work in Health Dispan	rities in the	e U.S. (R01 Clinical Trials Option	<u>al)</u>	National Institutes of Health/DHHS	PAR-21- 275 07-	May-2024	Not Specified
	Contact Name	Rada K. D	agher, PhD, MPH					
	Contact Telephone	301-451-2	2187					
	Contact Email	rada.dagh	ner@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	024 , 05-Jun-2024 , 07-Sep-2024	1				
	Synopsis	The purpo contribute outcomes determina	ose of this Funding Opportunity e to identifying and characterizi s and health status among popu ant of health.	Announcemen ng pathways ar lations with hea	t (FOA) is to support ad mechanisms throu alth and/or health ca	innovative popu Igh which work Ire disparities, a	Ilation-based resea or occupation influ nd how work funct	arch that can ences health ions as a social
108364	Health Care Models for Persons w Experience Health Disparities: Ad Trials Optional)	vith Multip vancing He	le Chronic Conditions from Pop ealth Care towards Health Equity	ulations that / (R01 - Clinical	National Institutes of Health/DHHS	PAR-22- 092 07-	May-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	Larissa Av 301-827-6 <u>avilessant</u>	rilés-Santa, MD, MPH 5924 cal@nih.gov					

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount	
	Drogram LIPI	Link to pr	ogram LIPI						
			$\frac{\text{Ogrann OKL}}{\text{Ogrann OKL}}$	Λ					
	Deadline Dates (ALL)	This initia	tive will support innovative, col	4 laborative, and	l multi-disciplinary re	search designed	to study the effec	tive	
	Synopsis	(MCCs) from populations that experience health disparities. Projects would be expected to involve more than one component and/or more than one level of influence within existing or newly proposed health care models. The goal of the initiative is attainment of optimal treatment and health outcomes goals to advance health care towards health equity.							
108571	Notice of Special Interest (NOSI): COVID-19-Associated Coagulopat	<u>Enhancing</u> <u>hy</u>	Research on Deciphering Mech	<u>anisms of</u>	National Institutes of Health/DHHS	NOT-HL- 23-003 07-I	May-2024	Not Specified	
	Contact Name	Anthony	Agresti						
	Contact Telephone	301-827-8	8014						
	Contact Email	agrestia@	nhlbi.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2	.024 , 05-Jun-2024 , 07-Sep-2024	4 , 05-Oct-2024	1 , 05-Feb-2025 , 05-J	un-2025			
	Synopsis	This Notio Associate hypercoa future de applied to	ce of Special Interest (NOSI) aim d Coagulopathy (CAC) which are gulability at genomic, molecular sign of early diagnostics and eff o on-going COVID-19 clinical tria	s to accelerate e provoked by v r, and cellular lo ective treatme lls.	a comprehensive un vascular endothelial d evels. Knowledge obt nt for high-risk patier	derstanding of th cell injury, hyperi ained from such nts as well as ena	ne mechanisms of immune response studies may be ar ible CAC research	COVID-19- s, and oplied to the findings to be	
114402	Multisite Clinical Research: Levera Women, Children, Pregnant and L Clinical Trial Optional)	aging Netw .actating Ir	vork Infrastructure to Advance F ndividuals, and Persons with Dis	Research for abilities (U01	National Institutes of Health/DHHS	PAR-23- 037 07-1	May-2024	Not Specified	
	Contact Name	Robert Ta	amburro, MD, MSc						
	Contact Telephone	301-480-2	2619						
	Contact Email	NICHD-Ne	etwork-ClinicalResearch@nih.gc	<u>)v</u>					
	Sponsor Website								
	Program URL	Link to pr	ogram URL						

SPIN ID	Program Title	Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount		
	Deadline Dates (ALL) 2025 , 0 The pur observa	-2024 , 05-Jun-2024 , 07-Sep-202 5-Oct-2025 , 07-Jan-2026 pose of this funding opportunity tional studies developed in conju	4,05-Oct-2024 announcement nction with NIC	, 07-Jan-2025 , 05-F (FOA) is to invite ap CHD Networks that v	eb-2025 , 07-Ma plications for mu vill be conducted	y-2025 , 05-Jun-20 Itisite clinical trials using NICHD-supp	25 , 07-Sep- and orted Network		
	<ul> <li>Synopsis</li> <li>Synopsis&lt;</li></ul>								
119254	Novel Mechanism Research on Neuropsyc Dementia (R01 Clinical Trial Optional)	hiatric Symptoms (NPS) in Alzheii	<u>mer's</u>	National Institutes of Health/DHHS	PAR-23- 207 05	Jun-2024	Not Specified		
	Contact Name Laura N	I. Rowland, Ph.D.							
	Contact Telephone 301-480	-8335							
	Contact Email laura.rc	wland@nih.gov							
	Sponsor Website								
	Program URL Link to	program URL							
	Deadline Dates (ALL) 05-Jun-	2024 , 05-Oct-2024 , 05-Feb-2025	, 05-Jun-2025	, 05-Oct-2025 , 05-F	eb-2026 , 05-Jun-	2026			
	The goa of mech disease Synopsis and neu advance mechar lack pre	l of this Notice of Funding Opport anisms associated with neuropsy related dementias (ADRD). The fi robiological pathways leading to ed into interventions to treat and ism, while the companion annou liminary data or utilize existing da	tunity (NOFO) i chiatric sympto ndings are exp NPS. Findings r prevent the de ncement PAR-2 ata may be mos	s to encourage appli oms (NPS) in persons ected to advance me may also provide ins evelopment of NPS in 23-208 uses the R21 st appropriate for th	cations for studies with Alzheimer' echanistic unders ght into novel th AD and/or ADRI mechanism. High e R21 mechanism	es that will enhanc s disease (AD) or A tanding of both bio erapeutic targets t D. This NOFO uses n risk/high payoff p n.	e knowledge Izheimer's obehavioral hat can be the R01 rojects that		

117793 Interventions to Expand Cancer Screening and Preventive Services to ADVANCE Health in National Institutes PAR-23- 05-Jun-2024 Not

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount			
	Populations that Experience Healt	th Disparit	ies (R01, Clinical Trial Required)	<u>.</u>	of Health/DHHS	170		Specified			
	Contact Name	JoyAnn C	ourtney, Ph.D.								
	Contact Telephone	301-402-3	3911								
	Contact Email	joyann.co	ourtney@nih.gov								
	Sponsor Website										
	Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	05-Jun-20	-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026								
	Synopsis	(ICs) are i screening preventiv care. Pro should ac neighbor leverage adapt new of the fol	ssuing this R01 to solicit applica and preventive services in pop e services, or other healthcare jects are encouraged to leverag dress barriers and facilitators a nood/community. Specific resea collaborations with community w combinations of evidence-bas lowing levels: patient, clinician,	tions to addres ulations that ex processes, inclu ce collaboration t two or more of arch interests of partners and so sed strategies. healthcare set	is barriers and facilit operience health disp uding timely follow-u s with community p of the following leve f participating NIH IC ervice providers to p Interventions should cing, and neighborho	ators that impede parities. Interven of abnormal fin artners and servi ls: patient, clinicia cs are detailed wi romote or enhan address barriers od/community.	e use or uptake of tions should inclu- ndings, and referra ce providers. Inter an, healthcare sett thin. Projects are ce existing interve s and facilitators at	cancer de screening, il to accessible ventions :ing, and encouraged to entions and/or t two or more			
	Maximizing Opportunities for Scie	entific and	Academic Independent Careers	(MOSAIC)	National Institutes	DAP_21_		Not			
106063	Postdoctoral Career Transition Av	vard to Pro	omote Diversity (K99/R00 - Inde	<u>pendent</u>	of Health/DHHS	272 07-	May-2024	Specified			
	<u>Clinical Trial Required)</u>	I									
	Contact Name	Lanay M.	Mudd, Ph.D., FACSM								
	Contact Telephone	301-594-9	9346								
	Contact Email	lanay.mu	dd@nih.gov								
	Sponsor Website										
	Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	07-May-2	.024 , 12-Jun-2024 , 07-Sep-202	4			<i>.</i>				
	Synopsis	The purp Transition from dive	ose of the Maximizing Opportur n Award to Promote Diversity (K rse backgrounds conducting res	nities for Scient (99/R00) progra search in NIH m	ific and Academic In am is to support a co hission areas. The lor	dependent Caree hort of early care ng-term goal of th	ers (MOSAIC) Posto eer, independent i nis program is to e	Ioctoral Career nvestigators nhance			

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
		diversity promising mentored The MOS awardees scientific coordinat Opportur independ career de clinical tri	ty in the biomedical research workforce. The MOSAIC K99/R00 program is designed to facilitate a timely transition of sing postdoctoral researchers from diverse backgrounds (e.g., see Notice of NIH's Interest in Diversity) from their red, postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. OSAIC K99/R00 program will provide independent NIH research support before and after this transition to help ees launch successful, independent research careers. Additionally, MOSAIC K99/R00 scholars will be part of organized fic cohorts and will be expected to participate in mentoring, networking, and professional development activities nated by MOSAIC Institutionally-Focused Research Education Award to Promote Diversity (UE5) grantees. This Funding tunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an endent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a I trial led by another investigator, must apply to companion FOA PAR-21-271.					
106062	Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC)       National Institutes       PAR-21-       07-May-2024       Not         Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)       National Institutes       PAR-21-       07-May-2024       Specifie							
	Contact Name	Kenneth	D. Gibbs, Jr., Ph.D.					
	Contact Telephone							
	Contact Email	kenneth.	gibbs@nih.gov					
	Sponsor Website	Link to pr	agrom LIDI					
Deadline Dates (ALL) 07-May-2024 12-Jun-2024 07-Sen-2024				Λ				
	Synopsis	The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of early career, independent investigators from diverse backgrounds conducting research in NIH mission areas. The long-term goal of this program is to enhance diversity in the biomedical research workforce. The MOSAIC K99/R00 program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds (e.g., see Notice of NIH's Interest in Diversity) from their mentored, postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The MOSAIC K99/R00 program will provide independent NIH research support before and after this transition to help awardees launch successful, independent research careers. Additionally, MOSAIC K99/R00 scholars will be part of organized scientific cohorts and will be expected to participate in mentoring, networking, and professional development activities coordinated by MOSAIC Institutionally-Focused Research Education Award to Promote Diversity (UE5) grantees. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an						
SPIN ID	Program Title		Sponsor Name	Sponsor Numl	ber		Deadline Date	Funding Amount
---------	---	--	---	--	--	--	---	---
		independ propose r clinical tri	ent clinical trial, a clinical trial fe research experience in a clinical al as lead investigator, should a	easibility study, trial led by a m pply to the con	or an ancillary clinic entor or co-mentor. npanion FOA PAR-21	al trial. Applican Applicants prop -272.	ts to this FOA are   osing a clinical tria	permitted to I or an ancillary
105617	Effectiveness of School-Based He Optional)	alth Cente	rs to Advance Health Equity (RO	<u>1 Clinical Trial</u>	National Institutes of Health/DHHS	PAR-21- 287 07-	May-2024	Not Specified
	Contact Name Contact Telephone Contact Email	<u>GrantsInf</u>	<u>o@nih.gov</u>					
	Sponsor Website Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	024 , 05-Jun-2024 , 07-Sep-2024	4 , 05-Oct-2024	, 07-Jan-2025			
	Synopsis	The purpo based hea populatio research chronic ill health of are also a model tha and how determin youth and disparitie lack acces	ose of this Funding Opportunity alth centers (SBHCs) as a health ons with health disparities (hence that investigates the effectivene nesses that disproportionately at-risk populations such as sexu relevant focus for understandir at describes hypothesized causa SBHCs may complement (or red e whether SBHCs can be adopte d if so, whether SBHCs given the s in chronic conditions, and beh as to health care.	Announcemen services care d e, underserved ess of SBHCs as burden underse al and gender n ng effective mo l pathways by w uce) the use of d as a best prae ir accessibility f avioral, oral, ar	it is to support resea elivery model to add youth). The goals o a health services car erved youth. The me minority youth, imm dels of SBHCs. Applie which SBHCs engage other services. Less ctice care model to a to students can be an d reproductive heal	rch that investig lress the needs of f this FOA are to re delivery mode chanisms of imp igrant youth, and cations are expe- underserved yo ons learned thro address the healt n effective site o th of youth from	ates the effectiver of school-aged child support multidisc I to detect, manag act by which SBHC d youth who reside cted to provide a c uth to improve hea ugh this initiative of th services needs c f intervention to a underserved com	ess of school- dren from plinary e, and prevent is improve the in rural areas conceptual alth outcomes can help of underserved ddress munities who
105755	nvestigator Initiated Research in Frial Not Allowed)	<u>Computat</u>	ional Genomics and Data Scienc	<u>e (R01 Clinical</u>	National Institutes of Health/DHHS	PAR-21- 254 05-	Jun-2024	2,500,000 USD
	Contact Name Contact Telephone Contact Email	Daniel Gil	christ, Ph.D. christ@nih.gov					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2024				
	Synopsis	The purpose of this funding opportunity computational genomics, data science, s science, and broadly applicable to huma develops innovative analytical methodol refinement or hardening of software and this FOA should be enabling for genomic	announcement (FOA) is to invite ap tatistics, and bioinformatics relevan n health and disease. This FOA supp ogies and approaches, early-stage d tools of high value to the biomedic s and be generalizable or broadly ap	plications for a b t to one or both orts fundamenta levelopment of to cal genomics com oplicable across d	road range of rese of basic or clinical I genomics researd pols and software, munity. Work sup liseases and biolog	arch efforts in genomic h that and ported under ical systems.
105618	Molecular Imaging of Inflammatic	on in Cancer (R01 Clinical Trial Not Allowe	d) National Institutes of Health/DHHS	PAR-21- 294 05-J	lun-2024	Not Specified
	Contact Name					
	Contact Telephone	301-945-7573				
	Contact Email	<u>GrantsInfo@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024				
	Synopsis	The purpose of this Funding Opportunity development and use of current and em inflammation in vivo. The motivation for in cancer is largely based on in vitro and significant new insights relevant to dyna pre-clinical and clinical investigations for approaches for identification and charac changes in response to treatment. This F to interrogate the role of inflammation i researchers and imaging scientists. Thes inflammation interactions.	Announcement (FOA) is to invite re erging molecular imaging methods to this initiative is that much of current ex vivo methods with limited utilizat mic cancer and inflammation interator precise temporal resolution at the terization of in vivo inflammatory ce GOA encourages applications that for n cancer through strong cross-field of e collaborations are expected to adv	esearch grant app to gain fundamer nt imaging researd tion of imaging a ctions. Utilization molecular and ce ellular physiology cus on developing collaboration bet vance science and	plications (R01) for ntal insights into ca ch into the role of pproaches that co of molecular imag llular level are valu in cancers and of g integrated imagin ween cancer basic d understanding of	the ncer inflammation uld lead to ging probes in uable molecular ng approaches science cancer
107429	Patient-Clinician Relationship: Im Health Care Disparities (R01 Clinic	proving Health Outcomes in Populations t cal Trial Optional)	hat Experience National Institutes of Health/DHHS	PAR-22- 064 05-J	lun-2024	Not Specified

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount		
	Contact Norma	Lovince Au	iles Conto MD MDU							
	Contact Name		iles-Santa, MD, MPH							
		501-627-6	1924							
		aviiessam	al@hin.gov							
	Sponsor website	1.1.1.1.1.1.1.1								
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	05-Jun-20	J-Juli-2024, UJ-OCI-2024							
	Synopsis	(e.g., pati- patient-cl disparities Relationsl populatio leading to	ose of this Funding Opportunity ent, clinician, interpersonal, hea inician communication and rela s. In addition, this initiative will hip (PCR) in the primary care an ns that experience health dispa better health outcomes and in	Announcemen alth care systen itionship affects support resear id chronic disea irities, and (2) id icreased health	t (FOA) is to support n, community) resea s health care outcom ch to (1) gain an unc ise care settings affe dentify best practice equity.	t innovative multi arch designed to u nes in patients fro derstanding of hor ects clinical and no is and interventio	-disciplinary and n inderstand how op om populations wit w the Patient-Clini on-clinical health o ns that build and in	nuiti-level otimizing th health care cian outcomes in mprove PCR		
114120 <u>E</u>	ngineering Next-Generation Hun linical Trials Not Allowed)	nan Nervo	us System Microphysiological S	<u>ystems (R01</u>	National Institutes of Health/DHHS	PAR-23- 046 07-1	May-2024	Not Specified		
	Contact Name	David M.	Panchision, Ph.D.							
	Contact Telephone	301-443-5	288							
	Contact Email	panchisio	nd@mail.nih.gov							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	07-May-2 2025 <i>,</i> 05-	024 , 05-Jun-2024 , 07-Sep-202 Oct-2025 , 07-Jan-2026	4 , 05-Oct-2024	, 07-Jan-2025 , 05-F	eb-2025 , 07-Ma	y-2025 <i>,</i> 05-Jun-20	25 , 07-Sep-		
	Synopsis	This Fund generatio architectu future stu intended proposing companio	ing Opportunity Announcemen n human cell-derived microphy ires and physiology with impro- dies of complex nervous syster to encourage the further develo s exploratory research at the ea on R21 FOA (PAR-23-047).	t (FOA) encoura siological syste ved fidelity ove n development opment of proje rly and concept	ages research grant a ms (MPS) and relate r current capabilities , function, and aging ects with feasibility s tual stages of projec	applications direc d assays that rep s. Supported proje g in healthy and d support for the lir t development m	ted toward develo licate complex ner ects will be expect isease states. This ne of investigation ay instead wish to	oping next- vous system ed to enable FOA is . Applicants apply to the		

\_\_\_\_

SPIN ID	Program Title	Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
116911	Research With Activities Related t	to Diversity (ReWARD) (R01 Clinical Trial O	ptional)	National Institutes of Health/DHHS	PAR-23- 122 07-1	May-2024	Not Specified
	Contact Name	Alison Gammie					
	Contact Telephone						
	Contact Email	alison.gammie@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Sep-2024 2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Fel	4 , 05-Oct-2024 b-2026 , 07-Ma	, 07-Jan-2025 , 05-Fe y-2026	eb-2025 , 07-Ma	y-2025 , 05-Jun-20	025 , 07-Sep-
	Synopsis	geographical location of research and res for the health-related research of scientis Accessibility (DEIA) and who have no curr both the scientific research and the DEIA to the programmatic interests of one or r focused on enhancing diversity in the bio	search-related a sts who are ma rent NIH resear activities of inv more of the par medical resear	activities supported b king a significant con ch project grant fund vestigators. The grant ticipating NIH Institu ch enterprise within	y NIH. The ReW, tribution to Dive ling. The ReWAR will support scie tes and Centers the United State	ARD program pro rsity, Equity, Inclu D program provid entific research in (ICs) and ongoing s and territories.	vides support ision, and es funding for areas related DEIA activities
116476	<u>Translational Research in Materna</u> <u>Clinical Trial Optional</u>	al and Pediatric Pharmacology and Therap	eutics (R01	National Institutes of Health/DHHS	PAR-23- 130 05-J	un-2024	Not Specified
	Contact Name	Katie M. Vance, Ph.D.					
	Contact Telephone	301-435-6640					
	Contact Email	Katie.Vance@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025	, 05-Jun-2025	, 05-Oct-2025 <i>,</i> 05-Fe	b-2026		
	Synopsis	The purpose of this notice of funding opp precision medicine in pregnant persons, I other technologies that could have a dire mechanisms of drug action, including the pregnancy and lactation; and (3) discover	portunity (NOFC lactating person ect clinical or he role of pediatu r and develop r	D) is to support transless, and children through ealth impact; (2) enhance ic ontogeny and the novel therapeutics or	lational and cliniugh the develops ance the underst dynamic physiologi enhance the usa	cal research to (1) ment of novel too anding of the und ogical changes tha ge of existing dru	advance ls, models, and erlying at occur during gs or drug

SPIN ID	Program Title		Sponsor Name	Sponsor Num	per		Deadline Date	Funding Amount	
		repurposi goal is to children, i	ng for safer and more effective improve safe and effective prec ncluding those with disabilities.	medications in ision therapeu	pregnant and lactat tics for pregnant and	ing persons I lactating p	, neonates, and childre ersons, fetuses, neona	en. The overall tes, and	
116616	Notice of Special Interest (NOSI): CAROL Act)	Research F	Project Grants in Valvular Heart	<u>Disease</u>	National Institutes of Health/DHHS	NOT-HL- 23-079	07-May-2024	Not Specified	
	Contact Name	Frank Eva	ns, PhD						
	Contact Telephone	301-435-0	0510						
	Contact Email	<u>evansf@r</u>	hlbi.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2026 , 07-May-2026 , 07-May-2026 , 07-May-2026								
	Synopsis	As part of Opportun heart dise	the National Heart, Lung, and E ities Legacy (CAROL) Act, this N pase.	Blood Institute' otice of Special	s implementation of Interest is seeking F	the Cardiov 01 applicat	vascular Advances in R ions that propose rese	esearch and arch in valvula	
123009	Discovery of in vivo Chemical Prol Allowed)	bes for the	Nervous System (R01 Clinical T	<u>rial Not</u>	National Institutes of Health/DHHS	PAR-24- 088	05-Jun-2024	Not Specified	
	Contact Name	Enrique L	Michelotti, Ph.D.						
	Contact Telephone	301-443 5	415						
	Contact Email	michelott	iel@mail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	05-Jun-20	24 , 05-Oct-2024 , 05-Feb-2025	, 05-Jun-2025	, 05-Oct-2025 , 05-Fe	eb-2026 , 05	-Jun-2026 , 05-Oct-20	26	
		The purpo	ose of this Notice of Funding Op ts for the discovery of in vivo ch	portunities (NC emical probes	OFOs) is to support in for novel brain targe	nvestigators	who have interest and	d capability to	

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
		National I discovery placed on	nstitute on Drug Abuse (NIDA), and/or validation of novel, biolo projects that provide new insig	National Eye Ir ogical targets t sht into import	nstitute (NEI), and/or hat will inform studie ant disease-related b	National Institu es of brain disea iological targets	te on Aging (NIA) a se mechanisms. En and biological pro	nnd 2) nphasis will be cesses.
112444 <u> </u>	IEAL Initiative: Career Developm Jse Prevention and Treatment (K	ent Award 23 - Clinica	s in Implementation Science for Il Trial Required)	<u>Substance</u>	National Institutes of Health/DHHS	PAS-22- 207 12-	Jun-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	Lori Duch 301-827-6 <u>Lori.Duch</u>	arme, Ph.D. 5331 <u>arme@nih.gov</u>					
	Program URL Deadline Dates (ALL)							
	Synopsis	Substance degree wi implement time" (3-5 of special interventi implement focuses of settings, a the past 1 and imple deeper be the substa foundation support a execution in one or treatment	be of this Mentored Patient-Or e Use Prevention and Treatment ho have made a commitment to natation science perspective. The by ears) for an intensive, supervi- ization. Realizing the return on p ons to address the ongoing oven tation science, who can help m in identifying modifiable barriers and developing replicable and so 5 years, there remain a limited ementation science, limiting the each of clinician researchers who ance use field. This Funding Opp nal clinical training in substance of an independent NIH-defined more of the four domains of the t; harm reduction; or recovery r y for applicants proposing to se	t (K23) is to sup o focus their re- se awards prov- ised career dev public investme rdose crisis de ove these inter- s to the uptake calable strategi number of ind field's capacity o can be called ortunity Anno e use preventio aining and rese d clinical trial ap e HHS Overdos research) is req	port the career developme search endeavors on vide salary and resear velopment experience ent in the developme oends on a cadre of s rventions into routine and sustained use of es to overcome those ependent clinician re v to address persister upon to meet ongoin uncement (FOA) will n or treatment and/o arch experience in in oplying implementati e Prevention Strategy uired. This Funding C	elopment of indi- patient-oriented rch support for a e leading to rese ent of evidence-k killed clinician re- e clinical practice f evidence-based e barriers. While searchers with c nt gaps in this ar- ng and emerging support early ca or co-occurring r nplementation s on science meth y (prevention; ev opportunity Anno-	viduals with a clini d research from an a sustained period arch independence based treatments a esearchers with ex e. Implementation d practices in real w this field has grow lual expertise in su ea. There is a press g implementation of reer investigators nental illness, and cience. Development ods to patient-orievidence-based add puncement (FOA) is	of "protected e in this area and preventive pertise in science vorld clinical vn rapidly over ibstance use sing need for a challenges in who have will provide ent and ented research iction is designed rial feasibility

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
		study, or planning a should co	a separate ancillary study to an an independent clinical trial, or nsult the NIH Research Career D	existing trial, as proposing to ga Development A	s part of their researd in research experier wards website for alt	ch and care nce in a clini ternative fu	er development. Appli cal trial led by another nding opportunities.	cants not investigator,
120821	RFA-HD-24-007 Understanding with Disabilities Caused by Ableis	<u>and Mitiga</u> m (R01 Clir	iting Health Disparities Experien nical Trial Optional)	ced by People	National Institutes of Health/DHHS	RFA-HD- 24-007	07-May-2024	2,499,995 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Toyin Ajis 301-827-9 toyin.ajisa Link to pr 07-May-2 The goal o underlyin developin	afe, PhD 9242 afe@nih.gov ogram URL 024 , 05-Jun-2024 , 07-Sep-2024 of this NOFO is to encourage res g mechanisms by which ableism ig and/or testing interventions a	4 , 05-Oct-2024 search to under adversely influ at a community	, 07-Jan-2025 , 05-Fe stand the impact of lences the health of or health systems le	eb-2025 , 07 ableism on persons wit vel to mitig	7-May-2025 health outcomes. Res h disabilities (PWD), a ate adverse health effo	earch on the s well as ects of ableism
120869	Screening, Brief Intervention and Alcohol, Tobacco, and Other Drug Experience Health Disparities (RO	are high p <u>Referral to</u> (ATOD) U 1, Clinical T	priority. <u>Treatment or Prevention (SBIR</u> ) <u>Jse and Misuse in Adult Populat</u> <u>Frial Required</u> )	T/P) for ions That	National Institutes of Health/DHHS	PAR-23- 270	05-Jun-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program LIBL	Denise St 301-402-9 denise.str	redrick, Ph.D. 9749 redrick@nih.gov					
	Deadline Dates (ALL) Synopsis	05-Jun-20 2027 The Offic (ICOs) are and other	e of Disease Prevention (ODP) a issuing this NOFO seeking appli	, 05-Jun-2025 , Ind participatin ications to test n adult populat	05-Oct-2025 , 05-Fe g National Institutes innovative approach ions that experience	b-2026 , 05 of Health (I hes to imple health disp	-Jun-2026 , 05-Oct-202 NIH) Institutes, Centers menting SBIRT/P for a parities, SBIRT/P. (a ter	26 , 05-Feb- 5, and Offices Icohol, tobacco, m used for

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
		purposes with a co needed. and comr	of this funding announcement), nversation about harmful substa Proposed research should incluc nunity partners Specific researcl	involves scree ance use, and r de prospective h interests of p	ening individuals for r referring individuals f tests of SBIRT/P and participating NIH ICOs	risk of ATOD or treatment should lever s are detailed	use and misuse, brief or preventive service age collaborations wit within.	y intervening s, as th healthcare
121246	Improving Care and Outcomes for (SGM) Populations (R01 Clinical T	r Cancer Su rial Optior	irvivors from Sexual and Gender al)	r Minority	National Institutes of Health/DHHS	PAR-23- 292	05-Jun-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	David Dea 240-276- bconnole Link to pr 05-Jun-20 Through assessme This fund survivors poorer he to unders orientatio	an Jr., Ph.D., M.S. 3703 <u>@mail.nih.gov</u> 0 <u>gram URL</u> 024 , 05-Oct-2024 , 05-Feb-2025 this notice of funding opportunit nt of barriers to quality cancer t ing opportunity is intended to a The goal is to address the disea ealth outcomes. The NCI solicits tand barriers and/or improve ca on and gender identity (SOGI) da	, 05-Jun-2025 ty (NOFO), the reatment and ddress a critica ise burden in a proposals for c are and outcon ita collection ir	, 05-Oct-2025 , 05-Fe National Cancer Inst follow-up care for se Il need for improved n underserved and u observational and/or nes for SGM people v n cancer care settings	eb-2026 , 05- itute (NCI) in xual and gen care delivery nderstudied intervention vith cancer, us, where app	Jun-2026 , 05-Oct-202 tends to support the der minority (SGM) ca and outcomes for SG population that is at h al studies of SGM surv ising interoperable se opriate.	26 rigorous Incer survivors. M cancer higher risk of vivors designed xual
120817	Population Approaches to Reduci Optional)	ng Alcoho	-related Cancer Risk (R01 Clinica	al Trial	National Institutes of Health/DHHS	PAR-23- 244	05-Jun-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	David Ber 240-276- <u>berrigad</u> Link to pr 05-Jun-20	rigan 5752 <u>Pmail.nih.gov</u> ogram URL 024 , 05-Oct-2024 , 05-Feb-2025 ce of Funding Opportunity (NOF	, 05-Jun-2025 Ω) aims to sup	, 05-Oct-2025 , 05-Fe	b-2026 , 05-	Jun-2026 , 05-Oct-202	26 es to

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
	i t i l c c	ncreasing to alcohol mplemen evels of c use disorc encourage disparities	g awareness of the relationship consumption, developing and/ ntation of population-level inter consumption, such as moderate der (AUD) from the perspective ed, as is attention to underrepress s such as American Indian, Alask	between alcoh or evaluating a ventions to rec and heavy drin of cancer prev esented minori can Native, and	ol and cancer risk, ur Icohol policy approa duce alcohol-related o hking, are of particula ention and control. P ty (URM) population I sexual and gender n	nderstanding and ches, and the de cancer risk. Appl ar interest, as we roposals address s experiencing co ninority populati	d changing social n velopment, testing ications that addre Il as those focusing sing understudied ancer and alcohol- ons.	orms related g, and ess multiple g on alcohol areas are related
109791	Accelerating the Pace of Child Heal Brain Cognitive Development (ABC	<u>th Resear</u> D) Study (	rch Using Existing Data from the (R01-Clinical Trial Not Allowed)	<u>Adolescent</u>	National Institutes of Health/DHHS	PAR-22- 137 07-	May-2024	1,250,000 USD
	Contact Name J Contact Telephone 3 Contact Email 2 Sponsor Website Program URL 1 Deadline Dates (ALL) 0 Synopsis t i i i i i	Iulia Zehr, 301-443-1 Zehrj@ma Link to pro O7-May-2 The Adole Substance years-old chrough the proposing nformation grant med	, Ph.D. L617 <u>ail.nih.gov</u> <u>ogram URL</u> 024 , 05-Jun-2024 , 07-Sep-2024 escent Brain Cognitive Developm e use, cultural and environments and following them longitudina he NIMH Data Archive. The purp g the analysis of this public use of on about the ABCD Study may b chanism, whereas its companior	4 , 05-Oct-2024 nent (ABCD) St al factors, and lly to early adu pose of this Fun lataset to incre e found on the n FOA, PAR-22-	4, 07-Jan-2025, 05-F udy is collecting data brain structure and fu lthood. These data w nding Opportunity Ar ease knowledge of ad e ABCD Study web pa 138, seeks shorter, h	eb-2025 , 07-Ma on health and n unction from you will be made ava nnouncement (Fi olescent health ge (www.abcdst igher-risk R21 gi	y-2025 nental health, cogr uth starting when t ilable to the scient OA) is to encourag and development. udy.org). This FOA rant applications.	itive function, hey are 9-10 ific community e applications More uses the R01
109941 [	ocused Technology Research and	Developn	nent (R01 Clinical Trial Not Allov	<u>ved)</u>	National Institutes of Health/DHHS	PAR-22- 127 07-	May-2024	Not Specified
	Contact Name F Contact Telephone Contact Email Sponsor Website Program URL	Fei Wang, wangf@m Link to pro	. Ph.D. nail.nih.gov ogram URL					

SPIN ID	Program Title	Sponsor Na	me	Sponsor Num	ber		Deadline Date	Funding Amount
	Deadline Dates (ALL) This insti enal tech sign of b devi by h dem As s que opti	lay-2024 , 05-Jun- Funding Opportur Jutes or Centers (I le acquisition of k ficantly advance t omedical research tes, algorithms an Juman intervention onstrated proof-o ich, applications s tions are not resp nization, hardenir	2024, 07-Sep-202 nity Announcemen Cs) participating in piomedical knowled or impacting future he current state of n questions. These d software, chemic n to become resear f-concept that hav hould not propose ponsive to this FOA ng, or obvious extra	4, 05-Oct-2024 at (FOA) support the FOA that for dge. Projects sh biomedical res f the art and be outcomes may cal reagents and rch tools. The go re remaining sig to test specific and will be adn apolations of es	, 07-Jan-2025, 05-F s projects relevant to ocus solely on the de nould be justified in t earch. Outcomes or sufficiently characte include, but are not d processes, biologica oal of this FOA is to s nificant technical cha biological questions ninistratively withdra tablished technolog	eb-2025 , 07-Ma o the NIGMS mis evelopment of te products of the rized for applica limited to: labor al molecules or s upport the deve allenges to full in . Applications pr awn without rev y will be a lower	y-2025 sion or those of ot chnologies with th al innovation and u proposed project s tion in addressing a atory instruments ystems that have b lopment of techno plementation and oposing to test spe ew. Applications w priority for funding	ther NIH e potential to atility of such should a broad range and other been modified logies with broad utility. ecific biological vith a focus on g.
120387	optimization, hardening, or obvious extrapolation condary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Re atcomes (R01 Clinical Trial Not Allowed)				National Institutes of Health/DHHS	PAR-23- 254 05-	Jun-2024	1,750,000 USD
	Contact Name Mel	ssa Rotunno, Ph.D	).					
	Contact Telephone 240	276-7245						
	Contact Email <u>rotu</u>	nnom@mail.nih.g	<u>ov</u>					
	Sponsor Website							
	Program URL <u>Link</u>	to program URL						
	Deadline Dates (ALL) 05-J	ın-2024 , 05-Oct-2	2024 , 05-Feb-2025	5 , 05-Jun-2025 ,	05-Oct-2025 , 05-Fe	eb-2026 , 05-Jun	2026	
	Thro Insti data redu Synopsis cano lifes exis met que	ugh this Notice of cutes encourages sets and database ction, survival, or er by supporting t yle, genomic, and ing data. Applicat nods of analyses, o tions in cancer re	Funding Opportur submission of appl resources, with the response to treatr the analysis of exist molecular profiles ions may include n or novel combinati search.	hity (NOFO), the lications propos ne ultimate aim ment, etc.). The ting clinical, env s data. Applican new research air ons and integra	National Cancer Ins ing to conduct secor to elucidate cancer i goal of this initiative ironmental, surveilla ts are encouraged to ns that are being add tion of datasets that	titute (NCI) alon idary data analys isk and related of is to address ke ance, health serv b leverage and po dressed with exist allow the explo	g with other partic sis and integration outcomes (e.g., risk y scientific questio ices, vital statistics erform innovative a sting data, new or a ration of importan	ipating of existing prediction or ns relevant to behavioral, analyses of the advanced t scientific

SPIN ID	Program Title	Sponsor Nai	ne	Sponsor Numl	ber		Deadline Date	Funding Amount
120101	Social Disconnection and Suicide	Risk in Late Life (R01 Cli	nical Trial Optiona	<u>l)</u>	National Institutes of Health/DHHS	PAR-23- 238 05-	Jun-2024	Not Specified
	Contact Name	Jovier Evans, Ph.D.						
	Contact Telephone	301-443-6328						
	Contact Email	jevans1@mail.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2	024 , 02-Feb-2025	<b>,</b> 05-Jun-2025	, 05-Oct-2025 <i>,</i> 05-Fe	b-2026 , 05-Jun	-2026	
	Synopsis	disconnection in late-li mechanisms by which behaviors in late life. N neurobiological, behav PAR-23-239 solicits R2 the R21 mechanism.	fe and late-life sui social disconnection fechanisms to be ioral, and environ applications. Hig	cidal thoughts a on confers risk f considered exis mental. This NC h risk/high payo	and behaviors. Of spe for, and social integra t at multiple levels o DFO solicits R01 appli off projects that lack	ecific interest is r ation protects ag f analysis, includ cations, while th preliminary data	resses the link ber research that iden gainst, suicidal tho ing but not limited the companion annu a may be most app	tifies ughts and to ouncement propriate for
120715	Personal Health Informatics for D Trial Optional)	elivering Actionable Ins	ghts to Individuals	s (R01 Clinical	National Institutes of Health/DHHS	PAR-23- 245 05-	Jun-2024	1,000,000 USD
	Contact Name	Allison Dennis, PhD						
	Contact Telephone	301-827-9721						
	Contact Email	allison.dennis@nih.gov	<u>/</u>					
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2	024 , 05-Feb-2025	<b>,</b> 05-Jun-2025	, 05-Oct-2025 <i>,</i> 05-Fe	b-2026 , 05-Jun	2026 , 05-Oct-202	<u>'</u> 6
	Synopsis	The purpose of this No science approaches the participating institutes by providing meaningf analysis, and personali informatics tools, syste	tice of Funding Op at can help individ listed in this NOF( ul and actionable i zed risk assessmen ems, and platforms	pportunity (NOF uals understand O seek applicati insights to indiv nts and interpress s can best prese	O) is to advance the d and improve their h ons that further the iduals through innov etation. Applications ent the results, interp	development of nealth through a science of perso ative personal h seeking to advar pretation, and lin	novel informatics ctionable insights. nal health informa ealth data collectince the understand nitations of persor	and data The NLM and atics on, integration, ding of how nalized

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
		assessme real-worl and platfe	nts for the benefit of individuals d evaluation to inform the desig orms for the benefit of individua	are encourage n of generaliza Ils in understan	ed. Applications shou ble, reusable, and sc ding and improving	ld include en alable person their health.	d user engaged appro al health informatics	oaches and tools, systems,
110112	Leveraging Health Information Te Disparities (R01 Clinical Trial Opti	<u>chnology (</u> onal <u>)</u>	Health IT) to Address and Reduc	ce Health Care	National Institutes of Health/DHHS	PAR-22- 145	)7-May-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Yewande 301-402-4 <u>beda.jear</u> <u>Link to pr</u> 07-May-2 This fund informati	A. Oladeinde, Ph.D. 4307 <u>h-francois@nih.gov</u> <u>ogram URL</u> .024 , 05-Jun-2024 , 07-Sep-2024 ing opportunity announcement on technology (bealth IT) to red	4 , 05-Oct-2024 (FOA) seeks to	, 07-Jan-2025 , 05-F support research tha	eb-2025 , 07- at examines tl	May-2025 ne impact of leveragin th care services nation	ng health
110794	Notice of Special Interest (NOSI): Prevention of HIV or Treatment o	communi Sustained f Latent TE	cation, and health outcomes for Release of Antivirals for Treatm 8/HBV (SRATP)	populations the	National Institutes of Health/DHHS	NOT-AI- 22-042	07-May-2024	Not
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Marina P 301-761- <u>marina.p</u> Link to pr 07-May-2 The purp portfolio of protec (implant,	rotopopova, Ph.D. 7653 rotopopova@niaid.nih.gov ogram URL .024 , 05-Jun-2024 , 07-Sep-2024 ose of this Notice is to encourag of SR/LA products for preventio tion of three (3) months from ei transdermal patch, etc.) to refle	4 , 05-Oct-2024 e new applicati n and treatmer ther a single do ect current state	, 07-Jan-2025 , 05-F ons to support furth It of HIV. SR/LA antir Ising (injection, oral a e of SR/LA drug mark	eb-2025 , 07- er developme etroviral proc administratio set for HIV tre	May-2025 ent of a diverse and c lucts will have a minin n) or continuous dosi atment or prevention	omprehensive mum window ng regimen n.
110513	Notice of Special Interest (NOSI): Developmental Neuroscience Bra	High Prior nch in the	ty Areas in Genetics, Epigenetic Division of Neuroscience and Be	s, and ehavior	National Institutes of Health/DHHS	NOT-DA- 23-004	)7-May-2024	Not Specified

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
		l						
	Contact Name	Jonathan	D. Pollock, Ph.D.					
	Contact Telephone	301-435-1	L309					
	Contact Email	Тропоска	<u>imail.nin.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL			1 2025 07 M		07.07.0
	Deadline Dates (ALL)	07-May-2 2025	024 , 05-Jun-2024 , 07-Sep-2024	4 , 05-Oct-2024	, 07-Jan-2025 , 05-F	eb-2025 , 07-Ma	y-2025 , 05-Jun-20	25 , 07-Sep-
	Synopsis	The missi animal an guide trea genetics,	on of the Division of Neuroscien d human research aimed at ide atment strategies. The Genetics, epigenetics, and developmenta	ice and Behavio ntifying the cau , Epigenetics, a I mechanisms t	or (DNB) is to discove uses and consequenc nd Development (GE hat underlie addictic	er, facilitate and es of drug addic D) Branch withir on and substance	promote outstandi tion across the life n DNB supports res e use disorders (SU	ng basic span and to earch on the D).
123847	Investigating Distinct and Overlap in LATE, FTD & other ADRDs (R01	ping Mech - Clinical T	aanisms in TDP-43 Proteinopath rial Not Allowed)	ies, including	National Institutes of Health/DHHS	PAR-24- 148 04-	Jun-2024	2,500,000 USD
	Contact Name	Linda Mc	Gavern, PhD					
	Contact Telephone							
	Contact Email	mcgavern	lm@ninds.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	04-Jun-20	24 , 04-Oct-2024					
	Synopsis	This Notic molecular between as, but no neuropat understar	e of Funding Opportunity (NOF r relationships between TDP-43 at least two TDP-43 proteinopat ot limited to, Limbic-predominar hological change (AD-NC), or Fro nd distinct and overlapping mec	O) supports stu pathology and thies, one of w nt Age-related ontotemporal l hanisms in the	idies establishing dee clinical phenotypic o hich must be an Alzh FDP-43 Encephalopa obar degeneration w se syndromes.	eper mechanistic outcomes. Additi eimer's Disease- thy (LATE), with ith TDP-43 inclu	insights and causa onally, it requires o Related Dementia or without Alzheim sions (FTLD-TDP), t	Il cellular and comparisons (ADRD), such ler's disease o further
106925	Notice of Special Interest (NOSI): Contributions to Cognitive Impair	Promoting ment and	Research To Understand Vascu Dementia (VCID)	lar	National Institutes of Health/DHHS	NOT-HL- 23-002 07-	May-2024	Not Specified
	Contact Name	Jue Chen,	Ph.D.					

SPIN ID	Program Title	Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
	Contact Telephone Contact Email	301-435-0550 jue.chen@nih.gov					
	Sponsor Website Program URL	Link to program URL					
	Deadline Dates (ALL) Synopsis	07-May-2024, 05-Jun-2024, 07-Sep-202 The purpose of this Notice is to inform p research to understand mechanisms of v new approaches for the treatment of VC	24 , 05-Oct-2024 ootential applica /ascular contrib CID.	, 07-Jan-2025 , 05-F nts about an area of utions to cognitive in	eb-2025 , 07-Ma special interest t npairment and d	y-2025 :o NHLBI, NINDS ai ementia (VCID) an	าd NIA in d to develop
111036	Dissemination and Implementatic	on Research in Health (R01 Clinical Trial O	ptional)	National Institutes of Health/DHHS	PAR-22- 105 07-1	May-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URI	Gila Neta, Ph.D. 240-276-6785 gila.neta@nih.gov					
	Deadline Dates (ALL) Synopsis	07-May-2024, 05-Jun-2024, 07-Sep-202 The purpose of this Funding Opportunity strategies for overcoming barriers to the interventions, practices, programs, tools and implementation of evidence-based there is a benefit in understanding circuit that are ineffective, unproven, low-value research methods and measures are end services (e.g. cancer screening) that may applications must be within the scope of	24 , 05-Oct-2024 y Announcemer e adoption, adap s, treatments, gu interventions ar mstances that c e, or harmful. In couraged. Applie y have dropped f the mission of	4, 07-Jan-2025, 05-F at (FOA) is to support otation, integration, s uidelines, and policies nong underrepresent reate a need to stop addition, studies to cations that focus on off amidst the ongoir one of the Institutes,	eb-2025 , 07-Ma studies that will scale-up, and sus s. Studies that pr ted communities or reduce ("de-ir advance dissemi re-implementati ng COVID pander /Centers listed al	y-2025 identify, develop, tainability of evide omote equitable of are encouraged. ( mplement") the us nation and implem on of evidence-ba nic are encouraged bove.	and/or test ince-based lissemination Conversely, e of practices nentation sed health d. All
111616	Notice of Special Interest (NOSI): for the INCLUDE (INvestigation of Understand Down syndromE) Pro	NIH Research Project Grants on Down Sy Co-occurring conditions across the Lifest ject	ndrome (R01) pan to	National Institutes of Health/DHHS	NOT-OD- 22-123 07-I	May-2024	Not Specified
	Contact Name	Charlene Schramm, PhD					

SPIN ID	Program Title		Sponsor Name	Sponsor Num	per		Deadline Date	Funding Amount		
	Contact Telephone	301-402-3	3739							
	Contact Email	schramm	c@nih.gov							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	07-May-2								
	Synopsis	The purpe on Down communi Applicant innovativ	ose of this Notice of Special Inte syndrome and that meet progra cation of outputs of appropriate s responding to this NOSI are st e data analytics approaches (see	rest (NOSI) is to ammatic object e interest to bro rongly encoura e Goal 3, NIH St	o support research p ives for the INCLUDE oader communities a ged to describe plan rategic Plan For Data	roject grant (R01 E Project. Sharing are a high priority s for rapid sharin a Science).	) applications that of resources and o of the INCLUDE P g of data and resu	are focused effective roject. Its as well as		
117550	Development and Application of F Discovery and for Pathophysiolog	PET and SP ical Studie	ECT Imaging Ligands as Biomarl s of CNS Disorders (R01 Clinical	kers for Drug Trial Optional)	National Institutes of Health/DHHS	PAR-23- 164 07-1	May-2024	Not Specified		
	Contact Name	Enrique N	/ichelotti, Ph.D.							
	Contact Telephone	301-443-	5415							
	Contact Email	<u>michelott</u>	<u>iel@mail.nih.gov</u>							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	07-May-2 2025 , 05	024 , 05-Jun-2024 , 07-Sep-202 -Oct-2025 , 07-Jan-2026 , 05-Fel	4 , 05-Oct-2024 b-2026 , 07-Ma	, 07-Jan-2025 , 05-F y-2026	eb-2025 , 07-Ma	y-2025 , 05-Jun-20	25 , 07-Sep-		
	Synopsis	This Fund evaluatio (SPECT) ir in pre-clir use in clir 164).	ing Opportunity Announcement n of novel radioligands for posit maging in human brain and the i nical studies. These studies are e nical research. Projects proposin	t (NOFO) invites ron emission to incorporation o expected to pro g only preclinic	s research grant app pmography (PET) or s f pilot or clinical feas vide the requisite da ral animal studies sho	lications that pro single photon em sibility evaluation ata needed to adv ould consider the	pose the developr ission computed to from previously c vance promising Pl companion NOFC	nent and omography ollected data ET ligands for (PAR-23-		
117551	Development and Application of F Discovery and for Pathophysiolog Allowed)	PET and SP ical Studie	ECT Imaging Ligands as Biomarks of CNS Disorders (R01 Clinical	kers for Drug Trial Not	National Institutes of Health/DHHS	PAR-23- 165 07-1	May-2024	Not Specified		
	Contact Name	Enrique N	/lichelotti, Ph.D.							

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
	Contact Telephone	301-443-1	5415					
	Contact Email	michelott	riel@mail.nih.gov					
	Sponsor Website		<u> </u>					
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2025 , 05		4 , 05-Oct-2024 b-2026 , 07-Ma	, 07-Jan-2025 , 05-F y-2026	eb-2025 <i>,</i> 07-Ma	y-2025 , 05-Jun-20	)25 , 07-Sep-
	Synopsis	This Notio novel rad in rodent appropria 23-164).	ce of Funding Opportunity (NOF ioligands for positron emission and nonhuman primate brain a ate model development. Project	O) invites resea tomography (P nd incorporatio s proposing clin	arch grant application ET) or single photon on of pilot or clinical nical assessments of	ns that propose t emission compu feasibility evalua novel radioligand	the preclinical devi ted tomography (S tion in pre-clinical ds should respond	elopment of PECT) imaging studies and to NOFO (PAR-
123846 <mark>A</mark>	<u>Aechanistic Investigations into AI</u> Ilowed)	<u>ORD Multi</u>	ple Etiology Dementias (R01 - Cl	linical Trial Not	National Institutes of Health/DHHS	PAR-24- 147 04-	Jun-2024	2,500,000 USD
	Contact Name	Linda Mc	Gavern, PhD					
	Contact Telephone							
	Contact Email	<u>mcgaverr</u>	nlm@ninds.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	04-Jun-20	024 , 04-Oct-2024					
	Synopsis	This Notio Dementia co-morbio whether, outcomes	ce of Funding Opportunity (NOF as (ADRD) co-pathologies (e.g., t dities, in the same model systen and when these interactive mu s, such as cognitive, behavioral,	O) supports inv au, alpha-synu n to identify int lti-pathology m or functional ir	vestigations with a m clein, TDP-43, TMEM veractions and cellula echanisms drive wor npairment.	inimum of two A 106B, vascular), r and molecular sening pathophy	Izheimer's Disease with or without ris mechanisms to de ysiology and clinica	e-Related sk factors and etermine how, al phenotypic
099859 <mark>N</mark>	lotice of Special Interest (NOSI): cute Respiratory Distress Syndro	The Influe me/Acute	nce of Host Resilience on Hetero Lung Injury (ARDS/ALI)	ogeneity of	National Institutes of Health/DHHS	NOT-HL- 20-814 07-	May-2024	Not Specified
	Contact Name	Guofei Zh	nou, PhD					
	Contact Telephone	301-827-7	7825					

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
	Contact Email	guofei.zh	ou@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	024 , 05-Jun-2024					
	Synopsis	The purport research t /acute lur	ose of this Notice of Special Inte to understand host resilience as ng injury (ALI).	rest (NOSI) is to a critical deter	o inform potential ap minant of outcomes	oplicants of the splicants of the splicants of the splication of t	pecial interest of N ory distress syndro	IHLBI in ome (ARDS)
109172 A	<u>Aicrobial-based Cancer Imaging a</u> Ilowed)	and Therap	y - Bugs as Drugs (R01 Clinical T	rial Not	National Institutes of Health/DHHS	PAR-22- 085	un-2024	Not Specified
	Contact Name	Avi Rasoo	ly, PhD					
	Contact Telephone	240-276-6	5196					
	Contact Email	rasoolya@	Dmail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	05-Jun-20	024 , 05-Oct-2024 , 05-Feb-2025					
	Synopsis	This Fund bacteriop interactio imaging, t tumor im tools and Applicant microbial funding o	ing Opportunity Announcement hages, or other non-oncolytic vi ns between microorganisms, tu therapeutics or diagnostics. Proj munity, or as delivery vehicles f approaches. This FOA will supp s are encouraged to address bo based cancer therapy (including pportunity is part of a broader f	t (FOA) solicits iruses and their mors, and the jects can focus or treatment, c ort basic mech th the microbia g therapies for NCI-sponsored	grant applications pr natural products to immune system, and on using microorgan liagnosis, or imaging, anistic and preclinica I and tumor aspects oral cancer), tumor i research on microbia	oposing to utilize study the under l to explore their isms as anti-tum , complementing I studies in cell co of microbial tum maging, tumor d al based cancer t	e bacteria, archaeb ying mechanisms clinical potential f or agents, as activa or synergizing wit ulture and animal or interactions rel etection, or diagno herapy.	acteria, of the complex or cancer ators of anti- h existing models. evant to osis. This
115307 <mark>N</mark>	lotice of Special Interest (NOSI): esearch	<u>Understan</u>	ding Sudden Death in the Youns	<u>g Through</u>	National Institutes of Health/DHHS	NOT-HL- 22-040 07-1	May-2024	Not Specified
	Contact Name	Kristin M.	Burns, MD					
	Contact Telephone	301-594-6	5859					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Contact Email Sponsor Website	<u>kristin.burns@nih.gov</u>							
	Program URL	Link to program URL							
	07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-S Deadline Dates (ALL) 2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 Feb-2027 , 07-May-2027 , 05-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 07-Jan-2028								
	This Notice of Special Interest (NOSI) highlights interest in receiving grant applications focused on mechanistic, genetic, ar other studies to evaluate causes and consequences of, and risk factors for sudden death in the young (SDY). Studies are required to use phenotypic data and/or DNA samples and/or associated sequence data from the NIH/CDC Sudden Death i Synopsis the Young (SDY) Case Registry as foundations for their research. Studies may use SDY Case Registry phenotypic data and/or samples and/or sequence data alone or in combination with other cohorts. Results of such studies are required to adhere the NIH Data Sharing Policy so that the data is disseminated widely and provides an evidence base to advance discussions about screening and prevention of SDY.								
116310 C	lotice of Special Interest (NOSI): I OVID-19-Associated Coagulopat	Enhancing Research on Deciphering Mech า <u>y</u>	anisms of National Institutes of Health/DHHS	NOT-HL- 23-003 07-N	May-2024	Not Specified			
	Contact Name	Anthony Agresti							
	Contact Telephone	301-827-8014							
	Contact Email	agrestia@nhlbi.nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Sep-2024	4 , 05-Oct-2024 , 05-Feb-2025 , 05-J	un-2025					
	Synopsis	This Notice of Special Interest (NOSI) aim Associated Coagulopathy (CAC) which are hypercoagulability at genomic, molecular future design of early diagnostics and effe applied to on-going COVID-19 clinical tria	s to accelerate a comprehensive un e provoked by vascular endothelial o ; and cellular levels. Knowledge obt ective treatment for high-risk patien ls.	derstanding of th cell injury, hyperi tained from such nts as well as ena	ne mechanisms of mmune responses studies may be ap ble CAC research f	COVID-19- 5, and plied to the findings to be			
122108 L	FA-AI-23-061 Long-Acting Drug iving with HIV-1 II (LADDS II) (R61	g Delivery Systems for ART Optimization in L/R33 Clinical Trial Not Allowed)	<u>Children</u> National Institutes of Health/DHHS	RFA-AI- 23-061 07-N	May-2024	5,450,000 USD			

Contact Name Tania B. Lombo Rodriguez, Ph.D.

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Contact Telephone 301-761	-/612							
	Contact Email tania.lor	nbo@mail.nih.gov							
	Sponsor Website								
	Program URL Link to p	rogram URL							
	Deadline Dates (ALL) 07-May-	2024 , 05-Jun-2024 , 07-Sep-202	4 , 05-Oct-2024 , 07-Jan-2025 , 05-F	eb-2025 , 07-Ma	y-2025				
	drug delivery systems for improved, simplified treatment of HIV-1 in children. This NOFO invites applicants engaged in the Synopsis development of existing long-acting platforms at early stages of development stages to perform specific preclinical activitie that enable product optimization and accelerated translation to HIV-infected children. Collaborative research partnerships with industry are required.								
	RFA-NS-22-024 HEAL Initiative Advanced	Postdoctoral-to-Independent Ca	National Institutes	REA-NS-		Not			
114710	Transition Award in PAIN and SUD Researc	h to Promote Diversity (K99/R00	Independent of Health/DHHS	22-024 11-J	lun-2024	Specified			
	Basic Experimental Studies with Humans R	equired)							
	Contact Name DP Moh	apatra, Ph.D.							
	Contact Telephone 301-496	-9964							
	Contact Email dp.moha	ipatra@nih.gov							
	Sponsor Website								
	Program URL <u>Link to p</u>	rogram URL							
	Deadline Dates (ALL) 11-Jun-2	024 , 11-Oct-2024 , 11-Feb-2025							
	and well Diversity working eligible p Synopsis equivale awardee Annound basic sci meet the	-trained, independent investigat -trained, independent investigat ) conducting Pain and/or SUD re in research areas supported by t postdoctoral researchers from th nt faculty positions. The program s establish independent research cement is for basic science exper- ence studies involving human pa e definition of basic research. Typ	ratinway to independence Award (K ors from diverse backgrounds (e.g. search, in order to promote a diver he NIH HEAL Initiative <sup>®</sup> . This progra eir mentored, postdoctoral researc n will provide independent NIH rese n programs in areas supported by th imental studies involving humans, r rticipants." These studies fall withir pes of studies that should be submit	see NOT-OD-20-0 se pool of availat am is designed to h positions to ind earch support dur ne NIH HEAL Initia referred to in NOT the NIH definition the NIH definition	Dis to support a co D31, Notice of NIH' ole independent in facilitate a timely lependent, tenure- ring this transition ative <sup>®</sup> . This Fundin T-OD-18-212 as "p on of a clinical trial DA include studies	s Interest in vestigators transition of track or to help g Opportunity rospective and also that			

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
		biomedica without s basic expo with hum proposed Centers (I	al or behavioral outcomes in hu pecific application towards pro erimental study with humans, o ans led by another investigator project must be related to the Cs) based on their scientific mi	imans for the p cesses or produ or proposing to r, must apply to programmatic ssions.	urpose of understand acts in mind. Applican gain research experie the 'Independent Cli interests of one or m	ling the fundame ts not planning a ence in a clinical nical Trial Not Al ore of the partic	ental aspects of ph in independent cli trial or basic exper lowed' companion ipating NIH Institu	enomena nical trial or imental study FOA. The tes and
114711	RFA-NS-22-025 HEAL Initiative A Transition Award in PAIN and SUE Clinical Trial Not Allowed)	Advanced I D Research	Postdoctoral-to-Independent C to Promote Diversity (K99/R00	<u>areer</u> ) Independent	National Institutes of Health/DHHS	RFA-NS- 22-025 11-J	un-2024	Not Specified
	Contact Name	DP Moha	patra, Ph.D.					
	Contact Telephone	301-496-9	9964					
	Contact Email	dp.moha	oatra@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	11-Jun-20	024 , 11-Oct-2024 , 11-Feb-2025	5				
	Synopsis	The purpe and well- Diversity) working in eligiblepo equivalen awardees Announce clinical tri with Hum co-mento	ose of this NIH HEAL Initiative® trained, independent investigat conducting Pain and/or SUD re- n research areas supported by a stdoctoral researchers from th t faculty positions. The program establish independent research ement (FOA) is designed specifi al, a clinical trial feasibility stud- nans (BESH). Applicants to this F or. Those proposing an independent	Pathway to Ind cors from divers esearch, in orde the NIH HEAL In eir mentored, p n will provide in h programs in a cally for candid ly, an ancillary s OA are permitt dent BESH as le	ependence Award (K se backgrounds (e.g. s r to promote a divers itiative <sup>®</sup> . This progra postdoctoral research independent NIH research areas supported by th ates proposing research study to a clinical trial red to propose research ad investigator, shou	99/R00) program see NOT-OD-20-( se pool of availab m is designed to positions to inde arch support dur e NIH HEAL Initia rch that does not l, or an independ ch experience in Id apply to the co	n is to support a co 031, Notice of NIH ole independent in facilitate a timely ependent, tenure- ing this transition ative <sup>®</sup> . This Fundin t involve leading a lent Basic Experim a clinical trial led ompanion FOA (RF	whort of new s Interest in vestigators transition of track or to help g Opportunity n independen ental Studies by a mentor o A-NS-22-024)
106064	Maximizing Opportunities for Scie Postdoctoral Career Transition Av	entific and vard to Pro	Academic Independent Careers	s (MOSAIC) ependent Basic	National Institutes	PAR-21- 07-1	May-2024	Not

Contact Name Lanay M. Mudd, Ph.D., FACSM

Experimental Studies with Humans Required (BESH))

of Health/DHHS

273

Specified

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Da	e Funding Amount
	Contact Telephone	301-594-	9346			
	Contact Email	lanay.mu	dd@nih.gov			
	Sponsor Website					
	Program URL	Link to pr	ogram URL			
	Deadline Dates (ALL)	07-May-2	2024 , 12-Jun-2024 , 07-Sep-202	4		
Title     Contact Telephone   301-594-9346     Contact Email   lanay.mudd@nih.gov     Sponsor Website   Program URL     Dradition   Data (dip nih.gov)     Sponsor Website   Program URL     Dradition   Diff. (dip nih.gov)     Deadline Dates (ALL)   07-May-2024, 12-Jun-2024, 07-Sep-2024     The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Post     Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of early career, indepe     investigators from diverse backgrounds conducting research in NIH mission areas. The long-term goal of this p     enhance diversity in the biomedical research positions to independent, tenue-track or equivalent research-intr     positions. The MOSAIC K99/R00 program will provide independent NIH research support before and after this     help awardees launch successful, independent research careers. Additionally, MOSAIC K99/R00 scholars will b     organized scientific cohorts and will be expected to participate in mentoring, networking, and professional dev     activities coordinated by MOSAIC Institutionally-Focused Research Education Award to Promote Diversity (UES     Synopsis   This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred     13:21 2 as "prospective basic science studies involving humans, referred <th>ependent s program is to tate a timely st in Diversity) intensive faculty his transition to II be part of development JE5) grantees. ed to in NOT-OD- H definition of a this FOA include ident variables) mental aspects of independent trial or basic Not Allowed' e participating NIH</th>	ependent s program is to tate a timely st in Diversity) intensive faculty his transition to II be part of development JE5) grantees. ed to in NOT-OD- H definition of a this FOA include ident variables) mental aspects of independent trial or basic Not Allowed' e participating NIH					
117692	RFA-MH-23-331 BRAIN Initiative Promote Diversity (K99/R00 Indep	<u>e Advance</u> pendent C	d Postdoctoral Career Transition linical Trial Not Allowed)	n Award to National Institutes RFA-MH- of Health/DHHS 23-331	13-Jun-2024	Not Specified

Contact Name James Churchill, Ph.D.

Contact Telephone 301-326-8800

Contact Email BRAINDIVERSITYK99R00@nih.gov

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	13-Jun-2024 , 11-Oct-2024 , 13-Feb-2025	,13-Jun-2025 ,15-Oct-2025 ,13-Fe	b-2026		
	Synopsis	The purpose of the NIH BRAIN Initiative program is to enhance diversity in the ner supported, independent investigators fro biomedical and behavioral sciences, in B transition of outstanding postdoctoral re postdoctoral research positions to indep independent NIH research support durin Notice of Funding Opportunity (NOFO) is leading an independent clinical trial, a cli Notice of Funding Opportunity (NOFO) a mentor. Those proposing a clinical trial o (RFA-MH-22-330).	Advanced Postdoctoral Career Trans euroscience workforce and maintain om diverse backgrounds, including the RAIN Initiative research areas. This p searchers with a research and/or cli endent, tenure-track or equivalent f g this transition to assist awardees i s designed specifically for candidates nical trial feasibility study, or an and re permitted to propose research ex r an ancillary clinical trial as lead inv	sition Award to P a strong cohort nose from under program is design nical doctorate c aculty positions. n launching inde s proposing resea illary study to a c perience in a clir estigator, should	promote Diversity of new and talente represented group ned to facilitate a t degree from mente The program will pendent research arch that does not clinical trial. Applic hical trial led by a r l apply to the com	(K99/R00) ed, NIH- os in the imely ored, provide careers. This involve cants to this mentor or co- panion NOFO
102740 <mark> </mark>	nnovation Grants to Nurture Initi Neurotherapeutic Agent Identifica	al Translational Efforts (IGNITE): Assay De ation (R61/R33 Clinical Trial Not Allowed)	velopment and National Institutes of Health/DHHS	PAR-21- 20-J 124 20-J	lun-2024	750,000 USD
	Contact Name	Becky Roof, PhD				
	Contact Telephone	301-496-1779				
	Contact Email	rebecca.roof@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	20-Jun-2024 , 21-Oct-2024				
	Synopsis	This funding opportunity announcement assays and conduct iterative screening en neuromuscular disorders. This FOA is par advance projects to the point where the other translational programs.	(FOA) encourages research grant ap fforts to identify and characterize po t of a suite of Innovation Grants to I y can meet the entry criteria for the	oplications to dev otential therapeu Nurture Initial Tr Blueprint Neuro	velop in vitro and/ tic agents for neu anslational Efforts therapeutics Netw	or ex vivo rological or (IGNITE) to vork (BPN) or
110969	National Cooperative Drug/Device Treatment of Mental Disorders or	e Discovery/Development Groups (NCDDO Alcohol Use Disorder (U19 Clinical Trial C	G) for theNational InstitutesOptional)of Health/DHHS	PAR-22- 144 25-J	lun-2024	Not Specified

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name L Contact Telephone 3 Contact Email I Sponsor Website Program URL 1 Deadline Dates (ALL) 2 T t synopsis C b p a f c t a f c t a f c t a f c t t a f c t t a f c t t a f c t t a f c t t a f t t t t t t t t t t t t t t t t	Linda Brace 301-443-3 brady@m Link to pro 25-Jun-20 The purpo cranslation neuromoo validate to for menta of promisi nvestigat applicatio candidate circuit-eng petween a projects d and often proposing put not lir bligonucle cherapies) area repre	dy, Ph.D. 563 hail.nih.gov Dgram URL 24 , 25-Oct-2024 , 24-Feb-2025 page of this Funding Opportunity in from discovery to early huma dulatory tools for basic and clinit pols (pharmacologic or neurostit I disorders; and support early-st ing drug candidates/devices and ional Device Exemption (IDE)-re- ins to advance the discovery, pri- agents and neurostimulation a gagement devices as tools to fur- academia and industry are stron- irected toward a specific major long-term approach should corr preclinical discovery of biotech- nited to, large biologic macrom eotide- and viral vector-based), . This FOA supports a discrete, esenting his or her specific inter	Announcement (FOA) is to n studies. Studies appropri cal research on mental hea mulation) in support of exp tage human studies to rapi d new indications for novel eady devices for the treatm eclinical development, and pproaches to treat mental rther characterize existing ngly encouraged. Projects s objective, basic theme or p sider the companion FOA mology products and biolo olecules, (e.g., proteins, an cell therapies, and novel er specified, circumscribed pr est and competencies.	accelerate innovative dr ate for this FOA will deve alth disorders or alcohol u perimental therapeutic st idly assess the safety, tole Investigational New Drug rent of mental disorders of proof of concept (PoC) to disorders or or AUD, and or to validate new drug/of eeking support for a rese program goal, requiring a (PAR-22-143). This FOA w gics with potential as can tibodies, and peptides), g merging therapies (e.g., n oject to be performed by	ug and device ther lop pharmacologic use disorder (AUD) udies of innovative erability, and pharr g (IND)-ready agen or AUD. This FOA e esting of new, ratio to develop novel l device targets. Part arch program of m broadly based, mu vill also support ap didate therapeutio gene-based therap nicrobial and micro	rapies and ; develop and e candidates macodynamics ts or ncourages onally based igands and merships nultiple ultidisciplinary plications es including, ies (i.e., obiome igator(s) in an
110968	National Cooperative Drug/Device I Treatment of Mental Disorders or A	Discovery Alcohol U	/Development Groups (NCDDG se Disorder (U01 Clinical Trial O	i) for the National Ir ptional) of Health/I	nstitutes PAR-22- DHHS 143	Jun-2024	Not Specified
	Contact Name L Contact Telephone 3 Contact Email <u>I</u> Sponsor Website	_inda Brac 301-443-3 brady@m	dy, Ph.D. 563 nail.nih.gov				

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount		
	Program URL Deadline Dates (ALL)	Link to pr 25-Jun-20	nk to program URL - Jun-2024 , 25-Oct-2024 , 24-Feb-2025							
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to accelerate innovative drug and device therapies translation from discovery to early human studies. Studies appropriate for this FOA will develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health disorders or alcohol use disorder (AUD); develop validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative candida for mental disorders or AUD; and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND) agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders or AUD. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders or AUD, and to develop n ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. Projects seeking support for a research program multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach should consider the companion FOA (PAR-22-144) This FOA will also sug applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therap including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therap including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therap including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therap including, but not limited to,								
110865	Notice of Special Interest (NOSI): related Adverse Events (irAEs) in (	Understan Cancer Imi	ding the Basic Mechanisms of Ir munotherapy	<u>mmune-</u>	National Institutes of Health/DHHS	NOT-CA- 22-063 07-	May-2024	Not Specified		
	Contact Name	Yin Liu, Pl	h.D.							
	Contact Telephone	240-276-0	6251							
	Contact Email	<u>liuy@mai</u>	<u>l.nih.gov</u>							
	Sponsor Website									
	Program URL	Link to pr	ogram URL	1. 10 1						
	Deadline Dates (ALL)	U/-May-2	024,05-Jun-2024,12-Jun-2024	+ , 16-JUN-2024	is to promoto mosts	nictio recorded	imed at batter	doretondiac		
	Synopsis	the patho	ophysiology of immune-related a	adverse events	(irAEs). It is anticipat	ed that the med	chanistic research	supported		

SPIN ID	D Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
		through t and/or ar outcomes underlyin and/or pa	his NOSI will build the foundation neliorate toxicities that can arise a. The proposed research can be g irAEs. Single investigators and stient characterization and select	onal knowledge e as a conseque basic or transl /or multidiscip ction are encou	which will ultimatel ence of current immu ational but should be linary teams with rele raged to apply.	y lead to better unotherapeutic e focused on rev evant expertise	strategies to predi regimens, and imp realing the mechan in the research are	ct, prevent rove treatment isms ra proposed
112346 <mark>(</mark>	lotice of Special Interest (NOSI): SGM)	<u>Research c</u>	on the Health of Sexual and Gen	<u>der Minority</u>	National Institutes of Health/DHHS	NOT-MD- 22-012 08-	Apr-2024	Not Specified
	Contact Name	Crystal L.	Barksdale, PhD MPH					
	Contact Telephone	301-827-4	1228					
	Contact Email	<u>crystal.ba</u>	rksdale@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2024 , 12 Jun-2025	024 , 05-Jun-2024 , 06-Jun-2024 ·Oct-2024 , 16-Oct-2024 , 07-Jar , 16-Jun-2025	4 , 12-Jun-2024 1-2025 , 05-Feb	, 16-Jun-2024 , 20-Ju -2025 , 12-Feb-2025	ın-2024 , 07-Sep , 16-Feb-2025 ,	o-2024 , 05-Oct-202 07-May-2025 , 05-	24 , 09-Oct- Jun-2025 , 12-
	Synopsis	This Notic limited to Individual included. orientatic orientatic	e calls for research on the healt , individuals who identify as lest s with same-sex or -gender attr These populations also encomp on, gender identity or expression on, gender, and/or sex.	th of sexual and bian, gay, bisex actions or beha bass those who n, or reproduct	d gender minority po ual, asexual, transge aviors and those with do not self-identify v ive development is cl	pulations. SGM nder, Two-Spirit a difference in vith one of thes haracterized by	populations includ c, queer, and/or int sex development a e terms but whose non-binary constru	e, but are not ersex. ire also sexual icts of sexual
112751	lotice of Special Interest (NOSI):	HEAL Initia	tive: Clinical Translation of Diag	nostic and	National Institutes	NOT-NS- 20-	Jun-2024	Not
<u><u> </u></u>	herapeutic Devices via Blueprint	MedTech			of Health/DHHS	23-002	5011-2024	Specified
	Contact Name	Eric Huda	k, Ph.D.					
	Contact Telephone	301-496-2	1779					
	Contact Email	NINDS-De	evices@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	20-Jun-20	24					

SPIN ID	Program Title		Sponsor Name	Sponsor Numb	ber		Deadline Date	Funding Amount
	Synopsis	This Notio to End Ac Small Bus subseque (OUD). Ap mission o	e of Special Interest (NOSI) enc diction Long-Term (HEAL) Initia iness Concerns (SBCs) are encou nt clinical feasibility studies of n oplications supporting the devel f the HEAL Initiative are encoura	ourages the tra tive and overse uraged to subm nedical devices opment and tra aged.	nslation of the novel en by the NIH Bluep it grant applications for the diagnosis and anslation of groundb	I neurotechnolo rint MedTech p that propose n d treatment of reaking neuroto	ogies, funded throu rogram. Academic on-clinical validatic pain and opioid use echnologies that fit	gh the Helping institutions and in for e disorder within the
112471	Notice of Special Interest (NOSI): Craniofacial Embryogenesis	Single-Cell	Level Spatiotemporal Mapping	of Dental and	National Institutes of Health/DHHS	NOT-DE- 22-003 07	-May-2024	Not Specified
	Contact Name Contact Telephone Contact Email	Kathryn S 301-827-4 kathryn S	tein, PhD 1653 tein@nih.gov					
	Sponsor Website	<u>Racin ynis</u>						
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2025 <i>,</i> 05	024 , 05-Jun-2024 , 12-Jun-2024 Feb-2025 , 12-Feb-2025 , 16-Fe	4 , 16-Jun-2024 b-2025 , 07-Ma	, 07-Sep-2024 , 05-O iy-2025 , 05-Jun-202	oct-2024 , 12-00 5 , 16-Jun-2025	ct-2024 , 16-Oct-20 , 05-Sep-2025	24 , 07-Jan-
	Synopsis	The Natic encourag understar	nal Institute of Dental and Cran e research that applies cutting e nd the complex spatiotemporal	iofacial Researd edge imaging ar context of the d	ch (NIDCR) is issuing nd high-throughput ' developing dental an	this Notice of S omics approach d craniofacial t	pecial Interest (NO nes at the single-cel issues in the embry	SI) to I level to o.
122207	Ethical, Legal and Social Implication	ons (ELSI) F	Research (R01 Clinical Trial Optic	onal)	National Institutes of Health/DHHS	PAR-23- 293	-Jun-2024	Not Specified
	Contact Name	Dave Kau	fman					
	Contact Telephone	301-402-4	1997					
	Contact Email	dave.kaut	man@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	18-Jun-20	24 , 21-Oct-2024 , 20-Feb-2025	, 17-Jun-2025 ,	20-Oct-2025 , 19-Fe	b-2026 , 18-Jur	n-2026 , 20-Oct-202	.6
	Synopsis	This Notic ethical, le	e of Funding Opportunity (NOF gal and social implications (ELSI	O) invites Resea ) of human gen	arch Project Grant (R etic or genomic rese	01) application arch. Applicatio	s that propose to stons may propose st	tudy the udies using

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	------------------	--------------	----------------	---------------	-------------------

either single or mixed methods. Approaches may include but are not limited to empirical qualitative and quantitative methods, and conceptual, legal, and normative analyses. Applied research designed to address ELSI issues in genetics and genomics will also be considered responsive. Direct engagement with communities and other interested groups is encouraged, but not required. Plan for Enhancing Diverse Perspectives The NIH recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to: Transdisciplinary research projects and collaborations among researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based). Individual applications and partnerships that enhance geographic and regional heterogeneity. Investigators and teams composed of researchers at different career stages. Participation of individuals from diverse backgrounds, including groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women. Opportunities to enhance the research environment to benefit early- and mid-career investigators. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

122256 Ethical, Legal and Social Implication (R21 Clinical Trial Optional)	ons (ELSI) Exploratory/Developmental Research Grant	National Institutes of Health/DHHS	PAR-23- 294	18-Jun-2024	275,000 USD
Contact Name	Dave Kaufman				
Contact Telephone	301-402-4997				
Contact Email	dave.kaufman@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	18-Jun-2024 , 21-Oct-2024 , 20-Feb-2025 , 17-Jun-2025 ,	, 20-Oct-2025 , 19-Fe	b-2026 , 18	-Jun-2026 , 20-Oct-2026	
Synopsis	This Notice of Funding Opportunity (NOFO) invites Explo propose to study the ethical, legal and social implication	oratory/Developmen ns (ELSI) of human ge	tal Research netic or ger	n Grant (R21) applications nomic research. Applicatic	that ons may

SPIN ID	Program Title		Sponsor Name	Sponsor Numb	ber		Deadline Date	Funding Amount
122258	Ethical, Legal and Social Implication	propose s or develo qualitativ ELSI issue stakehold	tudies using either single or mix p preliminary data in preparation e and quantitative methods, and s in genetics and genomics will a fers is encouraged, but not requion small Research Grant (R03 Clinic	ed methods, th on for larger stu d conceptual, le also be conside ired. <u>al Trial</u>	hat break new groun dies. Approaches ma gal, and normative a red responsive. Dire National Institutes	d, extend previo ay include but ar analyses. Applied ct engagement v PAR-23- 18-	us discoveries in n e not limited to en d research designe vith communities a Jun-2024	ew directions, npirical d to address and other 100,000
	<u>Jptional)</u>	1			of Health/DHHS	295		USD
	Contact Name	Dave Kau	fman					
	Contact Telephone	301-402-4	1997					
	Contact Email	dave.kauf	man@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	18-Jun-20	24 , 21-Oct-2024 , 20-Feb-2025	, 17-Jun-2025 ,	20-Oct-2025 , 19-Fe	b-2026 , 18-Jun-	2026 , 20-Oct-202	6
	Synopsis	This Notic legal and contained normative new or er existing d ELSI issue stakehold	e of Funding Opportunity (NOF social implications (ELSI) of hum I research projects, such as thos or conceptual analyses, includ nerging issues. This mechanism ata. Applications may propose s s in genetics and genomics will ers is encouraged, but not requ	O) invites Small nan genetic or g ie that involve s ing focused leg can also be use tudies using eit also be conside ired.	Research Grant (RO. genomic research. The ingle investigators. ( al, economic, philoso ed for the collection of ther single or mixed red responsive. Direct	3) applications tl ese applications Of particular interplications ophical, anthropo of preliminary da methods. Applie ct engagement v	nat propose to stud should be for sma crest are projects t plogical, or historic ata and the second d research designe with communities a	dy the ethical, III, self- hat propose al analyses of ary analysis of ed to address and other
106107	Blueprint Medtech: Small Busines	<u>s Translato</u>	or (U44 - Clinical Trial Optional)		National Institutes of Health/DHHS	PAR-21- 282 20-	Jun-2024	Not Specified
	Contact Name	Leonardo	Angelone, Ph.D					
	Contact Telephone							
	Contact Email	Blueprint	-MedTech@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	20-Jun-20	24					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The purpose of this Funding Opportunity (SBCs) to pursue translational activities a diagnostic devices for disorders that affe include implementation of clinical proto- validation activities leading to submissio Administration (FDA) or Institutional Rev is expected to provide information abour additional non-clinical assessments (e.g., This FOA is a milestone-driven cooperati- negotiating the final project plan before receive funding for all activities to be con- funded consultants to receive assistance commercialization, and strategic partner organizations (CROs) that specialize in la and medical monitoring. SBCs developing manufacturers are welcome to apply dire MedTech website: https://neuroscience	Announcement (FOA) is to encoura and limited-size clinical studies to ad ect the nervous or neuromuscular sy type devices, non-clinical safety and n of an Investigational Device Exemp- view Board (IRB) application for a No t the device function or final design , bench top or animal studies) due to ve agreement program and will invo award and monitoring of research p nducted in their own laboratories. In with specialty areas including regul rships. Participants can also augmen- rge animal testing, sterilization testi g their own devices or that already h ectly to this FOA or any of the comp blueprint.nih.gov/neurotherapeutics	ige applications f vance the develo stems.Activities s efficacy testing, otion (IDE) to the n-Significant Risk that cannot be p the novelty of t lve participation rogress. Participa- addition, applica- atory, reimburse t their project wi ng, biocompatibi- nave established anion opportunit s/blueprint-medt	from Small Busines opment of therape supported in this p design verification U.S. Food and Dru (NSR) study. The ractically obtained he device or its int of NIH program si ants in Blueprint N ants will collabora ment, intellectual th NIH contract re lity assessment, m collaborations wit cies. For more info	is Concerns utic and rogram and g clinical study l through :ended use. :aff in AedTech te with NIH- property, search nanufacturing, h device rmation see BP
106116 🖪	lueprint MedTech Translator (UC	<u>G3/UH3 - Clinical Trial Optional)</u>	National Institutes of Health/DHHS	PAR-21- 315 20-J	lun-2024	Not Specified
	Contact Name	Nick Langhals, PhD				
	Contact Telephone	301-496-1779				
	Contact Email	NINDS-Devices@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	20-Jun-2024				
	Synopsis	The purpose of this Funding Opportunity and clinical feasibility studies to advance nervous or neuromuscular systems. Activ non-clinical safety and efficacy testing, d Exemption (IDE) for a Significant Risk (SR study, as well as a subsequent clinical fea	Announcement (FOA) is to encoura the development of therapeutic, ar vities supported in this program incl lesign verification and validation act study or Institutional Review Board asibility study. The clinical study is e	nge investigators ad diagnostic dev ude implementativities, obtaining d (IRB) approval f xpected to provid	to pursue translat rices for disorders tion of clinical pro an Investigational for a Non-Significa de information abo	ional activities that affect the totype devices, Device nt Risk (NSR) out the device

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
function or final design that cannot be pr animal studies) due to the novelty of the program and will involve participation of of research progress. Participants in Blue laboratories. In addition, applicants will of including regulatory, reimbursement, int also augment their project with NIH cont testing, biocompatibility assessment, ma developing their own devices or that alro apply directly to this FOA or any of the co website: https://neuroscienceblueprint.				actically obtain device or its in NIH program s print MedTech ollaborate with ellectual prope ract research o nufacturing, an ady have estab mpanion oppo ih.gov/neuroth	ned through additionatended use. This FOA taff in negotiating the receive funding for a NIH-funded consult rty, commercializatio rganizations that spe d medical monitoring lished collaborations ortunities. For more in merapeutics/blueprint	al non-clinical as is a milestone-or e final project pl Il activities to be ants to receive a n, and strategic cialize in large a g. Individuals, in with device ma formation see for-	sessments (e.g., be driven cooperative an before award a e conducted in the passistance with spe partnerships. Part nimal testing, steri stitutions, or busin nufacturers are we BP MedTech	ench top or agreement nd monitoring ir own icialty areas icipants can ilization esses elcome to
108288	Notice of Special Interest (NOSI): Technologies from Early-stage De MedTech	<u>aking</u> Blueprint	National Institutes of Health/DHHS	NOT-NS- 22-052 20-	Jun-2024	Not Specified		
	Contact Name	Nick Lang	hals, PhD					
	Contact Telephone	301-496-2	1779					
	Contact Email	NINDS-De	evices@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	20-Jun-20	)24					
This Notice of Special Interest (NOSI) encourages the translation of the novel neurotechnologies, funded through the Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative and overseen by the NIH Blueprint MedTec Synopsis program. Academic and Small Business Concerns (SBCs) are encouraged to submit grant applications that propose non- clinical validation for subsequent clinical feasibility studies. Applications supporting the development and translation of groundbreaking neurotechnologies that fit within the mission of the BRAIN Initiative are encouraged.							gh the Brain int MedTech ose non- lation of	
111618	Notice of Special Interest (NOSI): (AREA) and Research Enhanceme Emphasis On Down Syndrome Re	Developin nt Award F search (R1	g Academic Research Enhancem Program (REAP) for Institutions \ 5 Clinical Trial Not Allowed)	lent Award Nith an	National Institutes of Health/DHHS	NOT-OD- 22-136 07-	Мау-2024	Not Specified
	Contact Name Contact Telephone	Sujata Ba 301-435-0	rhan, Ph.D. 0471					
			NIH Funding Opportu	nities Due: June	2024			202

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount			
	Contact Email	sujata.ba	rdhan@nih.gov								
	Sponsor Website										
	Program URL	Link to pr	<u>k to program URL</u> -May-2024 , 25-Jun-2024 , 07-Sep-2024 , 25-Oct-2024 , 07-Jan-2025								
	Deadline Dates (ALL)	07-May-2									
	Synopsis	The NIH I to improv announce Award Pro objective providing environm health pro this FOA, pathway	Nvestigation of Co-occurring co ve health and quality-of-life for i es NIH support for development ogram (REAP) applications to su s of the INCLUDE project at insti- biomedical research experience ent at applicant institutions. Eli- ofessions and have received less a college is a stand-alone entity of meritorious undergraduate a	nditions across ndividuals with of Academic R pport small sca tutions that do es primarily for gible institution s than \$6 millio and not a com nd graduate sta	the Lifespan to Und Down syndrome (D esearch Enhanceme le basic and translat not receive substan undergraduate and s must award NIH-ro n per year of NIH su ponent of a universi udents engaged in D	erstand Down s S). This Notice o nt Award (AREA ional research g tial funding fror for graduate stu elevant baccalau pport (total cost ty system. The g own syndrome f	yndromE (INCLUDE of Special Interest (N ) and Research Enh grants that meet pro m the NIH, with an e idents and enhancin ureate or advanced (s) in 4 of the last 7 goal of this NOSI is a research.	) Project seeks NOSI) ancement ogrammatic emphasis on ng the research degrees in fiscal years. In also to build a			
103023 <mark>A</mark>	Academic-Industrial Partnerships Treatment (R01 - Clinical Trial Not	<u>for Transla</u> ( Allowed	ation of Technologies for Diagno	osis and	National Institutes of Health/DHHS	PAR-21- 166	-Jun-2024	2,495,000 USD			
	Contact Name	Miguel O	ssandon MS								
	Contact Telephone	240-276-	5714								
	Contact Email	<u>ossandon</u>	<u>n@mail.nih.gov</u>								
	Sponsor Website										
	Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	05-Jun-20	)24								
	Synopsis	The purpe engineeri research meet evo clinical, cl institutes engaging inter-disc	ose of this Funding Opportunity ing developments into methods to assess risk, detect, prevent, c lving requirements for technolo linical and non-clinical settings, . This FOA specifies a partnershi the strengths of academic, indu iplinary, multi-institutional rese	Announcement or tools that active liagnose, treat, gies and methor domestic or for p structure that strial, and other arch team to w	t (FOA) is to stimulat ddress problems in b and/or manage dise ods relevant to the a reign, for conditions t is expected to help er investigators. The ork in strategic alliar	te efforts to trai asic research to ease. The rationa dvance of resea and diseases wi bridge gaps in partners on eac nce to implemer	nslate scientific disc o understand diseas ale is to deliver new irch and delivery of thin the missions of knowledge and exp h application shoul nt a coherent strate	overies and e, or in applied r capabilities to care in pre- f participating erience by d establish an egy to develop			

SPIN ID	Program Title		Sponsor Name	Sponsor Numb	er		Deadline Date	Funding Amount
		and trans suitable f partnersh to a statu translate of disease	late a solution to their chosen p or end users. Each partnership s ip should plan to transition a te s useful in the chosen setting. F technologies that address probl e status. This FOA defines "innov	roblem. They an hould include a chnology, meth unding may ben ems in biology, vation" as likelih	re expected to plan, t least one academi od, assay, device, ar requested to enhand pathology, risk asse tood to deliver a new	design, and valie c and one indust nd/or system fro ce, adapt, optim ssment, diagnos w capability to en	date that the solut rial organization. E m a demonstration ize, validate, and o is, treatment, and/ nd users.	ion will be Each n of possibility therwise Yor monitoring
113804	Notice of Special Interest (NOSI): and Evolving Public Health Crises	Research o on NICHD	on the Impact of Policy Changes Populations of Interest	and Emerging	National Institutes of Health/DHHS	NOT-HD- 22-038 07-	May-2024	Not Specified
	Contact Name	Elyse R. G	irossman					
	Contact Telephone	240-551-3	3628					
	Contact Email	elyse.gros	ssman@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2025 , 05 Jan-2026	.024 , 05-Jun-2024 , 16-Jun-2024 -Feb-2025 , 16-Feb-2025 , 07-M	l , 25-Jun-2024 , ay-2025 , 05-Jur	, 07-Sep-2024 , 05-C ו-2025 , 16-Jun-202!	oct-2024 , 16-Oct 5 , 07-Sep-2025 ,	-2024 , 25-Oct-202 05-Oct-2025 , 16-	24 , 07-Jan- Oct-2025 , 07-
	Synopsis	This notic Impact of research this Notic and/or po priority. T adults, pe The NIDA the life sp plan/nida	e informs applicants of an expa Policy Changes and Emerging a priority areas for the National Ir e of Special Interest (NOSI) to a plicy changes on the health, dev The NIDA populations of interest cople using or misusing substance supports research on the impac- ban. For information on the NID/ s-mission.	nsion to the NO nd Evolving Pub astitute on Drug nnounce that re elopment, and v include neonat ces, people with ct of policy in ur A Strategic Goal	T-HD-22-038 "Notic blic Health Crises on Abuse (NIDA). The search on the effect well-being of popula ces, infants, children substance use diso inderstanding and ad s and Mission, see h	e of Special Inter NICHD Populatio National Institute ts of: emerging a tions of interest , adolescents, yo rders, as well as dressing substar ttps://nida.nih.g	rest (NOSI): Resear ons of Interest" to e on Drug Abuse (N and evolving public to the NIDA is of h oung adults, adults the families of the nee use risk and be gov/about-nida/str	ch on the include NDA) is issuing health crises; high program , and older se individuals. havior across ategic-
116056	Notice of Special Interest (NOSI): NICHD Priority Populations in the	Mortality of United Sta	of Adolescents, Young Adults, ar ates	nd Other	National Institutes of Health/DHHS	NOT-HD- 23-001 07-	May-2024	Not Specified
	Contact Name	Juanita J.	Chinn, PhD					
	Contact Telephone	301-827-4	4901					
<u></u>			NIH Eunding Opportun	aitian Duas Juna	2024			

SPIN ID	Program Title	Sponsor Name	Sponsor Numbe	r		Deadline Date	Funding Amount
	Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	juanita.chinn@nih.gov Link to program URL 07-May-2024 , 05-Jun-2024 , 12-Jun-202 The Eunice Kennedy Shriver National Ins Special Interest (NOSI) to invite applicati underlying recent trends in mortality dur inequalities in overall mortality and by ca including suicide and homicide, and under well as family structure and living arrang among individuals with intellectual and p explanations, and modifiable risk factors individuals with intellectual and physical across unintentional and intentional inju individuals with intellectual and physical orientations and gender identities –espe Examine the impact of rising mortality ar health and development of the population development of decedents' offspring and populations of interest to the NICHD is o Notice are adolescents, young adults, an information on the NICHD Strategic Plan	4 , 16-Jun-2024 , 2 titute of Child Hea ons to: Identify m ring adolescence a ause of death and etermined), with a gements, income, ohysical disabilities . Improve the acc disabilities, and t ries, including sui disabilities. Impro- cially for suicide a mong adolescents on, including dem d other family me f high program pr d individuals with 2020 (https://ww	25-Jun-2024 , 07-Se alth and Human De echanisms, causes and young adultho manner of death ( attention to race, e education, and geo s with a particular uracy and granular o improve the accu cide and homicide, ove research on mo ind homicide, and o , adolescents trans ographic factors su mbers, and on the iority. The NICHD p intellectual, devel ww.nichd.nih.gov/a	ep-2024 evelopment (NIA , correlates, an od. Trends to b (natural, uninte ethnicity, sex, go ographic locatic interest in stud ity of cause of aracy of manne for adolescent ortality among other intention sitioning to adu uch as fertility a health, develop oppulations of i opmental, or p bout/org/strate	CHD) is issuing this I d modifiable risk fac e examined include ntional and intentic ender, age, disabilit n. Examine trends i ies that identify me death coding, espect of death coding, p s and young adults youth populations of al and unintentional thood and young a nd nuptiality, on the oment, and well-beinterest that are the hysical disabilities. F	Notice of ctors the growing onal injuries, y status, as n mortality chanisms, ially for articularly as well as for of all sexual l injuries. dults on the e health and ing of e focus of this For
117690	RFA-MH-23-330 BRAIN Initiative Promote Diversity (K99/R00 Indep	e Advanced Postdoctoral Career Transitio pendent Clinical Trial Required)	<u>n Award to</u> N	National Institutes of Health/DHHS	RFA-MH- 23-330 13	-Jun-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	James Churchill, Ph.D. 301-326-8800 <u>BRAINDIVERSITYK99R00@nih.gov</u>					
	Deadline Dates (ALL)	13-Jun-2024 , 11-Oct-2024 , 13-Feb-2025	5 , 13-Jun-2025 , 1	5-Oct-2025 , 13-Fe	eb-2026		

SPIN ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	The purp program supporte biomedia transitio postdoct indepene Notice o "prospec and also Synopsis that pros assess bi phenom clinical t experime compani NIH Insti specifica study, or planning must ap	pose of the NIH BRAIN Initiative A is to enhance diversity in the ner- ed, independent investigators fro cal and behavioral sciences, in Bl n of outstanding postdoctoral re- coral research positions to indep dent NIH research support durin f Funding Opportunity is for basis ctive basic science studies involve meet the definition of basic research omedical or behavioral outcome ena without specific application rial or basic experimental study ve ental study with humans led by a on NOFO. The proposed project tutes and Centers (ICs) based on Ily for applicants proposing to sea a separate ancillary study to an an independent clinical trial, or oby to companion NOFO (RFA-MI	Advanced Postdoctoral Career Tran euroscience workforce and maintain om diverse backgrounds, including to RAIN Initiative research areas. This searchers with a research and/or cl endent, tenure-track or equivalent g this transition to assist awardees c science experimental studies invo- ing human participants." These stud- earch. Types of studies that should ants to conditions (i.e., experiment es in humans for the purpose of unc- towards processes or products in m with humans, or proposing to gain r another investigator, must apply to must be related to the programma their scientific missions. This Noti- erve as the lead investigator of an ir existing trial, as part of their resear proposing to gain research experie H-22-331).	sition Award to P n a strong cohort those from under program is design linical doctorate of faculty positions in launching inde olving humans, re dies fall within th be submitted und ally manipulate in derstanding the fin hind. Applicants r research experier the 'Independen tic interests of or ce of Funding Op ndependent clinic rch and career de nce in a clinical th	romote Diversity ( of new and talent represented grou- ned to facilitate a r degree from ment . The program will pendent research ferred to in NOT-C e NIH definition of der this NOFO inclu- ndependent variat undamental aspec- not planning an inc- nce in a clinical triat t Clinical Trial Not ne or more of the portunity (NOFO) cal trial, a clinical t evelopment. Applie rial led by another	(K99/R00) ed, NIH- ps in the timely ored, provide careers. This DD-18-212 as f a clinical trial ude studies oles) and that ts of dependent al or basic Allowed' participating is designed rial feasibility cants not investigator,
115095 Mentored Career Development Primate Research Mode	opment Program fo ls (K01 Independer	or Early Stage Investigators Using at Clinical Trial Not Allowed)	<u>; Nonhuman</u> National Institutes of Health/DHHS	PAR-23- 073 07-	May-2024	Not Specified
Cont	act Name					
Contact T	elephone					
Cont	act Email <mark>AITrainir</mark>	ghelpdesk@niaid.nih.gov				
Sponso	Website					
Pro	gram URL Link to p	rogram URL				
Deadline D	ates (ALL) 07-May- 2025 , 12	2024 , 12-Jun-2024 , 07-Sep-202 2-Oct-2025 , 07-Jan-2026	4 , 12-Oct-2024 , 07-Jan-2025 , 12-I	Feb-2025 <i>,</i> 07-Ma	y-2025 , 12-Jun-20	025 , 07-Sep-
	Synopsis The purp	oose of this Funding Opportunity	Announcement (FOA) is to provide	e early-stage inve	stigators with sup	port and

SPIN ID	Program Title	Sponsor Nan	ne	Sponsor Num	ber		Deadline Date	Funding Amount
	"p of in hi of tra R( dd Ap	protected time" (up to an experienced men translation of the res ghly skilled scientists outcomes into the cl aining, awardees will 01) funding. This Func pes not involve leadin oplicants to this FOA a	o five years) for int torship team with sults from such stu using NHP models inic. The expectat launch independe ling Opportunity A g an independent are permitted to p	tensive, researd expertise in bo idies to clinical s to address con ion is that thro ent research can Announcement clinical trial, a propose researd	ch-focused career de oth the preclinical ap application. The focu mplex translational b ugh this sustained pe reers and become co (FOA) is designed sp clinical trial feasibility ch experience in a clin	velopment prog plication of non us of this progra iomedical resea eriod of research mpetitive for ne ecifically for ap y study, or an an nical trial led by	ram activities unden human primate (Ni m is to increase the rch designed to for a career developme w research project plicants proposing in ncillary study to a c a mentor or co-me	er the guidance HP) models and e number of ster translation ent and t grant (e.g., research that linical trial.
112644	Notice of Special Interest (NOSI): Pro Other Biological Properties of Minor	omoting Mechanistic Cannabinoids and Te	Research on Thera	apeutic and	National Institutes of Health/DHHS	NOT-AT- 22-027 07	-May-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Lin Deadline Dates (ALL) 07	<u>nk to program URL</u> 7-May-2024 , 05-Jun-2	2024					
	Synopsis Ca in ac ca in ai Pr th cc er	his Notice of Special Ir ICCIH) with participat search of therapeutic any and all cannabin terest include the foll nnabichromevarin (C id (THCA), carmagerc ryophyllene, Limoner tends to support high ming to investigate the cclinical studies of co erapeutic benefits an entribution of minor co compassing different	nterest (NOSI) is be ion from multiple benefits of minor oids from the can lowing: Δ8-THC, Ca BDV), tetrahydroc ol, cannabicitran, s ne, α -terpineol, Li one impact of minor ombinations of mir ad/or abate unwar cannabinoids and t t pathological con	eing issued by t NIH Institutes, r cannabinoids nabis plant oth annabidiol (CBE cannabivarin (T sesquicannabig inalool, α-phella c and/or mecha r cannabinoids nor cannabinoids nor cannabinoids neted effects are cerpenes to syn ditions and dise	the National Center f Centers, and Offices and terpenes in the over than $\Delta$ 9-tetrahydr D), Cannabigerol (CBO HCV), Tetrahydrocan erol. Terpenes of par andrene, $\alpha$ -pinene, $\beta$ anistic studies in app and terpenes on me ds with terpenes or co e encouraged. The mo nptoms relief and fur eases. This NOSI enco	or Complement (ICOs). This NO cannabis plant. ocannabinol (Δ G), Cannabinol ( mabivarin acid ( ticular interest s-pinene, β-terp ropriate model chanisms under other natural pro- ther natural pro- echanisms and p nctional restorat	ary and Integrative SI aims to promote Minor cannabinoid $\Theta$ -THC). Cannabinoi CBN), Cannabichro THCVA), tetrahydro include the followin inene, and $\alpha$ -humu organisms and/or h lying their therape oducts that may en processes underlyir cion may be very br ciplinary collaborat	e Health mechanistic s are defined ds of particular mene (CBC), ocannabinolic ng: Myrcene, ß- lene. This NOSI numan subjects utic effects. hance their ng potential road cions among

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
		experts from multiple fields, such as pharmacologists, chemists, physicists, physiologists, neuroscientists, psychologists, endocrinologists, immunologists, geneticists, behavioral scientists, clinicians, or others in relevant areas of inquiry.						
112791	Notice of Special Interest (NOSI): nitiative in Reducing and Elimina Diverse Representation in Resear	<u>Communit</u> ting Health ch On Dow	y-Based Participatory Research Disparities With a Focus on Ad In Syndrome (R21 Clinical Trial C	<u>(CBPR)</u> dressing Optional)	National Institutes of Health/DHHS	NOT-OD- 22-142 07	-May-2024	Not Specified
	Contact Name Sujata Bardhan, Ph.D.							
	Contact Telephone	301-435-0	0471					
	Contact Email	<u>sujata.ba</u>	rdhan@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	_) 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025						
	Synopsis	The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome (DS). This Notice of Special Interest (NOSI) announces NIH support for exploratory/developmental grant (R21) applications that are focused on community-based participatory research (CBPR) in DS to address health disparities and that meet programmatic objectives for the INCLUDE Project.						
121564	Developing Novel Theory and Me Complex Human Traits (R21 Clinic	thods for I al Trial No	Jnderstanding the Genetic Arch t Allowed)	itecture of	National Institutes of Health/DHHS	PAR-23- 301 16	-Jun-2024	275,000 USD
	Contact Name	Alexande	r Arguello, Ph.D.					
	Contact Telephone	240-731-3	3753					
	Contact Email	alexander	r.arguello@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	Deadline Dates (ALL) 16-Jun-2024, 16-Oct-2024, 16-Feb-2025, 16-Jun-2025, 16-Oct-2025, 16-Feb-2026, 16-Jun-2026, 16-Oct-2026 The goal of this NOFO is to support applications for novel theory and methods development that enable better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should account for interdependencies across scales of biological, social, and ecological organization, make extensive use of theory, modeling, and validation with available large-scale datasets, and may be interdisciplinary drawing						
	Synopsis							
SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
---------	--	--	---	---	--	---	---	--
		from the	natural and social sciences.					
117659	Centers of Excellence in Genomic	Science (R	M1 Clinical Trial Optional)		National Institutes of Health/DHHS	PAR-23- 10 098 [O	-May-2024 ptional][LOI/Pre-Ap	7,500,000 p] USD
	Contact Name	Stephanie	e A. Morris, Ph.D.					
	Contact Telephone	301-435-5	5738					
	Contact Email	morriss2(	@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	10-May-2	024 [Optional][LOI/Pre-App], 21	L-Jun-2024 , 09	-May-2025 [Optiona	l][LOI/Pre-App]	, 24-Jun-2025	
	Synopsis	Each CEG approach medicine, will entail will focus comprehe for under applicatio with its so methods, all career	S award supports a multi-invest es to address a biomedical prob , or computational genomics, pr substantial risk, balanced by ou on the development of novel te ensive data sets, on a genome-si standing biological systems or fu ons. Each CEGS will nurture geno cientific goals, CEGS will also exp concepts, and knowledge devel levels.	igator, interdis igator, interdis oposing a high utstanding scien echnological or cale biomedica urthering the a omics by facilita oand the pool o loped by the Cl	ciplinary team to dev roject will address a c ly innovative solution ntific and manageme computational meth l problem, or on othe pplication of genomi ating the interaction of genomic scientists EGS by providing edu	velop integrated critical issue in g in that would be ent plans and ve nods for the pro- er ways to deve c knowledge, d of investigators and engineers to cation and out	d, transformative gen genomic science, ge a major advance. T ery high potential pa duction or analysis elop and use genom ata, and methods to from several discip that can use and ap reach experiences to	ine research nomic he research yoff. A CEGS of ic approaches owards clinical lines. Along oly the novel o scientists at
109792	Accelerating the Pace of Child He Brain Cognitive Development (AB	alth Resea CD) Study	rch Using Existing Data from the (R21-Clinical Trial Not Allowed)	Adolescent	National Institutes of Health/DHHS	PAR-22- 138	'-May-2024	275,000 USD
	Contact Name	Julia Zehr	, Ph.D.					
	Contact Telephone	301-443-:	1617					
	Contact Email	Zehrj@m	ail.nih.gov					
	Sponsor Website	a						
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	.024 , 16-Jun-2024 , 07-Sep-2024	4 , 16-Oct-2024	, 07-Jan-2025 , 16-F	eb-2025 , 07-M	ay-2025	

SPIN ID Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
Syn	The Adol substanc years-old ppsis through t proposin informat shorter, h	escent Brain Cognitive Developn e use, cultural and environment and following them longitudina he NIMH Data Archive. The purp g the analysis of this public use o on about the ABCD Study may b nigher-risk	nent (ABCD) St al factors, and Ily to early adu pose of this Fu dataset to incre be found on the	udy is collecting data brain structure and f Ithood. These data w nding Opportunity Ar case knowledge of ac ABCD Study web pa	on health and unction from y will be made a nnouncement lolescent healt ge (www.abcd	mental health, cogr outh starting when vailable to the scient (FOA) is to encourag h and development. study.org). This FOA	nitive function, they are 9-10 tific community e applications More A seeks
114596 Development of Animal Moo Research (R21 Clinical Trials	els and Relate Not Allowed)	d Biological Materials for Down	Syndrome	National Institutes of Health/DHHS	PAR-23- 067 1	6-Jun-2024	275,000 USD
Contact N	ame Sige Zou,	PhD					
Contact Telep	one 301-435-	0749					
Contact I	mail <u>zous@m</u>	ail.nih.gov					
Sponsor We	osite						
Program	URL Link to p	ogram URL					
Deadline Dates	ALL) 16-Jun-20	024 , 16-Oct-2024 , 16-Feb-2025	, 16-Jun-2025	, 16-Oct-2025			
Syn	The INver Project e biologica animal m basic scie encourag single cel (ML), and preclinica	stigation of Co-occurring conditi ncourages exploratory and innov I materials for Down syndrome ( odels for DS research. The anim nce studies in areas highly relev res, but is not limited to, projects I or subcellular level, advanced i I integration of multiple animal n al DS research.	ons across the vative research (DS) related res al models and vant to DS. With s focusing on d nformatics tech models and tec	Lifespan to Understa to develop, characte earch and to improv related biological man this funding opport evelopment of variou nnologies including a hnology platforms fo	and Down synd erize, or impro e access to info iterials develop unity announc us animal mod irtificial intellig or enhancing ri	romE (INCLUDE) ve animal models an ormation about or fr bed must have utility ement, the INCLUDE els, genetic resource ence (AI) or machine gor and reproducibil	nd related From the use of a in targeted or E Project es, atlases at a e learning ity of
114857 Small Research Grants for Ar (R03 Clinical Trial Not Allowe	<u>alyses of Gabr</u> d <u>)</u>	iella Miller Kids First Pediatric Re	esearch Data	National Institutes of Health/DHHS	PAR-23- 075 1	6-Jun-2024	200,000 USD
Contact N	ame James N.	Coulombe, Ph.D.					
Contact Telep	one 301-451-	1390					
Contact I	mail <u>Coulomb</u>	eJ@mail.nih.gov					

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	16-Jun-20	024 , 16-Oct-2024 , 16-Feb-2025	, 16-Jun-2025	, 16-Oct-2025			
	Synopsis	The NIH C pediatric communi establishe childhooc to the res leading to meritorio generated appropria	Common Fund has established the research data resource populat ities of investigators who study the ed and continues to develop a D d cancer and structural birth def search community. Access to the pomore refined diagnostic capability us small research projects focus d by the Kids First program and/ ate for analyzing genomic, phene	he Gabriella Mi ed by genome s the genetics of pata Resource in ects cohorts ar ese data will pro- ilities and ultim sed on analyses for associated p otypic, and/or o	iller Kids First Pediati sequence and pheno childhood cancers a ncluding a collection ad a central portal wi omote comprehension nately more targeted of childhood cancer ohenotypic datasets. clinical data relevant	ric Research Prog atypic data that w nd/or structural of curated geno- nere these data a ve and cross-cutt therapies. This I and/or structure Development of to Kids First may	gram (Kids First) to vill be of high value birth defects. Kids mic and phenotypi and analysis tools a cing research and c FOA is intended to al birth defects ger approaches, tools y also be proposed	develop a for the First has c data from are accessible collaboration support nomic datasets f, or algorithms l.
120393	Secondary Analysis and Integratic Dutcomes (R21 Clinical Trials Not	on of Existin Allowed)	ng Data to Elucidate Cancer Risk	<u>k and Related</u>	National Institutes of Health/DHHS	PAR-23- 255 16-	Jun-2024	275,000 USD
	Contact Name	Melissa R	otunno, Ph.D.					
	Contact Telephone	240-276-7	7245					
	Contact Email	rotunnom	n@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	16-Jun-20	024 , 16-Oct-2024 , 16-Feb-2025	, 16-Jun-2025	, 16-Oct-2025 , 16-Fe	eb-2026 , 16-Jun	-2026	
	Synopsis	Through t Institutes datasets a reduction cancer by lifestyle, g existing d methods questions	this Notice of Funding Opportun encourages submission of appl and database resources, with th n, survival, or response to treatm r supporting the analysis of exist genomic, and molecular profiles lata. Applications may include n of analyses, or novel combinations in cancer research.	hity (NOFO), the ications propose of ultimate aim nent, etc.). The sing clinical, env data. Applican ew research air ons and integra	e National Cancer Ins sing to conduct secon to elucidate cancer is goal of this initiative vironmental, surveilla its are encouraged to ms that are being ad- ation of datasets that	titute (NCI) alon ndary data analys risk and related of s is to address ke ance, health serv b leverage and pe dressed with exist allow the explo	g with other partic sis and integration outcomes (e.g., risl y scientific questio rices, vital statistics erform innovative sting data, new or ration of importan	ipating of existing c prediction or ns relevant to s, behavioral, analyses of the advanced t scientific

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
120102	Social disconnection and Suicide F	Risk in Late Life (R21 Clinical Trial Optional	National Institutes of Health/DHHS	PAR-23- 239 16	Jun-2024	275,000 USD
	Contact Name	Jovier Evans, Ph.D.				
	Contact Telephone	2 301-443-6328				
	Contact Email	l jevans1@mail.nih.gov				
	Sponsor Website	2				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025	, 16-Jun-2025 , 16-Oct-2025 , 16-Fe	b-2026 , 16-Jun-	2026	
	Synopsis	disconnection in late-life and late-life suid mechanisms by which social disconnectio behaviors in late life. Mechanisms to be c neurobiological, behavioral, and environr announcement PAR-23-238 solicits R01 a appropriate for this R21 mechanism, whil 238.	cidal thoughts and behaviors. Of spectra on confers risk for, and social integra considered exist at multiple levels of mental. This NOFO solicits R21 appli pplications. High risk/high payoff pr le applications with preliminary data	ecific interest is r ation protects ag f analysis, includi cations, while th rojects that lack p a should apply to	resses the link bet esearch that ident ainst, suicidal thou ing but not limited e companion oreliminary data n o the R01 mechani	ifies ughts and to nay be most sm, PAR-23-
112267	Notice of Special Interest (NOSI):	Advancing Research on Early Pregnancy Lo	National Institutes of Health/DHHS	NOT-HD- 22-026 07-I	May-2024	Not Specified
	Contact Name	· Clara Cheng, PhD				
	Contact Telephone	: 301-435-6992				
	Contact Email	l <u>clara.cheng@nih.gov</u>				
	Sponsor Website	2				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2024 2025 , 07-May-2025 , 05-Jun-2025 , 16-Ju	l , 07-Sep-2024 , 05-Oct-2024 , 16-C n-2025 , 07-Sep-2025	oct-2024 , 07-Jan	-2025 , 05-Feb-202	25 , 16-Feb-
	Synopsis	Early Pregnancy loss (EPL), defined as a property complication, occurring in 12-15% of clini maternal age. The use of highly sensitive clinical recognition, and gives an even hig	regnancy loss occurring up to 20 we cally recognized pregnancies, with i hCG assays allows the detection of ther estimated loss of 50-70% of cor	eeks gestation, is ncreased prevale pregnancy earlie nceptions prior te	a very common p ence associated w er in gestation thar o the second trime	regnancy ith increasing 1 the time of ester. To

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
		achieve a embryos, to sustair approxim and pathe underlyin basic, trai includes r and place EPL and r	successful pregnancy, a series of favorable conditions for embry in the conceptus to term. In addit ately half of all cases of EPL app ophysiologic processes that und g causes of recurrent pregnancy inslational and clinical studies or research to understand implanta intation that are important for e ecurrent pregnancy loss.	of strict embryc o implantation tion, maternal bear to be due t erlie non-aneu y loss (RPL). Thi biological pro- ation mechanis early pregnancy	onic and maternal co , receptive maternal mmune tolerance ar to embryonic aneuple ploid EPL. As a result s NOSI seeks to addr cesses that may unco tically and identify a r establishment, inclu	nditions must b endometrium a nd hormonal fac oidy, very little , there is also a ess these critica over potential e range of key fac iding abnormal	e met, that include and optimal uterine ctors play a critical r is known about the lack of understand al knowledge gaps b tiologies of EPL and ctors, involved in in ities that contribute	high quality environment role. While physiologic ing for the by encouraging I RPL. This aplantation e to sporadic
123347	Pilot and Feasibility Studies in Pre Clinical Trial Optional)	paration f	or Substance Use Prevention Tri	ials (R34	National Institutes of Health/DHHS	PAR-24- 060 07	'-May-2024	450,000 USD
	Contact Name	Amy B. G	oldstein, PhD					
	Contact Telephone	301-827-4	4124					
	Contact Email	amy.gold	<u>stein@nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2025 , 16	2024 , 16-Jun-2024 , 07-Sep-2024 -Oct-2025 , 07-Jan-2026 , 16-Fel	4 , 16-Oct-2024 b-2026 , 07-Ma	, 07-Jan-2025 , 16-F y-2026 , 16-Jun-2026	eb-2025 , 07-M 5 , 07-Sep-2026	ay-2025 , 16-Jun-20 , 16-Oct-2026 , 07-	)25 , 07-Sep- Jan-2027
	Synopsis	The purpe in the foll of substa to the pre other ser addition t through t behavior hepatitis	ose of this notice of funding opp owing areas: 1) the developmen nce use and/or the progression evention of substance use. The l vice system-based research to a to the prevention of substance u his NOFO include a reduction in (e.g., nonfatal and fatal attempt among diverse populations and	portunity (NOFC nt and pilot test from use to mi atter may inclu ddress areas su use, misuse and negative seque ts), and substar settings.	D) is to encourage the ting of new or adapte suse or disorder and de pilot studies of st uch as economics, fun I disorder, other outo alae of use, such as d nce-related acquisitio	eoretically drive ed intervention 2) services rese rategies or app nding, service q comes of intere leaths related to on or transmissi	en pilot and/or feas s to prevent or dela earch examining qua roaches to interven uality and engagem st for the research o impaired driving, on of HIV infection	ibility research iy the initiation estions specific ition, and/or nent. In supported suicidal and viral
108483	Notice of Special Interest (NOSI):	COVID-19	Pandemic Mental Health Resea	rch	National Institutes of Health/DHHS	NOT-MH- 22-100 07	'-May-2024	Not Specified



SPIN ID Program	n	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount						
	Contact Name	Pim Brouwers, Ph.D.										
	Contact Telephone	240-627-3863										
	Contact Email	ebrouwer@mail.nih.gov										
	Sponsor Website											
	Program URL	Link to program URL										
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025										
100250 Explorato	Synopsis ry/Developmental Bioer	services research relevant to the COVID- to understand how mental illness contrib COVID-19, and the development of scala the pandemic both specifically related to disruptions, and loss of lives in the pande treatment and prevention are also of inte populations based on existing evidence of health disparities.	19 pandemic. NIMH is especially int outes to COVID-19 risk and mortality ble interventions to meet the public o the virus but also at a broader pop emic. Research addressing the inter- erest to NIMH. Research is anticipat of increased mental health symptom	erested in resear y, how incident m c mental health n julation level that section of COVID- ted to focus on pa ns and illness and	ch to provide an e nental illness devel eeds during and re is impacted by str -19, mental health articularly vulneral preexisting and w	vidence base ops with esulting from ess, , and HIV ole orsening 275,000						
108358 Allowed)	<i></i>		of Health/DHHS	090 16-J	lun-2024	USD						
	Contact Name	Miguel R. Ossandon, Ph.D.										
	Contact Telephone	240-276-5714										
	Contact Email	ossandom@mail.nih.gov										
	Sponsor Website											
	Program URL	Link to program URL										
	Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2024										
	Synopsis	The purpose of this engineering-oriented exploratory/developmental Bioengineeri utility of new capabilities or improvemer problems in basic biomedical, pre-clinica	d funding opportunity announcement ing Research Grant (EBRG) applicati nts in quality, speed, efficacy, opera I, or clinical research, clinical care d	nt (FOA) is to enc ons to demonstra bility, costs, and/ elivery, or access	ourage submissior ate feasibility and or accessibility of ibility	ns of potential solutions to						
111039 Dissemina	tion and Implementatio	on Research in Health (R21 Clinical Trial O	ptional) of Health/DHHS	PAR-22- 109 07-1	May-2024	275,000 USD						



SPIN ID	Program Title		Sponsor Name	Sponsor Numl	per		Deadline Date	Funding Amount		
	Contact Name Contact Telephone	Gila Neta 240-276-0	, Ph.D. 6785							
	Contact Email Sponsor Website	gila.neta(	<u>@nih.gov</u>							
	Program URL	Link to pr	ogram URL							
Deadline Dates (ALL) 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025										
	Synopsis	strategies intervent and imple there is a that are in research services ( applicatio	s for overcoming barriers to the ions, practices, programs, tools, ementation of evidence-based in benefit in understanding circun neffective, unproven, low-value, methods and measures are enco e.g. cancer screening) that may ons must be within the scope of	adoption, adap treatments, gunterventions an instances that co , or harmful. In ouraged. Applic have dropped of the mission of	t (FOA) is to support station, integration, s idelines, and policies nong underrepresent reate a need to stop addition, studies to cations that focus on off amidst the ongoin one of the Institutes,	studies that win scale-up, and sus s. Studies that pr ted communities or reduce ("de-ir advance dissemin re-implementating COVID pander (Centers listed al	tainability of evide omote equitable of are encouraged. nplement") the us nation and implen on of evidence-ba nic are encourage pove.	Indyor test ince-based lissemination Conversely, e of practices ientation sed health d. All		
111040 [	Dissemination and Implementatic	on Researc	h in Health (R03 Clinical Trial Nc	ot Allowed)	National Institutes of Health/DHHS	PAR-22- 106 07-1	May-2024	275,000 USD		
	Contact Name	Gila Neta	, Ph.D.							
	Contact Telephone	240-276-0	6785							
	Contact Email	gila.neta(	@nih.gov							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	07-May-2	024 , 16-Jun-2024 , 07-Sep-2024	4 , 16-Oct-2024	, 07-Jan-2025 , 16-F	eb-2025 , 07-Ma	y-2025			
	The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce ("de-implement") the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation									

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
		research i services ( applicatio	methods and measures are enco e.g. cancer screening) that may ons must be within the scope of	ouraged. Applic have dropped the mission of	cations that focus on off amidst the ongoi one of the Institutes,	re-implementa ng COVID pande /Centers listed a	tion of evidence-ba mic are encourage above.	ased health d. All
110996	Dissemination and Implementation	on Researc	h in Health (R03 Clinical Trial No	ot Allowed)	National Institutes of Health/DHHS	PAR-22- 160 07-	-May-2024	100,000 USD
	Contact Name	Gila Neta,	, PhD					
	Contact Telephone	240-276-6	5785					
	Contact Email	<u>Gila.Neta</u>	<u>@nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2025	024 , 16-Jun-2024 , 07-Sep-2024	4 , 16-Oct-2024	, 07-Jan-2025 , 16-F	eb-2025 , 07-M	ay-2025 , 16-Jun-20	025 , 07-Sep-
	Synopsis	The purpo strategies interventi and imple there is a that are in research i services (i applicatio	ose of this Funding Opportunity for overcoming barriers to the ons, practices, programs, tools, ementation of evidence-based in benefit in understanding circun neffective, unproven, low-value methods and measures are enco e.g. cancer screening) that may ons must be within the scope of	Announcemen adoption, adap treatments, gu nterventions ar stances that c , or harmful. In puraged. Applic have dropped the mission of	It (FOA) is to support otation, integration, s uidelines, and policie mong underrepresen- reate a need to stop addition, studies to cations that focus on off amidst the ongoin one of the Institutes,	studies that wil scale-up, and su s. Studies that p ted communitie or reduce ("de- advance dissem re-implementa ng COVID pande /Centers listed a	I identify, develop, stainability of evide promote equitable s are encouraged. implement") the us ination and impler tion of evidence-ba mic are encourage above.	and/or test ence-based dissemination Conversely, se of practices nentation ased health d. All
119255	lovel Mechanism Research on No Dementia (R21 Clinical Trial Optic	<u>europsychi</u> onal)	atric Symptoms (NPS) in Alzheir	<u>mer's</u>	National Institutes of Health/DHHS	PAR-23- 208 16-	-Jun-2024	275,000 USD
	Contact Name	Laura M.	Rowland, Ph.D.					
	Contact Telephone	301-480-8	3335					
	Contact Email	laura.row	land@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	16-Jun-20	24 , 16-Oct-2024 , 16-Feb-2025	, 16-Jun-2025	, 16-Oct-2025 , 16-Fe	eb-2026 , 16-Jun	-2026	

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
	Synopsis	The goal of of mecha disease-re and neuro advanced mechanis projects t who seek	of this Notice of Funding Opport nisms associated with neuropsy elated dementias (ADRD). The fi obiological pathways leading to into interventions to treat and m, while the companion PAR-23 hat lack preliminary data may b longer-term funding should app	cunity (NOFO) is chiatric sympto ndings are expe NPS. Findings n prevent the de 8-207 uses the f e more approp oly using the RC	s to encourage applic oms (NPS) in persons ected to advance me nay also provide insi velopment of NPS in R01 grant mechanism riate for the R21 me 01 mechanism.	cations for studie with Alzheimer's chanistic unders ght into novel the AD and/or ADRE n. Investigators p chanism, while a	is that will enhance s disease (AD) or A tanding of both bio erapeutic targets t D. This NOFO uses proposing high risk pplicants with prel	e knowledge Izheimer's obehavioral hat can be the R21 /high reward iminary data
110997 <mark> </mark>	imited Competition: Clinical and Collaborative and Innovative Acce	Translatio leration A	nal Science Award (CTSA) Progra ward (UG3/UH3 Clinical Trial Op	<u>am:</u> ptional)	National Institutes of Health/DHHS	PAR-22- 167 18-J	un-2024	3,250,000 USD
	Contact Name	Soju Char	ng, M.D., M.P.H.					
	Contact Telephone	301-827-9	9206					
	Contact Email	<u>soju.chan</u>	<u>g@nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	18-Jun-20	024 , 17-Oct-2024					
	Synopsis	The Clinic supports funding o to transfc more inte Centers, C	al and Translational Science Aw synergistic activities that accele pportunity announcement (FOA orm the field of translational scie erventions to all people more qu Offices (ICOs), and/or external s	ard (CTSA) Prog rate the transla a) invites applica ence by address ickly through c takeholders.	gram Collaborative a tional research proc ations to develop, de sing the inefficiencies ollaborative science	nd Innovative Ac tess through colla emonstrate and c s that are commo among the CTSA	celeration Award ( boration and inno lisseminate innova on across diseases Program hubs, NII	(CCIA) vation. This ative solutions and bringing H Institutes,
103168	Research on Autism Spectrum Dis	orders (RC	1 Clinical Trial Optional)		National Institutes of Health/DHHS	PA-21-201 05-J	un-2024	Not Specified
	Contact Name	Lisa Gilot	ty, Ph.D.					
	Contact Telephone	301-443-3	3825					
	Contact Email	gilottyl@i	mail.nih.gov					
	Sponsor Website							
	Program URL	<u>Link to pr</u>	ogram URL					

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber		Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	05-Jun-20 The purporesearch Autism Sp based in so of the part one or more generally project do data, and 21-199.	024 , 05-Oct-2024 ose of this Funding Opportunity designed to elucidate the etiolo pectrum Disorders (ASD). The Re scientific areas that represent the rticipating NIH Institutes and Ce ore of the participating NIH Insti- expected. Applicants pursuing e evelopment should consider the pilot or feasibility studies that o	Announcemen gy, epidemiolo esearch Project ne investigators nters (ICs). The itutes and Cent exploratory/dev companion R2 can be complet	t (FOA) is to encoura gy, diagnosis, and op Grant (R01) mechan S specific interests ar proposed project m ters (ICs) based on th velopmental researcl 1 FOA, PA-21-200. A ed with limited budg	age research grar otimal means of s nism supports dis nd competencies ust be related to neir scientific miss h to support earl opplicants pursuin gets should consid	nt applications to s ervice delivery in r crete, specified pr , and that fall with the programmatic sions, and prelimir y and conceptual s ng secondary analy der the companior	upport relation to ojects in the mission c interests of hary data are stages of ysis of existing n RO3 FOA, PA-
108898	Notice of Special Interest (NOSI): Services	Priority Re	esearch Opportunities in Crisis R	<u>esponse</u>	National Institutes of Health/DHHS	NOT-MH- 22-110 07-1	May-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Stephen ( 301-480-4 stephen.c Link to pr 07-May-2 2025 , 07 The Natic presentat considera are encou for childre including mobile cr	O'Connor, Ph.D. 8366 <u>o'connor2@nih.gov</u> <u>rogram URL</u> 2024 , 05-Jun-2024 , 16-Jun-2024 -May-2025 onal Institutes of Health seeks re- tions, psychosocial factors, age- ations, and health disparities infl uraged through this Notice addre en and under-resourced population the effectiveness of these compo- risis outreach and support, and o	4 , 07-Sep-2024 research conduc related (e.g., yo luence the type ess the continu tions are encou conents: call ce crisis services th	, 05-Oct-2024 , 16-C ted in real-world sett outh; adult; older adu es of care that are pro um of crisis service s traged. Topics of rese nter capabilities to a nat can diagnose and	Oct-2024 , 07-Jan tings, where a wi ult), geographic ( ovided. Examples systems. Applicat earch interest spa ddress distress a l provide short te	-2025 , 05-Feb-202 de range of clinica rural/remote setti s of NIMH and NID ions that include c an the crisis care c nd coordinate care rm stabilization.	25 , 16-Feb- Il ngs), cultural A studies that crisis services ontinuum, e, deployed
109173	Microbial-based Cancer Imaging a Allowed)	ind Therap	by - Bugs as Drugs (R21 Clinical T	rial Not	National Institutes of Health/DHHS	PAR-22- 086 16	lun-2024	275,000 USD
	Contact Name	Avi Rasoc	bly, PhD					

SPIN ID	Program Title		Sponsor Name	Sponsor Numbe	r		Deadline Date	Funding Amount		
	Contact Telephone	240-276-6	5196							
	Contact Email	rasoolya@	omail.nih.gov							
	Sponsor Website									
	Program URL Link to program URL Deadline Dates (ALL) 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025									
	Synopsis	bacteriop interactio imaging, t tumor im tools and Applicant microbial funding o	hages, or other non-oncolytic v ns between microorganisms, tu herapeutics or diagnostics. Pro- munity, or as delivery vehicles f approaches. This FOA will supp s are encouraged to address bo based cancer therapy (includin pportunity is part of a broader	viruses and their n umors, and the im ojects can focus or for treatment, dia port basic mechan oth the microbial a ng therapies for or NCI-sponsored rea	atural products to mune system, and n using microorgan gnosis, or imaging, istic and preclinica and tumor aspects ral cancer), tumor in search on microbia	study the unde to explore thei sms as anti-tur complementin studies in cell of microbial tur maging, tumor I based cancer	rlying mechanisms ir clinical potential f nor agents, as active g or synergizing wit culture and animal mor interactions rel detection, or diagno therapy.	of the complex or cancer ators of anti- h existing models. evant to osis This		
109181	Notice of Special Interest (NOSI):	Public Hea	Ith Research on Cannabis	N	lational Institutes of Health/DHHS	NOT-DA- 22-003 07	-May-2024	Not Specified		
	Contact Name	Marsha L	opez, PhD							
	Contact Telephone	(301) 402	-1846							
	Contact Email	<u>(301) 402</u>	- <u>1846</u>							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	07-May-2 2025	024 , 05-Jun-2024 , 16-Jun-2024	4 , 07-Sep-2024 , (	05-Oct-2024 , 16-O	ct-2024 , 07-Ja	n-2025 , 05-Feb-202	25 , 16-Feb-		
	Synopsis	The Natio cannabis	nal Institute on Drug Abuse (NI laws and policies in the US and	DA) is issuing this globally on public	notice to encourag health.	ge grant applica	ations on the effects	s of changing		

SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
114123 Engineering Next-Generation Human Nervous System Microphysiological	National Institutes of	PAR-23-	07-May-2024	275,000

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Systems (R21 Clinical Trials Not Al	lowed)		Health/DHHS	047		USD			
	Contact Name	David M.	Panchision, Ph.D.							
	Contact Telephone	301-443-5	5288							
	Contact Email	<u>panchisio</u>	nd@mail.nih.gov							
	Sponsor Website									
	Program URL	Link to pr	nk to program URL							
	Deadline Dates (ALL) 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2024 , 16-Oct-2025 , 07-Jan-2026									
This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing nex generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous syst architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to ena Synopsis future studies of complex nervous system development, function and aging in healthy and disease states. The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and concep stages of project development. High risk/high reward projects that lack preliminary data may be most appropriate for th FOA. Applicants with preliminary data may instead wish to apply to the companion R01 mechanism (PAR-23-046).										
114061	Notice of Special Interest (NOSI): Decoding and Modulating Neural	Explainabl Circuit Act	e Artificial Intelligence for iivity Linked to Behavior	National Institutes of Health/DHHS	NOT-MH- 23-110 07-	May-2024	Not Specified			
	Contact Name	Mauricio	Rangel-Gomez, Ph.D.							
	Contact Telephone	301-435-6	6908							
	Contact Email	<u>mauricio.</u>	rangel-gomez@nih.gov							
	Sponsor Website									
	Program URL	<u>Link to pr</u>	ogram URL							
	Deadline Dates (ALL)	07-May-2 2025 , 07	024 , 05-Jun-2024 , 16-Jun-2024 -May-2025 , 05-Jun-2025 , 16-Ju	4 , 07-Sep-2024 , 05-Oct-2 Jn-2025 , 07-Sep-2025 , 0	2024 , 16-Oct-2024 , 07-Jan 5-Oct-2025 , 16-Oct-2025 ,	1-2025 , 05-Feb-20 07-Jan-2026 , 05-I	25 , 16-Feb- Feb-2026			
	Synopsis	This Notic decoding, computat that are a humans c	ce of Special Interest (NOSI) soli , and modulation of neural circu cionally and experimentally focu ble to mechanistically explain h or animals. Proof-of-concept app	cits applications in the are nits linked to behavior. Th nsed investigators. This NG now experimental manipu plications aimed at impro-	ea of XAI applied to neuros is NOSI encourages collabo DSI seeks the development lations affect cognitive, aff ving the current state of th	scientific questions prations between of machine learni fective, or social pr ie technology that	s of encoding, ng algorithms rocessing in uses XAI to			

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		provide unbiased, hierarchical explanatio appropriate.	ons of causal relationships betweer	n complex neui	ral and behavioral dat	a are also:
115062	Notice of Special Interest (NOSI): Brain Health and Acute and Chroi	argeting the Endocannabinoid System for nic Diseases	National Institutes of Health/DHHS	NOT-DA- 22-048	)7-May-2024	Not Specified
	Contact Name	Yu (Woody) Lin, PhD				
	Contact Telephone	301-435-1318				
	Contact Email	ylin1@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2024 , 25-May-2024 , 05-Jun-202 2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jar May-2025 , 25-May-2025 , 05-Jun-2025 , , 16-Oct-2025 , 07-Jan-2026	24 , 12-Jun-2024 , 16-Jun-2024 , 07 n-2025 , 25-Jan-2025 , 05-Feb-2025 12-Jun-2025 , 16-Jun-2025 , 07-Se	-Sep-2024 , 25 5 , 12-Feb-2025 p-2025 , 25-Se	-Sep-2024 , 05-Oct-2( 5 , 13-Feb-2025 , 16-F p-2025 , 05-Oct-2025	)24 , 10-Oct- eb-2025 , 07- , 12-Oct-2025
	Synopsis	This Notice of Special Interest (NOSI) enc and acute and chronic disease, substance mechanistic understanding of how canna effects as well as the role of cannabinoid	ourages studies of the endocannal e use, and substance use disorder ( binoids and manipulation of the E s and ECS in symptom managemer	pinoid system ( SUD). The desi CS can elicit bo nt.	(ECS) and its roles in b ired outcomes of rese oth therapeutic and d	vrain health arch will be a eleterious
124219	Long-Term Effects of Disasters on Health Disparities (R01- Clinical T	Healthcare Systems in Populations with rial Optional)	National Institutes of Health/DHHS	PAR-24- 109	06-May-2024 Optional][LOI/Pre- App]	Not Specified
	Contact Name	Carolina Solis-Sanabria, MD, MPH, FACS				
	Contact Telephone	301-827-3460				
	Contact Email	carolina.solissanabria@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	06-May-2024 [Optional][LOI/Pre-App], 05 Jan-2025 [Optional][LOI/Pre-App], 07-Jan 2025 , 06-Sep-2025 [Optional][LOI/Pre-Ap 05-Feb-2026 , 06-May-2026 [Optional][LO	5-Jun-2024 , 06-Sep-2024 [Optiona n-2025 , 05-Feb-2025 , 06-May-202 pp], 07-Sep-2025 , 05-Oct-2025 , 0 DI/Pre-App], 07-May-2026 , 05-Jun	l][LOI/Pre-App 5 [Optional][L0 6-Jan-2026 [Op -2026 , 06-Sep	], 07-Sep-2024 , 05-C DI/Pre-App], 07-May- ptional][LOI/Pre-App] -2026 [Optional][LOI,	ct-2024 , 06- 2025 , 05-Jun- , 07-Jan-2026 /Pre-App], 07-

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis I c	Sep-2026 , 05-Oct-2026 , 06-Jan-2027 [O The purpose of this Notice of Funding Op ong-term effects of natural and/or huma disparities living in the U.S. and its territo	ptional][LOI/Pre-App], 07-Jan-2027 portunity (NOFO) is to support coll an-made disasters on healthcare sy pries.	, 05-Feb-2027 , aborative resear stems serving po	07-May-2027 ch focused on unde pulations that expe	rstanding the rience health
103419	Notice of Special Interest (NOSI): In Treatment and Prevention Regimer	nproving Patient Adherence to ns to Promote Health	National Institutes of Health/DHHS	NOT-OD- 21-100 07-	May-2024	Not Specified
	Contact Name V Contact Telephone 2 Contact Email Sponsor Website Program URL Deadline Dates (ALL) r Synopsis c	Wendy Nelson, PhD, MPH 240-276-6971 <u>nelsonw@mail.nih.gov</u> <u>Link to program URL</u> 07-May-2024 , 05-Jun-2024 This Notice of Special Interest (NOSI) is b Social Sciences Research (OBSSR) with paresearch grant applications that address putcomes. Applications may address hea	eing issued by the NIH Adherence N articipation from multiple NIH Instit patient adherence to treatment an Ithcare regimen initiation, impleme	letwork through utes, Centers, ar d prevention reg entation, and/or	the Office of Behav nd Offices. This NOS imens to promote H persistence by patie	vioral and I calls for nealth
	i I	Descriptive and intervention research manual network of the patient, caregiver/family, p	rovider, healthcare system, and cor	nmunity levels.	The specific researc	ents. fluence, h interests of
103180	ا i <u>Research on Autism Spectrum Diso</u>	Descriptive and intervention research manual ncluding the patient, caregiver/family, p participating NIH Institutes and Centers a rders (R21 Clinical Trial Optional)	rovider, healthcare system, and cor are detailed within. National Institutes of Health/DHHS	PA-21- 200	Jun-2024	ents. fluence, h interests of 275,000 USD

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
		research Autism Sp by provid ground or required I studies th larger stu FOA, PA-2	designed to elucidate the etiolo bectrum Disorders (ASD). The R2 ing support for the early and co extend previous discoveries to but may be included if available at can be completed with limite dies in established scientific are 21-201.	gy, epidemiology, diagnosis, and o 21 grant mechanism is intended to nceptual stages of project develop ward new directions are appropria . Applicants pursuing secondary ar ed budgets should consider the cor as where preliminary data are exp	optimal means encourage exp oment. Explora- ate for this mee nalysis of existi mpanion R03 F pected should c	of service delivery in bloratory/developme cory, novel studies th chanism. No prelimina ng data, and pilot or f OA,PA-21-199. Appli onsider the companio	relation to ntal research at break new ary data are reasibility cants pursuing on R01	
103183 <u>Research on Autism Spectrum Disorders (R03 Clinical Trial Optional)</u>			3 Clinical Trial Optional)	National Institutes of Health/DHHS	PA-21- 199	.6-Jun-2024	100,000 USD	
	Contact Name	Lisa Giloti	zy, Ph.D.					
	Contact Telephone	301-443-3	3825					
	Contact Email	gilottyl@i	mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	16-Jun-20	24 , 16-Oct-2024					
	The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). An R03 grant supports small, discrete, well-defined projects that can be completed in tw years and that require limited resources. R03 applications may include development of new research methodologies or technology, secondary analysis of existing data, and pilot or feasibility studies. Preliminary data are not required, particula in applications proposing pilot or feasibility studies. Applicants pursuing exploratory/developmental research to support e and conceptual stages of project development should consider the companion R21 FOA, PA-21-200. Applicants pursuing larger studies in established scientific areas where preliminary data are expected should consider the companion R01 FOA. PA-21-201.							
103732 <u>N</u>	otice of Special Interest (NOSI): rug and Alcohol Abuse/Depende	Women ar ence	nd Sex/Gender Differences in	National Institutes of Health/DHHS	NOT-DA- 21-012	)7-May-2024	Not Specified	
	Contact Name Contact Telephone	Keisher H	ighsmith, DrPH					

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Email	highsmith	iks@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2	 024 , 05-Jun-2024 , 16-Jun-2024	4,07-Sep-2024					
	Synopsis	Synopsis Synopsis The purpose of this Notice is to inform potential applicants of the National Institute on Drug Abuse (NIDA) special interest in grant applications to conduct rigorous basic, translational and/or clinical research to: (1) advance identification of sex and/or gender differences in risk for substance use disorders or the response or medical consequences of alcohol or substance misuse to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research.							
103983	Iotice of Special Interest (NOSI): I Cannabis-, Tobacco-, and Other D	Public Poli rug-Relate	cy Effects on Alcohol-, d Behaviors and Outcomes	National Institutes of Health/DHHS	NOT-AA- 21-028 07-N	May-2024	Not Specified		
	Contact Name	Gregory B	Bloss, M.A., M.P.P.						
	Contact Telephone								
	Contact Email	Gregory.B	Bloss@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2	024 , 05-Jun-2024 , 16-Jun-2024	4,07-Sep-2024					
	Synopsis	This anno and outco Notice is t its effects research t that may policies; e on alcoho and the ro measuren related be	uncement encourages applications ones associated with alcohol, ca to advance understanding of ho on behaviors and outcomes pe to examine policy effects that h be supported include, but are n evaluations of the effectiveness ol-, cannabis-, tobacco-, and oth ole of policy in exacerbating or p nent used in studying relationsh ehaviors and outcomes.	ions to conduct research on the effe annabis, tobacco, prescription drugs ow public policy may serve as a tool ertaining to alcohol and other drugs ave the potential to lead to meanin not necessarily limited to: causal and of specific public policies as tools fo er substance-related behaviors and potentially reducing health dispariti nips between public policies and alc	ects of public poli s, and other subs for improving pu . This Notice is in gful changes in p alyses of the effect or improving public outcomes; studi- es; and research ohol-, cannabis-,	cies on health-rela tances. The purpo blic health and we tended to support ublic health. Resea cts of one or multi lic health through es of disparities in to advance metho tobacco-, and oth	Ited behaviors se of the Ifare through innovative arch projects ple public their effects policy effects ods and er substance-		

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
104057	Joint NINDS/NIMH Exploratory Ne Trial Optional)	euroscience Research Grant (R21 Clinical	National Institutes of Health/DHHS	PA-21- 219 07-	May-2024	275,000 USD
	Contact Name	Karrah Benson				
	Contact Telephone	301-496-0838				
	Contact Email	Karrah.benson@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2024 , 16-Jun-2024 , 07-Sep-202	4 , 16-Oct-2024 , 07-Jan-2025			
	Synopsis	projects, which fall within the missions of stages of projects. These studies often as but have the potential to bring about bree development of novel techniques, agents this funding opportunity also accepts clin (studying pathophysiology or mechanism with humans (BESH) will be supported. For within scope of this funding opportunity Opportunity Description, below, respecti	f the NINDS and NIMH. Awards will seess the feasibility of a novel avenue eakthroughs in the understanding o s, methodologies, or models, of hig nical trials, only applications propos n of action of an intervention, but no or information on NIH clinical trial of announcement refer to the NIH De ively.	provide support ue of investigatio f important areas h value to the ne ing "mechanistic ot safety or effica definitions and th finition of a Clinio	for the early and on and involve cons of neuroscience, uroscience commu- clinical trials or str acy) or basic exper ne types of clinical cal Trial page and t	conceptual iderable risk, or to the unity. While udies" imental studies trials that are the Funding
104714	Limited Competition: Promoting a to Skin (R34 Clinical Trial Not Allow	Basic Understanding of Chemical Threats wed)	<u>s</u> National Institutes of Health/DHHS	PAS-21- 16 245	lun-2024	450,000 USD
	Contact Name	Hung Tseng PhD				
	Contact Telephone	301-496-0810				
	Contact Email	<u>tsengh@mail.nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jun-2024				
	Synopsis	This Funding Opportunity Announcemen research community to contribute to bas population, with an emphasis on investig	t (FOA) is to support applications to sic understanding of skin injuries ca gating the commonalities of such inj	a new NIAMS in used by chemical juries and identif	itiative to encoura threats to the civ ying potential sha	age the skin ilian red signaling

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		pathways	and therapeutic targets for cou	untermeasure development.			
105478	Notice of Special Interest (NOSI): A Dysfunction in People with Neuro	Advancing developm	<u>Research in Gastrointestinal</u> ental Disorders	National Institutes of Health/DHHS	NOT-NS- 22-003	-May-2024	Not Specified
	Contact Name	Adam L. H	lartman, MD				
	Contact Telephone	301-496-9	9135				
	Contact Email	adam.har	<u>tman@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	07-May-2	024 , 05-Jun-2024 , 16-Jun-2024	4			
	Synopsis	The Natio applicatio preventio	nal Institute of Neurological Dis ns focused in the following area n, or treatment of gastrointesti	sorders and Stroke is issuing this No a(s) to support basic, translational, a nal dysfunction in people with neur	tice to highlight and/or clinical re odevelopmenta	interest in receiving esearch on the caus Il disorders.	g grant es, diagnosis,
105756	Investigator Initiated Research in ( Science (R21 Clinical Trial Not Allo	<u>Computati</u> wed)	onal Genomics and Data	National Institutes of Health/DHHS	PAR-21- 255 16-	-Jun-2024	275,000 USD
	Contact Name	Daniel Gil	christ, Ph.D.				
	Contact Telephone						
	Contact Email	daniel.gilo	christ@nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	16-Jun-20	24				
	Synopsis	The purpe computat science, a develops refinemer this FOA s	ose of this funding opportunity ional genomics, data science, st nd broadly applicable to humar innovative analytical methodole nt or hardening of software and should be enabling for genomics	announcement (FOA) is to invite ap tatistics, and bioinformatics relevan n health and disease. This FOA supp ogies and approaches, early-stage d tools of high value to the biomedic s and be generalizable or broadly ap	plications for a t to one or both orts fundament levelopment of cal genomics cor oplicable across	broad range of reset of basic or clinical g al genomics researc tools and software, nmunity. Work supp diseases and biolog	arch efforts in genomic h that and ported under ical systems.
105890	Notice of Special Interest (NOSI): F	Precision I	maging of Oral Lesions	National Institutes of Health/DHHS	NOT-DE- 21-010 07-	-May-2024	Not Specified

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Nama	Zhong Cho							
	Contact Name		20, 100, 200						
	Contact Telephone	zhong che	n@nih gov						
	Sponsor Website	znong.cne	<u>nænn.gov</u>						
	Program LIRI	Link to pro	agram LIRI						
	Deadline Dates (ALL) 07-May-2024_05-Jun-2024_16-Jun-2024_07-Sep-2024								
	Synopsis	Diagnosing and treating lesions of the oral cavity and oropharynx are challenging due to reliance on subjective analyses of clinical features and histopathological diagnostic criteria. High resolution and quantitative tools are needed to enhance the precision of diagnostic approaches for oral pathologies to guide options for treatment. This Notice of Special Interest (NOSI) psis is to encourage research projects that develop, adapt, optimize, and validate imaging-based applications and data analysis tools to enhance oral disease detection, diagnosis, and treatment. The long-term goal is to facilitate translation of research findings into clinical practice, paving the way for personalized health care through objective measures that promote accurate and timely diagnosis, targeted therapies, and improved patient survival and quality of life.							
105732	Notice of Special Interest (NOSI):	Immune Re	esponses to Arthropod Feeding	National Institutes of Health/DHHS	NOT-AI- 21-059 07-N	May-2024	Not Specified		
	Contact Name	Oian "Iov"	Liu M.D. MSc				000000		
	Contact Telephone	301-761-6	621						
	Contact Email	liuiov@nia	aid.nih.gov						
	Sponsor Website	<u>,.,.</u>							
	Program URL	Link to pro	ogram URL						
	Deadline Dates (ALL)	07-May-20	 024 , 05-Jun-2024 , 16-Jun-2024	4,07-Sep-2024					
	Synopsis	This Notice of Special Interest (NOSI) solicits transdisciplinary research projects to understand the immunologic events in the vertebrate host that occur at the bite site (skin) and systemically during and after feeding by hematophagous and ectoparasitic arthropods. Exploratory research on arthropod blood feeding was formerly supported by NIAID through the expired FOA, PAR-18-860, "Immune Response to Arthropod Blood Feeding (R21 Clinical Trial Not Allowed). The intent of this NOSI is to indicate continued NIAID support for research in this area as described below through applications to the parent R01 and R21 FOAs.							
106126	Notice of Special Interest (NOSI): of COVID-19 in Underserved and N	<u>Social, Beha</u> Vulnerable	avioral, and Economic Impact Populations	National Institutes of Health/DHHS	NOT-MH- 21-330 07-N	May-2024	Not Specified		

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Name Adam Contact Telephone Contact Email haim Sponsor Website Program URL Link Deadline Dates (ALL) 07-M NIH I and I stren effec supp expe impa Synopsis level susta large	a Haim, Ph.D. a@mail.nih.gov o program URL ay-2024 , 05-Jun-2024 , 16-Jun-2024 hstitutes, Centers, and Offices parti- lealth Disparity Populations initiativ gthen the understanding and respo- tively for future public health emergented by other funding opportunities increa health disparities and in vulne- cts of interventions, particularly tho interventions in healthcare settings inability of services that are utilized scale data sources with broad popu- pations, macking, and physical dista	4 , 07-Sep-2024 cipating in the Social, Behavioral, and re are issuing this Notice of Special Ir nse to the Coronavirus Disease 2019 gencies. While research related to th rs, there are additional urgent public erable populations. The purpose of t use under the umbrella of digital hea to address access, reach, delivery, e during and following the pandemic, ulation coverage to improve prediction	d Economic Impa nterest (NOSI) to (COVID-19) pan he direct clinical e health needs, pa his Notice is to 1 lth, as well as co engagement, effe and 2) encourag on of various mit	acts of COVID-19 i highlight interest demic and help us effects of COVID-1 articularly in popu L) emphasize the r mmunity-engaged ectiveness, scalabi ge the leveraging of tigation efforts (in	n Vulnerable in research to s prepare more 9 are lations who oles and d and multi- lity, and of existing cluding
and e and v pand mitig	conomic impacts, and assess the do ulnerable populations. Additionally emic and subsequent social and ecc ation strategies.	ownstream health and healthcare ac , the use of large-scale data sources pnomic changes is needed to underst	cess effects, with to study the indi tand the costs ar	h an emphasis on irect health impac nd benefits of vario	underserved ts of the ous COVID-19
106119 Small Grants for New Investigators to P Research (R21 Clinical Trial Optional)	romote Diversity in Health-Related	National Institutes of Health/DHHS	PAR-21- 313 07-N	May-2024	375,000 USD
Contact Name Katri	ha J. Serrano, Ph.D.				
Contact Telephone 301- Contact Email <u>katri</u> Sponsor Website Program URL <u>Link</u>	180-7855 na.serrano@nih.gov o program URL av 2024 - 16 Jun 2024 - 07 Soc 202	4			

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Synopsis	The purpose of this Funding Opportunity backgrounds, including from groups nation research, to conduct small research project and Kidney Diseases (NIDDK), the Nation Imaging and Bioengineering (NIBIB). New direct costs of combined research funding research projects that can be carried out research independence. The R21 grant man secondary analysis of existing data; smal development of new research technolog	Announcement (FOA) is to provide onally underrepresented in biomed ects in the scientific mission areas o al Human Genome Research Institu v investigators at the time of award og (excluding NIH training and NIH ca in a short period of time with limite nechanism supports different types I, self-contained research projects; o y.	support for new ical, clinical, beha f the National Ins te (NHGRI) or the under this FOA w areer awards). Th ed resources and of projects includ development of r	investigators from avioral and social s atitute of Diabetes e National Institute vill have had less t is R21 will suppor seeks to facilitate ling pilot and feasi esearch methodo	n diverse sciences and Digestive e of Biomedical han \$125,000 t small transition to ibility studies; logy; and
106848 Notice of Special Interest (NOSI): and Craniofacial Health Disparitie	Biologic Factors Underlying Dental, Oral, Is	National Institutes of Health/DHHS	NOT-DE- 21-013 07-N	May-2024	Not Specified
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Hiroko Iida, DDS, MPH 301-594-7404 hiroko.iida@nih.gov Link to program URL 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 The National Institute of Dental and Crar encourage research studies designed to a immune, genetic) contribute to disparitie	4 , 07-Sep-2024 , 05-Oct-2024 , 16-0 niofacial Research (NIDCR) is issuing identify and understand the mechan es in dental, oral, and craniofacial di	Dct-2024 , 07-Jan this Notice of Sp nisms by which bi isease onset, prog	-2025 ecial Interest (NOS iologic factors (mig gression, and pers	51) to crobial, istence.
107449 Notice of Special Interest (NOSI): Human Service Settings	Reducing Stigma Related to Drug Use in	National Institutes of Health/DHHS	NOT-DA- 21-060 07-N	May-2024	Not Specified
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Richard A. Jenkins PhD 301-443-1923 jenkinsri@mail.nih.gov Link to program URL 07-May-2024 , 05-Jun-2024 , 16-Jun-2024	4 , 07-Sep-2024 , 05-Oct-2024 , 16-0	 Dct-2024 , 07-Jan	-2025	

SPIN ID	N ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
The National Institute on Drug Abuse (NIDA) recognizes that stigma is per related to HIV prevention and care. Stigma contributes to a lack of attenti people who use drugs (PWUD) and insufficient uptake of services to preve consequences of drug use) among PWUD. Stigmas of interest include: inte associated with providing services to PWUD, and stigma toward PWUD by that create or augment stigma also are of interest here, as well as stigma broaden their services to PWUD. Stigma reduction interventions for HIV s cases, implemented on a wide scale, but generally target sexual transmiss knowledge from this work can inform stigma among PWUD. Large literatu conditions (e.g., cancer, mental illness) which also can provide conceptual development of new interventions addressing PWUD.						al service and othe ening, inadequate te HIV infection (a ong drug users, st e settings. Policies viders who might been developed a behavioral risk; ho exist in a variety of bases to speed th	er settings outreach to nd related igma and practices otherwise and, in some wever, f other e	
106966	Notice of Special Interest (NOSI): So mprove Transplantation Outcomes	omatic Ce <u>s</u>	ell Gene Editing Therapies To	National Institutes of Health/DHHS	NOT-AI- 21-080 07-1	May-2024	Not Specified	
	Contact Name Nasrin Nabavi, Ph.D. Contact Telephone 240-627-3538 Contact Email <u>nnabavi@mail.nih.gov</u> Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 The National Institute of Allergy and Infectious Diseases (NIAID) is interested in supporting research that applies somatic cel gene editing (SCGE) approaches to improve graft survival and outcomes for recipients of allogenic solid organ, pancreatic islet, or vascularized composite allograft (VCA) transplants in animal models or human tissues or organs excluded from							
107609	Drug Discovery For Nervous System Allowed)	<u>n Disorde</u>	rs (R21 Clinical Trials Not	National Institutes of Health/DHHS	PAR-22- 032 16-J	un-2024	275,000 USD	
	Contact Name E Contact Telephone 3 Contact Email <u>n</u> Sponsor Website	Enrique M 801-443-5 michelott	Aichelotti, PhD 5415 Siel@mail.nih.gov					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Program URL	Link to program URL						
	Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2024						
	Synopsis Syn							
107543	Notice of Special Interest (NOSI): A Research	Accelerating Progress in Celiac Disease	National Institutes of Health/DHHS	NOT-AI- 22-004 07-1	May-2024	Not Specified		
	Contact Name	Annette L. Rothermel, Ph.D.						
	Contact Telephone	240-627-3477						
	Contact Email	arothermel@niaid.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2024 , 25-May-2024 , 05-Jun-202	24 , 16-Jun-2024 , 07-Sep-2024 , 25-	Sep-2024				
	Synopsis	The purpose of this Notice of Special Inte of special interest in research on the etic development of preventative or disease	erest (NOSI) is to inform potential ap ology and pathogenesis of celiac dise ameliorating therapies/strategies.	pplicants to the N ease, identification	lational Institutes on of therapeutic ta	of Health (NIH) argets, and		
107545	Notice of Special Interest (NOSI):	Expanding the Otitis Media Research	National Institutes of	NOT-DC-	May 2024	Not		
107545	Workforce: Focus on Early Stage I	nvestigators	Health/DHHS	22-001	viay-2024	Specified		
	Contact Name	Bracie Watson, Jr., Ph.D.						
	Contact Telephone	301-402-3458						
	Contact Email	watsonb@nidcd.nih.gov						
	Sponsor Website							

SPIN ID	Program Title	S	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Program URL	Link to prog	gram URL				
	Deadline Dates (ALL)	07-May-20 2025 , 16-F	 24 , 05-Jun-2024 , 16-Jun-2024 eb-2025 , 07-May-2025 , 05-Ju	4 , 20-Jun-2024 , 07-Sep-2024 , 05-( un-2025 , 16-Jun-2025 , 07-Sep-202	Dct-2024 , 16-Oct 5	-2024 , 07-Jan-202	5 , 05-Feb-
	Synopsis	The Nation basic and c is to invite NIH https:/ OM—comr approaches	al Institute on Deafness and C linical scientists who conduct Early Stage Investigators (ESIs //grants.nih.gov/grants/new_i nonly known as ear infections s that accelerate the developn	other Communication Disorderse (N research on otitis media (OM). The ), as defined by the nvestigators/index.htm#earlystage . There is a critical need for focused nent of effective ways to prevent a	IIDCD) is intereste purpose of this N , to submit resear d, novel, creative nd treat OM.	ed in expanding the lotice of Special In rch applications the and innovative res	e cadre of terest (NOSI) at focus on earch
107483	Notice of Special Interest (NOSI): Substance Use in Sex and Gender Neurocognitive Disorders	Mechanistic Differences	<u>Studies on the Impact of</u> in HIV-Associated	National Institutes of Health/DHHS	NOT-DA- 22-047 07-I	May-2024	Not Specified
	Contact Name						
	Contact Telephone						
	Contact Email						
	Sponsor Website						
	Program URL	Link to prog	gram URL				
	Deadline Dates (ALL)	07-May-20	24 , 05-Jun-2024 , 16-Jun-2024	4 , 07-Sep-2024 , 05-Oct-2024 , 16-0	Oct-2024 , 07-Jan	-2025	
	Synopsis	Compared notice is to gender-spe therapeutic	to men, women are often more inform potential applicants of ecific differences in HIV-associa cs and optimization of treatme	re likely to develop HIV-associated f NIDA's special interest in understa ated neurocognitive disorders. This ent options in HIV positive individua	neurocognitive in anding the neurol information can als with substance	npairments. The pr biological bases for be used for targeto e use disorders.	urpose of this r sex or ed
107484	Notice of Special Interest (NOSI):	The Functio	nal Oral Microbiome	National Institutes of Health/DHHS	NOT-DE- 21-015 07-I	May-2024	Not Specified
	Contact Name	Tamara Mo	Nealy, PhD.				
	Contact Telephone	202-430-14	174				
	Contact Email	tamara.mc	nealy@nih.gov				
	Sponsor Website	2					



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2024 2025 , 07-May-2025 , 05-Jun-2025 , 16-Ju	4 , 07-Sep-2024 , 05-Oct-2024 , 16-( In-2025 , 07-Sep-2025	Dct-2024 , 07-Jan	2025 , 05-Feb-202	25 , 16-Feb-
	Synopsis	The National Institute of Dental and Cran encourage research studies that focus be	iofacial Research (NIDCR) is issuing yond the bacteria to the multispec	this Notice of Spe ies communities i	ecial Interest (NOS making up the ora	31) to I microbiome.
108065	Notice of Special Interest (NOSI): Co-infection	Pediatric COVID-19 and Respiratory Viral	National Institutes of Health/DHHS	NOT-HL- 22-004 07-N	/lay-2024	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email					
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2024 2025 , 07-May-2025 , 05-Jun-2025 , 07-Se	4 , 16-Jun-2024 , 07-Sep-2024 , 05-0 ep-2025	Oct-2024 , 16-Oct	-2024 , 07-Jan-202	!5 , 05-Feb-
	Synopsis	This NOSI is intended to support projects screen for co-infection, phenotype and co investigator-initiated applications for bas	that will employ existing and new ollect biospecimens to answer som sic, translational and human subject	clinical trial cohoi e of these questic research (not cli	ts/observational on ons and to encoura nical trials) in this	cohorts to age space.
115289	Notice of Special Interest (NOSI): Response Services	Priority Research Opportunities in Crisis	National Institutes of Health/DHHS	NOT-MH- 23-140 07-N	/lay-2024	Not Specified
	Contact Name	Stephen O'Connor, Ph.D.				
	Contact Telephone	301-480-8366				
	Contact Email	stephen.o'connor2@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2024 2025 , 07-May-2025	4 , 07-Sep-2024 , 05-Oct-2024 , 16-0	Dct-2024 , 07-Jan	2025 , 05-Feb-202	25 , 16-Feb-
	Synopsis	The National Institute of Mental Health (I Health (ORWH) are issuing this Notice of	NIMH), National Institute on Drug A Special Interest (NOSI) to outline p	Abuse (NIDA), and riorities for resea	l Office of Researc rch in crisis respor	h on Women's 1se services.

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		Research age-relate influence well as ap	is sought that is conducted in re ed (e.g., youth; adult; older adul the types of care that are provid plications that address crisis ser	al-world settings, where a wide rar t), geographic (rural/remote setting ded. Studies are encouraged that a vices for children and under-resou	nge of clinical pre gs), cultural cons ddress the contir rced populations	esentations, psycho derations, and hea nuum of crisis servi	osocial factors, alth disparities ce systems, as
110102	Notice of Special Interest (NOSI): Research to Advance Mental, Emp Interventions in School Settings	Disseminat otional, an	tion and Implementation d Behavioral Health Preventive	National Institutes of Health/DHHS	NOT-AT- 22-004 07-1	May-2024	Not Specified
	Contact Name	Beda Jear	-Francois, Ph.D.				
	Contact Telephone	202-313-2	2144				
	Contact Email	Beda.Jear	n-Francois@nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Synopsis	The purpo innovative adaptatio emotiona and imple and/or pr MEB prog prevent o identificat	ose of this Notice of Special Inte e approaches to identifying, unc n, integration, scale-up and sust l, and behavioral (MEB) health i ementation research to deliver in event MEB disorders. Application rams designed to promote heal nset of an MEB disorder; or (2) st tion of MEB disorders to slow pr t of MEB disorders will be consid	rest (NOSI) is to stimulate dissemin lerstanding, and developing strateg anability of evidence-based preve in school settings. This NOSI encour interventions in the school setting the ns should include a focus on one of thy MEB development by decreasing secondary/selective prevention pro- ogression with early intervention.	ation and impler gies for overcomi ntive interventio ages applications hat will promote f the following: ( ng risk factors an ograms designed Applications focu	nentation research ng barriers to the a ns to support child which focus on di healthy MEB deve 1) primary/univers d increasing protec to support screeni ised on tertiary/inc	a to support adoption, ren's mental, ssemination lopment al prevention ctive factors to ng and early dicated
110578	Notice of Special Interest (NOSI): of Emerging and Existing Issues of Well-Being of Women, Children a Intellectual Disabilities	Administra f COVID-19 nd Individu	tive Supplements for Research Related to the Health and Jals with Physical and/or	National Institutes of Health/DHHS	NOT-HD- 22-003 07-I	Мау-2024	Not Specified
	Contact Name	Robert Ta	mburro, MD, MSc				
	Contact Telephone	301-480-2	2619				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email	robert.tar	nburro@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	.024 , 05-Jun-2024				
	Synopsis	The purpe suppleme pregnant The goal o available. address k hoped tha projects a be encour describe p related da	ose of this funding opportunity is ental funding to conduct research and lactating people, infants, ch of this NOSI is to not replace or Instead, the purpose is to comp ey issues not currently covered at the use of administrative sup addressing issues that are the for raged to submit to those annou plans for the rapid sharing of da ata and resources and the effect	s to provide an opportunity for fun- h addressing these emerging and co- hildren and adolescents, and individe to compete with the various COVID plement them by offering a funding by available COVID-related funding plements will foster research in the cus of currently available or future ncements. Also, applicants respondent ta and results as well as innovative tive communication of results are a	nded researchers other existing COV duals with physica p-related funding g opportunity for g announcements ese key areas in th COVID funding o ding to this NOSI a data analytics ap a high priority of t	in these various fie /ID-related issues al and/or intellectu opportunities curr currently funded in among these pop ne most timely ma pportunity annour are strongly encou proaches. The sha he NIH.	elds to pursue among ual disabilities. rently nvestigators to ulations. It is nner. Research ncements will raged to ring of COVID-
	Notice of Special Interest (NOSI):	Emerging a	and Existing Issues of				
110057	Coronavirus Disease 2019 (COVID	<u>-19) Resea</u> nd Individu	urch Related to the Health and	National Institutes of	NOT-HD- 22-002 07-N	May-2024	Not Specified
	Intellectual Disabilities		adis with hysical and of		22 002		Speemed
	Contact Name	Robert Ta	mburro, MD, MSc				
	Contact Telephone	301-480-2	2619				
	Contact Email	robert.tar	mburro@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	.024 , 05-Jun-2024				
	Synopsis	The purpo addressin children a	ose of this funding opportunity in g these and other emerging and and adolescents, and individuals	s to provide an avenue for researc d existing COVID-related issues amo with physical and/or intellectual d	hers to pursue fui ong pregnant and isabilities.	nding to conduct r lactating people,	esearch infants,
109942	Technology Development Researc	ch for Estal	blishing Feasibility and Proof of	National Institutes of	PAR-22- 07-1	May-2024	275,000

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Concept (R21 - Clinical Trial Not All	lowed)		Health/DHHS	126		USD
	Contact Name	Fei Wang	Ph.D.				
	Contact Telephone						
	Contact Email	wangf@n	nail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	024 , 16-Jun-2024 , 07-Sep-2024	4 , 16-Oct-2024 , 07-Jan-2025	, 16-Feb-2025 , 07-Ma	y-2025	
	Synopsis	technolog participat potential the curren software, to becom for feasib FOA does applicatio research. prelimina include un administr	gies for biomedical research tha ing in this FOA. Projects should impact in biomedical research. In the state of the art, may include, chemical reagents and process e research tools. The goal of thi ility and exploratory technology not support technology develo ns should propose developmen Moreover, feasibility of the pro ry data. Applications that are fo published or published data th atively withdrawn without revise	t is relevant to the NIGMS mis entail a high degree of risk an Outcomes or products of the but are not limited to: laborat es, biological molecules or sys s FOA is to support proof of co development. Due to the cor pment that is narrowly focuse t of innovative tools that can posed technology must not ha cused on technology develop at provide proof of concept an ew.	sion or that of other N d/or novelty, which wi proposed project, which tory instruments and o tems that have been n procept, high-risk and p istraints that would be d on addressing specif potentially benefit a br ave already been estab ment to address specif re not responsive to th	IIH Institutes or Ce II be offset by a high ther devices, algo nodified by humar otentially high-rev imposed on broad tic biological quest road spectrum of the blished in the literatic tic biological quest is FOA and will be	nters (ICs) gh future ntly advance rithms and n intervention vard studies d utility, this ions. Rather, biomedical nture or with ions and/or
110034	Notice of Special Interest (NOSI): R To Support the Delivery of Evidence Mental or General Medical Health	Research L ce-Based F care Settin	Jsing Implementation Science Practices in Community-Based ngs	National Institutes of Health/DHHS	NOT-MH- 22-170 07-N	May-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Link to pr	ogram URL				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Deadline Dates (ALL)	07-May-2 2025 , 07	.024 , 05-Jun-2024 , 16-Jun-2024 -May-2025	، 07-Sep-2024 , 05-Oct-2024 , 16-	Oct-2024 , 07-Jan	-2025 , 05-Feb-202	25 , 16-Feb-	
	Synopsis	This Notic support t people w (CCBHCs) Behaviora	ce of Special Interest (NOSI) high he adoption and sustainability o ith mental illness. These settings funded through the Substance al Health Clinic-Expansion (CCBH	lights interest in mental health set f evidence-based practices (EBPs) s could include, but are not limited Abuse and Mental Health Services IC-E) grant program.	rvices and implem in community-bas to, Certified Com Administration (S	nentation science r sed settings that d munity Behaviora AMHSA) Certified	esearch to eliver care to I Health Clinics Community	
116487	Translational Research in Materna Therapeutics (R21 Clinical Trial Op	al and Ped otional)	iatric Pharmacology and	National Institutes of Health/DHHS	PAR-23- 131 16-J	un-2024	275,000 USD	
	Contact Name	Katie M. V	Vance, Ph.D.					
	Contact Telephone	301-435-0	6640					
	Contact Email	Katie.Van	<u>ce@nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026						
Synopsis Synopsis The purpose of this notice of funding opportunity (NOFO) is to support translational and clinical respectively of the technologies that could have a direct clinical or health impact; (2) enhance the understanding mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of repurposing for safer and more effective medications in pregnant and lactating persons, neonates, goal is to improve safe and effective precision therapeutics for pregnant and lactating persons, fetuchildren, including those with disabilities.							advance s, models, and erlying t occur during gs or drug h. The overall es, and	
107841	<u>Risk and Protective Factors of Fam</u> (R01 - Clinical Trial Optional)	nily Health	and Family Level Interventions	National Institutes of Health/DHHS	PAR-21- 358 07-1	May-2024	Not Specified	
	Contact Name	Deborah	E. Linares, PhD, MA					
	Contact Telephone	301-402-2	2516					
	Contact Email	Deborah.	Linares@nih.gov					
	Sponsor Website							

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Program URL Deadline Dates (ALL)	Link to program URL 07-May-2024 , 05-Jun-2024 , 07-Sep-202 The purpose of this initiative is to advance	4 , 05-Oct-2024 , 07-Jan-2025 , 05-I ce the science of minority health an	-eb-2025 , 07-Ma d health dispariti	y-2025 es by supporting r	esearch on
	Synopsis	family health and well-being and resilien family resilience as critically important ar	ce. The NIMHD Research Framewo reas of research to decrease dispar	rk recognizes fam ities and promote	ily health, family v equity.	vell-being, and
107608	Drug Discovery For Nervous Syste Allowed)	m Disorders (R01 Clinical Trials Not	National Institutes of Health/DHHS	PAR-22- 05-J 031	un-2024	Not Specified
	Contact Name	Enrique Michelotti, PhD				
	Contact Telephone	301-443-5415				
	Contact Email	michelottiel@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024				
	Synopsis	This Funding Opportunity Announcemen treatment of nervous system disorders. T Identification, design, synthesis, and pred Initial hit-to-lead chemistry to improve a to improve efficacy and pharmacokinetic will be placed on projects that provide no	t (FOA) supports the discovery of n Through this FOA, NIMH, NIAAA, NI clinical testing of small molecules for ctivity of compounds against the ta es; and 4) Initial drug metabolism ar ovel approaches for identifying pot	ovel compounds DA and NIA wish or their potential rget of interest; 3 nd pharmacokinet ential therapeutio	for the prevention to stimulate resea as candidate thera ) Later stage lead tic properties (DM c agents.	and rch in: 1) peutics ; 2) optimization PK). Emphasis
121868	Unveiling Health and Healthcare I Chronic Diseases in Latin America Outcomes Across the Hemisphere	Disparities in Non-Communicable and : Setting the Stage for Better Health e (R01 - Clinical Trials Not Allowed)	National Institutes of Health/DHHS	PAR-23- 303	May-2024	Not Specified
	Contact Name	Larissa Avilés-Santa, MD, MPH, Director				
	Contact Telephone	301-827-6924				
	Contact Email	avilessantal@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Sep-202	4 , 05-Oct-2024 , 07-Jan-2025 , 05-l	Feb-2025 , 07-Ma	y-2025 , 05-Jun-20	025 , 07-Sep-

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	2025 , 05 This Notic clinical ep and healt mortality	Oct-2025, 07-Jan-2026, 05-Feb e of Funding Opportunity (NOF idemiology, evaluation of public hcare disparities related to non- in Latin America and among U.S	o-2026 , 07-May-2026 , 05-Jun-2026 O) will support innovative, collabor c and/or health care policies, and va communicable and chronic disease S. Hispanics/Latinos.	5 , 07-Sep-2026 , ative, and interdi alidation of meas es (NCDs) with th	05-Oct-2026 , 07-J sciplinary research surements that add e highest disease k	an-2027 focused on dress health ourden and
121869	Interventions on Health and Health and Chronic Diseases in Latin Ame the Hemisphere (R01 - Clinical Tri	hcare Disperica: Imprediate Required	oarities on Non-Communicable oving Health Outcomes Across d)	National Institutes of Health/DHHS	PAR-23- 304 07-1	May-2024	Not Specified
	Contact Name	Larissa Av	ilés-Santa, MD, MPH, Director				
	Contact Telephone	301-827-6	5924				
	Contact Email	<u>avilessant</u>	al@nih.gov				
	Sponsor Website						
	Program URL	<u>Link to pr</u>	ogram URL				
	Deadline Dates (ALL)	07-May-2 2025 , 05-	024 , 05-Jun-2024 , 07-Sep-202 Oct-2025 , 07-Jan-2026 , 05-Fel	4 , 05-Oct-2024 , 07-Jan-2025 , 05-F ɔ-2026 , 07-May-2026 , 05-Jun-2026	eb-2025 , 07-Ma 5 , 07-Sep-2026 ,	y-2025 , 05-Jun-20 05-Oct-2026 , 07-J	25 , 07-Sep- an-2027
	Synopsis	The purpo focused o related to and amor	ose of this Notice of Funding Op n clinical, health services, and/c non-communicable and chroni ng U.S. Hispanics/Latinos.	portunity (NOFO) is to support inno or community-based interventions t c diseases (NCDs) with the highest o	ovative and intero that address heal disease burden a	disciplinary team r th and healthcare nd mortality in Lat	esearch disparities in America
121337	NIAID and NIDDK Research Oppor Investigators to Promote Workfor	tunities fo ce Diversi	r New and "At-Risk" ty (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-23- 275 07-1	May-2024	Not Specified
	Contact Name	Diane Ad	ger-Johnson, MPH				
	Contact Telephone	240-669-2	2924				
	Contact Email	Altraining	helpdesk@niaid.nih.gov				
	Sponsor Website	-					
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2025	024 , 05-Jun-2024 , 07-Sep-2024	4 , 05-Oct-2024 , 07-Jan-2025 , 05-F	eb-2025 , 07-Ma	y-2025 <i>,</i> 05-Jun-20	25 , 07-Sep-

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The purpo with their seeks to s independ research substanti	ose of this notice of funding opp r institutions to submit applicati support either (a) a New Investig ent funding from NIH, or (b) an award and unless successful in s al research grant funding in the	portunity (NOFO) is to encourage a ons for research projects within th gator (NI), who has not previously 'At-Risk' investigator, who had pri- securing a substantial research gra following fiscal year.	researchers fro le mission of ei competed succ or support as a nt award in the	m diverse backgroun ther NIAID or NIDDK. essfully for substanti PD/PI on a substanti current fiscal year, v	ds to work This NOFO al, al independen vill have no
121563	Developing Novel Theory and Met Architecture of Complex Human T	hods for I raits (R01	<u>Jnderstanding the Genetic</u> Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-23- 302	95-Jun-2024	Not Specified
	Contact Name	Alexande	r Arguello, Ph.D.				
	Contact Telephone	240-731-3	3753				
	Contact Email	alexande	r.arguello@mail.nih.gov				
	Sponsor Website						
	Program URL	<u>Link to pr</u>	ogram URL				
	Deadline Dates (ALL)	05-Jun-20	024 , 05-Oct-2024 , 05-Feb-2025	, 05-Jun-2025 , 05-Oct-2025 , 05-F	eb-2026 , 05-J	un-2026 , 05-Oct-202	6
	Synopsis	The goal of how ge Approach scales of available	of this NOFO is to support applic enetic and non-genetic factors c les should be interdisciplinary d biological, social, and ecological large-scale datasets.	cations for novel theory and metho ontribute to complex trait variatio rawing from the natural and social organization, and make extensive	ods developme n across indivic sciences, acco use of theory,	nt that enable better duals, families, and po unt for interdepende modeling, and valida	understandin opulations. ncies across tion with
122024	Understanding the Impact of Heal Disparities in Maternal Morbidity Optional)	thcare System and Morta	stem and Clinician Factors on ality (R01 - Clinical Trial	National Institutes of Health/DHHS	PAR-24- 059	95-Jun-2024	Not Specified
	Contact Name	Rada K. D	agher, PhD, MPH				
	Contact Telephone	301-451-3	2187				
	Contact Email	rada.dagl	ner@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	05-Jun-20	024 , 05-Oct-2024 , 05-Feb-2025	, 05-Jun-2025 , 05-Oct-2025 , 05-F	eb-2026 , 05-J	un-2026 , 05-Oct-202	6

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis					
104359	Comprehensive Care for Adults with Typ Populations with Health Disparities (R01	e 2 Diabetes Mellitus from Clinical Trial Optional)	National Institutes of Health/DHHS	PA-21- 232 07-	-May-2024	2,500,000 USD
	Contact Name Larissa Contact Telephone 301-8 Contact Email aviles Sponsor Website Program URL Link to Deadline Dates (ALL) 07-Ma This in Synopsis	a Aviles-Santa, MD, MPH 27-6924 <u>santal@mail.nih.gov</u> <u>program URL</u> vy-2024 , 05-Jun-2024 , 07-Sep-202 itiative will support innovative res ling models of health care) to effect es mellitus from populations with	24 earch to develop, test and evaluate ctively adapt and implement compr health disparities concordant with	multi-level/mul ehensive clinical recommended a	ti-component strate l care for individuals nd evidence-based	egies s with Type 2 guidelines.
103967	Screening and Functional Validation of H Variants (R01 Clinical Trial Not Allowed)	uman Birth Defects Genomic	National Institutes of Health/DHHS	PAR-21- 229 05-	-Jun-2024	2,499,995 USD
	Contact Name Mahu Contact Telephone 301-43 Contact Email mukh Sponsor Website Program URL Link to Deadline Dates (ALL) 05-Jur Rapid that a develo Synopsis Synopsis	a Mukhopadhyay, Ph.D. 35-6886 <u>opam@mail.nih.gov</u> <u>o program URL</u> 1-2024 , 05-Feb-2025 advances in genotyping and next g re associated with a wide variety o opmental disabilities (IDDs) and ink ric birth defects cohorts are availa ypes and Phenotypes (dbGaP), the e and Clinical Genome Resource (C cion and characterization of birth o lual efforts using in-silico tools. ap	generation sequencing technologies of congenital defects including struct oorn errors of metabolism (IEMs). La ble to the research community thro Gabriella Miller Kids First Data Res ClinGen). The purpose of this initiati defects-associated genetic variants is propriate animal models. in vitro sv	have led to the tural birth defect arge quantities o bugh several data ource Portal, the ve is to promote dentified throug stems or multi-p	identification of ge ts (SBDs), intellectu of genomic data coll abases such as the I e European Genome the screening, fun th public facing data pronged approaches	netic variants al ected from Database of e-Phenome ctional abases and s. This initiative

SPIN ID	Program Title	Sponsor	Name	Sponsor Number		Deadline Date	Funding Amount
	a v	addresses a challer variations have fun	ging gap between ide ctional effects on the	ntifying sequence variations of pote phenotype of interest.	ential interest an	d recognizing whic	h of those
104500	Notice of Special Interest (NOSI): Be Research (BEIR) to Improve Use of Conditions	ehavioral Economi Evidence-Based Pr	cs for Implementation actices for HLBS	National Institutes of Health/DHHS	NOT-HL- 21-010 07-	May-2024	Not Specified
	Contact Name F	Rebecca A. Roper, I	MS, MPH				
	Contact Telephone 3	301-496-1051					
	Contact Email <u>F</u>	<u>Rebecca.Roper@ni</u>	<u>h.gov</u>				
	Sponsor Website						
	Program URL L	<u>ink to program UR</u>	<u>L</u>				
	Deadline Dates (ALL)	)7-May-2024 , 05-J	un-2024 <i>,</i> 07-Sep-2024	4			
	۲ ۲ ۲ ۲ Synopsis ۴ ۵ ۵ ۵	This Notice of Spec research (BEIR) in c neart, lung, blood, context, patterns o patients, parents, c pehavioral econom and minimally disru design, as appropri	ial Interest (NOSI) is in order to develop more and sleep (HLBS) cond f behavior change, and linicians, others), grou ics to develop implem optive when possible a ate to the research ob	tended to stimulate the use of behavior of behavior of the strategies for implemental effective strategies for implemental fitions. NHLBI encourages application dimotivators for change across decings, healthcare systems and/or complementation strategies for user-driven, are encouraged. Applications may projectives.	avioral economic aion of evidence- ons that recogniz sion-making leve munities. Applic sustainable inte ropose either a c	cs strategies for im based practices (E e the importance o els, including indivi ations that focus o rventions that may clinical trial or non-	plementation BP) to address of cultural duals (e.g., on the use of y be simplified clinical trial
108001	Notice of Special Interest (NOSI): Eg Native Hawaiians, and Pacific Island Allowed)	oidemiologic studie ders (Parent R01 Cl	<u>es in Asian Americans,</u> inical Trial Not	National Institutes of Health/DHHS	NOT-HL- 23-001 07-	May-2024	Not Specified
	Contact Name F	Robb Rowley, MD					
	Contact Telephone 3	801-827-9126					
	Contact Email <mark>F</mark>	Robb.Rowley@nih.	gov				
	Sponsor Website						
	Program URL L	ink to program UR.	L				
	Deadline Dates (ALL) 0	)7-May-2024 , 05-J	un-2024 , 07-Sep-2024	4 , 05-Oct-2024			

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Th ga fr Synopsis ar lif ex Ai	ne purpo aps with equently ncestry, e, a criti xposures merican	ose of this Notice of Special Inte in and between subpopulations y aggregated in research, poten culture, immigration patterns a cal need exists for epidemiolog s, lifestyle, behavioral, genomics , Native Hawaiian, and Pacific Is	rest (NOSI) is to stimulate novel ep of Asian Americans, Native Hawai tially masking important social and mong Asian Americans, socioecond ical research to enhance our under s, social, neighborhood, and biolog lander subpopulations.	oidemiological ians, and Pacifi health differe omic position, a standing of the ical factors tha	research to address k c Islanders. These po nces. Given clear het and acculturation int e interplay of enviror t impact the health c	ey knowledge pulations are erogeneity in o American mental of Asian
112441	Research to Action: Assessing and A Environmental Contaminants (R01 C	ddressin Clinical T	ng Community Exposures to rial Optional)	National Institutes of Health/DHHS	PAR-22- 210	5-Jun-2024	2,500,000 USD
	Contact Name Li Contact Telephone 98 Contact Email of Sponsor Website Program URL Li Deadline Dates (ALL) 05 Th of pl to Synopsis Ni to Re Er (h	am O'Fa 34-287-3 fallon@r nk to pro 5-Jun-20 nis Fund f enviror an base conduc imHD's o o nurture esearch nvironm attps://w	Illon 3298 <u>hiehs.nih.gov</u> 0gram URL 24 , 05-Oct-2024 , 05-Feb-2025 ing Opportunity Announcement omental exposures of concern to d on research findings. Projects at research and to translate rese commitment to environmental e and sustain trust and bi-direct to Action program is part of the ental Public Health" (PEPH) netw www.niehs.nih.gov/research/sup	, 05-Jun-2025 (FOA) encourages multidisciplinar o a community and to develop and supported under this program will arch findings into public health act health disparities and environment ional communication between aca National Institute of Environment work oported/translational/peph/index.	ry projects to in implement an employ comm tion. This anno tal justice rese demic research al Health Scien cfm).	nvestigate the potent environmental publi nunity-engaged resea uncement reflects NI arch. This FOA also a ners and affected cor ces (NIEHS) "Partner	ial health risks c health action rch methods EHS' and dvances efforts nmunities. The ships for
112472	Notice of Special Interest (NOSI): Re Muscular Dystrophies (R01)	spirator	y Complications of the	National Institutes of Health/DHHS	NOT-HL- 22-025	7-May-2024	Not Specified
	Contact Name Ai Contact Telephone 30 Contact Email <u>ar</u>	runa Nat 01-827-( runa.nat	tarajan, MD, PhD )180 <u>arajan@nih.gov</u>				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website						
	Program URL	Program URL Link to pr					
	Deadline Dates (ALL)	ites (ALL) 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025					
	Synopsis	The purpose of this NOSI is to encourage research grant applications focused on respiratory complications of the muscular dystrophies. This includes further elucidation of respiratory phenotypes in humans; research to optimize pulmonary function testing and existing respiratory therapies in humans; and mechanistic and translational research, including in vitro and in animal models, that examines respiratory muscle response to gene therapies and other therapeutic strategies in the muscular dystrophies.					
120789 <mark>-</mark>	RFA-NS-24-021 HEAL Initiative: Iuman Pain Conditions (R01 - Clii	Understan	nding Individual Differences in Optional)	National Institutes of Health/DHHS	RFA-NS- 24-021 06-J	un-2024	3,250,000 USD
	Contact Name	D.P. Moh	apatra, Ph.D.				
	Contact Telephone	301-496-9	9964				
	Contact Email	dp.moha	<u>patra@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
Deadline Dates (ALL) 06-Jun-2024 , 08-Oct-2024 , 06-Feb-2025							
	Synopsis	This notice of funding opportunity (NOFO) seeks to support research aimed at holistic understanding of inter-individual or between-person differences in human pain conditions, focusing on 'Whole Person Health' and enhancing pain treatment and management strategies towards personalized pain medicine. The goal of this NOFO is to support studies that focus on the collection of clinical and/or preclinical data to enable evidence-based modeling and understanding of inter-individual differences and/or heterogeneity of pain occurring with use of pain therapy/management, or with conditions such as a second pain condition, a comorbid health condition, a comorbid mental health condition, or conditions of use / misuse of opioids, alcohol or other substances. Applicants are encouraged to develop and implement novel, multidisciplinary research approaches, and include investigators with complementary expertise to fulfill the project and program goals. Input from patients and caregivers on the goals of the project is highly encouraged. Rigorous data-driven and evidence-based research approaches supported under this NOFO are expected to provide better understanding of biological and/or biopsychosocial underpinnings of inter-individual differences, heterogeneity, and stratification of persons with lived pain experience, which would accelerate the development of evidence-based solutions toward precision pain medicine.					
122946 <u>N</u>	Multidisciplinary Studies of HIV/A	IDS and A	ging (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-24- 092 07-N	May-2024	275,000 USD
SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
---------	------------------------------------	---	---	--	--	---	---
	Contact Name Contact Telephone	Ann Naml 301-496-6	kung, MPH 5838				
	Contact Email	ann.namk	kung@nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	07-May-2 2025 , 16-	024 , 16-Jun-2024 , 07-Sep-202 -Oct-2025 , 07-Jan-2026 , 16-Fe	4 , 16-Oct-2024 , 07-Jan-2025 , 16-F b-2026 , 07-May-2026 , 16-Jun-202	Feb-2025 , 07-Ma <sup>.</sup> 6 , 07-Sep-2026 ,	y-2025 , 16-Jun-20 16-Oct-2026 , 07-J	)25 , 07-Sep- lan-2027
	Synopsis	This NOFC objectives infection a related co aging scie Office of A	D invites applications at the inters: 1) Improve the understanding and its treatment; and 2) Impro pmorbidities, co-infections, and ince approaches. Proposed rese AIDS Research (OAR) as describe	ersection of HIV and aging by propo g of biological, clinical, and socio-be ove approaches for testing, prevent complications in different populati earch must be consistent with the H ed in NOT-OD-20-018.	sing research that havioral aspects of ing, and treating H ons and cultural s IIV/AIDS Research	t aims to meet the of aging through the HV infection, and settings by applyin Priorities outlined	e following he lens of HIV managing HIV- g current d by NIH s
122945	Multidisciplinary Studies of HIV/A	AIDS and Ag	ging (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-24- 091	/Jay-2024	Not Specified
	Contact Name	Ann Naml	kung, MPH				
	Contact Telephone	301-496-6	5838				
	Contact Email	ann.namk	kung@nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	07-May-2 2025 , 05-	024 , 05-Jun-2024 , 07-Sep-202 -Oct-2025 , 07-Jan-2026 , 05-Fe	4 , 05-Oct-2024 , 07-Jan-2025 , 05-f b-2026 , 07-May-2026 , 05-Jun-202	Feb-2025 , 07-Ma <sup>.</sup> 6 , 07-Sep-2026 ,	y-2025 , 05-Jun-20 05-Oct-2026 , 07-J	)25 , 07-Sep- lan-2027
	Synopsis	This NOFC objectives infection related co aging scie Office of A	D invites applications at the inters: 1) Improve the understanding and its treatment; and 2) Impro pmorbidities, co-infections, and nce approaches. Proposed rese AIDS Research (OAR), as describ	ersection of HIV and aging by propo g of biological, clinical, and socio-be ove approaches for testing, prevent complications in different populati earch must be consistent with the H ped in NOT-OD-20-018.	esing research that havioral aspects of ing, and treating H ons and cultural s IIV/AIDS Research	t aims to meet the of aging through t HV infection, and settings by applyin Priorities outlined	e following he lens of HIV managing HIV- g current d by NIH s
107248	Notice of Special Interest (NOSI):	Improving	Outcomes in Cancer	National Institutes of	NOT-CA- 07-N	/lav-2024	Not

Icahn School of Medicine at Mount Sinai

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Treatment-Related Cardiotoxicity		Health/DHHS	22-001		Specified		
	Contact Name	Crystal Wolfrey						
	Contact Telephone	240-276-6277						
	Contact Email	wolfreyc@mail.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Jun-202	4 , 16-Jun-2024 , 07-Sep-2024 , 08-0	Oct-2024				
	Synopsis	The purpose of this Notice of Special Inte cardiovascular dysfunction while optimiz cardiotoxicity and translating the finding	erest (NOSI) is to encourage collabo zing cancer outcomes by understand is to improve risk stratification, earl	rative and innova ding the mechanis y detection, preve	ative approaches to sms of cancer trea ention, and manag	o mitigate tment-related jement.		
111641	Notice of Special Interest (NOSI):	Climate Change and Health	National Institutes of Health/DHHS	NOT-ES- 22-006 08-A	Apr-2024	Not Specified		
	Contact Name	Claudia L. Thompson						
	Contact Telephone	984-287-3330						
	Contact Email	thompso1@niehs.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2024 , 25-May-2024 , 05-Jun-202 2024 , 07-Sep-2024 , 25-Sep-2024 , 05-O Dec-2024 , 09-Dec-2024 , 07-Jan-2025 , 2 07-May-2025	24 , 12-Jun-2024 , 16-Jun-2024 , 19- ct-2024 , 12-Oct-2024 , 16-Oct-2024 25-Jan-2025 , 05-Feb-2025 , 12-Feb-	Jun-2024 , 09-Jul 4 , 21-Oct-2024 , 1 2025 , 16-Feb-20	-2024 , 15-Jul-2024 12-Nov-2024 , 15-ľ 25 , 19-Feb-2025 ,	↓, 08-Aug- Nov-2024 , 08- 08-Apr-2025 ,		
O7-May-2025 The National Institute of Environmental Health Science (NIEHS), in partnership with Fogarty International Center (FIC), National Institute of Minority Health and Health Disparities (NIMHD), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Institute of Nursing Res (NINR), National Heart Blood and Lung Institute (NHBLI) and National Institute of Allergy and Infectious Disease (NIAID) leading an NIH-wide Climate Change and Health Initiative (CCHI) with the goals of: reducing the health threats posed by climate change across the lifespan; improving the health of people who are at increased risk from or disparately affecte climate change impacts; and building health resilience among individuals, communities, nations around the world, ther- increasing health equity. As a part of this CCHI, this NOSI encourages applications that address the impact of climate ch								

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
		on health and well-being over the life couglobally.	urse, including the health implicatio	ons of climate ch	ange in the United	States and		
111858	Notice of Special Interest (NOSI): Cardiometabolic Risk Factors in Pe Disparities	Preventive Interventions to Address opulations that Experience Health	National Institutes of Health/DHHS	NOT-OD- 22-154 07-	-May-2024	Not Specified		
	Contact Name	Jennifer Alvidrez, PhD						
	Contact Telephone	301-827-0071						
	Contact Email	Jennifer.alvidrez@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Jun-2024 2025 , 05-Feb-2025 , 16-Feb-2025 , 07-Ma	4 , 16-Jun-2024 , 07-Sep-2024 , 05-C ay-2025	Oct-2024 , 08-Oc	t-2024 , 16-Oct-202	24 , 07-Jan-		
	Synopsis	The purpose of this NOSI is to solicit projection populations that experience health dispa	ects on preventive interventions the rities.	at address cardi	ometabolic risk fact	ors in:		
117360	Notice of Special Interest (NOSI): Implementation among Populatic	Research to Address Vaccine Uptake and ons Experiencing Health Disparities	National Institutes of Health/DHHS	NOT-MD- 23-008 05-	-Jun-2024	Not Specified		
	Contact Name	Deborah E. Linares, Ph.D., M.A.						
	Contact Telephone	301-402-2516						
	Contact Email	deborah.linares@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Oc	, 05-Oct-2024 , 08-Oct-2024 , 16-O t-2025 , 16-Oct-2025 , 05-Feb-2026	ct-2024 , 07-Nov 5 , 16-Feb-2026 ,	/-2024 , 05-Feb-202 05-Jun-2026	.5 , 16-Feb-		
2025, 05-Jun-2025, 16-Jun-2025, 05-Oct-2025, 16-Oct-2025, 05-Feb-2026, 16-Feb-2026, 05-Jun-2026 This Notice of Special Interest (NOSI) highlights the need for research on strategies and interventions to increase vaccine uptake and implementation among populations experiencing health disparities in the United States (U.S.) and its territories Synopsis Research is needed to understand and address misinformation, uncertainty, distrust, and hesitancy regarding uptake of vaccines (e.g., SARS-CoV-2, pneumococcal, influenza, hepatitis B, human papilloma virus (HPV), varicella, tetanus, diphthe and pertussis [Tdap]) among individuals in the U.S. and its territories, especially in populations at increased risk for morbic								

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
		and mort focused o understar health dis disparitie reach, ad communi	ality due to long-standing system on individuals across the life spa nd and address barriers to incre sparities; 2) evaluate organizations in vaccine access, uptake, and dress psychosocial barriers, and ty contexts.	mic health and social inequities, as n (i.e., all ages). The purpose of th asing reach, access, and uptake of onal, local, state, and federal polici series completion, and 3) evaluate social determinants of health [SD	s well as chronic n is NOSI is to solici vaccinations amo es and initiatives e community-eng OH]) to facilitate	nedical conditions. t research that will ong populations ex that mitigate or ex aged interventions vaccination uptake	This NOSI is : 1) periencing acerbate (e.g., expand in clinical and	
112904	Notice of Special Interest (NOSI): Bisexual+ People	<u>Research c</u>	on the Health of Bisexual and	National Institutes of Health/DHHS	NOT-OD- 22-166 07-	May-2024	Not Specified	
	Contact Name	Christoph	er Barnhart, PhD					
	Contact Telephone	301-594-8	8983					
	Contact Email	<u>christoph</u>	er.barnhart@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 , 16-Oct-2	2024 , 05-Jun-2024 , 12-Jun-2024 2024 , 25-Oct-2024 , 12-Nov-202	4 , 16-Jun-2024 , 21-Jun-2024 , 25- 24 , 07-Jan-2025 , 05-Feb-2025 , 16	Jun-2024 , 09-Jul- 5-Feb-2025 , 07-M	2024 <i>,</i> 07-Sep-2024 ay-2025	4 , 05-Oct-2024	
	Synopsis	This Notice of Special Interest (NOSI) solicits research, research training, and research career development on the hea well-being of people who identify as bisexual or bisexual+. "Bisexual" or "bi" in this NOSI may describe those with the potential to be attracted, romantically and/or sexually, to people of more than one sex or gender, not necessarily at the time, not necessarily in the same way, and not necessarily to the same degree. "Bisexual+" or "bi+" in this NOSI is an umbrella term that is intended to encompass non-monosexual identities, including but not limited to bisexual, pansex sexually fluid, and queer.						
114765	Notice of Special Interest (NOSI): Research	<u>Firearm In</u>	jury and Mortality Prevention	National Institutes of Health/DHHS	NOT-OD- 23-039 03-	May-2024	Not Specified	
	Contact Name	Dara R. B	lachman, Ph.D.					
	Contact Telephone							
	Contact Email	Dara.blac	hman-demner@nih.gov					
	Sponsor Website							
	Program URL							

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Deadline Dates (ALL) 20 Se	3-May-2024 , 07-May-2024 , 05-Jun-202 024 , 16-Oct-2024 , 12-Nov-2024 , 07-Ja 29-2025 , 05-Oct-2025 , 16-Oct-2025 , 0	24 , 16-Jun-2024 , 21-Jun-2024 , 09- n-2025 , 05-Feb-2025 , 16-Feb-202 7-Jan-2026 , 05-Feb-2026	Jul-2024 , 07-Sep 5 , 07-May-2025 ,	-2024 , 08-Sep-202 05-Jun-2025 , 16-	24 , 05-Oct- Jun-2025 , 07-		
	th Synopsis in ex in	he identification of those at risk of firearm injury (including self- and other-directed, victims and perpetrators, accid njury), the development, piloting, and testing of innovative interventions to prevent firearm injury and mortality, ar examination of approaches to improve the implementation of existing, evidence-based interventions to prevent fire njury and mortality.						
112420	Notice of Special Interest (NOSI): Inc Screening in Diverse Populations Act	reasing Uptake of Evidence-Based ross the Lifespan	National Institutes of Health/DHHS	NOT-OD- 22-178 07-N	May-2024	Not Specified		
	Contact Name M	lelissa C. Green Parker, PhD						
	Contact Telephone 30	01-480-1161						
	Contact Email <u>m</u>	elissa.greenparker@nih.gov						
	Sponsor Website							
	Program URL <u>Li</u>	nk to program URL						
	Deadline Dates (ALL)	7-May-2024 , 05-Jun-2024 , 07-Jun-2024 025 , 05-Feb-2025 , 16-Feb-2025 , 07-M	4 , 16-Jun-2024 , 07-Sep-2024 , 05-0 ay-2025	Oct-2024 , 08-Oct	-2024 , 16-Oct-202	24 , 07-Jan-		
	Tł (Iú in bu ef sc	The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this Notice of Special Interest (NOSI) to encourage applications proposing to test multilevel strategies and interventions to improve the uptake of evidence-based screening services across the lifespan and in populations including, but not limited to, those experiencing health disparities and those that are underserved. Studies addressing efficacy, effectiveness, dissemination and implementation research, as well as studies seeking to understand and address barriers to screening are encouraged.						
112421	Notice of Special Interest (NOSI): Ad	dressing Evidence Gaps in Screening	National Institutes of Health/DHHS	NOT-OD- 22-179 07-N	May-2024	Not Specified		
	Contact Name M	lelissa C. Green Parker, PhD						
	Contact Telephone 30	01-480-1161						
	Contact Email <u>m</u>	elissa.greenparker@nih.gov						
	Sponsor Website							

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Program LIBI	Link to program LIRI						
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Jun-2024 2025 , 05-Feb-2025 , 16-Feb-2025 , 07-M	4 , 16-Jun-2024 , 07-Sep-2024 , 05-0 ay-2025	Oct-2024 , 08-Oct	-2024 , 16-Oct-202	24 , 07-Jan-		
	Synopsis	The Office of Disease Prevention (ODP) a (ICs) are issuing this Notice of Special Inte preventive screening services where the cannot be determined. This NOSI encour to close high priority evidence gaps to ele recommendation.	nd participating National Institutes erest (NOSI) to solicit applications p evidence is lacking, of poor quality, ages the development and use of ir evate screening services to a level s	of Health (NIH) Ir roposing to stren conflicting, or th movative and rigo uitable for a defir	nstitutes, Centers, gthen the evidence e balance of benef prous methods and nitive grade or	and Offices e base for fits and harms d approaches		
111986	Notice of Special Interest (NOSI): S Address Hunger, Food and Nutrition	Stimulating Research to Understand and on Insecurity	National Institutes of Health/DHHS	NOT-OD- 22-135 07-N	May-2024	Not Specified		
	Contact Name	Marya Levintova, PhD						
	Contact Telephone	301-496-9535						
	Contact Email	marya.levintova@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2024, 05-Jun-2024, 07-Jun-2024	4 , 16-Jun-2024 , 07-Sep-2024 , 05-0	Oct-2024 , 08-Oct	-2024 , 16-Oct-202	24		
	The purpose of this NOSI is to encourage research on the efficacy of interventions that address nutrition security and the mechanisms of food insecurity on a variety of health outcomes. It also calls for the development of new measures for nutrition security and assessment of food insecurity that are broadly applicable. It was developed by the Office of Nutri Research (ONR) Implementation Working Group on Nutrition and Health Disparities in collaboration with NIH Institutes Centers (ICs) and Offices in support of the goals and objectives of the Strategic Plan for NIH Nutrition Research.							
112325	Notice of Special Interest (NOSI): F Improve Health Outcomes	Research on Addressing Violence to	National Institutes of Health/DHHS	NOT-OD- 22-167 07-N	/lay-2024	Not Specified		
	Contact Name	Dara R. Blachman, Ph.D.						
	Contact Telephone	301-496-8522						
	Contact Email	Dara.blachman-demner@nih.gov						
	Sponsor Website							

	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2 2025 , 05-Feb-2025 , 16-Feb-2025 , 07	.024 , 09-Jul-2024 , 07-Sep-2024 , ?-May-2025 , 05-Jun-2025 , 16-Jur	05-Oct-2024 , 16-0 n-2025 , 07-Sep-20	Oct-2024 , 12-Nov-202 25 , 05-Oct-2025	24 , 07-Jan-		
	The purpose of this Notice is to highlight interest in addressing the role of violence in health outcomes and integrating violence-related screening and interventions into health care settings. This Notice is to encourage intervention research focused on addressing exposure to violence - including but not limited to child maltreatment, intimate partner violence/te dating violence, elder mistreatment, peer violence/bullying, and community violence – to improve individual-level health processes and outcomes.							
124566	RFA-MD-24-006 Innovations for Health and Eliminating Health Dis	r Healthy Living - Improving Minority parities (R43/R44 - Clinical Trial Optior	National Institutes of nal) Health/DHHS	RFA-MD- 24-006	10-Jun-2024	Not Specified		
	Contact Name	LCDR Michael Banyas, USPHS, MPA						
	Contact Telephone	240-619-9483						
	Contact Email	nimhdsbirsttr@mail.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
Deadline Dates (ALL)								
	Deadline Dates (ALL)	2026	024 , 10-Jun-2025 , 04-Aug-2025	, 09-Dec-2025 , 10	-Jun-2020 , 03-Aug-20	26 , 09-Dec-		
	Deadline Dates (ALL) Synopsis	2026 This Funding Opportunity Announcen Business Innovation Research (SBIR) g commercialization with the aim of im one or more populations that experie culturally acceptable.	024, 10-Jun-2025, 04-Aug-2025 nent (FOA) invites eligible United grant applications that propose to proving minority health and/or re nce health disparities. Appropriat	, 09-Dec-2025, 10 States small busing develop a produc educing and ultima te technologies sho	ess concerns (SBCs) to t, process or service fo tely eliminating health ould be effective, affo	26 , 09-Dec- submit Small or disparities ir rdable, and		
124567	Deadline Dates (ALL) Synopsis <u>RFA-MD-2D-24-007 Technologie</u> <u>Eliminating Health Disparities (R4</u>	2026 This Funding Opportunity Announcen Business Innovation Research (SBIR) g commercialization with the aim of im one or more populations that experie culturally acceptable. es for Improving Minority Health and 1/R42- Clinical Trial Optional)	National Institutes of Health/DHHS	, 09-Dec-2025, 10 States small busine develop a produc educing and ultima te technologies sho RFA-MD- 24-007	ess concerns (SBCs) to t, process or service fo tely eliminating health ould be effective, affo 11-May-2024 [Optional][LOI/Pre- App]	226 , 09-Dec- submit Small or disparities ir rdable, and Not Specified		
124567	Deadline Dates (ALL) Synopsis <u>RFA-MD-2D-24-007 Technologie</u> <u>Eliminating Health Disparities (R4</u> Contact Name	2026 This Funding Opportunity Announcen Business Innovation Research (SBIR) g commercialization with the aim of im one or more populations that experie culturally acceptable. es for Improving Minority Health and 1/R42- Clinical Trial Optional)	024 , 10-Jun-2025 , 04-Aug-2025 nent (FOA) invites eligible United grant applications that propose to proving minority health and/or re nce health disparities. Appropriat National Institutes of Health/DHHS	, 09-Dec-2025 , 10 States small busine develop a produce educing and ultima te technologies sho RFA-MD- 24-007	ess concerns (SBCs) to t, process or service for tely eliminating health ould be effective, affo 11-May-2024 [Optional][LOI/Pre- App]	26 , 09-Dec- submit Small or n disparities ir rdable, and Not Specified		
124567	Deadline Dates (ALL) Synopsis <u>RFA-MD-2D-24-007 Technologie</u> <u>Eliminating Health Disparities (R4</u> Contact Name Contact Telephone	10-Juli 2024       Job Aug 2024         2026         This Funding Opportunity Announcen         Business Innovation Research (SBIR) g         commercialization with the aim of im         one or more populations that experie         culturally acceptable.         es for Improving Minority Health and         1/R42- Clinical Trial Optional)         LCDR Michael Banyas, USPHS, MPA         240-619-9483	024 , 10-Jun-2025 , 04-Aug-2025 nent (FOA) invites eligible United grant applications that propose to proving minority health and/or re nce health disparities. Appropriat National Institutes of Health/DHHS	, 09-Dec-2025 , 10 States small busine develop a produc educing and ultima te technologies sho RFA-MD- 24-007	ess concerns (SBCs) to t, process or service fo tely eliminating health ould be effective, affo 11-May-2024 [Optional][LOI/Pre- App]	226 , 09-Dec- submit Small or disparities ir rdable, and Not Specified		
124567	Deadline Dates (ALL) Synopsis <u>RFA-MD-2D-24-007 Technologie</u> <u>Eliminating Health Disparities (R4</u> Contact Name Contact Telephone Contact Email	10-Juli 2024       JOS-Aug-2024       JO-Dec-2         2026       This Funding Opportunity Announcen         Business Innovation Research (SBIR) g       commercialization with the aim of im         one or more populations that experie       culturally acceptable.         es for Improving Minority Health and       1/R42- Clinical Trial Optional)         LCDR Michael Banyas, USPHS, MPA       240-619-9483         nimhdsbirsttr@mail.nih.gov       1/Init.gov	024 , 10-Jun-2025 , 04-Aug-2025 nent (FOA) invites eligible United grant applications that propose to proving minority health and/or re nce health disparities. Appropriat National Institutes of Health/DHHS	, 09-Dec-2025 , 10 States small busine develop a produc educing and ultima te technologies sho RFA-MD- 24-007	ess concerns (SBCs) to t, process or service fo tely eliminating health ould be effective, affo 11-May-2024 [Optional][LOI/Pre- App]	26 , 09-Dec- submit Small or disparities ir rdable, and Not Specified		

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Drogram URU	ink to pr	ogram LIRI				
			024 [Ontional][[ Ol/Dro Ana] 1	0 km 2024 00 km 2024 11 Nov	2024 [Ontional][]		- 2024 11
	د Deadline Dates (ALL) N 2	May-2025 2026 [Opt	5 [Optional][LOI/Pre-App], 10-Ju ional][LOI/Pre-App], 10-Ju	un-2025 , 07-Jul-2025 , 10-Nov-202 26 , 06-Jul-2026 , 10-Nov-202	2024 [Optional][LOI/ 25 [Optional][LOI/ 25 ptional][LOI/Pre-A	Pre-App], 10-De Pre-App], 09-Dec-2 .pp], 09-Dec-2026	2025 , 11-May-
	T E Synopsis c a	This Fund Business commercione or mo one or mo offordable	ing Opportunity Announcemen Fechnology Transfer (STTR) grau alization with the aim of impro pre NIH-defined populations that e, and culturally acceptable.	t (FOA) invites eligible United Stat nt applications that propose to dev ving minority health and/or reduc at expeience health disparities. Ap	es small business velop a product, p ing and ultimately propriate technol	concerns (SBCs) to rocess or service fo eliminating health ogies should be eff	submit Small or disparities in fective,
102069	Natural History of Disorders Screen Trial Optional)	able in th	ne Newborn Period (R01 Clinica	I National Institutes of Health/DHHS	PAR-21- 115 05-	Jun-2024	Not Specified
	Contact Name	Aelissa P	arisi, MD, PhD				
	Contact Telephone 3	801-435-6	5880				
	Contact Email g	oarisima@	amail.nih.gov				
	Sponsor Website						
	Program URL L	ink to pr	ogram URL				
	Deadline Dates (ALL) 0	)5-Jun-20	24 , 05-Oct-2024				
	T b b c t t a e t t	This fundi proad und py newbo element t iming of addition, other disc he clinica bility to: expression reat sym predictive	ng opportunity announcement derstanding of the natural histo rn screening. A comprehensive o facilitate appropriate interven the onset of symptoms and com for some disorders, specific gen orders, identification of modifyi al outcomes for an individual wi 1) accurately diagnose the diso n of the disorder; 3) identify un ptoms and complications of the e information about the disorder	(FOA) encourages applications that ry of disorders that already do or understanding of the natural histo- ntions for infants identified by new nplications of a disorder, a valuable totype-phenotype correlations main genetic, epigenetic, or environing th such a condition. Comprehension order; 2) understand the genetic ar derlying mechanisms related to bate disorder; and 5) provide children er.	at propose to deve could potentially b ory of a disorder h vborn screening. E e resource will be y allow prediction nental factors will ve data on natural nd clinical heterog asic defects; 4) por and their families	elop studies that w benefit from early i las been identified By defining the seq developed for the of the clinical cou enhance an under history will facilita eneity and phenot tentially prevent, n with needed supp	rill lead to a identification as a necessary uence and field. In rse, and for rstanding of ate the field's ypic nanage, and ort and

Icahn School of Medicine at Mount Sinai

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Optional)			Health/DHHS	022		USD
	Contact Name	Randy Kir	ng, Ph.D.				
	Contact Telephone	301-451-0	0707				
	Contact Email	Randy.Kir	ng@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2025 , 07	024 , 16-Jun-2024 , 16-Jul-2024 -May-2025 , 16-Jun-2025 , 16-Ju	4 , 07-Sep-2024 , 16-Oct-2 ul-2025 , 07-Sep-2025 , 16	024 , 16-Nov-2024 , 07-Jar 5-Oct-2025 , 16-Nov-2025 ,	n-2025 , 16-Feb-20 07-Jan-2026	25 , 16-Mar-
(https://grants.nih.gov/policy/early-investigators/index.htm) to pursue research programs of high interest to the integrate engineering and the physical sciences with the life and/or biomedical sciences. A Trailblazer project may exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, or driven, or hypothesis-driven. Importantly, applicants must propose research approaches for which there are mini preliminary data. A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged if available, minimal preliminary data are allowed. Preliminary data are defined as material which the applicant high independently produced and not yet published in a peer-reviewed journal.All preliminary data should be clearly relimited to one-half page, which may include one figure. Applications including data more than one-half page or more figure will be considered noncompliant with the FOA instructions and will not go forward to review.							ne NBB that nay be d, discovery- ninimal or no ged. However, t has ly marked and r more than
121565	Health and Health Care Disparitie (R01 - Clinical Trials Optional)	<u>s Among P</u>	ersons Living with Disabilities	National Institutes of Health/DHHS	PAR-23- 309 05-	Jun-2024	Not Specified
	Contact Name	Sundania	J. W. Wonnum, PhD, LCSW				
	Contact Telephone						
	Contact Email	sundania.	wonnum@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	05-Jun-20	024 , 05-Oct-2024 , 05-Feb-2025	5 , 05-Jun-2025 , 05-Oct-2	025 , 05-Feb-2026 , 05-Jun	-2026 , 05-Oct-202	26
	Synopsis	The purpo intervene persons v	ose of this Notice of Funding Op is on the underlying and multile vith disabilities at the intersecti	oportunity (NOFO) is to su evel causes, pathways, and ions of race and ethnicity,	apport novel and innovative d factors adversely impaction and socioeconomic status	e research that exa ing the health and	amines and/or well-being of

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
122756	Addressing Health and Health Car Minority Populations (R01 - Clinica	e Dispariti al Trials O	es among Sexual and Gender otional)	National Institutes of Health/DHHS	PAR-24- 077 07-1	Мау-2024	2,500,000 USD	
	Contact Name	Rada K. D	agher, Ph.D., M.P.H.					
	Contact Email	ada dagh	er@nih.gov					
	Sponsor Website	<u></u>	<u></u>					
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	y-2025 , 05-Jun-20 05-Oct-2026 , 07	025 , 07-Sep- Jan-2027					
The purpose of this Notice of Funding Opportunity (NOFO) is to support innovative observational and interve research to identify and characterize the pathways and mechanisms through which health and health care dis among sexual and gender minority populations of minoritized racial/ethnic and socio-economic statuses. Per Number: NOT-MH-24-170: Research Priorities The National Institute of Mental Health (NIMH) will only accep trials applications that reflect the mission and scientific priorities as identified in the strategic plan NIMH » Th Institute of Mental Health Strategic Plan (nih.gov) and also NIMH's Approach to Mental Health Disparities Re- trial applications will not be accepted under this notice. Per NOT-MH-20-067, NIMH expects that grant applic buman research participants will collect a minimum set of Common Data Elements								
114589	Notice of Special Interest (NOSI): Epidemic' Initiative Goals Relevan for or Living with HIV	Research t t to Subst	o Address 'Ending the HIV ance Using Populations At-Risk	National Institutes of Health/DHHS	NOT-DA- 23-013 07-M	Иау-2024	Not Specified	
	Contact Name	Vasundha	ara Varthakavi, PhD					
	Contact Telephone	301-443-	2146					
	Contact Email	<u>vasundha</u>	<u>ra.varthakavi@nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
Deadline Dates (ALL) Deadline Dates (ALL) Deadline Dates (ALL)								

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The purp the four p Projects p high risk f	ose of this NOSI is to support a illars, including Diagnose, Treat roposed in response to this NO or contracting HIV or living with	broad spectrum of multi-disciplina , Prevent, and Respond of the 'En SI are required to meet the needs n HIV in the geographically defined	ary, substance ding the HIV E of the substa d EHE priority a	use research to addre pidemic in the U.S. (E nce using populations areas within the U.S.	ess the goals of HE)' initiative. who are at
124951	Notice of Special Interest (NOSI): 3 NIH-supported Research	Supporting	the Exploration of Cloud in	National Institutes of Health/DHHS	NOT-OD- 24-078	18-Jun-2024	200,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Fenglou N 301-451-9 <u>cloudsupp</u> Link to pr 18-Jun-20 This notic	1ao 9389 <u>port@nih.gov</u> <u>ogram URL</u> 24 , 18-Jun-2025 , 18-Jun-2026 e announces the availability of f	unds from the Office of Data Scie	nce Strategy (	ODSS) to NIH-manage	d or NIH-
	Synopsis	majority-f potential apply to e Science, v	unded projects that may benefic opportunities for leveraging clo xplore and test cloud capabilitie which describes actions aimed a	it from using the cloud. The purpo ud solutions to enhance existing N es not yet leveraged. This initiative t building a better data infrastruct	ose of this anno NIH activities. e is aligned wi cure and a mo	ouncement is to explo Projects already using th the NIH Strategic Pl dernized data ecosyst	ire and test 3 cloud may lan for Data em.
105957	Time-Sensitive Obesity Policy and Allowed)	Program E	Evaluation (R01 Clinical Trial Not	National Institutes of Health/DHHS	PAR-21- 305	09-Apr-2024	Not Specified
	Contact Name Contact Telephone Contact Email	Mary Eva 301-594-4 <u>evansmar</u>	ns, Ph.D. 1578 y@mail.nih.gov				
	Sponsor Website Program URL Deadline Dates (ALL)	<u>Link to pr</u> 09-Apr-20	ogram URL 124 , 08-May-2024 , 10-Jun-2024	4,09-Aug-2024,10-Sep-2024,09	9-Oct-2024 , 0	7-Nov-2024 , 10-Dec-2	2024 , 09-Jan-
	Synopsis	2025 This Fund research t	ing Opportunity Announcement to evaluate a new policy or prog	t (FOA) establishes an accelerated gram that is likely to influence obe	review/award sity related be	d process to support t haviors (e.g., dietary	ime-sensitive intake, physical

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		activity, s intended expedited related po the resea eligible fo applicatio beyond th	edentary behavior, and/or sleep to support research where oppo d review and funding. All applica plicy or program offers an uncor rch is initiated with minimum de or re-submission. It is intended th on due date; however, administr nat timeline.	b) and/or weight outcomes in an effortunities for empirical study are, b ortunities for empirical study are, b tions submitted to this FOA must of mmon and scientifically-compelling elay. For these reasons, application hat eligible applications selected for rative requirements and other unfor	fort to prevent by their very nat demonstrate the gresearch oppo is submitted to or funding will b preseen circums	or reduce obesity. T ure, only available t at the evaluation of rtunity that will only this time-sensitive F e awarded within 4 tances may delay is	This FOA is through an obesity- y be available if FOA are not months of the suance dates
112749	Notice of Special Interest (NOSI): Pathways for Individuals with His	HEAL Initia tories of Ex	ative: Opioid Use Disorder Care oposure to Violence	National Institutes of Health/DHHS	NOT-DA- 23-007 12	-Jun-2024	Not Specified
	Contact Name	Carrie Mu	llford				
	Contact Telephone	301-827-6	5473				
	Contact Email	Carrie.Mu	<u>ulford@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	12-Jun-20	024 , 12-Oct-2024 , 12-Feb-2025	, 12-Jun-2025			
	Synopsis	The prope outcomes	osed initiative seeks to test inno s for individuals who have actior	vative models of service delivery to hable needs following exposure to	o improve subst violence.	ance use and ment	al health
108327	Research Enhancement Award Pr Schools and Graduate Schools (R:	ogram (RE L5 Clinical <sup>-</sup>	AP) for Health Professional Trial Required)	National Institutes of Health/DHHS	PAR-21- 357 07	'-May-2024	375,000 USD
	Contact Name	Mahua M	lukhopadhyay, Ph.D.				
	Contact Telephone	301-435-6	5886				
	Contact Email	<u>mukhopa</u>	<u>m@mail.nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	024 , 25-Jun-2024 , 07-Sep-2024	4 , 25-Oct-2024 , 07-Jan-2025			
	Synopsis	The purpo support s	ose of the Research Enhanceme mall scale research grants at ins	nt Award Program (REAP) for Heal titutions that do not receive subst	th Professional antial funding fr	Schools and Gradua om the NIH, with ar	te Schools is to n emphasis on

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	p e so c b d fu a c l c l c	providing enhancing cience de osts) in 4 pased on letermini unding of uddressing linical tri ow risks t	biomedical research experience g the research environment at a egrees and have received no mo of the last 7 fiscal years. For in the amount of NIH funding rece ng the Organization Funding Le pportunity announcement (FOA g the mission and research inte als are defined as those that do to potentially cause physical or	es primarily for health professional pplicant institutions. Eligible institu- ore than \$6 million dollars per year stitutions composed of multiple scl vived by all the schools and colleges vel can be found here or https://gr a) supports investigator-initiated m rests of the participating NIH institu- not require FDA oversight, do not psychological harm.	, undergraduate a utions must awar of NIH support (i nools and college s within the instit ants.nih.gov/grau echanistic and/ou utes. For purpose intend to formall	and graduate stude d baccalaureate or n both direct and F s, the \$6 million fu ution as a whole. F nts/funding/r15.ht minimal risk clinic s of this FOA, mini y establish efficacy	ents and advanced &A/indirect nding limit is lelp m. This REAP al trials mal risk r, and have		
108357	Research Enhancement Award Prog Schools and Graduate Schools (R15	gram (RE) Clinical 1	AP) for Health Professional Frial Not Allowed)	National Institutes of Health/DHHS	PAR-22- 07-1 060	May-2024	375,000 USD		
	Contact Name Li	Contact Name Lisa Chadwick							
	Contact Telephone 3	801-435-7	7275						
	Contact Email <u>li</u>	isa.chadv	vick@nih.gov						
	Sponsor Website								
	Program URL Li	ink to pro	ogram URL						
	Deadline Dates (ALL) 0	)7-May-2	024 , 25-Jun-2024 , 07-Sep-2024	4 , 25-Oct-2024 , 07-Jan-2025					
	T sı Synopsis sı b d	The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for health professional, undergraduate and graduate students and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate or advanced science degrees and have received no more than \$6 million dollars per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by all the schools and colleges within the institution as a whole. Help determining the Organization Funding Level can be found here or https://grants.nih.gov/grants/funding/r15.htm.							
109009	Notice of Special Interest (NOSI): Re	esearch A	Addressing Eye and Vision	National Institutes of	NOT-EY- 22-004 08-/	Apr-2024	Not Specified		
			(- D		22 007		Specifica		
	Contact Name Ji	immy Le,	SC.D.						
	Contact Telephone 3	501-435-8	510U						

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email	Jimmy.Le	<u>@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2024 , 05	024 , 25-May-2024 , 05-Jun-202 Jan-2025 , 07-Jan-2025 , 25-Jar	24 , 16-Jun-2024 , 08-Aug-2024 , 05 1-2025	5-Sep-2024 , 07-Se	p-2024 , 25-Sep-2	024 , 08-Dec-
	Synopsis	The purpe promote reduction application health ine	ose of this Notice of Special Inte health equity in the prevention, of health disparities experience ons that investigate the impact o equities.	erest (NOSI) is to highlight interest , treatment, and management of e ed by people who are visually impa of bias, structural racism, and discr	in supporting rese ye and vision cond aired or blind are e imination in causion	earch that aims to ditions. Application encouraged, as we ng or sustaining ey	ns that target II as /e or vision
110813	Notice of Special Interest (NOSI): <sup>-</sup> HV/HBV Co-Infection	<u>Towards D</u>	eveloping a Cure for HBV in	National Institutes of Health/DHHS	NOT-AI- 22-043 07-N	May-2024	Not Specified
	Contact Name	Chris Lam	ibros, PhD				
	Contact Telephone	240-627-3	3093				
	Contact Email	<u>clambros</u>	<u>@niaid.nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2025 , 05	:024 , 05-Jun-2024 , 16-Jun-2024 -Feb-2025 , 16-Feb-2025 , 05-Ap	4 , 05-Sep-2024 , 07-Sep-2024 , 05- pr-2025 , 07-May-2025	Oct-2024 , 16-Oct	-2024 , 05-Jan-202	25 , 07-Jan-
	Synopsis	The purpo identify a relating to	ose of this NOSI is to encourage nd address the unique challeng o the following areas will be end	applications for support of innova es to achieving HBV cure in the pre couraged: (1) immunology; (2) viro	tive basic, translat esence of HIV. Res logy; and (3) thera	tional, and clinical earch on HIV/HBV apeutics.	research to co-infection
108347	Notice of Special Interest (NOSI): A dentified Factors Into Models of M	Advancing Visual Syst	NEI AGI Research on newly em Regeneration	National Institutes of Health/DHHS	NOT-EY- 22-002 07-N	May-2024	Not Specified
	Contact Name						
	Contact Telephone						
	Contact Email						
	Sponsor Website						

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Program URI	Link to program URL					
	Deadline Dates (ALL)	07-May-2024 . 05-Jun-2024 . 16-Jun-2024	4.05-Sep-2024.07-Sep-2024.05	-Oct-2024 . 16-Oct	-2024		
	Synopsis	The National Eye Institute (NEI) is issuing newly identified factors into new or exist consortium of research teams as part of community. Applicants beyond the origin	this Notice of Special Interest (NC ing models of visual system regen the Audacious Goal Initiative (AGI) nal consortium are strongly encour	OSI) to encourage r eration. These fact and are being sha raged to apply.	novel research tha tors were identifie ared broadly with	t incorporates ed by a the research	
104784	Notice of Special Interest (NOSI): Actionable Data Dissemination Str	HIV Drug Resistance Assays and rategies	National Institutes of Health/DHHS	NOT-AI- 21-056 07-I	May-2024	Not Specified	
	Contact Name	Usha Sharma, PhD					
	Contact Telephone	240-292-4809					
	Contact Email	usharma@niaid.nih.gov					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2024	4,07-Sep-2024				
Synopsis Synopsis Synopsis							
111805	Research Opportunities for New a Workforce Diversity (R01 Clinical	and "At-Risk" Investigators to Promote Trial Optional)	National Institutes of Health/DHHS	PAR-22- 181 06-1	May-2024	Not Specified	
	Contact Name	Albert Avila, Ph.D.					
	Contact Telephone	301-496-8804					
	Contact Email	aavila@nida.nih.gov					
	Sponsor Website						

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Program LIRI	Link to pr	ogram LIRI				
	Deadline Dates (ALL)	06-May-2 2025 , 05-	024 , 07-May-2024 , 06-Jun-202 May-2025 , 07-May-2025 , 06-J	24 , 06-Sep-2024 , 07-Sep-2024 , 0 un-2025 , 07-Sep-2025	8-Oct-2024 , 07-Ja	ın-2025 , 08-Jan-20	25 , 06-Feb-
	Synopsis	This Fund that are w support N underrepu underrepu institutior work with	ing Opportunity Announcement within the scientific mission area lew Investigators and At-Risk Inv resented in the health-related s resented groups (e.g., see NOT- ns to apply for support under th a their institutions to apply.	t (FOA) solicits R01 grant applicati is of the participating NIH Institute vestigators from diverse backgrou ciences. Investigators from divers OD-20-031, Notice of NIH's Intere is program. Investigators from car	ions that propose es or Centers. This unds, including tho e backgrounds, in est in Diversity), ar tegories A and B a	independent resea program is intend se from groups cluding those from e encouraged to w re particularly enco	rch projects ed to ork with their ouraged to
114377	Notice of Special Interest (NOSI): Diseases (TBDs)	Advancing	Research for Tickborne	National Institutes of Health/DHHS	NOT-AI- 23-013 07-	May-2024	Not Specified
	Contact Name	Samuel Pe	erdue, Ph.D.				
	Contact Telephone	240-627-3	3341				
	Contact Email	<u>sperdue@</u>	Onih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2024 , 05- Sep-2025	024 , 05-Jun-2024 , 16-Jun-2024 Jan-2025 , 07-Jan-2025 , 05-Fek , 07-Sep-2025 , 05-Oct-2025 , 1	4 , 25-Jun-2024 , 05-Sep-2024 , 07 p-2025 , 16-Feb-2025 , 05-Apr-202 6-Oct-2025 , 05-Jan-2026 , 07-Jan	-Sep-2024 , 05-Oc 25 , 07-May-2025 , -2026	t-2024 , 16-Oct-20 05-Jun-2025 , 16-J	24 , 25-Oct- un-2025 , 05-
	Synopsis Synopsis Accelerate research to improve TBD prevention by supporting science to design, develop, and evaluate vaccine vector control strategies, and other prevention approaches. Promote research to improve treatment for all forms of TBDs, spin-2025 (07-361-2026), 07-361-2026 (07-36						

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		including infectious diagnosin developm	studies to develop effective the TBDs, and new antimicrobials. g, and treating TBDs, including ent and assessment of diagnos	erapies to treat symptoms that per Support tools and resources to ac repositories, genomic resources, a tic, vaccine, and therapeutic candi	rsist after TBD tre Ivance research ir Inimal models, an Idates.	atment, therapies 1 understanding, pr d preclinical servic	for non- reventing, es to aid the
114675	Notice of Special Interest (NOSI): Utilization for the Sequence Read	Optimizati Archive (S	on of Data Storage and RA)	National Institutes of Health/DHHS	NOT-GM- 23-015 08-	Apr-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	<u>Link to pr</u> 07-May-2 2024 , 05- Feb-2025 , 12-Jun-2 2025 , 16-	ogram URL 024 , 16-May-2024 , 05-Jun-202 Oct-2024 , 12-Oct-2024 , 16-Oc , 12-Feb-2025 , 16-Feb-2025 , 2 025 , 16-Jun-2025 , 25-Jun-202 Oct-2025 , 25-Oct-2025 , 08-De	24 , 12-Jun-2024 , 16-Jun-2024 , 25 t-2024 , 25-Oct-2024 , 08-Dec-202 5-Feb-2025 , 05-Apr-2025 , 12-Ap 5 , 08-Aug-2025 , 05-Sep-2025 , 05 tc-2025	5-Jun-2024 , 08-Au 24 , 05-Jan-2025 , r-2025 , 07-May-2 5-Sep-2025 , 07-Se	ıg-2024 , 05-Sep-20 07-Jan-2025 , 16-Ja 2025 , 16-May-2021 2025 , 05-Oct-20	024 , 07-Sep- an-2025 , 05- 5 , 05-Jun-2025 025 , 12-Oct-
	Synopsis	The purpo ODSS in s	ose of this Notice of Special Inte upporting efficiency optimization	the interest of NIG RA) data storage a	MS, NLM, and utilization.		
114367	Notice of Special Interest (NOSI): of-Care Hepatitis C Virus Diagnos	Advancing <u>ics</u>	Development of Rapid Point-	National Institutes of Health/DHHS	NOT-AI- 23-001 07-	May-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Julie Dyal 301-631-7 dyallj@ni Link to pr	I, PhD 7296 aid.nih.gov ogram URL	4 OF Sep 2024 07 Sep 2024 OF	Oct 2024 16 Oc	+ 2024 OF log 20	25 07 Jan
	Deadline Dates (ALL)	2025 , 05 Oct-2025	024 , 05-Jun-2024 , 16-Jun-2024 Feb-2025 , 16-Feb-2025 , 05-Ap , 16-Oct-2025 , 05-Jan-2026 , 0	+ , 05-Sep-2024 , 07-Sep-2024 , 05 pr-2025 , 07-May-2025 , 05-Jun-20 7-Jan-2026	-Oct-2024 , 16-Oc 125 , 16-Jun-2025	2024 , 05-Jan-20 , 05-Sep-2025 , 07-	25 , 07-Jan- Sep-2025 , 05-

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Synopsis	The purpo (NIAID) an encourag diagnose	ose of this Notice of Special Intend National Institute of Biomedi ing applications in the area of tr active viremic HCV infections.	rest is to announce that the Nation cal Imaging and Bioengineering (N anslational research and developn	nal Institute of A IBIB) and the Na nent of rapid Po	llergy and Infectiou tional Cancer Institu nt-of-Care diagnost	s Diseases ute (NCI) are lics that will		
113609	NLM Research Grants in Biomedic Clinical Trial Optional)	al Informa	itics and Data Science (R01	National Library of Medicine/NIH/DHHS	PAR-23- 034 07	-May-2024	1,000,000 USD		
	Contact Name	Meryl Suf	ian, PhD						
	Contact Telephone	301-496-4	1671						
	Contact Email	<u>sufianm@</u>	omail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2024 , 05-Oct-2024 , 05-Oct-2025 , 07-Sep-2024 , 05-Oct-2024 , 05-Oct-2025 , 07-Sep-2024 , 07-Sep-2024 , 07-Sep-2024 , 07-Sep-2024 , 07-Sep-2024 , 07-Sep-2024 , 07-Sep-2025 , 07-Sep-2024 , 07-Sep-2025 , 07-Se								
	Synopsis	The National Library of Medicine (NLM) supports innovative research and development in biomedical informatics and data science. This funding opportunity focuses on biomedical discovery and data-powered health, integrating streams of compl and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, an opsis personal wellness. The scope of NLM's interest in these research domains is broad, with emphasis on new and innovative methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, scalable, and reusable/reproducible approaches to discovery, curation, analysis, organization, and managem of health-related digital objects.							
115310	Notice of Special Interest (NOSI): Enhance Discovery from Health D	<u>Computati ata</u>	onal and Statistical Methods to	National Library of Medicine/NIH/DHHS	NOT-LM- 23-001 07	-May-2024	Not Specified		
	Contact Name	Meryl Suf	ian, PhD						
	Contact Telephone	301-496-4	4671						
	Contact Email	<u>sufianm@</u>	Omail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2 2025 , 05	024 , 05-Jun-2024 , 07-Sep-2024 Oct-2025 , 07-Jan-2026	4 , 05-Oct-2024 , 07-Jan-2025 , 05-	Feb-2025 , 07-N	ay-2025 , 05-Jun-20	125 , 07-Sep-		

Synopsis       The National Library of Medicine is issuing this Notice to highlight its interest in receiving grant appleresearch that aims to reduce or mitigate gaps and errors in health data sets.         113256       Notice of Special Interest (NOSI): Development and Preliminary Testing of Health-related Behavioral Interventions       Office of Behavioral and Social Sciences Research/NIH/DHHS       NOT-OD-22-203       07-May-202         Contact Name       William Elwood, PhD       301-402-0116       Sciences Research/NIH/DHHS       22-203       07-May-202         Sponsor Website       Program URL       William elwood@nih.gov       Sponsor Website       Villiam elwood@nih.gov         Deadline Dates (ALL)       07-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 18-Jun-2024 , 09-Jul-2024 , 2024       To achieve more potent strategies to promote sustained health-related behavior change, there is a interdocial translation of foundational behavioral and social science discoveries into new or improv         Synopsis       Synopsis       Office of Behavioral and Social Sciences Research (DBSSR) and participating ICOs are issuing this Note         Synopsis       Behavior change. This includes research (bBSSR) findings that posit causal or processual mechanisms behavior change. This includes research that focuses on use-inspired bBSSR, understanding of mech underlying initial and sustained behavior change, and systematic development and test interventions and their components.	olications focused on Not 024 Specified
113256       Notice of Special Interest (NOSI): Development and Preliminary Testing of Health-related Behavioral Interventions       Office of Behavioral and Social Sciences Research/NIH/DHHS       NOT-OD- 22-203       07-May-202         Contact Name Contact Telephone Contact Email       William Elwood, PhD       301-402-0116       Villiam.elwood@nih.gov       Villiam.elwood@nih.gov         Sponsor Website Program URL       Link to program URL       07-May-2024, 13-May-2024, 05-Jun-2024, 07-Jun-2024, 16-Jun-2024, 18-Jun-2024, 09-Jul-2024, 2024       07-Jul-2024, 12-Jul-2024, 09-Jul-2024, 09-Jul-2024, 2024         To achieve more potent strategies to promote sustained health-related behavior change, there is a methodical translation of foundational behavioral and social science discoveries into new or improv Office of Behavioral and Social Sciences Research (OBSSR) and participating ICOs are issuing this Not the systematic development of original health-related behavioral interventions that test hypotheses behavior change. This includes research (bBSSR) findings that posit causal or processual mechanisms behavior change. This includes research that focuses on use-inspired bBSSR, understanding of mech underlying initial and sustained behavior change, and systematic development and testing of health interventions and their components.	024 Not Specified
Contact Name       William Elwood, PhD         Contact Telephone       301-402-0116         Contact Email       william.elwood@nih.gov         Sponsor Website       Program URL         Deadline Dates (ALL)       07-May-2024 , 13-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 18-Jun-2024 , 09-Jul-2024 , 2024         To achieve more potent strategies to promote sustained health-related behavior change, there is a methodical translation of foundational behavioral and social science discoveries into new or improv         Office of Behavioral and Social Sciences Research (OBSSR) and participating ICOs are issuing this Not the systematic development of original health-related behavioral interventions that test hypotheses behavior change. This includes research (bBSSR) findings that posit causal or processual mechanisms behavior change. This includes research that focuses on use-inspired bBSSR, understanding of mech underlying initial and sustained behavior change, and systematic development and testing of health interventions and their components.	
Contact Telephone       301-402-0116         Contact Email       william.elwood@nih.gov         Sponsor Website       Program URL         Link to program URL       Link to program URL         Deadline Dates (ALL)       07-May-2024 , 13-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 18-Jun-2024 , 09-Jul-2024 , 2024         To achieve more potent strategies to promote sustained health-related behavior change, there is a methodical translation of foundational behavioral and social science discoveries into new or improv Office of Behavioral and Social Sciences Research (OBSSR) and participating ICOs are issuing this Not the systematic development of original health-related behavioral interventions that test hypotheses behavior change. This includes research (bBSSR) findings that posit causal or processual mechanisms behavior change. This includes research that focuses on use-inspired bBSSR, understanding of mech underlying initial and sustained behavior change, and systematic development and testing of health interventions and their components.	
Contact Email Sponsor Website Program URLwilliam.elwood@nih.govDeadline Dates (ALL)Link to program URL 07-May-2024 , 13-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 18-Jun-2024 , 09-Jul-2024 , 2024 To achieve more potent strategies to promote sustained health-related behavior change, there is a methodical translation of foundational behavioral and social science discoveries into new or improv Office of Behavioral and Social Sciences Research (OBSSR) and participating ICOs are issuing this Not the systematic development of original health-related behavioral interventions that test hypotheses behavioral and social sciences research (bBSSR) findings that posit causal or processual mechanisms behavior change. This includes research that focuses on use-inspired bBSSR, understanding of mech underlying initial and sustained behavior change, and systematic development and testing of health interventions and their components.	
Sponsor Website       Program URL         Program URL       Link to program URL         Deadline Dates (ALL)       07-May-2024, 13-May-2024, 05-Jun-2024, 07-Jun-2024, 16-Jun-2024, 18-Jun-2024, 09-Jul-2024, 2024         To achieve more potent strategies to promote sustained health-related behavior change, there is a methodical translation of foundational behavioral and social science discoveries into new or improv Office of Behavioral and Social Sciences Research (OBSSR) and participating ICOs are issuing this Not the systematic development of original health-related behavioral interventions that test hypotheses behavioral and social sciences research (bBSSR) findings that posit causal or processual mechanisms behavior change. This includes research that focuses on use-inspired bBSSR, understanding of mech underlying initial and sustained behavior change, and systematic development and testing of health interventions and their components.	
Program URLLink to program URLDeadline Dates (ALL)07-May-2024 , 13-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 18-Jun-2024 , 09-Jul-2024 , 2024To achieve more potent strategies to promote sustained health-related behavior change, there is a methodical translation of foundational behavioral and social science discoveries into new or improv Office of Behavioral and Social Sciences Research (OBSSR) and participating ICOs are issuing this Not the systematic development of original health-related behavioral interventions that test hypotheses behavioral and social sciences research (bBSSR) findings that posit causal or processual mechanisms behavior change. This includes research that focuses on use-inspired bBSSR, understanding of mech underlying initial and sustained behavior change, and systematic development and testing of health interventions and their components.	
Deadline Dates (ALL) Deadline Dates (ALL) Synopsis Context and social sciences (ALL) Deadline Dates (ALL) Deadline Dates (ALL) Do achieve more potent strategies to promote sustained health-related behavior change, there is a methodical translation of foundational behavioral and social science discoveries into new or improv Office of Behavioral and Social Sciences Research (OBSSR) and participating ICOs are issuing this Not the systematic development of original health-related behavioral interventions that test hypotheses behavioral and social sciences research (bBSSR) findings that posit causal or processual mechanisms behavior change. This includes research that focuses on use-inspired bBSSR, understanding of mech underlying initial and sustained behavior change, and systematic development and testing of health interventions and their components.	
SynopsisTo achieve more potent strategies to promote sustained health-related behavior change, there is a methodical translation of foundational behavioral and social science discoveries into new or improv Office of Behavioral and Social Sciences Research (OBSSR) and participating ICOs are issuing this Not the systematic development of original health-related behavioral interventions that test hypotheses behavioral and social sciences research (bBSSR) findings that posit causal or processual mechanisms behavior change. This includes research that focuses on use-inspired bBSSR, understanding of mech underlying initial and sustained behavior change, and systematic development and testing of health interventions and their components.	, 07-Sep-2024 , 13-Sep-
	need for intentional and ved interventions. The itice to highlight interest is that draw on basic s of action of healthier hanisms of action h-related behavioral
124675RFA-OD-24-014 Botanical Dietary Supplements Translational Research Teams (RM1 Clinical Trial Required)Office of Dietary Supplements/NIH/DHHSRFA-OD- [Optional][ App]	24 Not  [LOI/Pre- Specified
Contact Name Barbara C. Sorkin, Ph.D.	
Contact Telephone	
Contact Email <u>sorkinb@mail.nih.gov</u>	
Sponsor Website	
Program URL Link to program URL	
Deadline Dates (ALL) 09-Jun-2024 [Optional][LOI/Pre-App], 08-Jul-2024	

SPIN ID	N ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The purper chemicall trials of the products For exame the optime product se provide a for a trial outcomese by the pro- ingested target en- participare may influ this NOFC	ose of this Notice of Funding Op y complex botanical products o he efficacy of exceptionally pror are often challenged by gaps in ple, the molecular mechanism(s nal product chemistry, for a give pecifications, stability testing ar good test of the effect of that k of a product reputed to have m s might be relevant might benef oduct, and the health outcomes product will benefit from the av gagement by those constituents and characteristics, whether gene ence the effect of the intervent D.	portunity (NOFO) is to support tran r natural products traditionally used nising dietary supplements for impr understanding that critically affect s) of action of a botanical dietary sup n health outcome may not be know nd assessments of bioavailability and botanical on the health outcome(s) a sany different health effects, or to h it from deeper understanding of the expected from modulating those ta ailability of methods to assess bioav s. Clinical trial design will benefit fro tics, background diet, epigenomics, ion tested. The forgoing are example	s-disciplinary, tra l as dietary comp roving resilience. the design and/o pplement might r m; in the absence d absorption kine assessed. Similarl ave effects where e biological struct argets. Interpreta vailability of activ m an understanc gut microbiota, o es of the types of	Inslational researce onents, to inform Clinical efficacy tri r interpretation of not be well establi e of such informati stics a clinical trial y, the best outcom e many different of sure(s) and/or syst tion of a clinical tri e constituents of the ling of the ways in or health history, for knowledge gaps of	h on future clinical ials of such a clinical trial. shed and thus ion to guide might not ne measure juantitative em(s) affected rial of an the product or which trial for example, of interest for
[ 113926 <u>[</u> [	Development of Resources and Te Reproducibility, and Translatabilit Research (R01)	echnologie zy of Anima	<u>es for Enhancing Rigor,</u> al Models in Biomedical	Office of Research Infrastructure Programs/NIH/DHHS	PAR-23- 040	un-2024	Not Specified
	Contact Name	Sige Zou,	Ph.D.				
	Contact Telephone	301-435-0	0749				
	Contact Email	<u>zous@ma</u>	ail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	05-Jun-20	024 , 05-Oct-2024 , 05-Feb-2025	, 05-Jun-2025			
	Synopsis The Office of Research Infrastructure Programs (ORIP) encourages research project grant applications aimed at developing and implementing broadly applicable technologies, tools, and resources for validating animal models and enhancing rigor, reproducibility, and translatability of animal research. Research projects submitted under this Funding Opportunity Announcement (FOA) should be hypothesis driven with strong preliminary data. Proposed studies, models, resources, or technologies under this FOA must either address research interests of multiple NIH Institutes and Centers (ICs), explore multiple organ systems, or be applicable to diseases and processes that impact multiple organ systems in order to align						

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
		with ORIP's NIH-wide mission and programs. Applications should aim to enhance the rigor, reproducibility, and translatability of animal research through the development and implementation of technologies, tools, and resources that have significant impact across a broad range of research areas using animal models. Applications must demonstrate how the proposed resources and technologies impact rigor and reproducibility of animal studies.								
102835	Development of Animal Models a Research (R21 Clinical Trial Not A	ind Related llowed)	Biological Materials for	Office of Research Infrastructure Programs/NIH/DHHS	PAR-21- 167 07-N	/lay-2024	275,000 USD			
	Contact Name	Sige Zou,	Ph.D.							
	Contact Telephone	301-435-0	)749							
	Contact Email	<u>zous@ma</u>	<u>iil.nih.gov</u>							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL) 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 This funding opportunity announcement (FOA) encourages innovative research to develop, characterize, and improve anima models, biological materials, and novel technologies to better understand human health and disease. This FOA also seeks projects aimed at improving the diagnosis and control of diseases that interfere with animal use for biomedical research. Th proposed project must have broad application to multiple NIH Institutes or Centers (ICs) to align with the Office of Research Infrastructure Programs' (ORIP) trans-NIH mission. The proposed studies must explore multiple body systems or evaluate diseases that impact multiple body systems. Applications that develop models focused on a specific disease or area of research, or only propose studies primarily relevant to a single NIH IC, will be considered not acceptable to this FOA and will be withdrawn.									
123592	RFA-OD-24-009 Data Coordinat IDeA States Pediatric Clinical Trial Required—Infrastructure)	ing and Op s Network	erations Center for the ECHO - 3 (U24 Clinical Trial	Office of the Director, National Institutes of Health/NIH/DHHS	RFA-OD- 14-J 24-009	un-2024	26,250,000 USD			
	Contact Name	Tonse N.K	K. Raju, MD Program Officer							
	Contact Telephone	301-435-5	5236							
	Contact Email	Tonse.raj	u@nih.gov							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	14-Jun-20	)24							

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	------------------	--------------	----------------	---------------	-------------------

This Notice of Funding Opportunity (NOFO), issued by the Office of the Director (OD), National Institutes of Health (NIH), invites applications from entities/institutions in Institutional Development Award (IDeA)-eligible states to participate as the Data Coordinating and Operations Center (DCOC) in the Environmental influences on Child Health Outcomes IDeA States Pediatric Clinical Trials Network (ECHO ISPCTN). This RFA runs in parallel with companion RFA (Clinical Sites RFA-OD-24-008) that will solicit applications for ECHO ISPCTN Clinical Sites. The ECHO ISPCTN DCOC and Clinical Sites together will form the ECHO ISPCTN. The ECHO ISPCTN is the intervention component of the ECHO Program and supports its overall mission to enhance the health of children for generations to come. The DCOC award budget will fund approximately five multicenter pediatric clinical trials with each trial related to prevention or treatment of one or more of ECHO's five outcome areas of interest: pre-, peri-, and postnatal outcomes; upper and lower airways; obesity; neurodevelopment; and positive health. Overall, the five trials should address at least two of the five areas. The DCOC will support the ECHO ISPCTN Clinical Sites to Develop, conduct, and disseminate findings from multicenter clinical trials research, assuring the participation of children Synopsis living in rural or underserved communities in IDeA states Build pediatric clinical trial research capacity in IDeA states funded by the ECHO ISPCTN Engage interested parties such as community members, nonprofit organizations, and professional societies to enhance ECHO ISPCTN clinical trial impact, transferability, rigor, and feasibility Through the rigorous use of appropriate scientific methodology and by recruiting and retaining the numbers of participants that justify multicenter trials, the ECHO ISPCTN aims to provide valid and generalizable answers to intervention research questions relevant to the health of children from rural or underserved backgrounds. The ECHO ISPCTN awardees will be primarily responsible for initiating and conducting clinical trials, although they may collaborate with other NIH research networks or subject matter experts outside the network. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
120039	NSF National Quantum Virtual	Laboratory	National Science	23-604	09-Apr-202	4 [LOI/Pre-	1,000,000 USD
	Contact Nama		roundation		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
	Contact Name	702 202 8225					
		703-292-8235					
	Contact Email	NQVL@nsr.gov					
	Sponsor website	Link to sponsor website					
		Link to program UKL	24				
124484	Synopsis	The National Quantum Initiative (NQI) information science and technology. In on identifying and fostering early adop and Engineering (QISE) and to accelerat technology platforms by integrating en other sectors of the economy into cycle for end-users to pioneer new application existing strength in support of the under quantum technologies. With this prog Laboratory (NQVL) concept as an overa and engineering to the resultant techno value. The NQVL aims to develop and un NQVL researchers will explore quantum activities at all levels, and promote bro barriers at all entry points of the resear be necessary for this initiative to succe organizations who have expertise to co essential and will welcome these to be NQI umbrella are also encouraged. Th Science and Technology Demonstration in Quantum Systems (TAQS), as well as	Act1 aims to ensure the continuin conformance with the NQI goals, ition of quantum technologies to to the broader impacts on society. A se ad-users and potential customers if es of research, development, and ons. NSF support for use-inspired erlying foundational research, is a ram solicitation, the Foundation is arching shared infrastructure desig ology, while at the same time emp utilize use-inspired and application in frontiers6, foster QISE workforce adening participation, diversity, e rch enterprise. The engagement of ed, and, indeed, the project is deso ontribute. In particular, NSF recogn a part of the overall structure. Pa- is solicitation lays out a vision for in (QSTD) projects, support for ena- s a central coordination hub. Prop-	ng leade , an arg cransfor systema from ot demon and tra nticipat s introd gned to phasizin n-orient e educa quity, a of the er signed t nizes th intrersh the ent abling te osals fo	ership of the Unit ument was set for m the field of Qu atic approach to r her fields of scient stration should ru- nslational researd ted to accelerate ucing the National facilitate the tra- ng and advancing and advancing and inclusion in Qu ntire United State to include particip at the involveme- nips with other U. ire NQVL program echnologies throu- r Pilot phase QST	ed States (U.S rth for a rene lantum Inform naturing quar nce and engine esult in lower ch in QISE, cor development al Quantum V nslation from its scientific a nologies. In t c, engage in ou ISE, thereby lo es (U.S.) QISE of pation from a nt of industry S. Federal age n that include ugh Transform Ds are solicite	.) in quantum wed emphasis nation Science ntum eering and ng the barriers mbined with its of a market for irtual basic science and technical he process, atreach owering community will full spectrum of partners is encies under the s Quantum native Advances ed at this time.

SPIN ID	Program Title		Sponsor Name	Sp Ni	oonsor umber	Deadline Date	Funding Amount		
			Foundation						
		L	roundation						
	Contact Name	Tomek Bartoszynski							
	Contact Telephone	703-292-4885							
	Contact Email	tbartosz@nsf.gov							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	03-Jun-2024 , 05-Feb-2025 , 05-Feb-20	026						
	Synopsis	The Artificial Intelligence, Formal Methods, and Mathematical Reasoning (AIMing) program seeks to support resear interface of innovative computational and artificial intelligence (AI) technologies and new strategies/technologies mathematical reasoning to automate knowledge discovery. Mathematical reasoning is a central ability of human i that plays an important role in knowledge discovery. In the last decades, both the mathematics and computer scie ynopsis communities have contributed to research in machine-assisted mathematical reasoning, encompassing conjecture and verification. This has been in the form of both formal methods and interactive theorem provers, as well as usi techniques from artificial intelligence. Recent technological advances have led to a surge of interest in machine-assisted mathematical reasoning from the mathematical sciences, formal methods, and AI communities. In turn, advances have potential impact on research in AI.							
124523	Computer Science for All		National Science Foundation	24-555	04-Jun-2024	4	Not Specified		
	Contact Name	Allyson Kennedy							
	Contact Telephone	703-292-8950							
	Contact Email	aykenned@nsf.gov							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	04-Jun-2024 , 12-Feb-2025							
	Synopsis	This program aims to provide all U.S. students with the opportunity to participate in computer science (CS) and computational thinking (CT) education in their schools at the preK-12 levels. With this solicitation, the National Scier Foundation (NSF) focuses on both research and research-practice partnerships (RPPs) that foster the research and development needed to bring CS and CT to all schools. Specifically, this solicitation aims to provide (1) high school te							



SPIN ID	Program Title		Sponsor Name	Spo Nu	onsor mber	Deadline Date	Funding Amount
		with the preparation, professional deve courses; (2) preK-8 teachers with the ir teaching; and (3) schools and districts v	elopment (PD) and ongoing supponstructional materials and prepara with the resources needed to defi	ort they nee ation they i ne and eva	ed to teach rig need to integ Iluate multi-g	gorous comp rate CS and C rade pathway	uter science T into their /s in CS and CT.
124892	<u>Dear Colleague Letter: Nordic-U Development of the Arctic</u>	J.S. Research Collaboration on Sustainal	ole National Science Foundation	NSF 24- 070	04-Jun-202 App]	4 [LOI/Pre-	Not Specified
	Contact Name						
	Contact Telephone	703-292-5111					
	Contact Email	NSF-NordForsk@nsf.gov					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	04-Jun-2024 [LOI/Pre-App]					
	Synopsis	The U.S. National Science Foundation ( signed a Memorandum of Understandi encourage collaboration among U.S., N supported activities might be develope to bring forward new knowledge on ho designed to support interdisciplinary re with clear added value from multilater from multiple disciplines to contribute	NSF) and NordForsk, the science to ng (MOU) on Research Cooperation lordic, and Canadian research con- ed. NordForsk and NSF are pleased by to ensure sustainable develops esearch projects of the highest inter- al collaboration. Only interdisciplin new and groundbreaking knowle	funding bo on. The MC nmunities a d to annou nent of the ernational nary resea dge for the	dy of the Nord DU provides a and sets out t nce support fo Arctic. This f quality and p rch will be fur sustainable o	dic Council of in overarchin he principles or interdiscip unding opport otential for s nded that inte development	Ministers, have g framework to by which jointly linary research rtunity is ocietal impact egrates skills of the Arctic.
124652	Global Centers		National Science Foundation	24-556	11-Jun-202	4	5,000,000 USD
	Contact Name	Karen R. Lips					
	Contact Telephone	703-292-5133					
	Contact Email	globalcenters@nsf.gov					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	11-Jun-2024					
	Synopsis	This solicitation describes an ambitious	program to fund international, ir	nterdiscipli	nary collabora	ative research	n centers that



SPIN ID	Program Title		Sponsor Name	Spo Nu	onsor Imber	Deadline Date	Funding Amount	
		Ig participation and community engagement to develop use-inspired bioeconomy bal challenges identified by the scientific community. Here, the "used-inspired" nature of nes leading to foreseeable benefits to society. This program will prioritize research ce and community-engaged research, use knowledge-to-action frameworks whose earch directions are driven by the potential use of the results as illustrated by Pasteur's 17), "Pasteur's Quadrant - Basic Science and Technological Innovation," Brooking 5781776). Proposals should also indicate how research will be co-generated with fied in the proposal. The proposed research should maximize the benefits of orations, and describe the roles and responsibilities of each national team in achieving ter. Global Centers projects involving partnership between the U.S. and two or more raged. Global challenges must be addressed through international collaboration and op international teams to address research questions that can only be addressed						
109414	Industry-University Cooperativ	e Research Centers Program	National Science Foundation	20-570	12-Jun-2024	L I	Not Specified	
	Contact Name	Prakash G. Balan						
	Contact Telephone	703-292-5341						
	Contact Email	<u>pbalan@nsf.gov</u>						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	12-Jun-2024						
	Synopsis	The IUCRC program catalyzes breakthro industry innovators, world-class acader agencies connect directly and efficientl impact research to meet shared and cr driving innovative technology developr engineering workforce.	ough pre-competitive research by e mic teams, and government agenci y with university researchers to ac itical industrial needs in companies nent, and 3) Identify, mentor and c	enabling c ies. IUCR( hieve thre s of all size develop a	close and susta Cs help industi ee primary obj es; 2) Enhance diverse, highly	ained engagen ry partners an ectives: 1) Con U.S. global le y skilled sciend	nent between d government nduct high- adership in ce and	
124885	Mathematical Foundations of I	Digital Twins	National Science Foundation	24-559	20-Jun-2024	ـــــــــــــــــــــــــــــــــــــ	5,000,000 USD	

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Yuliya Gorb 703-292-2113 <u>ygorb@nsf.gov</u> <u>Link to sponsor website</u> <u>Link to program URL</u> 20-Jun-2024 , 17-Mar-2025 The Division of Mathematical Sciences Science Foundation (NSF) and the Air F	(DMS) in the Directorate for Mather orce Office of Scientific Research (A	matical and Physical FOSR) plan to jointly	Sciences (MPS) support found	at the National	
	mathematical and statistical research on Digital Twins in applied sciences. Recent years have witnessed a signifi in the demand and interest in applications that involve collaborative teams developing and analyzing Digital Tw decision making in various fields, including science, engineering, medicine, urban planning, and more. Both age Synopsis recognize the need to promote research aiming to stimulate an interplay between mathematics/statistics/comp practical applications in the realm of Digital Twins. This program encourages new collaborative efforts within th Digital Twins, aiming at stimulating fundamental research innovation, pushing, and expanding the boundaries o and exploring new frontiers in mathematics and computation for Digital Twin development, and its applications leveraging this synergy, the program aims to harness science, technology, and innovation to address some of or most pressing challenges						
124924	Foundations for Digital Twins a Innovation	s Catalyzers of Biomedical Technologica	l National Science 2 Foundation	4-561 21-Jun-202	24	Not Specified	
	Contact Name	Yulia R. Gel					
	Contact Telephone	703-292-7888					
	Contact Email	<u>ygel@nsf.gov</u>					
	Sponsor Website	Link to sponsor website					
	Program URL						
	Deadline Dates (ALL)	21-Jun-2024 , 05-May-2025			<b>T</b> (1)		
	Synopsis	ii innovation (FDT-Bid cal and engineering f healthcare applicatio elevance of the devel	foundations be foundations be ons, with a part loped models in	i supports hind the ticular focus on n addressing			



SPIN ID	Program Title		Sponsor Name	Sp Nu	oonsor umber	Deadline Date	Funding Amount
		current and emerging challenges affect BioTech initiative is to catalyze biomed algorithms relevant to digital twins and	ting the development and assessr lical technological innovation thro d synthetic humans.	ment of bio ough new f	omedical techr foundational d	nologies. The period	goal of the FDT- of methods and
124963	Data Science Corps		National Science Foundation	24-560	21-Jun-2024	4	1,200,000 USD
	Contact Name	Stephanie D. Teasley					
	Contact Telephone	703-292-8752					
	Contact Emai	steasley@nsf.gov					
	Sponsor Website	Link to sponsor website					
	Program URI	Link to program URL					
	Deadline Dates (ALL)	21-Jun-2024					
	Synopsis	The objective of the Data Science Corp The Data Science Corps program seeks This engagement will help bridge the d state, and national, and will empower will be able to sharpen their skills in da including rural communities, urban cor and data scientists will serve the nation who have experience with data science broaden participation in science, techn prompts the community to respond to and training, including in data science i The solicitation supports opportunities Institutions, other emerging research in https://www.congress.gov/bill/117th-o	as program is to help build a strong to engage data science students lata-to-knowledge gap in organiza better use of data for more effect ata science by working on real-wo mmunities, academia, industry, or n by helping produce a workforce e in action in real-world settings. The hology, engineering and mathema one or more mechanisms by which issues related to knowledge repre- ts for undergraduates (including stu- nstitutions as defined in the CHIP: congress/house-bill/4346, and ins	g national in real-wo ations and tive decision rld project governme -ready coh The progra tics (STEM ch to provision udents fro S and Scientitutions in	data science in rld data science communities a on making. Dat s focused on s ent. This partn nort of data sci am welcomes p 1) and STEM ec ide students w and creation a m community nce Act, n EPSCoR juris	nfrastructure ise implementa at all levels, in a Science Cor pecific comm ership betwee entists and te proposals that lucation. This rith data scien and use of kno colleges, Mine dictions), and	and workforce. Ition projects. cluding local, ps participants unity needs, en communities chnologists, seek to solicitation ce education owledge graphs. ority Serving grade 6-12
113761	Expanding Al Innovation throu	gh Capacity Building and Partnerships	National Science Foundation	23-506	24-Jun-2024	4	Not Specified
	Contact Name	2					



SPIN ID	rogram Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount				
	Contact Telephone	703-292-5111								
	Contact Email	ExpandAIProgram@nsf.gov								
	Sponsor Website	Link to sponsor website								
	Program URL	Link to program URL								
	Deadline Dates (ALL)	24-Jun-2024 , 18-Oct-2024 , 10-Mar-20	Oct-2024 , 10-Mar-2025 , 23-Jun-2025							
Synopsis Synopsis The National Science Foundation a research community for the advan promote the NSF vision and core v Building and Partnerships (Expand workforce development through c Institutes ecosystem.			ts partners support the continued growth ent of AI and AI-powered innovation, pro- es, especially inclusion and collaboration. program aims to significantly broaden par- city development projects and through par-	h of a broad and c oviding a unique c The Expanding AI rticipation in AI re artnerships withir	liverse interdis opportunity to Innovation thr search, educat the National A	ciplinary broadly ough Capacity ion, and Al Research				



SPIN ID	Program Title		Sponso	r Name	Spons	sor Number	Deadline Date	Funding Amount
115139	Special Emphasis Notice (SEN):Re Change and Healthcare	esearch on Climate		Agency for Healthcare Research a Quality/DHHS	and	NOT-HS-23-006	08-Apr-2024	Not Specified
	Contact Name	Brent Sandmeyer	, MPH					
	Contact Telephone	301-427-1441						
	Contact Email	Brent.sandmeyer	<u>@ahrq.</u>	hhs.gov				
	Sponsor Website							
	Program URL	Link to program L	<u>JRL</u>					
	Deadline Dates (ALL)	Deadline Dates (ALL) Deadline Dates (ALL) 12-Apr-2024, 25-May-2024, 05-Jun-2024, 12-Jun-2024, 16-Jun-2024, 26-Jun-2024, 08-Aug-2024, 12-Aug-2024, 05-Oct- 2024, 12-Oct-2024, 16-Oct-2024, 26-Oct-2024, 08-Dec-2024, 12-Dec-2024, 25-Jan-2025, 05-Feb-2025, 12-Feb-2025, 16- Feb-2025, 26-Feb-2025, 08-Apr-2025, 12-Apr-2025, 25-May-2025, 12-Jun-2025, 08-Aug-2025, 12-Aug-2025, 25-Sep-2025 , 25-Sep-2025, 12-Oct-2025, 12-Dec-2025, 12-Feb-2026, 12-Jun-2026, 12-Oct-2026, 12-Feb-2027 This Special Emphasic Notice (SEN) appropries AHRO's interact in receiving bastle convisor research grant applications that						
	Synopsis	This Special Emphasis Notice (SEN) announces AHRQ's interest in receiving health services research grant applications that address the intersection of climate change and healthcare.						
109186	Notice of Special Interest (NOSI): on Health System and Healthcare Responsiveness to COVID-19	Health Services Re Professional	<u>esearch</u>	Agency for Healthcare Research a Quality/DHHS	and	NOT-HS-22-010	25-May-2024	Not Specified
	Contact Name	Leeann Comfort,	PhD, M	PP				
	Contact Telephone							
	Contact Email	Leeann.Comfort@	<u>ahrq.h</u>	<u>hs.gov</u>				
	Sponsor Website							
	Program URL	Link to program U	JRL					
	Deadline Dates (ALL)	25-May-2024 , 05	Jun-20	24 , 16-Jun-2024 , 25-Sep-2024 , 0	5-Oct-	-2024 , 16-Oct-2024 ,	25-Jan-2025, 05-Feb	p-2025
	This Special Emphasis Notice (SEN) informs the research community that the Agency for Healthcare Research and Quality (AHRQ) is interested in receiving health services research grant applications to develop models of care that improve access quality, and outcomes of care related to COVID-19 and post-acute sequalae from COVID-19 (PASC).							ch and Quality t improve access,
123850	AHRQ Small Health Services Rese (R03)	arch Grant Progra	m	Agency for Healthcare Research a Quality/DHHS	and	PA-24-155	16-Jun-2024	100,000 USD
	Contact Name							



SPIN ID	Program Title	Spor	nsor Name	Sponsor Number	Deadline Date	Funding Amount			
	Contact Telephone	301-427-1025							
	Contact Email	kathryn.woolridge@ah	nrq.hhs.gov						
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2 2027 , 16-Jun-2027 , 10	2024 , 16-Feb-2025 , 16-Jun-2025 , 1 6-Oct-2027 , 16-Feb-2028 , 16-Jun-2	6-Oct-2025 , 16-Feb-2026 , 1 028 , 16-Oct-2028 , 16-Feb-2	.6-Jun-2026 , 16-Oct .029 , 16-Jun-2029	;-2026 , 16-Feb-			
	Synopsis	The purpose of this No AHRQ research prioriti practice improvement, including the hospital, Research may involve policymakers, payers, Government, and othe	HRQ research priorities, including improving healthcare quality and patient safety, improving healthcare delivery and ractice improvement, and enhancing whole-person healthcare delivery. AHRQ supports research in all healthcare settings, cluding the hospital, long-term care, ambulatory care, home healthcare, pharmacy, and care transitions between settings. esearch may involve many partners and other groups, including patients, families, clinicians, non-clinical healthcare staff, plicymakers, payers, healthcare organizations, providers and accreditors, local and State governments, the Federal overnment, and others.						
123849 /	AHRQ Health Services Research P	rojects (R01)	Agency for Healthcare Research Quality/DHHS	and PA-24-154	05-Jun-2024	2,000,000 USD			
	Contact Name								
	Contact Telephone	301-427-1025							
	Contact Email	kathryn.woolridge@al	nrq.hhs.gov						
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2 2027 , 05-Jun-2027 , 05	2024 , 05-Feb-2025 , 05-Jun-2025 , 0 5-Oct-2027 , 05-Feb-2028 , 05-Jun-2	5-Oct-2025 , 05-Feb-2026 , 0 028 , 05-Oct-2028 , 05-Feb-2	5-Jun-2026 , 05-Oct 029 , 05-Jun-2029	:-2026 , 05-Feb-			
	Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to seek health services research grant applications focused on AHRQ research priorities, including improving healthcare quality and patient safety, improving healthcare delivery and practice improvement, and enhancing whole-person healthcare delivery. AHRQ supports research in all healthcare settings, including the hospital, long-term care, ambulatory care, home healthcare, pharmacy, and care transitions between settings. Research may involve many partners and other groups, including patients, families, clinicians, non-clinical healthcare staff, policymakers, payers, healthcare organizations, providers and accreditors, local and State governments, the Federal Government, and others.							

SPIN ID	Program Title	Sponse	or Name	Sponsor Number	Deadline Date	Funding Amount
114270	Special Emphasis Notice (SEN): In Associated Infections and Comba Bacteria Research	terest in Healthcare ting Antibiotic Resistant	Agency for Healthcare Research Quality/DHHS	and NOT-HS-23-003	25-May-2024	Not Specified
	Contact Name	Leyi Lin, MD				
	Contact Telephone	301-427-1333				
	Contact Email	leyi.lin@ahrq.hhs.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	25-May-2024 , 05-Jun-20 2025 , 25-Jan-2026 , 05-I	024 , 25-Sep-2024 , 05-Oct-2024 , Feb-2026 , 25-May-2026 , 05-Jun-	25-Jan-2025 , 05-Feb-2025 2026 , 25-Sep-2026 , 05-Oct	, 25-May-2025 , 05-J t-2026 , 05-Oct-2026	un-2025 , 25-Sep-
	Synopsis	The purpose of this Spec Research and Quality (Al reduce the burden of he resistant organisms. HAI consequences for health observed increases of se developing and studying	cial Emphasis Notice (SEN) is to inf HRQ) continued interest in, and a althcare-associated infections (H s continue to cause significant pa icare facilities and for patients. Ur everal types of HAIs as well as incr resilient and adaptable countern	form the research communi- vailable funding for, suppor Als) and to address the grow tient harm and are also asso nfortunately, the COVID-19 eases in antimicrobial resist neasures.	ity of the Agency for ting innovative resea ving threat posed by ociated with consider pandemic has been a tance, highlighting th	Healthcare arch seeking to antimicrobial rable financial associated with e importance of
107009	Large Research Projects for Comb Resistant Bacteria (CARB) (R01)	pating Antibiotic-	Agency for Healthcare Research Quality/DHHS	and PA-22-047	05-Jun-2024	2,500,000 USD
	Contact Name	James Cleeman, MD				
	Contact Telephone	301-427-1330				
	Contact Email	james.cleeman@ahrq.hl	ns.gov			
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-20	24 , 05-Feb-2025 , 05-Jun-2025 , 0	)5-Oct-2025 , 05-Feb-2026 ,	05-Jun-2026 , 05-Oc	t-2026
	Synopsis	Agency for Healthcare R Demonstration and Disso use the R01 Research Pro	esearch and Quality (AHRQ) invite emination Projects (R18) focused oject Grant award mechanism.	es applications to conduct L on Combating Antibiotic-Re	arge Health Services esistant Bacteria (CAF	Research RB). This FOA will



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
119452	Biological Technologies		Defense Advanced Research Proj Agency/Department of Defense	ects HR001123S0045	20-Jun-2024 [LOI/Pr	e-App] Not Specified		
	Contact Name							
	Contact Telephone							
	Contact Email	BTOBAA2023@d	arpa.mil					
	Sponsor Website							
	Program URL	Link to program l	JRL					
	Deadline Dates (ALL)	20-Jun-2024 [LOI	/Pre-App], 20-Jun-2024					
	Synopsis	BTO's mission is t complexity, to re Research in BTO increase operatic readiness.	to develop capabilities that leverage the un volutionize how the United States defends creates biotechnological capabilities that p onal resilience, develop novel functional m	nique properties of biology s the homeland and prepar provide tactical care and re naterials, and detect and pr	<ul> <li>adaption, replicati</li> <li>res and protects its W</li> <li>estore function to inju</li> <li>rotect against threats</li> </ul>	on, resilience and /arfighters. ured warfighters, to maintain force		
123396	Accelerating STEM and Climate A	<u>mbitions</u>	Department of State	LUXEM-PDS-FY24- 01	05-May-2024 [LOI/F App]	2re- 15,000 USD		
	Contact Name							
	Contact Telephone							
	Contact Email	LuxembourgGran	nts@state.gov					
	Sponsor Website							
	Program URL	Link to program l	JRL					
	Deadline Dates (ALL)	05-May-2024 [LC	0I/Pre-App], 09-Jun-2024					
	Synopsis	The Public Diplomacy Section (PD) of the U.S. Embassy in Luxembourg, U.S. Department of State, announces an open sis competition for organizations to submit applications to carry out programs strengthening bilateral ties between the United States and Luxembourg on Accelerating STEM and Climate Ambitions. Awards may range from \$3,000 to \$15,000.						
125081	Space Experiential Learning Cente	er (SELC)	Department of State	ND-NOFO-24-104	03-Jun-2024	100,000 USD		
	Contact Name							



SPIN ID	Program Title	S	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone					
	Contact Email	ND_GrantApplicati	ions@state.gov			
	Sponsor Website					
	Program URL	Link to program UF	<u>RL</u>			
	Deadline Dates (ALL)	03-Jun-2024				
The U.S. Department of State's Public Diplomacy Section in New Delhi invites proposals for the operation and demonst of experiences at American Center New Delhi (ACND). The ACND will establish a Space Experiential Learning Center (SI enable next generation space enthusiasts to participate in space exploration studies, education, experiential learning activities, and networking to incline them towards pursuing higher education and a career in space science, innovation technology, and applications. This NOFO solicits proposals for running and showcasing experiences at ACND. Funding f award may range from \$75,000 to \$100,000.						
119530	Naval Air Warfare Center Aircraft Office-Wide Broad Agency Annou	Division (NAWCAD Incement	Department of the Navy/Depart of Defense	ment N00421-23-S-0001	22-Jun-2024 [LOI/Pr	e-App] Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	NAWCAD_PAXR_O	OfficeWide_BAA@us.navy.mil			
	Sponsor Website					
	Program URL	Link to program UF	<u>RL</u>			
	Deadline Dates (ALL)	22-Jun-2024 [LOI/F	Pre-App]			
	Synopsis	The Naval Air Warf Development proje	fare Center Aircraft Division (NAWCAD) ects which offer potential for advancem	is interested in receiving when the second state is a second structure of NA	hite papers for Resear AWCAD operations.	rch and
125167	Centers of Excellence to Enhance Newborns	Disease Detection	in National Center for Environmen Health/CDC/DHHS	tal CDC-RFA-EH-24- 0044	26-Apr-2024 [Optional][LOI/Pre-A	4,000,000 \pp] USD
	Contact Name	Cynthia Hinton, Pro	oject Officer			
	Contact Telephone					
	Contact Email	<u>ceh9@cdc.gov</u>				
	Sponsor Website					



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL Deadline Dates (ALL) Synopsis	Link to program L 26-Apr-2024 [Opt This funding oppo CDC's Newborn S to: Develop infras	JRL ional][LOI/Pre-App], 04-Jun-2024 ortunity will establish a newborn screenin creening and Molecular Biology Branch ( structure to implement advanced techno	ng (NBS) Center of Excellence NSMBB), partner jurisdiction logies to expand NBS system	e that will work collans, and other relevar	aboratively with nt partners, nced technologies
		as first and/or hig complex biochem	her tier testing platforms to optimize sci ical and molecular NBS data.	eening performance. Incorp	orate bioinformatics	s to analyze



### Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
124816	Global Centres (GC) Addressin Bioeconomy	ng Global Challenges Through	Biotechnology and Biological Sciences Researd Council (BBSRC)	<sup>ch</sup> 11-Jun-2024	2,683,800 USD
	Contact Name				
	Contact Telephone				
	Contact Email	global.centres.bioeconomy@bbsrc	c.ukri.org		
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-Jun-2024			
	Synopsis	Funding is available to support large bioeconomy. BBSRC will support G workforce training with diverse star which must include a US partner a economic cost (FEC) of a project car years in duration.	ge-scale international research projects to addr lobal Centres that facilitate international, inter akeholders. BBSRC funding is available for UK e nd encouraged to include partners in one or m an be up to £2.13 million. BBSRC will fund 80%	ess global challen disciplinary collab ligible researchers ore participating c of the FEC for proj	ges through the orations and for partnerships countries. The full fects of up to five
	Applicant Types				
	Funding Limit	2,130,000.00 maximum			
	Limited Submission	No			
115901	R Accelerated Award Grant		Alex's Lemonade Stand	06-Jun-2024	800,000 USD
	Contact Name				
	Contact Telephone	866-333-1213			
	Contact Email	Grants@AlexsLemonade.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			



Non Federal Funding Opportunities: June 2024
SPIN ID	Program Title	Spo	onsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	06-Jun-2024				
	Synopsis	The purpose of the childhood cancers to original project that effective, less toxic strong scientific rat award or equivalen as well as institution year grant.	R Accelerated Award Grant is to a by providing support to scientists t is not currently being funded that therapies for childhood cancers. F ionale. Applicants must be first-tin t independent award. Demonstra- nal support are critical componen	Idvance ALSF's mission to f focused on pediatric oncolo It has a clear focus on accel Research projects should ac me recipients of a pediatric tion of continued commitm ts of a successful applicatic	ind cures and bette ogy research. Applic lerating the discove ddress a testable hy cancer researchfoo nent to pediatric can on. The R Accelerate	r treatments for cants must have an ry of more pothesis based on cused NIH R01 ncer investigation ed Award is a four-
	Applicant Types					
	Funding Limit	200,000.00 per yea	r			
	Limited Submission	No				
053763	Innovation Grants (Building Tr	rust Through DEI)	Alliance for Acade	emic Internal Medicine	07-Jun-2024	Not Specified
	Contact Name					
	Contact Telephone	703-341-4540				
	Contact Email	innovationgrants@	im.org			
	Sponsor Website	Link to sponsor wel	<u>bsite</u>			
	Program URL	Link to program UR	<u>:L</u>			
	Deadline Dates (ALL)	07-Jun-2024				
	Synopsis	The Building Trust t projects that will in training. Funding to medicine residents this funding, \$100,0	through Diversity, Health Care Equ tegrate diversity, equity, and inclu otals \$400,000 and is designated to and faculty focused on improving D00 is specifically allocated for gra	ity, & Inclusion in Internal ision (DEI) into the fabric of o support inter-professiona trust and advancing health ints supporting projects de	Medicine Training p f internal medicine al projects that are l n equity in the healt signed to enhance c	orogram supports education and ed by internal th care system. Of diagnostic



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Applicant Types Funding Limit Limited Submission	excellence and age, and disabil 0.00 see detail No	address disparities based on fa ity.	ctors such as race, ethnicity, g	ender, sexual orientat	ion, geography,	
110437	Seed Grants		ALS Associ	ation	09-Apr-2024 [LOI/Pre-App	50,000 USD	
	Contact Name						
	Contact Telephone						
	Contact Email	researchgrants	@alsa-national.org				
	Sponsor Website	Link to sponsor	website				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	09-Apr-2024 [L0	DI/Pre-App], 20-Jun-2024				
	Synopsis	The ALS Association's Seed Grant program seeks to fund research with a strong scientific rationale and pote significant impact in ALS but limited preliminary data. These 1-year awards with a maximum budget of \$50,0 should be used to gather preliminary data that will support future applications to larger grant award program					
	Applicant Types						
	Funding Limit	50,000.00 maxi	mum				
	Limited Submission	No					
059708	ADDF-Harrington Scholar Prog	<u>ram</u>	Alzheimer'	s Drug Discovery Foundation	03-Jun-2024 [LOI/Pre-App	600,000 USD	
	Contact Name						
	Contact Telephone						



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Contact Email	grants@alzdisco	overy.org				
	Sponsor Website	Link to sponsor	website				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	03-Jun-2024 [LC	0I/Pre-App], 26-Au	ıg-2024			
	Synopsis	The ADDF-Harri disease and rela industry experts Medicines Cent	ngton Scholar Prog ated dementias. Th s through a collabo ers of the Harringt	gram is dedicated to his unique award pro- pration with the Alzho con Discovery Institut	advancing academic disco vides funding and project eimer's Drug Discovery For e.	veries into medicin support by a team o undation (ADDF) an	es for Alzheimer's of pharmaceutical id the Brain Health
	Applicant Types						
	Funding Limit	600,000.00 max	kimum				
	Limited Submission	No					
115885	Global Program to Help Custon Advance Health Equity	mers Develop Cl	oud Solutions to	Amazon Web Servi	ces	30-Jun-2024	Not Specified
	Contact Name						
	Contact Telephone						
	Contact Email	<u>aws-pr@amazo</u>	<u>n.com</u>				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	30-Jun-2024 , 1	5-Nov-2024				
	AWS is committing \$40.0 million to harness the power of the cloud to advance health equity globally. Amazon Web Services (AWS) is offering AWS Promotional Credit and technical expertise to selected institutions and companies addressing health disparities that impact underserved or underrepresented communities around the world. The program will support applications that develop culturally responsive solutions to: 1) increase access to health						



SPIN ID	Program Title	Sponsor	Name	Sponsor Number	Deadline Date	Funding Amount		
		services, 2) reduce dispar and inclusive systems of o	rities by addressing care.	social determinants of health, and	3) leverage data to p	promote equitable		
	Applicant Types							
	Funding Limit	0.00 see detail						
	Limited Submission	No						
064670	SkinCare for Developing Coun	tries Program	America	n Academy of Dermatology	30-Jun-2024	5,000 USD		
	Contact Name							
	Contact Telephone							
	Contact Email	RIGNAHS@aad.org						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	30-Jun-2024						
	Synopsis	The American Academy o and humanitarian project \$5,000 depending on the	The American Academy of Dermatology offers grants to individuals and organizations to fund internation and humanitarian projects under the Skin Care for Developing Countries program. Grants vary between S \$5,000 depending on the proposal, scope of the project, and availability of funds.					
	Applicant Types							
	Funding Limit	5,000.00 maximum						
	Limited Submission	No						
042399	Research Grants		America Foundat	n Academy of Otolaryngic Allergy ion	01-Jun-2024	10,000 USD		
	Contact Name	Kate Chenal						
	Contact Telephone	202-955-5010 x 600						
	Contact Email	foundation@aaoallergy.c	org					



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	01-Jun-2024					
	Synopsis	The American A for the treatme pathogenesis, p support multipl	cademy of Otolaryn nt of otolaryngic con athophysiology, diag e projects each year	gic Allergy (AAOA) aditions by inviting gnosis, prevention, ; each project may	Foundation seeks to adva applications for grants to or treatment of otolaryng have total direct costs of s	nce allergy research conduct research ir gic allergy. Funds an \$10,000.	n and knowledge n the re available to
	Applicant Types						
	Funding Limit	10,000.00 maxi	mum				
	Limited Submission	No					
115487	Patty and Paul Levi Research A	Award	/ F	American Academy Foundation	of Periodontology	01-Jun-2024	5,000 USD
	Contact Name	Ariel A. Medoff					
	Contact Telephone	312-573-3254					
	Contact Email	ariel@perio.org	l l				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	01-Jun-2024					
	Synopsis	The Patty and P related to preve considered a su	aul Levi Research Av entative periodontolo pplement to any sala	vard provides an ai ogy and being men ary, stipend or rese	nnual \$5,000 award to a p stored by a periodontal fac earch support.	redoctoral student culty member. The	doing research award should be
	Applicant Types						
	Funding Limit	5,000.00 maxim	ıum				



SPIN ID	Program Title	Sponsor Na	me	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No				
115485	Dr. Colin Richman and Family	Perio-Ortho Interface Award	American Academ Foundation	y of Periodontology	01-Jun-2024	20,000 USD
	Contact Name	Ariel A. Medoff				
	Contact Telephone	312-573-3254				
	Contact Email	ariel@perio.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2024				
	Synopsis	The Dr. Colin Richman and F basic science research relate annually to one or more ind	amily Perio-Ortho Interfa ed to the orthodontic/per ividuals.	ce Award will be made to a iodontal interface. A \$20,00	n individual perfor 00 fellowship will b	ming clinical or e awarded
	Applicant Types					
	Funding Limit	20,000.00 maximum				
	Limited Submission	No				
124908	Dr. Mark K. Setter Leadership Implantology Award	in Periodontology and Denta	<u>l</u> American Academ Foundation	y of Periodontology	01-Jun-2024	10,000 USD
	Contact Name	Ariel A. Medoff				
	Contact Telephone	312-573-3254				
	Contact Email	ariel@perio.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2024				



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Dr. Mark K amount of \$10, and encouraged	. Setter Leadership 000 to recognize a 1 throughout his life	in Periodontology a periodontal residen etime.	nd Dental Implantology Av t who exemplifies the lead	ward is presented a ership qualities tha	nnually in the t Dr. Setter lived
	Funding Limit	10,000.00 maxi	mum				
	Limited Submission	No					
014713	Gertrude B. Elion Cancer Rese	arch Award		American Associati	on for Cancer Research	03-Jun-2024	225,000 USD
	Contact Name						
	Contact Telephone	215-446-7280					
	Contact Email	grants@aacr.or	g				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	03-Jun-2024					
	Synopsis	The AACR Gertr faculty. The reso may be basic, tr related to the re	ude B. Elion Cance earch proposed for anslational, or clini esearch project	r Research Award is funding must focus ical in nature. The av	intended to encourage and on cancer etiology, diagno ward provides a one-year g	d support tenure-e osis, treatment, or p grant of \$225,000 fo	ligible junior prevention and pr expenses
	Applicant Types						
	Funding Limit	225,000.00 max	kimum				
	Limited Submission	Yes					
071222	General and Dedicated Resear	rch Grants		American Associati Foundation	on of Nurse Anesthetists	30-Jun-2024	Not Specified
	Contact Name						



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount				
	Contact Telephone	847-692-7050								
	Contact Email	foundation@aa	ina.com							
	Sponsor Website	Link to sponsor	website							
	Program URL	Link to program	<u>1 URL</u>							
	Deadline Dates (ALL)	30-Jun-2024 , 3	0-Sep-2024 , 31-Dec-2024							
	Synopsis	The American A education and r nurse anesthes member CRNAs	merican Association of Nurse Anesthetists Foundation's mission is to advance the science of anesthesia through tion and research. One of the goals of the AANA Foundation is to support new and seasoned investigators in anesthesia through grants. Programs are designed to develop researchers in nurse anesthesia. Only AANA per CRNAs (clinical or research) are appropriate for application.							
	Applicant Types									
	Funding Limit	0.00 see detail								
	Limited Submission	No								
032751	Eva King Killiam Research Awa	urd	American College Neuropsychophar	of macology	20-Jun-2024	Not Specified				
	Contact Name									
	Contact Telephone	615-324-2360								
	Contact Email	acnp@acnp.org	1							
	Sponsor Website	Link to sponsor	website							
	Program URL	Link to program	<u>1 URL</u>							
	Deadline Dates (ALL)	20-Jun-2024								
	Synopsis	The American C career research	College of Neuropsychopharmacology her on the basis of outstanding transla	(ACNP) presents the Eva Kii tional research contributior	ng Killam Research ns to neuropsychop	Award to an early harmacology.				
	Applicant Types									



SPIN ID	Program Title	Sponsor Nan	ne	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	0.00 see detail				
	Limited Submission	No				
072617	Joel Elkes Research Award		American College Neuropsychophari	of macology	20-Jun-2024	Not Specified
	Contact Name					
	Contact Telephone	615-324-2360				
	Contact Email	ancp@acnp.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	20-Jun-2024				
	Synopsis	The American College of Neu scientist in recognition of an receive a monetary award an	ropsychopharmacology ( outstanding clinical conti id a plaque to be given at	ACNP) presents the Joel E ribution to neuropsychoph the ACNP Annual Meeting	lkes Research Awar Iarmacology. Awarc g.	d to a young I recipients will
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
103871	Barbara Fish Memorial Award		American College Neuropsychophari	of macology	20-Jun-2024	Not Specified
	Contact Name					
	Contact Telephone	615-324-2360				
	Contact Email	acnp@acnp.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				



Deadline Dates (ALL)       20-Jun-2024         The American College of Neuropsychopharmacology (ACNP) presents the Barbara Fish Memorial Award to an ACN Synopsis         wember who has made an outstanding contribution to basic, translational or clinical neuroscience. Award recipier will receive a monetary award and a plaque to be given at the ACNP Annual Meeting.         Applicant Types         Funding Limit 0.00 see detail         Limited Submission         O95617       Media Award         Contact Name Contact Telephone         G15-324-2360         Contact Mame         Sponsor Website         Program URL         Deadline Dates (ALL)         Q0-Jun-2024         The ACNP Media Award was established to recognize major contributions to the education of the public about me Synopsis         illness and substance abuse research and the positive impact of research on treatment. The Media Award consists an expense paid trip to the ACNP Annual Meeting and a plaque to be presented at the Annual Meeting.         Applicant Types         Funding Limit	SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
Deadline Dates (ALL)       20-Jun-2024         The American College of Neuropsychopharmacology (ACNP) presents the Barbara Fish Memorial Award to an ACN         Synopsis       member who has made an outstanding contribution to basic, translational or clinical neuroscience. Award recipier will receive a monetary award and a plaque to be given at the ACNP Annual Meeting.         Applicant Types       Funding Limit 0.00 see detail         Limited Submission       No         095617       Media Award       American College of Neuropsychopharmacology       20-Jun-2024       Not Spect         Contact Name       Contact Telephone       615-324-2360       Veuropsychopharmacology       20-Jun-2024       Not Spect         Program URL       Link to sponsor website       Program URL       Deadline Dates (ALL)       20-Jun-2024       Not Spect         Deadline Dates (ALL)       20-Jun-2024       The ACNP Media Award was established to recognize major contributions to the education of the public about me       Synopsis         Illness and substance abuse research and the positive impact of research on treatment. The Media Award consists an expense paid trip to the ACNP Annual Meeting and a plaque to be presented at the Annual Meeting.         Applicant Types       Funding Limit 0.00 see detail       Limited Submission         Elizabeth Barrett-Connor Research Award for Young       Not								
The American College of Neuropsychopharmacology (ACNP) presents the Barbara Fish Memorial Award to an ACN member who has made an outstanding contribution to basic, translational or clinical neuroscience. Award recipier will receive a monetary award and a plaque to be given at the ACNP Annual Meeting.         Applicant Types       Funding Limit         Funding Limit       0.00 see detail         Limited Submission       No         095617       Media Award         Contact Name       American College of Neuropsychopharmacology         Contact Telephone       615-324-2360         Contact Tenali       acnp@acnp.org         Sponsor Website       Link to sponsor website         Program URL       Deadline Dates (ALL)         Deadline Dates (ALL)       20-Jun-2024         Not Spect       The ACNP Media Award was established to recognize major contributions to the education of the public about me synopsi         Illness and substance abuse research and the positive impact of research on treatment. The Media Award consists an expense paid trip to the ACNP Annual Meeting and a plaque to be presented at the Annual Meeting.         Applicant Types       Funding Limit         Limited Submission       No		Deadline Dates (ALL)	20-Jun-2024					
Synopsis       member who has made an outstanding contribution to basic, translational or clinical neuroscience. Award recipier will receive a monetary award and a plaque to be given at the ACNP Annual Meeting.         Applicant Types       Funding Limit         Funding Limit       0.00 see detail         Limited Submission       No         095617       Media Award         Contact Name       American College of Neuropsychopharmacology         Contact Telephone       615-324-2360         The ACNP Media Award was established to recognize major contributions to the education of the public about me         Illness and substance abuse research and the positive impact of research on treatment. The Media Award consists an expense paid trip to the ACNP Annual Meeting and a plaque to be presented at the Annual Meeting.         Applicant Types       Funding Limit         Funding L		, , , , , , , , , , , , , , , , , , ,	The American C	ollege of Neuropsy	chopharmacology (/	ACNP) presents the Barbar	a Fish Memorial Av	ward to an ACNP
will receive a monetary award and a plaque to be given at the ACNP Annual Meeting. Applicant Types Funding Limit Limited Submission No 095617 Media Award American College of Neuropsychopharmacology 20-Jun-2024 Not Spec Contact Name Contact Telephone 615-324-2360 Contact Telephone 615-324-2360 Contact Telephone 615-324-2360 Contact Email acnp@acnp.org Sponsor Website Program URL Deadline Dates (ALL) 20-Jun-2024 The ACNP Media Award was established to recognize major contributions to the education of the public about me Synopsis illness and substance abuse research and the positive impact of research on treatment. The Media Award consists an expense paid trip to the ACNP Annual Meeting and a plaque to be presented at the Annual Meeting. Applicant Types Funding Limit Limited Submission No		Synopsis	member who h	as made an outstai	nding contribution to	o basic, translational or clir	nical neuroscience.	Award recipients
Applicant Types       Funding Limit       0.00 see detail         Limited Submission       No         095617       Media Award       American College of Neuropsychopharmacology       20-Jun-2024       Not Spec         095617       Media Award       Contact Name Contact Telephone       615-324-2360       Not Spec         Contact Telephone       G15-324-2360       Contact Email       acnp@acnp.org         Sponsor Website       Link to sponsor website       Program URL       Link to program URL         Deadline Dates (ALL)       20-Jun-2024       The ACNP Media Award was established to recognize major contributions to the education of the public about me Synopsis       Synopsis         illness and substance abuse research and the positive impact of research on treatment. The Media Award consists an expense paid trip to the ACNP Annual Meeting and a plaque to be presented at the Annual Meeting.         Applicant Types       Funding Limit       0.00 see detail         Limited Submission       No         Elizabeth Barrett-Connor Research Award for Young       No			will receive a m	onetary award and	a plaque to be give	n at the ACNP Annual Mee	eting.	
Funding Limit       0.00 see detail         Limited Submission       No         095617       Media Award         Contact Name       Contact Telephone         Contact Telephone       615-324-2360         Contact Trail       acnp@acnp.org         Sponsor Website       Link to sponsor website         Program URL       Link to program URL         Deadline Dates (ALL)       20-Jun-2024         The ACNP Media Award was established to recognize major contributions to the education of the public about me         Synopsis       The ACNP Media Award was established to recognize major contributions to the education of the public about me         Synopsis       The ACNP Media Award was established to recognize major contributions to the education of the public about me         Applicant Types       No         Funding Limit       0.00 see detail         Limited Submission       No		Applicant Types						
Limited Submission       No         095617       Media Award       American College of Neuropsychopharmacology       20-Jun-2024       Not Spec         095617       Contact Name Contact Telephone       615-324-2360       Veuropsychopharmacology       20-Jun-2024       Not Spec         095617       Contact Email acnp@acnp.org       Sponsor Website       Figure 1       Figure 2       F		Funding Limit	0.00 see detail					
095617       Media Award       American College of Neuropsychopharmacology       20-Jun-2024       Not Spect         Contact Name Contact Telephone       615-324-2360       acnp@acnp.org       sector		Limited Submission	No					
OSJOL7       Meuropsychopharmacology       20-Juli 2024       Not spect         Contact Name       Contact Telephone       615-324-2360         Contact Telephone       615-324-2360       contact Telephone         Sponsor Website       Link to sponsor website       Link to program URL         Deadline Dates (ALL)       20-Jun-2024       The ACNP Media Award was established to recognize major contributions to the education of the public about me illness and substance abuse research and the positive impact of research on treatment. The Media Award consists an expense paid trip to the ACNP Annual Meeting and a plaque to be presented at the Annual Meeting.         Applicant Types       Funding Limit         Limited Submission       No         Elizabeth Barrett-Connor Research Award for Young	005617	Modia Award			American College c	of	20 Jun 2024	Not Specified
Contact Name       615-324-2360         Contact Telephone       615-324-2360         Contact Email       acnp@acnp.org         Sponsor Website       Link to sponsor website         Program URL       Link to program URL         Deadline Dates (ALL)       20-Jun-2024         The ACNP Media Award was established to recognize major contributions to the education of the public about me illness and substance abuse research and the positive impact of research on treatment. The Media Award consists an expense paid trip to the ACNP Annual Meeting and a plaque to be presented at the Annual Meeting.         Applicant Types       0.00 see detail         Limited Submission       No	093017				Neuropsychopharn	nacology	20-Juli-2024	Not specified
Contact Telephone       615-324-2360         Contact Email       acnp@acnp.org         Sponsor Website       Link to sponsor website         Program URL       Link to program URL         Deadline Dates (ALL)       20-Jun-2024         Synopsis       The ACNP Media Award was established to recognize major contributions to the education of the public about me illness and substance abuse research and the positive impact of research on treatment. The Media Award consists an expense paid trip to the ACNP Annual Meeting and a plaque to be presented at the Annual Meeting.         Applicant Types       0.00 see detail         Limited Submission       No		Contact Name						
Contact Email       acnp@acnp.org         Sponsor Website       Link to sponsor website         Program URL       Link to program URL         Deadline Dates (ALL)       20-Jun-2024         The ACNP Media Award was established to recognize major contributions to the education of the public about me illness and substance abuse research and the positive impact of research on treatment. The Media Award consists an expense paid trip to the ACNP Annual Meeting and a plaque to be presented at the Annual Meeting.         Applicant Types       0.00 see detail         Limited Submission       No		Contact Telephone	615-324-2360					
Sponsor Website       Link to sponsor website         Program URL       Link to program URL         Deadline Dates (ALL)       20-Jun-2024         The ACNP Media Award was established to recognize major contributions to the education of the public about me illness and substance abuse research and the positive impact of research on treatment. The Media Award consists an expense paid trip to the ACNP Annual Meeting and a plaque to be presented at the Annual Meeting.         Applicant Types       0.00 see detail         Limited Submission       No		Contact Email	acnp@acnp.org					
Program URL       Link to program URL         Deadline Dates (ALL)       20-Jun-2024         The ACNP Media Award was established to recognize major contributions to the education of the public about me synopsis illness and substance abuse research and the positive impact of research on treatment. The Media Award consists an expense paid trip to the ACNP Annual Meeting and a plaque to be presented at the Annual Meeting.         Applicant Types       Funding Limit         Limited Submission       No		Sponsor Website	Link to sponsor	<u>website</u>				
Deadline Dates (ALL)       20-Jun-2024         The ACNP Media Award was established to recognize major contributions to the education of the public about me illness and substance abuse research and the positive impact of research on treatment. The Media Award consists an expense paid trip to the ACNP Annual Meeting and a plaque to be presented at the Annual Meeting.         Applicant Types       Funding Limit         Limited Submission       No		Program URL	Link to program	URL				
Synopsis       The ACNP Media Award was established to recognize major contributions to the education of the public about me illness and substance abuse research and the positive impact of research on treatment. The Media Award consists an expense paid trip to the ACNP Annual Meeting and a plaque to be presented at the Annual Meeting.         Applicant Types       Funding Limit         Limited Submission       No		Deadline Dates (ALL)	20-Jun-2024					
Synopsis illness and substance abuse research and the positive impact of research on treatment. The Media Award consists an expense paid trip to the ACNP Annual Meeting and a plaque to be presented at the Annual Meeting. Applicant Types Funding Limit Limited Submission No Elizabeth Barrett-Connor Research Award for Young			The ACNP Medi	a Award was estab	lished to recognize i	major contributions to the	education of the p	ublic about mental
an expense paid trip to the ACNP Annual Meeting and a plaque to be presented at the Annual Meeting. Applicant Types Funding Limit Limited Submission No Elizabeth Barrett-Connor Research Award for Young		Synopsis	illness and subs	tance abuse resear	ch and the positive	impact of research on trea	tment. The Media	Award consists of
Applicant Types Funding Limit 0.00 see detail Limited Submission No Elizabeth Barrett-Connor Research Award for Young			an expense paid	trip to the ACNP /	Annual Meeting and	a plaque to be presented	at the Annual Meet	ting.
Funding Limit 0.00 see detail Limited Submission No Elizabeth Barrett-Connor Research Award for Young		Applicant Types						
Limited Submission No		Funding Limit	0.00 see detail					
Elizabeth Barrett-Connor Research Award for Young		Limited Submission	No					
023798 American Heart Association 06-lun-2024 1 000 US	023798	Elizabeth Barrett-Connor Rese	earch Award for	Young	American Heart As	sociation	06-lun-2024	
Investigators		Investigators			American ricart As	5001011	00 Jun 2024	1,000 000



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Contact Name						
	Contact Telephone	800-242-8721					
	Contact Email	council.awards(	heart.org				
	Sponsor Website	Link to sponsor	website				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	06-Jun-2024 , 10	)-Jun-2024				
	Synopsis	The Elizabeth Ba excellence in re careers broadly clinical problem	arrett-Connor Researc search by early career related to cardiovasco s.	h Award in Epide investigators and ular function and	miology and Prevention for d trainees and encourages diseases, including basic s	or Investigators in T continued biomed cience, integrated p	raining recognizes ical research physiology, and
	Applicant Types						
	Funding Limit	1,000.00 see de	tail				
	Limited Submission	No					
023802	Melvin Judkins Young Clinical	Investigator Awa	rd Ar	nerican Heart Ass	sociation	06-Jun-2024	1,000 USD
	Contact Name						
	Contact Telephone	214-570-5978					
	Contact Email	council.awards(	heart.org				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	06-Jun-2024 , 10	)-Jun-2024				
	Synopsis	The Melvin Judk and promotes c	ins Young Clinical Inve areers in cardiovascul	estigator Award r ar radiology.	ecognizes meritorious res	earch from early ca	reer investigators
	Applicant Types						



SPIN ID	Program Title	Sponsor Nam	e	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	1,000.00 see detail				
	Limited Submission	Yes				
023809	Vivien Thomas Young Investig	ator Award	American Heart As	sociation	06-Jun-2024	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	council.awards@heart.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	06-Jun-2024 <i>,</i> 10-Jun-2024				
	Synopsis	The Vivien Thomas Early Care members of the Council on Ca applied surgical research.	er Investigator Award ac ardiovascular Surgery and	knowledges the accomplis d Anesthesia (CVSA) who a	hments of early can re focusing on func	reer investigator Jamental and
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	Yes				
079306	Lifestyle and Cardiometabolic Award	Health Early Career Investigato	or American Heart As	sociation	31-May-2024	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	council.awards@heart.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	31-May-2024 , 0	)6-Jun-2024 , 10-Ju	un-2024			
	Synopsis	The Council on L career investiga also encourages develop and ma	Lifestyle and Cardi tor and trainee co young scientists t intain productive	ometabolic Health E uncil members for th o become involved i careers.	arly Career Investigator Aw heir achievements and thei in the Council on Lifestyle a	vard recognizes and ir continuing resear and Cardiometaboli	l awards early ch. The award c Health and to
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	Yes					
080457	Award for Outstanding Doctor Physics	ral Thesis Researd	<u>ch in Biological</u>	American Physical	Society	03-Jun-2024	Not Specified
	Contact Name						
	Contact Telephone						
	Contact Email	honors@aps.org	g				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	03-Jun-2024					
The Award for Outstanding Doctoral Thesis Research in Biological Physics recognizes doctoral thesis rese Synopsis outstanding quality and achievement in any area of experimental, computational, engineering, or theore Biological Physics, broadly construed, and to encourage effective written and oral presentation of resea						research of neoretical esearch results.	
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	Yes					



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
035693	ASRM/NIH/Duke Clinical Rese Training (CREST) Program	arch/Reproductive Scientist	American Society for Reproductive Medicine (ASRM)	15-Jun-2024	Not Specified			
	Contact Name							
	Contact Telephone	202-863-4985						
	Contact Email	Nicole.Goetz@cuanschutz.edu						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL) 15-Jun-2024							
	Synopsis	The CREST training program is off University, and ASRM. This 2-year practice to obtain formalized acad in reproductive medicine.	ered by the NICHD, the Clinical Research Trainin program meets an existing need for physicians demic training in the quantitative and methodo	ng Program (CRTP) s in private or acado logical principles o	at Duke emic clinical f clinical research			
	Applicant Types							
	Funding Limit	0.00 not provided						
	Limited Submission	No						
065121	Research Grants		American Society of PeriAnesthesia Nurses	15-Jun-2024	10,000 USD			
	Contact Name	Amy Berardinelli, ASPAN Director	for Clinical Inquiry					
	Contact Telephone	877-737-9696						
	Contact Email	aberardinelli@aspan.org						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	15-Jun-2024						



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
		The Nursing Read (ASPAN) memb	search Grants Program is de ers seeking to conduct resea	signed to support active American Sc irch that contributes to the advancer	ociety of PeriAnesth nent of perianesthe	esia Nurses esia nursing		
	Synopsis	and recomment An experienced	nd recommendations, as well as financial support. A beginning nurse researcher can expect between \$500-\$5,000. In experienced nurse researcher can expect between \$3,000-\$10,000.					
	Applicant Types							
	Funding Limit	10,000.00 maxi	mum					
	Limited Submission	No						
011252	Fellowship Research Awards		America	n Surgical Association Foundation	15-Jun-2024	75,000 USD		
	Contact Name							
	Contact Telephone	978-927-8330						
	Contact Email							
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	<u>I URL</u>					
	Deadline Dates (ALL)	15-Jun-2024						
	Synopsis	The purpose of the American Surgical Association Foundation Fellowship is to support and encourage gifted young surgeons who choose careers in investigation and academic surgery. Fellows will be supported in an initial year; the Fellowship can be renewed by review of the Fellowship Committee for a succeeding one-year period. During the Fellowship years, the Awardee should have a primary role in research and teaching. It is expected that the Fellow wi have a faculty position following the Fellowship in the Department of Surgery of the sponsoring institution.						
	Applicant Types							
	Funding Limit	75,000.00 per y	ear					
	Limited Submission	No						
116899	APSR Multi-Society Research I	Project	Asian Pa	cific Society of Respirology	30-Jun-2024	100,000 USD		



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Contact Name						
	Contact Telephone	+81-3-5684-337	70				
	Contact Email	research@thea	psr.org				
	Sponsor Website	Link to sponsor	website				
	Program URL	Link to program	<u>I URL</u>				
	Deadline Dates (ALL)	30-Jun-2024					
	Synopsis	The Asian Pacifi US\$100,000 for	c Society of Respire	ology (APSR) annual years.	ly offers one Multi-Society	Research Project g	rant of up to
	Applicant Types						
	Funding Limit	50,000.00 per y	ear				
	Limited Submission	No					
015721	Broadley Scholarship			Association for Me (AHRA)	dical Imaging Managemen	t 18-Jun-2024	2,500 USD
	Contact Name						
	Contact Telephone	978-235-5594					
	Contact Email	memberservice	<u>s@ahra.org</u>				
	Sponsor Website	Link to sponsor	website				
	Program URL	Link to program	<u>I URL</u>				
	Deadline Dates (ALL)	18-Jun-2024					
	Synopsis	This program preducation. The	rovides scholarship AHRA Education Fo	support to imaging oundation awards up	administrators seeking to to two Broadley Scholars	enhance their caree hips yearly at \$2,50	ers through formal 0 each.
	Applicant Types						
	Funding Limit	2,500.00 maxim	ıum				



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	Νο				
116615	Collaborative ARN and Agnes Research Grant	Marshall Walker Foundation	Association of Reh	abilitation Nurses	01-Jun-2024	10,000 USD
	Contact Name					
	Contact Telephone	847-375-6356				
	Contact Email	info@rehabnurse.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2024				
	Synopsis	The Association of Rehabilitation Walker Foundation (AMWF) requised science and practice of neuroscie	n Nurses (ARN) Advan uests applications for ence rehabilitation nu	cing Science and Practice C grant support for research rsing. Grants may be up to	ommittee and the a studies that aim to \$10,000.	Agnes Marshall advance the
	Applicant Types					
	Funding Limit	10,000.00 maximum				
	Limited Submission	No				
018455	Sir Harcourt Caughey Award		Auckland Medical	Research Foundation	26-Jun-2024	15,000 USD
	Contact Name	Research Programme Manager				
	Contact Telephone	+64 9 923 1701				
	Contact Email	amrf@medicalresearch.org.nz				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	26-Jun-2024				



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Synonsis	The Auckland M Zealanders. The	1edical Research Fo Poundation aim to	oundation's (AMRF) v o achieve this by pro	vision is to improve the heaving genuine advances ir	alth and quality of I 1 health, science an	ife for all New d medicine
		through fundinរ្ up to \$25,0000	g the highest qualit are offered in thre	y medical research c e categories.	of all kinds. As a part of this	s, the Sir Harcourt C	aughey Awards of
	Applicant Types						
	Funding Limit	25,000.00 maxi	mum				
	Limited Submission	NO					
089931	PhD Fellowships			Boehringer Ingelhe	im Fonds	01-Jun-2024	Not Specified
	Contact Name	2					
	Contact Telephone	+49 (0)6131 275	50 80				
	Contact Email	<u>secretariat@bif</u>	onds.de				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	<u>URL</u>				
	Deadline Dates (ALL)	01-Jun-2024 , 0	1-Oct-2024				
	Synopsis	The Boehringer worldwide who laboratory.	Ingelheim Fonds ( wish to pursue an	BIF) awards PhD fello ambitious PhD proje	owships of 2 to 3.5 years to ect in basic biomedical rese	o outstanding junio earch in an internat	scientists ionally leading
	Applicant Types	5					
	Funding Limit	0.00 see detail					
	Limited Submission	No					
098358	Catalyst Award			Citizens United for Epilepsy)	Research in Epilepsy (CURI	E 11-Jun-2024 [LOI/Pre-App]	250,000 USD
	Contact Name	2					



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount			
	Contact Telephone	312-255-1801								
	Contact Email	research@cure	epilepsy.org							
	Sponsor Website	Link to sponsor	<u>website</u>							
	Program URL	Link to program	<u>URL</u>							
	Deadline Dates (ALL)	11-Jun-2024 [L0	DI/Pre-App], 28-Au	g-2024						
	Synopsis	CURE Epilepsy f opportunity is t moving promisi made for up to	RE Epilepsy funds research that has the potential to truly transform and save lives. The purpose of this funding portunity is to stimulate and accelerate discovery and development of new, transformative therapies for epilepsy, aving promising, well-supported preclinical and/or clinical research closer to clinical application. Requests may be de for up to a total of \$250,000 paid over 2 years.							
	Applicant Types									
	Funding Limit	nit 250,000.00 maximum								
	Limited Submission	No								
071029	Evert Clark/Seth Payne Award	for Young Scien	<u>ce Journalists</u>	Council for the Adv Writing	ancement of Science	30-Jun-2024	1,000 USD			
	Contact Name	Laura Dattaro								
	Contact Telephone									
	Contact Email	ldattaro@casw.	org							
	Sponsor Website	Link to sponsor	<u>website</u>							
	Program URL	Link to program	<u>URL</u>							
	Deadline Dates (ALL)	30-Jun-2024								
	Synopsis	The Evert Clark, recognizing out expenses to att	/Seth Payne Award standing reporting end the ScienceWr	for Young Science Je and writing in any fi iters2024 conferenc	ournalists is intended to en ield of science. The 2024 w se to receive the award.	ncourage young sci vinner will receive \$	ence writers by 1,000 and			
	Applicant Types									



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
	Funding Limit	1,000.00 see detail						
	Limited Submission	No						
022157	Victor Cohn Prize for Excellen	ce in Medical Science Reporting	Council for the Advancement of Science Writing	30-Jun-2024	5,000 USD			
	Contact Name	Laura Dattaro						
	Contact Telephone	206-880-0177						
	Contact Email	ldattaro@casw.org						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	line Dates (ALL) 30-Jun-2024						
	Synopsis	The Victor Cohn Prize for Excellence in Medical Science Reporting is given annually, and seeks to honor a velocity of work published or broadcast within the last five years which, for reasons of uncommon clarity, access breadth of coverage, enterprise, originality, insight and narrative power, has made a profound and lasting contribution to public awareness and understanding of critical advances in medical science and their impact burgen boalth and well being.						
	Applicant Types							
	Funding Limit	5,000.00 see detail						
	Limited Submission	No						
002586	Grants Program		Cure Parkinsons Trust	08-Apr-2024	315,000 USD			
	Contact Name	Rosie Fuest, Research Manager						
	Contact Telephone	0207 487 3892						
	Contact Email	Rosie@cureparkinsons.org.uk						
	Sponsor Website	Link to sponsor website						



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	24-Jun-2024 , 2	1-Oct-2024					
	Synopsis	This programm Parkinson's. For likely to lead to trials and sub-st	is programme primarily funds preclinical and clinical research focused on slowing, stopping, or reversing rkinson's. For preclinical research, the sponsor funds grants up to £250,000 (GBP) and prioritise projects that are ely to lead to clinical trials in people with Parkinson's within 5 years. For clinical research, the sponsor funds clinical als and sub-studies of trials in people with Parkinson's.					
	Applicant Types							
	Funding Limit	250,000.00 see	detail					
	Limited Submission	No						
074665	Clinical Research Scholars Pro	gram Award	Cystic	Fibrosis Foundation	12-Jun-2024	Not Specified		
	Contact Name	Elizabeth Yu						
	Contact Telephone	301-841-2614						
	Contact Email	<u>eyu@cff.org</u>						
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	<u>I URL</u>					
	Deadline Dates (ALL)	12-Jun-2024						
	Synopsis	ynopsis verse studies. The Cystic Fibrosis Clinical Research Scholars Program (CRSP) Award is designed to enable promising early-career physician scientists to enhance their clinical research proficiency and support their development of the necessary clinical research capabilities to become independent investigators who formulate and lead multi-center, clinical research studies.						
	Applicant Types							
	Funding Limit	0.00 see detail						
	Limited Submission	No						



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
052754	lan McHarg Medal	Europea	in Geosciences Union	15-Jun-2024	Not Specified			
	Contact Name							
	Contact Telephone	+49-89-2050-76300						
	Contact Email	awards-medals@egu.eu						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	15-Jun-2024						
	Synopsis	The Ian McHarg Medal is reserved for distir sciences. The award consists of a medal.	guished research in information tecl	hnology applied to	Earth and space			
	Applicant Types							
	Funding Limit	0.00 see detail						
	Limited Submission	No						
006925	Study Visit Grants	Experim	ental Psychology Society	01-Jun-2024	4,536 USD			
	Contact Name							
	Contact Telephone							
	Contact Email	expsychsoc@kent.ac.uk						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	01-Jun-2024 , 01-Sep-2024 , 01-Dec-2024						
	The Experimental Psychology Society (EPS) offers Study Visits Grants with the aim of helping finance postgradua Synopsis and postdoctoral research in experimental psychology (as defined by the content of The Quarterly Journal of Experimental Psychology). Awards will pay for travel to and accommodation at another institution outside an							



SPIN ID	Program Title	Sponsor Nan	ne	Sponsor Number	Deadline Date	Funding Amount	
		individual's academic base. E in the UK.	ither the researcher's ho	me institution or the instit	ution to be visited,	or both, must be	
	Applicant Types						
	Funding Limit	3,600.00 see detail					
	Limited Submission	No					
014105	H. Thomas Austern Writing Co	mpetition	Food and Drug Law	r Institute	03-Jun-2024	Not Specified	
	Contact Name						
	Contact Telephone	202-371-1420					
	Contact Email	info@fdli.org					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	03-Jun-2024					
	Synopsis	Synopsis Synopsis The H. Thomas Austern Writing Competition is intended to encourage law students interested in the area affecting FDA-regulated industries: food, drugs, medical devices, biologics, dietary supplements, cosmetic veterinary, cannabis, or tobacco and nicotine products. Winners are awarded: \$750 for first place, \$500 for and \$250 for third. Top papers will be considered for publication in the Food and Drug Law Journal.					
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	No					
089587	Research Grant Program		Foundation for Icht	hyosis & Related Skin Type	es [LOI/Pre-App]	50,000 USD	
	Contact Name	Christine Wassel, Community	Engagement Director				

Contact Telephone 215-997-9400



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Contact Email	cwassel@firstsl	kinfoundation.org				
	Sponsor Website	Link to sponsor	website				
	Program URL	Link to program	<u>1 URL</u>				
	Deadline Dates (ALL)	14-Apr-2024 [L	OI/Pre-App], 16-Jun-2024				
	Synopsis	Foundation for investigation in	Ichthyosis & Related Skin Types (FIRST) to the causes, treatments, and potentia	) offers a research grants to al cures for ichthyosis.	o promote and stre	ngthen	
	Applicant Types						
	Funding Limit	50,000.00 see c	letail				
	Limited Submission	No					
123800	GenScript Life Science Researc	ch Grant Prograr	n GenScript Biotech	Corporation	15-Jun-2024	100,000 USD	
	Contact Name						
	Contact Telephone						
	Contact Email	LSRgrant@gens	script.com				
	Sponsor Website	Link to sponsor	website				
	Program URL	Link to program	<u>1 URL</u>				
	Deadline Dates (ALL)	15-Jun-2024 , 1	5-Sep-2024 , 15-Nov-2024				
	Synopsis	This research grant is an initiative dedicated to supporting breakthroughs in life science research areas including but not limited to gene and cell therapy development, antibody drug discovery, vaccine development, diagnostics, and plant sciences. This program is designed to empower researchers by providing grant funding specifically earmarked for purchasing GenScript reagents and services.					
	Applicant Types						
	Funding Limit	100,000.00 max	kimum				
	Limited Submission	Yes					



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount			
032594	Harrington Scholar-Innovators		Hai	rrington Discove	ry Institute	05-Jun-2024	Not Specified			
	Contact Name									
	Contact Telephone	216-983-3472								
	Contact Email	Questions@Har	ringtonDiscovery.org							
	Sponsor Website	Link to sponsor	<u>website</u>							
	Program URL	Link to program	URL							
	Deadline Dates (ALL)	05-Jun-2024								
	Synopsis	The Harrington Scholar-Innovator Award is issuing a call for proposals for the flagship Harrington Scholar program to recognize physician-scientists whose research has the potential to advance the standard of program provides dedicated support from a project management team and pharmaceutical industry as funding of \$100,000 for 2 years.								
	Applicant Types									
	Funding Limit	0.00 see detail	D.00 see detail							
	Limited Submission	No								
092434	UJA - Federation Selim and Ra	chel Benin Schol	arship He	brew Free Loan S	Society	02-Jun-2024	Not Specified			
	Contact Name									
	Contact Telephone	212-687-0188								
	Contact Email	scholarship@hf	ls.org							
	Sponsor Website	Link to sponsor	<u>website</u>							
	Program URL	Link to program	URL							
	Deadline Dates (ALL)	02-Jun-2024								
	Synopsis	The UJA - Feder students studyi	ation Selim and Rachel ng in certain STEM field	Benin Scholarsh ds.	ips are provided to except	ional Israeli Jewish:	graduate			



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	No					
117549	Transformative Research Awa	rd Program		Hereditary Disease	e Foundation	14-Jun-2024	1,000,000 USD
	Contact Name						
	Contact Telephone	212-928-2121					
	Contact Email	cures@hdfound	lation.org				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	14-Jun-2024					
	Synopsis	The HDF Transfo available to adv or create or imp advancement o	ormative Research ance transformatic plement tools and t f therapeutics.	Award program dev onal collaborative pr cechnologies not pre	veloped by the Hereditary rojects that will provide ne eviously applied to Hunting	Disease Foundatior w insights into dise ton's disease (HD)	will make funds ase mechanisms research for the
	Applicant Types						
	Funding Limit	500,000.00 per	year				
	Limited Submission	No					
070207	Michelson Prizes			Human Immunome	e Project	09-Jun-2024	150,000 USD
	Contact Name						
	Contact Telephone						
	Contact Email	michelsonprizes	ehumanimmunoi	meproject.org			
	Sponsor Website	Link to sponsor	<u>website</u>				
070207	Synopsis Applicant Types Funding Limit Limited Submission <u>Michelson Prizes</u> Contact Name Contact Telephone Contact Email Sponsor Website	michelsonprizes	s@humanimmunoi	Human Immunome	e Project	w insignts into dise ton's disease (HD) 09-Jun-2024	ase mechanis research for f



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Program URL	Link to program	<u>n URL</u>				
	Deadline Dates (ALL)	09-Jun-2024					
	Synopsis	The Michelson applications for grants to early- major global dis	Medical Research F • the 2024 Michelso career scientists ad seases.	oundation (MMRF) n Prizes: Next Gene vancing human imr	and the Human Immunom eration Grants. The annual nunology, vaccine discover	ne Project (HIP) are prizes award \$150, y, and immunothe	accepting 000 research rapy research for
	Applicant Types						
	Funding Limit	150,000.00 max	ximum				
	Limited Submission	No					
010629	IEEE Medal for Innovations in	Healthcare Tech	inology	Institute of Electric (IEEE)	cal and Electronics Enginee	rs 15-Jun-2024	Not Specified
	Contact Name						
	Contact Telephone	732-562-3844					
	Contact Email	awards@ieee.o	org				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	<u>n URL</u>				
	Deadline Dates (ALL)	15-Jun-2024 , 0	1-Jul-2024				
Synopsis The IEEE Medal for Innovations in Healthcare Technology is presented for exceptional contributions to techn and applications benefiting healthcare, medicine, and the health sciences. In the evaluation process, the foll criteria are considered: impact on the profession and/or society; succession of significant technical or other contributions; leadership in accomplishing worthwhile goal(s); previous honors; other achievements as evid publications or patents or other evidence; and quality of nomination. The award consists of a bronze medal, certificate, and cash honorarium.							s to technologies s, the following or other :s as evidenced by ze medal,
	Applicant Types						



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Funding Limit Limited Submission	0.00 see detail No				
125035	Bronchoscopy Research Grant		Intuitive Foundation	on	07-Jun-2024 [LOI/Pre-App]	75,000 USD
	Contact Name Contact Telephone					
	Contact Email Sponsor Website	grants@intuitive-foundation.org Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jun-2024 [LOI/Pre-App], 30-A	ug-2024			
	Synopsis	The Intuitive Foundation grant p of robotic-assisted bronchoscopy research at non-profit institution care of patients with pulmonary robotic-assisted bronchoscopy d \$75,000 (US) per project.	rogram is accepting a v on clinical care in 20 s worldwide focused disease. Successful p isease and patient ou	applications for Clinical Reso D24-2025. The purpose of t on the effect of robotic-as proposals will study importa itcomes. Applicants may ap	earch Grants for rel hese grants is to sup sisted bronchoscop ant questions relate oply for grant fundir	ated to the impact oport clinical y in the clinical ed to the impacts ng total costs up to
	Applicant Types					
	Funding Limit	75,000.00 maximum				
	Limited Submission	No				
125066	Training and Human Performa	nce Research Grants	Intuitive Foundation	on	07-Jun-2024 [LOI/Pre-App]	75,000 USD
	Contact Name Contact Telephone					



SPIN ID	Program Title	Spo	onsor Name		Sponsor Number	Deadline Date	Funding Amount
	Contact Email	grants@intuitive-fc	undation.org				
	Sponsor Website	Link to sponsor wel	<u>osite</u>				
	Program URL	Link to program UR	L				
	Deadline Dates (ALL)	07-Jun-2024 [LOI/P	re-App], 30-Au	g-2024			
	Synopsis	The Intuitive Found and Human Perforr to support training address important preserving patient costs up to \$75,000	ation grant pro nance Researcl and human pe questions abou safety, and ma (US) per grant	ogram is active and i h Grants for Robotic rformance research it assessing intraope intaining skill proficie	s accepting applications fo -assisted Surgery in 2024-2 in the field of robotic-assis rative performance, accele ency of surgical team mem	r grant funding to s 2025. The purpose c ted surgery. Succes erating skill acquisit bers. Applicants ma	upport Training of these grants is soful proposals will ion while ay apply for total
Applicant Types							
	Funding Limit	75,000.00 maximur	n				
	Limited Submission	No					
066688	Clinical Research Grants for Ro	obotic-Assisted Surg	ery	Intuitive Foundatic	on	07-Jun-2024 [LOI/Pre-App]	75,000 USD
	Contact Name						
	Contact Telephone						
	Contact Email	grants@intuitive-fo	undation.org				
	Sponsor Website	Link to sponsor wel	<u>osite</u>				
	Program URL	Link to program UR	L				
	Deadline Dates (ALL)	07-Jun-2024 [LOI/P	re-App], 30-Au	g-2024			
	Synopsis	The Intuitive Found focused on the field surgical care and pa	ation's Clinical I of robotic-ass itient outcome	Research Grants su isted surgery. Succe s. Applicants may a	oport clinical research at n ssful proposals will study in pply for grant funding tota	on-profit institutior mportant questions l costs up to \$75,00	ns worldwide 5 related to 90 (US) per project.



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Applicant Types					
	Funding Limit	75,000.00 maximum				
	Limited Submission	No				
000221	Postdoctoral Fellowships for F	Research in Japan (Short-term)	Japan Society for th	ne Promotion of Science	07-Jun-2024	Not Specified
	Contact Name					
	Contact Telephone	+81-3-3263-3810				
	Contact Email	postdoc-short@jsps.go.jp				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jun-2024				
	Synopsis	The Japan Society for the Promot Japan in all fields of the humaniti Europe may conduct cooperative universities and other Japanese i	tion of Science (JSPS) es, social sciences and research under the g nstitutions.	offers short-term Postdoc d natural sciences. Resear guidance of their hosts wit	toral Fellowships fo chers from the US, h leading research	r Research in Canada and groups in
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
016198	Grants Program		Johnson Controls F	oundation	01-Jun-2024	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email					
	Sponsor Website	Link to sponsor website				



SPIN ID	Program Title	Sponsor Name	Sp	oonsor Number	Deadline Date	Funding Amount
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2024				
	Synopsis	The Johnson Controls Foundation makes cl where Johnson Controls has a presence. Th purposes which include the distribution an organizations or causes which are fundame United States that operate not for profit an institutions.	haritable contri ne Foundation i Id application o entally philanth nd are recognize	ibutions to nonprofit or is organized and directe of financial support to so nropic. The Foundation zed by the Internal Reve	ganizations, prima ed to be operated f bundly managed ar contributes to orga nue Service as tax-	rily in communities or charitable nd operated anizations in the exempt
	Applicant Types					
	Funding Limit	0.00 not provided				
	Limited Submission	No				
036282	LEO Foundation Awards	LEO Fo	undation		27-Jun-2024	100,000 USD
	Contact Name					
	Contact Telephone	+ 45 32 72 51 10				
	Contact Email	applications@leo-foundation.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	27-Jun-2024				
The LEO Foundation Awards constitute global recognitions of individual scientists who represents excellence an advance our understanding of skin and skin diseases. Regional awards of USD 100,000 each are given annually t outstanding young scientists within regions Americas, EMEA and Asia-Pacific, whose work represent extraordina contributions to dermatology research.						xcellence and en annually to t extraordinary
	Applicant Types					
	Funding Limit	100,000.00 maximum				



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No				
109989	Minority Career Development	: Award (CDA) in Lung Cancer	Lung Cancer Resea	rch Foundation	10-Jun-2024	150,000 USD
	Contact Name					
	Contact Telephone	+1-212-588-1580				
	Contact Email	grants@lcrf.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	10-Jun-2024				
	Synopsis	The Minority Career Development Postdoctoral/Clinical Fellows and degrees. This program aims to close by funding minority researchers w	Award (CDA) in Lun Assistant Professors se the gap between t ith \$150,000 over a	g Cancer provides protector within 10 years of comple the mortality rates and rep period of two years.	ed time and mento ting their MD traini presentation in lung	ring to minority ng and/or PhD g cancer research
	Applicant Types					
	Funding Limit	75,000.00 per year				
	Limited Submission	No				
118890	Leading Edge Research Grant	Program	Lung Cancer Resea	rch Foundation	10-Jun-2024	150,000 USD
	Contact Name					
	Contact Telephone	+1-212-588-1580				
	Contact Email	grants@lcrf.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	10-Jun-2024				



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
		The Lung Cance	r Research Founda	ation (LCRF) Leading I	Edge Research Grant Prog	ram will fund innov	ative projects	
	Synopsis	across the full sp and social deter	pectrum of basic, i minants of bealth	translational, clinical,	, epidemiological, health s	ervices, early detec	tion, disparities,	
	Applicant Types		initiants of health	research.				
	Funding Limit	150.000.00 max	imum					
	Limited Submission	No						
123721	Research Grants on Understa	nding Resistance	in Lung Cancer	Lung Cancer Resear	rch Foundation	10-Jun-2024	150,000 USD	
	Contact Name							
	Contact Telephone	+1-212-588-158	0					
	Contact Email	grants@lcrf.org						
	Sponsor Website	Link to sponsor	ink to sponsor website					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	10-Jun-2024						
	Synopsis	The Lung Cancer Research Foundation (LCRF) Research Grants on Understanding Resistance in Lung Cancer focuse on understanding the development, prevention, and therapy of resistance by supporting research projects that ar identifying, characterizing, treating, or preventing resistance to therapies in lung tumor cells, tissues, mouse mode and/or patients. These awards provide a maximum of \$150,000 in funding over a period of two years to post-doct researchers, clinical fellows, or investigators with less than 10 years of experience since their initial faculty appointment.						
	Applicant Types							
	Funding Limit	150,000.00 max	imum					
	Limited Submission	No						
109988	Research Grant on Early Deter Cancer	ction and Pre-Ne	oplasia in Lung	Lung Cancer Resear	rch Foundation	10-Jun-2024	150,000 USD	



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Contact Name						
	Contact Telephone	212-588-1580					
	Contact Email	grants@lcrf.org	L				
	Sponsor Website	Link to sponsor	website				
	Program URL	Link to program	<u>ı URL</u>				
	Deadline Dates (ALL)	10-Jun-2024					
	Synopsis	LCRF is offering characterization mechanism add	this funding mechanis n of pre-neoplasia or a dresses important ques	m to support res pproaches for ea tions in non-sma	search projects that facilita Irly detection of lung cance all cell and small cell lung c	te or advance the er. Work supported ancer.	understanding and I through this
	Applicant Types						
	Funding Limit	75,000.00 per y	ear				
	Limited Submission	No					
108503	Grant Program		Ma	athers (G.Harold	and Leila Y.) Foundation	07-Jun-2024	Not Specified
	Contact Name						
	Contact Telephone						
	Contact Email	grants@mathe	rsfoundation.org				
	Sponsor Website	Link to sponsor	website				
	Program URL	Link to program	<u>I URL</u>				
	Deadline Dates (ALL)	07-Jun-2024 , 2	0-Sep-2024 , 04-Oct-20	024 [LOI/Pre-App	), 06-Dec-2024		
	Synopsis	The G. Harold a scientific resear central to this g	nd Leila Y. Mathers Fo rch that will benefit ma goal, and fundamental f	undation's mission nkind. Basic scie to the Foundatio	on is to advance knowledg ntific research, with poten n's operating principles.	e in the life science tial translational a	s by sponsoring pplication, is
	Applicant Types						



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	0.00 not provided				
	Limited Submission	Yes				
022414	Fellowship Program		Matsumae Interna	tional Foundation	30-Jun-2024	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	application@mif-japan.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	30-Jun-2024				
	Synopsis	The Matsumae International Fou who possess excellent academic research activities in Japan, ther friendship and goodwill. Fields o	undation offers fellow ability, regardless of eby contributing to ac f research such as nat	ships of six months in dura race, sex, religion, or ideolo cademic development in Ja cural science, engineering,	ition to provide ove ogy, with opportun pan as well as inter and medicine are g	erseas researchers ities to carry out mational iven first priority.
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
013058	<u>Neurology - Clinical Neurophy</u> <u>Fellowship - (Florida)</u>	siology, Electromyography	Mayo Clinic Colleg	e of Medicine and Science	01-Jun-2024	Not Specified
	Contact Name	Devon Rubin, M.D., Program Dir	ector			
	Contact Telephone	904-953-0110				
	Contact Email	rubin.devon@mayo.edu				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	01-Jun-2024 The Clinical Neu the ACGME. The be eligible to ta of Psychiatry an electromyograp including single disorders	irophysiology Prog ose fellows who m ke the Subspecialt Id Neurology. This Iny laboratory in a fiber EMG, nerve	ram at Mayo Clinic in eet the requirement y Certification Exami one-year fellowship n academic center or conduction techniqu	n Jacksonville has been acc s, including a broad experi nation in Clinical Neuroph program will prepare fello r integrated group practice es, evoked potentials, surg	credited as a one-ye ence in clinical neu ysiology given by th ws to establish and e. Training emphasis gical monitoring and	ear fellowship by rophysiology, will te American Board supervise an s is on EMG, d related clinical
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	No					
012311	Gastrointestinal & Hepatobilia Minnesota	ary Pathology Fel	llowship -	Mayo Clinic College	e of Medicine and Science	30-Jun-2024	Not Specified
	Contact Name	Courtney Schra	ufnagel, Education	Coordinator			
	Contact Telephone	507-422-6123					
	Contact Email	schraufnagel.co	urtney@mayo.edu	<u>1</u>			
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	30-Jun-2024					
The one-year Gastrointestinal and Hepatobiliary Pathology Fellowship at Mayo Clinic in Rochester, Minnesota, Synopsis exposure to a broad spectrum of biopsy material and surgical specimens relating to gastrointestinal and hepato disease.						Vinnesota, offers and hepatobiliary	
	Applicant Types						
	Funding Limit	0.00 see detail					


SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount			
	Limited Submission	No							
013262	Minimally Invasive Gynecolog	ic Surgery Fellowship (Arizona)	Mayo Clinic College	e of Medicine and Science	30-Jun-2024	Not Specified			
	Contact Name	Treene Vito, Education Coordinate	or						
	Contact Telephone	480-574-1194							
	Contact Email	vito.treene@mayo.edu							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	30-Jun-2024							
	Synopsis	wo positions are available on a competitive basis each year in the Minimally Invasive Gynecologic Surgery Fello t Mayo Clinic's campus in Arizona.							
	Applicant Types								
	Funding Limit	0.00 see detail							
	Limited Submission	No							
058805	Investigator Studies Program	(MISP) Anesthesia	Merck		01-Jun-2024	Not Specified			
	Contact Name	Lisa Mount							
	Contact Telephone	267-305-1258							
	Contact Email	lisa_mount@merck.com							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	01-Jun-2024							
	Synopsis	The Investigator Studies Program provision of drug/vaccine and/or	aims to advance scie total/partial funding,	nce and improve patient on high-quality research that	care by supporting, t is initiated, desigr	through the red, implemented			



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit Limited Submission	and sponsored publications. 0.00 not provid No	by external investigators. Resu ed	Its will be generated and proper	ly disseminated in pe	er-reviewed
064085	Lloyd V. Berkner Space Policy	Internships	National A	cademies	03-Jun-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	David H. Smith 202-334-3477 <u>dsmith@nas.ed</u> <u>Link to sponsor</u> <u>Link to program</u> 03-Jun-2024 The goal of the in the area of ci Policy Internshi designed to ass committees and a regular basis.	lu website DURL program is to provide promisir vil space research policy in the ps are offered twice annually. ist with or to enhance ongoing d ad hoc task groups are in con Although this makes it difficult	ng undergraduate and graduate s Nation's capital, under the aegis Interns typically undertake one of study projects. The projects und stant flux, with studies being con to predict just what the interns	students with the opp s of the SSB. The Lloy or more short-term re dertaken by the SSB s mpleted and new stu- will get to work on, it	portunity to work d V. Berkner Space esearch projects tanding dies beginning on t also ensures their
		exposure to the the final publication of the f	e different stages of the study p ation of committee reports - as	process –from project initiation, several studies are being under	through the committ taken simultaneously	ee process, and <sup>,</sup> .
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
002024	Judith Graham Pool Postdocto	oral Research Fel	lowships	National Bleeding D	isorders Foundation	06-May-2024 [LOI/Pre-App]	104,000 USD	
	Contact Name	Samantha Carls	on, LMSW, Directo	or of Research				
	Contact Telephone	212-328-3765						
	Contact Email	scarlson@hemo	ophilia.org					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	06-May-2024 [L	.OI/Pre-App], 03-Ju	un-2024				
	Synopsis	The National He providing suppo	emophilia Foundat ort for basic science	ion (NHF) offers the J e and pre-clinical rese	udith Graham Pool (JGP) I earch in bleeding disorder	Postdoctoral Reseaus.	rch Fellowships,	
	Applicant Types							
	Funding Limit	52,000.00 per y	ear					
	Limited Submission	No						
116579	Grace Wall Barreda Memorial	<u>Scholarship</u>		Native Forward Sch	olars Fund	01-Jun-2024	Not Specified	
	Contact Name							
	Contact Telephone	505-881-4584						
	Contact Email	<u>scholarships@r</u>	ativeforward.org					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	<u>URL</u>					
	Deadline Dates (ALL)	01-Jun-2024						
	Synopsis	s (ALL) 01-Jun-2024 Native Forward Scholars Fund offers the Grace Wall Barreda Scholarship program to provide financial assistance to nopsis eligible American Indian and Alaska Native graduate students pursuing degrees full-time at an accredited institution in Public Health or Environmental Science/Studies. This opportunity is a need-based award.						



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit Limited Submission	0.00 not provided No				
091882	Spinal Cord Injury Research or	n the Translational Spectrum	Neilsen (Craig H.)	Foundation	07-Jun-2024 [LOI/Pre-App]	Not Specified
	Contact Name Contact Telephone	Tracey Wheeler 818-925-1245				
	Contact Email	tracey@chnfoundation.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jun-2024 [LOI/Pre-App], 08-N	Nov-2024			
	Synopsis	The Spinal Cord Injury Research approaches to improving function emphasizes SCI (vs. spinal cord of develop new strategies to restor continuous funding to individual	on the Translational S on and developing cur disease or related disc re function resulting f I labs but to fund nove	Spectrum (SCIRTS) grants Porative therapies after spinal orders) and is intended to fi rom SCI. The Neilsen Found el research throughout the	ortfolio is intended cord injury (SCI). T Il gaps in the field a lation does not inte translational spect	to advance novel his portfolio and to further and to provide rum.
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
082654	Mentored Research Award		Neuroendocrine T	umor Research Foundation	24-Jun-2024	100,000 USD
	Contact Name Contact Telephone Contact Email	617-946-1780 grants@netrf.org				



SPIN ID	Program Title	Spon	sor Name		Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor webs	<u>ite</u>				
	Program URL	Link to program URL					
	Deadline Dates (ALL)	24-Jun-2024					
	Synopsis	The Neuroendocrine investigators to pursu Awards are in the am work requiring two ye	Tumor Resear ue neuroendoo ount of \$100, ears to comple	ch Foundation (NET crine tumor researc 200 over two years ete. They have one	TRF) Mentored Award is de h and make a commitmen . These proposals typically PI with or without collabor	esigned to encourage t to the field. Ment have two aims tha rators.	ge early career cored Research t provide
	Applicant Types						
	Funding Limit	100,000.00 maximum	ı				
	Limited Submission	No					
024601	Resident Research Project Gra	ant		Orthopaedic Resea (OREF)	rch & Education Foundatic	on 08-Apr-2024 [LOI/Pre-App]	5,000 USD
	Contact Name						
	Contact Telephone	847-430-5109					
	Contact Email	grants@oref.org					
	Sponsor Website	Link to sponsor webs	<u>ite</u>				
	Program URL	Link to program URL					
	Deadline Dates (ALL)	20-Jun-2024					
	Synopsis	The Resident Researc	h Project Gran	nt provides up to \$5	5,000 to residents who are	interested in resea	irch.
	Applicant Types						
	Funding Limit	5,000.00 maximum					
	Limited Submission	No					
083547	Collaborative Research Develo	opment Grant		Ovarian Cancer Res	search Alliance	13-Jun-2024	900,000 USD



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount		
	Contact Name	Kristin McGowa	in						
	Contact Telephone	212-268-1002							
	Contact Email	grants@ocraho	pe.org						
	Sponsor Website	Link to sponsor	website						
	Program URL	Link to program	URL						
	Deadline Dates (ALL)	13-Jun-2024							
	Synopsis	Ovarian Cancer Grant (CRDG). 1 gynecologic car between group	varian Cancer Research Alliance is requesting Letters of Intent for the 2025 Collaborative Research Development rant (CRDG). The purpose of this grantmaking program is to provide funds for ovarian cancer and/or related rnecologic cancers research projects that may involve several investigators within one institution or collaboration etween groups in multiple institutions. Interdisciplinary collaborations are encouraged.						
	Applicant Types	es							
	Funding Limit	300,000.00 per	year						
	Limited Submission	No							
078435	Early Career Investigator Gran	<u>t</u>		Ovarian Cancer Re	search Alliance	13-Jun-2024	450,000 USD		
	Contact Name	Kristin McGowa	in						
	Contact Telephone	212-268-1002							
	Contact Email	grants@ocraho	pe.org						
	Sponsor Website	Link to sponsor	website						
	Program URL	Link to program	URL						
	Deadline Dates (ALL)	13-Jun-2024							
	Synopsis	Ovarian Cancer called the Liz Ti	Research Alliance is beris Early Career A	requesting Letters ward). The Early Ca	s of Intent for the 2025 Ear areer Investigator Grant (E	ly Career Investigat CIG) is for junior fa	tor Grant (formerly culty with a strong		



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Applicant Tupos	commitment to a substantial tin	an investigative care ne commitment to re	er in the field of o search and acade	ovarian cancer research. Tl mic endeavors in ovarian	ne intent of these gr cancer.	ants is to support
	Eunding Limit	150 000 00 per	vear				
	Limited Submission	No	year				
124390	Health Equity Research Grant		0	varian Cancer Res	search Alliance	13-Jun-2024	200,000 USD
	Contact Name						
	Contact Telephone	212-268-1002					
	Contact Email	grants@ocraho	oe.org				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	13-Jun-2024					
	Synopsis	Ovarian Cancer Research Alliance (OCRA) is requesting Letters of Intent (LOI) for the 2025 Health Equity Re Grant. The grant will support t research projects that promote equity, inclusivity, and evidence-based appr overcome the barriers faced by marginalized communities with a focus on ovarian cancers and/or related g cancers. The grant will provide \$100,000 per year for two years.					
	Applicant Types						
	Funding Limit	100,000.00 per	year				
	Limited Submission	No					
089498	Emerging Investigator Fellows	hip Grant	Pe	ediatric Cancer Re	esearch Foundation	01-Jun-2024	60,000 USD
	Contact Name						
	Contact Telephone						
	Contact Email	jwilson@pcrf-ki	ds.org				



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	01-Jun-2024						
	Synopsis	Emerging Invest training for eme	tigator Fellowship erging pediatric ca	Grants are designed ncer researchers to	l to support Post-Doctoral I pursue exciting research id	Fellowships and Clir eas.	nical Investigator	
	Applicant Types							
	Funding Limit	60,000.00 per y	ear					
	Limited Submission	No						
089497	Translational Research Grant			Pediatric Cancer R	esearch Foundation	01-Jun-2024	200,000 USD	
	Contact Name							
	Contact Telephone							
	Contact Email	jwilson@pcrf-ki	ds.org					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	<u>I URL</u>					
	Deadline Dates (ALL)	01-Jun-2024						
	Synopsis	Translational Re trials or consort whose endpoin years.	anslational Research Grants are given to single or multi-institutional programs that involve open, cancer clinical fals or consortia, and implement new approaches to therapy. These grants support "bench to bedside" research, hose endpoint is often the planning or initiation of a clinical trial. Funding is up to \$100,00 per year, for up to 2 ears.					
	Applicant Types							
	Funding Limit	100,000.00 per	year					
	Limited Submission	No						
089495	Basic Research Science Grant			Pediatric Cancer R	esearch Foundation	01-Jun-2024	450,000 USD	



SPIN ID	Program Title	Sponsor Nar	ne	Sponsor Number	Deadline Date	Funding Amount			
	Contact Name								
	Contact Telephone								
	Contact Email	jwilson@pcrf-kids.org							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	01-Jun-2024							
	Synopsis	Basic Science Research Grant the direction of improved tre research into the clinic by pro up to 3 years.	asic Science Research Grants fund work that is the basis for childhood cancer research, helping to move science ne direction of improved treatments and eventually finding a cure. These projects help move hypothesis-driven esearch into the clinic by providing support for important preclinical projects. Funding is up to \$150,000 per year p to 3 years.						
	Applicant Types								
	Funding Limit	150,000.00 per year							
	Limited Submission	No							
102068	Competitive Grant Program: T Fellowship	ransthyretin Cardiac Amyloid	DSIS Pfizer Pharmaceut	icals	20-Jun-2024	80,000 USD			
	Contact Name	Amanda Stein, Grant Officer							
	Contact Telephone								
	Contact Email	amanda.j.stein@pfizer.com							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	20-Jun-2024							



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Synopsis	Pfizer is acceptir focus on clinical amyloidosis. Gra	ng applications to s practice, research ant funding is avail	support institutions , and education to f able to support one	with fellowship programs f further the understanding of fellow for up to a year at \$	for Cardiologists that of transthyretin card \$80,000.	at have a strong diac
	Applicant Types Funding Limit Limited Submission	80,000.00 maxir No	num				
125033	Competitive Grant Program: C Support Development of Card	Quality Improvem iac Amyloid Cent	<u>ient Grants to</u> :ers	Pfizer Pharmaceut	icals	03-Jun-2024	50,000 USD
	Contact Name	Amanda Stein, G	Grant Officer				
	Contact Telephone						
	Contact Email	amanda.j.stein@	pfizer.com				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	03-Jun-2024					
	Synopsis	Pfizer is issuing t through funding to \$50,000 will k	this Request for Pr thealthcare quality the considered.	oposals (RFP) to sur y improvement initi	pport the development of e atives in areas of higher ne	emerging cardiac an ed. Individual proje	nyloid centers ects requesting up
	Applicant Types						
	Funding Limit	50,000.00 maxir	num				
	Limited Submission	No					
035362	PCF Challenge Award			Prostate Cancer Fo	oundation	08-Apr-2024 [LOI/Pre-App]	1,000,000 USD
	Contact Name						



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone	310-570-4700				
	Contact Email	applications@p	cf.org			
	Sponsor Website	Link to sponsor	website			
	Program URL	Link to program	<u>1 URL</u>			
	Deadline Dates (ALL)	17-Jun-2024				
	Synopsis	The Prostate Ca Challenge Awar awards will be f unfunded proje	ncer Foundation (PCF) is pleased to an ds for novel investigator-initiated clini funded depending on the level of inno- ects from academic institutions around	nnounce a Request for Tear cal investigations of metast vation in applications receiv the world.	n Science Applicatio tatic, lethal prostation ved. PCF seeks high	ons for PCF e cancer. These -risk, currently
	Applicant Types					
	Funding Limit	1,000,000.00 m	aximum			
	Limited Submission	No				
070888	RPB Stein Innovation Awards		Research to Preve	nt Blindness	15-Jun-2024	300,000 USD
	Contact Name	Pattie Moran				
	Contact Telephone	646-892-9566				
	Contact Email	pmoran@rpbus	sa.org			
	Sponsor Website	Link to sponsor	website			
	Program URL	Link to program	<u>1 URL</u>			
	Deadline Dates (ALL)	15-Jun-2024 , 0	1-Jul-2024			
	Synopsis	The RPB Stein II understanding provide seed m demonstrates c	nnovation (SI) Awards provide funds to the visual system and the diseases tha oney to proposed high-risk/high-gain v out-of-the-box thinking.	o two groups of researchers t compromise its function. vision science research whi	s, both with a comn These SI Awards are ch is innovative, cu	non goal of e intended to tting-edge, and
	Applicant Types					



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	300,000.00 maximum				
	Limited Submission	No				
006942	Career Development Awards		Research to Prever	nt Blindness	15-Jun-2024 [LOI/Pre-App]	350,000 USD
	Contact Name	Pattie Moran, Director of Grants	Administration			
	Contact Telephone	646-892-9566				
	Contact Email	pmoran@rpbusa.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Jun-2024 [LOI/Pre-App], 01-J	ul-2024			
	Synopsis	The RPB Career Development Av Candidates (MDs, PhDs, or MD/ to and including Assistant Profes within three years of the applica granted the full \$350,000. Other	ward will not have a sp PhDs) must have prima ssor. Candidate's first f tion deadline. Awarde wise, the awardee is r	pecific focus and is open to ary appointments in ophth full-time ophthalmology fa ees will be required to expo required to expend the init	any topic within vis almology with acad culty appointment end the award withi cial \$150,000 within	sion research. lemic positions up must have been in four years if three years.
	Applicant Types					
	Funding Limit	350,000.00 maximum				
	Limited Submission	Yes				
070892	RPB International Research Co	ollaborators Award	Research to Prever	nt Blindness	15-Jun-2024 [LOI/Pre-App]	75,000 USD
	Contact Name	Pattie Moran				
	Contact Telephone	646-892-9566				
	Contact Email	pmoran@rpbusa.org				



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount			
	Sponsor Website	Link to sponsor	website							
	Program URL	Link to program	URL							
	Deadline Dates (ALL)	15-Jun-2024 [L0	5-Jun-2024 [LOI/Pre-App], 01-Jul-2024							
	Synopsis	The RPB Interna collaborating re collaborations h affecting large p any institution of each researche	The RPB International Research Collaborators Award promotes international collaborations through which ollaborating researchers in the U.S. and outside the U.S. gain new knowledge and skills. These international ollaborations have the potential to accelerate the development of treatments for blinding disorders, positively fecting large populations worldwide for years to come. This award of up to \$75,000 is available to researchers from ny institution of higher education in the United States. A three- to six-month stay in the other country is expected by ach researcher, with a minimum stay of three months.							
	Applicant Types									
	Funding Limit	75,000.00 maxi	mum							
	Limited Submission	Yes								
006943	Medical Student Fellowships		Res	earch to Preven	it Blindness	15-Jun-2024 [LOI/Pre-App]	30,000 USD			
	Contact Name	Pattie Moran								
	Contact Telephone	646-892-9566								
	Contact Email	pmoran@rpbus	a.org							
	Sponsor Website	Link to sponsor	<u>website</u>							
	Program URL	Link to program	URL							
	Deadline Dates (ALL)	15-Jun-2024 [L0	0I/Pre-App], 01-Jul-202	4						
	Synopsis	The Medical Student Eye Research Fellowships allow gifted students to take a year off from allopathic or osteopar medical school and devote time to the pursuit of a research project within an RPB-supported department of ophthalmology. Research to Prevent Blindness (RPB) is partnering with the American Osteopathic Colleges of Ophthalmology & Otolaryngology-Head and Neck Surgery Foundation (AOCOO-HNS) to offer one (1) award								



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit Limited Submission	specifically targ allopathic medi vision research. 30,000.00 see d Yes	eted to a student of osteopa cine, will not have a specific letail	athic medicine. The remaining Fello discipline criteria or scientific focus	wships, targeted to s and will be open to	students of any topic within
093261	Fellowship Training Award		Rheuma	tology Research Foundation	03-Jun-2024	150,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	404-365-1373 foundation@rh Link to sponsor Link to program 03-Jun-2024 The Amgen Fell needs of childre investigators to Fellowship Train fellowship train	eumatology.org website URL owship Training Award help en and adults with rheumation train future clinicians and a ning Award may be used to so ing program.	s ensure an adequate supply of (a) r c diseases in all areas of the country dvance research in rheumatic and m support the salary of any fellow in an	heumatology provid and (b) rheumatolo husculoskeletal disea h ACGME-accredited	ers meeting the gy educators and uses. The rheumatology
	Applicant Types					
	Funding Limit Limited Submission	50,000.00 per y Yes	ear			
027718	International Exchanges Schei	ne	Royal Sc	ociety	05-Jun-2024	15,120 USD
	Contact Name					



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount				
	Contact Telephone	+44 20 7451 26	56							
	Contact Email	international.ex	changes@royalsociety.org							
	Sponsor Website	Link to sponsor	ink to sponsor website ink to program URL							
	Program URL	Link to program								
	Deadline Dates (ALL)	05-Jun-2024 , 26-Sep-2024								
	Synopsis	<sup>-</sup> hese schemes are for scientists based in the UK who want to stimulate collaborations with leading scientists overseas through either a one-off visit or bilateral travel.								
	Applicant Types									
	Funding Limit	12,000.00 maxi	num							
	Limited Submission	No								
000657	Visiting Scholar Program		Sage (Russell) Four	ndation	25-Jun-2024	Not Specified				
	Contact Name									
	Contact Telephone	212-750-6000								
	Contact Email	programs@rsag	e.org							
	Sponsor Website	Link to sponsor	<u>website</u>							
	Program URL	Link to program	URL							
	Deadline Dates (ALL)	25-Jun-2024								
	Synopsis	Synopsis Synopsis The Russell Sage Foundation's Visiting Scholars Program provides a unique opportunity for select scholar foundation's headquarters in New York City. The foundation annually awards 15 to 17 Visiting Scholar for Applicants must be at least two years beyond the Ph.D. when applying, and if selected, typically work or related to the foundation's core programs (Behavioral Science and Decision Making in Context; Future of Ethnicity and Immigration; Social, Political and Economic Inequality) and special initiatives.								



Applicant Types Funding Limit 0.00 see detail   Limited Submission No No   049628 Stanley Smith Horticultural Trust Grants Smith (Stanley) Horticultural Trust 14-Jun-2024 [LOI/Pre-App] 25,0   Contact Name Contact Telephone 415-332-0166 25,0   Contact Telephone 415-332-0166 25,0   Sponsor Website Link to sponsor website 25,0   Program URL Link to program URL 2020	Deadline Date Funding Amount
Applicant Types Funding Limit 0.00 see detail   Limited Submission No   049628 Stanley Smith Horticultural Trust Grants Smith (Stanley) Horticultural Trust 14-Jun-2024 25,0   Contact Name Contact Telephone 415-332-0166 25,0   Contact Telephone 415-332-0166 25,00   Program URL Link to sponsor website Program URL   Program URL Link to program URL 2024   Date (ALM) 14 Jun 2024 2024	
Funding Limit 0.00 see detail   Limited Submission No   049628 Stanley Smith Horticultural Trust Grants Smith (Stanley) Horticultural Trust 14-Jun-2024 [LOI/Pre-App] 25,0   Contact Name Contact Telephone 415-332-0166 25,0   Contact Telephone grants@smithct.org 114-Jun-2024 25,0   Program URL Link to program URL 114 lup 2024 25,0	
Limited Submission No   049628 Stanley Smith Horticultural Trust Grants Smith (Stanley) Horticultural Trust 14-Jun-2024 [LOI/Pre-App] 25,0   Contact Name Contact Telephone 415-332-0166 25,0   Contact Email grants@smithct.org 25,0   Sponsor Website Link to sponsor website 11,00   Program URL Link to program URL 2024   Deadling Dates (ALM) 14,00 2024	
049628 Stanley Smith Horticultural Trust Grants Smith (Stanley) Horticultural Trust 14-Jun-2024 [LOI/Pre-App] 25,0   Contact Name Contact Telephone 415-332-0166 25,0   Contact Email grants@smithct.org 5ponsor Website Link to sponsor website   Program URL Link to program URL Deadling Dates (ALU) 14 - Jun-2024 25,0	
Contact Name Contact Telephone 415-332-0166 Contact Email grants@smithct.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadling Dates (ALL) 14 Jun 2024 [COL/Pro Appl. 15 Jul 2024	14-Jun-2024 [LOI/Pre-App] 25,000 USD
Contact Telephone 415-332-0166 Contact Email grants@smithct.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 14 Jun 2024 [LOL/Bre Appl. 15 Jul 2024	
Contact Email grants@smithct.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadling Dates (ALL) 14 Jun 2024 [LOL/Bro App], 15 Jul 2024	
Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 14 Jun 2024 [LOL/Bro App] 15 Jul 2024	
Program URL Link to program URL Deadline Dates (ALL) 14 Jun 2024 [LOL/Bro App] 15 Jul 2024	
Deadline Dates (ALL) 14 Jun 2024 [LOL/Bro App] 15 Jul 2024	
Deauline Dates (ALL) 14-Juli-2024 [LOI/FIE-APP], 15-Jul-2024	
The Stanley Smith Horticultural Trust supports education and research in ornamental horticulture through gr Synopsis botanical gardens, arboreta, universities, and other charitable organizations strongly-aligned with its funding interests. The maximum grant awarded by the Trust is \$25,000, however, grants normally do not exceed \$20	Ital horticulture through grants to gly-aligned with its funding ormally do not exceed \$20,000.
Applicant Types	
Funding Limit 25,000.00 maximum	
Limited Submission Yes	
095262Humanitarian AwardSociety for Industrial & Organizational Psychology (SIOP)30-Jun-20241,50	30-Jun-2024 1,500 USD
Contact Name	
Contact Telephone 419-353-0032	
Contact Email <u>SIOP@siop.org</u>	
Sponsor Website Link to sponsor website	



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
	Program URL	Link to program	<u>u URL</u>					
	Deadline Dates (ALL)	30-Jun-2024						
	Synopsis	The SIOP Humanitarian Award is given for sustained, significant, and outstanding humanitarian contribution to I-O psychology. The recipient of the award is given a plaque and a cash prize of \$1,500 (or a donation of t amount donated to the charity/foundation of the recipient's choice).						
	Applicant Types		,,		, ,			
	Funding Limit	1,500.00 see de	etail					
	Limited Submission	No						
066849	Mentored Clinical Scientist Re Award (K08)	search Career D	evelopment Society	for Vascula	ar Surgery	12-Jun-2024	Not Specified	
	Contact Name							
	Contact Telephone	800-258-7188						
	Contact Email	svsfoundation@	vascularsociety.org					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	<u>ı URL</u>					
	Deadline Dates (ALL)	12-Jun-2024 , 1	2-Jul-2024 , 12-Oct-2024 , 1	2-Nov-202	4			
	Synopsis	The Mentored of for careers that support and pro- biomedical, beh	Clinical Scientist Research C have a significant impact o ptected time for an intensiv navioral, or clinical research	areer Deve n the healt e, supervise , including t	lopment Award (K08) will p h-related research needs o ed research career develop translational research.	repare clinically tra f the Nation. This p ment experience in	ined individuals rogram provides the fields of	
	Applicant Types							
	Funding Limit	50,000.00 per y	ear					
	Limited Submission	No						



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
091553	Student Scholarship Program		Society of Diagnostic Medical Sonography Foundation	30-Jun-2024	2,500 USD
	Contact Name				
	Contact Telephone	214-473-8057			
	Contact Email	scholarship@sdmsfoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jun-2024 , 31-Dec-2024			
	Synopsis	The SDMS Foundation Sonography sonography student who has been sonography or cardiovascular tech Health Educational Programs (CAA	y Student Scholarship provides provides a \$2,5 n accepted or is currently enrolled in an educa nnology which has been accredited by the Con AHEP).	500 scholarship to a tional program in d nmission on Accred	a deserving liagnostic medical itation of Allied
	Applicant Types				
	Funding Limit	2,500.00 maximum			
	Limited Submission	No			
067272	Grants Program		Sorenson Legacy Foundation	01-Jun-2024	Not Specified
	Contact Name	Lisa Meiling			
	Contact Telephone	801-461-9700			
	Contact Email	lisa@sorensonlegacyfoundation.o	rg		
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2024 , 01-Sep-2024			



SPIN ID	Program Title	S	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
		1							
	Synopsis	The Sorenson Leg by the late bioted Beverley Taylor S development and	e Sorenson Legacy Foundation was created to improve the lives of others and the world in which we live. Founded the late biotechnology pioneer and entrepreneur James LeVoy Sorenson and his wife, education philanthropist verley Taylor Sorenson, the foundation provides support for a wide range of endeavors, from community velopment and education to health care, scientific and artistic pursuits.						
	Applicant Types								
	Funding Limit	0.00 not provided	d						
	Limited Submission	No							
003009	Vatican Film Library Mellon Fe	ellowship Program	Vatican Microfilm	Library	01-Jun-2024	4,500 USD			
	Contact Name								
	Contact Telephone	314-977-3096							
	Contact Email	<u>vfl@slu.edu</u>							
	Sponsor Website	Link to sponsor w	<u>vebsite</u>						
	Program URL	Link to program l	JRL						
	Deadline Dates (ALL)	01-Jun-2024 , 01-	-Oct-2024						
	Synopsis	Short-term resea utilizing the colle materials of the I theology, literatu	rch fellowships are available for perio ctions of the Vatican Film Library. Ap ibrary. All topics will be considered th ire, art, science, paleography, codicol	ods between two and eight plications must demonstra nat are served by the collec ogy, illumination, text edit	t weeks in length to te need to consult ctions, such as histo ing, library history,	support research the primary source ory, philosophy, etc.			
	Applicant Types								
	Funding Limit	2,250.00 per mor	nth						
	Limited Submission	No							
009730	Grants-in-Aid		Whitehall Foundat	ion, Inc.	15-Apr-2024 [LOI/Pre-App]	30,000 USD			



SPIN ID	Program Title	Sp	ponsor Name	Sponsor Number	Deadline Date	Funding Amount			
	Contact Name								
	Contact Telephone	561-655-4474							
	Contact Email	<u>email@whitehall.c</u>	org						
	Sponsor Website	Link to sponsor we	<u>ebsite</u>						
	Program URL	Link to program U	<u>RL</u>						
	Deadline Dates (ALL)	_) 15-Apr-2024 [LOI/Pre-App], 01-Jun-2024 , 02-Sep-2024 , 01-Oct-2024 [LOI/Pre-App]							
	Synopsis	sciences. It is the Foundation, through its program of grants and grants-in-aid, assists scholarly research in the life sciences. It is the Foundation's policy to assist those dynamic areas of basic biological research that are not heavil supported by Federal Agencies or other foundations with specialized missions. The Foundation is currently interes in basic research in neurobiology. The Grants-in-Aid program is designed for researchers at the assistant professo level who experience difficulty in competing for research funds because they have not yet become firmly establish Grants-in-Aid can also be made to senior scientists. All applications will be judged on the scientific merit and innovative aspects of the proposal, as well as on past performance and evidence of the applicant's continued productivity. Grants-in-Aid are awarded for a one-year period and do not exceed \$20,000							
	Applicant Types								
	Funding Limit	30,000.00 maximu	JM						
	Limited Submission	No							
001018	Research Grants		Whitehall Foundat	ion, Inc.	15-Apr-2024 [LOI/Pre-App]	300,000 USD			
	Contact Name								
	Contact Telephone	561-655-4474							
	Contact Email	email@whitehall.c	org						
	Sponsor Website	Link to sponsor we	<u>ebsite</u>						

Program URL Link to program URL



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount			
	Deadline Dates (ALL) 15-Apr-2024 [LOI/Pre-App], 03-Jun-2024 , 01-Sep-2024 , 01-Oct-2024 [LOI/Pre-App]									
	Synopsis	The Whitehall F invertebrate ne institutions in th	e Whitehall Foundation is focused exclusively on assisting basic research in vertebrate (excluding clinical) and vertebrate neurobiology. They offer research grants to established scientists of all ages working at accredited stitutions in the United States. Research grants of up to three years are available. A renewal grant with a maximum two years is possible, but it will be awarded on a competitive basic							
	Applicant Types			be awarded on a co						
	Funding Limit	100.000.00 per	vear							
	Limited Submission	No	,							
071378	Norman Borlaug Award for Fie	eld Research and	Application	World Food Prize F	oundation	15-Jun-2024	10,000 USD			
	Contact Name	Ms.Ellen Franze	nburg, Director of S	Secretariat Operation	ons					
	Contact Telephone	515-245-3783								
	Contact Email	efranzenburg@	worldfoodprize.org							
	Sponsor Website	Link to sponsor	<u>website</u>							
	Program URL	Link to program	<u>URL</u>							
	Deadline Dates (ALL)	15-Jun-2024								
	Synopsis	The Norman Bo recognize excep under 40 who h global hunger a	rlaug Award for Fie otional, science-base as clearly demonstr nd poverty.	ld Research and Ap ed achievement in i rated intellectual co	plication is presented annu international agriculture ar purage, stamina, and deter	ually in the amount nd food production mination in the figl	of \$10,000 to by an individual ht to eliminate			
	Applicant Types									
	Funding Limit	10,000.00 maxi	mum							
	Limited Submission	No								
024760	Sustainability Prize			Zayed Sustainabilit	y Prize	23-Jun-2024	Not Specified			



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
	Contact Name							
	Contact Telephone	+971 2 653 333	3					
	Contact Email	info@zayedsust	ainabilityprize.com					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	.L) 23-Jun-2024						
	Synopsis	The Zayed Sustainability Prize recognises nonprofit organisations (NPOs), small and medium sized enterpri and high schools for their impactful, innovative and inspiring sustainable solutions across the categories of Food, Energy, Water and Global High Schools. In response to the pressing climate crisis, and to further sup UAE's efforts to accelerate practical solutions needed to drive climate action and uplift vulnerable commu around the world, the Prize has increased its funds from US \$3.6 million to US \$5.9 million. The Prize will is \$1 million to each winner in the organisational categories of Health, Food, Energy, Water and Climate Act the Global High Schools category, which is split into six world regions, each school can claim up to US \$15 start or further expand their project. The six world regions of the Global High Schools category are The Ar Europe & Central Asia, Middle East & North Africa, Sub-Saharan Africa, South Asia, and East Asia & Pacific recent Zayed Sustainability Prize wigners were recognized at an Awards Coremony hold during COD28 LIA						
	Applicant Types							
	Funding Limit	0.00 see detail						
	Limited Submission	No						

